Text,CUIS
,
age $nmbr$ yr,C0001779;C0439234
characteristic,C1521970
$nmbr$,
placebo n $nmbr$,C0032042;C1696465;C1706408
race white,C0007457;C0043157;C0220938
gemfibrozil n $nmbr$,C0017245
black,C0005680;C0027567;C0085756;C0439541
age yr,C0001779;C0439234
other,
$nmbr$ $nmbr$,
education $nmbr$ yr,C0013621;C0439234;C0013622;C0013658;C0039401
age $nmbr$ yr,C0001779;C0439234
current smoker,C3173209;C3241966
$nmbr$,
alcohol consumption,C0001948
race white,C0007457;C0043157;C0220938
$nmbr$ $nmbr$ drinks dav,C0452428
black,C0005680;C0027567;C0085756;C0439541
$nmbr$ drinks dav,C0452428
other,
hypertension,C0020538;C1963138
education $nmbr$ yr,C0013621;C0439234;C0013622;C0013658;C0039401
diabetes,C0011847;C0011849
current smoker,C3173209;C3241966
prior myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
alcohol consumption,C0001948
time since most recent myocardial,C0040223;C3541383
$nmbr$ $nmbr$ drinks dav,C0452428
infarction yr history of congestive heart failure,C0455531
$nmbr$ drinks dav,C0452428
cabg or ptca,C0010055;C2936173
hypertension,C0020538;C1963138
medication use aspirin,C0240320;C0004057
diabetes,C0011847;C0011849
nitratesf,
prior myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
calcium channel blockers,C0006684;C2757014
time since most recent myocardial,C0040223;C3541383
ace inhibitors,C0003015
infarction yr history of congestive heart failure,C0455531
beta blockers,C0001645
cabg or ptca,C0010055;C2936173
any antianginal drug,C0013227;C1254351
medication use aspirin,C0240320;C0004057
body mass index,C0005893;C0578022;C1305855
nitratesf,
waist to hip ratio,C0205682
calcium channel blockers,C0006684;C2757014
$nmbr$ $nmbr$ $nmbr$ $nmbr$,
ace inhibitors,C0003015
blood pressure mm hg systolic,C0005823;C0039155;C1271104;C1272641
beta blockers,C0001645
diastolic,C0012000
any antianginal drug,C0013227;C1254351
plasma lipids mg dl $nmbr$ total cholesterol mean,C0444504;C2347634;C2348143
body mass index,C0005893;C0578022;C1305855
interquartile range,C1711350
waist to hip ratio,C0205682
ldl cholesterol mean,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$,
hdl cholesterol mean,C0444504;C2347634;C2348143
blood pressure mm hg systolic,C0005823;C0039155;C1271104;C1272641
triglycerides mean,C0444504;C2347634;C2348143
diastolic,C0012000
plasma lipids mg dl $nmbr$ total cholesterol mean,C0444504;C2347634;C2348143
plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$,C0042295;C1704970;C0010055;C0190211;C0920394;C0011847;C0011849;C0011198;C0017480;C3541240;C0205232;C0687757;C0745732;C3272378;C0040028;C0028125;C0332257;C1552866;C2700399;C1521827;C3812761;C0013227;C1254351;C0699857;C3848573;C0006684;C3536851;C4521885;C0001645;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074;C0008377;C0439190;C0475211;C1719797;C2911648;C0041004;C1532563
interquartile range,C1711350
nct $nmbr$,
ldl cholesterol mean,C0444504;C2347634;C2348143
characteristics,C1521970
hdl cholesterol mean,C0444504;C2347634;C2348143
chlorthalidone group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
triglycerides mean,C0444504;C2347634;C2348143
doxazosin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
no of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$,C0042295;C1704970;C0010055;C0190211;C0920394;C0011847;C0011849;C0011198;C0017480;C3541240;C0205232;C0687757;C0745732;C3272378;C0040028;C0028125;C0332257;C1552866;C2700399;C1521827;C3812761;C0013227;C1254351;C0699857;C3848573;C0006684;C3536851;C4521885;C0001645;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074;C0008377;C0439190;C0475211;C1719797;C2911648;C0041004;C1532563
age y,C0001779
nct $nmbr$,
women,C0043210
characteristics,C1521970
race ethnicity white non hispanic,C1533020;C1533021
chlorthalidone group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
black non hispanic,C1533017;C1533018
doxazosin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
white hispanic,C1533020;C1533021
no of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
black hispanic,C1533017;C1533018
age y,C0001779
other race,C0034510;C1706779;C3853635
women,C0043210
education y,C0013621;C0013622;C0013658;C0039401
race ethnicity white non hispanic,C1533020;C1533021
blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
black non hispanic,C1533017;C1533018
treated for hypertension,C1522326;C0020538;C1963138
white hispanic,C1533020;C1533021
eligibility risk factors t ascvo,C0035648;C1553898
black hispanic,C1533017;C1533018
st t wave changes,C0392747;C0443172
other race,C0034510;C1706779;C3853635
type $nmbr$ diabetes,C1320657
education y,C0013621;C0013622;C0013658;C0039401
cigarette smoking,C0239059;C0700219
blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
hdl c,C3715113
treated for hypertension,C1522326;C0020538;C1963138
lvh from electrocardiogram,C0149721;C0013798;C1547122;C1623258
eligibility risk factors t ascvo,C0035648;C1553898
lvh from echocardiogram,C0149721;C0013516;C2243117
st t wave changes,C0392747;C0443172
serum biochemistry potassium mmol l,C0302353;C1532563;C0543465
type $nmbr$ diabetes,C1320657
fasting glucose mg dl,C0015663;C0439269
cigarette smoking,C0239059;C0700219
creatinine mg dl,C0010294;C0439269;C1561535
hdl c,C3715113
cholesterol mg dl,C0008377;C0439269
lvh from electrocardiogram,C0149721;C0013798;C1547122;C1623258
ldl c mg dl,C0439269
lvh from echocardiogram,C0149721;C0013516;C2243117
hdl c mg dl,C3715113;C0439269
serum biochemistry potassium mmol l,C0302353;C1532563;C0543465
fasting triglycerides mg dl,C0015663;C0041004;C0439269
fasting glucose mg dl,C0015663;C0439269
variable,C0439828;C4553760
creatinine mg dl,C0010294;C0439269;C1561535
abciximab n $nmbr$,C0288672
cholesterol mg dl,C0008377;C0439269
p value,C1709380
ldl c mg dl,C0439269
male sex,C0086582
hdl c mg dl,C3715113;C0439269
weight kg,C0022718;C0439209;C4054209
fasting triglycerides mg dl,C0015663;C0041004;C0439269
clinical characteristics,C0683325
variable,C0439828;C4553760
hyperlipidemia,C0020473;C0428465;C4555212
abciximab n $nmbr$,C0288672
history of hypertension,C0455527
p value,C1709380
histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
male sex,C0086582
histor y of unstable angina,C0002965
weight kg,C0022718;C0439209;C4054209
histor y of stable angina,C0340288
clinical characteristics,C0683325
histor y of heart failure,C0018801;C0018802;C4554158
hyperlipidemia,C0020473;C0428465;C4555212
congestive heart failure,C0018802
history of hypertension,C0455527
cardiogenic shock during first $nmbr$ hr after randomization,C0036980;C0205435;C1279901;C0034656
histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
previous intervention,C0184661;C0886296;C1273869
histor y of unstable angina,C0002965
percutaneous transluminal coronary angioplasty,C2936173
histor y of stable angina,C0340288
coronar y artery bypass grafting,C0332835;C1527362;C1961139
histor y of heart failure,C0018801;C0018802;C4554158
administration of study drug,C0150270;C0262754;C3469597
congestive heart failure,C0018802
bolus,C1186706;C1511237;C1705509;C3812160
cardiogenic shock during first $nmbr$ hr after randomization,C0036980;C0205435;C1279901;C0034656
bolus and infusion,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
previous intervention,C0184661;C0886296;C1273869
infarct territory,C1301808;C2983136
percutaneous transluminal coronary angioplasty,C2936173
$nmbr$ $nmbr$ f,C0016327
coronar y artery bypass grafting,C0332835;C1527362;C1961139
anterior,C0205094
administration of study drug,C0150270;C0262754;C3469597
inferior,C0542339;C0678975
bolus,C1186706;C1511237;C1705509;C3812160
infarct related vessel,C0021308;C0005847
bolus and infusion,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
l eft anterior descending,C0439394;C0205094;C1706495;C3642217;C0205386;C1547177
infarct territory,C1301808;C2983136
r ight coronary,C0205090;C0018787;C0684010;C2603358
$nmbr$ $nmbr$ f,C0016327
circumflex,C1880089
anterior,C0205094
graft,C0181074;C0332835;C1961139
inferior,C0542339;C0678975
age yrs,C0001779
infarct related vessel,C0021308;C0005847
digoxin,C0012265
l eft anterior descending,C0439394;C0205094;C1706495;C3642217;C0205386;C1547177
placebo,C0032042;C1696465;C1706408
r ight coronary,C0205090;C0018787;C0684010;C2603358
n,C0369718;C0441922
circumflex,C1880089
male,C0086582;C1706180;C1706428;C1706429
graft,C0181074;C0332835;C1961139
nonwhite,
age yrs,C0001779
prior mi,C0332152;C3810814;C2826257
digoxin,C0012265
diabetes etiology,C0015127;C1314792;C1524003
placebo,C0032042;C1696465;C1706408
ischemic,C0475224
n,C0369718;C0441922
nonischemic,
male,C0086582;C1706180;C1706428;C1706429
heart rate min_ $nmbr$ mean,C0444504;C2347634;C2348143
nonwhite,
systolic bp mm hg mean nyha class,C0488053;C1882083
prior mi,C0332152;C3810814;C2826257
ttf fv,C1332112;C1705840;C4087167
diabetes etiology,C0015127;C1314792;C1524003
ct ratio $nmbr$ $nmbr$,C0456603;C1547037
ischemic,C0475224
ejection fraction mean,C0444504;C2347634;C2348143
nonischemic,
creatinine $nmbr$ $nmbr$ mg dl medications,C0013227;C0802604;C2598133;C4284232
heart rate min_ $nmbr$ mean,C0444504;C2347634;C2348143
diuretics,C0012798
systolic bp mm hg mean nyha class,C0488053;C1882083
losartan n $nmbr$,C0126174
ttf fv,C1332112;C1705840;C4087167
atenolol n $nmbr$,C0004147
ct ratio $nmbr$ $nmbr$,C0456603;C1547037
all with diabetes n $nmbr$,C0011847;C0011849
ejection fraction mean,C0444504;C2347634;C2348143
all without diabetes n $nmbr$,C0011847;C0011849
creatinine $nmbr$ $nmbr$ mg dl medications,C0013227;C0802604;C2598133;C4284232
demographic and clinical characteristics,C0011298;C0683325
diuretics,C0012798
age years,C1510829
losartan n $nmbr$,C0126174
$nmbr$ $nmbr$ $nmbr$,
atenolol n $nmbr$,C0004147
ethnic origin white,C0007457;C0043157;C0220938
all with diabetes n $nmbr$,C0011847;C0011849
hispanic,C0086409
all without diabetes n $nmbr$,C0011847;C0011849
asian,C0078988
demographic and clinical characteristics,C0011298;C0683325
heart rate bpm,C0018810
age years,C1510829
bmi kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ $nmbr$,
cornell voltage duration product mmxmsec,C0598352;C0449238;C2926735
ethnic origin white,C0007457;C0043157;C0220938
sokolow lyon mm,C4330985;C4554674
hispanic,C0086409
framingham risk score,C0035647;C0449820;C4050231;C4552904
asian,C0078988
current smokers,C3173209;C3241966
heart rate bpm,C0018810
medical history,C0262926;C1704706
bmi kg m $nmbr$,C0022718;C0439209;C4054209
any vascular diasease,C0005847;C1558950;C1801960
cornell voltage duration product mmxmsec,C0598352;C0449238;C2926735
coronary heart disease,C0010054;C0010068;C1956346
sokolow lyon mm,C4330985;C4554674
cerebrovascular disease,C0007820
framingham risk score,C0035647;C0449820;C4050231;C4552904
current smokers,C3173209;C3241966
peripheral vascular disease,C0085096
atrial fibrillation,C0004238;C0344434;C1963067
medical history,C0262926;C1704706
isolated systolic hypertension^,C0745133
any vascular diasease,C0005847;C1558950;C1801960
table $nmbr$ characteristics of patients treated with losartan and atenolol,C0039224;C0815172;C1706074;C0332293;C0126174;C0004147
coronary heart disease,C0010054;C0010068;C1956346
women no,C0043210
cerebrovascular disease,C0007820
ethnicity no,C0015031;C0243103
peripheral vascular disease,C0085096
white,C0007457;C0043157;C0220938
atrial fibrillation,C0004238;C0344434;C1963067
systolic,C0039155
isolated systolic hypertension^,C0745133
heart rate beats min,C0439385
table $nmbr$ characteristics of patients treated with losartan and atenolol,C0039224;C0815172;C1706074;C0332293;C0126174;C0004147
body mass index kg m $nmbr$,C0022718;C0439209;C4054209
women no,C0043210
cornell voltage duration product mm x ms,C2349943;C3539704;C3713294
ethnicity no,C0015031;C0243103
framingham risk score arbitrary units,C0035647;C0439183;C4552904
white,C0007457;C0043157;C0220938
current smoker no,C3173209;C3241966
systolic,C0039155
medical history no,C0262926;C1704706
heart rate beats min,C0439385
previously untreated isolated systolic hypertension,C0745133
body mass index kg m $nmbr$,C0022718;C0439209;C4054209
overall n $nmbr$,C0282416;C1561607
cornell voltage duration product mm x ms,C2349943;C3539704;C3713294
rate control group n $nmbr$,C0441848
framingham risk score arbitrary units,C0035647;C0439183;C4552904
rhythm control group n $nmbr$,C0441848
current smoker no,C3173209;C3241966
female sex no,C0086287
medical history no,C0262926;C1704706
ethnic minority group no,C0015031;C1879937
previously untreated isolated systolic hypertension,C0745133
predominant cardiac diagnosis no,C0011900;C1704338;C1704656
overall n $nmbr$,C0282416;C1561607
coronar y artery disease,C0852949
rate control group n $nmbr$,C0441848
cardiomyopathy,C0878544
rhythm control group n $nmbr$,C0441848
valvular disease,C3258293
female sex no,C0086287
no apparent heart disease,C0750489;C0018799
ethnic minority group no,C0015031;C1879937
histor y of congestive heart failure no,C0018802
predominant cardiac diagnosis no,C0011900;C1704338;C1704656
duration of qualifying atrial fibrillation $nmbr$ days no,C0449238;C2926735;C1514624;C0004238;C0439228;C0344434;C1963067
coronar y artery disease,C0852949
first episode of atrial fibrillation vs recurrent episode no f,C0332189;C0439615;C0443287;C0016327
cardiomyopathy,C0878544
valvular disease,C3258293
any prerandomization failure of an antiarrhythmic drug no,C0231174;C0680095
no apparent heart disease,C0750489;C0018799
size of left atrium normal no,C0225860;C0332506
histor y of congestive heart failure no,C0018802
left ventricular ejection fraction,C0428772;C0488728
duration of qualifying atrial fibrillation $nmbr$ days no,C0449238;C2926735;C1514624;C0004238;C0439228;C0344434;C1963067
first episode of atrial fibrillation vs recurrent episode no f,C0332189;C0439615;C0443287;C0016327
normal left ventricular ejection fraction no j,C0428772;C0488728
no of participants,C0679646
any prerandomization failure of an antiarrhythmic drug no,C0231174;C0680095
$nmbr$ chlorthalidone n $nmbr$,C0008294
size of left atrium normal no,C0225860;C0332506
amlodipine n $nmbr$,C0051696
left ventricular ejection fraction,C0428772;C0488728
i lisinopril n $nmbr$,C0021966;C0065374;C0221138
age mean sd y,C0001779;C0444504;C2347634;C2348143
normal left ventricular ejection fraction no j,C0428772;C0488728
age range y,C0001779;C1514721;C2348147;C3542016
no of participants,C0679646
a $nmbr$,
$nmbr$ chlorthalidone n $nmbr$,C0008294
ethnicity,C0015031;C0243103
amlodipine n $nmbr$,C0051696
white non hispanic,C1533020;C1533021
i lisinopril n $nmbr$,C0021966;C0065374;C0221138
education mean sd y,C0013621;C0013622;C0013658;C0039401
age mean sd y,C0001779;C0444504;C2347634;C2348143
receiving antihypertensive,C1514756;C0003364
age range y,C0001779;C1514721;C2348147;C3542016
treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
a $nmbr$,
ethnicity,C0015031;C0243103
blood pressure mean sd mm hg,C0428886;C0439475
treated at baseline,C1522326;C0168634;C1442488
white non hispanic,C1533020;C1533021
untreated at baseline,C0332155;C0168634;C1442488
education mean sd y,C0013621;C0013622;C0013658;C0039401
$nmbr$ $nmbr$ s $nmbr$ $nmbr$,
receiving antihypertensive,C1514756;C0003364
eligibility risk factors,C0035648;C1553898
treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
cigarette smoker,C0337667
blood pressure mean sd mm hg,C0428886;C0439475
atherosclerotic cvdj,C0333482
treated at baseline,C1522326;C0168634;C1442488
history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
untreated at baseline,C0332155;C0168634;C1442488
history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ $nmbr$ s $nmbr$ $nmbr$,
revascularization,C0581603
eligibility risk factors,C0035648;C1553898
other atherosclerotic cvd,C0333482;C0007222
cigarette smoker,C0337667
major st depression or,C0041696;C1269683
atherosclerotic cvdj,C0333482
t wave inversion,C0520888
history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
lvh by electrocardiogram,C0149721;C0013798;C1547122;C1623258
history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
lvh by echocardiogram,C0149721;C0013516;C2243117
revascularization,C0581603
other atherosclerotic cvd,C0333482;C0007222
history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
major st depression or,C0041696;C1269683
body mass index mean sd,C0005893;C2699239;C0578022;C1305855
t wave inversion,C0520888
current medication use,C0240320
aspirin,C0004057
lvh by electrocardiogram,C0149721;C0013798;C1547122;C1623258
estrogen supplementation,C0014939;C0242297;C2936882;C4542544
lvh by echocardiogram,C0149721;C0013516;C2243117
women only,C0043210
history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
lioid trial participants,C1997894;C2242969
body mass index mean sd,C0005893;C2699239;C0578022;C1305855
patients treated with losartan n $nmbr$,C0030705;C0332293;C0126174
current medication use,C0240320
patients treated with atenoloi n $nmbr$,C0030705;C0332293
aspirin,C0004057
aii patients n $nmbr$,C1424250;C0030705;C2698414
estrogen supplementation,C0014939;C0242297;C2936882;C4542544
age x,C0001779
women only,C0043210
women n,C0043210
lioid trial participants,C1997894;C2242969
ethnicity n,C0015031;C0243103
patients treated with losartan n $nmbr$,C0030705;C0332293;C0126174
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
patients treated with atenoloi n $nmbr$,C0030705;C0332293
bmi kg m^,C0022718;C0439209;C4054209
aii patients n $nmbr$,C1424250;C0030705;C2698414
cornell voltage x duration product mm x ms,C2349943;C3539704;C3713294
age x,C0001779
sokolow lyon voltage mm,C4330985;C4554674
women n,C0043210
current smokers n,C3173209;C3241966
ethnicity n,C0015031;C0243103
atrial fibrillation n,C0004238;C0344434;C1963067
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
isolated systolic hypertension n,C0745133
bmi kg m^,C0022718;C0439209;C4054209
diabetes n,C0011847;C0011849
cornell voltage x duration product mm x ms,C2349943;C3539704;C3713294
sokolow lyon voltage mm,C4330985;C4554674
patients with clinically evident vascular disease,C0683521
current smokers n,C3173209;C3241966
patients without clinically evident vascular disease,C0683521
atrial fibrillation n,C0004238;C0344434;C1963067
treated with losartan n $nmbr$,C0332293;C0126174
isolated systolic hypertension n,C0745133
treated with atenolol n $nmbr$,C0332293;C0004147
diabetes n,C0011847;C0011849
adjusted hazard ratio $nmbr$ cl,C2985465;C0596019
patients with clinically evident vascular disease,C0683521
unadjusted hazard ratio $nmbr$ cl,C2985465;C0596019
unadjusted hazard ratio $nmbr$ ci,C0008107;C3259781
patients without clinically evident vascular disease,C0683521
patients,C0030705
treated with losartan n $nmbr$,C0332293;C0126174
ratet,
treated with atenolol n $nmbr$,C0332293;C0004147
primary composite end points,C0205199;C2349179;C1547335
adjusted hazard ratio $nmbr$ cl,C2985465;C0596019
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
unadjusted hazard ratio $nmbr$ cl,C2985465;C0596019
$nmbr$ ^ $nmbr$,
unadjusted hazard ratio $nmbr$ ci,C0008107;C3259781
cardiovascular mortality,C0026565;C0026566
patients,C0030705
\ $nmbr$ $nmbr$ $nmbr$,
ratet,
stroke,C0038454;C4554100
primary composite end points,C0205199;C2349179;C1547335
myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
total mortality,C0026565;C0026566
$nmbr$ ^ $nmbr$,
hospitalization,C0019993
cardiovascular mortality,C0026565;C0026566
angina pectoris,C0002962
\ $nmbr$ $nmbr$ $nmbr$,
heart failure,C0018801;C0018802;C4554158
stroke,C0038454;C4554100
new onset diabetes,C0011847;C0011849
myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
candesartan group n $nmbr$,C0717550;C0441848
total mortality,C0026565;C0026566
control group n $nmbr$,C0441848
hospitalization,C0019993
mean age y,C0444504;C0001779;C2347634;C2348143
angina pectoris,C0002962
ejection fraction,C0489482;C2700378
heart failure,C0018801;C0018802;C4554158
history of,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
new onset diabetes,C0011847;C0011849
smoking status,C1519386
candesartan group n $nmbr$,C0717550;C0441848
exsmoker,C0337671;C4555205
control group n $nmbr$,C0441848
hypercholesterolemia,C0020443;C1522133
mean age y,C0444504;C0001779;C2347634;C2348143
type of lipid lowering regimen,C0332307;C1547052;C0441994;C2003888;C0040808;C2945654
ejection fraction,C0489482;C2700378
i moderate $nmbr$ mg of pravastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history of,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
i intensive $nmbr$ mg of atorvastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
smoking status,C1519386
mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0444504;C2699239;C2347634;C2348143
exsmoker,C0337671;C4555205
cholesterol mg dl total,C0201950;C0543421
hypercholesterolemia,C0020443;C1522133
low density lipoprotein,C0023823
type of lipid lowering regimen,C0332307;C1547052;C0441994;C2003888;C0040808;C2945654
high density lipoprotein,C0023821
i moderate $nmbr$ mg of pravastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
triglycerides mg dl,C0041004;C0439269
i intensive $nmbr$ mg of atorvastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apolipoprotein b $nmbr$ mg dl,C0003593;C0439269
mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0444504;C2699239;C2347634;C2348143
cholesterol mg dl total,C0201950;C0543421
c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
low density lipoprotein,C0023823
men n $nmbr$,C0025266
no $nmbr$ $nmbr$,
high density lipoprotein,C0023821
white n $nmbr$,C0007457;C0043157;C0220938
triglycerides mg dl,C0041004;C0439269
smoking status current smoker n $nmbr$,C1519386;C3173209;C3241966
apolipoprotein b $nmbr$ mg dl,C0003593;C0439269
past or nonsmoker n $nmbr$,C0337672;C0425293;C4554605
c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
history of hypertension n $nmbr$,C0455527
men n $nmbr$,C0025266
prior statin use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
no $nmbr$ $nmbr$,
history of diabetes mellitus n $nmbr$,C0455488
white n $nmbr$,C0007457;C0043157;C0220938
metabolic syndrome n $nmbr$,C0524620
smoking status current smoker n $nmbr$,C1519386;C3173209;C3241966
subgroup,C1079230;C1515021
past or nonsmoker n $nmbr$,C0337672;C0425293;C4554605
test for interaction p value,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
history of hypertension n $nmbr$,C0455527
demographics,C0011298;C1704791
prior statin use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
age,C0001779
history of diabetes mellitus n $nmbr$,C0455488
gender,C0079399;C1522384
metabolic syndrome n $nmbr$,C0524620
country,C0454664;C1511538
subgroup,C1079230;C1515021
ethnic group,C0015031;C1879937
test for interaction p value,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
disease history,C0683519
demographics,C0011298;C1704791
mi,C3810814
age,C0001779
ihd,C0151744
gender,C0079399;C1522384
angina,C0002962
country,C0454664;C1511538
microalbuminuria,C0730345
ethnic group,C0015031;C1879937
ish,
disease history,C0683519
alcohol intake,C0001948
mi,C3810814
exercise status,C0015259;C0449438;C1522704
ihd,C0151744
bmi,C0578022
angina,C0002962
systolic bp,C0871470
microalbuminuria,C0730345
diastolic bp,C0428883
ish,
total cholesterol,C0201950;C0543421
alcohol intake,C0001948
hdl cholesterol,C0023822;C0392885
exercise status,C0015259;C0449438;C1522704
ecg lvh cornell,C0232306
bmi,C0578022
ecg lvh sokolow lyon,C0232306
systolic bp,C0871470
a worldwide black and non black patients,C0005680;C0027567;C0085756;C0439541;C1829939
diastolic bp,C0428883
worldwide black patients,C0005680;C0030705;C0027567;C0085756;C0439541
total cholesterol,C0201950;C0543421
crude rate,C0871208;C1521828
hdl cholesterol,C0023822;C0392885
adjusted hazard ratio $nmbr$ ci,C0008107;C3259781
ecg lvh cornell,C0232306
rate,C0871208;C1521828
ecg lvh sokolow lyon,C0232306
composite,C0205199;C1547335
a worldwide black and non black patients,C0005680;C0027567;C0085756;C0439541;C1829939
components of primary composite end point secondary end points,C1882460
worldwide black patients,C0005680;C0030705;C0027567;C0085756;C0439541
mi fatal nonfatal,C1302234;C1705232
crude rate,C0871208;C1521828
stroke fatal nonfatal,C0038454;C1302234;C1705232;C4554100
adjusted hazard ratio $nmbr$ ci,C0008107;C3259781
worldwide non black patients,C1829939;C0005680;C0027567;C0085756;C0439541
rate,C0871208;C1521828
losartan n $nmbr$ $nmbr$,C0126174
composite,C0205199;C1547335
atenolol n $nmbr$ $nmbr$,C0004147
components of primary composite end point secondary end points,C1882460
b u s black and non black patients,C0005680;C0027567;C0085756;C0439541;C1829939
mi fatal nonfatal,C1302234;C1705232
u s black patients,C0041703;C0030705
stroke fatal nonfatal,C0038454;C1302234;C1705232;C4554100
u s non black patients,C0041703;C1829939
worldwide non black patients,C1829939;C0005680;C0027567;C0085756;C0439541
monteiukast n $nmbr$,
losartan n $nmbr$ $nmbr$,C0126174
sex no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
atenolol n $nmbr$ $nmbr$,C0004147
female,C0043210;C0086287;C1705497;C1705498
b u s black and non black patients,C0005680;C0027567;C0085756;C0439541;C1829939
race no,C0034510;C1706779;C3853635
u s black patients,C0041703;C0030705
patients receiving immunotherapy no,C0030705;C1514756;C0005525;C0021083
u s non black patients,C0041703;C1829939
allergic rhinitis duration mean sd y,C1334103;C2607914;C4552864
monteiukast n $nmbr$,
baseline daytime nasal symptoms score mean sd,C0231918;C2699239
sex no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
pollen exposure,C0274281;C0332157
female,C0043210;C0086287;C1705497;C1705498
patients included in analysis,C0030705;C0332257;C0002778;C0936012;C1524024
race no,C0034510;C1706779;C3853635
daytime nasal symptoms score change from baseline mean se,C0436315
patients receiving immunotherapy no,C0030705;C1514756;C0005525;C0021083
ls mean difference $nmbr$ cl,C0023668;C0596019
allergic rhinitis duration mean sd y,C1334103;C2607914;C4552864
monteiukast,
baseline daytime nasal symptoms score mean sd,C0231918;C2699239
monteiukast vs placebo,C0032042;C1696465;C1706408
pollen exposure,C0274281;C0332157
pollent $nmbr$,
patients included in analysis,C0030705;C0332257;C0002778;C0936012;C1524024
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
daytime nasal symptoms score change from baseline mean se,C0436315
pollent s $nmbr$,
ls mean difference $nmbr$ cl,C0023668;C0596019
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ t,C2603360
monteiukast,
factor,C1521761;C2827422
monteiukast vs placebo,C0032042;C1696465;C1706408
no of strokes no of patients in category and,C0038454;C0030705;C0683312;C3889287
pollent $nmbr$,
hazard ratio and $nmbr$ ci,C2985465;C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
factor present,C0150312;C0449450
pollent s $nmbr$,
factor absent,C1521761;C2827422;C0332197;C4285062
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ t,C2603360
crude,
factor,C1521761;C2827422
adjusted,C0456081
no of strokes no of patients in category and,C0038454;C0030705;C0683312;C3889287
diabetes mellitus,C0011849
hazard ratio and $nmbr$ ci,C2985465;C0008107;C3259781
myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959;C0002962
factor present,C0150312;C0449450
smoking in the past year,C0037369;C0453996;C1881674
factor absent,C1521761;C2827422;C0332197;C4285062
ica stenosis $nmbr$ $nmbr$ f,C0201519;C0016327
crude,
irregular or ulcerated ica plaquef,C0205271;C0041582;C0201519;C3887532
adjusted,C0456081
infarct on brain imaging^,C0021308;C0203860
diabetes mellitus,C0011849
intracranial disease of major artery disease t,C0752138
myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959;C0002962
duration of symptoms $nmbr$ min,C0436359;C0702093;C1524029;C3813700
smoking in the past year,C0037369;C0453996;C1881674
none n $nmbr$,C0369718;C0441922
ica stenosis $nmbr$ $nmbr$ f,C0201519;C0016327
$nmbr$ $nmbr$ week n $nmbr$,C0332174;C0439230
irregular or ulcerated ica plaquef,C0205271;C0041582;C0201519;C3887532
$nmbr$ $nmbr$ week n $nmbr$ $nmbr$ $nmbr$ week n $nmbr$,C0332174;C0439230
infarct on brain imaging^,C0021308;C0203860
$nmbr$ week n $nmbr$,C0332174;C0439230
intracranial disease of major artery disease t,C0752138
age years s d,C1510829
duration of symptoms $nmbr$ min,C0436359;C0702093;C1524029;C3813700
x $nmbr$ n,
none n $nmbr$,C0369718;C0441922
female n,C0043210;C0086287;C1705497;C1705498
$nmbr$ $nmbr$ week n $nmbr$,C0332174;C0439230
white n,C0007457;C0043157;C0220938
$nmbr$ $nmbr$ week n $nmbr$ $nmbr$ $nmbr$ week n $nmbr$,C0332174;C0439230
black n,C0005680;C0027567;C0085756;C0439541
$nmbr$ week n $nmbr$,C0332174;C0439230
hispanic n,C0086409
age years s d,C1510829
asian n,C0078988
x $nmbr$ n,
other race n,C0034510;C1706779;C3853635
female n,C0043210;C0086287;C1705497;C1705498
cigarette smoking n,C0239059;C0700219
white n,C0007457;C0043157;C0220938
never,C2003901
black n,C0005680;C0027567;C0085756;C0439541
previous smokers,C0337671
hispanic n,C0086409
$nmbr$ $nmbr$ day,C0332173;C0439228;C0439505
asian n,C0078988
$nmbr$ day,C0332173;C0439228;C0439505
other race n,C0034510;C1706779;C3853635
exercise n,C0015259;C1522704
cigarette smoking n,C0239059;C0700219
none,
never,C2003901
p $nmbr$ min twice week,C0332174;C0439230
previous smokers,C0337671
$nmbr$ min twice week,C0332174;C0439230
$nmbr$ $nmbr$ day,C0332173;C0439228;C0439505
enoxaparin n $nmbr$,C0206460
$nmbr$ day,C0332173;C0439228;C0439505
unfractionated heparin n $nmbr$,C0019134;C2825026
exercise n,C0015259;C1522704
age median iqr y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
none,
female sex no total,C0086287;C0439175;C0439810
p $nmbr$ min twice week,C0332174;C0439230
region no total,C0017446;C0205147;C0439175;C0439810
$nmbr$ min twice week,C0332174;C0439230
austral ia new zealand,C0027978;C0324547
enoxaparin n $nmbr$,C0206460
europe,C0015176
unfractionated heparin n $nmbr$,C0019134;C2825026
north america,C0028405
age median iqr y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
south america,C0037713
female sex no total,C0086287;C0439175;C0439810
race no total,C0034510;C1706779;C3853635;C0439175;C0439810
region no total,C0017446;C0205147;C0439175;C0439810
american indian,C0002460
austral ia new zealand,C0027978;C0324547
pacific islander,C0242191
europe,C0015176
clinical variables median iqr,C0205210;C0439828
north america,C0028405
medical history and risk factors no total,C0262926;C1704706;C0035648;C1553898;C0439175;C0439810
south america,C0037713
killip class $nmbr$,C1881332
race no total,C0034510;C1706779;C3853635;C0439175;C0439810
ii,
american indian,C0002460
iii,C0439070;C1705160
pacific islander,C0242191
iv,C0022326;C4265176
clinical variables median iqr,C0205210;C0439828
prior angina,C0332152;C0002962;C2826257
medical history and risk factors no total,C0262926;C1704706;C0035648;C1553898;C0439175;C0439810
prior infarction,C0332152;C0021308;C2826257
killip class $nmbr$,C1881332
prior oabg surgery,C0455610
ii,
prior pci,C0332152;C4049621;C2826257
iii,C0439070;C1705160
g $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439267
iv,C0022326;C4265176
prior congestive heart failure,C0332152;C0018802;C2826257
prior angina,C0332152;C0002962;C2826257
prior stroke,C0038454;C4554100
prior infarction,C0332152;C0021308;C2826257
prior oabg surgery,C0455610
history of peripheral vascular disease,C1881056
current,C0521116;C1705970
prior pci,C0332152;C4049621;C2826257
previous,C0205156;C1552607
g $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439267
prior congestive heart failure,C0332152;C0018802;C2826257
family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
prior stroke,C0038454;C4554100
time from symptom onset to enrollment,C0449244;C1516879;C1696073;C3888021
median iqr h,C0033727;C0369286;C0441932;C0564385;C4528284
history of peripheral vascular disease,C1881056
time from hospital admission to enrollment,C3854258;C3854259;C1516879;C1696073;C3888021
current,C0521116;C1705970
niacin n $nmbr$,C0027996;C1142562
previous,C0205156;C1552607
p,C0369773;C2603361
family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
male gender n,C0086582;C1706180
time from symptom onset to enrollment,C0449244;C1516879;C1696073;C3888021
age mean sd,C0001779;C2699239
median iqr h,C0033727;C0369286;C0441932;C0564385;C4528284
type $nmbr$ diabetes mellitus n,C1320657
time from hospital admission to enrollment,C3854258;C3854259;C1516879;C1696073;C3888021
hypertension n,C0020538;C1963138
niacin n $nmbr$,C0027996;C1142562
tobacco use n,C0040335;C0543414;C0841002;C3853727
p,C0369773;C2603361
family history ot chd n,C0241889;C0280604;C3542407
male gender n,C0086582;C1706180
metabolic syndrome n,C0524620
age mean sd,C0001779;C2699239
history ot chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
type $nmbr$ diabetes mellitus n,C1320657
ml,C0439526;C1705224;C3887665
hypertension n,C0020538;C1963138
percutaneous coronary revascularization,C1532338
tobacco use n,C0040335;C0543414;C0841002;C3853727
cabg,C0010055
family history ot chd n,C0241889;C0280604;C3542407
angina with documented ischemia,C0002962;C0022116;C4321499
metabolic syndrome n,C0524620
medications n,C0013227;C0802604;C2598133;C4284232
history ot chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ blocker,
ml,C0439526;C1705224;C3887665
angiotensin converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
percutaneous coronary revascularization,C1532338
vitamin e,C0042874;C3714803
cabg,C0010055
vitamin c,C0003968;C2349136;C3714687;C4522080
angina with documented ischemia,C0002962;C0022116;C4321499
medications n,C0013227;C0802604;C2598133;C4284232
figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus,C0392747;C0443172;C1705241;C4319952;C0439231;C0030705;C0332293;C0032042;C1696465;C1706408;C0027996;C1142562;C0332197;C1689985;C1320657
$nmbr$ blocker,
angiotensin converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol,C1504308;C1742862;C2349179;C2826544;C1709595;C1532737;C2349200;C4522255;C0074554;C0449450;C2985777;C0237753;C0449788;C0552369
vitamin e,C0042874;C3714803
normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^,C0205307;C0231683;C0439166;C2347086;C4553972;C1417190;C3815103
vitamin c,C0003968;C2349136;C3714687;C4522080
mild decrease in gfr $nmbr$ $nmbr$ ml mln per $nmbr$ $nmbr$ m^,C0392756;C0547047
figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus,C0392747;C0443172;C1705241;C4319952;C0439231;C0030705;C0332293;C0032042;C1696465;C1706408;C0027996;C1142562;C0332197;C1689985;C1320657
moderate or severe decrease in gfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0392756;C0547047
$nmbr$ chlorthalidone,C0008294
amlodipine,C0051696
figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol,C1504308;C1742862;C2349179;C2826544;C1709595;C1532737;C2349200;C4522255;C0074554;C0449450;C2985777;C0237753;C0449788;C0552369
ii lisinopril i,C0021966;C0221138
normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^,C0205307;C0231683;C0439166;C2347086;C4553972;C1417190;C3815103
chlorthalidone,C0008294
mild decrease in gfr $nmbr$ $nmbr$ ml mln per $nmbr$ $nmbr$ m^,C0392756;C0547047
ii lisinopril,C1710602;C0065374;C4082587
moderate or severe decrease in gfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0392756;C0547047
$nmbr$ lisinopril,C0065374
$nmbr$ chlorthalidone,C0008294
no randomized,C0034656;C3815594
amlodipine,C0051696
age mean sd y ethnicity no,C0015031;C0243103
ii lisinopril i,C0021966;C0221138
biack non hispanic,C1518424
chlorthalidone,C0008294
biack hispanic,C0086409
ii lisinopril,C1710602;C0065374;C4082587
bmi mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ lisinopril,C0065374
no randomized,C0034656;C3815594
baseline systolic blood pressure mean sd mm hg,C4274438;C0439475
age mean sd y ethnicity no,C0015031;C0243103
baseline diastolic blood pressure mean sd mm hg,C4274392;C0439475
biack non hispanic,C1518424
history of coronary heart disease no,C0683519;C0730226;C0850708;C0944983
biack hispanic,C0086409
estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^,C0017654;C0444504;C2347634;C2348143;C1424601
bmi mean sd,C0444504;C2699239;C2347634;C2348143
eligibility risk factors no t,C0035648;C1553898;C2603360
baseline systolic blood pressure mean sd mm hg,C4274438;C0439475
current cigarette smoking,C0239059;C0700219
baseline diastolic blood pressure mean sd mm hg,C4274392;C0439475
atherosclerotic cardiovascular disease,C0004153
history of coronary heart disease no,C0683519;C0730226;C0850708;C0944983
history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^,C0017654;C0444504;C2347634;C2348143;C1424601
st segment depression or t wave inversion on ecg,C0520887;C0520888
eligibility risk factors no t,C0035648;C1553898;C2603360
type $nmbr$ diabetes meiiitus,C1320657
current cigarette smoking,C0239059;C0700219
low hdl c,C0151691
atherosclerotic cardiovascular disease,C0004153
lvh by ecg,C0232306
history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
lvh by echocardiography,C0149721;C0013516
st segment depression or t wave inversion on ecg,C0520887;C0520888
total no of events total no of participants,C0439175;C0439810;C0679646
type $nmbr$ diabetes meiiitus,C1320657
mean se $nmbr$ year rates per $nmbr$ population,C0871208;C1521828
low hdl c,C0151691
rr $nmbr$ cl [ value],C4554402;C0596019;C1522609
$nmbr$ chlorthalidone amlodipine,C0008294;C0051696
lvh by ecg,C0232306
lisinopril,C0065374
lvh by echocardiography,C0149721;C0013516
ii chiorthaiidone amiodipine,C1710602;C4082587
total no of events total no of participants,C0439175;C0439810;C0679646
ii $nmbr$ amlodipine lisinopril chlorthalidone chlorthalidone,C0051696;C0008294
mean se $nmbr$ year rates per $nmbr$ population,C0871208;C1521828
total by baseline diabetic status,C0439175;C0439810
rr $nmbr$ cl [ value],C4554402;C0596019;C1522609
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
$nmbr$ chlorthalidone amlodipine,C0008294;C0051696
diabetic participants,C0241863;C0679646
lisinopril,C0065374
nondiabetic participants,C0679646
ii chiorthaiidone amiodipine,C1710602;C4082587
by gfr stratum for all participants ml min per $nmbr$ $nmbr$ m,C0017654;C0439445;C1424601
ii $nmbr$ amlodipine lisinopril chlorthalidone chlorthalidone,C0051696;C0008294
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
total by baseline diabetic status,C0439175;C0439810
by gfr stratum for diabetic participants mt min per $nmbr$ $nmbr$ m,C0017654;C0241863;C1424601
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
diabetic participants,C0241863;C0679646
total no of events of participants total no of participants,C0439175;C0439810;C0679646
nondiabetic participants,C0679646
rr $nmbr$ aci [p value],C0814206;C1510682;C2346870;C4050575;C1709380
by gfr stratum for all participants ml min per $nmbr$ $nmbr$ m,C0017654;C0439445;C1424601
$nmbr$ amlodipine chlorthalidone,C0051696;C0008294
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
$nmbr$ lisinopril chlorthalidone,C0065374;C0008294
by gfr stratum for diabetic participants mt min per $nmbr$ $nmbr$ m,C0017654;C0241863;C1424601
total,C0439175;C0439810
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
total no of events of participants total no of participants,C0439175;C0439810;C0679646
by baseline diabetic status,C0168634;C0449438;C1442488
rr $nmbr$ aci [p value],C0814206;C1510682;C2346870;C4050575;C1709380
by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^,C0076836;C1199517;C1419603;C3539732;C0679646;C0439445
$nmbr$ amlodipine chlorthalidone,C0051696;C0008294
by gfr stratum tor diabetic participants ml min per $nmbr$ $nmbr$ m,C0017654;C0439445;C1424601
$nmbr$ lisinopril chlorthalidone,C0065374;C0008294
vertebral fracture and or t score s $nmbr$ $nmbr$,C0080179;C0718146
total,C0439175;C0439810
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
vertebral fracture and or t score $nmbr$ $nmbr$,C0080179;C3854607
alendronate n $nmbr$,C0102118
by baseline diabetic status,C0168634;C0449438;C1442488
mean age years,C0444504;C1510829;C2347634;C2348143
by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^,C0076836;C1199517;C1419603;C3539732;C0679646;C0439445
mean years since menopause,C0439234;C0025320;C0567312
by gfr stratum tor diabetic participants ml min per $nmbr$ $nmbr$ m,C0017654;C0439445;C1424601
mean femoral neck t score,C3533236;C0015815
vertebral fracture and or t score s $nmbr$ $nmbr$,C0080179;C0718146
mean lumbar spine t score,C3533236;C0024091;C3887615
vertebral fracture and or t score $nmbr$ $nmbr$,C0080179;C3854607
$nmbr$ $nmbr$ q $nmbr$,
alendronate n $nmbr$,C0102118
number of prevalent vertebral fractures,C0237753;C0449788
mean age years,C0444504;C1510829;C2347634;C2348143
$nmbr$ or more,
mean years since menopause,C0439234;C0025320;C0567312
history of falls in year before randomization,C1561668;C2919132;C0439234;C0439508
mean femoral neck t score,C3533236;C0015815
prior clinical fracture since age $nmbr$,C0016658;C0001779
mean lumbar spine t score,C3533236;C0024091;C3887615
age group,C0027362;C2348001
$nmbr$ $nmbr$ q $nmbr$,
hip,C0019552;C0022122;C1505163;C3538851;C4284725
number of prevalent vertebral fractures,C0237753;C0449788
spine,C0037949;C2752558
$nmbr$ or more,
wrist,C0043262;C1322271
history of falls in year before randomization,C1561668;C2919132;C0439234;C0439508
hip wrist or spine,C0043262;C1322271;C0037949;C2752558
prior clinical fracture since age $nmbr$,C0016658;C0001779
alendronate,C0102118
age group,C0027362;C2348001
$nmbr$ to,
hip,C0019552;C0022122;C1505163;C3538851;C4284725
sdc $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C1419891;C0439275;C3273112
spine,C0037949;C2752558
race non white,C0007457;C0043157;C0220938
wrist,C0043262;C1322271
previous digoxin use,C0042153;C0457083;C1947944
hip wrist or spine,C0043262;C1322271;C0037949;C2752558
previous mi,C0205156;C3810814;C1552607
alendronate,C0102118
current angina,C0521116;C0002962;C1705970
$nmbr$ to,
ischemic etiology,C0015127;C1314792;C1524003
sdc $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C1419891;C0439275;C3273112
nyha functional class,C1882083;C0205245;C0542341;C2700217
race non white,C0007457;C0043157;C0220938
i,C0021966;C0221138
previous digoxin use,C0042153;C0457083;C1947944
ace inhibitor,C0003015;C4541021
previous mi,C0205156;C3810814;C1552607
diuretic,C0012798
current angina,C0521116;C0002962;C1705970
nitrate,C0028125;C0699857;C3848573
ischemic etiology,C0015127;C1314792;C1524003
vasodilator therapy,C0039798;C0087111;C1363945
nyha functional class,C1882083;C0205245;C0542341;C2700217
lvef u,C0428772;C0439148;C0488728
i,C0021966;C0221138
duration of chf months,C0449238;C2926735
ace inhibitor,C0003015;C4541021
sbp mm hg,C0085805;C0439475
diuretic,C0012798
dbp mm hg,C0536221;C0439475;C3813197;C4281799
nitrate,C0028125;C0699857;C3848573
ct ratio,C0456603;C1547037
vasodilator therapy,C0039798;C0087111;C1363945
chf score u,C0018802;C0439148
lvef u,C0428772;C0439148;C0488728
egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
duration of chf months,C0449238;C2926735
sdc ng ml,C1419891;C0439275;C3273112
sbp mm hg,C0085805;C0439475
na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
dbp mm hg,C0536221;C0439475;C3813197;C4281799
time sample drawn h,C0033727;C0369286;C0441932;C0564385;C4528284
ct ratio,C0456603;C1547037
lrg,C1428862
chf score u,C0018802;C0439148
hrg,C1437978;C1705020
egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
losartan,C0126174
sdc ng ml,C1419891;C0439275;C3273112
atenolol,C0004147
na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
ns,C0038944;C1112705;C1705982
time sample drawn h,C0033727;C0369286;C0441932;C0564385;C4528284
sex women n [ ],C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
lrg,C1428862
race white n [ ],C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
hrg,C1437978;C1705020
heart rate min $nmbr$,C0702093;C1524029;C3813700
losartan,C0126174
cornell voltage duration mv ms,C2349943;C3539704;C3713294
atenolol,C0004147
sokolow lyon voltage mv,C1454484;C1705503;C4281602
ns,C0038944;C1112705;C1705982
smoking,C0037369;C0453996;C1881674
sex women n [ ],C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
serum glucose mmol l,C0202041;C1532563;C3534430
race white n [ ],C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
total cholesterol mmol l,C0201950;C1532563;C0543421
heart rate min $nmbr$,C0702093;C1524029;C3813700
hdl cholesterol mmol l,C0023822;C1532563;C0392885
cornell voltage duration mv ms,C2349943;C3539704;C3713294
sokolow lyon voltage mv,C1454484;C1705503;C4281602
serum creatinine mmol l,C0201976;C1532563;C0600061
smoking,C0037369;C0453996;C1881674
urine albumin creatinine mg mmol,C0567349;C2348885
serum glucose mmol l,C0202041;C1532563;C3534430
bp component mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
sbp baseline,C0168634;C1442488
total cholesterol mmol l,C0201950;C1532563;C0543421
sbp last,C0085805
hdl cholesterol mmol l,C0023822;C1532563;C0392885
sbp difference,C1705241;C1705242
serum creatinine mmol l,C0201976;C1532563;C0600061
difference in sbp between treatment,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
urine albumin creatinine mg mmol,C0567349;C2348885
mean arterial pressure baseline,C0443150
bp component mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
mean arterial pressure last,C0428886
sbp baseline,C0168634;C1442488
mean arterial pressure difference,C0563547
sbp last,C0085805
end point,C2349179;C2826544
sbp difference,C1705241;C1705242
higher risk n $nmbr$,C0332167;C3272283;C4050568;C4319571
difference in sbp between treatment,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
lower risk n $nmbr$,C3272281;C3538919
mean arterial pressure baseline,C0443150
adjusted hr,C0456081
mean arterial pressure last,C0428886
unadjusted hr,C1439367
mean arterial pressure difference,C0563547
$nmbr$ ci,C0008107;C3259781
end point,C2349179;C2826544
primary composite end point,C2986535;C0205199;C1547335
higher risk n $nmbr$,C0332167;C3272283;C4050568;C4319571
components,C0449432
lower risk n $nmbr$,C3272281;C3538919
other prespecified end points,C2349179
adjusted hr,C0456081
hospitalization for,C0019993
unadjusted hr,C1439367
sudden cardiac death,C0085298
$nmbr$ ci,C0008107;C3259781
new onset atrial fibrillation,C0741281
primary composite end point,C2986535;C0205199;C1547335
endpoint,C2349179;C2826544
components,C0449432
pvalue,
other prespecified end points,C2349179
primary composite endpoint,C2986535;C0205199;C1547335
hospitalization for,C0019993
demographic and clinical,C0011298;C0205210
sudden cardiac death,C0085298
cornell voltage duration product mm ms,C2349943;C3539704;C3713294
new onset atrial fibrillation,C0741281
medical history n,C0262926;C1704706
endpoint,C2349179;C2826544
pvalue,
any vascular disease,C0042373
isolated systolic hypertension,C0745133
primary composite endpoint,C2986535;C0205199;C1547335
with aspirin n $nmbr$ $nmbr$,C0004057
demographic and clinical,C0011298;C0205210
without aspirin n $nmbr$ $nmbr$,C0004057
cornell voltage duration product mm ms,C2349943;C3539704;C3713294
sys ns dia,C0038944;C1706546;C1112705;C1705982
medical history n,C0262926;C1704706
pioglitazone n $nmbr$,C0071097
any vascular disease,C0042373
patients characteristics,C0815172
isolated systolic hypertension,C0745133
age years mean sd,C1510829;C2699239
with aspirin n $nmbr$ $nmbr$,C0004057
time since diagnosis of diabetes years median iqr,C0556970;C0011847;C0011849
without aspirin n $nmbr$ $nmbr$,C0004057
body mass index kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
sys ns dia,C0038944;C1706546;C1112705;C1705982
pioglitazone n $nmbr$,C0071097
blood pressure systolic diastolic mm hg mean sd,C0428886;C2699239
patients characteristics,C0815172
past smoker,C0337664
age years mean sd,C1510829;C2699239
microvascular disease,C0443258;C0012634
time since diagnosis of diabetes years median iqr,C0556970;C0011847;C0011849
blood glucose lowering treatment,C0005802;C0441994;C2003888;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
body mass index kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
metformin only,C0025598
sulphonylureas only,C0038766
blood pressure systolic diastolic mm hg mean sd,C0428886;C2699239
metformin sulphonylureas,C0025598;C0038766
past smoker,C0337664
insulin only,C0021641;C1533581;C1579433;C3714501
microvascular disease,C0443258;C0012634
insulin metformin,C0021641;C0025598;C1533581;C1579433;C3714501
blood glucose lowering treatment,C0005802;C0441994;C2003888;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
insulin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
metformin only,C0025598
insulin metformin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
sulphonylureas only,C0038766
other combination,C0205195;C1947911;C3811910
metformin sulphonylureas,C0025598;C0038766
diet only,C0012155;C0012159;C1519433;C2983588;C3668949
insulin only,C0021641;C1533581;C1579433;C3714501
laboratory data,C1511726;C3245479;C3714741
insulin metformin,C0021641;C0025598;C1533581;C1579433;C3714501
hba $nmbr$ c median iqr,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
insulin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
ldl cholesterol mmol l median iqr,C0023824;C0202117
insulin metformin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ s,
other combination,C0205195;C1947911;C3811910
hdl cholesterol mmol l median iqr,C0023822;C0392885
diet only,C0012155;C0012159;C1519433;C2983588;C3668949
triglycerides mmol l median iqr,C0041004;C1532563
laboratory data,C1511726;C3245479;C3714741
creatinine ^mol l median iqr,C0010294;C0347982;C1561535
hba $nmbr$ c median iqr,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
micral test result,C0456984;C0587081
ldl cholesterol mmol l median iqr,C0023824;C0202117
negative,C0205160;C1513916;C2825415;C2825491;C3853545
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ s,
about $nmbr$ mg l,C0439268
hdl cholesterol mmol l median iqr,C0023822;C0392885
about $nmbr$ mg l or more,C0439268
triglycerides mmol l median iqr,C0041004;C1532563
creatinine ^mol l median iqr,C0010294;C0347982;C1561535
figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d,C0439165;C1549488;C1561533;C0008976;C1096775;C0441833;C1706365;C1999270;C0544452;C0687702;C0545082;C1512346;C2826704;C0332174;C0441837;C0439230
micral test result,C0456984;C0587081
a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown,C0871261;C1704632;C1706817;C2911692;C1704788;C3539106;C0168634;C1442488;C0011198;C0017480;C3541240;C0205232;C0687757;C0449820;C4050231;C0237881;C0750502;C1546944;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1547282
negative,C0205160;C1513916;C2825415;C2825491;C3853545
clopidogrel n $nmbr$ $nmbr$,C0070166
about $nmbr$ mg l,C0439268
placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
about $nmbr$ mg l or more,C0439268
age at entry years,C1510829;C1705654
figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d,C0439165;C1549488;C1561533;C0008976;C1096775;C0441833;C1706365;C1999270;C0544452;C0687702;C0545082;C1512346;C2826704;C0332174;C0441837;C0439230
mean sd,C0444504;C2699239;C2347634;C2348143
sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown,C0871261;C1704632;C1706817;C2911692;C1704788;C3539106;C0168634;C1442488;C0011198;C0017480;C3541240;C0205232;C0687757;C0449820;C4050231;C0237881;C0750502;C1546944;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1547282
time since onset h,C0449244;C0033727;C0369286;C0441932;C0564385;C4528284
clopidogrel n $nmbr$ $nmbr$,C0070166
placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
age at entry years,C1510829;C1705654
ecg abnormality at entry,C1623258;C1704258
mean sd,C0444504;C2699239;C2347634;C2348143
st elevation,C0520886
sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
bundle branch block,C0006384;C1879286
time since onset h,C0449244;C0033727;C0369286;C0441932;C0564385;C4528284
st depression without st elevation,C0520887
killip class,C1881332
systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
ii or iii,C0439070;C1705160
ecg abnormality at entry,C1623258;C1704258
previous disease and drug use,C0205156;C0012634;C1552607;C0242510
st elevation,C0520886
previous hypertension,C0020538;C1963138
bundle branch block,C0006384;C1879286
aspirin before admission,C0004057;C0184666;C0809949
st depression without st elevation,C0520887
$nmbr$ blocker before admission,C0184666;C0809949
killip class,C1881332
fibrinolytic agent before randomisation,C0016018;C0034656
ii or iii,C0439070;C1705160
non trial treatment during hospital stay,C0019948;C3166479
previous disease and drug use,C0205156;C0012634;C1552607;C0242510
non trial antiplatelet,C1518422;C0008976
previous hypertension,C0020538;C1963138
fibrinolytic agents before or after entry,C0016018;C1705654
aspirin before admission,C0004057;C0184666;C0809949
anticoagulant,C0003280;C0848112;C3536711
$nmbr$ blocker before admission,C0184666;C0809949
antiarrhythmic,C0003195;C3537142
fibrinolytic agent before randomisation,C0016018;C0034656
nitrate oral or intravenous,C0442027;C4521986;C0348016
non trial treatment during hospital stay,C0019948;C3166479
calcium antagonist,C0006684
non trial antiplatelet,C1518422;C0008976
metoprolol n $nmbr$ $nmbr$,C0025859
fibrinolytic agents before or after entry,C0016018;C1705654
ai $nmbr$,C0003504;C4551710
anticoagulant,C0003280;C0848112;C3536711
p blocker before admission,C0369773;C0184666;C0809949;C2603361
antiarrhythmic,C0003195;C3537142
non trial p blocker,C1518422;C0008976
nitrate oral or intravenous,C0442027;C4521986;C0348016
score $nmbr$ $nmbr$,C0449820;C4050231
calcium antagonist,C0006684
mfns n $nmbr$,
metoprolol n $nmbr$ $nmbr$,C0025859
mean age y range,C1514721;C2348147;C3542016
ai $nmbr$,C0003504;C4551710
gender male,C0086582;C1706180;C1706428;C1706429
p blocker before admission,C0369773;C0184666;C0809949;C2603361
mean baseline nasal congestion score,C3533236;C0027424;C4554631
non trial p blocker,C1518422;C0008976
tenecteplase and pci n $nmbr$,C0872913;C4049621
score $nmbr$ $nmbr$,C0449820;C4050231
pci alone n $nmbr$,C0205171;C0439044;C0679994
mfns n $nmbr$,
age $nmbr$ years,C1510829
mean age y range,C1514721;C2348147;C3542016
height cm,C0489786
gender male,C0086582;C1706180;C1706428;C1706429
ii iii,C0439070;C1705160
mean baseline nasal congestion score,C3533236;C0027424;C4554631
congestive heart failure at randomisation,C0018802;C0034656
tenecteplase and pci n $nmbr$,C0872913;C4049621
infarct location,C0450429;C1515974;C4284930;C4284931
pci alone n $nmbr$,C0205171;C0439044;C0679994
previous infarction,C0205156;C0021308;C1552607
age $nmbr$ years,C1510829
previous congestive heart failure,C0205156;C0018802;C1552607
height cm,C0489786
previous pci,C0205156;C4049621;C1552607
ii iii,C0439070;C1705160
previous coronary artery bypass graft,C2144990
congestive heart failure at randomisation,C0018802;C0034656
outcome,C1274040
infarct location,C0450429;C1515974;C4284930;C4284931
glucosamine,C0017718
previous infarction,C0205156;C0021308;C1552607
chondroitin sulfate,C0008466
previous congestive heart failure,C0205156;C0018802;C1552607
glucosamine chondroitin sulfate,C0017720
previous pci,C0205156;C4049621;C1552607
celecoxib,C0538927
previous coronary artery bypass graft,C2144990
all randomized patients,C0034656;C0030705;C3815594
outcome,C1274040
no of patients,C0030705
glucosamine,C0017718
primary outcome $nmbr$ decrease in womac pain score,C0392756;C0547047
chondroitin sulfate,C0008466
at end of follow up no,C0444930;C2746065
glucosamine chondroitin sulfate,C0017720
$nmbr$ $nmbr$ j,
celecoxib,C0538927
secondary outcomes,C0027627;C1274040;C0175668;C0205436
all randomized patients,C0034656;C0030705;C3815594
omeract oarsi response,C0871261;C1704632;C1706817;C2911692
no of patients,C0030705
$nmbr$ decrease in womac pain score,C0392756;C0547047
primary outcome $nmbr$ decrease in womac pain score,C0392756;C0547047
womac pain score,C0582148
at end of follow up no,C0444930;C2746065
change from baseline,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ j,
at end of follow up,C0444930;C2746065
secondary outcomes,C0027627;C1274040;C0175668;C0205436
womac stiffness score,C0449820;C4050231
omeract oarsi response,C0871261;C1704632;C1706817;C2911692
womac function score,C0449820;C4050231
$nmbr$ decrease in womac pain score,C0392756;C0547047
normalized womac score,C0449820;C4050231
womac pain score,C0582148
haq alternative disability score,C0449820;C4050231
change from baseline,C0392747;C0443172;C1705241;C4319952
haq pain score,C0102923;C0582148;C0451208
at end of follow up,C0444930;C2746065
patient s global assessment of response to therapy score,C0030705;C0281858;C0871261;C1704632;C1706817;C2911692;C0449820;C4050231
womac stiffness score,C0449820;C4050231
patient s global assessment of disease status score,C0030705;C0281858;C3176928
womac function score,C0449820;C4050231
normalized womac score,C0449820;C4050231
physician s global assessment of disease status score,C0031831;C0804815;C0281858;C3176928
haq alternative disability score,C0449820;C4050231
joint swelling effusion or both on clinical examination,C1253936;C1963136;C4554335;C0031809
haq pain score,C0102923;C0582148;C0451208
at baseline no,C0168634;C1442488
patient s global assessment of response to therapy score,C0030705;C0281858;C0871261;C1704632;C1706817;C2911692;C0449820;C4050231
at end of follow up no total no,C0444930;C2746065;C0439175;C0439810
patient s global assessment of disease status score,C0030705;C0281858;C3176928
no of $nmbr$ mg tablets of acetaminophen,C0024671;C1243102;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
physician s global assessment of disease status score,C0031831;C0804815;C0281858;C3176928
patients with moderate to severe pain womac pain score $nmbr$ $nmbr$,C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0582148
joint swelling effusion or both on clinical examination,C1253936;C1963136;C4554335;C0031809
no of $nmbr$ mg acetaminophen tablets day,C0439422;C1243102
at baseline,C0168634;C1442488
at baseline no,C0168634;C1442488
at end of follow up no total no,C0444930;C2746065;C0439175;C0439810
patients with mild pain womac pain score $nmbr$ $nmbr$,C0030705;C0278138;C4522280
baseline characteristic,C0168634;C1521970;C1442488
no of $nmbr$ mg tablets of acetaminophen,C0024671;C1243102;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mtx plus placebo,C0025677;C1417487
patients with moderate to severe pain womac pain score $nmbr$ $nmbr$,C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0582148
mtx plus infliximab,C0025677;C1417487
no of $nmbr$ mg acetaminophen tablets day,C0439422;C1243102
coefficient,C1707429
at baseline,C0168634;C1442488
swollen joint count $nmbr$ $nmbr$,C0451521
patients with mild pain womac pain score $nmbr$ $nmbr$,C0030705;C0278138;C4522280
tender joint count $nmbr$ $nmbr$,C0451530
baseline characteristic,C0168634;C1521970;C1442488
rf mg dl,C0035448;C0439269;C0201660;C0748398;C1547111
mtx plus placebo,C0025677;C1417487
crp mg dl,C3890735;C0439269;C4048285
mtx plus infliximab,C0025677;C1417487
esr mm hour,C0439227;C0564385
coefficient,C1707429
baseline shs $nmbr$ $nmbr$,C0168634;C1442488
swollen joint count $nmbr$ $nmbr$,C0451521
j $nmbr$ coefficient,C1707429
tender joint count $nmbr$ $nmbr$,C0451530
or $nmbr$ ci,C0008107;C3259781
rf mg dl,C0035448;C0439269;C0201660;C0748398;C1547111
age per $nmbr$ years,C1510829
crp mg dl,C3890735;C0439269;C4048285
sex male,C0086582
esr mm hour,C0439227;C0564385
swollen joint count $nmbr$ $nmbr$ per swollen joint,C0451521;C0152031;C4554794;C4696257
baseline shs $nmbr$ $nmbr$,C0168634;C1442488
tender joint count $nmbr$ $nmbr$ per tender joint,C0451530;C0240094;C4554549;C4696258
j $nmbr$ coefficient,C1707429
rf mg dl per unit,C0439269
or $nmbr$ ci,C0008107;C3259781
crp mg dl per unit,C0439269
age per $nmbr$ years,C1510829
esr mm hour per unit,C3811131;C0456685
sex male,C0086582
shs $nmbr$ $nmbr$ per $nmbr$ score,C0449820;C4050231
swollen joint count $nmbr$ $nmbr$ per swollen joint,C0451521;C0152031;C4554794;C4696257
baseline inflammation markers,C0021368;C0005516
tender joint count $nmbr$ $nmbr$ per tender joint,C0451530;C0240094;C4554549;C4696258
changes in shs,C0392747;C0443172
rf mg dl per unit,C0439269
normal crp and,C3890735;C4048285
crp mg dl per unit,C0439269
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
esr mm hour per unit,C3811131;C0456685
esr,C3811131
shs $nmbr$ $nmbr$ per $nmbr$ score,C0449820;C4050231
high crp or esr,C3890735;C4048285;C3811131
baseline inflammation markers,C0021368;C0005516
high crp and esr,C3890735;C4048285;C3811131
changes in shs,C0392747;C0443172
figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231;C0332174;C0439230;C0681867;C1514756;C0666743;C3899278;C0008976
normal crp and,C3890735;C4048285
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group,C1547282;C0168634;C0201657;C1442488;C1176468;C1619634;C0441837;C0032042;C1696465;C1706408;C0025677;C0666743;C0072053
esr,C3811131
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C0008976;C4706353
high crp or esr,C3890735;C4048285;C3811131
high crp and esr,C3890735;C4048285;C3811131
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C3890735;C0441889;C4048285;C3811131;C0451521;C1510992;C2825518;C0008976
figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231;C0332174;C0439230;C0681867;C1514756;C0666743;C3899278;C0008976
crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups,C3890735;C3811131;C4048285;C0451521;C1510992;C2825518;C0008976;C0750572;C0017446;C0205146;C0025663;C0021966;C0221138;C0449851;C0871511;C0025677;C1417487;C1550452;C1704788;C3539107;C3888054;C0681841;C0374505
enoxaparin n $nmbr$ $nmbr$,C0206460
shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group,C1547282;C0168634;C0201657;C1442488;C1176468;C1619634;C0441837;C0032042;C1696465;C1706408;C0025677;C0666743;C0072053
fondaparinux n $nmbr$ $nmbr$,C1098510
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C0008976;C4706353
male sex no,C0086582
time from onset of pain to randomization hr,C0449244;C0034656
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C3890735;C0441889;C4048285;C3811131;C0451521;C1510992;C2825518;C0008976
diagnosis at study entry no,C1704656;C4068481
crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups,C3890735;C3811131;C4048285;C0451521;C1510992;C2825518;C0008976;C0750572;C0017446;C0205146;C0025663;C0021966;C0221138;C0449851;C0871511;C0025677;C1417487;C1550452;C1704788;C3539107;C3888054;C0681841;C0374505
unstable angina,C0002965
enoxaparin n $nmbr$ $nmbr$,C0206460
suspected myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
fondaparinux n $nmbr$ $nmbr$,C1098510
cabg or pci,C0010055;C4049621
male sex no,C0086582
current or former smoker,C0521116;C1705970;C0337671
time from onset of pain to randomization hr,C0449244;C0034656
any electrocardiographic abnormality no,C0522055
diagnosis at study entry no,C1704656;C4068481
st segment depression $nmbr$ mm no,C4330985;C4554674
unstable angina,C0002965
medications at the time of randomization no,C0013227;C0802604;C2598133;C4284232
suspected myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
clopidogrel or ticlopidine,C0070166;C0040207
cabg or pci,C0010055;C4049621
unfractionated heparin,C0019134;C2825026
current or former smoker,C0521116;C1705970;C0337671
low molecular weight heparin,C0019139;C3536766
any electrocardiographic abnormality no,C0522055
ace inhibitor or arb,C0003015;C4541021;C3888198
st segment depression $nmbr$ mm no,C4330985;C4554674
beta blocker,C0001645
medications at the time of randomization no,C0013227;C0802604;C2598133;C4284232
calcium channel blocker,C0006684;C3536851;C4521885
clopidogrel or ticlopidine,C0070166;C0040207
lipid lowering agent,C0086440
unfractionated heparin,C0019134;C2825026
medications in the hospital after randomization no,C0013227;C0802604;C2598133;C4284232;C0034656
low molecular weight heparin,C0019139;C3536766
procedures in the hospital no,C0025664;C0184661;C2700391;C3538935
ace inhibitor or arb,C0003015;C4541021;C3888198
coronary angiography,C0085532;C1548829
beta blocker,C0001645
pci,C4049621
calcium channel blocker,C0006684;C3536851;C4521885
procedures after discharge no,C0012621;C0030685;C2926602
lipid lowering agent,C0086440
panel a,C0441833;C1706365;C1999270
medications in the hospital after randomization no,C0013227;C0802604;C2598133;C4284232;C0034656
no of,
procedures in the hospital no,C0025664;C0184661;C2700391;C3538935
percentage of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
coronary angiography,C0085532;C1548829
interaction p value,C1704675;C1709380
pci,C4049621
enoxaparin,C0206460
procedures after discharge no,C0012621;C0030685;C2926602
fondaparinux,C1098510
panel a,C0441833;C1706365;C1999270
$nmbr$ yr,C0439234
no of,
creatinine,C0010294;C1561535
percentage of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
at or above median,C0549183;C0876920;C2347635;C2348144;C2939193
interaction p value,C1704675;C1709380
less than median,C0549183;C0876920;C2347635;C2348144;C2939193
enoxaparin,C0206460
heparin at randomization,C0019134;C0770546
fondaparinux,C1098510
yes,C1549445;C1705108;C1710701
$nmbr$ yr,C0439234
no,
creatinine,C0010294;C1561535
revascularization in $nmbr$ days,C0581603;C0439228
at or above median,C0549183;C0876920;C2347635;C2348144;C2939193
catheterization laboratory in center,C0007430;C0022877;C3244292;C4283904
less than median,C0549183;C0876920;C2347635;C2348144;C2939193
panel b,C0441833;C1706365;C1999270
heparin at randomization,C0019134;C0770546
percentage of p,C0439165;C1549488;C1561533
yes,C1549445;C1705108;C1710701
atients with event,C0441471;C4019010
no,
catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
revascularization in $nmbr$ days,C0581603;C0439228
center,C0205099;C3810851
catheterization laboratory in center,C0007430;C0022877;C3244292;C4283904
unfractionated heparin n $nmbr$ $nmbr$,C0019134;C2825026
panel b,C0441833;C1706365;C1999270
median,C0549183;C0876920;C2347635;C2348144;C2939193
percentage of p,C0439165;C1549488;C1561533
age $nmbr$ yr no,C0001779;C0439234
atients with event,C0441471;C4019010
white race no total no f,C0007457;C0043157;C0439175;C0439810;C0016327
catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
hypertension no total no,C0020538;C1963138;C0439175;C0439810
center,C0205099;C3810851
hyperlipidemia no total no,C0020473;C0428465;C4555212;C0439175;C0439810
unfractionated heparin n $nmbr$ $nmbr$,C0019134;C2825026
current smoker no total no,C3173209;C3241966;C0439175;C0439810
median,C0549183;C0876920;C2347635;C2348144;C2939193
diabetes mellitus no total no,C0011849;C0439175;C0439810
age $nmbr$ yr no,C0001779;C0439234
prior myocardial infarction no total no,C0027051;C0428953;C2926063;C3810814;C4552959;C0439175;C0439810
white race no total no f,C0007457;C0043157;C0439175;C0439810;C0016327
prior angina pectoris no total no,C0332152;C0002962;C2826257;C0439175;C0439810
hypertension no total no,C0020538;C1963138;C0439175;C0439810
prior percutaneous coronary intervention no total no,C0332152;C1532338;C2826257;C0439175;C0439810
hyperlipidemia no total no,C0020473;C0428465;C4555212;C0439175;C0439810
anterior myocardial infarction no total no,C0340293;C0439175;C0439810
current smoker no total no,C3173209;C3241966;C0439175;C0439810
long term treatment with aspirin no total no,C0023977;C0004057;C0439175;C0439810
diabetes mellitus no total no,C0011849;C0439175;C0439810
unfractionated heparin within $nmbr$ hr before randomization no total no,C0019134;C2825026;C0034656;C0439175;C0439810
prior myocardial infarction no total no,C0027051;C0428953;C2926063;C3810814;C4552959;C0439175;C0439810
lmwh within $nmbr$ days before randomization no total no,C0019139;C3536766;C0034656;C0439175;C0439810
prior angina pectoris no total no,C0332152;C0002962;C2826257;C0439175;C0439810
creatinine clearance ml min,C0812399;C0439445
prior percutaneous coronary intervention no total no,C0332152;C1532338;C2826257;C0439175;C0439810
killip class no i,C1881332;C0021966;C0221138
anterior myocardial infarction no total no,C0340293;C0439175;C0439810
data missing,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743
long term treatment with aspirin no total no,C0023977;C0004057;C0439175;C0439810
timi risk score no total no c,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810
unfractionated heparin within $nmbr$ hr before randomization no total no,C0019134;C2825026;C0034656;C0439175;C0439810
time from symptom onset to start of fibrinolytic therapy hr,C0449244;C0439659;C0040044
lmwh within $nmbr$ days before randomization no total no,C0019139;C3536766;C0034656;C0439175;C0439810
fibrinolytic therapy no,C0040044
creatinine clearance ml min,C0812399;C0439445
tenecteplase,C0872913
killip class no i,C1881332;C0021966;C0221138
alteplase,C0032143
data missing,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743
reteplase,C0256103
timi risk score no total no c,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810
streptokinase,C0038418
time from symptom onset to start of fibrinolytic therapy hr,C0449244;C0439659;C0040044
time from fibrinolytic therapy to study drug administration no total no,C0040223;C3541383;C0150270;C3469597;C0439175;C0439810
fibrinolytic therapy no,C0040044
$nmbr$ min,C0702093;C1524029;C3813700
tenecteplase,C0872913
$nmbr$ $nmbr$ min,C0702093;C1524029;C3813700
alteplase,C0032143
cardiac medications during index hospitalization no,C0013227;C0802604;C2598133;C4284232
reteplase,C0256103
clopidogrel,C0070166
streptokinase,C0038418
ace inhibitors or angiotensin receptor blockers,C0003015;C0521942;C0815017
time from fibrinolytic therapy to study drug administration no total no,C0040223;C3541383;C0150270;C3469597;C0439175;C0439810
statin,C0360714
$nmbr$ min,C0702093;C1524029;C3813700
baseline to year $nmbr$,C0168634;C1442488
$nmbr$ $nmbr$ min,C0702093;C1524029;C3813700
relative risk $nmbr$ cl,C0242492;C0596019
cardiac medications during index hospitalization no,C0013227;C0802604;C2598133;C4284232
age $nmbr$,C0001779
clopidogrel,C0070166
age a $nmbr$,C0001779
ace inhibitors or angiotensin receptor blockers,C0003015;C0521942;C0815017
non black,C0005680;C0027567;C0085756;C0439541
statin,C0360714
men,C0025266
baseline to year $nmbr$,C0168634;C1442488
diabetic,C0241863
relative risk $nmbr$ cl,C0242492;C0596019
non diabetic,C1518422;C0241863
age $nmbr$,C0001779
year $nmbr$,C0439234;C0439508
age a $nmbr$,C0001779
figure $nmbr$ subgroup analyses for primary outcome event,C2986480;C1624730
non black,C0005680;C0027567;C0085756;C0439541
estimated gfr at baseline ml min $nmbr$,C0017654;C1424601
men,C0025266
m $nmbr$,
diabetic,C0241863
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
non diabetic,C1518422;C0241863
$nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
year $nmbr$,C0439234;C0439508
female sex n of patients,C0086287
figure $nmbr$ subgroup analyses for primary outcome event,C2986480;C1624730
race white n of patients,C0007457;C0043157
estimated gfr at baseline ml min $nmbr$,C0017654;C1424601
medical history n of patients,C0262926
m $nmbr$,
history of diabetes,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
documented mi,C1301725;C3810814;C1609436
$nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
ptca,C2936173
female sex n of patients,C0086287
current cigarette n,C0521116;C0677453;C1704760;C3890423;C1705970
race white n of patients,C0007457;C0043157
mean blood pressure mm hg,C0428886;C0439475;C0488053
medical history n of patients,C0262926
laboratory determinations,C0022877;C0680730;C3244292;C4283904
history of diabetes,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean serum creatinine mg dl,C0201976;C0439269;C0600061
documented mi,C1301725;C3810814;C1609436
lv ejection fraction $nmbr$ and,C0489482;C2700378
ptca,C2936173
current cigarette n,C0521116;C0677453;C1704760;C3890423;C1705970
n of patients,C0369718;C0441922
lv ejection fraction n $nmbr$,C0489482;C2700378
mean blood pressure mm hg,C0428886;C0439475;C0488053
medications n of patients,C0013227;C0030705;C0802604;C2598133;C4284232
laboratory determinations,C0022877;C0680730;C3244292;C4283904
aspirin antiplatelet medication,C0085826
mean serum creatinine mg dl,C0201976;C0439269;C0600061
lipid lowering drug,C0086440
lv ejection fraction $nmbr$ and,C0489482;C2700378
diuretic any,C0012798
n of patients,C0369718;C0441922
hrt use,C0042153;C0457083;C1947944
lv ejection fraction n $nmbr$,C0489482;C2700378
egfr category,C0683312;C3889287
medications n of patients,C0013227;C0030705;C0802604;C2598133;C4284232
trandolapril n $nmbr$,C0076891
aspirin antiplatelet medication,C0085826
multivariable adjusted hr $nmbr$ ci,C0008107;C3259781
lipid lowering drug,C0086440
events n,C0441471;C3541888
diuretic any,C0012798
hr $nmbr$ ci,C0008107;C3259781
hrt use,C0042153;C0457083;C1947944
trandolapril,C0076891
egfr category,C0683312;C3889287
egfr $nmbr$,C1739039;C3811844;C3812682
trandolapril n $nmbr$,C0076891
egfr $nmbr$ $nmbr$ $nmbr$ $nmbr$ vs egfr $nmbr$,C1739039;C3811844;C3812682
multivariable adjusted hr $nmbr$ ci,C0008107;C3259781
reference,C1514811;C1706462
events n,C0441471;C3541888
cardiovascular mortality or mi,C0026565;C0026566;C3810814
hr $nmbr$ ci,C0008107;C3259781
cardiovascular mortality mi or revascularization,C0007226;C3810814;C3887460;C0581603
trandolapril,C0076891
no pretreatment,C1550147;C2709094;C3539075;C3539076
egfr $nmbr$,C1739039;C3811844;C3812682
ufh only,
egfr $nmbr$ $nmbr$ $nmbr$ $nmbr$ vs egfr $nmbr$,C1739039;C3811844;C3812682
enoxaparin only,C0206460
reference,C1514811;C1706462
both,
cardiovascular mortality or mi,C0026565;C0026566;C3810814
unadjusted p value,C1439367;C1709380
cardiovascular mortality mi or revascularization,C0007226;C3810814;C3887460;C0581603
region,C0017446;C0205147
no pretreatment,C1550147;C2709094;C3539075;C3539076
australia new zealand,C0027978;C0324547
ufh only,
latin america,C0023122
enoxaparin only,C0206460
race,C0034510;C1706779;C3853635
both,
caucasian,C0007457;C0043157
unadjusted p value,C1439367;C1709380
diastolic blood pressure mm hg,C0428883;C0439475;C1305849
region,C0017446;C0205147
ecg at time of qualifying symptoms,C1623258;C0040223;C3541383;C1514624;C0683368;C1457887
australia new zealand,C0027978;C0324547
st segment elevation,C0520886
latin america,C0023122
race,C0034510;C1706779;C3853635
st segment depression,C0520887
caucasian,C0007457;C0043157
inclusion criteria,C1512693
age is $nmbr$ vrs significant ecg changes and no positive bi omark ers,C0001779;C0237881;C0855329;C0750502;C1546944;C1704489;C2931783
diastolic blood pressure mm hg,C0428883;C0439475;C1305849
ecg at time of qualifying symptoms,C1623258;C0040223;C3541383;C1514624;C0683368;C1457887
age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes,C0001779;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269;C4050619;C0855329
st segment elevation,C0520886
si gni fi canr ecg changes positive biomarkers and age,C0855329;C0005516;C0001779
st segment depression,C0520887
age is $nmbr$ vrs significant ecg changes and positive biomarkers,C0001779;C0237881;C0855329;C0750502;C1546944;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269
inclusion criteria,C1512693
time to randomization h,C0040223;C3541383
hvpertension,
age is $nmbr$ vrs significant ecg changes and no positive bi omark ers,C0001779;C0237881;C0855329;C0750502;C1546944;C1704489;C2931783
current smoking,C0037369;C0453996;C1881674
age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes,C0001779;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269;C4050619;C0855329
hvpercholesterolemia,
si gni fi canr ecg changes positive biomarkers and age,C0855329;C0005516;C0001779
familv historv of cad,C1504769;C2239547;C3813548;C4284121
age is $nmbr$ vrs significant ecg changes and positive biomarkers,C0001779;C0237881;C0855329;C0750502;C1546944;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269
medical historv,C0199168;C0205476
time to randomization h,C0040223;C3541383
chf,C0018802
hvpertension,
transient ischemic attack,C0007787;C0917805
current smoking,C0037369;C0453996;C1881674
with t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
hvpercholesterolemia,
without t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
familv historv of cad,C1504769;C2239547;C3813548;C4284121
eze simva $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
medical historv,C0199168;C0205476
rosuva $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
chf,C0018802
gender n,C0079399;C1522384
transient ischemic attack,C0007787;C0917805
race n,C0034510;C1706779;C3853635
with t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
fpg mg dl,C0439269
without t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
duration of hypercholesterolemia yr,C0449238;C2926735
eze simva $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current smoker n,C3173209;C3241966
rosuva $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nob systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
gender n,C0079399;C1522384
history of hypertension n,C0455527
race n,C0034510;C1706779;C3853635
history of chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fpg mg dl,C0439269
duration of hypercholesterolemia yr,C0449238;C2926735
history of pvd n,C4534349
current smoker n,C3173209;C3241966
statin potency stratum n,C0360714
low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
nob systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
history of hypertension n,C0455527
concomitant medications,C0013227;C0802604;C2598133;C4284232
history of chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
drugs used in diabetes n,C0013227;C3687832;C1273517;C0011847;C0011849
history of pvd n,C4534349
antithrombotic agents n,C1704311
statin potency stratum n,C0360714
antihypertensive agents n,C0003364
low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
cardiac therapy n d,C3654025
high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
concomitant medications,C0013227;C0802604;C2598133;C4284232
figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization,C0021149;C0220856;C0449618;C0001779;C0039798;C3810814;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0027051;C0428953;C2926063;C4552959;C0581603
drugs used in diabetes n,C0013227;C3687832;C1273517;C0011847;C0011849
age dependent effect of abcixima,C1280500;C1518681;C2348382
antithrombotic agents n,C1704311
unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$,C0019134;C2825026;C0206460;C0016011
antihypertensive agents n,C0003364
bivalirudin plus glycoprotein iib iiia inhibitors n $nmbr$,C0168273;C0016011
cardiac therapy n d,C3654025
bivalirudin alone n $nmbr$,C0168273;C0205171;C0439044;C0679994
range,C1514721;C2348147;C3542016
figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization,C0021149;C0220856;C0449618;C0001779;C0039798;C3810814;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0027051;C0428953;C2926063;C4552959;C0581603
male sex no medical history no total no,C0086582;C0262926;C1704706;C0439175;C0439810
age dependent effect of abcixima,C1280500;C1518681;C2348382
insulin requiring diabetes,C0011847;C0011849
unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$,C0019134;C2825026;C0206460;C0016011
percutaneous coronary intervention,C1532338
bivalirudin plus glycoprotein iib iiia inhibitors n $nmbr$,C0168273;C0016011
coronary artery bypass grafting,C0010055
bivalirudin alone n $nmbr$,C0168273;C0205171;C0439044;C0679994
renal insufficiency,C0035078;C1565489
range,C1514721;C2348147;C3542016
elevation of cardiac biomarker levels no total no,C0439775;C0702240;C0439175;C0439810
male sex no medical history no total no,C0086582;C0262926;C1704706;C0439175;C0439810
elevation of troponin levels no total no,C0439775;C0702240;C0439175;C0439810
insulin requiring diabetes,C0011847;C0011849
st segment deviation $nmbr$ mm no total no,C4330985;C4554674;C0439175;C0439810
percutaneous coronary intervention,C1532338
elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no,C0439775;C0702240;C4330985;C4554674;C0439175;C0439810
coronary artery bypass grafting,C0010055
timi risk score no total no f,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810;C0016327
renal insufficiency,C0035078;C1565489
i $nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
elevation of cardiac biomarker levels no total no,C0439775;C0702240;C0439175;C0439810
$nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
elevation of troponin levels no total no,C0439775;C0702240;C0439175;C0439810
body mass index mean sd t,C0005893;C0578022;C1305855
st segment deviation $nmbr$ mm no total no,C4330985;C4554674;C0439175;C0439810
general health self reported,C0424575;C4018875;C0681906;C2700446
elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no,C0439775;C0702240;C4330985;C4554674;C0439175;C0439810
very good or excellent,C3641222;C1548784;C1961136
timi risk score no total no f,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810;C0016327
good,C0205170
i $nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
fair or poor,C2911689;C0032854;C0542537;C2700379
$nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
walk for exercise,C0080331;C0015259;C1522704
body mass index mean sd t,C0005893;C0578022;C1305855
fall in last $nmbr$ mo,C0085639;C0238715;C4553726
general health self reported,C0424575;C4018875;C0681906;C2700446
baseline vertebral fracture,C0168634;C0080179;C1442488
very good or excellent,C3641222;C1548784;C1961136
history of clinical fracture $nmbr$ years old,C1272071;C0205210
good,C0205170
high fracture risk stratum,C0332167;C3272283;C4050568;C4319571
fair or poor,C2911689;C0032854;C0542537;C2700379
former,C0205156;C0750523
walk for exercise,C0080331;C0015259;C1522704
duration of alendronate use mean sd y,C1881378;C2826775
fall in last $nmbr$ mo,C0085639;C0238715;C4553726
current alendronate use,C0042153;C0457083;C1947944
baseline vertebral fracture,C0168634;C0080179;C1442488
current use of hormone therapy,C1524063;C0279025
history of clinical fracture $nmbr$ years old,C1272071;C0205210
or raloxifene,C0244404
high fracture risk stratum,C0332167;C3272283;C4050568;C4319571
time since start of fit mean sd y,C1301880;C0036572;C2349186;C4048158;C4553125
former,C0205156;C0750523
time since end of fit mean sd y,C1522314;C0036572;C2349186;C4048158;C4553125
duration of alendronate use mean sd y,C1881378;C2826775
flex baseline bmd mean sd g cm $nmbr$,C0168634;C0439267;C1442488
current alendronate use,C0042153;C0457083;C1947944
total hip,C0019552;C0022122;C1505163;C3538851;C4284725
current use of hormone therapy,C1524063;C0279025
femoral neck,C0015815
or raloxifene,C0244404
lumbar spine,C0024091;C3887615
time since start of fit mean sd y,C1301880;C0036572;C2349186;C4048158;C4553125
forearm,C0016536
time since end of fit mean sd y,C1522314;C0036572;C2349186;C4048158;C4553125
total body,C0229960
flex baseline bmd mean sd g cm $nmbr$,C0168634;C0439267;C1442488
flex baseline bmd t score,C0449820;C4050231
total hip,C0019552;C0022122;C1505163;C3538851;C4284725
at femoral neck mean sd,C0015815;C2699239
femoral neck,C0015815
$nmbr$ $nmbr$ to,
lumbar spine,C0024091;C3887615
serum bone specific alkaline,C0205369;C1552740;C1979842
forearm,C0016536
phosphatase mean sd ng mlf,C0017887;C0066495;C0028074
total body,C0229960
serum c terminal telopeptide of,C0229671;C1707271;C1546774;C1550100
flex baseline bmd t score,C0449820;C4050231
type $nmbr$ collagen mean sd ng ml,C0009325;C0439275
at femoral neck mean sd,C0015815;C2699239
$nmbr$ $nmbr$ to,
serum n propeptide of type $nmbr$ collagen,C1709708;C1875696
mean sd ng ml,C0444504;C0439275;C2347634;C2348143
serum bone specific alkaline,C0205369;C1552740;C1979842
phosphatase mean sd ng mlf,C0017887;C0066495;C0028074
dietary calcium intake mean sd mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
serum c terminal telopeptide of,C0229671;C1707271;C1546774;C1550100
figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals,C1705117;C4035091;C0425043;C0581603;C0439231;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1707455;C0680395;C1707156;C3274014;C3541345;C1272706
type $nmbr$ collagen mean sd ng ml,C0009325;C0439275
vildagliptin $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
serum n propeptide of type $nmbr$ collagen,C1709708;C1875696
rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd ng ml,C0444504;C0439275;C2347634;C2348143
hispanic or latino,C0086409;C0086528
all other,
dietary calcium intake mean sd mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bmi group kg m^,C0022718;C0439209;C4054209
figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals,C1705117;C4035091;C0425043;C0581603;C0439231;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1707455;C0680395;C1707156;C3274014;C3541345;C1272706
alc,C1424945;C3811058
vildagliptin $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alc group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fpg mmol $nmbr$,C0439190
hispanic or latino,C0086409;C0086528
disease duration years,C0872146;C0439234
all other,
rosiglitazone $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bmi group kg m^,C0022718;C0439209;C4054209
adjusted mean change kg,C0022718;C0439209;C4054209
alc,C1424945;C3811058
whole cohort,C0009247;C0599755
alc group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
bmi $nmbr$,C0578022
fpg mmol $nmbr$,C0439190
etoricoxib $nmbr$ mg n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
disease duration years,C0872146;C0439234
diclofenac $nmbr$ mg n $nmbr$ n,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rosiglitazone $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age mean yrs sd,C0001779;C2699239
adjusted mean change kg,C0022718;C0439209;C4054209
sex n,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
whole cohort,C0009247;C0599755
native american,C0282204;C1515945
bmi $nmbr$,C0578022
body mass index mean kg m^ sd,C0022718;C0439209;C4054209;C2699239
etoricoxib $nmbr$ mg n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
primary study joint n,C0205225;C0022417;C0392905;C1706309;C0439612;C0439631
diclofenac $nmbr$ mg n $nmbr$ n,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
knee,C0022742;C0022745;C1963703
age mean yrs sd,C0001779;C2699239
hand,C0018563;C1552914
sex n,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
left shoulder,C0524469
native american,C0282204;C1515945
acr functional class n,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
body mass index mean kg m^ sd,C0022718;C0439209;C4054209;C2699239
class i,C0441885;C1319793;C2698967
primary study joint n,C0205225;C0022417;C0392905;C1706309;C0439612;C0439631
class ii,C0441886;C2698968
knee,C0022742;C0022745;C1963703
class $nmbr$,C0456387;C1518526;C1705943
hand,C0018563;C1552914
prior antiinflammatory antirheumatic products n,C0003209;C0003191;C1515999
left shoulder,C0524469
rofecoxib,C0762662
acr functional class n,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
valdecoxib,C0913246
class i,C0441885;C1319793;C2698967
ibuprofen,C0020740
class ii,C0441886;C2698968
naproxen,C0027396
class $nmbr$,C0456387;C1518526;C1705943
prior analgesic products n,C0332152;C0002771;C2826257
prior antiinflammatory antirheumatic products n,C0003209;C0003191;C1515999
acetaminophen,C0000970;C2917659
rofecoxib,C0762662
history of upper gl events perforations ulcers bleeding n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
valdecoxib,C0913246
low dose aspirin use strata n,C2608320;C0042153;C0457083;C1947944
ibuprofen,C0020740
user,C1548600;C1706077
naproxen,C0027396
nonuser,
prior analgesic products n,C0332152;C0002771;C2826257
increased risk for thrombotic cardiovascular event^ n,C1273410
acetaminophen,C0000970;C2917659
history of diagnosed hypertension prior to randomization n,C0455527;C0011900;C0034656
history of upper gl events perforations ulcers bleeding n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline aspirin use strata,C0004057;C0042153;C0457083;C1947944
low dose aspirin use strata n,C2608320;C0042153;C0457083;C1947944
rr $nmbr$ ci,C0008107;C3259781
user,C1548600;C1706077
patient years,C0030705;C0439234
nonuser,
pt years $nmbr$,C0032743;C0439234;C0699718
increased risk for thrombotic cardiovascular event^ n,C1273410
continued use of gpa,C0549178;C1524063
history of diagnosed hypertension prior to randomization n,C0455527;C0011900;C0034656
new use of gpa,C0205314;C1524063
baseline aspirin use strata,C0004057;C0042153;C0457083;C1947944
$nmbr$ years,C0439234
rr $nmbr$ ci,C0008107;C3259781
non caucasian,C0007457;C0043157
patient years,C0030705;C0439234
no of individuals,C0027361;C0237401
pt years $nmbr$,C0032743;C0439234;C0699718
i rosuvastatin n $nmbr$,C0021966;C0221138
continued use of gpa,C0549178;C1524063
i placebo n $nmbr$,C0021966;C0032042;C1696465;C1706408;C0221138
new use of gpa,C0205314;C1524063
white race,C0007457;C0043157
$nmbr$ years,C0439234
blood pressure mean sd mm hgt,C0428886;C2699239
non caucasian,C0007457;C0043157
no of individuals,C0027361;C0237401
fasting blood glucose mean sd mg dlt,C1413248;C3273706
i rosuvastatin n $nmbr$,C0021966;C0221138
impaired renal function,C1565489
i placebo n $nmbr$,C0021966;C0032042;C1696465;C1706408;C0221138
estimated glomerular filtration rate,C3811844
white race,C0007457;C0043157
normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
mild decrease $nmbr$,C0392756;C0547047
blood pressure mean sd mm hgt,C0428886;C2699239
moderate decrease $nmbr$,C0392756;C0547047
fasting blood glucose mean sd mg dlt,C1413248;C3273706
concomitant medication use,C0521115;C0240320
impaired renal function,C1565489
antihypertensive,C0003364
estimated glomerular filtration rate,C3811844
the metabolic syndrome^,C0524620
normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
body mass index $nmbr$ t,C0005893;C0578022;C1305855
mild decrease $nmbr$,C0392756;C0547047
triglycerides $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
moderate decrease $nmbr$,C0392756;C0547047
diastolic blood pressure $nmbr$ mm hg,C0428883;C0439475;C1305849
concomitant medication use,C0521115;C0240320
antihypertensive,C0003364
systolic blood pressure $nmbr$ mm hg,C0488055;C0439475;C0871470;C1306620
the metabolic syndrome^,C0524620
or taking antihypertensive medication,C1290952
body mass index $nmbr$ t,C0005893;C0578022;C1305855
fasting blood glucose $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
triglycerides $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
$nmbr$ chd risk factors,C0035648;C1282512;C1553898
diastolic blood pressure $nmbr$ mm hg,C0428883;C0439475;C1305849
chd risk factors,C0035648;C1282512;C1553898
systolic blood pressure $nmbr$ mm hg,C0488055;C0439475;C0871470;C1306620
family history of premature chd,C0241889;C0151526;C0205252;C4018905
or taking antihypertensive medication,C1290952
smoking during the previous month,C2114448;C0332177;C0439231
hypertension $nmbr$ $nmbr$ mm hg or taking,C0020538;C0439475;C1963138
fasting blood glucose $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
antihypertensive medication,C0003364
$nmbr$ chd risk factors,C0035648;C1282512;C1553898
$nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
chd risk factors,C0035648;C1282512;C1553898
n $nmbr$,C0369718;C0441922
family history of premature chd,C0241889;C0151526;C0205252;C4018905
mean of maximum cimt mean sd mm,C0444504;C0806909;C1552615;C2826546;C2347634;C2348143
smoking during the previous month,C2114448;C0332177;C0439231
$nmbr$ carotid artery sites,C0007272;C0205145;C0162859
hypertension $nmbr$ $nmbr$ mm hg or taking,C0020538;C0439475;C1963138
common carotid artery sites,C0007272;C0205145;C0162859
antihypertensive medication,C0003364
carotid bulb sites,C0007281;C0205145
$nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
internal carotid artery sites,C0007276;C0205145
n $nmbr$,C0369718;C0441922
mean of mean cimt mean sd mm,C0444504;C2347634;C2348143
mean of maximum cimt mean sd mm,C0444504;C0806909;C1552615;C2826546;C2347634;C2348143
tolvaptan n $nmbr$,C1176308
$nmbr$ carotid artery sites,C0007272;C0205145;C0162859
otherf,
common carotid artery sites,C0007272;C0205145;C0162859
systolic blood pressure mean sd mm hg,C0428886;C0439475
carotid bulb sites,C0007281;C0205145
ejection fraction mean sd,C0489482;C2699239;C2700378
internal carotid artery sites,C0007276;C0205145
ischemic heart failure etiology,C0015127;C1314792;C1524003
mean of mean cimt mean sd mm,C0444504;C2347634;C2348143
previous hospitalization for heart failure,C0205156;C3898876;C1552607
tolvaptan n $nmbr$,C1176308
nyha class,C1882083
otherf,
chronic renal insufficiency,C0403447;C1561643
systolic blood pressure mean sd mm hg,C0428886;C0439475
valvular disease mitral,C3258293;C0746591
ejection fraction mean sd,C0489482;C2699239;C2700378
baseline therapy,C0039798;C0087111;C1363945
ischemic heart failure etiology,C0015127;C1314792;C1524003
ace inhibitors arbs,C0003015;C3888198
previous hospitalization for heart failure,C0205156;C3898876;C1552607
p blockers,C0369773;C2603361
nyha class,C1882083
aldosterone blockers,C0002006
chronic renal insufficiency,C0403447;C1561643
baseline cardiovascular assessment,C4684571
valvular disease mitral,C3258293;C0746591
dyspnea frequent continuous,C0013404;C0549178;C1963100
baseline therapy,C0039798;C0087111;C1363945
orthopnea frequent continuous,C0085619;C0549178
ace inhibitors arbs,C0003015;C3888198
rales,C0034642;C0240859
p blockers,C0369773;C2603361
pedal edema slight moderate marked,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0522501;C1706089
aldosterone blockers,C0002006
jugular venous distention $nmbr$ cm,C0425687
baseline cardiovascular assessment,C4684571
younger subjects aged,C0681850;C1550501;C1706203;C2349001;C2697811;C0001779;C0001792;C1999167
dyspnea frequent continuous,C0013404;C0549178;C1963100
older subjects aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
orthopnea frequent continuous,C0085619;C0549178
all,
rales,C0034642;C0240859
sertraline,C0074393;C0524265
pedal edema slight moderate marked,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0522501;C1706089
female sex,C0086287
jugular venous distention $nmbr$ cm,C0425687
married,C0024841;C0555047
younger subjects aged,C0681850;C1550501;C1706203;C2349001;C2697811;C0001779;C0001792;C1999167
education years,C0013621;C0439234;C0013622;C0013658;C0039401
older subjects aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
no of events sample size i i,C0242618;C3811654
all,
kaplan meier rates i i,C0021966;C0221138
sertraline,C0074393;C0524265
ranolazine,C0073633
female sex,C0086287
hr $nmbr$ cl,C0596019
married,C0024841;C0555047
pfor interaction,C1151635;C1704675
education years,C0013621;C0439234;C0013622;C0013658;C0039401
] $nmbr$,
no of events sample size i i,C0242618;C3811654
timi risk score,C0035647;C0449820;C4050231;C4552904
kaplan meier rates i i,C0021966;C0221138
] j $nmbr$,
ranolazine,C0073633
index diagnosis,C0011900;C1704338;C1704656
hr $nmbr$ cl,C0596019
non st elevation ml,C0439526;C1705224;C3887665
pfor interaction,C1151635;C1704675
st segment depression $nmbr$ mm,C4330985;C4554674
] $nmbr$,
creatinine clearance,C0812399
timi risk score,C0035647;C0449820;C4050231;C4552904
$nmbr$ mlymin,
] j $nmbr$,
early invasive,C0205281;C1334278
index diagnosis,C0011900;C1704338;C1704656
overall,C0282416;C1561607
non st elevation ml,C0439526;C1705224;C3887665
figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups,C1705241;C1705242;C3890735;C0441889;C4048285;C0030705;C0042295;C1882932;C2360800;C1709595;C0074554;C2349200;C4522255;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0369773;C2603361;C0332529;C1547017;C1079230
st segment depression $nmbr$ mm,C4330985;C4554674
tiotropium,C0213771
creatinine clearance,C0812399
total randomised n,C0439175;C0439810
$nmbr$ mlymin,
male n,C0086582;C1706180;C1706428;C1706429
early invasive,C0205281;C1334278
overall,C0282416;C1561607
smoking history pack years,C1519384;C1277691
screening visit $nmbr$,C0545082;C1512346;C2826704
figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups,C1705241;C1705242;C3890735;C0441889;C4048285;C0030705;C0042295;C1882932;C2360800;C1709595;C0074554;C2349200;C4522255;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0369773;C2603361;C0332529;C1547017;C1079230
fev $nmbr$ l pre bronchodilator,C3714541;C2599602
tiotropium,C0213771
fev $nmbr$ predicted normal,C0520835;C0681842;C1882327
total randomised n,C0439175;C0439810
fev $nmbr$ fvc,C3714541
male n,C0086582;C1706180;C1706428;C1706429
fvc l,C3714541
smoking history pack years,C1519384;C1277691
nice classification of copd severity of obstruction n [ $nmbr$ ],C0008902;C0008903;C0678229
screening visit $nmbr$,C0545082;C1512346;C2826704
mild fev $nmbr$ predicted,C0681842;C1882327
fev $nmbr$ l pre bronchodilator,C3714541;C2599602
moderate $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
fev $nmbr$ predicted normal,C0520835;C0681842;C1882327
severe fev,C0205082;C3714541;C4050465;C4050466
fev $nmbr$ fvc,C3714541
pulmonary medication during baseline,C0013227;C3244316;C4284232
fvc l,C3714541
laba n,
nice classification of copd severity of obstruction n [ $nmbr$ ],C0008902;C0008903;C0678229
laba no ics n,C0815320;C4551720
mild fev $nmbr$ predicted,C0681842;C1882327
ics n,C0815320;C4551720
moderate $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
ics no laba n,C0815320;C4551720
severe fev,C0205082;C3714541;C4050465;C4050466
laba plus ics n,C0815320;C4551720
pulmonary medication during baseline,C0013227;C3244316;C4284232
no laba no ics n,C0815320;C4551720
laba n,
saba use occasions weekt,C0042153;C0457083;C1947944
laba no ics n,C0815320;C4551720
trough fev response l,C0444506;C0871261;C1704632;C1706817;C2911692
ics n,C0815320;C4551720
trough fvc response l,C0444506;C0871261;C1704632;C1706817;C2911692
ics no laba n,C0815320;C4551720
effect size^,C0814843
laba plus ics n,C0815320;C4551720
laba tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
no laba no ics n,C0815320;C4551720
ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
saba use occasions weekt,C0042153;C0457083;C1947944
ics no laba tiotropium n $nmbr$ placebo n $nmbr$,C0815320;C4551720;C0213771;C0032042;C1696465;C1706408
trough fev response l,C0444506;C0871261;C1704632;C1706817;C2911692
laba plus ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
trough fvc response l,C0444506;C0871261;C1704632;C1706817;C2911692
no laba no ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
effect size^,C0814843
trough fev response l i,C0021966;C0221138
laba tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
effect size,C0814843
ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
fev $nmbr$ predicted,C0681842;C1882327
ics no laba tiotropium n $nmbr$ placebo n $nmbr$,C0815320;C4551720;C0213771;C0032042;C1696465;C1706408
tiotropium n $nmbr$ placebo n,C0213771;C0032042;C1696465;C1706408
laba plus ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
fev,C3714541
no laba no ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
placebo group n $nmbr$ j,C0441844
trough fev response l i,C0021966;C0221138
certolizumab group n $nmbr$,C1872109;C0441848
effect size,C0814843
mean age yr range,C1514721;C2348147;C3542016
fev $nmbr$ predicted,C0681842;C1882327
mean body mass indexj,C0444504;C0518010;C2347634;C2348143
tiotropium n $nmbr$ placebo n,C0213771;C0032042;C1696465;C1706408
duration of disease yr^ mean,C0872146;C0439234
fev,C3714541
cdai score,C0449820;C4050231
placebo group n $nmbr$ j,C0441844
mean,C0444504;C2347634;C2348143
certolizumab group n $nmbr$,C1872109;C0441848
geometric mean ofcrp mg liter range,C1514721;C2348147;C3542016
mean age yr range,C1514721;C2348147;C3542016
disease site no ^,C0205145;C1515974;C2825164
mean body mass indexj,C0444504;C0518010;C2347634;C2348143
terminal ileum,C0227327
duration of disease yr^ mean,C0872146;C0439234
colon,C0009368;C3888384
cdai score,C0449820;C4050231
lleocolon,
mean,C0444504;C2347634;C2348143
previous infliximab therapy,C0205156;C4076075;C1552607
geometric mean ofcrp mg liter range,C1514721;C2348147;C3542016
any therapy no,C0039798;C0087111;C1363945
disease site no ^,C0205145;C1515974;C2825164
median infusions no range,C0549183;C0574032;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
terminal ileum,C0227327
previous hypersensitivity reaction no,C0205156;C0020517;C1552607
colon,C0009368;C3888384
resection performed no,C0015252;C0728940;C0884358
lleocolon,
concurrent treatment at study entry no,C0679827;C1521826;C3161471
previous infliximab therapy,C0205156;C4076075;C1552607
glucocorticoids only,C0017710;C3540777;C3540778
any therapy no,C0039798;C0087111;C1363945
immunosuppressive agents only,C0021081
median infusions no range,C0549183;C0574032;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778;C0205195;C0021081
previous hypersensitivity reaction no,C0205156;C0020517;C1552607
neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778;C0021081
resection performed no,C0015252;C0728940;C0884358
placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
concurrent treatment at study entry no,C0679827;C1521826;C3161471
certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
glucocorticoids only,C0017710;C3540777;C3540778
no total,C0439175;C0439810
immunosuppressive agents only,C0021081
a decrease of $nmbr$ points in the cdai score,C0392756;C0547047;C0449820;C4050231
glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778;C0205195;C0021081
with baseline crp level of $nmbr$ mg liter,C0441889;C0456079;C1547707;C2946261
neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778;C0021081
at week $nmbr$,C0332174;C0439230
placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
at weeks $nmbr$ and $nmbr$,C0439230
certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
all patients,C0030705
no total,C0439175;C0439810
no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
a decrease of $nmbr$ points in the cdai score,C0392756;C0547047;C0449820;C4050231
immunosuppressive agents at baseline,C0021081;C0168634;C1442488
with baseline crp level of $nmbr$ mg liter,C0441889;C0456079;C1547707;C2946261
no glucocorticoids at baseline,C0017710;C3540777;C3540778
at week $nmbr$,C0332174;C0439230
glucocorticoids at baseline,C0017710;C3540777;C3540778
at weeks $nmbr$ and $nmbr$,C0439230
no previous treatment with infliximab,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
all patients,C0030705
previous treatment with infliximab,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
patients with remission,C1277626
immunosuppressive agents at baseline,C0021081;C0168634;C1442488
no glucocorticoids at baseline,C0017710;C3540777;C3540778
figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter,C1280519;C1707887;C1872109;C0030705;C0871261;C1704632;C1706817;C2911692;C0441837;C1547282;C0034746;C0032659;C1257890;C0332174;C0439230;C0441889;C0456079;C1547707;C2946261;C0441833;C1706365;C1999270;C0439165;C1549488;C1561533;C0205210;C1704788;C3539106;C0087111;C1292734;C1522326;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0475211
glucocorticoids at baseline,C0017710;C3540777;C3540778
fondaparinux n $nmbr$,C1098510
no previous treatment with infliximab,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
age median range years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
previous treatment with infliximab,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
gender male female,C0043210;C0086287;C1705497;C1705498
patients with remission,C1277626
weight mean sd kg,C0022718;C0439209;C4054209
body mass index mean sd kg m $nmbr$,C0022718;C0439209;C4054209
figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter,C1280519;C1707887;C1872109;C0030705;C0871261;C1704632;C1706817;C2911692;C0441837;C1547282;C0034746;C0032659;C1257890;C0332174;C0439230;C0441889;C0456079;C1547707;C2946261;C0441833;C1706365;C1999270;C0439165;C1549488;C1561533;C0205210;C1704788;C3539106;C0087111;C1292734;C1522326;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0475211
risk factor for venous thromboembolism no,C3495424;C3496592
fondaparinux n $nmbr$,C1098510
obesity,C0028754;C1963185
age median range years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
history of venous,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
gender male female,C0043210;C0086287;C1705497;C1705498
thromboembolism,C0040038
weight mean sd kg,C0022718;C0439209;C4054209
nyha grade iii or iv,C0205617;C0450094;C0475271;C0687697;C3889290;C4050000;C4283820;C4283821;C4283822;C0022326;C4265176
body mass index mean sd kg m $nmbr$,C0022718;C0439209;C4054209
chronic obstructive pulmonary,C0205191;C0549186;C0024109;C2707265;C2709248;C4522268
risk factor for venous thromboembolism no,C3495424;C3496592
disease,C0012634
obesity,C0028754;C1963185
inflammatory bowel disease,C0021390
history of venous,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cancer surgery,C0920424
thromboembolism,C0040038
no of risk factors for venous thromboembolism no,C0035648;C1553898;C1861172
nyha grade iii or iv,C0205617;C0450094;C0475271;C0687697;C3889290;C4050000;C4283820;C4283821;C4283822;C0022326;C4265176
creatinine clearance no,C0812399
chronic obstructive pulmonary,C0205191;C0549186;C0024109;C2707265;C2709248;C4522268
$nmbr$ $nmbr$ ml min $nmbr$,C0439445
disease,C0012634
$nmbr$ ml min $nmbr$,C0439445
inflammatory bowel disease,C0021390
sample size n,C0242618
cancer surgery,C0920424
age in years mean,C1510829;C0444504;C2347634;C2348143
no of risk factors for venous thromboembolism no,C0035648;C1553898;C1861172
$nmbr$ to $nmbr$ y n,
creatinine clearance no,C0812399
$nmbr$ y n,
$nmbr$ $nmbr$ ml min $nmbr$,C0439445
education in years mean,C0013621;C0013622;C0013658;C0039401
$nmbr$ ml min $nmbr$,C0439445
clinic research experience n,C0002424;C0035168;C0242481;C0442592
sample size n,C0242618
on bp medication n,C0037623;C0013227;C3244316;C4284232;C1415692;C1708288;C4318478
age in years mean,C1510829;C0444504;C2347634;C2348143
hx of diabetes n,C0262926;C3814444
$nmbr$ to $nmbr$ y n,
chd n,C0280604;C3542407
$nmbr$ y n,
baseline ecg with lvh n,C0168634;C0232306;C1442488
education in years mean,C0013621;C0013622;C0013658;C0039401
ascvd n,C3665365
clinic research experience n,C0002424;C0035168;C0242481;C0442592
bmi kg m $nmbr$ mean,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
on bp medication n,C0037623;C0013227;C3244316;C4284232;C1415692;C1708288;C4318478
glucose mg dl mean,C0444504;C2347634;C2348143
hx of diabetes n,C0262926;C3814444
potassium meq dl mean,C0444504;C2347634;C2348143
chd n,C0280604;C3542407
creatinine mg dl mean,C0444504;C2347634;C2348143
baseline ecg with lvh n,C0168634;C0232306;C1442488
geographic region,C0017446
ascvd n,C3665365
south n,C1710133
bmi kg m $nmbr$ mean,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
pr virgin islands n,C0279759;C0042752;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
glucose mg dl mean,C0444504;C2347634;C2348143
others n,C1955473;C3539125
potassium meq dl mean,C0444504;C2347634;C2348143
time in trial,C0040223;C3541383;C0150312;C0008976;C0332285;C1707101
creatinine mg dl mean,C0444504;C2347634;C2348143
no with visit,C0545082;C1512346;C2826704
geographic region,C0017446
sbp dbp mean,C0444504;C2347634;C2348143
south n,C1710133
no of drugs,C0013227;C3687832
pr virgin islands n,C0279759;C0042752;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
on step $nmbr$ drug,C0013227;C1254351
others n,C1955473;C3539125
sd,C2699239
time in trial,C0040223;C3541383;C0150312;C0008976;C0332285;C1707101
baseline,C0168634;C1442488
no with visit,C0545082;C1512346;C2826704
$nmbr$ mo,C0026544;C0332177
sbp dbp mean,C0444504;C2347634;C2348143
$nmbr$ y,
no of drugs,C0013227;C3687832
figure percentage of subgroup with bp controlled sbp,C0439165;C1549488;C1561533;C0037623;C0085805;C1415692;C1708288;C4318478
on step $nmbr$ drug,C0013227;C1254351
aged,C0001779;C0001792;C1999167
sd,C2699239
aged a $nmbr$ years,C0001779;C0001792;C1999167;C0439234
baseline,C0168634;C1442488
diff_measure dm added this as table had multiple headings,C0011816;C3250443;C1524062;C0039224;C1706074;C0439064
$nmbr$ mo,C0026544;C0332177
bl,C0005918;C0006413;C1552663;C2827109
$nmbr$ y,
diff_measure,C0079809;C0242485
figure percentage of subgroup with bp controlled sbp,C0439165;C1549488;C1561533;C0037623;C0085805;C1415692;C1708288;C4318478
am_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
aged,C0001779;C0001792;C1999167
$nmbr$ $nmbr$ o lt,C0023376;C0230426;C3887647;C4521399
aged a $nmbr$ years,C0001779;C0001792;C1999167;C0439234
$nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
diff_measure dm added this as table had multiple headings,C0011816;C3250443;C1524062;C0039224;C1706074;C0439064
body weight kg,C0022718;C0439209;C4054209
bl,C0005918;C0006413;C1552663;C2827109
$nmbr$ $nmbr$ l ot,C1318464;C1418208;C1705587
diff_measure,C0079809;C0242485
responder analyses achieving alc,C0002778;C0936012;C1524024;C1424945;C3811058
am_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
n responders,C0369718;C0441922
$nmbr$ $nmbr$ o lt,C0023376;C0230426;C3887647;C4521399
$nmbr$ $nmbr$ $nmbr$ t,C2603360
$nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
baseline alc,C1424945;C3811058
body weight kg,C0022718;C0439209;C4054209
fasting lipids mmol $nmbr$,C0015663;C0023779;C0439190
$nmbr$ $nmbr$ l ot,C1318464;C1418208;C1705587
am_ delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
responder analyses achieving alc,C0002778;C0936012;C1524024;C1424945;C3811058
triglycerides,C0041004
n responders,C0369718;C0441922
ldl,
$nmbr$ $nmbr$ $nmbr$ t,C2603360
hdl,C3715113
baseline alc,C1424945;C3811058
non hdl,C1518422;C3715113
fasting lipids mmol $nmbr$,C0015663;C0023779;C0439190
vldl,C0523560
am_ delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
blood pressure mmhg,C0005823;C0439475;C1271104;C1272641
triglycerides,C0041004
mean_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
ldl,
subgroup analyses,C2986480
hdl,C3715113
bl alc,C1424945;C3811058
non hdl,C1518422;C3715113
blaic $nmbr$ $nmbr$,
vldl,C0523560
blaic,
blood pressure mmhg,C0005823;C0439475;C1271104;C1272641
bl bmioo kg m^,C0022718;C0439209;C4054209
mean_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
bl bml $nmbr$ kg m^,C0022718;C0439209;C4054209
subgroup analyses,C2986480
bl bm $nmbr$,C0005918;C0006416;C0006413;C1552663;C2827109
bl alc,C1424945;C3811058
bl bml,C0005918;C0006413;C1552663;C2827109
blaic $nmbr$ $nmbr$,
bl bml $nmbr$ ke m^,C0005918;C0022558;C0006413;C1552663;C2827109
blaic,
treatment group,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bl bmioo kg m^,C0022718;C0439209;C4054209
air n $nmbr$,C0001861;C3536832
bl bml $nmbr$ kg m^,C0022718;C0439209;C4054209
ig n $nmbr$,C0021027;C0305052;C0360506
bl bm $nmbr$,C0005918;C0006416;C0006413;C1552663;C2827109
air ig n $nmbr$,C0001861;C0021027;C0305052;C0360506;C3536832
bl bml,C0005918;C0006413;C1552663;C2827109
$nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
bl bml $nmbr$ ke m^,C0005918;C0022558;C0006413;C1552663;C2827109
gender [n ],C0079399;C1522384;C0369718;C0441922
treatment group,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
origin [n ],C0079946;C0439659;C1550512;C0369718;C0441922
air n $nmbr$,C0001861;C3536832
african,C0027567
ig n $nmbr$,C0021027;C0305052;C0360506
duration of diabetes years,C0449238;C2926735
air ig n $nmbr$,C0001861;C0021027;C0305052;C0360506;C3536832
oam use [n ],C0042153;C0457083;C1947944;C0369718;C0441922
$nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
insulin secretagogue,C0021641;C4704833;C1533581;C1579433;C3714501
gender [n ],C0079399;C1522384;C0369718;C0441922
biguanides,C0005382;C0360396;C3540012
origin [n ],C0079946;C0439659;C1550512;C0369718;C0441922
tzd,
african,C0027567
baseline insulin dose u kg [lsm se ],C0366513;C1300561;C0036919
duration of diabetes years,C0449238;C2926735
baseline a $nmbr$ c [lsm se ],C0168634;C0036919;C1442488
oam use [n ],C0042153;C0457083;C1947944;C0369718;C0441922
a $nmbr$ c [n ],C1272460
insulin secretagogue,C0021641;C4704833;C1533581;C1579433;C3714501
$nmbr$ $nmbr$ to $nmbr$ $nmbr$,
biguanides,C0005382;C0360396;C3540012
prior insulin use years,C0240016;C0439234
tzd,
algorithm $nmbr$,C0002045;C1553907
baseline insulin dose u kg [lsm se ],C0366513;C1300561;C0036919
number,C0237753;C0449788
baseline a $nmbr$ c [lsm se ],C0168634;C0036919;C1442488
female male,C0086582;C1706180;C1706428;C1706429
a $nmbr$ c [n ],C1272460
duration since diagnosis years,C0449238;C2926735
$nmbr$ $nmbr$ to $nmbr$ $nmbr$,
time since start insulin years,C1301880
prior insulin use years,C0240016;C0439234
hba $nmbr$ c baseline,C0168634;C1442488
algorithm $nmbr$,C0002045;C1553907
fbg baseline,C0168634;C1442488
number,C0237753;C0449788
mg dl,C0439269
female male,C0086582;C1706180;C1706428;C1706429
mmol l,C1532563
duration since diagnosis years,C0449238;C2926735
premixed insulin only,C0021641;C1533581;C1579433;C3714501
time since start insulin years,C1301880
premixed insulin with oads,C0021641;C1533581;C1579433;C3714501
hba $nmbr$ c baseline,C0168634;C1442488
insulin glargine oad,C0907402
fbg baseline,C0168634;C1442488
insulin glargine oad od prandial,C0229089;C0439164;C1512019;C3273373;C3665488;C1998602;C4553624
mg dl,C0439269
insulin glargine oad bd prandial,C0005126;C2344255;C4050145;C1998602;C4553624
mmol l,C1532563
hba $nmbr$ c,C0019016;C1825777;C3538758
premixed insulin only,C0021641;C1533581;C1579433;C3714501
change,C0392747;C0443172;C1705241;C4319952
premixed insulin with oads,C0021641;C1533581;C1579433;C3714501
fbg mg dl,C0439269
insulin glargine oad,C0907402
fbg mmol l,C1532563
insulin glargine oad od prandial,C0229089;C0439164;C1512019;C3273373;C3665488;C1998602;C4553624
assigned to topiramate,C1516050;C1552601
insulin glargine oad bd prandial,C0005126;C2344255;C4050145;C1998602;C4553624
assigned to placebo,C1516050;C1552601
hba $nmbr$ c,C0019016;C1825777;C3538758
migraine occurrence days month,C0149931;C0556971
change,C0392747;C0443172;C1705241;C4319952
migraine duration h,C0033727;C0369286;C0441932;C0564385;C4528284
fbg mg dl,C0439269
migraine severity score,C0149931;C0457451
fbg mmol l,C1532563
acute medication intake days month,C0013227;C0556971;C3244316;C4284232
assigned to topiramate,C1516050;C1552601
midas score,C0449820;C4050231
assigned to placebo,C1516050;C1552601
patients assessed,C0030705;C1516048
migraine occurrence days month,C0149931;C0556971
hit $nmbr$ score,C0449820;C4050231
migraine duration h,C0033727;C0369286;C0441932;C0564385;C4528284
sf $nmbr$ mcs score,C0449820;C4050231
migraine severity score,C0149931;C0457451
sf $nmbr$ pcs score,C0449820;C4050231
acute medication intake days month,C0013227;C0556971;C3244316;C4284232
participants with metabolic syndrome,C0679646;C0524620
midas score,C0449820;C4050231
participants without metabolic syndrome,C0679646;C0524620
patients assessed,C0030705;C1516048
number randomized,C0237753;C0449788;C0034656;C3815594
hit $nmbr$ score,C0449820;C4050231
womens,
sf $nmbr$ mcs score,C0449820;C4050231
years of education,C0439234;C0013621;C0013622;C0013658;C0039401
sf $nmbr$ pcs score,C0449820;C4050231
antihypertensive treatments,C0003364;C0087111
participants with metabolic syndrome,C0679646;C0524620
sbp mmhg,C0085805;C0439475
participants without metabolic syndrome,C0679646;C0524620
dbp mmhg,C0536221;C0439475;C3813197;C4281799
number randomized,C0237753;C0449788;C0034656;C3815594
atherosclerotic cvd,C0333482;C0007222
womens,
history ol mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
years of education,C0439234;C0013621;C0013622;C0013658;C0039401
history ol coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
antihypertensive treatments,C0003364;C0087111
other ascvd,C3665365
sbp mmhg,C0085805;C0439475
st t wave,C0036056;C0429103;C3272372
dbp mmhg,C0536221;C0439475;C3813197;C4281799
lelt ventricular hypertrophy,C0340279
atherosclerotic cvd,C0333482;C0007222
history ol chd at baselines,C0280604;C3542407
history ol mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
bmi kg m,C0022718;C0439209;C4054209
history ol coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
fasting glucose,C0015663;C0017725
other ascvd,C3665365
$nmbr$ $nmbr$ mg dl,C0439269
st t wave,C0036056;C0429103;C3272372
cardiovascular metabolic syndrome risk lactors,C0007226;C0524620;C3887460
lelt ventricular hypertrophy,C0340279
fasting glucose $nmbr$ mg dl,C0015663;C0439269
history ol chd at baselines,C0280604;C3542407
bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
bmi kg m,C0022718;C0439209;C4054209
fasting triglycerides $nmbr$ mg dl,C0015663;C0041004;C0439269
fasting glucose,C0015663;C0017725
low hdl cholesterol,C0151691
$nmbr$ $nmbr$ mg dl,C0439269
high blood pressure,C0020538;C2926615
cardiovascular metabolic syndrome risk lactors,C0007226;C0524620;C3887460
lipid trial participantss,C0023779;C0008976
fasting glucose $nmbr$ mg dl,C0015663;C0439269
table_group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
comparison,C1707455
fasting triglycerides $nmbr$ mg dl,C0015663;C0041004;C0439269
with metabolic syndrome,C0524620
low hdl cholesterol,C0151691
without metabolic syndrome,C0524620
high blood pressure,C0020538;C2926615
chd,C0280604;C3542407
lipid trial participantss,C0023779;C0008976
a,
table_group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
amlodipine chlorthalidone,C0051696;C0008294
comparison,C1707455
all cause mortality,C0015127;C0026565;C0026566;C1524003
with metabolic syndrome,C0524620
combined cvd,C0205195;C0007222
without metabolic syndrome,C0524620
esrd,C0022661;C0035078;C2316810
chd,C0280604;C3542407
b,
a,
lisinopril chlorthalidone,C0065374;C0008294
amlodipine chlorthalidone,C0051696;C0008294
baseline characteristics,C4684572
all cause mortality,C0015127;C0026565;C0026566;C1524003
categories of urinary acr ^g mg,C0683312;C1300563
combined cvd,C0205195;C0007222
p for trend,C0369773;C2603361
esrd,C0022661;C0035078;C2316810
lowest normal n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
b,
low normal n $nmbr$,C0205251;C0205307;C0231683;C0439166;C2347086;C4553972;C1550472;C3890211;C4048187;C4321351;C4522223
lisinopril chlorthalidone,C0065374;C0008294
medium normal n $nmbr$,C0009458;C0205307;C0231683;C0439166;C2347086;C4553972;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
baseline characteristics,C4684572
high normal n $nmbr$,C0205250;C0205307;C0231683;C0439166;C2347086;C4553972;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
categories of urinary acr ^g mg,C0683312;C1300563
low medium microalbuminuria n $nmbr$,C0205251;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C1550472;C3890211;C4048187;C4321351;C4522223
p for trend,C0369773;C2603361
high microalbuminuria to macroalbuminuria n $nmbr$,C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
lowest normal n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
male acr definition ^ g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
low normal n $nmbr$,C0205251;C0205307;C0231683;C0439166;C2347086;C4553972;C1550472;C3890211;C4048187;C4321351;C4522223
female acr definition ^g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
medium normal n $nmbr$,C0009458;C0205307;C0231683;C0439166;C2347086;C4553972;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
female sex n,C0086287
high normal n $nmbr$,C0205250;C0205307;C0231683;C0439166;C2347086;C4553972;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
white n medical history n,C0262926;C1704706
low medium microalbuminuria n $nmbr$,C0205251;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C1550472;C3890211;C4048187;C4321351;C4522223
prior angina pectoris,C0332152;C0002962;C2826257
high microalbuminuria to macroalbuminuria n $nmbr$,C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
prior cabg,C0332152;C0010055;C2826257
male acr definition ^ g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior ptca or cabg,C0332152;C2936173;C2826257;C0010055
female acr definition ^g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current smoker n of patients,C3173209;C3241966
female sex n,C0086287
dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations,C0536221;C3813197;C4281799;C0439475;C0680730
white n medical history n,C0262926;C1704706
egfr ml mn $nmbr$ $nmbr$ m $nmbr$,C0026327;C0026405;C4285072
prior angina pectoris,C0332152;C0002962;C2826257
mean serum potassium mg dl,C0302353;C0439269;C0543465
prior cabg,C0332152;C0010055;C2826257
mean serum cholesterol mg dl,C0587184;C0439269
prior ptca or cabg,C0332152;C2936173;C2826257;C0010055
lv function $nmbr$ $nmbr$ and,C0031843;C0542341;C0700205;C1705273
current smoker n of patients,C3173209;C3241966
j $nmbr$ blocker,
dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations,C0536221;C3813197;C4281799;C0439475;C0680730
potassium sparing diuretic,C0304490;C3536751
egfr ml mn $nmbr$ $nmbr$ m $nmbr$,C0026327;C0026405;C4285072
other diuretic,C0012798
mean serum potassium mg dl,C0302353;C0439269;C0543465
digitalis,C0012252;C0304520
mean serum cholesterol mg dl,C0587184;C0439269
active treatment,C1704532
lv function $nmbr$ $nmbr$ and,C0031843;C0542341;C0700205;C1705273
hr and $nmbr$ ci,C0008107;C3259781
j $nmbr$ blocker,
low to medium microalbuminuria n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
potassium sparing diuretic,C0304490;C3536751
urinary acr,C1412134;C1515941
other diuretic,C0012798
males,C0086582
digitalis,C0012252;C0304520
females,C0086287
active treatment,C1704532
primary outcome n $nmbr$,C0205225;C0439612;C0439631
hr and $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ reference,C1514811;C1706462
low to medium microalbuminuria n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
cardiovascular death n $nmbr$,C0007226;C0011065;C1306577;C4082313;C4552775;C3887460
urinary acr,C1412134;C1515941
all cause mortality n $nmbr$,C0015127;C0026565;C0026566;C1524003
males,C0086582
females,C0086287
figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b,C0520511;C1704711;C1522706;C2349188;C3714939;C3854213;C1274040;C1546471;C2825142;C1524063;C0002778;C0030705;C0936012;C1524024;C4684790;C0009247;C0599755;C1522326;C0288672;C0032042;C1696465;C1706408;C0871208;C1521828;C0168634;C1442488;C0449820;C4050231;C1547282
primary outcome n $nmbr$,C0205225;C0439612;C0439631
subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes,C1079230;C1527178;C1705938;C0683970;C0235828;C0205225;C1274040;C0439612;C0439631
$nmbr$ $nmbr$ reference,C1514811;C1706462
black participants,C0005680;C0679646;C0027567;C0085756;C0439541
cardiovascular death n $nmbr$,C0007226;C0011065;C1306577;C4082313;C4552775;C3887460
nonblack participants,C0679646
all cause mortality n $nmbr$,C0015127;C0026565;C0026566;C1524003
i with mets n $nmbr$,C0021966;C0221138
i without mets n $nmbr$,C0021966;C0221138
figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b,C0520511;C1704711;C1522706;C2349188;C3714939;C3854213;C1274040;C1546471;C2825142;C1524063;C0002778;C0030705;C0936012;C1524024;C4684790;C0009247;C0599755;C1522326;C0288672;C0032042;C1696465;C1706408;C0871208;C1521828;C0168634;C1442488;C0449820;C4050231;C1547282
$nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes,C1079230;C1527178;C1705938;C0683970;C0235828;C0205225;C1274040;C0439612;C0439631
$nmbr$ $nmbr$ $nmbr$ b,
black participants,C0005680;C0679646;C0027567;C0085756;C0439541
years of education mean sd,C0439234;C0013621;C0013622;C0013658;C0039401
nonblack participants,C0679646
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c,
i with mets n $nmbr$,C0021966;C0221138
currentd,
i without mets n $nmbr$,C0021966;C0221138
past,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
aspirin use,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ $nmbr$ b,
antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
years of education mean sd,C0439234;C0013621;C0013622;C0013658;C0039401
treated,C1522326
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c,
untreated,C0332155
currentd,
history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
past,
history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
aspirin use,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ $nmbr$ c,
antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
other atherosclerotic cvdd e,C0333482;C1859330
treated,C1522326
st t wave abnormality d,C0036056;C1839341;C3272372
untreated,C0332155
lvh by ecg or echocardiographyd,C0232306
history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
glycemic status f,C0449438;C0016327
history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
impaired fasting glucose,C1272092
$nmbr$ $nmbr$ $nmbr$ c,
normoglycemic,C0580545
other atherosclerotic cvdd e,C0333482;C1859330
history of chd at baseline d g,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488;C0439267
st t wave abnormality d,C0036056;C1839341;C3272372
lipid trial participants,C1997894;C2242969
lvh by ecg or echocardiographyd,C0232306
blood pressure,C0005823;C1271104;C1272641
glycemic status f,C0449438;C0016327
systolic mean sd mm hg h,C0456680
impaired fasting glucose,C1272092
diastolic mean sd mm hg,C0012000;C0439475
normoglycemic,C0580545
serum potassium level mean sd meq l,C0302353;C0439375;C0543465
history of chd at baseline d g,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488;C0439267
lipid trial participants,C1997894;C2242969
fasting serum glucose level mean sd mg dl,C0202045;C0439269
blood pressure,C0005823;C1271104;C1272641
serum creatinine level mean sd mg dl,C0600061;C0439269
systolic mean sd mm hg h,C0456680
tc level mean sd mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
diastolic mean sd mm hg,C0012000;C0439475
ldl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
serum potassium level mean sd meq l,C0302353;C0439375;C0543465
hdl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
hdl c level $nmbr$ mg dld,C1414063;C2826331
fasting serum glucose level mean sd mg dl,C0202045;C0439269
fasting triglyceride level mean sd mg dl,C0015663;C0428475;C0439269
serum creatinine level mean sd mg dl,C0600061;C0439269
cv mortality,C0026565;C0026566
tc level mean sd mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
combined chd,C0280604;C3542407
ldl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
non black participants,C0005680;C0679646;C0027567;C0085756;C0439541
hdl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
hdl c level $nmbr$ mg dld,C1414063;C2826331
ii $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1710602;C4082587
fasting triglyceride level mean sd mg dl,C0015663;C0428475;C0439269
doxazosin,C0114873
cv mortality,C0026565;C0026566
figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease,C1707455;C0077770;C1511726;C3245479;C3714741;C2985465;C0009667;C0871208;C1521828;C4330837;C0013227;C1254351;C0034510;C1706779;C3853635;C0280604;C3542407;C0010054;C0010068;C1956346;C0022661
combined chd,C0280604;C3542407
p women vs men,C0369773;C0043210;C2603361;C0025266
non black participants,C0005680;C0679646;C0027567;C0085756;C0439541
overaii n $nmbr$,
i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
atenoioi n $nmbr$,
ii $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1710602;C4082587
biack,
doxazosin,C0114873
systoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease,C1707455;C0077770;C1511726;C3245479;C3714741;C2985465;C0009667;C0871208;C1521828;C4330837;C0013227;C1254351;C0034510;C1706779;C3853635;C0280604;C3542407;C0010054;C0010068;C1956346;C0022661
diastoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
p women vs men,C0369773;C0043210;C2603361;C0025266
body mass index kg m^,C0022718;C0439209;C4054209
overaii n $nmbr$,
corneii product mm ms,C2349943;C3539704;C3713294
atenoioi n $nmbr$,
sokoiow lyon voitage mv,C1454484;C1705503;C4281602
biack,
current smokers n medicai history n,C3173209;C3241966
systoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
isoiated systoiic hypertension,C0020538;C1963138
diastoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
cerebrovascuiar disease,C0012634
body mass index kg m^,C0022718;C0439209;C4054209
peripherai arteriai disease,C0012634
corneii product mm ms,C2349943;C3539704;C3713294
adjusted hr losartan vs atenolol,C0456081;C0126174;C0004147
sokoiow lyon voitage mv,C1454484;C1705503;C4281602
women n $nmbr$ events,C0441471;C3541888
current smokers n medicai history n,C3173209;C3241966
women n $nmbr$,C0043210
isoiated systoiic hypertension,C0020538;C1963138
events,C0441471;C3541888
cerebrovascuiar disease,C0012634
ratet n,
peripherai arteriai disease,C0012634
primary composite^,C0205199;C1547335
adjusted hr losartan vs atenolol,C0456081;C0126174;C0004147
cardiovascuiar mortaiity,
women n $nmbr$ events,C0441471;C3541888
myocardiai infarction,C0021308
women n $nmbr$,C0043210
totai mortaiity,
events,C0441471;C3541888
hospitaiization for angina,C0002962
ratet n,
hospitaiization for heart faiiure,C0018787
primary composite^,C0205199;C1547335
vildagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cardiovascuiar mortaiity,
viidagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
myocardiai infarction,C0021308
placebo glimepiride,C0032042;C0061323;C1696465;C1706408
totai mortaiity,
age years mean s d,C1510829;C0444504;C2347634;C2348143
hospitaiization for angina,C0002962
hispanic latino,C0086409;C0086528
hospitaiization for heart faiiure,C0018787
bmi kg m^ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
vildagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hbaic mean s d,C0444504;C2347634;C2348143
viidagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hbaic group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
placebo glimepiride,C0032042;C0061323;C1696465;C1706408
fpg mmol l mean s d,C0439433
age years mean s d,C1510829;C0444504;C2347634;C2348143
disease duration years mean s d,C0872146;C0439234
hispanic latino,C0086409;C0086528
duration of sulphonylurea use months mean s d,C1881378;C2826775
bmi kg m^ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged,C0349966;C1337208;C0444504;C2347634;C2348143;C0392747;C0443172;C1705241;C4319952;C2349179;C2826544;C0001779;C0001792;C1999167
hbaic mean s d,C0444504;C2347634;C2348143
mets,C0812270;C1705694;C2939420
hbaic group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
non mets,C0812270;C1705694;C2939420
fpg mmol l mean s d,C0439433
placebo dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
disease duration years mean s d,C0872146;C0439234
eze simva $nmbr$ $nmbr$ mg dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
duration of sulphonylurea use months mean s d,C1881378;C2826775
feno $nmbr$ dn $nmbr$,C1333964;C1707618
fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged,C0349966;C1337208;C0444504;C2347634;C2348143;C0392747;C0443172;C1705241;C4319952;C2349179;C2826544;C0001779;C0001792;C1999167
eze simva $nmbr$ $nmbr$ mg feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
mets,C0812270;C1705694;C2939420
placebo dn $nmbr$,C1333964;C1707618
non mets,C0812270;C1705694;C2939420
eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
eze simva $nmbr$ $nmbr$ mg dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
bmi kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
feno $nmbr$ dn $nmbr$,C1333964;C1707618
waist circumference cm mean sd,C0455829;C2699239
eze simva $nmbr$ $nmbr$ mg feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
diagnosis of diabetes n,C0011900;C1704338;C1704656
placebo dn $nmbr$,C1333964;C1707618
tg mg dl,C0337445;C0439269
eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
non hdl c mg dl,C1518422;C0439269
feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
apo b mg dl,C0003593;C0439269;C3252643
bmi kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
waist circumference cm mean sd,C0455829;C2699239
apo a i mg dl,C0085201;C0439269;C1677784
diagnosis of diabetes n,C0011900;C1704338;C1704656
data are expressed as median sd except,C1511726;C3245479;C3714741;C0549183;C0876920;C2347635;C2348144;C2939193
tg mg dl,C0337445;C0439269
data are expr,C1511726;C3245479;C3714741
non hdl c mg dl,C1518422;C0439269
ssed as ls means,C0023668;C1704970
apo b mg dl,C0003593;C0439269;C3252643
by treatment arm,C1522541
tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
icd,C0021122
apo a i mg dl,C0085201;C0439269;C1677784
syncope,C0039070;C3541349;C4554644
data are expressed as median sd except,C1511726;C3245479;C3714741;C0549183;C0876920;C2347635;C2348144;C2939193
amiodarone,C0002598
data are expr,C1511726;C3245479;C3714741
by cause of death,C0007465;C4050444
ssed as ls means,C0023668;C1704970
sudden death,C0011071;C1964022;C4554103
by treatment arm,C1522541
figure $nmbr$ subgroup analyses for the primary outcome,C2986480;C0205225;C0439612;C0439631
icd,C0021122
sal n $nmbr$ $nmbr$,C0036140;C0037494;C0206136
syncope,C0039070;C3541349;C4554644
fp n $nmbr$ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
amiodarone,C0002598
sfc n $nmbr$ $nmbr$,C4521536
by cause of death,C0007465;C4050444
mean age sd yr,C0001779;C0439234
sudden death,C0011071;C1964022;C4554103
mean body mass index sd kg m $nmbr$,C0022718;C0439209;C4054209
figure $nmbr$ subgroup analyses for the primary outcome,C2986480;C0205225;C0439612;C0439631
baseline post bronchodilator fev $nmbr$ sd ml,C0439526;C1705224;C3887665
sal n $nmbr$ $nmbr$,C0036140;C0037494;C0206136
predicted post bronchodilator fev sd ml,C0439526;C1705224;C3887665
fp n $nmbr$ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
region n,C0017446;C0205147
sfc n $nmbr$ $nmbr$,C4521536
united states,C0041703
mean age sd yr,C0001779;C0439234
asia pacific,C0003980
mean body mass index sd kg m $nmbr$,C0022718;C0439209;C4054209
eastern europe,C0015177
baseline post bronchodilator fev $nmbr$ sd ml,C0439526;C1705224;C3887665
western europe,C0043129
predicted post bronchodilator fev sd ml,C0439526;C1705224;C3887665
number of subjects in analysis,C0237753;C0449788;C0002778;C0936012;C1524024
region n,C0017446;C0205147
baseline mean fev $nmbr$ sd ml,C0439526;C1705224;C3887665
united states,C0041703
adjusted rate of fev $nmbr$ decline se ml yr,C0456081;C0871208;C1521828
asia pacific,C0003980
effect of covariates on slopes,C1280500;C1518681;C2348382;C0807955
eastern europe,C0015177
p $nmbr$ $nmbr$,C0369773;C2603361
western europe,C0043129
current n $nmbr$ $nmbr$,C0521116;C1705970
number of subjects in analysis,C0237753;C0449788;C0002778;C0936012;C1524024
former n $nmbr$ $nmbr$,C0205156;C0750523
baseline mean fev $nmbr$ sd ml,C0439526;C1705224;C3887665
female n $nmbr$ $nmbr$,C0043210;C0086287;C1705497;C1705498
adjusted rate of fev $nmbr$ decline se ml yr,C0456081;C0871208;C1521828
male n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
effect of covariates on slopes,C1280500;C1518681;C2348382;C0807955
$nmbr$ n $nmbr$,C0369718;C0441922
p $nmbr$ $nmbr$,C0369773;C2603361
$nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
current n $nmbr$ $nmbr$,C0521116;C1705970
predicted fev $nmbr$,C0681842;C3714541;C1882327
former n $nmbr$ $nmbr$,C0205156;C0750523
$nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
female n $nmbr$ $nmbr$,C0043210;C0086287;C1705497;C1705498
united states n $nmbr$ $nmbr$,C0041703
male n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
asia pacific n $nmbr$,C0003980
$nmbr$ n $nmbr$,C0369718;C0441922
eastern europe n $nmbr$ $nmbr$,C0015177
$nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
western europe n $nmbr$ $nmbr$,C0043129
predicted fev $nmbr$,C0681842;C3714541;C1882327
other n $nmbr$,C0369718;C0441922
$nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
ethnic origin,C0015031
united states n $nmbr$ $nmbr$,C0041703
white n $nmbr$ $nmbr$,C0007457;C0043157;C0220938
asia pacific n $nmbr$,C0003980
black n $nmbr$,C0005680;C0027567;C0085756;C0439541
eastern europe n $nmbr$ $nmbr$,C0015177
asian n $nmbr$,C0078988
western europe n $nmbr$ $nmbr$,C0043129
american hispanic n $nmbr$,C0596070;C0086409
other n $nmbr$,C0369718;C0441922
$nmbr$ to $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
ethnic origin,C0015031
exacerbations in the year before study,C4086268;C0439234;C0439508;C0557651;C2603343
white n $nmbr$ $nmbr$,C0007457;C0043157;C0220938
baseline sgrq total score,C0168634;C2964552;C1442488
black n $nmbr$,C0005680;C0027567;C0085756;C0439541
intensive therapy n $nmbr$,C0039798;C0087111;C1363945
asian n $nmbr$,C0078988
standard therapy n $nmbr$,C2936643
american hispanic n $nmbr$,C0596070;C0086409
median duration of diabetes yr,C0449238;C2926735
$nmbr$ to $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
previous cardiovascular event,C0205156;C1320716;C1552607
exacerbations in the year before study,C4086268;C0439234;C0439508;C0557651;C2603343
race or ethnic group f,C0034510;C1706779;C3853635;C0441840
baseline sgrq total score,C0168634;C2964552;C1442488
education,C0013621;C0013622;C0013658;C0039401
intensive therapy n $nmbr$,C0039798;C0087111;C1363945
less than high school,C0599395;C0683862;C0870649
standard therapy n $nmbr$,C2936643
high school graduate,C0870649;C1549971
median duration of diabetes yr,C0449238;C2926735
some college,C0557806
previous cardiovascular event,C0205156;C1320716;C1552607
college degree or higher,C0441889;C0449286;C0542560;C2348088;C0205250
race or ethnic group f,C0034510;C1706779;C3853635;C0441840
cigarette smoking status,C1519386
education,C0013621;C0013622;C0013658;C0039401
waist circumference cm,C0455829
less than high school,C0599395;C0683862;C0870649
medications,C0013227;C0802604;C2598133;C4284232
high school graduate,C0870649;C1549971
insulin,C0021641;C1533581;C1579433;C3714501
some college,C0557806
metformin,C0025598
college degree or higher,C0441889;C0449286;C0542560;C2348088;C0205250
any sulfonylurea,C0038766;C3536898
cigarette smoking status,C1519386
any thiazolidinedione,C0289779;C1257987;C3537039
waist circumference cm,C0455829
any antihypertensive agent,C0003364
medications,C0013227;C0802604;C2598133;C4284232
any thiazide diuretic,C0012802;C3536861
insulin,C0021641;C1533581;C1579433;C3714501
glycated hemoglobin,C0017853
metformin,C0025598
fasting serum glucose mg dl,C0202041;C0439269;C3534430
any sulfonylurea,C0038766;C3536898
median triglyceride mg dl,C0041004;C0439269
any thiazolidinedione,C0289779;C1257987;C3537039
potassium mg dl,C0032821;C0439269;C0202194;C0304475;C0597277;C3714637
any antihypertensive agent,C0003364
serum creatinine mg dl,C0201976;C0439269;C0600061
any thiazide diuretic,C0012802;C3536861
oxypurinol n $nmbr$,C0030086
glycated hemoglobin,C0017853
age yrs mean sd,C0001779;C2699239
fasting serum glucose mg dl,C0202041;C0439269;C3534430
male gender,C0086582;C1706180
median triglyceride mg dl,C0041004;C0439269
nyha functional class iii,C1882086;C0205245;C0542341;C2700217
potassium mg dl,C0032821;C0439269;C0202194;C0304475;C0597277;C3714637
lvef mean sd,C0428772;C2699239;C0488728
serum creatinine mg dl,C0201976;C0439269;C0600061
$nmbr$ mwt m,
oxypurinol n $nmbr$,C0030086
medication use,C0240320
age yrs mean sd,C0001779;C2699239
arb,C3888198
male gender,C0086582;C1706180
carvedilol,C0054836
nyha functional class iii,C1882086;C0205245;C0542341;C2700217
spironolactone,C0037982
lvef mean sd,C0428772;C2699239;C0488728
nitrates,C0028125
$nmbr$ mwt m,
etiology,C0015127;C1314792;C1524003
medication use,C0240320
idiopathic,C0332240
arb,C3888198
hypertensive,C0857121
carvedilol,C0054836
entry criteria,C1705654;C0243161
spironolactone,C0037982
hospitalized,C0701159
nitrates,C0028125
er visit,C0545082;C1512346;C2826704
etiology,C0015127;C1314792;C1524003
new hf medication,C0013227;C3244316;C4284232
idiopathic,C0332240
on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl,C0013227;C0439269;C0802604;C2598133;C4284232
hypertensive,C0857121
sua,
entry criteria,C1705654;C0243161
mean $nmbr$ th to $nmbr$ thquartile bnp pg ml,C0039725;C0039738;C1420718;C4282123;C4285344
hospitalized,C0701159
sildenafil n $nmbr$,C0529793
er visit,C0545082;C1512346;C2826704
mean sd age y mean bmi category,C0683312;C3889287
new hf medication,C0013227;C3244316;C4284232
missing ed duration y,C1551393;C0449238;C2926735;C1705492;C3272743
on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl,C0013227;C0439269;C0802604;C2598133;C4284232
range ed etiology n,C0015127;C1314792;C1524003
sua,
mixed,C0205430;C3160715
mean $nmbr$ th to $nmbr$ thquartile bnp pg ml,C0039725;C0039738;C1420718;C4282123;C4285344
organic,C0747055
sildenafil n $nmbr$,C0529793
psychogenic,C0458006
mean sd age y mean bmi category,C0683312;C3889287
mean iief ef score mean iief domain score by bmi,C3533236;C0578022
missing ed duration y,C1551393;C0449238;C2926735;C1705492;C3272743
ef domain,C1880389;C1883221;C3541951
range ed etiology n,C0015127;C1314792;C1524003
os domain,C1880389;C1883221;C3541951
mixed,C0205430;C3160715
is domain luts severity,C0439793;C0522510
organic,C0747055
moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
psychogenic,C0458006
severe,C0205082;C4050465;C4050466
mean iief ef score mean iief domain score by bmi,C3533236;C0578022
mean total ipss mean ipss by bmi,C0439175;C0439810
ef domain,C1880389;C1883221;C3541951
storage subscore,C0337174;C1698986;C1753314
os domain,C1880389;C1883221;C3541951
voiding subscore,C0042034;C4067975
is domain luts severity,C0439793;C0522510
mean qmax score by bmi,C3533236;C0578022
moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
sd standard deviation bmi body mass index ed erectile,C1305855;C3538926;C0030847
severe,C0205082;C4050465;C4050466
dysfunction ef erectile function iief i,C0021966;C0221138
mean total ipss mean ipss by bmi,C0439175;C0439810
nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
storage subscore,C0337174;C1698986;C1753314
erectile function ipss,C1019118;C1998280;C2827405;C3811063
voiding subscore,C0042034;C4067975
international prostate symptom score,C1998280
mean qmax score by bmi,C3533236;C0578022
luts lower urinary tract symptoms is,C0574785
sd standard deviation bmi body mass index ed erectile,C1305855;C3538926;C0030847
intercourse satisfac,C0009253
dysfunction ef erectile function iief i,C0021966;C0221138
tion os overall satisfaction qmax maximal urinary flow rate,C4086680;C0429784
nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
total n $nmbr$,C0439175;C0439810
erectile function ipss,C1019118;C1998280;C2827405;C3811063
famotidine $nmbr$ mg n $nmbr$,C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
international prostate symptom score,C1998280
sex male female n,C0086287
luts lower urinary tract symptoms is,C0574785
weight kg bmi kg m $nmbr$,C0005910;C1319635;C0043100;C1305866;C1705104
intercourse satisfac,C0009253
smoking status ongoing n,C1519386;C0549178
tion os overall satisfaction qmax maximal urinary flow rate,C4086680;C0429784
smoking status previous n,C1519386;C0205156;C1552607
total n $nmbr$,C0439175;C0439810
alcohol consumption yes n,C0001948;C1549445;C1705108;C1710701
famotidine $nmbr$ mg n $nmbr$,C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
caffeine consumption yes n,C0948365;C1549445;C1705108;C1710701
sex male female n,C0086287
hiatal hernia yes n,C3489393;C1549445;C1705108;C1710701
weight kg bmi kg m $nmbr$,C0005910;C1319635;C0043100;C1305866;C1705104
helicobacter pylori infection n,C0850666
smoking status ongoing n,C1519386;C0549178
pepsinogen i ii ratio,C0456603;C1547037
smoking status previous n,C1519386;C0205156;C1552607
days with heartburna days,C0439228
alcohol consumption yes n,C0001948;C1549445;C1705108;C1710701
severity of heartburnb,C0439793;C0522510
caffeine consumption yes n,C0948365;C1549445;C1705108;C1710701
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
hiatal hernia yes n,C3489393;C1549445;C1705108;C1710701
normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972;C0017654;C0439445;C1424601
helicobacter pylori infection n,C0850666
mildlydecreased baseline gfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
pepsinogen i ii ratio,C0456603;C1547037
pravastatin,C0085542
days with heartburna days,C0439228
usual care,C3538928;C1947933
severity of heartburnb,C0439793;C0522510
patients randomly assigned,C0030705;C1516050;C1552601
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
age at lipid randomization y,C0001779;C0065033
normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972;C0017654;C0439445;C1424601
body mass index kg m $nmbr$ baseline systolic blood,C0022718;C0439209;C4054209;C0005767;C0005768;C0229664
mildlydecreased baseline gfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
pravastatin,C0085542
baseline diastolic blood,C0005767;C0005768;C0229664
usual care,C3538928;C1947933
history of coronary heart disease at,C0683519;C0730226;C0850708;C0944983
patients randomly assigned,C0030705;C1516050;C1552601
history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
age at lipid randomization y,C0001779;C0065033
other atherosclerotic cvd st depression on,C0007222;C0520887
body mass index kg m $nmbr$ baseline systolic blood,C0022718;C0439209;C4054209;C0005767;C0005768;C0229664
electrocardiogram,C0013798;C1547122;C1623258
pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile,C0017654;C0439445;C1424601;C1979963;C2003903
baseline diastolic blood,C0005767;C0005768;C0229664
ldl cholesterol,C0023824;C0202117
history of coronary heart disease at,C0683519;C0730226;C0850708;C0944983
fasting triglycerides,C0015663;C0041004
history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
randomly assigned to ace,C1516050;C1552601
other atherosclerotic cvd st depression on,C0007222;C0520887
inhibitor,C1999216
electrocardiogram,C0013798;C1547122;C1623258
randomly assigned to calcium channel blocker,C1516050;C1552601
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile,C0017654;C0439445;C1424601;C1979963;C2003903
randomly assigned to diuretic,C1516050;C1552601
ldl cholesterol,C0023824;C0202117
esrd or $nmbr$ dedine in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
fasting triglycerides,C0015663;C0041004
esrd or $nmbr$ decline in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
randomly assigned to ace,C1516050;C1552601
gfr $nmbr$ $nmbr$,C0017654;C1424601
inhibitor,C1999216
gfr,C0017654;C1424601
randomly assigned to calcium channel blocker,C1516050;C1552601
parameter mean s d,C0549193;C0444504;C2347634;C2348143;C1704769;C2350001
randomly assigned to diuretic,C1516050;C1552601
total study itt population n $nmbr$,C3258257
esrd or $nmbr$ dedine in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
asian itt population total n $nmbr$,C0078988;C0032659;C1257890
esrd or $nmbr$ decline in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
asian itt population by treatment group,C1257890
gfr $nmbr$ $nmbr$,C0017654;C1424601
combination n $nmbr$,C0205195;C1947911;C3811910
gfr,C0017654;C1424601
dutasteride n $nmbr$,C0754659
parameter mean s d,C0549193;C0444504;C2347634;C2348143;C1704769;C2350001
tamsulosin n $nmbr$,C0257343
total study itt population n $nmbr$,C3258257
time since first luts years,C0556970;C0205435;C1279901
asian itt population total n $nmbr$,C0078988;C0032659;C1257890
prostate volume cm $nmbr$,C1441416
asian itt population by treatment group,C1257890
mean s d,C0444504;C2347634;C2348143
combination n $nmbr$,C0205195;C1947911;C3811910
mean total serum psa,C2986589;C0229671;C1546774;C1550100
dutasteride n $nmbr$,C0754659
ngml total mean ipss score,C2964552
tamsulosin n $nmbr$,C0257343
qmax ml s,C0439526;C1705224;C3887665
time since first luts years,C0556970;C0205435;C1279901
bii score,C0449820;C4050231
prostate volume cm $nmbr$,C1441416
bph related health status,C0005001;C0018759;C1704272
mean s d,C0444504;C2347634;C2348143
sexually active,C0241028
mean total serum psa,C2986589;C0229671;C1546774;C1550100
previous a blocker use,C0205156;C1552607;C0042153;C0457083;C1947944
ngml total mean ipss score,C2964552
previous $nmbr$ ari use,C0042153;C0457083;C1947944
qmax ml s,C0439526;C1705224;C3887665
chondroitin,C0008454
bii score,C0449820;C4050231
g c,C0439267
bph related health status,C0005001;C0018759;C1704272
structural,C0678594
sexually active,C0241028
gait,C0016928
previous a blocker use,C0205156;C1552607;C0042153;C0457083;C1947944
subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
previous $nmbr$ ari use,C0042153;C0457083;C1947944
age in years mean sd,C1510829;C0444504;C2347634;C2348143
chondroitin,C0008454
haq pain scale mean,C0444504;C2347634;C2348143
g c,C0439267
years duration oa,C0029408;C3887876
structural,C0678594
symptoms mean sd,C0444504;C2699239;C2347634;C2348143
gait,C0016928
percentages,C0439165;C1549488;C1561533
subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
bmi $nmbr$ $nmbr$ overweight,C0578022;C0497406
age in years mean sd,C1510829;C0444504;C2347634;C2348143
bmi $nmbr$ obese,C0578022;C0028754
haq pain scale mean,C0444504;C2347634;C2348143
knees n,C0022742
years duration oa,C0029408;C3887876
kl $nmbr$,C1366480;C1416656;C1704887
symptoms mean sd,C0444504;C2699239;C2347634;C2348143
mean of jsw mm,C0444504;C2347634;C2348143
percentages,C0439165;C1549488;C1561533
median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
bmi $nmbr$ $nmbr$ overweight,C0578022;C0497406
interquartile range mm,C4330985;C4554674
bmi $nmbr$ obese,C0578022;C0028754
figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width,C1518681;C3875154;C1517945;C0205363;C0224497;C1547282;C0681850;C1550501;C1706203;C2349001;C2697811
knees n,C0022742
figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C0028873;C1696465;C1706408;C1511726;C3245479;C3714741;C0022742;C0224497
kl $nmbr$,C1366480;C1416656;C1704887
colesevelam hydrochloride group n $nmbr$,C0541154;C0441848
mean of jsw mm,C0444504;C2347634;C2348143
placebo group n $nmbr$,C0032042;C0441848;C1696465;C1706408
median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
height cm mean sd,C0444504;C2699239;C2347634;C2348143
interquartile range mm,C4330985;C4554674
weight kg mean sd,C0005910;C2699239;C0043100;C1305866;C1705104
figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width,C1518681;C3875154;C1517945;C0205363;C0224497;C1547282;C0681850;C1550501;C1706203;C2349001;C2697811
hbalc mean sd,C0444504;C2699239;C2347634;C2348143
figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C0028873;C1696465;C1706408;C1511726;C3245479;C3714741;C0022742;C0224497
fasting plasma glucose mg dl mean sd,C0202042;C2699239;C0455280
colesevelam hydrochloride group n $nmbr$,C0541154;C0441848
oral anti dm drug status no,C0442027;C4521986
placebo group n $nmbr$,C0032042;C0441848;C1696465;C1706408
metformin alone,C0025598;C0205171;C0439044;C0679994
height cm mean sd,C0444504;C2699239;C2347634;C2348143
metformin other oral anti dm drugs,C0025598;C0029167;C0175795;C0304289
weight kg mean sd,C0005910;C2699239;C0043100;C1305866;C1705104
concomitant medications in $nmbr$ of subjects no,C0013227;C0802604;C2598133;C4284232
hbalc mean sd,C0444504;C2699239;C2347634;C2348143
angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
fasting plasma glucose mg dl mean sd,C0202042;C2699239;C0455280
p blocking agents selective,C0233660;C0332206
oral anti dm drug status no,C0442027;C4521986
hmg coa reductase inhibitors,C0360714;C2756999;C3539119
metformin alone,C0025598;C0205171;C0439044;C0679994
multivitamins,C0301532;C3714835
metformin other oral anti dm drugs,C0025598;C0029167;C0175795;C0304289
other plain vitamin preparations,C0042890
concomitant medications in $nmbr$ of subjects no,C0013227;C0802604;C2598133;C4284232
platelet aggregation inhibitors excluding heparin,C0032177;C0019134;C0770546
angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
propionic acid derivatives,C0033482;C0695274;C3540752
p blocking agents selective,C0233660;C0332206
proton pump inhibitors,C0358591;C1384478;C3540020
hmg coa reductase inhibitors,C0360714;C2756999;C3539119
thiazides,C0541746
multivitamins,C0301532;C3714835
thyroid hormone,C0040135;C4522017
other plain vitamin preparations,C0042890
concomitant oral anti dm drugs no a,C0029167;C0175795;C0304289
platelet aggregation inhibitors excluding heparin,C0032177;C0019134;C0770546
sulfonylureasb,
propionic acid derivatives,C0033482;C0695274;C3540752
thiazolidinedionesc,
proton pump inhibitors,C0358591;C1384478;C3540020
a glucosidase inhibitors $nmbr$,C1512211
thiazides,C0541746
nateglinide and repaglinide,C0903898;C0246689
thyroid hormone,C0040135;C4522017
concomitant oral anti dm drugs no a,C0029167;C0175795;C0304289
abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol,C0022709;C1305855;C0444686;C1441506;C0439209;C0332849;C0489786;C0681850;C1550501;C1706203;C2349001;C2697811;C1515187;C0442027;C4521986;C0013227;C1254351;C4288115;C3687832;C0042295;C0541154;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408;C0332257;C1552866;C2700399;C0008287;C0017642;C0040372;C0872972;C0289313;C0795660;C1512211;C0050393;C0066535
sulfonylureasb,
rolofylline dose,C0178602;C0869039;C1114758
thiazolidinedionesc,
$nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
a glucosidase inhibitors $nmbr$,C1512211
male n n,C0086582;C1706180;C1706428;C1706429
nateglinide and repaglinide,C0903898;C0246689
ischemic heart disease,C0010054;C0151744
atrial fibrillation atrial flutter,C0155709
abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol,C0022709;C1305855;C0444686;C1441506;C0439209;C0332849;C0489786;C0681850;C1550501;C1706203;C2349001;C2697811;C1515187;C0442027;C4521986;C0013227;C1254351;C4288115;C3687832;C0042295;C0541154;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408;C0332257;C1552866;C2700399;C0008287;C0017642;C0040372;C0872972;C0289313;C0795660;C1512211;C0050393;C0066535
nyha class when patient was last in stable condition before admission,C1882083;C0030705;C0677946;C3538874;C0184666;C0809949
rolofylline dose,C0178602;C0869039;C1114758
bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n,C0054015;C0439297;C1095989;C1417808;C2982014;C4284038
$nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
creatinine clearance by c g ml min,C0151280
male n n,C0086582;C1706180;C1706428;C1706429
medications on admission,C0013227;C0802604;C2598133;C4284232;C0457453
ischemic heart disease,C0010054;C0151744
aldosterone inhibitor,C0002007
atrial fibrillation atrial flutter,C0155709
iv nitrates,C0022326;C0028125;C4265176
nyha class when patient was last in stable condition before admission,C1882083;C0030705;C0677946;C3538874;C0184666;C0809949
rank based on treatment placebo,C0032042;C1696465;C1706408
bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n,C0054015;C0439297;C1095989;C1417808;C2982014;C4284038
baseline variable,C0439828;C4553760
creatinine clearance by c g ml min,C0151280
placeboa,
medications on admission,C0013227;C0802604;C2598133;C4284232;C0457453
atorvastatinb,
aldosterone inhibitor,C0002007
treatment lipid interaction,C0023779;C1704675
iv nitrates,C0022326;C0028125;C4265176
unadjusted hr $nmbr$ ci for $nmbr$ sd increment,C0008107;C3259781
rank based on treatment placebo,C0032042;C1696465;C1706408
likelihood test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
baseline variable,C0439828;C4553760
unadjusted hr $nmbr$ ci for $nmbr$ standard deviation increment,C0008107;C3259781
placeboa,
apob apoa i,C0085201;C1677784
atorvastatinb,
$nmbr$ e $nmbr$,
treatment lipid interaction,C0023779;C1704675
ldlc hdlc,C1416822;C1704429
unadjusted hr $nmbr$ ci for $nmbr$ sd increment,C0008107;C3259781
ldlc,C1416822
likelihood test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
apob,C0003593;C3252643
unadjusted hr $nmbr$ ci for $nmbr$ standard deviation increment,C0008107;C3259781
apoa i,C0085201;C1677784
apob apoa i,C0085201;C1677784
non hdlc,C1518422;C1704429
$nmbr$ e $nmbr$,
tc hdlc,C0039411;C1704429;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
ldlc hdlc,C1416822;C1704429
cholesterol,C0008377
ldlc,C1416822
febuxostat $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apob,C0003593;C3252643
allopurinol $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apoa i,C0085201;C1677784
age mean sd years,C1510829;C0444504;C2347634;C2348143
non hdlc,C1518422;C1704429
minority,C0026192
tc hdlc,C0039411;C1704429;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
bmi mean sd kg m $nmbr$,C0022718;C0439209;C4054209
cholesterol,C0008377
cardiovascular disease,C0007222
febuxostat $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gout history mean sd years,C0018099;C0439234
allopurinol $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history presence of tophi,C0150312;C0392148;C3854307
age mean sd years,C1510829;C0444504;C2347634;C2348143
recent use of allopurinol within $nmbr$ days of,C1524063;C0002144;C0439228
minority,C0026192
randomization,C0034656
bmi mean sd kg m $nmbr$,C0022718;C0439209;C4054209
low dose aspirin use,C0042153;C0457083;C1947944
cardiovascular disease,C0007222
mild to moderate renal impairment,C1299392;C1565489
gout history mean sd years,C0018099;C0439234
chlorthalidone vs amlodipine,C0008294;C0051696
history presence of tophi,C0150312;C0392148;C3854307
chlorthalidone vs lisinopril,C0008294;C0065374
recent use of allopurinol within $nmbr$ days of,C1524063;C0002144;C0439228
chlorthalidone vs doxazosin,C0008294;C0114873
randomization,C0034656
hr $nmbr$ ci univariate cox proportional hazard regression,C0684320;C0684321;C1836830
low dose aspirin use,C0042153;C0457083;C1947944
pef,C0030771;C1518922;C1542834
mild to moderate renal impairment,C1299392;C1565489
ref,C1425988
chlorthalidone vs amlodipine,C0008294;C0051696
no ef data,C1511726;C3245479;C3714741
chlorthalidone vs lisinopril,C0008294;C0065374
hr $nmbr$ ci multivariate cox proportional hazard regression,C0684320;C0684321;C1836830
chlorthalidone vs doxazosin,C0008294;C0114873
hospitalized hf,C0018488;C1313497;C1538440;C3273279
hr $nmbr$ ci univariate cox proportional hazard regression,C0684320;C0684321;C1836830
atorvastatin $nmbr$ mg ezetimibe $nmbr$ mg n $nmbr$,C1319635;C3643658
pef,C0030771;C1518922;C1542834
atorvastatin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ref,C1425988
mean age yrs,C0444504;C0001779;C2347634;C2348143
no ef data,C1511726;C3245479;C3714741
mean body mass index kg m $nmbr$,C0022718;C0439209;C4054209
hr $nmbr$ ci multivariate cox proportional hazard regression,C0684320;C0684321;C1836830
ncep atp iii risk factors,C0035648;C1553898
hospitalized hf,C0018488;C1313497;C1538440;C3273279
the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides,C0023824;C0202117;C0439269;C0205195;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2360800;C0332257;C0023822;C1442160;C0392885;C0025266;C0043210;C0062152
atorvastatin $nmbr$ mg ezetimibe $nmbr$ mg n $nmbr$,C1319635;C3643658
other forms of atherosclerosis^,C0348078;C0376315
atorvastatin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean age yrs,C0444504;C0001779;C2347634;C2348143
multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$,C0035648;C1282512;C1553898;C0439234;C0439508
mean body mass index kg m $nmbr$,C0022718;C0439209;C4054209
family history of premature chdj,C0241889;C0151526;C0205252;C4018905
ncep atp iii risk factors,C0035648;C1553898
metabolic syndrome $nmbr$ of $nmbr$ characteristics,C0524620;C1521970
waist circumference s $nmbr$ men or $nmbr$ cm women,C0455829;C0025266;C0043210
the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides,C0023824;C0202117;C0439269;C0205195;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2360800;C0332257;C0023822;C1442160;C0392885;C0025266;C0043210;C0062152
triglycerides $nmbr$ mg dl,C0041004;C0439269
other forms of atherosclerosis^,C0348078;C0376315
fasting blood glucose $nmbr$ mg dl,C0428568;C0439269;C1261430
multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$,C0035648;C1282512;C1553898;C0439234;C0439508
visit $nmbr$ ldl cholesterol strata,C0023824;C0202117
family history of premature chdj,C0241889;C0151526;C0205252;C4018905
metabolic syndrome $nmbr$ of $nmbr$ characteristics,C0524620;C1521970
values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel,C0042295;C0444504;C2347634;C2348143;C0205448;C0030705;C1881192;C0348078;C0376315;C0277793;C1261512;C1304680;C0260518;C1261367;C0280604;C3542407;C0439475;C0003364;C0011900;C1704338;C1704656;C1527178;C1705938
waist circumference s $nmbr$ men or $nmbr$ cm women,C0455829;C0025266;C0043210
benazepril amlodipine group n $nmbr$,C0051696;C0441848
triglycerides $nmbr$ mg dl,C0041004;C0439269
benazepril hydrochlorothiazide group n $nmbr$,C0717481;C0441848
fasting blood glucose $nmbr$ mg dl,C0428568;C0439269;C1261430
$nmbr$ yr no,C0439234
visit $nmbr$ ldl cholesterol strata,C0023824;C0202117
race or ethnic group no f,C0034510;C1706779;C3853635;C0015031;C1879937;C0016327
region no,C0017446;C0205147
values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel,C0042295;C0444504;C2347634;C2348143;C0205448;C0030705;C1881192;C0348078;C0376315;C0277793;C1261512;C1304680;C0260518;C1261367;C0280604;C3542407;C0439475;C0003364;C0011900;C1704338;C1704656;C1527178;C1705938
nordic countries,C0036273
benazepril amlodipine group n $nmbr$,C0051696;C0441848
body mass index blood pressure mm hg,C0005893;C0439475;C0578022;C1305855
benazepril hydrochlorothiazide group n $nmbr$,C0717481;C0441848
pulse beats min,C0232117;C0439385;C0391850;C1947910
$nmbr$ yr no,C0439234
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C3811844;C0439445;C0005902
race or ethnic group no f,C0034510;C1706779;C3853635;C0015031;C1879937;C0016327
serum values^,C0229671;C0042295;C1546774;C1550100
region no,C0017446;C0205147
glucose mg dl,C0017725;C0439269
nordic countries,C0036273
potassium mmol liter,C0032821;C0475211;C0202194;C0304475;C0597277;C3714637
body mass index blood pressure mm hg,C0005893;C0439475;C0578022;C1305855
total cholesterol mg dl,C0201950;C0439269;C0543421
pulse beats min,C0232117;C0439385;C0391850;C1947910
high density lipoprotein cholesterol mg dl,C0023822;C0439269
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C3811844;C0439445;C0005902
previous antihypertensive treatment no,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
serum values^,C0229671;C0042295;C1546774;C1550100
no of agents,C0450442;C1254351;C1521826
glucose mg dl,C0017725;C0439269
lipid lowering agents,C0086440
potassium mmol liter,C0032821;C0475211;C0202194;C0304475;C0597277;C3714637
antiplatelets agents,C0085826
total cholesterol mg dl,C0201950;C0439269;C0543421
risk factors no,C0035648;C1553898
high density lipoprotein cholesterol mg dl,C0023822;C0439269
previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
previous antihypertensive treatment no,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previous stroke,C0038454;C4554100
no of agents,C0450442;C1254351;C1521826
previous hospitalization for unstable angina,C0019993;C0002965
lipid lowering agents,C0086440
renal disease,C0022658
antiplatelets agents,C0085826
previous coronary revascularization,C0205156;C0877341;C1552607
risk factors no,C0035648;C1553898
left ventricular hypertrophy,C0149721;C3484363
previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
dyslipidemia,C0242339
previous stroke,C0038454;C4554100
week o baseline mean sd,C0168634;C2699239;C1442488
previous hospitalization for unstable angina,C0019993;C0002965
week $nmbr$ mean sd,C0332174;C2699239;C0439230
renal disease,C0022658
ls mean change from baseline $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
previous coronary revascularization,C0205156;C0877341;C1552607
ls mean difference between treatment groups $nmbr$ ci,C1705241;C2347634;C1705242
left ventricular hypertrophy,C0149721;C3484363
fasting indices,C0015663;C4033634
dyslipidemia,C0242339
fasting insulin miu ml,C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
week o baseline mean sd,C0168634;C2699239;C1442488
placebo $nmbr$,C0032042;C1696465;C1706408
week $nmbr$ mean sd,C0332174;C2699239;C0439230
sitagliptin $nmbr$,C1565750
ls mean change from baseline $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
fasting proinsulin pmol l,C0015663;C0033362;C0439284;C3813208
ls mean difference between treatment groups $nmbr$ ci,C1705241;C2347634;C1705242
fasting c peptide ng ml,C0015663;C0006558;C0439275
fasting indices,C0015663;C4033634
homa b,
fasting insulin miu ml,C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
homa ir,C0022065;C0022071;C1448132
placebo $nmbr$,C0032042;C1696465;C1706408
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ z,
sitagliptin $nmbr$,C1565750
quicki,
fasting proinsulin pmol l,C0015663;C0033362;C0439284;C3813208
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ y,
fasting c peptide ng ml,C0015663;C0006558;C0439275
postprandial indices,C0376674;C4033634
homa b,
$nmbr$ h postprandial insulin miu ml,C0021641;C0439457;C1533581;C1579433;C3714501
homa ir,C0022065;C0022071;C1448132
$nmbr$ h postprandial proinsulin pmol l,C2827799;C0033362;C3813208
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ z,
$nmbr$ h postprandial c peptide ng ml,C2827809;C0006558
quicki,
insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min,C0600653;C0702093;C1524029;C3813700;C0918012;C1552854;C1637833;C2986546
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ y,
placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
postprandial indices,C0376674;C4033634
composite index of insulin sensitivity isi,C0600653;C0918012;C1552854;C1637833;C2986546
$nmbr$ h postprandial insulin miu ml,C0021641;C0439457;C1533581;C1579433;C3714501
disposition index,C0743223;C0600653;C0918012;C1552854;C1637833;C2986546;C1705555
$nmbr$ h postprandial proinsulin pmol l,C2827799;C0033362;C3813208
$nmbr$ h postprandial c peptide ng ml,C2827809;C0006558
figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides,C1705241;C1705242;C1142985;C0360714;C0032042;C1696465;C1706408;C0392747;C0443172;C4319952;C3890735;C4048285;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0062152
insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min,C0600653;C0702093;C1524029;C3813700;C0918012;C1552854;C1637833;C2986546
figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup,C3484017;C3484018;C0168634;C1442488;C0039798;C0679199;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1079230;C0005680;C0027567;C0085756;C0439541;C1305855;C0745133;C0237753;C0449788;C0030705;C1292734
placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
no draining fistulas,C0013103;C0180499;C4265177;C0016169
composite index of insulin sensitivity isi,C0600653;C0918012;C1552854;C1637833;C2986546
week $nmbr$ of patients,C0332174;C0439230;C0030705
disposition index,C0743223;C0600653;C0918012;C1552854;C1637833;C2986546;C1705555
no baseline immunosuppressant use,C0042153;C0457083;C1947944
figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides,C1705241;C1705242;C1142985;C0360714;C0032042;C1696465;C1706408;C0392747;C0443172;C4319952;C3890735;C4048285;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0062152
both adalimumab groups n $nmbr$ baseline immunosuppressant use,C0042153;C0457083;C1947944
$nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup,C3484017;C3484018;C0168634;C1442488;C0039798;C0679199;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1079230;C0005680;C0027567;C0085756;C0439541;C1305855;C0745133;C0237753;C0449788;C0030705;C1292734
both adalimumab groups n $nmbr$ no baseline cd related antibiotic use,C1122087;C0441848;C0042153;C0457083;C1947944
no draining fistulas,C0013103;C0180499;C4265177;C0016169
both adalimumab groups n $nmbr$ baseline cd related antibiotic use,C0042153;C0457083;C1947944
week $nmbr$ of patients,C0332174;C0439230;C0030705
both adalimumab groups n $nmbr$,C1122087;C0441848
no baseline immunosuppressant use,C0042153;C0457083;C1947944
figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively,C0565965;C0019016;C1825777;C3538758;C0168634;C1442488;C0042295;C0167117;C0332173;C0243174
both adalimumab groups n $nmbr$ baseline immunosuppressant use,C0042153;C0457083;C1947944
dexlansoprazole mr,C0024485;C1417249;C2347167;C3254418;C4050513
$nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
$nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
both adalimumab groups n $nmbr$ no baseline cd related antibiotic use,C1122087;C0441848;C0042153;C0457083;C1947944
non hispanic or latino,C1518424;C0086528
both adalimumab groups n $nmbr$ baseline cd related antibiotic use,C0042153;C0457083;C1947944
american indian or alaskan native,C0002460;C0238611;C0302891
both adalimumab groups n $nmbr$,C1122087;C0441848
native hawaiian or other pacific islander,C0337920;C0242191
figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively,C0565965;C0019016;C1825777;C3538758;C0168634;C1442488;C0042295;C0167117;C0332173;C0243174
multiracial,C1881928
dexlansoprazole mr,C0024485;C1417249;C2347167;C3254418;C4050513
age y mean s d,C0001779;C0444504;C2347634;C2348143
$nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
weight kg mean s d,C0005910;C1275571;C0043100;C1305866;C1705104
non hispanic or latino,C1518424;C0086528
height cm mean s d,C0439392;C0444504;C2347634;C2348143
american indian or alaskan native,C0002460;C0238611;C0302891
bm $nmbr$ kg m $nmbr$ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
native hawaiian or other pacific islander,C0337920;C0242191
helicobacter pylori negative n,C4688581
multiracial,C1881928
eo severity by la classification at baseline baseline of the healing study n,C0439793;C0522510;C0168634;C0043240;C0205249;C1442488
age y mean s d,C0001779;C0444504;C2347634;C2348143
c,
weight kg mean s d,C0005910;C1275571;C0043100;C1305866;C1705104
d,
height cm mean s d,C0439392;C0444504;C2347634;C2348143
duration of treatment in the healing study n,C0444921;C0043240;C0205249
bm $nmbr$ kg m $nmbr$ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
$nmbr$ week,C0332174;C0439230
helicobacter pylori negative n,C4688581
previous treatment in the healing study n,C1521826;C3161471
eo severity by la classification at baseline baseline of the healing study n,C0439793;C0522510;C0168634;C0043240;C0205249;C1442488
dexlansoprazole mr $nmbr$ mg qd,C0024485;C0332173;C1417249;C2347167;C3254418;C4050513
c,
lansoprazole $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
d,
characteristic age mean sd yr,C0001779;C0439234
duration of treatment in the healing study n,C0444921;C0043240;C0205249
dronedarone n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0766326
$nmbr$ week,C0332174;C0439230
placebo n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
previous treatment in the healing study n,C1521826;C3161471
all n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
dexlansoprazole mr $nmbr$ mg qd,C0024485;C0332173;C1417249;C2347167;C3254418;C4050513
atrial fibrillation or flutter no,C0004238;C0344434;C1963067;C0016385;C2242390
lansoprazole $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
structural heart disease no f,C1290384;C0016327
characteristic age mean sd yr,C0001779;C0439234
hypertension no,C0020538;C1963138
dronedarone n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0766326
coronary heart disease no,C0010054;C0010068;C1956346
placebo n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
valvular heart disease no,C0018824;C1963123
all n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
nonischemic cardiomyopathy no,C0878544
atrial fibrillation or flutter no,C0004238;C0344434;C1963067;C0016385;C2242390
history of chf nyha class ii or iii no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439070;C1705160
structural heart disease no f,C1290384;C0016327
lvef no i,C0428772;C0488728;C0021966;C0221138
hypertension no,C0020538;C1963138
lone atrial fibrillation no,C0340489
coronary heart disease no,C0010054;C0010068;C1956346
pacemaker no,C0030163;C0810633;C1546728;C3275122;C3853703
valvular heart disease no,C0018824;C1963123
medications in use at baseline no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
nonischemic cardiomyopathy no,C0878544
calcium antagonists,C0006684
history of chf nyha class ii or iii no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439070;C1705160
statins,C0360714
lvef no i,C0428772;C0488728;C0021966;C0221138
vitamin k antagonists,C3653316
lone atrial fibrillation no,C0340489
early eptifibatide group n $nmbr$,C0253563;C0441848
pacemaker no,C0030163;C0810633;C1546728;C3275122;C3853703
delayed eptifibatide group n $nmbr$,C0205421;C0441848;C1545665;C3272602
medications in use at baseline no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
median yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
calcium antagonists,C0006684
interquartile range yr,C1711350;C0439234
statins,C0360714
region ofenrollment,C0017446;C0205147
vitamin k antagonists,C3653316
middle east africa or asia pacific,C0001741;C0003980
early eptifibatide group n $nmbr$,C0253563;C0441848
previous cabg,C0205156;C0010055;C1552607
delayed eptifibatide group n $nmbr$,C0205421;C0441848;C1545665;C3272602
estimated creatinine clearance,C0750572;C0812399
median yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
median ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
interquartile range yr,C1711350;C0439234
interquartile range ml min,C1711350;C0439445
region ofenrollment,C0017446;C0205147
killip class ii iii or iv,C2697846;C0022326;C4265176
middle east africa or asia pacific,C0001741;C0003980
qualifying high risk features,C1514624;C0035648
previous cabg,C0205156;C0010055;C1552607
age $nmbr$ yr elevated biomarkers and st segment changes,C0001779;C0005516;C0232326
estimated creatinine clearance,C0750572;C0812399
age $nmbr$ yr and elevated biomarkers,C0001779;C0439234;C0205250;C0005516;C3163633
median ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
elevated biomarkers and st segment changes,C0205250;C0005516;C3163633;C0232326
interquartile range ml min,C1711350;C0439445
age $nmbr$ yr and st segment changes,C0001779;C0439234;C0232326
killip class ii iii or iv,C2697846;C0022326;C4265176
age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular,C0001779;C0005516;C0005847;C1558950;C1801960
qualifying high risk features,C1514624;C0035648
elevated troponin,C0205250;C0041199;C3163633
age $nmbr$ yr elevated biomarkers and st segment changes,C0001779;C0005516;C0232326
presentation to tertiary care hospital,C0449450;C0337954
age $nmbr$ yr and elevated biomarkers,C0001779;C0439234;C0205250;C0005516;C3163633
randomized,C0034656;C3815594
elevated biomarkers and st segment changes,C0205250;C0005516;C3163633;C0232326
low $nmbr$ $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
age $nmbr$ yr and st segment changes,C0001779;C0439234;C0232326
intermediate $nmbr$ $nmbr$,C0205103;C1550465;C2827755;C3889971
age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular,C0001779;C0005516;C0005847;C1558950;C1801960
high $nmbr$ $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
elevated troponin,C0205250;C0041199;C3163633
medical therapy during index hospitalization,C0418981;C0019993
presentation to tertiary care hospital,C0449450;C0337954
antithrombin,C0003438;C0003440;C4521254
randomized,C0034656;C3815594
unfractionated heparin only,C0019134;C2825026
low $nmbr$ $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
low molecular weight heparin only,C0019139;C3536766
intermediate $nmbr$ $nmbr$,C0205103;C1550465;C2827755;C3889971
both unfractionated heparin and low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
high $nmbr$ $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
neither unfractionated heparin nor low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
medical therapy during index hospitalization,C0418981;C0019993
at any time,C0040223;C3541383
antithrombin,C0003438;C0003440;C4521254
early use intended,C0042153;C0457083;C1947944;C1283828;C1551357
unfractionated heparin only,C0019134;C2825026
angiotensin receptor blocker,C0034787;C1622222
low molecular weight heparin only,C0019139;C3536766
temporal data and management strategy,C1511726;C3245479;C3714741;C0001554;C0679199;C0376636;C1273870;C3273539
both unfractionated heparin and low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
time from onset of symptoms to presentation hr,C1320528;C0449450
neither unfractionated heparin nor low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
time from presentation to randomization hr,C0040223;C3541383;C0034656
at any time,C0040223;C3541383
time from randomization to study drug initiation hr,C0040223;C3541383;C0013175;C0589507;C1158830;C1704686
early use intended,C0042153;C0457083;C1947944;C1283828;C1551357
time from randomization to coronary angiography hr,C0040223;C3541383;C0085532;C1548829
angiotensin receptor blocker,C0034787;C1622222
pci no,C4049621
temporal data and management strategy,C1511726;C3245479;C3714741;C0001554;C0679199;C0376636;C1273870;C3273539
time from randomization to pci hr,C0040223;C3541383;C4049621
time from onset of symptoms to presentation hr,C1320528;C0449450
duration of infusion before pci hr,C0449238;C2926735;C4049621
time from presentation to randomization hr,C0040223;C3541383;C0034656
duration of infusion after pci hr,C0449238;C2926735;C4049621
time from randomization to study drug initiation hr,C0040223;C3541383;C0013175;C0589507;C1158830;C1704686
cabg no,C0010055
time from randomization to coronary angiography hr,C0040223;C3541383;C0085532;C1548829
time from randomization to cabg hr,C0040223;C3541383;C0010055
pci no,C4049621
duration of infusion before cabg hr,C0449238;C2926735;C0010055
time from randomization to pci hr,C0040223;C3541383;C4049621
medical management only no,C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
duration of infusion before pci hr,C0449238;C2926735;C4049621
duration of infusion during medical management hr,C0449238;C2926735;C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
duration of infusion after pci hr,C0449238;C2926735;C4049621
total no of patients,C0439175;C0439810;C0030705
cabg no,C0010055
early eptifibatide,C1279919;C0253563
time from randomization to cabg hr,C0040223;C3541383;C0010055
delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
duration of infusion before cabg hr,C0449238;C2926735;C0010055
troponin,C0041199
medical management only no,C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
positive,C0439178;C1446409;C1514241;C2825490;C3812269
duration of infusion during medical management hr,C0449238;C2926735;C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
early clopidogrel intended,C1279919;C0070166;C1283828;C1551357
total no of patients,C0439175;C0439810;C0030705
time to randomization,C0040223;C3541383
early eptifibatide,C1279919;C0253563
$nmbr$ hr,
delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
heparin use,C0239945
troponin,C0041199
unfractionated only,
positive,C0439178;C1446409;C1514241;C2825490;C3812269
low molecular weight only,C0041667
early clopidogrel intended,C1279919;C0070166;C1283828;C1551357
type of hospital care,C0332307;C1547052
time to randomization,C0040223;C3541383
primary,C0205225;C0439612;C0439631
$nmbr$ hr,
tertiary,C0205372
heparin use,C0239945
region of the world,C0017446;C0205147
unfractionated only,
region ofthe world,C0017446;C2700280;C0205147
low molecular weight only,C0041667
clopidogrel plus aspirin n $nmbr$,C0070166;C0004057
type of hospital care,C0332307;C1547052
aspirin n $nmbr$,C0004057
primary,C0205225;C0439612;C0439631
body mass indexf,C0518010
tertiary,C0205372
chads $nmbr$ ^,C0007928;C1413373
region of the world,C0017446;C0205147
mean score,C3533236
region ofthe world,C0017446;C2700280;C0205147
score no,C0449820;C4050231
clopidogrel plus aspirin n $nmbr$,C0070166;C0004057
history of atrial fibrillation type no,C0729790;C0332307;C1547052
aspirin n $nmbr$,C0004057
permanent,C0205355
body mass indexf,C0518010
paroxysmal,C0205311
chads $nmbr$ ^,C0007928;C1413373
persistent,C0205322;C0332996
mean score,C3533236
atrial fibrillation duration no,C0449238;C2926735
score no,C0449820;C4050231
$nmbr$ mo to $nmbr$ yr,C0026544;C0332177
history of atrial fibrillation type no,C0729790;C0332307;C1547052
history of hypertension no,C0455527
permanent,C0205355
history of stroke or tia no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
paroxysmal,C0205311
history of ischemic heart disease no,C0683519;C0730226;C0850708;C0944983
persistent,C0205322;C0332996
cad,C1504769;C2239547;C3813548;C4284121
atrial fibrillation duration no,C0449238;C2926735
diabetes mellitus no,C0011849
$nmbr$ mo to $nmbr$ yr,C0026544;C0332177
peripheral artery disease no,C1704436;C4025272
history of hypertension no,C0455527
congestive heart failure no,C0018802
history of stroke or tia no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
cardiac pacemaker no,C0030163;C0037189
history of ischemic heart disease no,C0683519;C0730226;C0850708;C0944983
ecg findings at baseline no,C0438154;C0168634;C1442488
cad,C1504769;C2239547;C3813548;C4284121
atrial flutter,C0004239;C0344423;C1963068
diabetes mellitus no,C0011849
sinus rhythm,C0232201
peripheral artery disease no,C1704436;C4025272
medication use at baseline no,C0240320;C0168634;C1442488
congestive heart failure no,C0018802
vka,
cardiac pacemaker no,C0030163;C0037189
antiarrhythmic agent,C0003195;C0301380
ecg findings at baseline no,C0438154;C0168634;C1442488
reason for enrollment in active a no,C0392360;C0205177;C3853793;C3888249
atrial flutter,C0004239;C0344423;C1963068
specific risk of bleeding^,C0205369;C3251812;C1552740
sinus rhythm,C0232201
physician s judgment that vka inappropriate],C0031831;C0804815;C0022423;C1548788;C3537135;C3542467
medication use at baseline no,C0240320;C0168634;C1442488
patient s preference not to take vka only reason,C0030705;C0558295;C1549513;C1518422;C1515187;C0392360
vka,
western europe and israel,C0043129;C0022271
antiarrhythmic agent,C0003195;C0301380
south africa,C0037712
reason for enrollment in active a no,C0392360;C0205177;C3853793;C3888249
tadalafil $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
specific risk of bleeding^,C0205369;C3251812;C1552740
tadalafil $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
physician s judgment that vka inappropriate],C0031831;C0804815;C0022423;C1548788;C3537135;C3542467
ed severity visit $nmbr$,C0545082;C1512346;C2826704
patient s preference not to take vka only reason,C0030705;C0558295;C1549513;C1518422;C1515187;C0392360
normal or mild iief ef $nmbr$ $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972;C2945599;C3641331
western europe and israel,C0043129;C0022271
moderate iief ef $nmbr$ $nmbr$ n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
south africa,C0037712
severe iief ef $nmbr$ $nmbr$ n,C0205082;C3641331;C4050465;C4050466
tadalafil $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ed duration visit $nmbr$,C0545082;C1512346;C2826704
tadalafil $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ moto,
ed severity visit $nmbr$,C0545082;C1512346;C2826704
$nmbr$ yr n,C0439234
normal or mild iief ef $nmbr$ $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972;C2945599;C3641331
iief ef domain score visit $nmbr$,C0545082;C1512346;C2826704
moderate iief ef $nmbr$ $nmbr$ n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
iief ef domain score visit $nmbr$ y,C0449820;C0545082;C1512346;C2826704;C4050231
tadalafil,C1176316
severe iief ef $nmbr$ $nmbr$ n,C0205082;C3641331;C4050465;C4050466
p values,C1709380
ed duration visit $nmbr$,C0545082;C1512346;C2826704
$nmbr$ moto,
$nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ yr n,C0439234
$nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
iief ef domain score visit $nmbr$,C0545082;C1512346;C2826704
interaction,C1704675
$nmbr$ yr n $nmbr$,C0439234
iief ef domain score visit $nmbr$ y,C0449820;C0545082;C1512346;C2826704;C4050231
tadalafil,C1176316
$nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
p values,C1709380
bph luts severity,C0439793;C0522510
$nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
moderate ipss,C1019118;C1998280;C2827405;C3811063
$nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
severe ipss $nmbr$ n $nmbr$,C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
interaction,C1704675
psa,C3810537;C3813209
$nmbr$ yr n $nmbr$,C0439234
$nmbr$ $nmbr$ ng ml n $nmbr$,C0439275
$nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
prior a blocker use,C0332152;C2826257;C0042153;C0457083;C1947944
bph luts severity,C0439793;C0522510
yes n $nmbr$,C1549445;C1705108;C1710701
moderate ipss,C1019118;C1998280;C2827405;C3811063
no n $nmbr$,C0369718;C0441922
severe ipss $nmbr$ n $nmbr$,C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
prior ed therapy,C1514463;C3538926
psa,C3810537;C3813209
age y gender n,C0001779;C0079399;C1522384
$nmbr$ $nmbr$ ng ml n $nmbr$,C0439275
african descent,C0205386;C0680043
prior a blocker use,C0332152;C2826257;C0042153;C0457083;C1947944
weight kg duration of pah n,C0449238;C2926735
yes n $nmbr$,C1549445;C1705108;C1710701
$nmbr$ y pathogenesis n,C0543483;C0699748
no n $nmbr$,C0369718;C0441922
idiopathic familial,C0015576;C0241888
prior ed therapy,C1514463;C3538926
anorexigen use,C0042153;C0457083;C1947944
age y gender n,C0001779;C0079399;C1522384
connective tissue disease,C0009782
african descent,C0205386;C0680043
associated with an atrial septal defect,C0332281;C0018817
weight kg duration of pah n,C0449238;C2926735
surgical repair of vsd or pda $nmbr$ year duration,C0374711;C0018818;C0449238;C2926735
$nmbr$ y pathogenesis n,C0543483;C0699748
concomitant use of bosentan n,C1524063;C0252643
idiopathic familial,C0015576;C0241888
six minute walk distance m,C3900196
anorexigen use,C0042153;C0457083;C1947944
borg dyspnea score who functional class n,C0013404;C0205245;C0542341;C2700217;C1963100
connective tissue disease,C0009782
class iii,C0441887;C2698969
associated with an atrial septal defect,C0332281;C0018817
class iv,C0441888;C2698970
surgical repair of vsd or pda $nmbr$ year duration,C0374711;C0018818;C0449238;C2926735
hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0449381;C4281788;C0030705;C4684790
concomitant use of bosentan n,C1524063;C0252643
mean pulmonary artery pressure mm hg,C0428642;C0439475
six minute walk distance m,C3900196
cardiac index l mn m $nmbr$,C0026327;C0026405;C4285072
borg dyspnea score who functional class n,C0013404;C0205245;C0542341;C2700217;C1963100
pulmonary vascular resistance dyne s cm $nmbr$,C0308914;C0600130
class iii,C0441887;C2698969
all itt sutajects,
class iv,C0441888;C2698970
bosentan use,C0042153;C0457083;C1947944
hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0449381;C4281788;C0030705;C4684790
pah etiology,C0015127;C1314792;C1524003
mean pulmonary artery pressure mm hg,C0428642;C0439475
repaired s p shunts,C0205340;C0232180;C0542331;C1442858
cardiac index l mn m $nmbr$,C0026327;C0026405;C4285072
others,C1955473;C3539125
baseline $nmbr$ mlnute walk distance,C0168634;C0429886;C1442488
pulmonary vascular resistance dyne s cm $nmbr$,C0308914;C0600130
$nmbr$ meters,C0441074
all itt sutajects,
medan $nmbr$ year old,C0439234;C0580836;C0439508
bosentan use,C0042153;C0457083;C1947944
pah etiology,C0015127;C1314792;C1524003
baseline who function class,C0456387;C1518526;C1705943
repaired s p shunts,C0205340;C0232180;C0542331;C1442858
lor ii,C1710602;C4082587
others,C1955473;C3539125
iii or iv,C0439070;C1705160;C0022326;C4265176
baseline $nmbr$ mlnute walk distance,C0168634;C0429886;C1442488
table $nmbr$ not standard baseline characteristics table,C0039224;C1706074
$nmbr$ meters,C0441074
fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs,C0349966;C3272907;C1337208;C0023824;C0445604;C1079230;C1515021
medan $nmbr$ year old,C0439234;C0580836;C0439508
saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$,C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline who function class,C0456387;C1518526;C1705943
saxa $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lor ii,C1710602;C4082587
metformin n $nmbr$ $nmbr$,C0025598
iii or iv,C0439070;C1705160;C0022326;C4265176
age $nmbr$ years t,C1510829
table $nmbr$ not standard baseline characteristics table,C0039224;C1706074
sexy,
racey z,
fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs,C0349966;C3272907;C1337208;C0023824;C0445604;C1079230;C1515021
black african american,C0085756
saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$,C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diabetes duration years,C0011847;C0439234;C0011849
saxa $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ t,C2603360
metformin n $nmbr$ $nmbr$,C0025598
fpg mg dl x,C0439269
age $nmbr$ years t,C1510829
sexy,
figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin,C0019016;C2986480;C1825777;C3538758;C1611934
racey z,
golimumab,C2353893
black african american,C0085756
proportion of patients who achieved acr $nmbr$ n n,C1709707;C0030705
diabetes duration years,C0011847;C0439234;C0011849
odds ratio $nmbr$ ci,C0008107;C3259781
$nmbr$ t,C2603360
$nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fpg mg dl x,C0439269
combined golimumab groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin,C0019016;C2986480;C1825777;C3538758;C1611934
dmard at baseline,C0242708;C0168634;C1442488
golimumab,C2353893
number of previous tnfa inhibitors,C0237753;C0449788
proportion of patients who achieved acr $nmbr$ n n,C1709707;C0030705
anti ccp antibodies,C1624602
odds ratio $nmbr$ ci,C0008107;C3259781
rheumatoid factor,C0035448;C0201660
$nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
reason for discontinuation of previous tnfa inhibitor,C0392360;C0205156;C1552607
combined golimumab groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
patient assessment of pain $nmbr$ $nmbr$ cm vas,C0679830
dmard at baseline,C0242708;C0168634;C1442488
lack of effectiveness,C0235828
number of previous tnfa inhibitors,C0237753;C0449788
patient global assessment of disease activity $nmbr$ $nmbr$ cm vas,C4054228;C0042815;C3536884;C3827561
anti ccp antibodies,C1624602
unrelated to effectiveness,C0445356;C1704623
rheumatoid factor,C0035448;C0201660
physician global assessment of disease activity $nmbr$ $nmbr$ cm vas,C4050369;C0042815;C3536884;C3827561
reason for discontinuation of previous tnfa inhibitor,C0392360;C0205156;C1552607
assessment of physical function $nmbr$ $nmbr$ haq di,C0031809
patient assessment of pain $nmbr$ $nmbr$ cm vas,C0679830
c reactive protein concentration mg l,C0006560;C0439268;C1413716;C4048285
lack of effectiveness,C0235828
erythrocyte sedimentation rate mm h,C1176468;C0456680;C1619634
patient global assessment of disease activity $nmbr$ $nmbr$ cm vas,C4054228;C0042815;C3536884;C3827561
das $nmbr$ score,C0449820;C4050231
unrelated to effectiveness,C0445356;C1704623
facit f score,C3272505;C0449820;C4050231
physician global assessment of disease activity $nmbr$ $nmbr$ cm vas,C4050369;C0042815;C3536884;C3827561
methotrexate treatment,C0746573
assessment of physical function $nmbr$ $nmbr$ haq di,C0031809
hydroxychloroquine treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
c reactive protein concentration mg l,C0006560;C0439268;C1413716;C4048285
sulfasalazine treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
erythrocyte sedimentation rate mm h,C1176468;C0456680;C1619634
no methotrexate hydroxychloroquine or sulfasalazine treatment,C0025677;C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
das $nmbr$ score,C0449820;C4050231
treatment for latent tuberculosis^,C0749724
facit f score,C3272505;C0449820;C4050231
zoledronic acid,C0257685
methotrexate treatment,C0746573
$nmbr$ $nmbr$ yr,C0439234
hydroxychloroquine treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
age at menopause yr,C1625754;C1629609
sulfasalazine treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
stratum,
americas,C0002454;C0596070
no methotrexate hydroxychloroquine or sulfasalazine treatment,C0025677;C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
asia,C0003980
treatment for latent tuberculosis^,C0749724
bmi kg m $nmbr$ a,C0578022;C1532718
zoledronic acid,C0257685
bmia,
$nmbr$ $nmbr$ yr,C0439234
$nmbr$ $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
age at menopause yr,C1625754;C1629609
$nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
stratum,
weight kg a,C0022718;C0439209;C4054209
americas,C0002454;C0596070
asia,C0003980
height loss,C0424641
$nmbr$ $nmbr$ to $nmbr$ cm,
bmi kg m $nmbr$ a,C0578022;C1532718
$nmbr$ cm,
bmia,
baseline vfx,C0168634;C1442488
$nmbr$ $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
history of falls,C1561668;C2919132
unknown,C0439673;C3541433;C4050014
weight kg a,C0022718;C0439209;C4054209
height loss,C0424641
physical activity hours walking wk,C0015259;C0439227;C0026606;C0080331;C4283795;C4321241;C4321242;C0332174;C0439230
$nmbr$ $nmbr$ to $nmbr$ cm,
prior bisphosphonate usage,C0012544;C0457083;C2267018
$nmbr$ cm,
total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
baseline vfx,C0168634;C1442488
standardized total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
history of falls,C1561668;C2919132
femoral neck bmd g cm $nmbr$,C0015815;C0439267
unknown,C0439673;C3541433;C4050014
femoral neck t score,C0449820;C4050231
physical activity hours walking wk,C0015259;C0439227;C0026606;C0080331;C4283795;C4321241;C4321242;C0332174;C0439230
femoralneck t scorebybaselinevfxstatus,
prior bisphosphonate usage,C0012544;C0457083;C2267018
$nmbr$ $nmbr$ vfx,
total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
$nmbr$ ml min,C0439445
standardized total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
category,C0683312;C3889287
femoral neck bmd g cm $nmbr$,C0015815;C0439267
mean change in fn bmd,C0392747;C0443172;C1705241;C4319952
femoral neck t score,C0449820;C4050231
least squares mean between treatment difference $nmbr$ ci,C0023189;C0444504;C2347634;C2348143
femoralneck t scorebybaselinevfxstatus,
p value within category,C1709380;C0683312;C3889287
$nmbr$ $nmbr$ vfx,
p value interaction,C1709380;C1704675
$nmbr$ ml min,C0439445
and vfx status,C0449438
category,C0683312;C3889287
op no vfx,
mean change in fn bmd,C0392747;C0443172;C1705241;C4319952
op vfx,
least squares mean between treatment difference $nmbr$ ci,C0023189;C0444504;C2347634;C2348143
no op no vfx,
p value within category,C1709380;C0683312;C3889287
no op vfx,
p value interaction,C1709380;C1704675
height loss cm,C0424641
$nmbr$ $nmbr$ to $nmbr$,
and vfx status,C0449438
op no vfx,
prior bp use,C0042153;C0457083;C1947944
op vfx,
crcl ml min,C1846718;C0439445
no op no vfx,
infliximab,C0666743
no op vfx,
p valuea,C0369773;C2603361
height loss cm,C0424641
$nmbr$ mg kg,C0439272
$nmbr$ $nmbr$ to $nmbr$,
combined,C0205195
prior bp use,C0042153;C0457083;C1947944
patients randomized n,C0030705;C0034656;C3815594
crcl ml min,C1846718;C0439445
male sex n,C0086582
infliximab,C0666743
white race n,C0007457;C0043157
p valuea,C0369773;C2603361
disease duration y,C0872146
$nmbr$ mg kg,C0439272
colonic area involved,C0017446;C0205146;C1314939
combined,C0205195
left side n,C0205091
patients randomized n,C0030705;C0034656;C3815594
extensive n,C0205231
male sex n,C0086582
mayo clinic scoreb,C0002424;C0442592
white race n,C0007457;C0043157
c reactive proteinc,C0205332
disease duration y,C0872146
mean mg dl,C0444504;C0439269;C2347634;C2348143
colonic area involved,C0017446;C0205146;C1314939
median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
left side n,C0205091
elevated crp n,C0742906
extensive n,C0205231
concomitant medication n,C0521115;C0013227;C3244316;C4284232
mayo clinic scoreb,C0002424;C0442592
any ulcerative colitis medication,C0013227;C3244316;C4284232
c reactive proteinc,C0205332
corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
mean mg dl,C0444504;C0439269;C2347634;C2348143
$nmbr$ mg day,C0439422
median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
aminosalicylates,C0368663
elevated crp n,C0742906
immunomodulators,C0001551;C0005525;C1527392
concomitant medication n,C0521115;C0013227;C3244316;C4284232
azathioprine,C0004482
any ulcerative colitis medication,C0013227;C3244316;C4284232
$nmbr$ mercaptopurine,C0000618
corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
refractory to corticosteroids n,C0205269;C0001617;C3539185;C3540725;C3540726;C3540727
$nmbr$ mg day,C0439422
smoking status n,C1519386
aminosalicylates,C0368663
nonsmoker,C0337672;C0425293;C4554605
immunomodulators,C0001551;C0005525;C1527392
prior smoker,C0337671
azathioprine,C0004482
infliiimab i,C0021966;C0221138
$nmbr$ mercaptopurine,C0000618
hazard inleraction,C0598697
s $nmbr$,
refractory to corticosteroids n,C0205269;C0001617;C3539185;C3540725;C3540726;C3540727
ratio,C0456603;C1547037
smoking status n,C1519386
$nmbr$ cl,C0596019
nonsmoker,C0337672;C0425293;C4554605
study,C0557651;C2603343
prior smoker,C0337671
act $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
infliiimab i,C0021966;C0221138
nap,C0870935;C1423800;C4283878
hazard inleraction,C0598697
inhixanab $nmbr$ mgikg versus piacom,
s $nmbr$,
inflotmas io mgluj versus piecew,C1046794;C3146236
ratio,C0456603;C1547037
$nmbr$ cl,C0596019
cortteosterom relrsclory status,C0449438
study,C0557651;C2603343
uc disease durslion,C0012634
act $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
ss years,C2699257;C0439234;C3891295;C4551874
nap,C0870935;C1423800;C4283878
$nmbr$ j $nmbr$ $nmbr$ $nmbr$,
inhixanab $nmbr$ mgikg versus piacom,
$nmbr$ yearstos is years,C0439234
inflotmas io mgluj versus piecew,C1046794;C3146236
ibs $nmbr$ $nmbr$,C0022104;C0432306
cortteosterom relrsclory status,C0449438
is years,C0439234
uc disease durslion,C0012634
$nmbr$ z $nmbr$ $nmbr$ $nmbr$,
ss years,C2699257;C0439234;C3891295;C4551874
exlertl ot disease,C1318464;C0012634;C1418208;C1705587
$nmbr$ j $nmbr$ $nmbr$ $nmbr$,
umied,
extenswe,
$nmbr$ yearstos is years,C0439234
batellna c reective protein,C0033684
ibs $nmbr$ $nmbr$,C0022104;C0432306
$nmbr$ $nmbr$ tng cll,C0023434
is years,C0439234
$nmbr$ mgrdl,
$nmbr$ z $nmbr$ $nmbr$ $nmbr$,
baseline mayo score,C0449820;C4050231
exlertl ot disease,C1318464;C0012634;C1418208;C1705587
umied,
center location,C0450429;C1515974;C4284930;C4284931
extenswe,
czech repumc,C0337799
batellna c reective protein,C0033684
nc,C0027964;C0028407;C0067895;C0265987
$nmbr$ $nmbr$ tng cll,C0023434
israel,C0022271
$nmbr$ mgrdl,
southern hemisphere,C1710133
baseline mayo score,C0449820;C4050231
s asa compounds at baseline,C0205198;C1706082
center location,C0450429;C1515974;C4284930;C4284931
recervini,
czech repumc,C0337799
$nmbr$ $nmbr$ s s,C0565930;C2603362
nc,C0027964;C0028407;C0067895;C0265987
noirecerving,
israel,C0022271
coiticosieroids at baseline,C0168634;C1442488
southern hemisphere,C1710133
$nmbr$ mgday p eq,C0205163;C0439185
s asa compounds at baseline,C0205198;C1706082
ssomgdayp eq,C0205163;C0439185
recervini,
$nmbr$ up and or aza at baseline,C0004482;C0168634;C1442488
$nmbr$ $nmbr$ s s,C0565930;C2603362
recervng,
noirecerving,
not receiving,C1518422;C1514756
coiticosieroids at baseline,C0168634;C1442488
conieosieroids and or $nmbr$ mp,C0024944
$nmbr$ mgday p eq,C0205163;C0439185
and or aza at baseline,C0004482;C0168634;C1442488
ssomgdayp eq,C0205163;C0439185
noliecervrig,
$nmbr$ up and or aza at baseline,C0004482;C0168634;C1442488
$nmbr$ $nmbr$ s,
recervng,
combined infliximab,C0205195;C0666743
not receiving,C1518422;C1514756
hazard interaction,C0598697;C1704675
conieosieroids and or $nmbr$ mp,C0024944
gertder,
and or aza at baseline,C0004482;C0168634;C1442488
baseline age,C0168634;C0001779;C1442488
noliecervrig,
baseline smoking status,C0168634;C1519386;C1442488
$nmbr$ $nmbr$ s,
non smoker,C0337672;C0425293;C4554605
combined infliximab,C0205195;C0666743
previous segments resection s,C0015252;C0728940
hazard interaction,C0598697;C1704675
other uc related gi surgical procedure,C0439849;C0543467;C0445223
gertder,
glulisine oad,
baseline age,C0168634;C0001779;C1442488
glulisine monotherapy,
baseline smoking status,C0168634;C1519386;C1442488
oad only,
non smoker,C0337672;C0425293;C4554605
itt patients n,C0030705
previous segments resection s,C0015252;C0728940
mean age s d years,C0444504;C0001779;C2347634;C2348143;C0439234
other uc related gi surgical procedure,C0439849;C0543467;C0445223
mean bmi s d kg m $nmbr$,C0444504;C0578022;C2347634;C2348143;C0022718;C0439209;C4054209
glulisine oad,
mean hba $nmbr$ c s d,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
glulisine monotherapy,
treatment with sulphonylurea n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
oad only,
treatment with sulphonylurea biguanide n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
itt patients n,C0030705
fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0013175;C1710181
mean age s d years,C0444504;C0001779;C2347634;C2348143;C0439234
mean bmi s d kg m $nmbr$,C0444504;C0578022;C2347634;C2348143;C0022718;C0439209;C4054209
fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0444504;C2347634;C2348143;C0019016;C0033727;C0369286;C0441932;C0564385;C4528284;C1825777;C3538758;C2348070;C0202042;C0455280;C0015663;C1955477;C1710181
mean hba $nmbr$ c s d,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
placebo pioglitazone n $nmbr$,C0032042;C0071097;C1696465;C1706408
treatment with sulphonylurea n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatment with sulphonylurea biguanide n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
alogliptin $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0013175;C1710181
$nmbr$ n,C0369718;C0441922
black or african american,C0005680;C0027567;C0085756;C0439541
fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0444504;C2347634;C2348143;C0019016;C0033727;C0369286;C0441932;C0564385;C4528284;C1825777;C3538758;C2348070;C0202042;C0455280;C0015663;C1955477;C1710181
non hispanic,C1518424
placebo pioglitazone n $nmbr$,C0032042;C0071097;C1696465;C1706408
diabetes history mean sd years,C0011847;C0439234;C0011849
alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pioglitazone dose mean sd mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alogliptin $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
other hypoglycemic agent n,C0020616
$nmbr$ n,C0369718;C0441922
sulfonylurea,C0038766;C3536898
black or african american,C0005680;C0027567;C0085756;C0439541
median range,C1514721;C2348147;C3542016
non hispanic,C1518424
$nmbr$ n of patients,C0369718;C0441922
diabetes history mean sd years,C0011847;C0439234;C0011849
figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo,C0392747;C0443172;C0332174;C0439230;C0439780;C0062259;C0042295;C0019016;C1825777;C3538758;C0369773;C1520214;C2603361;C0032042;C1696465;C1706408
pioglitazone dose mean sd mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with tamsulosin,C0257343
other hypoglycemic agent n,C0020616
without tamsulosin,C0257343
sulfonylurea,C0038766;C3536898
no japanese,C0376247;C1556094
median range,C1514721;C2348147;C3542016
time since bph diagnosis years,C0556970;C0005001;C1704272
$nmbr$ n of patients,C0369718;C0441922
no previous alpha blocker use,C0042153;C0457083;C1947944
figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo,C0392747;C0443172;C0332174;C0439230;C0439780;C0062259;C0042295;C0019016;C1825777;C3538758;C0369773;C1520214;C2603361;C0032042;C1696465;C1706408
ipss unit,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
with tamsulosin,C0257343
prostate volume ml,C0439526;C1705224;C3887665
without tamsulosin,C0257343
figure $nmbr$ primary e cacy results by patient subgroup,C0205225;C1547647;C0439612;C0439631
no japanese,C0376247;C1556094
shfm annual mortality,C0026565;C0026566
time since bph diagnosis years,C0556970;C0005001;C1704272
quintile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C1508496
no previous alpha blocker use,C0042153;C0457083;C1947944
randomized treatment n,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C3815594
ipss unit,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
nyha class iii n,C1882086
prostate volume ml,C0439526;C1705224;C3887665
ischemic hf n,C0475224;C0018488;C1313497;C1538440;C3273279
figure $nmbr$ primary e cacy results by patient subgroup,C0205225;C1547647;C0439612;C0439631
serum sodium meq l,C0523891;C0439375
shfm annual mortality,C0026565;C0026566
systolic bp mm hg,C0871470;C0439475
quintile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C1508496
furosemide equivalent mg kg,C0016860;C0439272
randomized treatment n,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C3815594
digoxin n,C0012265
nyha class iii n,C1882086
ace i or arb n,C0021966;C0221138;C3888198
ischemic hf n,C0475224;C0018488;C1313497;C1538440;C3273279
j $nmbr$ blocker n,
serum sodium meq l,C0523891;C0439375
statin n,C0360714
systolic bp mm hg,C0871470;C0439475
carvedilol n,C0054836
furosemide equivalent mg kg,C0016860;C0439272
qrs $nmbr$ ms n,C2349943;C3539704;C3713294
digoxin n,C0012265
qrs width ms,C2349943;C3539704;C3713294
ace i or arb n,C0021966;C0221138;C3888198
$nmbr$ min walk distance ft,C1881534;C3890579
j $nmbr$ blocker n,
quintile n,C1508496
statin n,C0360714
total deaths n,C0439175;C0011065;C1306577;C0439810
carvedilol n,C0054836
placebo mortality rate events per $nmbr$ person y,C0441471;C3541888
qrs $nmbr$ ms n,C2349943;C3539704;C3713294
relative risk comparing icd therapy and placebo,C0242492;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408
qrs width ms,C2349943;C3539704;C3713294
relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd,C0242492;C0596019;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408;C1524063;C0233324;C1515273;C1705313;C2826302
$nmbr$ min walk distance ft,C1881534;C3890579
rr $nmbr$ cl,C4554402;C0596019
quintile n,C1508496
ii $nmbr$,C1710602;C4082587
total deaths n,C0439175;C0011065;C1306577;C0439810
iii $nmbr$,C0439070;C1705160
placebo mortality rate events per $nmbr$ person y,C0441471;C3541888
iv $nmbr$,C0022326;C4265176
relative risk comparing icd therapy and placebo,C0242492;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408
v $nmbr$,
relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd,C0242492;C0596019;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408;C1524063;C0233324;C1515273;C1705313;C2826302
dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rr $nmbr$ cl,C4554402;C0596019
warfarin,C0043031
ii $nmbr$,C1710602;C4082587
male sex no total no,C0086582;C0439175;C0439810
iii $nmbr$,C0439070;C1705160
type of atrial fibrillation no total no,C0332307;C1547052;C0439175;C0439810
iv $nmbr$,C0022326;C4265176
chads $nmbr$ scoref,C0007928;C1413373
v $nmbr$,
$nmbr$ or $nmbr$ no total no,C0439175;C0439810
dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ no total no,C0439175;C0439810
warfarin,C0043031
$nmbr$ $nmbr$ no total no,C0439175;C0439810
male sex no total no,C0086582;C0439175;C0439810
previous stroke or transient ischemic attack no total,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
type of atrial fibrillation no total no,C0332307;C1547052;C0439175;C0439810
heart failure no total no,C0018801;C0018802;C4554158;C0439175;C0439810
chads $nmbr$ scoref,C0007928;C1413373
medications in use at baseline no total no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101;C0439175;C0439810
$nmbr$ or $nmbr$ no total no,C0439175;C0439810
arb or ace inhibitor,C3888198;C0003015;C4541021
$nmbr$ no total no,C0439175;C0439810
stating,C1301808;C1442792;C3148680
$nmbr$ $nmbr$ no total no,C0439175;C0439810
proton pump inhibitor,C0358591;C3536754;C4521480
previous stroke or transient ischemic attack no total,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
h $nmbr$ receptor antagonist,C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
heart failure no total no,C0018801;C0018802;C4554158;C0439175;C0439810
long term vka therapy,C0039798;C0087111;C1363945
medications in use at baseline no total no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101;C0439175;C0439810
patients total no,C0439175;C0439810
arb or ace inhibitor,C3888198;C0003015;C4541021
dabigatran $nmbr$ mg $nmbr$ mg per yr,C1319635;C0439234
stating,C1301808;C1442792;C3148680
hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl,C2985465;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
proton pump inhibitor,C0358591;C3536754;C4521480
p value for interaction dosage with dabigatran $nmbr$ mg,C1709380;C0178602;C2986497;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
h $nmbr$ receptor antagonist,C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
b i,C0021966;C0221138
long term vka therapy,C0039798;C0087111;C1363945
g,C0439267
patients total no,C0439175;C0439810
weight,C0005910;C0043100;C1305866;C1705104
dabigatran $nmbr$ mg $nmbr$ mg per yr,C1319635;C0439234
$nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl,C2985465;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ kg,C0022718;C0439209;C4054209
p value for interaction dosage with dabigatran $nmbr$ mg,C1709380;C0178602;C2986497;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bi,
b i,C0021966;C0221138
european or arab,C0239307;C1535514;C0282540;C1561448
g,C0439267
r,C0205090;C0684010;C2603358
weight,C0005910;C0043100;C1305866;C1705104
$nmbr$ $nmbr$ ml min,C0439445
$nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
chads $nmbr$ score,C0449820;C4050231
$nmbr$ kg,C0022718;C0439209;C4054209
$nmbr$ or $nmbr$,
bi,
h,C0033727;C0369286;C0441932;C0564385;C4528284
european or arab,C0239307;C1535514;C0282540;C1561448
symptomatic heart fail,C0018787;C0231175
r,C0205090;C0684010;C2603358
ure,
$nmbr$ $nmbr$ ml min,C0439445
stroke ortia,C0038454;C4554100
chads $nmbr$ score,C0449820;C4050231
k,C0597277;C1708601
$nmbr$ or $nmbr$,
u,C0439148
h,C0033727;C0369286;C0441932;C0564385;C4528284
central europe,C0682369
symptomatic heart fail,C0018787;C0231175
south asia,C1710133;C0003980
ure,
east asia,C0015631
stroke ortia,C0038454;C4554100
j,
k,C0597277;C1708601
in,
u,C0439148
aspirin use at baseline,C0042153;C0457083;C1947944
central europe,C0682369
b h,C0033727;C0369286;C0441932;C0564385;C4528284
south asia,C1710133;C0003980
amiodarone use at baseline yes $nmbr$ $nmbr$,C0042153;C0457083;C1947944
east asia,C0015631
ppi use at baseline,C0042153;C0457083;C1947944
j,
$nmbr$ ],
in,
dexlansoprazole mr n $nmbr$,C0024485;C1417249;C2347167;C3254418;C4050513
aspirin use at baseline,C0042153;C0457083;C1947944
lansoprazole n $nmbr$,C0050940
b h,C0033727;C0369286;C0441932;C0564385;C4528284
mean age s d year,C0444504;C0001779;C2347634;C2348143;C0439234;C0439508
amiodarone use at baseline yes $nmbr$ $nmbr$,C0042153;C0457083;C1947944
missing,C1551393;C1705492;C3272743
ppi use at baseline,C0042153;C0457083;C1947944
mean bmii s d kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ ],
alcohol users n,C0556297
dexlansoprazole mr n $nmbr$,C0024485;C1417249;C2347167;C3254418;C4050513
smokers n,C0337664
lansoprazole n $nmbr$,C0050940
caffeine users n,C3532939
mean age s d year,C0444504;C0001779;C2347634;C2348143;C0439234;C0439508
observation,C0302523;C0700325;C1964257;C3889687
missing,C1551393;C1705492;C3272743
$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean bmii s d kg m $nmbr$,C0022718;C0439209;C4054209
participants,C0679646
alcohol users n,C0556297
demographic characteristics,C0683970
smokers n,C0337664
mean sd age y,C0444504;C0001779;C2347634;C2348143
caffeine users n,C3532939
minimum maximum,C0806909;C1552615;C2826546
observation,C0302523;C0700325;C1964257;C3889687
study eye characteristics,C1568011;C0015392;C0700042
$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd e etdrs visual acuity letter score snellen equivalent,C0205163;C0439185
participants,C0679646
duration of macular edema mo,C0449238;C2926735
demographic characteristics,C0683970
iop mm hg,C0578862;C0439475
mean sd age y,C0444504;C0001779;C2347634;C2348143
iop lowering medication,C0578862;C0441994;C2003888;C0013227;C3244316;C4284232
minimum maximum,C0806909;C1552615;C2826546
phakic,
study eye characteristics,C1568011;C0015392;C0700042
imaging data mean sd,C0011923;C2699239;C0079595
mean sd e etdrs visual acuity letter score snellen equivalent,C0205163;C0439185
oct center point thickness pm,C0030266;C4049155
duration of macular edema mo,C0449238;C2926735
total macular volume mean sd mm $nmbr$,C4330985;C4554674
iop mm hg,C0578862;C0439475
area of retinal thickening within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
iop lowering medication,C0578862;C0441994;C2003888;C0013227;C3244316;C4284232
area of retinal hemorrhage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
phakic,
area of fluorescein leakage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
imaging data mean sd,C0011923;C2699239;C0079595
$nmbr$ da of capillary nonperfusion in the eyec,C0011318;C3668815
oct center point thickness pm,C0030266;C4049155
mean sd nonstudy eye e etdrs visual acuity letter score,C3533236;C0042812
total macular volume mean sd mm $nmbr$,C4330985;C4554674
other clinical characteristics,C0683325
area of retinal thickening within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
coronary artery disease,C0010054;C0010068;C1956346
area of retinal hemorrhage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
history of cancer,C0455471
area of fluorescein leakage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
abbreviations da disc area e etdrs electronic early treatment diabetic retinopathy study iop intraocular pressure oct optical coherence tomography,C3161471;C0920367
$nmbr$ da of capillary nonperfusion in the eyec,C0011318;C3668815
age gd lesion,C0221198;C1546698
mean sd nonstudy eye e etdrs visual acuity letter score,C3533236;C0042812
effect estimate,C1280500;C0750572;C1518681;C2348382
other clinical characteristics,C0683325
age $nmbr$ gd lesion $nmbr$ n $nmbr$,C0001779;C0221198;C1546698
coronary artery disease,C0010054;C0010068;C1956346
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0596019
history of cancer,C0455471
age $nmbr$ n $nmbr$,C0001779
abbreviations da disc area e etdrs electronic early treatment diabetic retinopathy study iop intraocular pressure oct optical coherence tomography,C3161471;C0920367
cutoffs,C1442160
age gd lesion,C0221198;C1546698
combo facilitated pci,C4049621
effect estimate,C1280500;C0750572;C1518681;C2348382
abciximab facilitated pci,C0288672;C4049621
age $nmbr$ gd lesion $nmbr$ n $nmbr$,C0001779;C0221198;C1546698
primary pci,C0205225;C0439612;C0439631
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0596019
combo vs primary,C0205225;C0439612;C0439631
age $nmbr$ n $nmbr$,C0001779
abciximab vs primary,C0288672;C0205225;C0439612;C0439631
cutoffs,C1442160
timi $nmbr$,
combo facilitated pci,C4049621
timi $nmbr$ and spoke,
abciximab facilitated pci,C0288672;C4049621
timi $nmbr$ and spoke and time $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
primary pci,C0205225;C0439612;C0439631
figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population,C0028873;C2986535;C0011900;C1704338;C1704656;C0087111;C0032659;C1257890;C1292734;C1522326
combo vs primary,C0205225;C0439612;C0439631
lm $nmbr$ $nmbr$,C1261082;C1551056
abciximab vs primary,C0288672;C0205225;C0439612;C0439631
glargine $nmbr$,C0907402
timi $nmbr$,
sex male female,C0086287
timi $nmbr$ and spoke,
race ethnicity zz,C0015031;C2347310;C0243103
timi $nmbr$ and spoke and time $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
black african,C0337824
figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population,C0028873;C2986535;C0011900;C1704338;C1704656;C0087111;C0032659;C1257890;C1292734;C1522326
descent,C0205386;C0680043
lm $nmbr$ $nmbr$,C1261082;C1551056
hbaie,
glargine $nmbr$,C0907402
concomitant oral glucose lowering agents zz,C0442027;C0017725;C4521986;C0441994;C2003888;C0450442;C2347310;C1254351;C1521826
sex male female,C0086287
met su tzd,C0428210;C0038642;C1705534;C1550543;C4317104
race ethnicity zz,C0015031;C2347310;C0243103
su tzd,C0038642;C1705534
black african,C0337824
su met,C0428210;C1550543;C4317104
descent,C0205386;C0680043
met tzd,C0428210;C1550543;C4317104
hbaie,
mmf n $nmbr$,C0083765;C0209368;C3848524
concomitant oral glucose lowering agents zz,C0442027;C0017725;C4521986;C0441994;C2003888;C0450442;C2347310;C1254351;C1521826
ivc n $nmbr$,C4085887
met su tzd,C0428210;C0038642;C1705534;C1550543;C4317104
age at diagnosis of sle years,C1828181;C3173302
su tzd,C0038642;C1705534
time since diagnosis of sle years,C0556970;C0011900;C1704338;C1704656
su met,C0428210;C1550543;C4317104
age at diagnosis of ln years,C1828181;C3173302
met tzd,C0428210;C1550543;C4317104
time since diagnosis of ln years,C0556970;C0011900;C1704338;C1704656
mmf n $nmbr$,C0083765;C0209368;C3848524
renal biopsy class,C0456387;C1518526;C1705943
ivc n $nmbr$,C4085887
class iii iii v,C0441887;C2698969
age at diagnosis of sle years,C1828181;C3173302
class iv iv v,C0441888;C2698970
time since diagnosis of sle years,C0556970;C0011900;C1704338;C1704656
class iv only,C0441888;C2698970
age at diagnosis of ln years,C1828181;C3173302
class v only,C0456387;C1518526;C1705943
time since diagnosis of ln years,C0556970;C0011900;C1704338;C1704656
scarring on renal biopsy,C0194073
renal biopsy class,C0456387;C1518526;C1705943
$nmbr$ $nmbr$ $nmbr$ a,
class iii iii v,C0441887;C2698969
urine p cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
class iv iv v,C0441888;C2698970
$nmbr$ $nmbr$ $nmbr$ $nmbr$ d,
class iv only,C0441888;C2698970
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e,
class v only,C0456387;C1518526;C1705943
$nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
scarring on renal biopsy,C0194073
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
$nmbr$ $nmbr$ $nmbr$ a,
serum albumin concentration g l,C0439294;C0456615
urine p cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
$nmbr$ $nmbr$ $nmbr$ $nmbr$ g,C0439267
$nmbr$ $nmbr$ $nmbr$ $nmbr$ d,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e,
patients with negative anti dsdna,C0030705;C0741099
$nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
antibody binding level at baseline,C0428536
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
geometric anti dsdna antibody binding level,C0428536
serum albumin concentration g l,C0439294;C0456615
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
$nmbr$ $nmbr$ $nmbr$ $nmbr$ g,C0439267
$nmbr$ $nmbr$ $nmbr$ $nmbr$ j,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
patients with low,C0030705;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
patients with negative anti dsdna,C0030705;C0741099
concentrations at baseline,C0086045;C0168634;C1442488
antibody binding level at baseline,C0428536
geometric c $nmbr$ concentration mg dl,C0086045;C0439269;C1446561;C3827302
geometric anti dsdna antibody binding level,C0428536
$nmbr$ $nmbr$ $nmbr$ $nmbr$ k,C0597277;C1708601
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
selena sledai total score,C0451528;C2964552
$nmbr$ $nmbr$ $nmbr$ $nmbr$ j,
dabigatran n $nmbr$,C2348066
patients with low,C0030705;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
warfarin n $nmbr$,C0043031
concentrations at baseline,C0086045;C0168634;C1442488
race no f,C0034510;C1706779;C3853635;C0016327
geometric c $nmbr$ concentration mg dl,C0086045;C0439269;C1446561;C3827302
estimated creatinine clearance ml min,C0812399;C0439445
$nmbr$ $nmbr$ $nmbr$ $nmbr$ k,C0597277;C1708601
type of index event no,C1561488;C0600653;C0918012;C1552854;C1637833;C2986546
selena sledai total score,C0451528;C2964552
deep vein thrombosis only,C0149871
dabigatran n $nmbr$,C2348066
pulmonary embolism only,C0034065
warfarin n $nmbr$,C0043031
both deep vein thrombosis and pulmonary embolism,C0149871;C0034065
race no f,C0034510;C1706779;C3853635;C0016327
neither deep vein thrombosis nor pulmonary embolism^,C0149871;C0034065
estimated creatinine clearance ml min,C0812399;C0439445
cancer no,C0006826;C0998265;C1306459
type of index event no,C1561488;C0600653;C0918012;C1552854;C1637833;C2986546
previous venous thromboembolism no,C0205156;C1861172;C1552607
deep vein thrombosis only,C0149871
parenteral anticoagulation,C0003281;C2917212;C2919015;C3537050
pulmonary embolism only,C0034065
treatment before randomization days,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
both deep vein thrombosis and pulmonary embolism,C0149871;C0034065
treatment after randomization in the single dummy phase days],C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0037179;C0439228;C0087136;C0205171
neither deep vein thrombosis nor pulmonary embolism^,C0149871;C0034065
unfractionated heparin no,C0019134;C2825026
cancer no,C0006826;C0998265;C1306459
low molecular weight heparin no,C0019139;C3536766
previous venous thromboembolism no,C0205156;C1861172;C1552607
fondaparinux no,C1098510
parenteral anticoagulation,C0003281;C2917212;C2919015;C3537050
double dummy phase,C0205390;C1710475
treatment before randomization days,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
exposure to study drug days,C0332157
treatment after randomization in the single dummy phase days],C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0037179;C0439228;C0087136;C0205171
adherence to study regimen no,C1510802;C0040808;C2945654
unfractionated heparin no,C0019134;C2825026
percent of the time that inr was in the therapeutic range,C0439165;C0040223;C3541383;C0525032;C1704538;C0460097
low molecular weight heparin no,C0019139;C3536766
dabigatran,C2348066
fondaparinux no,C1098510
percentages of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
double dummy phase,C0205390;C1710475
p value for interaction,C1709380;C1704675
exposure to study drug days,C0332157
\ge category,C0683312;C3889287
adherence to study regimen no,C1510802;C0040808;C2945654
weight category,C0683312;C3889287
percent of the time that inr was in the therapeutic range,C0439165;C0040223;C3541383;C0525032;C1704538;C0460097
bmi category kg m $nmbr$,C0022718;C0439209;C4054209
dabigatran,C2348066
creatinine clearance category [ml min],C0683312;C3889287;C0439445
percentages of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
$nmbr$ ml mln,C1417190;C3815103
p value for interaction,C1709380;C1704675
previous vte,C0205156;C0630906;C1552607
\ge category,C0683312;C3889287
initial symptomatic pe,C0070939;C1880476;C4284304
weight category,C0683312;C3889287
active cancer at baseline,C0006826;C0998265;C1306459
bmi category kg m $nmbr$,C0022718;C0439209;C4054209
measure,C0079809;C0242485
creatinine clearance category [ml min],C0683312;C3889287;C0439445
fenofibric acid,C0060179
$nmbr$ ml mln,C1417190;C3815103
low dose statin,C0445550;C0360714;C1708745
previous vte,C0205156;C0630906;C1552607
fenofibric acid low dose statin,C0060179;C0360714
initial symptomatic pe,C0070939;C1880476;C4284304
mean percentage change from baseline to final visit,C0392747;C0443172;C1705241;C4319952;C0545082;C1512346;C2826704
active cancer at baseline,C0006826;C0998265;C1306459
final,C0205088;C1546485;C3853528
measure,C0079809;C0242485
tg,C0337445
fenofibric acid,C0060179
ldl c,
low dose statin,C0445550;C0360714;C1708745
efficacy variable,C0439828;C4553760
fenofibric acid low dose statin,C0060179;C0360714
fenofibric acid i low dose statin,C0060179;C0360714
mean percentage change from baseline to final visit,C0392747;C0443172;C1705241;C4319952;C0545082;C1512346;C2826704
non hdl c,C1518422;C3715113
final,C0205088;C1546485;C3853528
baseline mean,C0444504;C2347634;C2348143
tg,C0337445
final mean,C0444504;C2347634;C2348143
ldl c,
change mean se,C0392747;C0036919;C0443172;C1705241;C4319952
efficacy variable,C0439828;C4553760
apoal,
fenofibric acid i low dose statin,C0060179;C0360714
change meanlse,C0392747;C0443172;C1705241;C4319952
non hdl c,C1518422;C3715113
hscrp,
baseline mean,C0444504;C2347634;C2348143
baseline median,C0549183;C0876920;C2347635;C2348144;C2939193
final mean,C0444504;C2347634;C2348143
change median q $nmbr$ q $nmbr$,C0392747;C0443172;C1705241;C4319952
change mean se,C0392747;C0036919;C0443172;C1705241;C4319952
vldl c,C0523560
apoal,
total c,C0439175;C0439810
change meanlse,C0392747;C0443172;C1705241;C4319952
moderate dose statin,C1709056;C0360714
hscrp,
fenofibric acid moderate dose statin,C0060179;C0360714
baseline median,C0549183;C0876920;C2347635;C2348144;C2939193
change meantse,C0392747;C0443172;C1705241;C4319952
change median q $nmbr$ q $nmbr$,C0392747;C0443172;C1705241;C4319952
safety variable,C0439828;C4553760
vldl c,C0523560
fenofibric acid $nmbr$ low dose statin,C0060179;C0360714
total c,C0439175;C0439810
fenofibric acid i moderate dose statin,C0060179;C0360714
moderate dose statin,C1709056;C0360714
investigator reported aes,C1412268;C2699274
fenofibric acid moderate dose statin,C0060179;C0360714
any treatment emergent ae,C0039798;C3887670;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
change meantse,C0392747;C0443172;C1705241;C4319952
myalgia,C0231528;C4552646
safety variable,C0439828;C4553760
rhabdomyolysis,C0035410;C4552660
fenofibric acid $nmbr$ low dose statin,C0060179;C0360714
laboratory evaluations,C0022877;C0220825;C3244292;C4283904
fenofibric acid i moderate dose statin,C0060179;C0360714
alt $nmbr$ x uln on two consecutive visits,C1519815;C0205448
investigator reported aes,C1412268;C2699274
ast $nmbr$ x uln on two consecutive visits,C1519815;C0205448
any treatment emergent ae,C0039798;C3887670;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ck $nmbr$ xuln,C0009212;C0010287;C1872855
myalgia,C0231528;C4552646
creatinine $nmbr$ $nmbr$ x baseline and above uln,C0168634;C1442488;C1519815
rhabdomyolysis,C0035410;C4552660
creatinine $nmbr$ x baseline,C0168634;C1442488
laboratory evaluations,C0022877;C0220825;C3244292;C4283904
mean change s in fasting blood glucose [mg dl mmol l ],C0392747;C0443172;C1705241;C4319952;C0428568;C1261430;C0439268
alt $nmbr$ x uln on two consecutive visits,C1519815;C0205448
f $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
ast $nmbr$ x uln on two consecutive visits,C1519815;C0205448
age y mean sd,C0001779;C2699239
ck $nmbr$ xuln,C0009212;C0010287;C1872855
men with ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
creatinine $nmbr$ $nmbr$ x baseline and above uln,C0168634;C1442488;C1519815
men without ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
creatinine $nmbr$ x baseline,C0168634;C1442488
age $nmbr$ y,C0001779
mean change s in fasting blood glucose [mg dl mmol l ],C0392747;C0443172;C1705241;C4319952;C0428568;C1261430;C0439268
previous a blocker,C0205156;C1552607
f $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
use,C0042153;C0457083;C1947944
age y mean sd,C0001779;C2699239
sexually active $nmbr$,C0241028
men with ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
comorbidities,C0009488
men without ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
coronary artery,C0205042
age $nmbr$ y,C0001779
calcium channel,C0006685
previous a blocker,C0205156;C1552607
blocker,
use,C0042153;C0457083;C1947944
angiotensin,C0003018;C4521302
sexually active $nmbr$,C0241028
converting enzyme inhibitor,C0014432;C0919438;C4521603
comorbidities,C0009488
angiotensin receptor,C0034787;C1622222
coronary artery,C0205042
oral diabetic agent,C0450442;C1254351;C1521826
calcium channel,C0006685
ipss mean sd,C0444504;C2699239;C2347634;C2348143
blocker,
ipss qol,C1019118;C0518214;C1998280;C2827405;C3811063
angiotensin,C0003018;C4521302
bii mean sd,C0444504;C2699239;C2347634;C2348143
converting enzyme inhibitor,C0014432;C0919438;C4521603
$nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
angiotensin receptor,C0034787;C1622222
moderate to,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
oral diabetic agent,C0450442;C1254351;C1521826
mild ed,C2945599;C3538926
ipss mean sd,C0444504;C2699239;C2347634;C2348143
severe ed,C0205082;C3538926;C4050465;C4050466
ipss qol,C1019118;C0518214;C1998280;C2827405;C3811063
mild ed severe ed,C2945599;C0205082;C4050465;C4050466
bii mean sd,C0444504;C2699239;C2347634;C2348143
p interaction,C0369773;C1704675;C2603361
$nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
n $nmbr$ n $nmbr$,C0369718;C0441922
moderate to,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
n $nmbr$ $nmbr$,C0369718;C0441922
mild ed,C2945599;C3538926
ipss ls mean se,C0023668;C0036919
severe ed,C0205082;C3538926;C4050465;C4050466
ipss qol ls,C0518214;C0023668
mild ed severe ed,C2945599;C0205082;C4050465;C4050466
mean se bii ls mean se,C0036919;C0023668
p interaction,C0369773;C1704675;C2603361
a $nmbr$ e $nmbr$ n $nmbr$,C1272460
n $nmbr$ n $nmbr$,C0369718;C0441922
a $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
n $nmbr$ $nmbr$,C0369718;C0441922
mean age years race,C0034510;C1706779;C3853635
ipss ls mean se,C0023668;C0036919
body mass index $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
ipss qol ls,C0518214;C0023668
$nmbr$ concomitant medication,C0013227;C3244316;C4284232
mean se bii ls mean se,C0036919;C0023668
other forms of atherosclerosis,C0348078;C0376315
a $nmbr$ e $nmbr$ n $nmbr$,C1272460
diabetes mellitus type $nmbr$ or $nmbr$,C1320657
a $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
metabolic syndrome visit $nmbr$ low density lipoprotein cholesterol strata,C0524620;C0023824
mean age years race,C0034510;C1706779;C3853635
$nmbr$ but,
body mass index $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ mg dl,C0439269
$nmbr$ concomitant medication,C0013227;C3244316;C4284232
mn na ve population,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0032659;C1257890
other forms of atherosclerosis,C0348078;C0376315
uplift population,C0032659;C1257890
diabetes mellitus type $nmbr$ or $nmbr$,C1320657
all mn na ve patients,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0030705
metabolic syndrome visit $nmbr$ low density lipoprotein cholesterol strata,C0524620;C0023824
all non mn,C0026327;C0026405;C4285072
$nmbr$ but,
sex m f,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0016327
$nmbr$ mg dl,C0439269
active smokers,C0205177;C0337664;C3853793;C3888249
mn na ve population,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0032659;C1257890
copd history yrs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
uplift population,C0032659;C1257890
pre fev $nmbr$ pred,C0032952;C0044955
all mn na ve patients,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0030705
post fev $nmbr$ pred,C0032952;C0044955
all non mn,C0026327;C0026405;C4285072
pre fvc pred,C0032952;C0044955
sex m f,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0016327
post fvc pred,C0032952;C0044955
active smokers,C0205177;C0337664;C3853793;C3888249
gold stage,C0205390;C1300072;C1306673
copd history yrs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
usa,C0041703
pre fev $nmbr$ pred,C0032952;C0044955
$nmbr$ day l,C0332173;C0439228;C0439505
post fev $nmbr$ pred,C0032952;C0044955
$nmbr$ month l,C0332177;C0439231
pre fvc pred,C0032952;C0044955
$nmbr$ yrs l,
post fvc pred,C0032952;C0044955
decline ml yr $nmbr$,C0439526;C0439234;C1705224;C3887665
gold stage,C0205390;C1300072;C1306673
pre fev $nmbr$,C0332152;C3714541;C0740175;C2257086;C3669034
usa,C0041703
post fev $nmbr$,C0687676;C3714541;C1704687;C3469826
$nmbr$ day l,C0332173;C0439228;C0439505
pre fvc,C0332152;C3714541;C0740175;C2257086;C3669034
$nmbr$ month l,C0332177;C0439231
post fvc,C0687676;C3714541;C1704687;C3469826
$nmbr$ yrs l,
pre svc,C0332152;C0231957;C0740175;C2257086;C3669034
decline ml yr $nmbr$,C0439526;C0439234;C1705224;C3887665
post svc,C0687676;C0231957;C1704687;C3469826
pre fev $nmbr$,C0332152;C3714541;C0740175;C2257086;C3669034
glipizide n $nmbr$,C0017642
post fev $nmbr$,C0687676;C3714541;C1704687;C3469826
rosiglitazone n $nmbr$,C0289313
pre fvc,C0332152;C3714541;C0740175;C2257086;C3669034
duration of diabetes mellitus median iqr y,C0449238;C2926735
post fvc,C0687676;C3714541;C1704687;C3469826
dyslipidemia n,C0242339
pre svc,C0332152;C0231957;C0740175;C2257086;C3669034
prior myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
post svc,C0687676;C0231957;C1704687;C3469826
presenting condition n,C0449450;C0012634;C0348080;C1705253;C3864998
glipizide n $nmbr$,C0017642
acute coronary syndrome,C0948089
rosiglitazone n $nmbr$,C0289313
elective procedure,C0747973
duration of diabetes mellitus median iqr y,C0449238;C2926735
baseline procedure n,C0168634;C0184661;C2700391;C3274430;C3539779;C1442488
dyslipidemia n,C0242339
medication use n,C0240320
prior myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
other antiplatelet,
presenting condition n,C0449450;C0012634;C0348080;C1705253;C3864998
fibrate or other lipid lowering agent,C0086440
acute coronary syndrome,C0948089
serum creatinine mean sd mg dl,C0201976;C0439269;C0600061
elective procedure,C0747973
hemoglobin a $nmbr$ c mean sd,C0019020;C2699239;C3889898
baseline procedure n,C0168634;C0184661;C2700391;C3274430;C3539779;C1442488
bnp median iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
medication use n,C0240320
fasting insulin median iqr gu ml,C0015663;C0439526;C1705224;C3887665
other antiplatelet,
ldl cholesterol mean sd mg dl,C0023824;C0439269;C0202117
fibrate or other lipid lowering agent,C0086440
hdl cholesterol mean sd mg dl,C0023822;C0439269;C0392885
serum creatinine mean sd mg dl,C0201976;C0439269;C0600061
triglycerides median iqr mg dl,C0041004;C0439269
hemoglobin a $nmbr$ c mean sd,C0019020;C2699239;C3889898
hscrp median iqr mg l,C0549183;C0439268;C0876920;C2347635;C2348144;C2939193
bnp median iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
mmp $nmbr$ median iqr gg l,C0017454;C0018370
fasting insulin median iqr gu ml,C0015663;C0439526;C1705224;C3887665
subgroups,C1079230
ldl cholesterol mean sd mg dl,C0023824;C0439269;C0202117
treatment difference $nmbr$ cl,C0039798;C0596019;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
hdl cholesterol mean sd mg dl,C0023822;C0439269;C0392885
as,
triglycerides median iqr mg dl,C0041004;C0439269
eu,C0015179;C3665627
hscrp median iqr mg l,C0549183;C0439268;C0876920;C2347635;C2348144;C2939193
sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
mmp $nmbr$ median iqr gg l,C0017454;C0018370
cardiac procedure,C1279986
subgroups,C1079230
prior oad,C0332152;C2826257
treatment difference $nmbr$ cl,C0039798;C0596019;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
drug naive,C0013227;C1254351
as,
low dose combination therapy,C0009429;C0556895
eu,C0015179;C3665627
metformin monotherapy,C0025598
sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
su monotherapy,C0038642;C1705534
cardiac procedure,C1279986
smi,
prior oad,C0332152;C2826257
systolic bp at baseline,C0871470;C0168634;C1442488
drug naive,C0013227;C1254351
s $nmbr$ mmhg,C0439475
low dose combination therapy,C0009429;C0556895
$nmbr$ mmhg,C0439475
metformin monotherapy,C0025598
statin use at baseline,C0042153;C0457083;C1947944
su monotherapy,C0038642;C1705534
diabetes duration,C0449238;C2926735
smi,
s median,C0549183;C0876920;C2347635;C2348144;C2939193
systolic bp at baseline,C0871470;C0168634;C1442488
hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
s $nmbr$ mmhg,C0439475
hdl c at baseline,C3715113;C0168634;C1442488
$nmbr$ mmhg,C0439475
ldl c at baseline,C0168634;C1442488
statin use at baseline,C0042153;C0457083;C1947944
triglycerides at baseline,C0041004;C0168634;C1442488
diabetes duration,C0449238;C2926735
hscrp at baseline,C0168634;C1442488
s median,C0549183;C0876920;C2347635;C2348144;C2939193
percent atheroma volume at baseline,C1690016;C3887614
hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
without baseline vertebral fracture,C0168634;C0080179;C1442488
hdl c at baseline,C3715113;C0168634;C1442488
with baseline vertebral fracture,C0168634;C0080179;C1442488
ldl c at baseline,C0168634;C1442488
flex pbo,C0031962
triglycerides at baseline,C0041004;C0168634;C1442488
flex ain,C0347129
hscrp at baseline,C0168634;C1442488
flex aln^,C0729594;C2681220
percent atheroma volume at baseline,C1690016;C3887614
body mass index kg m^ meanisd,C0022718;C0439209;C4054209
without baseline vertebral fracture,C0168634;C0080179;C1442488
fall in last $nmbr$ months,C0085639;C0238715;C4553726
with baseline vertebral fracture,C0168634;C0080179;C1442488
history of clinical fracture $nmbr$ years,C1272071;C0205210
flex pbo,C0031962
duration alendronate use years meanisd,C0102118;C0042153;C0457083;C1947944
flex ain,C0347129
using alendronate at baseline,C1524063;C0102118;C0168634;C1442488
flex aln^,C0729594;C2681220
using hrt or raloxifene at baseline,C1524063;C0282402;C0244404;C0168634;C1442488
body mass index kg m^ meanisd,C0022718;C0439209;C4054209
time since start of fit years meanisd,C1301880
fall in last $nmbr$ months,C0085639;C0238715;C4553726
time from end of fit years meanisd,C1522314
history of clinical fracture $nmbr$ years,C1272071;C0205210
flex baseline bmd g cm^ meanisd,C0168634;C0439267;C1442488
duration alendronate use years meanisd,C0102118;C0042153;C0457083;C1947944
flex baseline bmd t score at femoral neck meanisd,C0449820;C4050231
using alendronate at baseline,C1524063;C0102118;C0168634;C1442488
$nmbr$ $nmbr$ fn t score,C0449820;C4050231
using hrt or raloxifene at baseline,C1524063;C0282402;C0244404;C0168634;C1442488
$nmbr$ $nmbr$ fn t score $nmbr$ $nmbr$,C0449820;C4050231
time since start of fit years meanisd,C1301880
fn t score $nmbr$ $nmbr$,C0449820;C4050231
time from end of fit years meanisd,C1522314
flex baseline bmd t score at lumbar spine meanisd,C0449820;C4050231
flex baseline bmd g cm^ meanisd,C0168634;C0439267;C1442488
$nmbr$ $nmbr$ ls t score,C0449820;C4050231
flex baseline bmd t score at femoral neck meanisd,C0449820;C4050231
$nmbr$ $nmbr$ ls t score $nmbr$ $nmbr$,C0449820;C4050231
$nmbr$ $nmbr$ fn t score,C0449820;C4050231
ls t score $nmbr$ $nmbr$,C0449820;C4050231
$nmbr$ $nmbr$ fn t score $nmbr$ $nmbr$,C0449820;C4050231
change in femoral neck bmd from fit baseline to flex baseline,C0742135;C0036572;C0168634;C1442488;C2349186;C4048158;C4553125
fn t score $nmbr$ $nmbr$,C0449820;C4050231
gained bmd,C1517378
flex baseline bmd t score at lumbar spine meanisd,C0449820;C4050231
lost bmd,C0745777;C3815882
$nmbr$ $nmbr$ ls t score,C0449820;C4050231
femoral neck f score at flex baseline,C0016327;C0449820;C4050231
$nmbr$ $nmbr$ ls t score $nmbr$ $nmbr$,C0449820;C4050231
nonvertebral,
ls t score $nmbr$ $nmbr$,C0449820;C4050231
morphometric vertebral,C0549207
change in femoral neck bmd from fit baseline to flex baseline,C0742135;C0036572;C0168634;C1442488;C2349186;C4048158;C4553125
pbo no o o ^,C0031962;C0483204
gained bmd,C1517378
ain no,C0347129
lost bmd,C0745777;C3815882
pbo no ^,C0031962
femoral neck f score at flex baseline,C0016327;C0449820;C4050231
nvf at flex baseline $nmbr$ flex fn t score,C0168634;C0449820;C4050231;C1442488
nonvertebral,
$nmbr$ $nmbr$ flex fn f score $nmbr$,C0449820;C4050231
morphometric vertebral,C0549207
flex fn f score $nmbr$ $nmbr$,C0449820;C4050231
pbo no o o ^,C0031962;C0483204
p value for interaction vertebral fracture at flex baseline,C1709380;C0080179;C0168634;C1442488
ain no,C0347129
$nmbr$ flex fn f score,C0449820;C4050231
pbo no ^,C0031962
nateglinide n $nmbr$,C0903898
nvf at flex baseline $nmbr$ flex fn t score,C0168634;C0449820;C4050231;C1442488
race no i,C0034510;C1706779;C3853635;C0021966;C0221138
$nmbr$ $nmbr$ flex fn f score $nmbr$,C0449820;C4050231
body mass index^,C0005893;C0578022;C1305855
flex fn f score $nmbr$ $nmbr$,C0449820;C4050231
waist circumference cmj,C0455829
p value for interaction vertebral fracture at flex baseline,C1709380;C0080179;C0168634;C1442488
blood pressure while seated mm hg,C0005823;C1271104;C1272641;C0277814;C0439475;C1283233
$nmbr$ flex fn f score,C0449820;C4050231
cardiovascular risk factors no,C0850624
nateglinide n $nmbr$,C0903898
any,
race no i,C0034510;C1706779;C3853635;C0021966;C0221138
family history of premature heart disease,C0850707
body mass index^,C0005893;C0578022;C1305855
reduced hdl cholesterol,C0151691
waist circumference cmj,C0455829
elevated non hdl cholesterol,C0729627;C1535899
blood pressure while seated mm hg,C0005823;C1271104;C1272641;C0277814;C0439475;C1283233
history of cardiovascular disease no,C0455539
cardiovascular risk factors no,C0850624
any,
angina or positive stress test,C0002962;C0015260;C3494508
multivessel coronary artery bypass grafting,C0010055
family history of premature heart disease,C0850707
intermittent claudication,C0021775
reduced hdl cholesterol,C0151691
peripheral arterial stenosis,C4025272
elevated non hdl cholesterol,C0729627;C1535899
lower limb angioplasty or bypass surgery,C0745788;C1536078
history of cardiovascular disease no,C0455539
nontraumatic leg or foot amputation,C0023216;C1140621;C0188605
angina or positive stress test,C0002962;C0015260;C3494508
family history of diabetes mellitus no,C0260526;C1313937
multivessel coronary artery bypass grafting,C0010055
intermittent claudication,C0021775
plasma glucose mmol per liter,C0202042;C0439190;C0455280
fasting,C0015663
peripheral arterial stenosis,C4025272
$nmbr$ hr after glucose challenge,C3840385
lower limb angioplasty or bypass surgery,C0745788;C1536078
metabolic syndrome no ^,C0524620
nontraumatic leg or foot amputation,C0023216;C1140621;C0188605
lipids mg dl,C0023779;C0439269
family history of diabetes mellitus no,C0260526;C1313937
estimated gfr ml min $nmbr$ $nmbr$ m^,C0017654;C0439445;C1424601
plasma glucose mmol per liter,C0202042;C0439190;C0455280
estimated gfr,C0017654;C1424601
fasting,C0015663
ratio of urinary albumin mg to creatinine g,C0456603;C1547037;C0010294;C0439267;C1561535
$nmbr$ hr after glucose challenge,C3840385
medications no,C0013227;C0802604;C2598133;C4284232
metabolic syndrome no ^,C0524620
last study visit,C0545082;C1512346;C2826704
lipids mg dl,C0023779;C0439269
alpha blocker,C0001641
estimated gfr ml min $nmbr$ $nmbr$ m^,C0017654;C0439445;C1424601
aspirin or other antiplatelet drug,C0004057;C0085826
estimated gfr,C0017654;C1424601
lipid modulating drug,C0023779;C0443264;C0013227;C1254351
ratio of urinary albumin mg to creatinine g,C0456603;C1547037;C0010294;C0439267;C1561535
antidiabetic drug i j,C0935929;C0021966;C0221138
medications no,C0013227;C0802604;C2598133;C4284232
section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
last study visit,C0545082;C1512346;C2826704
nateglinide n n,C0903898
alpha blocker,C0001641
progression to diabetes,C1735364
aspirin or other antiplatelet drug,C0004057;C0085826
hazard ratio $nmbr$ cl nateglinide vs placebo,C2985465;C0903898;C0032042;C1696465;C1706408
lipid modulating drug,C0023779;C0443264;C0013227;C1254351
two sided p value for hetero geneity,C0205448;C1709380
antidiabetic drug i j,C0935929;C0021966;C0221138
placebo n n,C0032042;C1696465;C1706408
section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
all patients p $nmbr$ $nmbr$,C0030705
nateglinide n n,C0903898
$nmbr$ $nmbr$ years,C0439234
progression to diabetes,C1735364
aslan,
hazard ratio $nmbr$ cl nateglinide vs placebo,C2985465;C0903898;C0032042;C1696465;C1706408
fasting plasma glucose,C0202042;C0455280
two sided p value for hetero geneity,C0205448;C1709380
$nmbr$ hr prandial glucose,C1998602;C0017725;C4553624
placebo n n,C0032042;C1696465;C1706408
[kg m^],C0022718;C0439209;C4054209
all patients p $nmbr$ $nmbr$,C0030705
waist circumference,C0455829
$nmbr$ $nmbr$ years,C0439234
[cm female cm male ],C0086582;C1706180;C1706428;C1706429
aslan,
blood pressure control,C0005823;C1271104;C1272641
fasting plasma glucose,C0202042;C0455280
hypertension^,C0020538;C1963138
$nmbr$ hr prandial glucose,C1998602;C0017725;C4553624
history of cardiovascular disease,C0455539
[kg m^],C0022718;C0439209;C4054209
ace inhibitor treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
waist circumference,C0455829
section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
[cm female cm male ],C0086582;C1706180;C1706428;C1706429
extended cardiovascular endpoint,C2349179;C2826544
blood pressure control,C0005823;C1271104;C1272641
section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
hypertension^,C0020538;C1963138
core cardiovascular endpoint,C2349179;C2826544
history of cardiovascular disease,C0455539
valsartan n $nmbr$,C0216784
ace inhibitor treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
sitting blood pressure mmhg,C0580946;C0439475
section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
peripheral artery stenosis,C0038449
extended cardiovascular endpoint,C2349179;C2826544
stroke of atherosclerotic origin,C0038454;C4554100
section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
glycemic indexes,C1136206
core cardiovascular endpoint,C2349179;C2826544
fasting plasma glucose mmol liter,C0202042;C0475211;C0455280
valsartan n $nmbr$,C0216784
plasma glucose $nmbr$ hr after glucose load mmol liter,C0202042;C0455280
sitting blood pressure mmhg,C0580946;C0439475
metabolic syndrome no $nmbr$,C0524620
peripheral artery stenosis,C0038449
estimated gfr^,C0017654;C1424601
stroke of atherosclerotic origin,C0038454;C4554100
mean ml min $nmbr$ $nmbr$ m^,C0444504;C0439445;C2347634;C2348143
glycemic indexes,C1136206
ratio of urinary albumin mg to creatinine g median,C0456603;C1547037;C0549183;C0876920;C2347635;C2348144;C2939193
fasting plasma glucose mmol liter,C0202042;C0475211;C0455280
concomitant medication no ace inhibitor,C0013227;C3244316;C4284232;C0003015;C4541021
plasma glucose $nmbr$ hr after glucose load mmol liter,C0202042;C0455280
any antihypertensive drug,C0003364
metabolic syndrome no $nmbr$,C0524620
aspirin orother antiplatelet drug,C0004057
estimated gfr^,C0017654;C1424601
antidiabetic drug,C0935929
mean ml min $nmbr$ $nmbr$ m^,C0444504;C0439445;C2347634;C2348143
valsartan n n,C0216784
ratio of urinary albumin mg to creatinine g median,C0456603;C1547037;C0549183;C0876920;C2347635;C2348144;C2939193
hazard ratio $nmbr$ cl valsartan vs placebo,C2985465;C0216784;C0032042;C1696465;C1706408
concomitant medication no ace inhibitor,C0013227;C3244316;C4284232;C0003015;C4541021
all patients p,C0030705
any antihypertensive drug,C0003364
all patients n $nmbr$,C0030705
aspirin orother antiplatelet drug,C0004057
fenofibrate n $nmbr$,C0033228
antidiabetic drug,C0935929
education no,C0013621;C0013622;C0013658;C0039401
valsartan n n,C0216784
high school graduate or ged,C0870649;C1549971;C1880947
hazard ratio $nmbr$ cl valsartan vs placebo,C2985465;C0216784;C0032042;C1696465;C1706408
missing data,C4684714
all patients p,C0030705
previous cardiovascular event no,C0205156;C1320716;C1552607
all patients n $nmbr$,C0030705
previous congestive heart failure no,C0205156;C0018802;C1552607
fenofibrate n $nmbr$,C0033228
cigarette smoking status no,C1519386
education no,C0013621;C0013622;C0013658;C0039401
any lipid lowering agent,C0086440
high school graduate or ged,C0870649;C1549971;C1880947
duration of diabetes yr,C0449238;C2926735
missing data,C4684714
fasting plasma glucose mg dl,C0202042;C0439269;C0455280
previous cardiovascular event no,C0205156;C1320716;C1552607
amputation due to diabetes no,C0678226;C0598284
previous congestive heart failure no,C0205156;C0018802;C1552607
estimated glomerular filtration rate no,C3811844
cigarette smoking status no,C1519386
$nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
any lipid lowering agent,C0086440
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
duration of diabetes yr,C0449238;C2926735
plasma cholesterol mg dl,C0858034;C0439269
fasting plasma glucose mg dl,C0202042;C0439269;C0455280
plasma triglyceride mg dl,C0032105;C0439269;C1550098;C4521445
amputation due to diabetes no,C0678226;C0598284
febuxostat $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
estimated glomerular filtration rate no,C3811844
febuxostat $nmbr$ mg daily n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
american indian or alaska native,C0002460;C0682125
plasma cholesterol mg dl,C0858034;C0439269
native hawaiian or other pacific,C0337920
plasma triglyceride mg dl,C0032105;C0439269;C1550098;C4521445
islander,
febuxostat $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
not hispanic or latino,C1518424;C0086528
febuxostat $nmbr$ mg daily n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ to $nmbr$,
allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alcohol use,C0001948
american indian or alaska native,C0002460;C0682125
non ex drinker,C0457801
native hawaiian or other pacific,C0337920
drinker $nmbr$ to $nmbr$ drinks week,C0556338;C0332174;C0439230
islander,
serum urate mg dl,C0455272;C0439269
not hispanic or latino,C1518424;C0086528
years with gout,C0439234;C0018099
$nmbr$ to $nmbr$,
completed previous febuxostat study,C2348557;C0205156;C1552607
alcohol use,C0001948
renal functionb,C0022646
non ex drinker,C0457801
moderately impaired,C0205081;C0221099;C1881878;C4085643;C4321491
drinker $nmbr$ to $nmbr$ drinks week,C0556338;C0332174;C0439230
mildly impaired,C0750532;C0221099;C2945599
serum urate mg dl,C0455272;C0439269
normal,C0205307;C0231683;C0439166;C2347086;C4553972
years with gout,C0439234;C0018099
including hypertension,C0020538;C1963138
completed previous febuxostat study,C2348557;C0205156;C1552607
use of low dose aspirin $nmbr$,C1524063;C2608320
renal functionb,C0022646
mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
moderately impaired,C0205081;C0221099;C1881878;C4085643;C4321491
febuxostat $nmbr$ mg daily n $nmbr$ n n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mildly impaired,C0750532;C0221099;C2945599
renal functiona,C0022646
normal,C0205307;C0231683;C0439166;C2347086;C4553972
baseline serum urate mg dl a,C0455272;C0439269
including hypertension,C0020538;C1963138
baseline tophusa,C0168634;C1442488
use of low dose aspirin $nmbr$,C1524063;C2608320
completed prior febuxostat studya,C0205197;C0249529;C3854010
mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age $nmbr$ y n n,C0001779
febuxostat $nmbr$ mg daily n $nmbr$ n n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
white n n,C0007457;C0043157;C0220938
renal functiona,C0022646
diabetes mellitus n n,C0011849
baseline serum urate mg dl a,C0455272;C0439269
hypertension n n,C0020538;C1963138
baseline tophusa,C0168634;C1442488
hyperlipidemia n n,C0020473;C0428465;C4555212
completed prior febuxostat studya,C0205197;C0249529;C3854010
metabolic syndrome n n,C0524620
age $nmbr$ y n n,C0001779
current smoker n n,C3173209;C3241966
white n n,C0007457;C0043157;C0220938
prior mi n n,C0332152;C2826257
diabetes mellitus n n,C0011849
prior coronary revascularization n n,C0332152;C0877341;C2826257
hypertension n n,C0020538;C1963138
prior angina n n,C0332152;C0002962;C2826257
hyperlipidemia n n,C0020473;C0428465;C4555212
prior heart failure n n,C0018801;C0018802;C4554158
metabolic syndrome n n,C0524620
timi risk score n n,C0035647;C0449820;C4050231;C4552904
current smoker n n,C3173209;C3241966
index event n n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
prior mi n n,C0332152;C2826257
ua,C0041580;C0042014
prior coronary revascularization n n,C0332152;C0877341;C2826257
nstemi,C3537184;C4255010
prior angina n n,C0332152;C0002962;C2826257
time from symptoms to randomization h,C0040223;C3541383;C0033727;C0369286;C0441932;C0564385;C4528284
prior heart failure n n,C0018801;C0018802;C4554158
azathioprine n $nmbr$,C0004482
timi risk score n n,C0035647;C0449820;C4050231;C4552904
infliximab n $nmbr$,C0666743
index event n n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
combination therapy n $nmbr$,C0009429;C0556895
ua,C0041580;C0042014
p valued,C0369773;C2603361
nstemi,C3537184;C4255010
white race no t,C0007457;C0043157;C2603360
time from symptoms to randomization h,C0040223;C3541383;C0033727;C0369286;C0441932;C0564385;C4528284
median age yr,C0001779;C0439234
azathioprine n $nmbr$,C0004482
median body weight kg,C0022718;C0439209;C4054209
infliximab n $nmbr$,C0666743
median disease duration yr,C0872146;C0439234
combination therapy n $nmbr$,C0009429;C0556895
median c reactive protein mg dl^,C0006560;C0439269;C1413716;C4048285
p valued,C0369773;C2603361
white race no t,C0007457;C0043157;C2603360
crohn s disease activity index score],C0010346;C4706353;C0600653;C0918012;C1552854;C1637833;C2986546
median age yr,C0001779;C0439234
gastrointestinal area involved no total no,C0017446;C0205146;C1314939;C0439175;C0439810
ileum or colon,C0020885;C0009368;C3888384
median body weight kg,C0022718;C0439209;C4054209
ileum only,C0020885
median disease duration yr,C0872146;C0439234
colon only,C0009368;C3888384
median c reactive protein mg dl^,C0006560;C0439269;C1413716;C4048285
ileum and colon,C0020885;C0009368;C3888384
crohn s disease activity index score],C0010346;C4706353;C0600653;C0918012;C1552854;C1637833;C2986546
proximal gastrointestinal tract,C0017189;C0521362
gastrointestinal area involved no total no,C0017446;C0205146;C1314939;C0439175;C0439810
systemic corticosteroids no,C4053960
ileum or colon,C0020885;C0009368;C3888384
any type according to daily dose,C0332307;C1547052
ileum only,C0020885
budesonide no,C0054201
colon only,C0009368;C3888384
$nmbr$ aminosalicylic compounds no,C0205198;C1706082
ileum and colon,C0020885;C0009368;C3888384
proportion of patients in corticosteroid free clinical remission at week $nmbr$,C1709707;C0030705;C0205210;C0544452;C0687702
proximal gastrointestinal tract,C0017189;C0521362
ifx aza n $nmbr$,C0020823;C0004482
systemic corticosteroids no,C4053960
aza n $nmbr$,C0004482
any type according to daily dose,C0332307;C1547052
odds ratio,C0028873
budesonide no,C0054201
d value,C1522609
$nmbr$ aminosalicylic compounds no,C0205198;C1706082
crohn s disease related surgery,C0010346;C0038894;C0038895;C0543467;C1274039
proportion of patients in corticosteroid free clinical remission at week $nmbr$,C1709707;C0030705;C0205210;C0544452;C0687702
with previous surgery,C0038894;C0038895;C0543467;C1274039
ifx aza n $nmbr$,C0020823;C0004482
without previous surgery,C0038894;C0038895;C0543467;C1274039
aza n $nmbr$,C0004482
baseline corticosteroid use mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
odds ratio,C0028873
with corticosteroid treatment $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
d value,C1522609
duration of crohn s disease yrs,C0449238;C2926735;C0012634
crohn s disease related surgery,C0010346;C0038894;C0038895;C0543467;C1274039
baseline crp mg dl,C0168634;C0439269;C1442488
with previous surgery,C0038894;C0038895;C0543467;C1274039
europe lsrael,C0015176
without previous surgery,C0038894;C0038895;C0543467;C1274039
baseline $nmbr$ asa,C0004057;C3853627
baseline corticosteroid use mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
use $nmbr$ asa compounds,C0205198;C1706082
with corticosteroid treatment $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no use of $nmbr$ asa compounds,C1524063;C0004057;C3853627
duration of crohn s disease yrs,C0449238;C2926735;C0012634
total group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
baseline crp mg dl,C0168634;C0439269;C1442488
ifx n $nmbr$,C0020823
europe lsrael,C0015176
enox,C3147679
baseline $nmbr$ asa,C0004057;C3853627
ufh,
use $nmbr$ asa compounds,C0205198;C1706082
location,C0450429;C1515974;C4284930;C4284931
no use of $nmbr$ asa compounds,C1524063;C0004057;C3853627
no dm,C0011816;C3250443
total group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
dm,C0011816;C3250443
ifx n $nmbr$,C0020823
prior ml,C0439526;C1705224;C3887665
enox,C3147679
no prior ml,C0439526;C1705224;C3887665
ufh,
fibrinolytic,C0040044
location,C0450429;C1515974;C4284930;C4284931
fibrin specilic,C0015982
no dm,C0011816;C3250443
time to rx,C0040223;C3541383
dm,C0011816;C3250443
amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior ml,C0439526;C1705224;C3887665
amlodipine $nmbr$ to $nmbr$ mg n $nmbr$,C0051696;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no prior ml,C0439526;C1705224;C3887665
age sd yrs,C0001779;C2699239
fibrinolytic,C0040044
age category n,C0001779;C0683312;C3889287
fibrin specilic,C0015982
mssbp mm hg,C0439475
time to rx,C0040223;C3541383
msdbp mm hg,C0439475
amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hypertension severity at baseline n,C0439793;C0522510
amlodipine $nmbr$ to $nmbr$ mg n $nmbr$,C0051696;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mm hg,C0439475
age sd yrs,C0001779;C2699239
diabetic status n,C0241863;C0449438
age category n,C0001779;C0683312;C3889287
ish status n,C0449438
mssbp mm hg,C0439475
bmi n,C0578022
msdbp mm hg,C0439475
figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean,C0030771;C1518922;C1542834;C1707156;C3274014;C3541345;C1882932;C1710181
hypertension severity at baseline n,C0439793;C0522510
figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean,C0392747;C0443172;C1705241;C4319952;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
$nmbr$ mm hg,C0439475
diabetic status n,C0241863;C0449438
figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean,C0436315;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
ish status n,C0449438
nyha ll lll patients with lvef,C1275491;C0030705;C0428772;C0488728
bmi n,C0578022
remaining patients,C1527428;C0030705
dronedarone n $nmbr$,C0766326
figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean,C0030771;C1518922;C1542834;C1707156;C3274014;C3541345;C1882932;C1710181
age years sd,C1510829;C2699239
figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean,C0392747;C0443172;C1705241;C4319952;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
ischaemic dilated cardiomyopathy,C1960867
figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean,C0436315;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
non rheumatic valvular heart disease,C1518422;C0264757
nyha ll lll patients with lvef,C1275491;C0030705;C0428772;C0488728
non ischaemic dilated cardiomyopathy,C1518422;C1960867
remaining patients,C1527428;C0030705
pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
dronedarone n $nmbr$,C0766326
implanted cardioverter defibrillator,C0021102;C0810516;C2828363
age years sd,C1510829;C2699239
overall population,C0032659;C1257890
ischaemic dilated cardiomyopathy,C1960867
hr [ $nmbr$ ci,C0008107;C3259781
non rheumatic valvular heart disease,C1518422;C0264757
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
non ischaemic dilated cardiomyopathy,C1518422;C1960867
lvef^ $nmbr$ $nmbr$ and nyha class ii iii at baseline,C0428772;C0488728;C1882086
pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
implanted cardioverter defibrillator,C0021102;C0810516;C2828363
outcome measure,C0086749
overall population,C0032659;C1257890
hazard ratio $nmbr$ cl,C2985465;C0596019
hr [ $nmbr$ ci,C0008107;C3259781
time to first cv hospitalization or death from any cause,C0040223;C3541383;C0007465
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
first cv hospitalization,C0205435;C0019993;C1279901
lvef^ $nmbr$ $nmbr$ and nyha class ii iii at baseline,C0428772;C0488728;C1882086
death from any cause,C0007465
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
first hospitalization for chf or cv death,C0019993;C0018802;C0011065;C1306577;C4082313;C4552775
outcome measure,C0086749
hazard ratio $nmbr$ cl,C2985465;C0596019
figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups,C0444506;C3714541;C1705241;C1705242;C1554093;C3242279;C3242455;C0332849;C0168634;C1442488;C0001779;C1519386;C0004048;C0239126;C0009924;C1979874;C0032042;C2825972;C1696465;C1706408;C0178602;C0213771;C1079230
time to first cv hospitalization or death from any cause,C0040223;C3541383;C0007465
arm,C0446516;C3715044;C4553528
first cv hospitalization,C0205435;C0019993;C1279901
pad at baseline,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
death from any cause,C0007465
control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
first hospitalization for chf or cv death,C0019993;C0018802;C0011065;C1306577;C4082313;C4552775
no pad baseline,C0168634;C1442488
epa,
figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups,C0444506;C3714541;C1705241;C1705242;C1554093;C3242279;C3242455;C0332849;C0168634;C1442488;C0001779;C1519386;C0004048;C0239126;C0009924;C1979874;C0032042;C2825972;C1696465;C1706408;C0178602;C0213771;C1079230
figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population,C0024501;C0871261;C1704632;C1706817;C2911692;C0544452;C0687702;C0332152;C0032659;C1257890
arm,C0446516;C3715044;C4553528
lce n $nmbr$,C1423759;C3273355
pad at baseline,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
lc n $nmbr$,
control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
age mean yr,C0001779;C0439234
no pad baseline,C0168634;C1442488
men no,C0025266
epa,
mean duration of pd yr,C0449238;C2926735
figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population,C0024501;C0871261;C1704632;C1706817;C2911692;C0544452;C0687702;C0332152;C0032659;C1257890
updrs total ii iii,C0439070;C1705160
lce n $nmbr$,C1423759;C3273355
updrs part ii adl,C0001288;C1420005
lc n $nmbr$,
updrs part iii motor,C1513492;C1705994
age mean yr,C0001779;C0439234
hoehn yahr stage,C0205390;C1300072;C1306673
men no,C0025266
schwab england score,C0449820;C4050231
mean duration of pd yr,C0449238;C2926735
pdq $nmbr$,
updrs total ii iii,C0439070;C1705160
previous antiparkinson medication no,C0205156;C0003405;C1552607
updrs part ii adl,C0001288;C1420005
dopamine agonist use no,C0042153;C0457083;C1947944
updrs part iii motor,C1513492;C1705994
lce l dopa carbidopa entacapone lc l dopa carbidopa pd parkinson disease updrs rating scale adl activities of daily living pdq $nmbr$ parkinson disease questionnaire,C1292728;C0337645;C0034394
hoehn yahr stage,C0205390;C1300072;C1306673
unified parkinson disease,C0030567;C1521736
schwab england score,C0449820;C4050231
olmesartan medoxomil $nmbr$ mg hctz $nmbr$ $nmbr$ mg n $nmbr$,C0386393;C1319635
pdq $nmbr$,
olmesartan medoxomil $nmbr$ mg n $nmbr$,C0386393;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous antiparkinson medication no,C0205156;C0003405;C1552607
age y [mean sd],C0001779;C0444504;C2699239;C2347634;C2348143
dopamine agonist use no,C0042153;C0457083;C1947944
$nmbr$ [n ],C0369718;C0441922
lce l dopa carbidopa entacapone lc l dopa carbidopa pd parkinson disease updrs rating scale adl activities of daily living pdq $nmbr$ parkinson disease questionnaire,C1292728;C0337645;C0034394
males [n ],C0086582;C0369718;C0441922
unified parkinson disease,C0030567;C1521736
diabetes mellitus [n ],C0011849;C0369718;C0441922
olmesartan medoxomil $nmbr$ mg hctz $nmbr$ $nmbr$ mg n $nmbr$,C0386393;C1319635
bmi kg m $nmbr$ [mean sd],C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
olmesartan medoxomil $nmbr$ mg n $nmbr$,C0386393;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sedbp mmhg [mean_ sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
age y [mean sd],C0001779;C0444504;C2699239;C2347634;C2348143
sesbp mmhg [mean _sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
$nmbr$ [n ],C0369718;C0441922
severity ofhypertension [n ]b,C0439793;C0522510;C0369718;C0441922
males [n ],C0086582;C0369718;C0441922
mild,C2945599
diabetes mellitus [n ],C0011849;C0369718;C0441922
pre treatedforhypertension [n ],C0332152;C0740175;C2257086;C3669034;C0369718;C0441922
bmi kg m $nmbr$ [mean sd],C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
pre treatment[n ]c,C1550147;C2709094;C3539075;C3539076;C2349138
sedbp mmhg [mean_ sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
b blocker,
sesbp mmhg [mean _sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
severity ofhypertension [n ]b,C0439793;C0522510;C0369718;C0441922
low ceiling diuretic,C0205251;C0012798;C1550472;C3890211;C4048187;C4321351;C4522223
mild,C2945599
a blocker,
pre treatedforhypertension [n ],C0332152;C0740175;C2257086;C3669034;C0369718;C0441922
bp in pre treated patients,C0037623;C1415692;C1708288;C4318478
pre treatment[n ]c,C1550147;C2709094;C3539075;C3539076;C2349138
sedbp mmhg [mean _sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
b blocker,
sesbp mmhg [mean sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
scd,
low ceiling diuretic,C0205251;C0012798;C1550472;C3890211;C4048187;C4321351;C4522223
hradj $nmbr$ ci,C0008107;C3259781
a blocker,
qtc,
bp in pre treated patients,C0037623;C1415692;C1708288;C4318478
$nmbr$ $nmbr$ referent,C1706462
sedbp mmhg [mean _sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
qtc $nmbr$ n $nmbr$,
sesbp mmhg [mean sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
no prior mi n $nmbr$,C0332152;C2826257
scd,
prior mi n $nmbr$,C0332152;C2826257
hradj $nmbr$ ci,C0008107;C3259781
no prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
qtc,
prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
$nmbr$ $nmbr$ referent,C1706462
bnp,C0054015;C1095989;C1417808;C2982014
qtc $nmbr$ n $nmbr$,
bnp $nmbr$ pg ml n $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
no prior mi n $nmbr$,C0332152;C2826257
ef $nmbr$ n $nmbr$,
prior mi n $nmbr$,C0332152;C2826257
ef,
no prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
ranolazine n $nmbr$,C0073633
prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time,C0488055;C0871470;C1306620;C0428883;C1305849;C0949236;C0439234;C1705117;C0439508;C0040223;C3541383
bnp,C0054015;C1095989;C1417808;C2982014
om $nmbr$ mg aml $nmbr$ mg n $nmbr$,C1319635;C0023465;C0023467
bnp $nmbr$ pg ml n $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
ef $nmbr$ n $nmbr$,
om $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
ef,
aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
ranolazine n $nmbr$,C0073633
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
age group no,C0027362;C2348001
figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time,C0488055;C0871470;C1306620;C0428883;C1305849;C0949236;C0439234;C1705117;C0439508;C0040223;C3541383
height mean sd cm,C0489786;C0444504;C2347634;C2348143
om $nmbr$ mg aml $nmbr$ mg n $nmbr$,C1319635;C0023465;C0023467
bmi mean sd kg m^,C0022718;C0439209;C4054209
om $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
bmi category no,C0683312;C3889287
aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
$nmbr$ kg m^ obesity,C0022718;C0439209;C4054209;C0028754;C1963185
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
diabetes no,C0011847;C0011849
age group no,C0027362;C2348001
chronic kidney disease no t,C1561643;C4553188;C2603360
height mean sd cm,C0489786;C0444504;C2347634;C2348143
chronic cardiovascular disease no,C1290380
bmi mean sd kg m^,C0022718;C0439209;C4054209
bp goal no,C0018017;C1571704
bmi category no,C0683312;C3889287
baseline sesbp mean sd mm hg,C0168634;C0439475;C1442488
$nmbr$ kg m^ obesity,C0022718;C0439209;C4054209;C0028754;C1963185
baseline sedbp mean sd mm hg,C0168634;C0439475;C1442488
diabetes no,C0011847;C0011849
om $nmbr$ mg aml $nmbr$ mg,C1319635;C0023465;C0023467
chronic kidney disease no t,C1561643;C4553188;C2603360
om $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
chronic cardiovascular disease no,C1290380
aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
bp goal no,C0018017;C1571704
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
baseline sesbp mean sd mm hg,C0168634;C0439475;C1442488
bp variable mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
baseline sedbp mean sd mm hg,C0168634;C0439475;C1442488
moderate severe n $nmbr$ n $nmbr$,C0205081;C0205082;C4050465;C4050466;C1881878;C4049705;C4049706;C4085643;C4321335
om $nmbr$ mg aml $nmbr$ mg,C1319635;C0023465;C0023467
baseline bp mean sd,C0488053;C2699239
om $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
change in sesbp ls mean se,C0392747;C0443172;C1705241;C4319952
aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
change in sedbp ls mean se,C0392747;C0443172;C1705241;C4319952
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ll,
bp variable mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
severe oab subgroup,C1079230;C1515021
moderate severe n $nmbr$ n $nmbr$,C0205081;C0205082;C4050465;C4050466;C1881878;C4049705;C4049706;C4085643;C4321335
fas,
baseline bp mean sd,C0488053;C2699239
solifenacin n $nmbr$,C1099677
change in sesbp ls mean se,C0392747;C0443172;C1705241;C4319952
age year,C0439234;C0439508
change in sedbp ls mean se,C0392747;C0443172;C1705241;C4319952
age cohort no,C2348001
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ll,
diary variables mean sd,C0376660;C2699239
severe oab subgroup,C1079230;C1515021
urgency episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
fas,
incontinence episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
solifenacin n $nmbr$,C1099677
micturitions $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
age year,C0439234;C0439508
nocturia episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
age cohort no,C2348001
wt second median,C0549183;C0876920;C2347635;C2348144;C2939193
diary variables mean sd,C0376660;C2699239
ppbc score mean sd,C0444504;C2699239;C2347634;C2348143
urgency episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
iuss score mean sd,C0444504;C2699239;C2347634;C2348143
incontinence episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
ups score mean sd,C0334463;C2699239;C3542434
micturitions $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
oab q score mean sd,C3641332;C2699239
nocturia episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
symptom bother,C1457887;C3854129
wt second median,C0549183;C0876920;C2347635;C2348144;C2939193
hrql mean sd,C0444504;C2699239;C2347634;C2348143
ppbc score mean sd,C0444504;C2699239;C2347634;C2348143
coping,C0009967
iuss score mean sd,C0444504;C2699239;C2347634;C2348143
concern,C2699424
ups score mean sd,C0334463;C2699239;C3542434
sleep,C0037313
oab q score mean sd,C3641332;C2699239
social interaction,C0037420
symptom bother,C1457887;C3854129
all n $nmbr$ $nmbr$,C0369718;C0441922
hrql mean sd,C0444504;C2699239;C2347634;C2348143
bivalirudin n $nmbr$ $nmbr$,C0168273
coping,C0009967
heparin plus gpi n $nmbr$ $nmbr$,C0019134;C0770546
concern,C2699424
symptom onset to pci h,C4086878;C0033727;C0369286;C0441932;C0564385;C4528284
sleep,C0037313
killip class $nmbr$ $nmbr$,C1881332
social interaction,C0037420
anemia,C0002871;C1000483;C4554633
all n $nmbr$ $nmbr$,C0369718;C0441922
$nmbr$ diseased vessels,C0005847
bivalirudin n $nmbr$ $nmbr$,C0168273
anterior infarct location,C0450429;C1515974;C4284930;C4284931
heparin plus gpi n $nmbr$ $nmbr$,C0019134;C0770546
initial timi flow grade $nmbr$,C0441800;C0919553;C3244287
symptom onset to pci h,C4086878;C0033727;C0369286;C0441932;C0564385;C4528284
lvef,C0428772;C0488728
killip class $nmbr$ $nmbr$,C1881332
stent implanted,C0522776
anemia,C0002871;C1000483;C4554633
final timi flow grade,C0441800;C0919553;C3244287
$nmbr$ diseased vessels,C0005847
heart rate group at baseline,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
anterior infarct location,C0450429;C1515974;C4284930;C4284931
$nmbr$ bpm n $nmbr$ l $nmbr$,
initial timi flow grade $nmbr$,C0441800;C0919553;C3244287
cardiac parameters,C0018787;C0449381;C1522601
lvef,C0428772;C0488728
egfr ml min per $nmbr$ $nmbr$ kg m^,C1739039;C0439402;C3811844;C3812682
stent implanted,C0522776
duration of heart failure years,C0449238;C2926735
final timi flow grade,C0441800;C0919553;C3244287
primary cause of heart failure,C0205225;C0015127;C1524003;C0439612;C0439631
heart rate group at baseline,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
ischaemic,C0475224
$nmbr$ bpm n $nmbr$ l $nmbr$,
non ischaemic,C1518422;C0475224
cardiac parameters,C0018787;C0449381;C1522601
history of atrial fibrillation and or flutter,C0729790;C0016385;C2242390
egfr ml min per $nmbr$ $nmbr$ kg m^,C1739039;C0439402;C3811844;C3812682
treatment at randomisation,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
duration of heart failure years,C0449238;C2926735
p blocker,C0369773;C2603361
primary cause of heart failure,C0205225;C0015127;C1524003;C0439612;C0439631
arbs,C3888198
ischaemic,C0475224
diuretic agents excluding antialdosterone,C0450442;C1254351;C1521826
non ischaemic,C1518422;C0475224
antialdosterone agents,C0450442;C1254351;C1521826
history of atrial fibrillation and or flutter,C0729790;C0016385;C2242390
cardiac glycosides,C0007158
treatment at randomisation,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
devices,C0025080;C0220819;C0699733
p blocker,C0369773;C2603361
crt,
arbs,C3888198
heart rate at baseline bpm,C0018810;C0168634;C1442488
diuretic agents excluding antialdosterone,C0450442;C1254351;C1521826
ivabradine group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
antialdosterone agents,C0450442;C1254351;C1521826
cardiac glycosides,C0007158
devices,C0025080;C0220819;C0699733
figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min,C0013806;C2199618;C2363129;C4050504;C1707455;C0032042;C1696465;C1706408;C2986535;C0184666;C0332271;C1457868;C1546960;C0018801;C0018802;C4554158;C0007226;C1555024;C3887460;C1508496;C0018810;C0332257;C1552866;C2700399;C0011065;C1306577;C0456081;C1512806;C0428876;C0812399;C2985465;C0702093;C1524029;C3813700
crt,
heparin dose regimen,C0019134;C2348331;C0770546
heart rate at baseline bpm,C0018810;C0168634;C1442488
$nmbr$ standard n $nmbr$,C1442989;C2828392
ivabradine group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ low n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
heart failure at entry no,C0018801;C0018802;C4554158
previous events no,C0441471;C3541888
figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min,C0013806;C2199618;C2363129;C4050504;C1707455;C0032042;C1696465;C1706408;C2986535;C0184666;C0332271;C1457868;C1546960;C0018801;C0018802;C4554158;C0007226;C1555024;C3887460;C1508496;C0018810;C0332257;C1552866;C2700399;C0011065;C1306577;C0456081;C1512806;C0428876;C0812399;C2985465;C0702093;C1524029;C3813700
cabg surgery,C0038894;C0038895;C0543467;C1274039
heparin dose regimen,C0019134;C2348331;C0770546
pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
$nmbr$ standard n $nmbr$,C1442989;C2828392
cancer,C0006826;C0998265;C1306459
$nmbr$ low n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
electrocardiograph results no,C1274040;C1546471;C2825142
heart failure at entry no,C0018801;C0018802;C4554158
changes at baseline,C0392747;C0443172
previous events no,C0441471;C3541888
st depression $nmbr$ mm,C4330985;C4554674
cabg surgery,C0038894;C0038895;C0543467;C1274039
any dynamic st segment shift,C0333051;C2347509
pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
transient st elevation,C0040704;C0520886;C0205374
cancer,C0006826;C0998265;C1306459
positive troponin i or t no,C0439178;C0077401;C1446409;C1514241;C2825490;C3812269;C2603360
electrocardiograph results no,C1274040;C1546471;C2825142
changes at baseline,C0392747;C0443172
time from median iqr h,C0040223;C3541383
symptom onset to hospitalization,C4086878;C0019993
st depression $nmbr$ mm,C4330985;C4554674
hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
any dynamic st segment shift,C0333051;C2347509
enrollment to randomization,C1516879;C1696073;C3888021
transient st elevation,C0040704;C0520886;C0205374
symptom onset to enrollment,C4086878;C1516879;C1696073;C3888021
positive troponin i or t no,C0439178;C0077401;C1446409;C1514241;C2825490;C3812269;C2603360
symptom onset to randomization,C4086878;C0034656
time from median iqr h,C0040223;C3541383
angiographic characteristics no,C1521970
symptom onset to hospitalization,C4086878;C0019993
single vessel disease,C0037179;C0042373;C0087136;C0205171
hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
multivessel disease,C0012634
enrollment to randomization,C1516879;C1696073;C3888021
antithrombotic use before enrollment no,C0042153;C0457083;C1947944
symptom onset to enrollment,C4086878;C1516879;C1696073;C3888021
non pci intravenous unfractionated heparin,C1518422;C0354566
symptom onset to randomization,C4086878;C0034656
subcutaneous unfractionated heparin,C0353681
angiographic characteristics no,C1521970
oral anticoagulants,C0354604
single vessel disease,C0037179;C0042373;C0087136;C0205171
lmwh,C0019139;C3536766
multivessel disease,C0012634
gpiib iiia inhibitors,C0016011;C0243077
antithrombotic use before enrollment no,C0042153;C0457083;C1947944
bivalirudin,C0168273
non pci intravenous unfractionated heparin,C1518422;C0354566
commercially available fondaparinux,C0470187;C1098510
subcutaneous unfractionated heparin,C0353681
medication use before enrollment no,C0240320;C1516879;C1696073;C3888021
oral anticoagulants,C0354604
g blockers,C0439267
lmwh,C0019139;C3536766
angiotensin receptor blockers,C0521942;C0815017
gpiib iiia inhibitors,C0016011;C0243077
oral hypoglycemic agents,C0359086
bivalirudin,C0168273
ticlopidine,C0040207
commercially available fondaparinux,C0470187;C1098510
prasugrel,C1620287
medication use before enrollment no,C0240320;C1516879;C1696073;C3888021
aspirin dose mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
g blockers,C0439267
total time of fondaparinux treatment before,C0439175;C0040223;C3541383;C0439810
angiotensin receptor blockers,C0521942;C0815017
and after pci median iqr d,C0549183;C0876920;C2347635;C2348144;C2939193
oral hypoglycemic agents,C0359086
supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups,C0598697;C0456603;C1610540;C0439064;C1079230
ticlopidine,C0040207
prasugrel,C1620287
supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease,C0598697;C0456603;C1610540;C0439064;C1079230;C0348078;C0042373;C0376315
aspirin dose mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
figure $nmbr$ a subgroup results for primary endpoint,C1274040;C1546471;C2825142
total time of fondaparinux treatment before,C0439175;C0040223;C3541383;C0439810
figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou,C1274040;C1546471;C2825142;C0007226;C3887460;C0022646
and after pci median iqr d,C0549183;C0876920;C2347635;C2348144;C2939193
rosuvastatin n $nmbr$,C0965129
supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups,C0598697;C0456603;C1610540;C0439064;C1079230
fenofibric acid n $nmbr$,C0060179
rosuvastain fenofibric acid n $nmbr$,C0060179
supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease,C0598697;C0456603;C1610540;C0439064;C1079230;C0348078;C0042373;C0376315
type $nmbr$ diabetes mellitusa,C1320657
figure $nmbr$ a subgroup results for primary endpoint,C1274040;C1546471;C2825142
metabolic syndromeb,C0311400;C1524026;C2707259
figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou,C1274040;C1546471;C2825142;C0007226;C3887460;C0022646
baseline lipids mg dl,C0023779;C0439269
rosuvastatin n $nmbr$,C0965129
hdl c mean sd,C0444504;C2699239;C2347634;C2348143
fenofibric acid n $nmbr$,C0060179
tg median min max,C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
rosuvastain fenofibric acid n $nmbr$,C0060179
ldl c mean sd,C0444504;C2699239;C2347634;C2348143
type $nmbr$ diabetes mellitusa,C1320657
rosuvastatin,C0965129
metabolic syndromeb,C0311400;C1524026;C2707259
rosuvastatin fenofibric acid,C0965129;C0060179
baseline lipids mg dl,C0023779;C0439269
diabeticb,
hdl c mean sd,C0444504;C2699239;C2347634;C2348143
baseline mean mg dl,C0168634;C0439269;C1442488
tg median min max,C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
final mean mg dl,C0205088;C0439269;C1546485;C3853528
ldl c mean sd,C0444504;C2699239;C2347634;C2348143
mean change se,C0392747;C0036919;C0443172;C1705241;C4319952
rosuvastatin,C0965129
$nmbr$ $nmbr$ c,
rosuvastatin fenofibric acid,C0965129;C0060179
diabeticb,
hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sestandard error tg triglycerides,C0062152
baseline mean mg dl,C0168634;C0439269;C1442488
ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group,C0002680;C1522609;C3887950;C0023779;C1280500;C1518681;C2348382;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
final mean mg dl,C0205088;C0439269;C1546485;C3853528
brandomization was stratified by diabetic status,C0205363;C0241863
mean change se,C0392747;C0036919;C0443172;C1705241;C4319952
crosuvastatin fenofibric acid vs rosuvastatin monotherapy,C0060179;C0965129
$nmbr$ $nmbr$ c,
drosuvastatin fenofibric acid vs fenofibric acid monotherapy,C0060179
all participants n $nmbr$,C0679646
hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sestandard error tg triglycerides,C0062152
dha n $nmbr$,C0142831;C2348308
ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group,C0002680;C1522609;C3887950;C0023779;C1280500;C1518681;C2348382;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
education mean sd ya,C0013621;C0013622;C0013658;C0039401
brandomization was stratified by diabetic status,C0205363;C0241863
apoe e $nmbr$ carriers no,C0003595;C0007294;C0523511;C1412481
crosuvastatin fenofibric acid vs rosuvastatin monotherapy,C0060179;C0965129
body mass indexb,C0518010
drosuvastatin fenofibric acid vs fenofibric acid monotherapy,C0060179
modified hachinski ischemia scale mean sd c,C0022116;C0175659;C0349674;C1947916;C4321499
all participants n $nmbr$,C0679646
smokers no,C0337664
dha n $nmbr$,C0142831;C2348308
education mean sd ya,C0013621;C0013622;C0013658;C0039401
blood pressure mean sd mm hg systolic,C0428886;C0039155
apoe e $nmbr$ carriers no,C0003595;C0007294;C0523511;C1412481
mini mental state examination mean sd d,C0451306;C2699239
body mass indexb,C0518010
cognitive subscale on alzheimer s disease assessment scale mean sd e,C0450989
modified hachinski ischemia scale mean sd c,C0022116;C0175659;C0349674;C1947916;C4321499
clinical dementia rating sum of boxes mean sd f,C0451074;C1515051
smokers no,C0337664
dha intake on food frequency questionnaire mean sd mg d,C1286336
blood pressure mean sd mm hg systolic,C0428886;C0039155
plasma dha mean sd weight,C0005910;C0043100;C1305866;C1705104
mini mental state examination mean sd d,C0451306;C2699239
cholinesterase inhibitor use at baseline no,C0042153;C0457083;C1947944
memantine use at baseline no,C0042153;C0457083;C1947944
cognitive subscale on alzheimer s disease assessment scale mean sd e,C0450989
$nmbr$ mg dabigatran n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
clinical dementia rating sum of boxes mean sd f,C0451074;C1515051
previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
dha intake on food frequency questionnaire mean sd mg d,C1286336
no previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
plasma dha mean sd weight,C0005910;C0043100;C1305866;C1705104
on aspirin at baseline,C0004057;C0168634;C1442488
cholinesterase inhibitor use at baseline no,C0042153;C0457083;C1947944
vitamin k antagonist naive,C1096489;C2267235
memantine use at baseline no,C0042153;C0457083;C1947944
on statins at baseline,C0360714;C0168634;C1442488
$nmbr$ mg dabigatran n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rate per year,C0871208;C1521828
previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
interaction p,C1704675
no previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
$nmbr$ mg dabigatran,C0024671;C2348066;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
on aspirin at baseline,C0004057;C0168634;C1442488
wafarin,
vitamin k antagonist naive,C1096489;C2267235
previous stroke or tl a,C0038454;C4554100;C0220928
on statins at baseline,C0360714;C0168634;C1442488
no previous stroke ortia,C0205156;C0038454;C4554100;C1552607
rate per year,C0871208;C1521828
ischaemic or unknown stroke,C0475224;C0038454;C4554100
interaction p,C1704675
previous stroke ortia $nmbr$ $nmbr$,C0205156;C0038454;C4554100;C1552607
$nmbr$ mg dabigatran,C0024671;C2348066;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous stroke ortia,C0205156;C0038454;C4554100;C1552607
wafarin,
haemorrhagic stroke,C0553692
previous stroke or tl a,C0038454;C4554100;C0220928
total bleeding,C0232100
no previous stroke ortia,C0205156;C0038454;C4554100;C1552607
major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
ischaemic or unknown stroke,C0475224;C0038454;C4554100
$nmbr$ gi,C1708130;C3539617;C4050121
previous stroke ortia $nmbr$ $nmbr$,C0205156;C0038454;C4554100;C1552607
intracranial bleeding,C0151699
previous stroke ortia,C0205156;C0038454;C4554100;C1552607
gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
haemorrhagic stroke,C0553692
previous stroke or tl a $nmbr$ $nmbr$,C0038454;C4554100;C0220928
total bleeding,C0232100
silodosin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
tamsulosin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ gi,C1708130;C3539617;C4050121
age yr n,C0001779;C0439234
intracranial bleeding,C0151699
min max,C0702093;C1524029;C3813700
gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
not estimable,C1518422
previous stroke or tl a $nmbr$ $nmbr$,C0038454;C4554100;C0220928
bmi kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
silodosin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ipss total score,C1019118;C2964552;C1998280;C2827405;C3811063
tamsulosin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ipss storage subscore,C1019118;C0337174;C1698986;C1753314;C1998280;C2827405;C3811063
age yr n,C0001779;C0439234
ipss voiding subscore,C1019118;C0042034;C4067975;C1998280;C2827405;C3811063
min max,C0702093;C1524029;C3813700
qol due to urinary symptoms,C0518214;C0426359
not estimable,C1518422
delighted,C3830544
bmi kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
pleased,C3829994;C4264468
ipss total score,C1019118;C2964552;C1998280;C2827405;C3811063
mostly satisfied,C0242428;C4049977;C4084799
ipss storage subscore,C1019118;C0337174;C1698986;C1753314;C1998280;C2827405;C3811063
mostly dissatisfied,C0870433;C4085546
ipss voiding subscore,C1019118;C0042034;C4067975;C1998280;C2827405;C3811063
unhappy,C1688635
qol due to urinary symptoms,C0518214;C0426359
terrible,C3827840
delighted,C3830544
urine qmax ml s,C0439526;C1705224;C3887665
pleased,C3829994;C4264468
acute dvt study,C0557651;C2603343
mostly satisfied,C0242428;C4049977;C4084799
continued treatment study,C0549178;C3161471
mostly dissatisfied,C0870433;C4085546
rivaroxaban n $nmbr$,C1739768
unhappy,C1688635
standard therapyy n $nmbr$,C1442989;C2828392
terrible,C3827840
male sex no weight no,C0086582;C0005910;C0043100;C1305866;C1705104
urine qmax ml s,C0439526;C1705224;C3887665
missing data initial diagnosis no,C0011900;C1704338;C1704656
acute dvt study,C0557651;C2603343
dvt,C0149871;C2926618;C3899446
continued treatment study,C0549178;C3161471
$nmbr$ only $nmbr$ distal,C0205108;C4522154
rivaroxaban n $nmbr$,C1739768
pe,C0070939;C1880476;C4284304
standard therapyy n $nmbr$,C1442989;C2828392
time from onset of symptoms to randomization days,C1320528;C0034656;C0439228
male sex no weight no,C0086582;C0005910;C0043100;C1305866;C1705104
cause of dvt or pe no,C0015127;C1524003;C0070939;C1880476;C4284304
missing data initial diagnosis no,C0011900;C1704338;C1704656
unprovoked,
dvt,C0149871;C2926618;C3899446
recent surgery or trauma,C0038894;C0038895;C0543467;C1274039;C0043251;C1510467;C3263723;C3714660;C4049136
$nmbr$ only $nmbr$ distal,C0205108;C4522154
immobilization,C0020944;C4048292
pe,C0070939;C1880476;C4284304
estrogen therapy,C0279494
time from onset of symptoms to randomization days,C1320528;C0034656;C0439228
active cancer,C0006826;C0998265;C1306459
cause of dvt or pe no,C0015127;C1524003;C0070939;C1880476;C4284304
puerperium,C0034042;C0086839;C1879329
unprovoked,
known thrombophilic condition no,C0012634;C0348080;C1705253;C3864998
recent surgery or trauma,C0038894;C0038895;C0543467;C1274039;C0043251;C1510467;C3263723;C3714660;C4049136
previous vte no,C0205156;C0630906;C1552607
immobilization,C0020944;C4048292
qveral,
estrogen therapy,C0279494
riva roxa ban n n $nmbr$ $nmbr$ $nmbr$,C0683610;C4553947
active cancer,C0006826;C0998265;C1306459
enoxaparin vka n n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0206460
puerperium,C0034042;C0086839;C1879329
wegu,
known thrombophilic condition no,C0012634;C0348080;C1705253;C3864998
wssng,
previous vte no,C0205156;C0630906;C1552607
ofl,
qveral,
mae,C0286540;C4085238
riva roxa ban n n $nmbr$ $nmbr$ $nmbr$,C0683610;C4553947
renal fmclicn creatntoe clearance,C0232813;C0699829
enoxaparin vka n n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0206460
$nmbr$ rrmnl,
wegu,
$nmbr$ $nmbr$ nlmw,
wssng,
m being,
ofl,
cardiac disease,C0018799
mae,C0286540;C4085238
ns cardiac cisease,C0038944;C0018787;C1522601;C1112705;C1705982
renal fmclicn creatntoe clearance,C0232813;C0699829
intended durat sm of antccagubficn,C0036154;C4553627
$nmbr$ rrmnl,
$nmbr$ mortis,
$nmbr$ $nmbr$ nlmw,
$nmbr$ mentis,
m being,
$nmbr$ months,C0439231
cardiac disease,C0018799
m,
ns cardiac cisease,C0038944;C0018787;C1522601;C1112705;C1705982
rarertd antocagibtcn before andorrtzafon,
intended durat sm of antccagubficn,C0036154;C4553627
pre rtous eptscde s d dvt pe,C0070939;C1880476;C4284304
$nmbr$ mortis,
kheeatne index dvt,C0149871;C2926618;C3899446
$nmbr$ mentis,
sco ita rojs dvt pe,C0070939;C1880476;C4284304
$nmbr$ months,C0439231
secondary dvt fe,C0027627;C3848561;C0175668;C0205436
m,
ill,C0231218
rarertd antocagibtcn before andorrtzafon,
known t rc iitoji cccndilon,C0205309;C1167159;C1419366
pre rtous eptscde s d dvt pe,C0070939;C1880476;C4284304
known tiromtcch c ccndifeon,C0205309
kheeatne index dvt,C0149871;C2926618;C3899446
p $nmbr$,C0369773;C2603361
sco ita rojs dvt pe,C0070939;C1880476;C4284304
no known frtrontxtfufoc cond aon,C0205309;C1856054;C2826243;C4597943
secondary dvt fe,C0027627;C3848561;C0175668;C0205436
$nmbr$ j $nmbr$,
ill,C0231218
locafon of index dvt,C0600653;C0149871;C2926618;C3899446;C0918012;C1552854;C1637833;C2986546
known t rc iitoji cccndilon,C0205309;C1167159;C1419366
extensive,C0205231
known tiromtcch c ccndifeon,C0205309
non extensive,C1518422;C0205231
p $nmbr$,C0369773;C2603361
ms ng,C0017887;C0028074
no known frtrontxtfufoc cond aon,C0205309;C1856054;C2826243;C4597943
p o,C0369773;C2603361
$nmbr$ j $nmbr$,
mafcaiancy at randorrtzaton,
locafon of index dvt,C0600653;C0149871;C2926618;C3899446;C0918012;C1552854;C1637833;C2986546
no adk e cancer,C0006826;C0998265;C1306459
extensive,C0205231
ac tve cancer,C0006826;C0998265;C1306459
non extensive,C1518422;C0205231
modmy al randcnxzaton,C0202311
ms ng,C0017887;C0028074
immobazaton,
p o,C0369773;C2603361
no immomtedion,
mafcaiancy at randorrtzaton,
$nmbr$ j,
no adk e cancer,C0006826;C0998265;C1306459
miami k antagonist received,C0597277;C0231491;C1708601;C1514756
ac tve cancer,C0006826;C0998265;C1306459
acenocoumaroi,
modmy al randcnxzaton,C0202311
redon,
immobazaton,
western friroce,C1705493
no immomtedion,
austrafca and new zealand,C0027978;C0324547
$nmbr$ j,
cm,
miami k antagonist received,C0597277;C0231491;C1708601;C1514756
sonti amenca,
acenocoumaroi,
kg,C0022718;C0439209;C4054209
redon,
sou ti africa,C0039247;C0001737;C0040302;C1553045;C1704756
western friroce,C1705493
rivaroxaban,C1739768
austrafca and new zealand,C0027978;C0324547
enoxaparin vka,C0206460
cm,
n n $nmbr$ $nmbr$,C0369718;C0441922
sonti amenca,
mate,C0682323;C1260875
kg,C0022718;C0439209;C4054209
renal function creatinine clearance,C0232813;C0699829
sou ti africa,C0039247;C0001737;C0040302;C1553045;C1704756
sd ml min,C2699239;C0439445
rivaroxaban,C1739768
intended duration of anticoagulation,C0449238;C2926735
enoxaparin vka,C0206460
$nmbr$ montlts,
n n $nmbr$ $nmbr$,C0369718;C0441922
parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
mate,C0682323;C1260875
malignancy at randomization,C0006826;C1306459;C4282132
renal function creatinine clearance,C0232813;C0699829
no active cancer,C0006826;C0998265;C1306459
sd ml min,C2699239;C0439445
not available,C0686905
intended duration of anticoagulation,C0449238;C2926735
uncodable,
$nmbr$ montlts,
vka naive,
parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
vka experienced,
malignancy at randomization,C0006826;C1306459;C4282132
never been on a vka,C2003901
no active cancer,C0006826;C0998265;C1306459
ever been on a vka,
not available,C0686905
no vka at randomization,C0034656
uncodable,
vka at randomization,C0034656
vka naive,
total randomized,C0439175;C0439810;C0034656;C3815594
vka experienced,
dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
never been on a vka,C2003901
chads $nmbr$ scoret,C0007928;C1413373
ever been on a vka,
prior transient ischemic attack,C0007787;C0917805
no vka at randomization,C0034656
baseline aspirin use,C0042153;C0457083;C1947944
vka at randomization,C0034656
event,C0441471;C4019010
total randomized,C0439175;C0439810;C0034656;C3815594
d $nmbr$,
dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
d $nmbr$ vs warfarin,C0043031
chads $nmbr$ scoret,C0007928;C1413373
y,
prior transient ischemic attack,C0007787;C0917805
interaction pf,C1704675;C3815179
baseline aspirin use,C0042153;C0457083;C1947944
stroke or systemic embolism,C0038454;C4554100;C0013922;C1704212
event,C0441471;C4019010
life threatening bleeding disabling stroke and death,C1546953;C0019080;C2826244;C3537125;C0038454;C4554100;C0011065;C1306577;C4082313;C4552775
d $nmbr$,
gastrointestinal bleeding,C0017181
d $nmbr$ vs warfarin,C0043031
dexlansoprazole mr $nmbr$ mg n $nmbr$,C0024485;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1417249;C2347167;C3254418;C4050513
y,
age at baseline years,C1510829;C0168634;C1442488
interaction pf,C1704675;C3815179
ppi use within $nmbr$ months of randomization,C1524063;C0034656
stroke or systemic embolism,C0038454;C4554100;C0013922;C1704212
alcohol drinker,C0001962;C0556338;C0001975
life threatening bleeding disabling stroke and death,C1546953;C0019080;C2826244;C3537125;C0038454;C4554100;C0011065;C1306577;C4082313;C4552775
smoker,C0337664
gastrointestinal bleeding,C0017181
caffeine user,C3532939
dexlansoprazole mr $nmbr$ mg n $nmbr$,C0024485;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1417249;C2347167;C3254418;C4050513
indacaterol $nmbr$ gg qd,C0017454;C0332173;C0018370
age at baseline years,C1510829;C0168634;C1442488
formoterol $nmbr$ gg bid,C0017454;C0018370
ppi use within $nmbr$ months of randomization,C1524063;C0034656
salmeterol $nmbr$ gg bid,C0017454;C0018370
alcohol drinker,C0001962;C0556338;C0001975
tiotropium $nmbr$ gg qd,C0017454;C0332173;C0018370
smoker,C0337664
male female,C0043210;C0086287;C1705497;C1705498
caffeine user,C3532939
fev $nmbr$ la,C0023031;C0023749;C0230347;C2346906;C4553351
indacaterol $nmbr$ gg qd,C0017454;C0332173;C0018370
fev $nmbr$ predicteda,C3714541
formoterol $nmbr$ gg bid,C0017454;C0018370
ics use yes no,C0042153;C0457083;C1947944;C1512698
salmeterol $nmbr$ gg bid,C0017454;C0018370
ex smoker smoker,C0337671;C4555205
tiotropium $nmbr$ gg qd,C0017454;C0332173;C0018370
history of or current cardiac disorders,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0521116;C0018799;C1705970
male female,C0043210;C0086287;C1705497;C1705498
treatment duration days,C0444921;C0439228;C3259042
fev $nmbr$ la,C0023031;C0023749;C0230347;C2346906;C4553351
patients treated for $nmbr$ weeks,C0030705;C1522326;C0439230
fev $nmbr$ predicteda,C3714541
figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline,C0439165;C1549488;C1561533;C1412268;C2699274;C1518422;C0850624;C0168634;C1442488
ics use yes no,C0042153;C0457083;C1947944;C1512698
ex smoker smoker,C0337671;C4555205
ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus,C4049864;C1722260;C0439272;C0011849
carisbamate $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history of or current cardiac disorders,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0521116;C0018799;C1705970
carisbamate $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatment duration days,C0444921;C0439228;C3259042
patients treated for $nmbr$ weeks,C0030705;C1522326;C0439230
time since epilepsy diagnosis years,C0556970;C0011900;C1704338;C1704656
number of previous reported aeds,C0237753;C0449788
figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline,C0439165;C1549488;C1561533;C1412268;C2699274;C1518422;C0850624;C0168634;C1442488
baseline monthly pos seizure rate,C0871208;C1521828
ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus,C4049864;C1722260;C0439272;C0011849
number of co aeds n,C0237753;C0449788
carisbamate $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients with $nmbr$ co aed,C0030705;C0887457
carisbamate $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients with $nmbr$ co aeds,C0030705;C0180309
time since epilepsy diagnosis years,C0556970;C0011900;C1704338;C1704656
ugt induction status as randomizeda n,C0205263;C0449438;C0857127
number of previous reported aeds,C0237753;C0449788
inducing,C0205263
baseline monthly pos seizure rate,C0871208;C1521828
noninducing,
number of co aeds n,C0237753;C0449788
ugt induction status per aeda n,C0205263;C0449438;C0857127
patients with $nmbr$ co aed,C0030705;C0887457
syndrome n,C0039082
patients with $nmbr$ co aeds,C0030705;C0180309
symptomatic localization related,C0475264;C1744691;C0439849;C0445223
ugt induction status as randomizeda n,C0205263;C0449438;C0857127
cryptogenic localization related,C0475264;C1744691;C0439849;C0445223
inducing,C0205263
undetermined,C0205258;C3536725;C4082977
noninducing,
overall w $nmbr$ $nmbr$ $nmbr$,C0282416;C1561607
ugt induction status per aeda n,C0205263;C0449438;C0857127
combined therapy v $nmbr$ $nmbr$ $nmbr$,C0033972
syndrome n,C0039082
dutasteride w $nmbr$ $nmbr$ $nmbr$,C0754659
symptomatic localization related,C0475264;C1744691;C0439849;C0445223
tamsulosin w $nmbr$ $nmbr$ $nmbr$,C0257343
cryptogenic localization related,C0475264;C1744691;C0439849;C0445223
ipss o,C1019118;C1998280;C2827405;C3811063
undetermined,C0205258;C3536725;C4082977
pv ml,C0439526;C1705224;C3887665
overall w $nmbr$ $nmbr$ $nmbr$,C0282416;C1561607
psa level ng ml,C4086720;C0439275
combined therapy v $nmbr$ $nmbr$ $nmbr$,C0033972
qmaxi rn l s,C2827110;C3540639;C4281819
dutasteride w $nmbr$ $nmbr$ $nmbr$,C0754659
previous treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
tamsulosin w $nmbr$ $nmbr$ $nmbr$,C0257343
ipss hrql,C1019118;C1998280;C2827405;C3811063
ipss o,C1019118;C1998280;C2827405;C3811063
at $nmbr$ years,C0439234
pv ml,C0439526;C1705224;C3887665
rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl,C0301630;C0596019;C0392756;C1293152;C4551656
psa level ng ml,C4086720;C0439275
combined dutasteride ta msu losi n,C0039297;C0024776;C1412759;C1506978;C1705538;C3272501;C4553364
qmaxi rn l s,C2827110;C3540639;C4281819
dutasteride,C0754659
previous treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
tamsulosin,C0257343
ipss hrql,C1019118;C1998280;C2827405;C3811063
no of events,C0441471;C3541888
at $nmbr$ years,C0439234
incidence o $nmbr$ $nmbr$ cl,C0021149;C0596019;C0220856
rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl,C0301630;C0596019;C0392756;C1293152;C4551656
combined therapy vsdutasteride,C0033972
combined dutasteride ta msu losi n,C0039297;C0024776;C1412759;C1506978;C1705538;C3272501;C4553364
combined therapy vsta msu iosin,C0033972;C0024776;C1412759
dutasteride,C0754659
ipss,C1019118;C1998280;C2827405;C3811063
tamsulosin,C0257343
non white,C0007457;C0043157;C0220938
no of events,C0441471;C3541888
change in das $nmbr$ $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
incidence o $nmbr$ $nmbr$ cl,C0021149;C0596019;C0220856
week $nmbr$ responders n $nmbr$,C0332174;C0439230
combined therapy vsdutasteride,C0033972
acr $nmbr$ week $nmbr$ responders n $nmbr$,C0332174;C0439230
combined therapy vsta msu iosin,C0033972;C0024776;C1412759
all responders n $nmbr$,
ipss,C1019118;C1998280;C2827405;C3811063
no previous dmard mean sd,C0205156;C2699239;C1552607
non white,C0007457;C0043157;C0220938
disease duration yrs mean sd,C0872146;C2699239
change in das $nmbr$ $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
mtx dose $nmbr$ mg week,C0332174;C0439230
week $nmbr$ responders n $nmbr$,C0332174;C0439230
steroid use,C0281991
acr $nmbr$ week $nmbr$ responders n $nmbr$,C0332174;C0439230
rf positive $nmbr$ iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
all responders n $nmbr$,
sjc mean sd,C0444504;C2699239;C2347634;C2348143
no previous dmard mean sd,C0205156;C2699239;C1552607
tjc mean sd,C0444504;C2699239;C2347634;C2348143
disease duration yrs mean sd,C0872146;C2699239
mtss mean sd,C0444504;C2699239;C2347634;C2348143
mtx dose $nmbr$ mg week,C0332174;C0439230
das $nmbr$ range $nmbr$ $nmbr$ mean sd,C0051767;C2699239;C0057671
steroid use,C0281991
pain vas range $nmbr$ $nmbr$ mm mean sd,C0042815;C2699239
rf positive $nmbr$ iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
haq di range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
sjc mean sd,C0444504;C2699239;C2347634;C2348143
fas range $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
tjc mean sd,C0444504;C2699239;C2347634;C2348143
crp mean mg l sd,C0439268;C2699239
mtss mean sd,C0444504;C2699239;C2347634;C2348143
olmesartan n $nmbr$,C1098320
das $nmbr$ range $nmbr$ $nmbr$ mean sd,C0051767;C2699239;C0057671
mean yr,C0444504;C0439234;C2347634;C2348143
pain vas range $nmbr$ $nmbr$ mm mean sd,C0042815;C2699239
duration yr,C0449238;C0439234;C2926735
haq di range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
prior treatment no,C1514463
fas range $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
smoking status no,C1519386
crp mean mg l sd,C0439268;C2699239
never smoked,C0037366;C0439994;C1881674
olmesartan n $nmbr$,C1098320
former smoker,C0337671
mean yr,C0444504;C0439234;C2347634;C2348143
metabolic syndrome no,C0524620
duration yr,C0449238;C0439234;C2926735
cardiovascular history no,C1880008
prior treatment no,C1514463
stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
smoking status no,C1519386
glucose mmol liter,C0017725;C0475211
never smoked,C0037366;C0439994;C1881674
overall freedom population n $nmbr$,C0016694;C0032659;C1257890
former smoker,C0337671
prevalent vertebral fracture status,C0080179;C0449438
metabolic syndrome no,C0524620
femoral neck bmd t score,C0449820;C4050231
cardiovascular history no,C1880008
$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0000768;C0221430;C0302142;C0369718;C0441922
stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
age yr mean sd bmd t score mean sd,C0001779;C3533236
glucose mmol liter,C0017725;C0475211
subjects with prevalent vertebral fracture n prevalent vertebral fracture,C0681850;C1550501;C1706203;C2349001;C2697811
overall freedom population n $nmbr$,C0016694;C0032659;C1257890
numbera,
prevalent vertebral fracture status,C0080179;C0449438
severitya,
femoral neck bmd t score,C0449820;C4050231
tiotropium n $nmbr$,C0213771
$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0000768;C0221430;C0302142;C0369718;C0441922
salmeterol n $nmbr$,C0073992
age yr mean sd bmd t score mean sd,C0001779;C3533236
smoking history pack yr,C1519384;C0439234
subjects with prevalent vertebral fracture n prevalent vertebral fracture,C0681850;C1550501;C1706203;C2349001;C2697811
duration of copd yr f,C0449238;C2926735
numbera,
gold stage c,C0018026;C0441785;C1304897
severitya,
spirometry after bronchodilation,C0037981;C1371299;C3537072
tiotropium n $nmbr$,C0213771
fev $nmbr$ liters,C3714541;C0475211
salmeterol n $nmbr$,C0073992
fev $nmbr$ of predicted value,C3714541;C0681842;C1522609;C1882327
smoking history pack yr,C1519384;C0439234
fvc liters,C3714541;C0475211
duration of copd yr f,C0449238;C2926735
ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
gold stage c,C0018026;C0441785;C1304897
pulmonary medications,C0013227;C0802604;C2598133;C4284232
spirometry after bronchodilation,C0037981;C1371299;C3537072
anticholinergic drug,C0242896
fev $nmbr$ liters,C3714541;C0475211
short acting,C1282927;C1806781;C2350002
fev $nmbr$ of predicted value,C3714541;C0681842;C1522609;C1882327
js $nmbr$ agonists,C0243192;C2987634
fvc liters,C3714541;C0475211
long acting^,C0205166;C1706317
ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
glucocorticoids,C0017710;C3540777;C3540778
pulmonary medications,C0013227;C0802604;C2598133;C4284232
inhaled^,C0004048
anticholinergic drug,C0242896
with tiotropium,C0213771
short acting,C1282927;C1806781;C2350002
with long acting j $nmbr$ agonists,C0243192;C2987634
js $nmbr$ agonists,C0243192;C2987634
oral,C0442027;C4521986
long acting^,C0205166;C1706317
methylxanthines,C0066447
glucocorticoids,C0017710;C3540777;C3540778
tiotropium salmeterol no of patients total no,C0213771;C0073992;C0030705;C0439175;C0439810
inhaled^,C0004048
hazard ratio $nmbr$ ci,C0008107;C3259781
with tiotropium,C0213771
copd severity stage gold,C0018026;C1304897
with long acting j $nmbr$ agonists,C0243192;C2987634
stage ii,C0441767
oral,C0442027;C4521986
stage iii,C0441771
methylxanthines,C0066447
stage iv,C0022326;C4265176
tiotropium salmeterol no of patients total no,C0213771;C0073992;C0030705;C0439175;C0439810
noncurrent smoker,C0337664
hazard ratio $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
copd severity stage gold,C0018026;C1304897
use of inhaled glucocorticoids at baseline,C1524063;C0004048;C0168634;C1442488
stage ii,C0441767
stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$,C1739039;C3811844;C3812682;C0439445
stage iii,C0441771
stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$,C0205390;C0439526;C1705224;C3887665;C1300072;C1306673
stage iv,C0022326;C4265176
years since menopause,C0439234;C0025320;C0567312
noncurrent smoker,C0337664
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
taking calcium supplements at baseline n,C3540037;C0168634;C1442488
use of inhaled glucocorticoids at baseline,C1524063;C0004048;C0168634;C1442488
no alcohol consumption on average,C0001948;C1510992;C2825518
over past $nmbr$ years n,C0439234
stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$,C1739039;C3811844;C3812682;C0439445
eq $nmbr$ da health index status score,C0449820;C4050231
stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$,C0205390;C0439526;C1705224;C3887665;C1300072;C1306673
opaqb physical function score,C4483112
years since menopause,C0439234;C0025320;C0567312
low trauma fracture since age $nmbr$ n,C0521170;C0001779
taking calcium supplements at baseline n,C3540037;C0168634;C1442488
prevalent vertebral fracture n,C0080179
no alcohol consumption on average,C0001948;C1510992;C2825518
over past $nmbr$ years n,C0439234
serum albumin adjusted calcium mg dl,C0036785;C0439269;C0728876
eq $nmbr$ da health index status score,C0449820;C4050231
serum vitamin d nmol l,C0312532
opaqb physical function score,C4483112
lumbar spine bmd t score,C0449820;C4050231
low trauma fracture since age $nmbr$ n,C0521170;C0001779
total hip bmd t score,C2964552;C0019552;C0022122;C1505163;C3538851;C4284725
prevalent vertebral fracture n,C0080179
facilitated pci n $nmbr$,C4049621
serum albumin adjusted calcium mg dl,C0036785;C0439269;C0728876
primary pci n $nmbr$,C0205225;C0439612;C0439631
p vaiue,C0369773;C2603361
serum vitamin d nmol l,C0312532
actual or estimated weight kg,C0237400;C0022718;C0439209;C4054209
lumbar spine bmd t score,C0449820;C4050231
killip class iv at randomization,C2697847;C0034656
total hip bmd t score,C2964552;C0019552;C0022122;C1505163;C3538851;C4284725
prior cabg surgery,C0455610;C0010055
facilitated pci n $nmbr$,C4049621
chronic treatment with aspirin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
primary pci n $nmbr$,C0205225;C0439612;C0439631
infarct location anterior,C0021308;C0205094
p vaiue,C0369773;C2603361
time intervals,C0872291
actual or estimated weight kg,C0237400;C0022718;C0439209;C4054209
symptoms onset to first balloon inflation min,C4086878;C0021398;C1318493
killip class iv at randomization,C2697847;C0034656
randomization to first balloon inflation min,C0034656;C0021398;C1318493
prior cabg surgery,C0455610;C0010055
treatment before catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
chronic treatment with aspirin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bolus of heparin given,C1186706;C1511237;C1705509;C3812160
infarct location anterior,C0021308;C0205094
loading dose of clopidogrel or ticlopidine,C3714444;C0070166;C0040207
time intervals,C0872291
glycoprotein llb illa inhibitor,C0017968;C1999216
symptoms onset to first balloon inflation min,C4086878;C0021398;C1318493
pci performed,C4049621;C0884358
randomization to first balloon inflation min,C0034656;C0021398;C1318493
cabg performed during index hospitalization,C0010055;C0884358;C0019993
treatment before catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0007430
bolus of heparin given,C1186706;C1511237;C1705509;C3812160
additional heparin,C0019134;C0770546
loading dose of clopidogrel or ticlopidine,C3714444;C0070166;C0040207
glycoprotein llb llia inhibitor,C0017968;C1999216
glycoprotein llb illa inhibitor,C0017968;C1999216
$nmbr$ day mortality,C0026565;C0026566
pci performed,C4049621;C0884358
$nmbr$ day cce,C0332173;C0439228;C0439505
cabg performed during index hospitalization,C0010055;C0884358;C0019993
covariates,
treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0007430
or,
additional heparin,C0019134;C0770546
assigned treatment by sex interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
glycoprotein llb llia inhibitor,C0017968;C1999216
fpci vs ppci in women,C0043210
$nmbr$ day mortality,C0026565;C0026566
fpci vs ppci in men,C0025266
$nmbr$ day cce,C0332173;C0439228;C0439505
or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603;C0549178;C0439828
covariates,
univariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
or,
multivariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
assigned treatment by sex interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ yrs,
fpci vs ppci in women,C0043210
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
fpci vs ppci in men,C0025266
baseline crcl ml min,C0168634;C0439445;C1442488
or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603;C0549178;C0439828
hemoglobin $nmbr$ men $nmbr$ women,C0019046;C0043210
univariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
total diuretic dose iv oral on day $nmbr$ mg,C0442027;C4521986
multivariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
jvp $nmbr$ cm,
$nmbr$ yrs,
rolofylline rx,C1425688;C1521941;C2709207
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
baseline crcl ml min,C0168634;C0439445;C1442488
weight kg blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
$nmbr$ $nmbr$ no totalno,
hemoglobin $nmbr$ men $nmbr$ women,C0019046;C0043210
previous stroke or transient ischemic attack no total no,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
total diuretic dose iv oral on day $nmbr$ mg,C0442027;C4521986
jvp $nmbr$ cm,
hypertension no total no medications in use at baseline no total no,C0020538;C1963138;C0439175;C0439810;C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
rolofylline rx,C1425688;C1521941;C2709207
long term vitamin k antagonist,C1096489;C2267235
weight kg blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
pts,C1419129;C2698747
$nmbr$ $nmbr$ no totalno,
war,C0043027
previous stroke or transient ischemic attack no total no,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
dabigatran $nmbr$ vs warfarin p inter,C2348066;C0043031;C0205103;C1548610
age $nmbr$ $nmbr$,C0001779
hypertension no total no medications in use at baseline no total no,C0020538;C1963138;C0439175;C0439810;C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
weight $nmbr$ $nmbr$,C0005910;C0043100;C1305866;C1705104
long term vitamin k antagonist,C1096489;C2267235
weight $nmbr$,C0005910;C0043100;C1305866;C1705104
pts,C1419129;C2698747
cclear,
war,C0043027
cclear $nmbr$ $nmbr$,
dabigatran $nmbr$ vs warfarin p inter,C2348066;C0043031;C0205103;C1548610
cclear $nmbr$,
age $nmbr$ $nmbr$,C0001779
asa,C0004057;C3853627
weight $nmbr$ $nmbr$,C0005910;C0043100;C1305866;C1705104
no asa,C0004057;C3853627
weight $nmbr$,C0005910;C0043100;C1305866;C1705104
no amiodarone,C0002598
cclear,
ppi,C0358591;C0871125;C3811894
cclear $nmbr$ $nmbr$,
noppi,
cclear $nmbr$,
p inter,C0369773;C2603361;C0205103;C1548610
asa,C0004057;C3853627
no ppi,C0358591;C0871125;C3811894
no asa,C0004057;C3853627
figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients,C0040223;C3541383;C1319635;C0439422;C0030705
no amiodarone,C0002598
ppi,C0358591;C0871125;C3811894
in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$,C2986480;C0040223;C3541383;C1441672;C0332283;C0694649
noppi,
figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0439234;C0017446;C0205147;C0030705;C1522326;C0032042;C1696465;C1706408;C4521536;C0449820;C4050231;C0332272;C0018684;C4522046;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1518681;C1273937
p inter,C0369773;C2603361;C0205103;C1548610
figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$,C2045651;C2964552;C0392747;C0443172;C1705241;C4319952;C0683312;C3889287;C0449820;C4050231;C0184511;C0018684;C0332272;C1561611;C4084203;C1524063;C0814908;C1705242;C0598981;C3146232;C0369773;C2603361
no ppi,C0358591;C0871125;C3811894
charm,C0849759
figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients,C0040223;C3541383;C1319635;C0439422;C0030705
adhere,C3714578
in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$,C2986480;C0040223;C3541383;C1441672;C0332283;C0694649
week $nmbr$,C0332174;C0439230
steroid free remission,C0544452;C0687702
figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0439234;C0017446;C0205147;C0030705;C1522326;C0032042;C1696465;C1706408;C4521536;C0449820;C4050231;C0332272;C0018684;C4522046;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1518681;C1273937
steroid sparing remission,C0544452;C0687702
figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$,C2045651;C2964552;C0392747;C0443172;C1705241;C4319952;C0683312;C3889287;C0449820;C4050231;C0184511;C0018684;C0332272;C1561611;C4084203;C1524063;C0814908;C1705242;C0598981;C3146232;C0369773;C2603361
steroid free cr $nmbr$,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
charm,C0849759
remission by baseline steroid doses,C0544452;C0687702
adhere,C3714578
high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
week $nmbr$,C0332174;C0439230
low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
steroid free remission,C0544452;C0687702
remission by baseline duration of steroid,C0814126;C0038317
steroid sparing remission,C0544452;C0687702
used,C1273517
steroid free cr $nmbr$,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
$nmbr$ $nmbr$ months,C0439231
remission by baseline steroid doses,C0544452;C0687702
week $nmbr$ mayo endoscopy subscorea,C0332174;C0014245;C0439230
high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
symptomatic remissionb n n,C0231220
low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
sustained mucosal healingc n n,C0443318;C0026724
remission by baseline duration of steroid,C0814126;C0038317
mucosal healingc n n,C0026724
used,C1273517
sustained mucosal healingc,C0443318;C0026724
$nmbr$ $nmbr$ months,C0439231
p value n n,C1709380
week $nmbr$ mayo endoscopy subscorea,C0332174;C0014245;C0439230
nesiritide n $nmbr$,C0054015
symptomatic remissionb n n,C0231220
sex no total no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0439175;C0439810
sustained mucosal healingc n n,C0443318;C0026724
race no total no f,C0034510;C1706779;C3853635;C0439175;C0439810;C0016327
mucosal healingc n n,C0026724
systolic pressure mm hg,C0871470;C0439475
sustained mucosal healingc,C0443318;C0026724
heart rate at rest beats min,C0018810
p value n n,C1709380
bnp pg ml i,C0023806
nesiritide n $nmbr$,C0054015
sex no total no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0439175;C0439810
n terminal pro bnp pg ml,C0669479;C0439297
race no total no f,C0034510;C1706779;C3853635;C0439175;C0439810;C0016327
serum sodium mmol liter,C0523891;C0475211
systolic pressure mm hg,C0871470;C0439475
left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$,C0428772;C0488728;C0439175;C0439810
heart rate at rest beats min,C0018810
medical history no total no,C0262926;C1704706;C0439175;C0439810
bnp pg ml i,C0023806
heart failure $nmbr$ yr before admission,C0018801;C0439234;C0018802;C4554158
n terminal pro bnp pg ml,C0669479;C0439297
atrial fibrillation or flutter,C0004238;C0344434;C1963067;C0016385;C2242390
serum sodium mmol liter,C0523891;C0475211
medical therapy before randomization no total no,C0418981;C0034656;C0439175;C0439810
aldosterone blocker,C0002006
left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$,C0428772;C0488728;C0439175;C0439810
nitrate oral or topical,C0442027;C4521986;C0332237
medical history no total no,C0262926;C1704706;C0439175;C0439810
digoxin or digitalis glycoside,C0012265;C0012253
heart failure $nmbr$ yr before admission,C0018801;C0439234;C0018802;C4554158
hydralazine,C0020223
atrial fibrillation or flutter,C0004238;C0344434;C1963067;C0016385;C2242390
loop diuretic,C0354100;C3536704
medical therapy before randomization no total no,C0418981;C0034656;C0439175;C0439810
inotropic agent,C0304509
aldosterone blocker,C0002006
vasodilator,C0042402;C3537240
nitrate oral or topical,C0442027;C4521986;C0332237
use of medication from randomization through $nmbr$ hr no total no,C1524063;C0034656;C0439175;C0439810
digoxin or digitalis glycoside,C0012265;C0012253
time from hospitalization to randomization hr,C0040223;C3541383;C0034656
hydralazine,C0020223
time from randomization to study drug administration hr,C0040223;C3541383;C0013175;C0150270;C3469597
loop diuretic,C0354100;C3536704
inotropic agent,C0304509
administration of study drug bolus no total no,C0150270;C0262754;C3469597;C0439175;C0439810
vasodilator,C0042402;C3537240
duration of study drug administration hr,C0920470;C2348354
use of medication from randomization through $nmbr$ hr no total no,C1524063;C0034656;C0439175;C0439810
figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus,C1707455;C0772326;C2353292;C1705241;C1705242;C1628982;C0013227;C3687832;C0030705;C3538926;C1079230;C1518422;C0439801;C1549649;C2349209
time from hospitalization to randomization hr,C0040223;C3541383;C0034656
age yr mean sd,C0001779;C2699239
time from randomization to study drug administration hr,C0040223;C3541383;C0013175;C0150270;C3469597
baseline total ipss mean sd,C0168634;C2699239;C1442488
administration of study drug bolus no total no,C0150270;C0262754;C3469597;C0439175;C0439810
baseline bii mean sd,C0168634;C2699239;C1442488
duration of study drug administration hr,C0920470;C2348354
baseline luts severity n,C0168634;C0439793;C0522510;C1442488
mild ipss,C1019118;C1998280;C2827405;C3811063
figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus,C1707455;C0772326;C2353292;C1705241;C1705242;C1628982;C0013227;C3687832;C0030705;C3538926;C1079230;C1518422;C0439801;C1549649;C2349209
moderate $nmbr$ ipss,C1019118;C1998280;C2827405;C3811063
age yr mean sd,C0001779;C2699239
severe ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
baseline total ipss mean sd,C0168634;C2699239;C1442488
qmax category n,C0683312;C3889287
baseline bii mean sd,C0168634;C2699239;C1442488
$nmbr$ ml s,C0439526;C1705224;C3887665
baseline luts severity n,C0168634;C0439793;C0522510;C1442488
qmax ml s mean sd,C0439390;C2699239
mild ipss,C1019118;C1998280;C2827405;C3811063
pvr volume ml mean sd,C0242852;C2699239;C0456261;C1419141
moderate $nmbr$ ipss,C1019118;C1998280;C2827405;C3811063
psa ng ml mean sd,C0439275;C2699239
severe ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
ed history n yes,C1549445;C1705108;C1710701
qmax category n,C0683312;C3889287
ed severity n,C0439793;C0522510
$nmbr$ ml s,C0439526;C1705224;C3887665
ed duration $nmbr$ yr n,C0449238;C0439234;C2926735
qmax ml s mean sd,C0439390;C2699239
sexually active with female,C0241028;C0043210;C0086287;C1705497;C1705498
pvr volume ml mean sd,C0242852;C2699239;C0456261;C1419141
partner n yes,C1549445;C1705108;C1710701
psa ng ml mean sd,C0439275;C2699239
pgi s n y,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
ed history n yes,C1549445;C1705108;C1710701
cgi s n z,C4526016
ed severity n,C0439793;C0522510
previous therapies n,C0205156;C0087111;C1552607
ed duration $nmbr$ yr n,C0449238;C0439234;C2926735
a blockers,
sexually active with female,C0241028;C0043210;C0086287;C1705497;C1705498
other bph luts therapy,C0039798;C0087111;C1363945
partner n yes,C1549445;C1705108;C1710701
oab therapy,C0039798;C0087111;C1363945
pgi s n y,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
ed therapy,C0039798;C0087111;C1363945
cgi s n z,C4526016
placebo mean change sd,C0032042;C2699239;C1696465;C1706408
previous therapies n,C0205156;C0087111;C1552607
tadalafil $nmbr$ mg mean change sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
a blockers,
ls mean treatment difference $nmbr$ ci,C0008107;C3259781
other bph luts therapy,C0039798;C0087111;C1363945
baseline luts severity,C0439793;C0522510
oab therapy,C0039798;C0087111;C1363945
moderate n $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
ed therapy,C0039798;C0087111;C1363945
severe n $nmbr$ $nmbr$,C0205082;C4050465;C4050466
placebo mean change sd,C0032042;C2699239;C1696465;C1706408
baseline ed severity,C0439793;C0522510
tadalafil $nmbr$ mg mean change sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mild n $nmbr$ $nmbr$ $nmbr$,C2945599
ls mean treatment difference $nmbr$ ci,C0008107;C3259781
characteristic^,C1521970
baseline luts severity,C0439793;C0522510
bud fm $nmbr$ $nmbr$ atg n ^ $nmbr$,C2700462;C2945744
moderate n $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
bud $nmbr$ ptg n $nmbr$,C0039512;C1418830
severe n $nmbr$ $nmbr$,C0205082;C4050465;C4050466
self reported descent n,C0681906;C2700446
baseline ed severity,C0439793;C0522510
mexican,C0240339
mild n $nmbr$ $nmbr$ $nmbr$,C2945599
puerto rican,C0034043
characteristic^,C1521970
cuban,C1553379
bud fm $nmbr$ $nmbr$ atg n ^ $nmbr$,C2700462;C2945744
south or central american,C1710133;C0238914
bud $nmbr$ ptg n $nmbr$,C0039512;C1418830
caribbean,C0043122;C0206155;C1331005
self reported descent n,C0681906;C2700446
mixed hispanic,C0205430;C0086409;C3160715
mexican,C0240339
total ics dose at entry xg d,C2986497;C0017209;C1292284;C1421532
puerto rican,C0034043
predose fev^ at screening,C0439565;C3714541;C3812758;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
cuban,C1553379
l,C0439394;C1706495;C3642217
south or central american,C1710133;C0238914
predicted,C0681842;C1882327
caribbean,C0043122;C0206155;C1331005
predose fev at randomization,C3714541;C0034656
mixed hispanic,C0205430;C0086409;C3160715
predose fvc l,C0439565;C3714541;C3812758
total ics dose at entry xg d,C2986497;C0017209;C1292284;C1421532
at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
predose fev^ at screening,C0439565;C3714541;C3812758;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
at randomization,C0034656
l,C0439394;C1706495;C3642217
predose fev fvc,C0439565;C3714541;C3812758
predicted,C0681842;C1882327
postdose fev fvc at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
predose fev at randomization,C3714541;C0034656
reversibility in fev^ at,C0449261;C3714541
predose fvc l,C0439565;C3714541;C3812758
screening l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
pef at baseline l_ min,C0030771;C1518922;C1542834
at randomization,C0034656
morning,C0332170
predose fev fvc,C0439565;C3714541;C3812758
evening,C0587117
postdose fev fvc at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
reversibility in fev^ at,C0449261;C3714541
figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min,C0687676;C0010992;C1704687;C3469826;C0205363;C0017446;C0205147;C0392747;C0443172;C0444504;C2347634;C2348143;C0030771;C1518922;C1542834;C1705241;C4319952;C0439230;C0016529;C1306036;C1511726;C3245479;C3714741;C0849355;C0030705;C1522609;C0441846
screening l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
nonobese,
pef at baseline l_ min,C0030771;C1518922;C1542834
obese $nmbr$ kg m^ $nmbr$,C0022718;C0439209;C4054209
morning,C0332170
a aml n $nmbr$,C0023465;C0023467
evening,C0587117
aml n $nmbr$,C0023465;C0023467
mets n,C0812270;C1705694;C2939420
figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min,C0687676;C0010992;C1704687;C3469826;C0205363;C0017446;C0205147;C0392747;C0443172;C0444504;C2347634;C2348143;C0030771;C1518922;C1542834;C1705241;C4319952;C0439230;C0016529;C1306036;C1511726;C3245479;C3714741;C0849355;C0030705;C1522609;C0441846
nonobese,
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi,C0301630;C4551656;C0332174;C0439230;C1319893;C0005893;C0578022;C1305855
obese $nmbr$ kg m^ $nmbr$,C0022718;C0439209;C4054209
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine,C0301630;C4551656;C0332174;C0439230;C1319893;C1319894;C0524620;C0812270;C1705694;C2939420;C0168634;C1710181;C1442488;C2937472;C0023465;C0023467
a aml n $nmbr$,C0023465;C0023467
aml n $nmbr$,C0023465;C0023467
figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine,C0439165;C1549488;C1561533;C0005823;C0018017;C0681850;C1550501;C1706203;C2349001;C2697811;C0524620;C0812270;C1705694;C2939420;C2937472;C0023465;C0023467
mets n,C0812270;C1705694;C2939420
oma oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi,C0301630;C4551656;C0332174;C0439230;C1319893;C0005893;C0578022;C1305855
age distribution years n,C1510829
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine,C0301630;C4551656;C0332174;C0439230;C1319893;C1319894;C0524620;C0812270;C1705694;C2939420;C0168634;C1710181;C1442488;C2937472;C0023465;C0023467
serum total ige iu ml,C1441420;C0439458
fev $nmbr$ predicted at baseline,C0681842;C1882327
figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine,C0439165;C1549488;C1561533;C0005823;C0018017;C0681850;C1550501;C1706203;C2349001;C2697811;C0524620;C0812270;C1705694;C2939420;C2937472;C0023465;C0023467
number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0449788;C0439234;C0439508
oma oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
number of er visits in last year prior to baseline,C3810541;C1549755;C3811131;C0439234;C0439508
oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
number of hospitalizations in last year prior to baseline,C4086639;C0439234;C0439508
age distribution years n,C1510829
night time awakenings in past $nmbr$ weeks prior to baseline,C0860510;C0439230;C0332152
serum total ige iu ml,C1441420;C0439458
ocs reduced stopped,C0392756;C1272691
fev $nmbr$ predicted at baseline,C0681842;C1882327
ocs maintained increased,C0205217;C0442805
number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0449788;C0439234;C0439508
oma oat,C0028753;C0331496;C0939905;C3539067;C3897364
number of er visits in last year prior to baseline,C3810541;C1549755;C3811131;C0439234;C0439508
oat,C0028753;C0331496;C0939905;C3539067;C3897364
number of hospitalizations in last year prior to baseline,C4086639;C0439234;C0439508
mean change from baseline in fev $nmbr$ predicted sd,C0392747;C0443172;C1705241;C4319952;C0681842;C2699239;C1882327
night time awakenings in past $nmbr$ weeks prior to baseline,C0860510;C0439230;C0332152
mean number of clinically significant asthma exacerbations,C0444504;C0237753;C0449788;C2347634;C2348143
ocs reduced stopped,C0392756;C1272691
mean number of combined visits hospitalizations,C4086639
ocs maintained increased,C0205217;C0442805
mean change from baseline in acq overall score sd,C0392747;C0443172;C1705241;C4319952;C0282416;C2699239;C1561607
oma oat,C0028753;C0331496;C0939905;C3539067;C3897364
mean change from baseline in the number of,C0392747;C0443172;C1705241;C4319952;C0237753;C0449788
oat,C0028753;C0331496;C0939905;C3539067;C3897364
night time awakenings in past $nmbr$ weeks sd,C0860510;C0439230;C2699239
mean change from baseline in fev $nmbr$ predicted sd,C0392747;C0443172;C1705241;C4319952;C0681842;C2699239;C1882327
metabolic syndrome,C0524620
mean number of clinically significant asthma exacerbations,C0444504;C0237753;C0449788;C2347634;C2348143
no metabolic syndrome,C0524620
mean number of combined visits hospitalizations,C4086639
canrenone n z $nmbr$,C0006882
mean change from baseline in acq overall score sd,C0392747;C0443172;C1705241;C4319952;C0282416;C2699239;C1561607
placebo n z $nmbr$,C0032042;C1696465;C1706408
mean change from baseline in the number of,C0392747;C0443172;C1705241;C4319952;C0237753;C0449788
men n [ ],C0025266
night time awakenings in past $nmbr$ weeks sd,C0860510;C0439230;C2699239
$nmbr$ [ $nmbr$ $nmbr$ ],
metabolic syndrome,C0524620
heart rate bpm $nmbr$,C0018810
no metabolic syndrome,C0524620
systolic bp mmhg,C0871470;C0439475
canrenone n z $nmbr$,C0006882
diastolic bp mmhg,C0428883;C0439475
placebo n z $nmbr$,C0032042;C1696465;C1706408
diabetes n [ ],C0011847;C0011849
men n [ ],C0025266
$nmbr$ [ $nmbr$ ],
$nmbr$ [ $nmbr$ $nmbr$ ],
placebo n $nmbr$ n,C0032042;C1696465;C1706408
heart rate bpm $nmbr$,C0018810
denosumab n $nmbr$ n,C1690432
systolic bp mmhg,C0871470;C0439475
western europe australia new zealand,C0027978;C0324547
diastolic bp mmhg,C0428883;C0439475
prevalent vertebral fracture,C0080179
diabetes n [ ],C0011847;C0011849
prior nonvertebral fracture at age $nmbr$ years,C0016658;C1510829
$nmbr$ [ $nmbr$ ],
prior use of osteoporosis medications,C1524063
placebo n $nmbr$ n,C0032042;C1696465;C1706408
female subjects n $nmbr$,C0043210;C0086287;C1705497;C1705498
denosumab n $nmbr$ n,C1690432
male subjects n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
western europe australia new zealand,C0027978;C0324547
african american black,C0005680;C0027567;C0085756;C0439541
prevalent vertebral fracture,C0080179
american indian native alaskan,C0682125
prior nonvertebral fracture at age $nmbr$ years,C0016658;C1510829
serum creatinine level,C0600061
prior use of osteoporosis medications,C1524063
estimated creatinine clearancet,C0750572;C0010294;C1561535
female subjects n $nmbr$,C0043210;C0086287;C1705497;C1705498
$nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
male subjects n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
baseline sua mean sd mg dl,C0168634;C0439269;C1442488
african american black,C0005680;C0027567;C0085756;C0439541
presence of tophi,C0150312;C0392148;C3854307
american indian native alaskan,C0682125
years since last gout flare,C0439234;C0018099
serum creatinine level,C0600061
years with gout mean sd,C0439234;C0018099
estimated creatinine clearancet,C0750572;C0010294;C1561535
obesity bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
baseline renal function eclcr,C0168634;C0232804;C1442488
baseline sua mean sd mg dl,C0168634;C0439269;C1442488
febuxostat $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
presence of tophi,C0150312;C0392148;C3854307
allopurinolt,
years since last gout flare,C0439234;C0018099
normal $nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
years with gout mean sd,C0439234;C0018099
mild impairment $nmbr$ to,C0221099;C0684336
obesity bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0221099;C0684336
baseline renal function eclcr,C0168634;C0232804;C1442488
vorapaxar n $nmbr$,C2974521
febuxostat $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
median q $nmbr$ q $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
allopurinolt,
region of enrollment,C0017446;C0205147
normal $nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
cardiovascular risk factors,C0850624
mild impairment $nmbr$ to,C0221099;C0684336
tobacco use,C0040335;C0543414;C0841002;C3853727
moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0221099;C0684336
renal function ml min,C0232804;C0439445
vorapaxar n $nmbr$,C2974521
$nmbr$ $nmbr$ crcl,C1846718
median q $nmbr$ q $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ crcl,C1846718
region of enrollment,C0017446;C0205147
cardiovascular disease history,C1880008
cardiovascular risk factors,C0850624
peripheral arterial disease,C0085096;C1704436
tobacco use,C0040335;C0543414;C0841002;C3853727
positive troponin or ck mb,C0439178;C0041199;C1446409;C1514241;C2825490;C3812269;C0010290
renal function ml min,C0232804;C0439445
ecg findings,C0438154
$nmbr$ $nmbr$ crcl,C1846718
symmetric t wave inversions,C0332516;C0520888;C2699744
$nmbr$ crcl,C1846718
iii iv,C0022326;C4265176
cardiovascular disease history,C1880008
stratification factors,C1514984
peripheral arterial disease,C0085096;C1704436
intent to use glycoprotein iib iiia inhibitor,C0162425;C1283828;C1550453
positive troponin or ck mb,C0439178;C0041199;C1446409;C1514241;C2825490;C3812269;C0010290
intent to use direct thrombin,C0162425;C1283828;C1550453
ecg findings,C0438154
antiplatelet at randomization,C0034656
symmetric t wave inversions,C0332516;C0520888;C2699744
thienopyridine,C1120149
iii iv,C0022326;C4265176
chads $nmbr$ score $nmbr$,C0449820;C4050231
stratification factors,C1514984
patients n,C0030705
intent to use glycoprotein iib iiia inhibitor,C0162425;C1283828;C1550453
mean age sd y,C0444504;C0001779;C2347634;C2348143
intent to use direct thrombin,C0162425;C1283828;C1550453
mean weight sd kg,C0022718;C0439209;C4054209
antiplatelet at randomization,C0034656
thienopyridine,C1120149
mean systolic blood pressure sd mm hg,C0428886;C0439475;C0488053
chads $nmbr$ score $nmbr$,C0449820;C4050231
mean diastolic blood pressure sd mm hg,C0428886;C0439475;C0488053
patients n,C0030705
men n,C0025266
mean age sd y,C0444504;C0001779;C2347634;C2348143
type of atrial fibrillation n,C0332307;C1547052
mean weight sd kg,C0022718;C0439209;C4054209
chads $nmbr$ components n,C0007928;C0449432;C1413373
mean systolic blood pressure sd mm hg,C0428886;C0439475;C0488053
stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
previous myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
mean diastolic blood pressure sd mm hg,C0428886;C0439475;C0488053
medications in use at baseline n,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
men n,C0025266
histamine $nmbr$ receptor antagonist,C0019590;C4521896
type of atrial fibrillation n,C0332307;C1547052
median time in therapeutic range for warfarin recipients,C1554109;C0043031;C1709854
chads $nmbr$ components n,C0007928;C0449432;C1413373
chads $nmbr$ score per outcome stroke or systemic embolism,C0449820;C4050231;C0013922;C1704212
stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
rate in all participants y,C0871208;C1521828
previous myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
dabigatran $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
medications in use at baseline n,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
absolute risk reduction $nmbr$ ci y,C3179139;C0008107;C3259781
histamine $nmbr$ receptor antagonist,C0019590;C4521896
total events n,C0439175;C0439810
median time in therapeutic range for warfarin recipients,C1554109;C0043031;C1709854
rate y,C0871208;C1521828
chads $nmbr$ score per outcome stroke or systemic embolism,C0449820;C4050231;C0013922;C1704212
dabigatran $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
rate in all participants y,C0871208;C1521828
vs warfarin,C0043031
dabigatran $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
major bleeding $nmbr$ to $nmbr$,C0205082;C0019080;C0205164;C4318856;C4521762
absolute risk reduction $nmbr$ ci y,C3179139;C0008107;C3259781
$nmbr$ $nmbr$ t,C2603360
total events n,C0439175;C0439810
vascular death,C0011065;C1306577;C4082313;C4552775
rate y,C0871208;C1521828
total death,C0011065;C1306577;C4082313;C4552775
dabigatran $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
placebo plus statin n $nmbr$,C0032042;C1696465;C1706408
vs warfarin,C0043031
extended release niacin plus statin n $nmbr$,C0027996;C1142562
major bleeding $nmbr$ to $nmbr$,C0205082;C0019080;C0205164;C4318856;C4521762
distribution no,C0520511;C1704711
$nmbr$ $nmbr$ t,C2603360
american indian alaskan native or aboriginal canadian,C0886378;C0935542;C0238884
vascular death,C0011065;C1306577;C4082313;C4552775
multiracial or other,C1881928
total death,C0011065;C1306577;C4082313;C4552775
hispanic or non hispanic ethnic group no f,C0086409;C0015031;C1879937;C0016327
placebo plus statin n $nmbr$,C0032042;C1696465;C1706408
presenting history or diagnosis no,C0449450;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0011900;C1704338;C1704656
extended release niacin plus statin n $nmbr$,C0027996;C1142562
history of myocardial infarction,C1275835
distribution no,C0520511;C1704711
stroke or cerebrovascular disease,C0038454;C4554100;C0007820
american indian alaskan native or aboriginal canadian,C0886378;C0935542;C0238884
laboratory values in patients with history of diabetes,C0022877;C0042295;C3244292;C4283904;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
multiracial or other,C1881928
insulin tu ml,C0439526;C1705224;C3887665
hispanic or non hispanic ethnic group no f,C0086409;C0015031;C1879937;C0016327
concomitant medications no,C0013227;C0802604;C2598133;C4284232
presenting history or diagnosis no,C0449450;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0011900;C1704338;C1704656
use at baseline,C0042153;C0457083;C1947944
history of myocardial infarction,C1275835
duration of prior statin therapy^,C0444917
stroke or cerebrovascular disease,C0038454;C4554100;C0007820
previous use of niacin or niaspan,C1524063;C0027996;C1142562;C1161310
laboratory values in patients with history of diabetes,C0022877;C0042295;C3244292;C4283904;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
aspirin or other antiplatelet or anticoagulant agent,C0004057;C0003280
insulin tu ml,C0439526;C1705224;C3887665
baseline hemoglobin aj^ values,C0004486;C0042295;C0230613
concomitant medications no,C0013227;C0802604;C2598133;C4284232
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
use at baseline,C0042153;C0457083;C1947944
hemoglobin aj^,C0004486;C0230613
duration of prior statin therapy^,C0444917
diabetes duration y,C0011847;C0011849
previous use of niacin or niaspan,C1524063;C0027996;C1142562;C1161310
baseline alc category,C0683312;C3889287
aspirin or other antiplatelet or anticoagulant agent,C0004057;C0003280
liraglutide $nmbr$ $nmbr$ mg oad,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline hemoglobin aj^ values,C0004486;C0042295;C0230613
sitagliptin oad,C1565750
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
giimepiride oad,
hemoglobin aj^,C0004486;C0230613
rosigiitazone oad,
diabetes duration y,C0011847;C0011849
exenatide oad,C0167117
baseline alc category,C0683312;C3889287
insuiin giargine oad,
liraglutide $nmbr$ $nmbr$ mg oad,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alc at weeko,C1424945;C3811058
sitagliptin oad,C1565750
l i $nmbr$ $nmbr$,C0021966;C0221138
giimepiride oad,
alc at week $nmbr$,C1424945;C3811058
rosigiitazone oad,
$nmbr$ $nmbr$ g l,C0439294;C0456615
exenatide oad,C0167117
alc $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1424945;C3811058
insuiin giargine oad,
$nmbr$ s,
alc at weeko,C1424945;C3811058
of patients,C0030705
l i $nmbr$ $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ fi $nmbr$,C4050619
alc at week $nmbr$,C1424945;C3811058
a $nmbr$ c s $nmbr$ s $nmbr$,
$nmbr$ $nmbr$ g l,C0439294;C0456615
$nmbr$ s $nmbr$,
alc $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1424945;C3811058
a $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,
$nmbr$ s,
a $nmbr$ c $nmbr$ $nmbr$,
of patients,C0030705
value,C1522609
$nmbr$ $nmbr$ fi $nmbr$,C4050619
$nmbr$ no,
a $nmbr$ c s $nmbr$ s $nmbr$,
white no,C0007457;C0043157;C0220938
$nmbr$ s $nmbr$,
black no,C0005680;C0027567;C0085756;C0439541
a $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,
other no,
a $nmbr$ c $nmbr$ $nmbr$,
taking antihypertensive treatment at,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
value,C1522609
baseline no,C0168634;C1442488
$nmbr$ no,
treated at baseline mean sd mm hg,C1522326;C0439475
white no,C0007457;C0043157;C0220938
untreated at baseline mean sd mm hg,C0332155;C0439475
black no,C0005680;C0027567;C0085756;C0439541
eligibility risk factorsa,C0013893;C0035647;C4552904;C1548635
other no,
cigarette smoker no,C0337667
taking antihypertensive treatment at,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ascvd b no,C3665365
baseline no,C0168634;C1442488
history of mi or stroke no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
treated at baseline mean sd mm hg,C1522326;C0439475
history of coronary revascularization no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
untreated at baseline mean sd mm hg,C0332155;C0439475
other ascvd no,C3665365
eligibility risk factorsa,C0013893;C0035647;C4552904;C1548635
st t wave no,C0036056;C0429103;C3272372
cigarette smoker no,C0337667
lvh by ecg or echocardiography no,C0232306;C0013516
ascvd b no,C3665365
lvh by minnesota code no,C0149721;C0009219;C0805701;C3889831
history of mi or stroke no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
diabetes no c,C0011847;C0011849
history of coronary revascularization no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of chd at baseline no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
other ascvd no,C3665365
lipid trial participants no,C1997894;C2242969
st t wave no,C0036056;C0429103;C3272372
non cardiovascular mortality,C0026565;C0026566
lvh by ecg or echocardiography no,C0232306;C0013516
fatal chd nonfatal ml,C0439526;C1705224;C3887665
lvh by minnesota code no,C0149721;C0009219;C0805701;C3889831
fatal nonfatal ccvd,C1302234;C1705232
diabetes no c,C0011847;C0011849
fatal nonfatal hospitalized heart failure,C0018801;C0018802;C4554158
history of chd at baseline no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
fatal nonfatal hospitalized stroke,C0038454;C4554100
lipid trial participants no,C1997894;C2242969
kidney disease usrds,C0022658
non cardiovascular mortality,C0026565;C0026566
age $nmbr$ $nmbr$ y,C0001779
fatal chd nonfatal ml,C0439526;C1705224;C3887665
nonblack,
fatal nonfatal ccvd,C1302234;C1705232
nondiabetic,
fatal nonfatal hospitalized heart failure,C0018801;C0018802;C4554158
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os,C0229090;C0230028;C0262950;C0393706;C1561953
fatal nonfatal hospitalized stroke,C0038454;C4554100
cangrelor,C1121991
kidney disease usrds,C0022658
comparator,C1707454;C4553389;C4553390
age $nmbr$ $nmbr$ y,C0001779
or [ $nmbr$ cl],C0596019
nonblack,
death udmi idr,C0011065;C1306577;C4082313;C4552775
nondiabetic,
death q mi idr,C0011065;C1306577;C4082313;C4552775
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os,C0229090;C0230028;C0262950;C0393706;C1561953
death q ml stent thrombosis,C0011065;C3897493;C1306577;C4082313;C4552775
cangrelor,C1121991
diabetic yes,C1549445;C1705108;C1710701
comparator,C1707454;C4553389;C4553390
diabetic no,C0241863
or [ $nmbr$ cl],C0596019
prior thienopyridine,C0332152;C1120149;C2826257
death udmi idr,C0011065;C1306577;C4082313;C4552775
gfr $nmbr$,C0017654;C1424601
death q mi idr,C0011065;C1306577;C4082313;C4552775
parameter,C0549193;C1704769;C2350001
death q ml stent thrombosis,C0011065;C3897493;C1306577;C4082313;C4552775
subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811;C0205363;C0168634;C1442488
diabetic yes,C1549445;C1705108;C1710701
low renin pra,C0633231;C1141951;C1419788;C3274822;C3669212;C4283900
diabetic no,C0241863
normal high renin pra $nmbr$ $nmbr$ ng ml h n $nmbr$,C1533072;C4050009
prior thienopyridine,C0332152;C1120149;C2826257
received antihypertensive within last $nmbr$ days n,C0003364;C0439228
gfr $nmbr$,C0017654;C1424601
diabetic n,C0241863
parameter,C0549193;C1704769;C2350001
mssbp sd mmhg,C2699239;C0439475
subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811;C0205363;C0168634;C1442488
msdbp sd mmhg,C2699239;C0439475
low renin pra,C0633231;C1141951;C1419788;C3274822;C3669212;C4283900
pra median min max ng ml h,C1533072;C4050009
normal high renin pra $nmbr$ $nmbr$ ng ml h n $nmbr$,C1533072;C4050009
african american n $nmbr$,C0085756
received antihypertensive within last $nmbr$ days n,C0003364;C0439228
caucasian n $nmbr$ $nmbr$,C0007457;C0043157
diabetic n,C0241863
alcohol use n,C0001948
mssbp sd mmhg,C2699239;C0439475
drinker $nmbr$ $nmbr$ drinks week,C0332174;C0439230
msdbp sd mmhg,C2699239;C0439475
non ex tobacco user,C1518422;C3853727
pra median min max ng ml h,C1533072;C4050009
tobacco user,C3853727
african american n $nmbr$,C0085756
tophi present n,C0221248;C0150312;C0449450
caucasian n $nmbr$ $nmbr$,C0007457;C0043157
renal function bn,C0005005;C0034700;C1706574;C4551963
alcohol use n,C0001948
any cardiovascular disease,C0007222
drinker $nmbr$ $nmbr$ drinks week,C0332174;C0439230
cardiac arrhythmia,C0003811;C0264886;C1560249
non ex tobacco user,C1518422;C3853727
use of low dose aspirin $nmbr$ mg daily,C1524063;C2608320
tobacco user,C3853727
tophi present n,C0221248;C0150312;C0449450
figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min,C1280519;C1707887;C0085756;C0681850;C1550501;C1706203;C2349001;C2697811;C2945599;C1565489;C0439445
renal function bn,C0005005;C0034700;C1706574;C4551963
semuloparin n $nmbr$,C2700104
any cardiovascular disease,C0007222
hazard ratio $nmbr$ ci j,C2985465;C0008107;C3259781
cardiac arrhythmia,C0003811;C0264886;C1560249
any vte or vte related death no,C0630906;C0011065;C1306577;C4082313;C4552775
use of low dose aspirin $nmbr$ mg daily,C1524063;C2608320
symptomatic deep vein thrombosis,C0231220;C0149871
upper limbs,C1140618
figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min,C1280519;C1707887;C0085756;C0681850;C1550501;C1706203;C2349001;C2697811;C2945599;C1565489;C0439445
lower limbs,C0023216
semuloparin n $nmbr$,C2700104
proximal,C0205107;C4489236
hazard ratio $nmbr$ ci j,C2985465;C0008107;C3259781
distal,C0205108;C4522154
any vte or vte related death no,C0630906;C0011065;C1306577;C4082313;C4552775
pulmonary embolism,C0034065
symptomatic deep vein thrombosis,C0231220;C0149871
nonfatal,
upper limbs,C1140618
symptomatic,C0231220
lower limbs,C0023216
detected during tumor evaluation,C0442726;C1511790
proximal,C0205107;C4489236
ne,C0027608;C0028219;C3538705
distal,C0205108;C4522154
any vte related death,C0011065;C1306577;C4082313;C4552775
pulmonary embolism,C0034065
outcome according to primary cancer site no total no,C1274040;C0872338;C0439175;C0439810
nonfatal,
lung,C0024109
symptomatic,C0231220
pancreas,C0030274
detected during tumor evaluation,C0442726;C1511790
stomach,C0038351;C3714551
ne,C0027608;C0028219;C3538705
colon or rectum,C0009368;C3888384;C0034896
any vte related death,C0011065;C1306577;C4082313;C4552775
bladder,C0005682;C4319531
outcome according to primary cancer site no total no,C1274040;C0872338;C0439175;C0439810
ovary,C0029939;C0227898
lung,C0024109
outcome according to stage of cancer no total no,C1274040;C0027646;C0439175;C0439810
pancreas,C0030274
metastatic,C0036525;C1522484;C4085632
stomach,C0038351;C3714551
locally advanced,C1517927;C0205179
colon or rectum,C0009368;C3888384;C0034896
outcome according to no of risk factors for vte,C1274040;C0035648;C1553898;C0630906
bladder,C0005682;C4319531
total phase $nmbr$ pooled n $nmbr$,C0439175;C0205390;C1710475;C0439810
ovary,C0029939;C0227898
low complement anti dsdna positive n $nmbr$,C0432633
outcome according to stage of cancer no total no,C1274040;C0027646;C0439175;C0439810
mean selena sledai score sd,C3533236;C2699239
metastatic,C0036525;C1522484;C4085632
selena sledai $nmbr$,C0451528
locally advanced,C1517927;C0205179
proteinuria $nmbr$ g $nmbr$ h,C0033687;C0560020;C1962972;C4554346
outcome according to no of risk factors for vte,C1274040;C0035648;C1553898;C0630906
anti dsdna $nmbr$ iu ml,C0741099;C0439458
total phase $nmbr$ pooled n $nmbr$,C0439175;C0205390;C1710475;C0439810
igg $nmbr$ $nmbr$ g l,C0439294;C0456615
low complement anti dsdna positive n $nmbr$,C0432633
low c $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
mean selena sledai score sd,C3533236;C2699239
corticosteroid use,C0239126
selena sledai $nmbr$,C0451528
$nmbr$ $nmbr$ mg day,C0439422
proteinuria $nmbr$ g $nmbr$ h,C0033687;C0560020;C1962972;C4554346
immunosuppressant use,C0042153;C0457083;C1947944
anti dsdna $nmbr$ iu ml,C0741099;C0439458
mean slicc damage index score sd,C3533236;C2699239
igg $nmbr$ $nmbr$ g l,C0439294;C0456615
mean pga score sd,C3533236;C2699239
low c $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis,C0024141;C0600653;C0918012;C1552854;C1637833;C2986546;C0683962
corticosteroid use,C0239126
$nmbr$ $nmbr$ mg day,C0439422
horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p,C0205126;C0205132;C0008107;C0458097;C3259781;C1882932;C1705241;C1705242;C0032042;C1696465;C1706408;C1552961;C2347617;C3714763;C0205250;C0871261;C0441994;C1548802;C2003888;C0750572;C1518681;C0205128;C1723401;C0439272;C1704675
immunosuppressant use,C0042153;C0457083;C1947944
troponin positive n $nmbr$,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
mean slicc damage index score sd,C3533236;C2699239
troponin negative n $nmbr$,C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
mean pga score sd,C3533236;C2699239
age median [iqr] y,C0549183;C0876920;C2347635;C2348144;C2939193
figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis,C0024141;C0600653;C0918012;C1552854;C1637833;C2986546;C0683962
weight median [iqr] kg,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
insulin treated diabetes,C0011847;C0011849
horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p,C0205126;C0205132;C0008107;C0458097;C3259781;C1882932;C1705241;C1705242;C0032042;C1696465;C1706408;C1552961;C2347617;C3714763;C0205250;C0871261;C0441994;C1548802;C2003888;C0750572;C1518681;C0205128;C1723401;C0439272;C1704675
high risk,C0332167;C3272283;C4050568;C4319571
troponin positive n $nmbr$,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
cardiac biomarker elevation,C0439775;C0702240
troponin negative n $nmbr$,C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
st segment deviation timi risk score,C0035647;C0449820;C4050231;C4552904
age median [iqr] y,C0549183;C0876920;C2347635;C2348144;C2939193
weight median [iqr] kg,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
white blood cell count cellsx $nmbr$,C0023508;C0427512
insulin treated diabetes,C0011847;C0011849
hemoglobin g dl,C0439267
high risk,C0332167;C3272283;C4050568;C4319571
golimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cardiac biomarker elevation,C0439775;C0702240
sex no male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0086582;C1706180;C1706428;C1706429
st segment deviation timi risk score,C0035647;C0449820;C4050231;C4552904
race no white,C0034510;C1706779;C3853635;C0007457;C0043157;C0220938
psa duration years,C0449238;C0439234;C2926735
white blood cell count cellsx $nmbr$,C0023508;C0427512
number of swollen joints $nmbr$ assessed,C0449813
hemoglobin g dl,C0439267
number of tender joints $nmbr$ assessed,C0449813
golimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
das $nmbr$ crp,C3890735;C4048285
sex no male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0086582;C1706180;C1706428;C1706429
psa modified shs of hands and feet,C0392747;C0018563;C1552914;C3889737;C0016504;C0347981
race no white,C0034510;C1706779;C3853635;C0007457;C0043157;C0220938
erosion score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
psa duration years,C0449238;C0439234;C2926735
jsn score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
number of swollen joints $nmbr$ assessed,C0449813
total score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
number of tender joints $nmbr$ assessed,C0449813
no of patients with $nmbr$ bsa affected,C0030705;C0392760;C1314939
das $nmbr$ crp,C3890735;C4048285
bsa affected,C0392760;C1314939
psa modified shs of hands and feet,C0392747;C0018563;C1552914;C3889737;C0016504;C0347981
pasi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
erosion score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
no of patients with fingernail involvement,C0030705;C0222001;C1314939
jsn score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
no fingernails,C0222001
total score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
target nail napsi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
no of patients with $nmbr$ bsa affected,C0030705;C0392760;C1314939
patients with dactylitis no,C0030705;C0239161
bsa affected,C0392760;C1314939
dactylitis score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
pasi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
patients with enthesitis no,C0030705;C1282952
no of patients with fingernail involvement,C0030705;C0222001;C1314939
psa modified mases score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
no fingernails,C0222001
haq score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
target nail napsi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
sf $nmbr$ health survey,C0037712;C0018762
patients with dactylitis no,C0030705;C0239161
pcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
dactylitis score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
mcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
patients with enthesitis no,C0030705;C1282952
patients taking mtx no,C0025677;C1417487
psa modified mases score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
mean median mtx dose mg week,C0332174;C0439230
haq score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
golimumab combined n $nmbr$,C2353893;C0205195
sf $nmbr$ health survey,C0037712;C0018762
change in psa modified shs baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
pcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
total score,C2964552
mcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
mtx at baseline,C0025677;C1417487
patients taking mtx no,C0025677;C1417487
p vs placebo,C0369773;C2603361;C0032042;C1696465;C1706408
mean median mtx dose mg week,C0332174;C0439230
no mtx at baseline,C0025677;C1417487
golimumab combined n $nmbr$,C2353893;C0205195
hands,C0018563;C1552914
change in psa modified shs baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
erosion score,C0449820;C4050231
total score,C2964552
jsn score,C0449820;C4050231
mtx at baseline,C0025677;C1417487
total hands score,C2964552;C0018563;C1552914
p vs placebo,C0369773;C2603361;C0032042;C1696465;C1706408
feet,C0016504;C0347981
no mtx at baseline,C0025677;C1417487
total feet score,C2964552;C0016504;C0347981
hands,C0018563;C1552914
additional radiographic findings at week $nmbr$,C2607943;C2926606;C3539655
erosion score,C0449820;C4050231
no new erosions among patients with $nmbr$ uninvolved joint at baseline,C0333307;C1959609;C0022417;C0392905;C1706309
jsn score,C0449820;C4050231
no new jsn among patients with $nmbr$ uninvolved joint at baseline,C0205314;C0030705;C0022417;C0392905;C1706309
total hands score,C2964552;C0018563;C1552914
feet,C0016504;C0347981
radiographic progression based on change from baseline sdc,C0242656;C0449258;C1527178;C1705938;C1419891;C3273112
total feet score,C2964552;C0016504;C0347981
total psa modified shs,C2986589;C0392747;C3889737
additional radiographic findings at week $nmbr$,C2607943;C2926606;C3539655
patients with change from baseline in total psa modified shs $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
diabetes bl,C0005918;C0006413;C1552663;C2827109
no new erosions among patients with $nmbr$ uninvolved joint at baseline,C0333307;C1959609;C0022417;C0392905;C1706309
idm,C0270221
no new jsn among patients with $nmbr$ uninvolved joint at baseline,C0205314;C0030705;C0022417;C0392905;C1706309
no diabetes,C0011847;C0011849
radiographic progression based on change from baseline sdc,C0242656;C0449258;C1527178;C1705938;C1419891;C3273112
no pts,C1419129;C2698747
total psa modified shs,C2986589;C0392747;C3889737
ascvd,C3665365
patients with change from baseline in total psa modified shs $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
lvh by ecgt blood pressure mm hg,C0149721;C0005823;C1271104;C1272641
diabetes bl,C0005918;C0006413;C1552663;C2827109
sbp,C0085805
idm,C0270221
dbp,C0536221;C3813197;C4281799
no diabetes,C0011847;C0011849
bmi kg m $nmbr$ cholesterol mg dl,C0022718;C0439209;C4054209;C0008377;C0439269
no pts,C1419129;C2698747
total no of events participants,C0439175;C0439810;C0441471;C0679646;C3541888
ascvd,C3665365
unadjusted $nmbr$ y risk per $nmbr$ population se adjusted rate,C0242444;C2987720
lvh by ecgt blood pressure mm hg,C0149721;C0005823;C1271104;C1272641
adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$,C0008107;C3259781;C1707455;C0011847;C0011849;C0005918;C0006413;C1552663;C2827109;C0439234;C0439508
sbp,C0085805
adjusted hr $nmbr$ ci comparing idm with bl,C0008107;C3259781;C1707455;C0270221;C0005918;C0006413;C1552663;C2827109
dbp,C0536221;C3813197;C4281799
cvd mortality,C0026565;C0026566
bmi kg m $nmbr$ cholesterol mg dl,C0022718;C0439209;C4054209;C0008377;C0439269
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p,C0369773;C2603361
total no of events participants,C0439175;C0439810;C0441471;C0679646;C3541888
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
unadjusted $nmbr$ y risk per $nmbr$ population se adjusted rate,C0242444;C2987720
non cvd mortality,C0026565;C0026566
adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$,C0008107;C3259781;C1707455;C0011847;C0011849;C0005918;C0006413;C1552663;C2827109;C0439234;C0439508
nonfatal mi fatal chdt,C1302234;C1705232
adjusted hr $nmbr$ ci comparing idm with bl,C0008107;C3259781;C1707455;C0270221;C0005918;C0006413;C1552663;C2827109
lisinopril cvd total,C0439175;C0439810
cvd mortality,C0026565;C0026566
no cases,C0868928;C1533148
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p,C0369773;C2603361
allopurinol $nmbr$ $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
participated in a previous febuxostat studyb n,C0205156;C0249529;C1552607
non cvd mortality,C0026565;C0026566
prior urate lowering therapies n,C1514463;C0441994;C2003888
nonfatal mi fatal chdt,C1302234;C1705232
yes any,C1549445;C1705108;C1710701
lisinopril cvd total,C0439175;C0439810
febuxostat,C0249529
no cases,C0868928;C1533148
allopurinol,C0002144
allopurinol $nmbr$ $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
probenecid,C0033209
participated in a previous febuxostat studyb n,C0205156;C0249529;C1552607
renal functionc n,C0022646
prior urate lowering therapies n,C1514463;C0441994;C2003888
any cardiovascular diseased,C0007226;C3887460
yes any,C1549445;C1705108;C1710701
use of low dose aspirin,C1524063;C2608320
febuxostat,C0249529
figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit,C0444504;C3272907;C2347634;C2348143;C0455272;C0086960;C0205539;C1571999
allopurinol,C0002144
p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation,C0369773;C2603361;C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0743559;C1608199;C1882932;C0871420
probenecid,C0033209
vorapaxar n $nmbr$ $nmbr$,C2974521
renal functionc n,C0022646
demographic,C0011298
any cardiovascular diseased,C0007226;C3887460
qualifying type of atherosclerosis no,C1514624;C0332307;C1547052
use of low dose aspirin,C1524063;C2608320
ischemic stroke,C0948008
figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit,C0444504;C3272907;C2347634;C2348143;C0455272;C0086960;C0205539;C1571999
selected clinical characteristics no total no,C1707391;C0683325;C0439175;C0439810
p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation,C0369773;C2603361;C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0743559;C1608199;C1882932;C0871420
any coronary artery disease,C0010054;C0010068;C1956346
vorapaxar n $nmbr$ $nmbr$,C2974521
any peripheral arterial disease,C0085096;C1704436
demographic,C0011298
previous cerebrovascular event,C0441471;C4019010
qualifying type of atherosclerosis no,C1514624;C0332307;C1547052
use of antiplatelet agents no total no,C1524063;C0085826;C0439175;C0439810
ischemic stroke,C0948008
qualifying myocardial infarction,C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
selected clinical characteristics no total no,C1707391;C0683325;C0439175;C0439810
qualifying peripheral arterial disease,C1514624;C0085096;C1704436
any coronary artery disease,C0010054;C0010068;C1956346
qualifying stroke,C1514624;C0038454;C4554100
any peripheral arterial disease,C0085096;C1704436
dipyridamole,C0012582
previous cerebrovascular event,C0441471;C4019010
use of other medications no,C1524063
use of antiplatelet agents no total no,C1524063;C0085826;C0439175;C0439810
angiotensin converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021;C0034787;C1622222
qualifying myocardial infarction,C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
subgroup overall,C1079230;C1515021;C0282416;C1561607
qualifying peripheral arterial disease,C1514624;C0085096;C1704436
total no $nmbr$,C0439175;C0439810
qualifying stroke,C1514624;C0038454;C4554100
vorapaxar placebo $nmbr$ yr,C0032042;C0439234;C1696465;C1706408
dipyridamole,C0012582
hazard ratio $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C2985465;C0596019
use of other medications no,C1524063
body weight,C0005910;C1305866
angiotensin converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021;C0034787;C1622222
qualifying atherosclerosis,C1514624;C0003850;C0004153
subgroup overall,C1079230;C1515021;C0282416;C1561607
history of stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
total no $nmbr$,C0439175;C0439810
aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
vorapaxar placebo $nmbr$ yr,C0032042;C0439234;C1696465;C1706408
thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
hazard ratio $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C2985465;C0596019
egfr mumin $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
body weight,C0005910;C1305866
europe i,C0021966;C0221138
qualifying atherosclerosis,C1514624;C0003850;C0004153
europe ii,C1710602;C4082587
history of stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
australia nz,C0004340;C0027978
aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
vorapaxar placebo,C0032042;C1696465;C1706408
thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
overall $nmbr$,C0282416;C1561607
egfr mumin $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
estimated glomerular filtration,C0750572;C0232809
europe i,C0021966;C0221138
sample size n by treatment,C0242618
europe ii,C1710602;C4082587
american indian alaskan native n,C0886378
australia nz,C0004340;C0027978
asian pacific islander n,C0078988;C0242191
vorapaxar placebo,C0032042;C1696465;C1706408
other n,C0369718;C0441922
overall $nmbr$,C0282416;C1561607
on antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
estimated glomerular filtration,C0750572;C0232809
blood pressure at baseline,C0005823;C1271104;C1272641
sample size n by treatment,C0242618
all participants mm hg sbp mean sd,C0439475;C2699239
american indian alaskan native n,C0886378
dbp mean sd,C0444504;C2699239;C2347634;C2348143
asian pacific islander n,C0078988;C0242191
treated at baseline mm hg sbp mean sd,C1522326;C0439475
other n,C0369718;C0441922
untreated at baseline mm hg sbp mean sd,C0332155;C0439475
on antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
current cigarette smoker n,C3173209;C3241966
blood pressure at baseline,C0005823;C1271104;C1272641
type $nmbr$ diabetes n,C1320657
all participants mm hg sbp mean sd,C0439475;C2699239
hdl c $nmbr$ mg dl n,C3715113;C0439269
dbp mean sd,C0444504;C2699239;C2347634;C2348143
lvh by electrocardiogram n,C0149721;C0013798;C1547122;C1623258
treated at baseline mm hg sbp mean sd,C1522326;C0439475
fasting glucose mean sd mg dl,C0015663;C0439269
untreated at baseline mm hg sbp mean sd,C0332155;C0439475
total cholesterol mean sd mg dl,C0201950;C0439269;C0543421
current cigarette smoker n,C3173209;C3241966
fasting triglycerides mean sd mg dl,C0015663;C0041004;C0439269
type $nmbr$ diabetes n,C1320657
nos $nmbr$ $nmbr$ c t n,C0326287;C1518425
hdl c $nmbr$ mg dl n,C3715113;C0439269
cc,C0008318;C3538933
lvh by electrocardiogram n,C0149721;C0013798;C1547122;C1623258
ct,C0007673;C3540513;C3813556;C3888140
fasting glucose mean sd mg dl,C0015663;C0439269
tt,C1452561;C4554543
total cholesterol mean sd mg dl,C0201950;C0439269;C0543421
nos $nmbr$ $nmbr$ a g n,C0326287;C1518425;C0439267
fasting triglycerides mean sd mg dl,C0015663;C0041004;C0439269
aa,C0282379;C1235746;C1882141;C4554792
nos $nmbr$ $nmbr$ c t n,C0326287;C1518425
ag,C0002037;C0051080;C0152305;C3888235
cc,C0008318;C3538933
gg,C0017454;C0018370
ct,C0007673;C3540513;C3813556;C3888140
nos $nmbr$ glu $nmbr$ asp g t n,C0326287;C0125690;C1518425
tt,C1452561;C4554543
gt,C1435727;C1704693;C2697657
nos $nmbr$ $nmbr$ a g n,C0326287;C1518425;C0439267
number of events event per $nmbr$ person years,C4330837;C0027361;C0439234;C2347489
aa,C0282379;C1235746;C1882141;C4554792
rates,C0871208;C1521828
ag,C0002037;C0051080;C0152305;C3888235
genotype specific treatment effect hazard ratio $nmbr$ ci,C0008107;C3259781
gg,C0017454;C0018370
genotype by treatment interaction p values,C0017431;C1709380
nos $nmbr$ glu $nmbr$ asp g t n,C0326287;C0125690;C1518425
outcome variant,C1274040;C0205419
gt,C1435727;C1704693;C2697657
genotype,C0017431
number of events event per $nmbr$ person years,C4330837;C0027361;C0439234;C2347489
aml,C0023465;C0023467
rates,C0871208;C1521828
lis,C2247545
genotype specific treatment effect hazard ratio $nmbr$ ci,C0008107;C3259781
chl,C0019829
genotype by treatment interaction p values,C0017431;C1709380
aml vs lis,C0023465;C0023467;C2247545
outcome variant,C1274040;C0205419
aml vs chl,C0023465;C0023467;C0019829
genotype,C0017431
chd primary outcome,C0205225;C1274040;C0439612;C0439631
aml,C0023465;C0023467
$nmbr$ c t,
lis,C2247545
ct tt,C1452561;C4554543
chl,C0019829
$nmbr$ a g,C0439267
aml vs lis,C0023465;C0023467;C2247545
ag gg,C0017454;C0018370
aml vs chl,C0023465;C0023467;C0019829
glu $nmbr$ asp g t,C0125690;C0439267
chd primary outcome,C0205225;C1274040;C0439612;C0439631
gt tt,C1452561;C4554543
$nmbr$ c t,
end stage renal disease,C0022661;C2316810
ct tt,C1452561;C4554543
normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972;C1739039;C3811844;C3812682
$nmbr$ a g,C0439267
mild reduction in egfr,C0301630;C0392756;C1293152;C4551656
ag gg,C0017454;C0018370
moderate severe reduction in egfr,C0301630;C0392756;C1293152;C4551656
glu $nmbr$ asp g t,C0125690;C0439267
$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
gt tt,C1452561;C4554543
$nmbr$ $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
end stage renal disease,C0022661;C2316810
sample size,C0242618
normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972;C1739039;C3811844;C3812682
sbp mmghg mean sd,C0085805;C2699239
mild reduction in egfr,C0301630;C0392756;C1293152;C4551656
dbp mmghg mean sd,C0444504;C2699239;C2347634;C2348143
moderate severe reduction in egfr,C0301630;C0392756;C1293152;C4551656
egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
follow up in trial at $nmbr$ yr,C0589120;C1522577;C1704685;C3274571;C0150312;C0008976;C0332285;C1707101
$nmbr$ $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
sample sizea,C0370003;C2347026
sample size,C0242618
taking statins n a,C0360714
sbp mmghg mean sd,C0085805;C2699239
mean sd d,C0444504;C2699239;C2347634;C2348143
dbp mmghg mean sd,C0444504;C2699239;C2347634;C2348143
egfr,C1739039;C3811844;C3812682
egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
total number of events participants,C4330837
follow up in trial at $nmbr$ yr,C0589120;C1522577;C1704685;C3274571;C0150312;C0008976;C0332285;C1707101
$nmbr$ yr rate $nmbr$ participants,C0439234;C0679646
sample sizea,C0370003;C2347026
a compared wi,C0043193;C1520135
taking statins n a,C0360714
th c,C0039725;C0039738;C1420718;C4282123;C4285344
mean sd d,C0444504;C2699239;C2347634;C2348143
l compared wit,C0439394;C0043197;C1706495;C3642217
egfr,C1739039;C3811844;C3812682
hc,C0020268;C0262499;C1413512
total number of events participants,C4330837
chd total,C0439175;C0439810
$nmbr$ yr rate $nmbr$ participants,C0439234;C0679646
cvd total,C0439175;C0439810
a compared wi,C0043193;C1520135
stroke total,C0439175;C0439810
th c,C0039725;C0039738;C1420718;C4282123;C4285344
hf total,C0439175;C0439810
l compared wit,C0439394;C0043197;C1706495;C3642217
a compared w,C1707455
hc,C0020268;C0262499;C1413512
l compared wi,C0043193;C1520135
chd total,C0439175;C0439810
option,C1518601;C1550456
cvd total,C0439175;C0439810
ambition,C0870128
stroke total,C0439175;C0439810
radiate,C0332301
hf total,C0439175;C0439810
toward,
a compared w,C1707455
lithe,
l compared wi,C0043193;C1520135
all trials,C0008976
option,C1518601;C1550456
patient population,C0032659;C1257890
ambition,C0870128
mtx ir,C0022065;C0022071;C1448132
radiate,C0332301
mtx naive or free,C0025677;C1417487;C0332296;C1880497;C1996904
toward,
anti tnf ir,C0022065;C0022071;C1448132
lithe,
dmard ir,C0022065;C0022071;C1448132
all trials,C0008976
dmard ir anti tnf ir,C0022065;C0022071;C1448132
patient population,C0032659;C1257890
$nmbr$ tcz mtx,C0025677;C1417487
mtx ir,C0022065;C0022071;C1448132
$nmbr$ tcz,
mtx naive or free,C0025677;C1417487;C0332296;C1880497;C1996904
mtx,C0025677;C1417487
anti tnf ir,C0022065;C0022071;C1448132
$nmbr$ tcz mtx mtx,C0025677;C1417487
dmard ir,C0022065;C0022071;C1448132
total n,C0439175;C0439810
dmard ir anti tnf ir,C0022065;C0022071;C1448132
tcz mtx n,C0025677;C1417487
$nmbr$ tcz mtx,C0025677;C1417487
$nmbr$ mono,C1551432;C1551969
$nmbr$ tcz,
mtx n,C0025677;C1417487
mtx,C0025677;C1417487
white tcz mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
$nmbr$ tcz mtx mtx,C0025677;C1417487
white mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
total n,C0439175;C0439810
age mean s e,C0444504;C2347634;C2348143
tcz mtx n,C0025677;C1417487
sex female,C0086287
$nmbr$ mono,C1551432;C1551969
height cm mean s e,C0444504;C2347634;C2348143
mtx n,C0025677;C1417487
weight kg mean s e,C0444504;C2347634;C2348143
white tcz mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
ra duration years mean s e,C0444504;C2347634;C2348143
white mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
rf positive,C0439178;C1446409;C1514241;C2825490;C3812269
age mean s e,C0444504;C2347634;C2348143
baseline das $nmbr$ mean s e,C0444504;C2347634;C2348143
sex female,C0086287
baseline haq mean s e,C0444504;C2347634;C2348143
height cm mean s e,C0444504;C2347634;C2348143
baseline sjc mean s e,C0444504;C2347634;C2348143
weight kg mean s e,C0444504;C2347634;C2348143
baseline tjc mean s e,C0444504;C2347634;C2348143
ra duration years mean s e,C0444504;C2347634;C2348143
shared epitope a positive,C0237876;C0003316;C1522138;C0439178;C1446409;C1514241;C2825490;C3812269
rf positive,C0439178;C1446409;C1514241;C2825490;C3812269
high dose arb n $nmbr$,C0444956;C3888198
baseline das $nmbr$ mean s e,C0444504;C2347634;C2348143
arb ccb n $nmbr$,C3888198;C0006684
baseline haq mean s e,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ y n,
baseline sjc mean s e,C0444504;C2347634;C2348143
body height cm,C0005890;C0487985
baseline tjc mean s e,C0444504;C2347634;C2348143
bmi $nmbr$ n,C0578022
shared epitope a positive,C0237876;C0003316;C1522138;C0439178;C1446409;C1514241;C2825490;C3812269
egfr $nmbr$ n,C1739039;C3811844;C3812682
high dose arb n $nmbr$,C0444956;C3888198
serum values,C0229671;C0042295;C1546774;C1550100
arb ccb n $nmbr$,C3888198;C0006684
potassium mmol l,C0032821;C1532563;C0202194;C0304475;C0597277;C3714637
$nmbr$ $nmbr$ y n,
hdl cholesterol mg dl,C0023822;C0439269;C0392885
body height cm,C0005890;C0487985
casual plasma glucose mg dl,C0202042;C0439269;C0455280
bmi $nmbr$ n,C0578022
current alcohol n,C0001962;C0001975
egfr $nmbr$ n,C1739039;C3811844;C3812682
drug therapy n,C0013216;C0013217
serum values,C0229671;C0042295;C1546774;C1550100
previous antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
potassium mmol l,C0032821;C1532563;C0202194;C0304475;C0597277;C3714637
insulin treatment,C0745343
hdl cholesterol mg dl,C0023822;C0439269;C0392885
antiplatelet agents,C0085826
casual plasma glucose mg dl,C0202042;C0439269;C0455280
arb angiotensin ii receptor blocker ccb,C0521942;C0006684;C3536793
current alcohol n,C0001962;C0001975
calcium channel blocker bmi body,C0242821;C0460148;C1268086;C4082212
drug therapy n,C0013216;C0013217
mass index,C0600653;C0918012;C1552854;C1637833;C2986546
previous antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
insulin treatment,C0745343
bp blood pressure egfr estimated glomerular filtration rate men $nmbr$ en $nmbr$ x cr $nmbr$ $nmbr$ x age $nmbr$ $nmbr$ x $nmbr$ $nmbr$ hdl high density lipoprotein,C1363845
antiplatelet agents,C0085826
x cr $nmbr$ $nmbr$ x age,C0201975;C0001779;C3539604;C3711669;C4084730;C4553336;C4553337
arb angiotensin ii receptor blocker ccb,C0521942;C0006684;C3536793
$nmbr$ wom,
calcium channel blocker bmi body,C0242821;C0460148;C1268086;C4082212
data are mean standard deviation for continuous variables and number for categoric variables p,C1511726;C3245479;C3714741;C0871420;C0237753;C0449788
mass index,C0600653;C0918012;C1552854;C1637833;C2986546
values were calculated using t tests for continuous variables and chi square,C0042295;C0444686;C1441506;C1524063;C0871472;C0439828;C1552646
tests for categoric,C0022885;C0392366
bp blood pressure egfr estimated glomerular filtration rate men $nmbr$ en $nmbr$ x cr $nmbr$ $nmbr$ x age $nmbr$ $nmbr$ x $nmbr$ $nmbr$ hdl high density lipoprotein,C1363845
variables,C0439828
x cr $nmbr$ $nmbr$ x age,C0201975;C0001779;C3539604;C3711669;C4084730;C4553336;C4553337
supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period,C2986480;C0237629;C0205263;C0439531;C1948053;C0857127
$nmbr$ wom,
non hispanic latino,C1518424;C0086528
data are mean standard deviation for continuous variables and number for categoric variables p,C1511726;C3245479;C3714741;C0871420;C0237753;C0449788
baseline data,C1511726;C3245479;C3714741
values were calculated using t tests for continuous variables and chi square,C0042295;C0444686;C1441506;C1524063;C0871472;C0439828;C1552646
a $nmbr$ c,
tests for categoric,C0022885;C0392366
gender m f,C0079399;C1522384;C0016327
variables,C0439828
at c data,C1511726;C3245479;C3714741
supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period,C2986480;C0237629;C0205263;C0439531;C1948053;C0857127
final a $nmbr$ c,C0205088;C1546485;C3853528
non hispanic latino,C1518424;C0086528
at c change,C0392747;C0443172;C1705241;C4319952
baseline data,C1511726;C3245479;C3714741
$nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
a $nmbr$ c,
fpg data,C1511726;C3245479;C3714741
gender m f,C0079399;C1522384;C0016327
final mg dl,C0205088;C0439269;C1546485;C3853528
at c data,C1511726;C3245479;C3714741
fpg change mg dl,C0392747;C0439269;C0443172;C1705241;C4319952
final a $nmbr$ c,C0205088;C1546485;C3853528
withdrawals n n,C1710677;C2349954;C2825032;C3812880;C4049634
at c change,C0392747;C0443172;C1705241;C4319952
voluntary,C0439656;C3543419
$nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
noncompliant,C0457432
fpg data,C1511726;C3245479;C3714741
all noncompleters,
final mg dl,C0205088;C0439269;C1546485;C3853528
no men,C0025266
fpg change mg dl,C0392747;C0439269;C0443172;C1705241;C4319952
no women,C0043210
withdrawals n n,C1710677;C2349954;C2825032;C3812880;C4049634
known duration,C0449238;C2926735
voluntary,C0439656;C3543419
of t $nmbr$ dm years,C0011816;C0439234;C3250443
noncompliant,C0457432
hba $nmbr$ c range,C1514721;C2348147;C3542016
all noncompleters,
hba $nmbr$ c distribution at baseline,C0520511;C1704711
no men,C0025266
fpg mmol l,C1532563
no women,C0043210
$nmbr$ h pmg mmol l,C2827804
known duration,C0449238;C2926735
metformin dose,C0178602;C0869039;C1114758
of t $nmbr$ dm years,C0011816;C0439234;C3250443
hba $nmbr$ c range,C1514721;C2348147;C3542016
figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index,C1705241;C1705242;C0168634;C1442488;C3875154;C0023668;C0205132;C0700221;C1550648;C1552960;C0369718;C0042295;C0441922;C2360800;C0032042;C1305855;C1696465;C1706408
hba $nmbr$ c distribution at baseline,C0520511;C1704711
dabigatran $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fpg mmol l,C1532563
prior oac,C0332152;C2826257
$nmbr$ h pmg mmol l,C2827804
crcl sd ml min,C1846718;C0439445
metformin dose,C0178602;C0869039;C1114758
prior history of bleeding on oac,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
type of surgery,C0332307;C1547052
figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index,C1705241;C1705242;C0168634;C1442488;C3875154;C0023668;C0205132;C0700221;C1550648;C1552960;C0369718;C0042295;C0441922;C2360800;C0032042;C1305855;C1696465;C1706408
pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703;C0021122
dabigatran $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
dental procedure,C0011331
prior oac,C0332152;C2826257
other diagnostic procedure,C0430022;C1546908
crcl sd ml min,C1846718;C0439445
cataract removal,C0007389
prior history of bleeding on oac,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
colonoscopy,C0009378;C1548837
type of surgery,C0332307;C1547052
total hip or knee replacement,C0019552;C0022122;C1505163;C3538851;C4284725;C0086511
pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703;C0021122
cystoscopic procedure,C0184661;C2700391;C3274430;C3539779
dental procedure,C0011331
inguinal hernia repair,C0021446
other diagnostic procedure,C0430022;C1546908
laparoscopic cholecystectomy,C0162522
cataract removal,C0007389
cabg or valve,C0010055;C0184252;C1186983;C1704414;C3888056
colonoscopy,C0009378;C1548837
colectomy partial or total,C0728938;C1550516;C0439175;C0439810
total hip or knee replacement,C0019552;C0022122;C1505163;C3538851;C4284725;C0086511
peripheral angioplasty,C0162577;C1548817
cystoscopic procedure,C0184661;C2700391;C3274430;C3539779
prostate biopsy,C0194804
inguinal hernia repair,C0021446
carotid endarterectomy,C0014099
laparoscopic cholecystectomy,C0162522
limb amputation,C0002689
cabg or valve,C0010055;C0184252;C1186983;C1704414;C3888056
d $nmbr$ n n,C0369718;C0441922
colectomy partial or total,C0728938;C1550516;C0439175;C0439810
warfarin n n,C0043031
peripheral angioplasty,C0162577;C1548817
d $nmbr$ vs warfarin rr $nmbr$ ci p value,C0008107;C1709380;C3259781
prostate biopsy,C0194804
urgent surgery,C2188405
carotid endarterectomy,C0014099
elective surgery,C0206058
limb amputation,C0002689
major surgery,C0679637
d $nmbr$ n n,C0369718;C0441922
minor surgery,C0038904
warfarin n n,C0043031
original dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
d $nmbr$ vs warfarin rr $nmbr$ ci p value,C0008107;C1709380;C3259781
amended dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
urgent surgery,C2188405
figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test,C0205210;C0544452;C0687702;C0332174;C0872146;C0439230;C0042295;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
elective surgery,C0206058
general anaesthesia,C0002915;C2930406
major surgery,C0679637
neuraxial anaesthesia,C0002903;C0002912;C0002930;C4049933
minor surgery,C0038904
combination,C0205195;C1947911;C3811910
original dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
number of patients,C2360800
amended dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
mean age years sd,C1510829;C2699239
figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test,C0205210;C0544452;C0687702;C0332174;C0872146;C0439230;C0042295;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
mean bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
general anaesthesia,C0002915;C2930406
minimum,C1524031;C1552614;C2826545
neuraxial anaesthesia,C0002903;C0002912;C0002930;C4049933
maximum,C0806909;C1552615;C2826546
combination,C0205195;C1947911;C3811910
smoker or ex smoker n,C0337664;C0337671;C4555205
number of patients,C2360800
$nmbr$ years n,C0439234
mean age years sd,C1510829;C2699239
$nmbr$ years or,C0439234
mean bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events,C1707455;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1571583;C0205449;C1274040;C0680240;C1305863;C1861172;C0630906;C0026565;C0019080;C0026566
minimum,C1524031;C1552614;C2826545
maximum,C0806909;C1552615;C2826546
data are presented as the odds ratio with $nmbr$ confidence intervals,C1511726;C3245479;C3714741;C0449450;C0028873;C0009667
smoker or ex smoker n,C0337664;C0337671;C4555205
t $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C2603360;C0439275
$nmbr$ years n,C0439234
no patients,C0030705
$nmbr$ years or,C0439234
hr b p m,
sbp dbp mmhg,C0085805;C0439475
figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events,C1707455;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1571583;C0205449;C1274040;C0680240;C1305863;C1861172;C0630906;C0026565;C0019080;C0026566
ischaemic aetiology,C0015127;C1314792;C1524003
data are presented as the odds ratio with $nmbr$ confidence intervals,C1511726;C3245479;C3714741;C0449450;C0028873;C0009667
nyha classes iii iv,C0278962
t $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C2603360;C0439275
laboratory values,C0022877;C0042295;C3244292;C4283904
no patients,C0030705
ldl cholesterol mg dl,C0023824;C0439269;C0202117
hr b p m,
co morbidities,C0009488
sbp dbp mmhg,C0085805;C0439475
atrial fibrillation flutter,C0155709
ischaemic aetiology,C0015127;C1314792;C1524003
pharmacological therapy for hf,C0039798;C0087111;C1363945
nyha classes iii iv,C0278962
aceis,
laboratory values,C0022877;C0042295;C3244292;C4283904
aldosterone receptor antagonists,C1579268
ldl cholesterol mg dl,C0023824;C0439269;C0202117
biomarkers at baseline,C0005516;C0168634;C1442488
co morbidities,C0009488
ptx $nmbr$ ng ml,C0030899;C0439275
atrial fibrillation flutter,C0155709
hscrp mg l,C0439268
pharmacological therapy for hf,C0039798;C0087111;C1363945
nt probnp pg ml,C0669479;C0439297;C0754710
aceis,
all cause mortality per $nmbr$ person years,C0015127;C0026565;C0026566;C1524003
aldosterone receptor antagonists,C1579268
cardiovascular mortality per $nmbr$ person years,C0026565;C0026566
biomarkers at baseline,C0005516;C0168634;C1442488
ptx $nmbr$ ng ml,C0030899;C0439275
figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr,C0683150;C0683325;C1547282;C0086045;C1446561;C3827302;C1527178;C1705938;C0750572;C1739039;C3811844;C3812682
hscrp mg l,C0439268
groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C1707455;C1708930;C2360800;C0683312;C3889287;C1444656;C1707156;C3274014;C3541345
nt probnp pg ml,C0669479;C0439297;C0754710
figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0376674;C0017725;C0021641;C1533581;C1579433;C3714501;C0870536;C1275991;C2827788;C0168634;C1442488;C0444930;C0557651;C2603343;C2746065;C0030705;C0439375;C0597277;C1708601;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
all cause mortality per $nmbr$ person years,C0015127;C0026565;C0026566;C1524003
cardiovascular mortality per $nmbr$ person years,C0026565;C0026566
figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0392747;C0443172;C1705241;C4319952;C0444930;C2746065;C0202042;C0455280;C0428357;C0376690;C1261415;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
tofacitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr,C0683150;C0683325;C1547282;C0086045;C1446561;C3827302;C1527178;C1705938;C0750572;C1739039;C3811844;C3812682
white race no f,C0007457;C0043157;C0016327
groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C1707455;C1708930;C2360800;C0683312;C3889287;C1444656;C1707156;C3274014;C3541345
duration of rheumatoid arthritis yr,C0449238;C2926735
figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0376674;C0017725;C0021641;C1533581;C1579433;C3714501;C0870536;C1275991;C2827788;C0168634;C1442488;C0444930;C0557651;C2603343;C2746065;C0030705;C0439375;C0597277;C1708601;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
tender and swollen joints mean no,C0234234;C0444504;C2347634;C2348143
tender,C0234234
figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0392747;C0443172;C1705241;C4319952;C0444930;C2746065;C0202042;C0455280;C0428357;C0376690;C1261415;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
swollen,C0038999
tofacitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean score on haq di,C3533236;C3826998;C4321476
white race no f,C0007457;C0043157;C0016327
das $nmbr$ $nmbr$ esr $nmbr$,C0051767;C3811131;C0057671
duration of rheumatoid arthritis yr,C0449238;C2926735
score of $nmbr$ $nmbr$,C0449820;C4050231
tender and swollen joints mean no,C0234234;C0444504;C2347634;C2348143
mean score on das $nmbr$ $nmbr$ crp ^,C3533236;C0051767;C0057671
tender,C0234234
erythrocyte sedimentation rate mm hr,C1176468;C1619634
swollen,C0038999
c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
mean score on haq di,C3533236;C3826998;C4321476
das $nmbr$ $nmbr$ esr $nmbr$,C0051767;C3811131;C0057671
positive for rheumatoid factor anti cyclic citrullinated peptide antibodies or both ff,C0741132;C1829901;C4554348
score of $nmbr$ $nmbr$,C0449820;C4050231
prior treatment,C1514463
mean score on das $nmbr$ $nmbr$ crp ^,C3533236;C0051767;C0057671
tnf inhibitor,C1448177;C1999216
erythrocyte sedimentation rate mm hr,C1176468;C1619634
other biologic agent,C0005515
methotrexate,C0025677
c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
nonbiologic disease modifying drug other than methotrexate,C0392747;C4036059
positive for rheumatoid factor anti cyclic citrullinated peptide antibodies or both ff,C0741132;C1829901;C4554348
prior disease modifying drugs resulting in inadequate response mean no patient,C0012634;C0013227;C3687832;C0332294;C0205412;C0439856;C0030705
prior treatment,C1514463
tofacitinib,C2930696
tnf inhibitor,C1448177;C1999216
gender female,C0043210;C0086287;C1705497;C1705498
other biologic agent,C0005515
rheumatoid factor positive,C0439178;C1446409;C1514241;C2825490;C3812269
methotrexate,C0025677
anti ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269
nonbiologic disease modifying drug other than methotrexate,C0392747;C4036059
dmard biologic ir,C0022065;C0022071;C1448132
prior disease modifying drugs resulting in inadequate response mean no patient,C0012634;C0013227;C3687832;C0332294;C0205412;C0439856;C0030705
region united states,C0017446;C0041703;C0205147
tofacitinib,C2930696
europe $nmbr$,C0015176
gender female,C0043210;C0086287;C1705497;C1705498
colesevelam n $nmbr$,C0541155
rheumatoid factor positive,C0439178;C1446409;C1514241;C2825490;C3812269
country n,C0454664;C1511538
anti ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269
mexico,C0025885
dmard biologic ir,C0022065;C0022071;C1448132
colombia,C3245499
region united states,C0017446;C0041703;C0205147
hba $nmbr$ ca mean sd,C0019016;C1825777;C3538758;C0444504;C2699239;C2347634;C2348143
europe $nmbr$,C0015176
fpg mg dl mean sd,C0439269;C2699239
colesevelam n $nmbr$,C0541155
$nmbr$ hour postload glucose,C0439227;C0017725;C0564385
country n,C0454664;C1511538
mg dl mean sd,C0439269;C2699239
mexico,C0025885
fasting insulin iiiu ml mean sd,C0015663;C0021641;C2699239;C1533581;C1579433;C3714501
colombia,C3245499
ldl c mg dl mean sd,C0439269;C2699239
hba $nmbr$ ca mean sd,C0019016;C1825777;C3538758;C0444504;C2699239;C2347634;C2348143
aspirin plus placebo n $nmbr$,C0004057;C0032042;C1696465;C1706408
fpg mg dl mean sd,C0439269;C2699239
aspirin plus clopidogrel n $nmbr$,C0004057;C0070166
$nmbr$ hour postload glucose,C0439227;C0017725;C0564385
mean age yr,C0001779;C0439234
mg dl mean sd,C0439269;C2699239
male sex race or ethnic group f,C0034510;C1706779;C3853635;C0441840
fasting insulin iiiu ml mean sd,C0015663;C0021641;C2699239;C1533581;C1579433;C3714501
black region or country,C0017446;C0205147;C0454664;C1511538
ldl c mg dl mean sd,C0439269;C2699239
spain,C0037747
aspirin plus placebo n $nmbr$,C0004057;C0032042;C1696465;C1706408
aspirin plus clopidogrel n $nmbr$,C0004057;C0070166
mean blood pressure at screening visit mm hg,C0428886;C0488053
mean age yr,C0001779;C0439234
previous clinical stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
male sex race or ethnic group f,C0034510;C1706779;C3853635;C0441840
current tobacco smoker qualifying event,C3173209;C3241966;C1514624;C0441471;C4019010
black region or country,C0017446;C0205147;C0454664;C1511538
transient ischemic attack type of lacunar syndrome,C0455703
spain,C0037747
pure motor hemiparesis,C1513492;C0018989;C1705994
pure sensory stroke,C0445254;C0038454;C4554100
mean blood pressure at screening visit mm hg,C0428886;C0488053
sensorimotor stroke,C0038454;C4554100
previous clinical stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
use of aspirin at time of qualifying event,C1524063;C0004057;C0040223;C3541383;C1514624;C0441471;C4019010
current tobacco smoker qualifying event,C3173209;C3241966;C1514624;C0441471;C4019010
use of statin at any follow up visit,C1524063;C0360714;C0589121
transient ischemic attack type of lacunar syndrome,C0455703
vorapaxar group n $nmbr$,C2974521;C0441848
pure motor hemiparesis,C1513492;C0018989;C1705994
median age iqr years,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
pure sensory stroke,C0445254;C0038454;C4554100
white ethnic origin,C0007457;C0015031;C0043157;C0220938
sensorimotor stroke,C0038454;C4554100
time from qualifying myocardial infarction,C0040223;C3541383;C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
use of aspirin at time of qualifying event,C1524063;C0004057;C0040223;C3541383;C1514624;C0441471;C4019010
hyperlipidaemia,C0020473;C0428465;C4555212
use of statin at any follow up visit,C1524063;C0360714;C0589121
previous coronary revascularisation,C0205156;C0877341;C1552607
vorapaxar group n $nmbr$,C2974521;C0441848
concomitant drugs,C0013227;C3687832
median age iqr years,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
total no,C0439175;C0439810
white ethnic origin,C0007457;C0015031;C0043157;C0220938
vorapaxar placebo $nmbr$ yr km,C0032042;C3887676;C1696465;C1706408
time from qualifying myocardial infarction,C0040223;C3541383;C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
hr $nmbr$ ci p value for interaction,C0008107;C1709380;C3259781
hyperlipidaemia,C0020473;C0428465;C4555212
prior stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
previous coronary revascularisation,C0205156;C0877341;C1552607
planned thienopyridine at enrollment,C1709561;C1120149
concomitant drugs,C0013227;C3687832
prior stent,C0332152;C0038257;C2826257
total no,C0439175;C0439810
stemi,C1536220;C3538872
vorapaxar placebo $nmbr$ yr km,C0032042;C3887676;C1696465;C1706408
azl m cld n $nmbr$,
hr $nmbr$ ci p value for interaction,C0008107;C1709380;C3259781
azl m hctz n $nmbr$,C0020261
prior stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
$nmbr$ f,C0016327
planned thienopyridine at enrollment,C1709561;C1120149
age categories y n,C2916832
prior stent,C0332152;C0038257;C2826257
multiple,C0439064
stemi,C1536220;C3538872
egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n,C0683312;C0439445;C3889287;C0369718;C0441922
azl m cld n $nmbr$,
moderate impairment,C0221099;C0684336
azl m hctz n $nmbr$,C0020261
mild impairment,C0221099;C0684336
$nmbr$ f,C0016327
chronic kidney disease n,C1561643;C4553188
age categories y n,C2916832
multiple,C0439064
figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408;C1511728;C0032659;C1257890;C0205132;C0700221;C1550648;C1552960;C0441889;C0456079;C1547707;C2946261;C0023189;C0444504;C2347634;C2348143;C0162425;C1283828;C1550453;C0521346;C1546767
egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n,C0683312;C0439445;C3889287;C0369718;C0441922
bivalirudin n $nmbr$,C0168273
moderate impairment,C0221099;C0684336
heparin plus a gpi n $nmbr$,C0019134;C0770546
mild impairment,C0221099;C0684336
treated with insulin,C0332293;C0021641;C1533581;C1579433;C3714501
chronic kidney disease n,C1561643;C4553188
arterial hypertension no,C0020538
hypercholesterolemia no,C0020443;C1522133
figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408;C1511728;C0032659;C1257890;C0205132;C0700221;C1550648;C1552960;C0441889;C0456079;C1547707;C2946261;C0023189;C0444504;C2347634;C2348143;C0162425;C1283828;C1550453;C0521346;C1546767
coronary artery treated no,C0205042;C1522326
bivalirudin n $nmbr$,C0168273
multivessel disease no,C0012634
heparin plus a gpi n $nmbr$,C0019134;C0770546
previous myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
treated with insulin,C0332293;C0021641;C1533581;C1579433;C3714501
previous percutaneous coronary intervention,C0205156;C1532338;C1552607
arterial hypertension no,C0020538
previous coronary artery bypass surgery no,C2144990
hypercholesterolemia no,C0020443;C1522133
estimated gfr ml min,C0017654;C0439445;C1424601
coronary artery treated no,C0205042;C1522326
time point,C2348792
multivessel disease no,C0012634
ckd,C1561643
previous myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
chronic cvd,C0205191;C0007222
previous percutaneous coronary intervention,C0205156;C1532338;C1552607
om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous coronary artery bypass surgery no,C2144990
to goal,C0018017;C1571704
estimated gfr ml min,C0017654;C0439445;C1424601
week $nmbr$ et,C0332174;C0040028;C0439230
time point,C2348792
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
ckd,C1561643
om $nmbr$ aml $nmbr$ hctz $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
chronic cvd,C0205191;C0007222
sitagliptin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
american indian alaska native,C0886378
to goal,C0018017;C1571704
body weight kg mean sd,C0005910;C2699239;C1305866
week $nmbr$ et,C0332174;C0040028;C0439230
known duration of type $nmbr$ diabetes,C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
years mean sd,C0439234;C2699239
om $nmbr$ aml $nmbr$ hctz $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba $nmbr$ c mean sd [range],C0019016;C2699239;C1825777;C3538758;C1514721;C2348147;C3542016
sitagliptin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
american indian alaska native,C0886378
hba $nmbr$ c distribution at baseline n,C0520511;C1704711
body weight kg mean sd,C0005910;C2699239;C1305866
b $nmbr$,
known duration of type $nmbr$ diabetes,C0449238;C2926735
fpg mmol l mean sd,C1532563;C2699239
years mean sd,C0439234;C2699239
$nmbr$ h pmg mmol l mean sd,C2827804;C2699239
hba $nmbr$ c mean sd [range],C0019016;C2699239;C1825777;C3538758;C1514721;C2348147;C3542016
fasting insulin pmol l mean sd,C0015663;C0439284;C2699239
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
canakinumab dose per mo,C0178602;C0869039;C1114758
hba $nmbr$ c distribution at baseline n,C0520511;C1704711
total group n $nmbr$,C0439175;C0441848;C0439810
b $nmbr$,
fpg mmol l mean sd,C1532563;C2699239
blood pressure mm,C4330985;C4554674
geographic site,C0017446
$nmbr$ h pmg mmol l mean sd,C2827804;C2699239
duration of diabetes mellitus y,C0449238;C2926735
fasting insulin pmol l mean sd,C0015663;C0439284;C2699239
previous metformin use,C0042153;C0457083;C1947944
canakinumab dose per mo,C0178602;C0869039;C1114758
metformin dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total group n $nmbr$,C0439175;C0441848;C0439810
glucose mmol l,C0017725;C1532563
blood pressure mm,C4330985;C4554674
insulin pmol l,C0021641;C0439284;C1533581;C1579433;C3714501
geographic site,C0017446
ldl c mmol l,C1532563
duration of diabetes mellitus y,C0449238;C2926735
hdl c mmol l,C3715113;C1532563
previous metformin use,C0042153;C0457083;C1947944
non hdl c mmol l,C1518422;C1532563
metformin dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
triglyceride mmol l,C0041004;C1532563
glucose mmol l,C0017725;C1532563
il $nmbr$ ng l,C0020898;C0439297;C0021764;C0022271
insulin pmol l,C0021641;C0439284;C1533581;C1579433;C3714501
fibrinogen g l,C0439294;C0456615
ldl c mmol l,C1532563
canakinumab dose per month,C0178602;C0869039;C1114758
hdl c mmol l,C3715113;C1532563
crp,C3890735;C4048285
non hdl c mmol l,C1518422;C1532563
change median baseline crp $nmbr$ mg l,C0168634;C0439268;C1442488
triglyceride mmol l,C0041004;C1532563
baseline crp,C3890735;C4048285
il $nmbr$ ng l,C0020898;C0439297;C0021764;C0022271
il $nmbr$,C0020898;C0021764;C0022271
fibrinogen g l,C0439294;C0456615
fibrinogen,C0016006;C1167394;C2587184;C3540039
canakinumab dose per month,C0178602;C0869039;C1114758
parameters,C0449381
crp,C3890735;C4048285
n v n $nmbr$,C0369718;C0441922
change median baseline crp $nmbr$ mg l,C0168634;C0439268;C1442488
v $nmbr$ n $nmbr$,C0369718;C0441922
baseline crp,C3890735;C4048285
race asian n,C0034510;C0078988;C1706779;C3853635
il $nmbr$,C0020898;C0021764;C0022271
mean sd kg m $nmbr$,C0022718;C0439209;C4054209
fibrinogen,C0016006;C1167394;C2587184;C3540039
nonsmoker n,C0337672;C0425293;C4554605
parameters,C0449381
baseline sbp,C0168634;C0085805;C1442488
n v n $nmbr$,C0369718;C0441922
mean sd mmhg,C0444504;C0439475;C2347634;C2348143
v $nmbr$ n $nmbr$,C0369718;C0441922
baseline dbp,C0536221;C3813197;C4281799
race asian n,C0034510;C0078988;C1706779;C3853635
metabolism and nutrition,C0025519;C0025520;C0028707;C0392209;C0518896;C1442959
mean sd kg m $nmbr$,C0022718;C0439209;C4054209
disorders soc,C0012634
nonsmoker n,C0337672;C0425293;C4554605
cardiac disorders soc,C0018799
baseline sbp,C0168634;C0085805;C1442488
cerebral infarction,C0007785
mean sd mmhg,C0444504;C0439475;C2347634;C2348143
cerebral ischemia,C0007785;C0917798
baseline dbp,C0536221;C3813197;C4281799
cerebrovascular accident,C0038454
metabolism and nutrition,C0025519;C0025520;C0028707;C0392209;C0518896;C1442959
normal weight bmi,C4229017
disorders soc,C0012634
overweight bmi $nmbr$ to,C0497406;C0578022
cardiac disorders soc,C0018799
obese bmi $nmbr$,C0028754;C0578022
cerebral infarction,C0007785
b a n $nmbr$,
cerebral ischemia,C0007785;C0917798
b h n $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
cerebrovascular accident,C0038454
sex men women,C0009253;C0043210;C0036864;C0079399;C0804628;C1314687;C1522384
normal weight bmi,C4229017
previous coronary heart disease,C0010054;C0010068;C1956346
overweight bmi $nmbr$ to,C0497406;C0578022
previous chronic kidney disease,C1561643;C4553188
obese bmi $nmbr$,C0028754;C0578022
change in retinal pathology,C0392747;C0443172;C1705241;C4319952
b a n $nmbr$,
$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
b h n $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ or $nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
sex men women,C0009253;C0043210;C0036864;C0079399;C0804628;C1314687;C1522384
$nmbr$ step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463;C1551358;C0042903;C0023694;C1328010
previous coronary heart disease,C0010054;C0010068;C1956346
baseline a $nmbr$ c,C0168634;C1442488
previous chronic kidney disease,C1561643;C4553188
baseline sbp mm,C4330985;C4554674
change in retinal pathology,C0392747;C0443172;C1705241;C4319952
baseline ldl mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
outcomes during accord,C1274040;C0680240
$nmbr$ or $nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
accord primary n,C0205225;C0439612;C0439631
$nmbr$ step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463;C1551358;C0042903;C0023694;C1328010
fatal nonfatal mi n,C1302234;C1705232
baseline a $nmbr$ c,C0168634;C1442488
fatal nonfatal stroke n,C1302234;C0038454;C4554100;C1705232
baseline sbp mm,C4330985;C4554674
concomitant antiplatelet,C0521115
baseline ldl mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no concomitant antiplatelet,C0521115
outcomes during accord,C1274040;C0680240
de $nmbr$ n $nmbr$,C0011198;C0017480;C3541240
accord primary n,C0205225;C0439612;C0439631
previous htn n,C0205156;C0020538;C1552607
fatal nonfatal mi n,C1302234;C1705232
previous dm n,C0205156;C0011816;C3250443;C1552607
fatal nonfatal stroke n,C1302234;C0038454;C4554100;C1705232
previous mi n,C0205156;C1552607
concomitant antiplatelet,C0521115
previous cad n,C0205156;C1504769;C2239547;C3813548;C4284121;C1552607
no concomitant antiplatelet,C0521115
previous chf n,C0205156;C0018802;C1552607
de $nmbr$ n $nmbr$,C0011198;C0017480;C3541240
previous stroke n,C0205156;C0038454;C4554100;C1552607
previous htn n,C0205156;C0020538;C1552607
chads score n,C0449820;C4050231
previous dm n,C0205156;C0011816;C3250443;C1552607
previous renal disease n,C0205156;C0022658;C1552607
previous mi n,C0205156;C1552607
type of af n,C0332307;C1547052
previous cad n,C0205156;C1504769;C2239547;C3813548;C4284121;C1552607
duration antiplatelet use as of study duration sd,C1881378;C2826775
previous chf n,C0205156;C0018802;C1552607
rate year,C0439234;C0439508
previous stroke n,C0205156;C0038454;C4554100;C1552607
hr,
chads score n,C0449820;C4050231
stroke embolism,C0013922;C1704212
previous renal disease n,C0205156;C0022658;C1552607
all stroke,C0038454;C4554100
type of af n,C0332307;C1547052
cv death,C0011065;C1306577;C4082313;C4552775
duration antiplatelet use as of study duration sd,C1881378;C2826775
major bleed,C0205082;C0019080;C0205164;C4318856;C4521762
rate year,C0439234;C0439508
minor bleed,C0026193;C0019080;C0205165
hr,
all bleed,C0019080
stroke embolism,C0013922;C1704212
intracranial,C0524466
all stroke,C0038454;C4554100
extracranial,C0580586
cv death,C0011065;C1306577;C4082313;C4552775
with mets,C0812270;C1705694;C2939420
major bleed,C0205082;C0019080;C0205164;C4318856;C4521762
ez simva $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
minor bleed,C0026193;C0019080;C0205165
doubling statin dose,C0178602;C0869039;C1114758
all bleed,C0019080
rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
intracranial,C0524466
multi racial,C0439064;C3266262
extracranial,C0580586
without mets,C0812270;C1705694;C2939420
with mets,C0812270;C1705694;C2939420
figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p,C0392747;C0443172;C1705241;C4319952;C1274040;C1546471;C2825142;C0449450;C0084844;C1538994;C0332174;C0439230;C0007447;C0162425;C1283828;C1550453;C0032659;C0042295;C1257890
ez simva $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
subgoup_name,C0027365;C1547383;C4522128
doubling statin dose,C0178602;C0869039;C1114758
subgroup_level,C0441889;C0456079;C1547707;C2946261
rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
image only,C1704254;C1704922;C3542466
multi racial,C0439064;C3266262
chads $nmbr$,C0007928;C1413373
without mets,C0812270;C1705694;C2939420
r $nmbr$,C0205090;C0684010;C2603358
figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p,C0392747;C0443172;C1705241;C4319952;C1274040;C1546471;C2825142;C0449450;C0084844;C1538994;C0332174;C0439230;C0007447;C0162425;C1283828;C1550453;C0032659;C0042295;C1257890
af pattern,C0344434;C0449774;C4049859
subgoup_name,C0027365;C1547383;C4522128
laa ostium,C0444567
subgroup_level,C0441889;C0456079;C1547707;C2946261
$nmbr$ mm,C4330985;C4554674
image only,C1704254;C1704922;C3542466
laa length,C1444754;C1706316
chads $nmbr$,C0007928;C1413373
device watchman filter,C0180860;C0335390
r $nmbr$,C0205090;C0684010;C2603358
control warfarin,C0243148;C0043031;C1550141;C1882979;C2587213;C3274648;C4553389
af pattern,C0344434;C0449774;C4049859
age y $nmbr$ th $nmbr$ th percentiles,C0001779;C1264641
laa ostium,C0444567
months from qualifying stroke,C0439231;C1514624;C0038454;C4554100
$nmbr$ mm,C4330985;C4554674
selected clinical characteristics,C1707391;C0683325
laa length,C1444754;C1706316
rankin scale $nmbr$,C0451405
device watchman filter,C0180860;C0335390
aspirin alone,C0004057;C0205171;C0439044;C0679994
control warfarin,C0243148;C0043031;C1550141;C1882979;C2587213;C3274648;C4553389
thienopyridine alone,C1120149;C0205171;C0439044;C0679994
age y $nmbr$ th $nmbr$ th percentiles,C0001779;C1264641
dipyridamole alone,C0012582;C0205171;C0439044;C0679994
months from qualifying stroke,C0439231;C1514624;C0038454;C4554100
aspirin thienopyridine,C0004057;C1120149
selected clinical characteristics,C1707391;C0683325
aspirin dipyridamole,C0732279
rankin scale $nmbr$,C0451405
thienopyridine dipyridamole,C1120149;C0012582
aspirin alone,C0004057;C0205171;C0439044;C0679994
other medications at enrollment,C0013227;C0802604;C2598133;C4284232
thienopyridine alone,C1120149;C0205171;C0439044;C0679994
vorapaxar no $nmbr$ y km,C2974521;C3887676
dipyridamole alone,C0012582;C0205171;C0439044;C0679994
placebo no $nmbr$ y km,C0032042;C1696465;C1706408;C3887676
aspirin thienopyridine,C0004057;C1120149
efficacy end points,C1280519;C2349179;C1707887
aspirin dipyridamole,C0732279
cv death mi or stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
thienopyridine dipyridamole,C1120149;C0012582
cv death mi stroke or urgent coronary revascularization,C0038454;C4554100;C0439609;C0877341;C3272275
other medications at enrollment,C0013227;C0802604;C2598133;C4284232
any stroke,C0038454;C4554100
vorapaxar no $nmbr$ y km,C2974521;C3887676
urgent coronary revascularization,C0439609;C0877341;C3272275
placebo no $nmbr$ y km,C0032042;C1696465;C1706408;C3887676
all cause death,C0011065;C1306577;C4082313;C4552775
efficacy end points,C1280519;C2349179;C1707887
bleeding end points,C0019080;C2349179
cv death mi or stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
gusto moderate or severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
cv death mi stroke or urgent coronary revascularization,C0038454;C4554100;C0439609;C0877341;C3272275
gusto severe,C0205082;C4050465;C4050466
any stroke,C0038454;C4554100
timi clinically significant,C0237881;C0750502;C1546944
urgent coronary revascularization,C0439609;C0877341;C3272275
timi non cabg major,C0205082;C0205164;C4318856;C4521762
all cause death,C0011065;C1306577;C4082313;C4552775
timi minor,C0026193;C0205165
bleeding end points,C0019080;C2349179
fatal bleeding,C1302234;C0019080;C1705232
gusto moderate or severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
intracranial hemorrhage,C0151699;C4554169
gusto severe,C0205082;C4050465;C4050466
intracerebral,C0442111
timi clinically significant,C0237881;C0750502;C1546944
subdural epidural,C0228134;C0812144
timi non cabg major,C0205082;C0205164;C4318856;C4521762
active control study,C2347179
timi minor,C0026193;C0205165
placebo control study,C0683952
fatal bleeding,C1302234;C0019080;C1705232
estimated creatinine clearance ml min i,C0023806
intracranial hemorrhage,C0151699;C4554169
neither deep vein thrombosis nor pulmonary embolism,C0149871;C0034065
intracerebral,C0442111
immobilization no,C0020944;C4048292
subdural epidural,C0228134;C0812144
transient,C0040704;C0205374
active control study,C2347179
known thrombophilia no,C0205309;C0398623
placebo control study,C0683952
active cancer no,C0006826;C0998265;C1306459
estimated creatinine clearance ml min i,C0023806
previous cancer no,C0006826;C0998265;C1306459
neither deep vein thrombosis nor pulmonary embolism,C0149871;C0034065
coronary artery disease no,C0010054;C0010068;C1956346
immobilization no,C0020944;C4048292
treatment duration before randomization days,C0444921;C3259042
transient,C0040704;C0205374
enrolled from re cover study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
known thrombophilia no,C0205309;C0398623
dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
active cancer no,C0006826;C0998265;C1306459
warfarin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
previous cancer no,C0006826;C0998265;C1306459
enrolled from re cover ii study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
coronary artery disease no,C0010054;C0010068;C1956346
adherence to study regimen no ff,C1510802;C0040808;C2945654;C4554348
treatment duration before randomization days,C0444921;C3259042
factors dabigatran event incidence n,C0021149;C0220856
enrolled from re cover study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
wafarin event incidence n,C0021149;C0220856
dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
age category,C0683312;C3889287
warfarin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
geographical region,C0017446;C0205147
enrolled from re cover ii study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
creatine clearance category $nmbr$ to,C0683312;C3889287
adherence to study regimen no ff,C1510802;C0040808;C2945654;C4554348
smoking history,C1519384
factors dabigatran event incidence n,C0021149;C0220856
ex smoker,C0337671;C4555205
wafarin event incidence n,C0021149;C0220856
currently smokes,C0521116;C0037369
age category,C0683312;C3889287
subgroup w r t re cover,C0180153;C1999244;C3888055
geographical region,C0017446;C0205147
re cover $nmbr$ dabigatran,C0556581;C0180153;C1999244;C3888055;C2986904;C2348066
creatine clearance category $nmbr$ to,C0683312;C3889287
re cover $nmbr$ warfarin,C0556581;C0180153;C1999244;C3888055;C2986904;C0043031
smoking history,C1519384
re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
ex smoker,C0337671;C4555205
non rollover,C0517067;C0543436
currently smokes,C0521116;C0037369
symptomatic pe,C0070939;C1880476;C4284304
subgroup w r t re cover,C0180153;C1999244;C3888055
history of $nmbr$ previous vte excluding index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
re cover $nmbr$ dabigatran,C0556581;C0180153;C1999244;C3888055;C2986904;C2348066
history of non hemor rhagic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
re cover $nmbr$ warfarin,C0556581;C0180153;C1999244;C3888055;C2986904;C0043031
re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
history of coronary artery disease,C1881055
factors dabigatran,C1521761;C2348066;C2827422
non rollover,C0517067;C0543436
symptomatic pe,C0070939;C1880476;C4284304
p value for,C1709380
event incidence n,C0021149;C0220856
history of $nmbr$ previous vte excluding index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
black or asian,C0005680;C0027567;C0085756;C0439541;C0078988
history of non hemor rhagic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
rest of the world,C0035253;C1622890
history of coronary artery disease,C1881055
l $nmbr$ kg,C1637390
factors dabigatran,C1521761;C2348066;C2827422
creatine clearance category,C0683312;C3889287
p value for,C1709380
$nmbr$ m b m in,C0369637;C0441923
event incidence n,C0021149;C0220856
$nmbr$ ^ $nmbr$ t $nmbr$ c u,C2603360;C0439148
black or asian,C0005680;C0027567;C0085756;C0439541;C0078988
qualifying index event as pe,C1514624;C0441471;C4019010
rest of the world,C0035253;C1622890
budesonide mmx $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
l $nmbr$ kg,C1637390
entocort ec n $nmbr$,C1170256
creatine clearance category,C0683312;C3889287
mean age years range,C1514721;C2348147;C3542016
$nmbr$ m b m in,C0369637;C0441923
uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ ^ $nmbr$ t $nmbr$ c u,C2603360;C0439148
mean disease duration years,C0872146;C0439234
qualifying index event as pe,C1514624;C0441471;C4019010
duration,C0449238;C2926735
budesonide mmx $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration $nmbr$ to,C0449238;C2926735
entocort ec n $nmbr$,C1170256
duration $nmbr$ years n,C0449238;C0439234;C2926735
mean age years range,C1514721;C2348147;C3542016
disease extent n,C0012634;C0439792
uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
proctosigmoiditis,C0033252
mean disease duration years,C0872146;C0439234
left sided colitis,C2887821
duration,C0449238;C2926735
extensive pancolitis,C0205231;C0868908
duration $nmbr$ to,C0449238;C2926735
mean baseline ucdai score,C3533236;C0168634;C1442488
duration $nmbr$ years n,C0449238;C0439234;C2926735
mean baseline ei score,C3533236;C0022067;C1414370;C2348481
disease extent n,C0012634;C0439792
proctosigmoiditis,C0033252
prior mesalazine use,C0042153;C0457083;C1947944
prior sulfasalazine use,C0042153;C0457083;C1947944
left sided colitis,C2887821
nerd,
extensive pancolitis,C0205231;C0868908
eo,C0332120
mean baseline ucdai score,C3533236;C0168634;C1442488
gender male n,C0079399;C0086582;C1706180;C1706428;C1706429;C1522384
mean baseline ei score,C3533236;C0022067;C1414370;C2348481
american indian alaskan native,C0886378
prior mesalazine use,C0042153;C0457083;C1947944
native hawaiian pacific islander,C0337920;C0242191
prior sulfasalazine use,C0042153;C0457083;C1947944
alcohol drinker n,C0001962;C0001975
nerd,
smoker n,C0337664
eo,C0332120
caffeine user n,C3532939
gender male n,C0079399;C0086582;C1706180;C1706428;C1706429;C1522384
h pylori status n,C0079488;C0449438
american indian alaskan native,C0886378
baseline los angeles grade of eo n,C0441800;C0919553;C3244287
native hawaiian pacific islander,C0337920;C0242191
n a,C1272460
alcohol drinker n,C0001962;C0001975
smoker n,C0337664
figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0267055;C0030705
caffeine user n,C3532939
statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0521095;C1524063;C1708614
h pylori status n,C0079488;C0449438
figure $nmbr$ subgroup analyses of the primary endpoint of weekly angina frequency,C2986480;C3695257
baseline los angeles grade of eo n,C0441800;C0919553;C3244287
incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention,C0456603;C1547037;C1705241;C1705242;C0023732;C0332152;C0007447;C0740175;C2257086;C3669034;C1079231;C1547282;C2986480;C0397581
n a,C1272460
clinical characteristics n,C0683325
figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0267055;C0030705
egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0521095;C1524063;C1708614
pervious cerebrovascular event,C0441471;C4019010
figure $nmbr$ subgroup analyses of the primary endpoint of weekly angina frequency,C2986480;C3695257
pad details n,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
peripheral arterial revascularization,C0003842;C0581603;C0221464
incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention,C0456603;C1547037;C1705241;C1705242;C0023732;C0332152;C0007447;C0740175;C2257086;C3669034;C1079231;C1547282;C2986480;C0397581
prior amputation,C0002688;C0332840;C1546539
clinical characteristics n,C0683325
prior carotid intervention,C0184661;C0886296;C1273869
egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
abi,C1328319;C3888326
pervious cerebrovascular event,C0441471;C4019010
abi $nmbr$ $nmbr$,C1328319;C3888326
pad details n,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
claudication fontaine class $nmbr$,C0456387;C1518526;C1705943
peripheral arterial revascularization,C0003842;C0581603;C0221464
baseline medical therapy n,C0168634;C0418981;C1442488
prior amputation,C0002688;C0332840;C1546539
no antiplatelet therapy,C1096021
prior carotid intervention,C0184661;C0886296;C1273869
aspirin and thienopyridine therapy,C0004057;C0039798;C0087111;C1363945
abi,C1328319;C3888326
cilostazol,C0055729
abi $nmbr$ $nmbr$,C1328319;C3888326
vorapaxar n $nmbr$ n,C2974521
claudication fontaine class $nmbr$,C0456387;C1518526;C1705943
overall efficacy,C1280519;C1707887
baseline medical therapy n,C0168634;C0418981;C1442488
cvd mi stroke,C0038454;C4554100
no antiplatelet therapy,C1096021
cvd mi stroke urgent coronary revascularization,C0007222;C0877341
aspirin and thienopyridine therapy,C0004057;C0039798;C0087111;C1363945
cvd mi stroke urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
cilostazol,C0055729
cvd mi stroke revascularization urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
vorapaxar n $nmbr$ n,C2974521
overall efficacy,C1280519;C1707887
peripheral limb vascular efficacy,C1280519;C1707887
cvd mi stroke,C0038454;C4554100
hospitalization for acute limb ischemia,C0019993;C2945695
cvd mi stroke urgent coronary revascularization,C0007222;C0877341
any peripheral revascularization,C0205100;C0581603
urgent peripheral revascularization,C0205100;C0581603
cvd mi stroke urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
elective peripheral revascularization,C0205100;C0581603
cvd mi stroke revascularization urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
any vascular efficacy,C1280519;C1707887
peripheral limb vascular efficacy,C1280519;C1707887
urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
hospitalization for acute limb ischemia,C0019993;C2945695
any revascularization,C0581603
any peripheral revascularization,C0205100;C0581603
bleeding,C0019080
urgent peripheral revascularization,C0205100;C0581603
gusto moderate severe bleed,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
elective peripheral revascularization,C0205100;C0581603
gusto severe bleed,C0205082;C0019080;C4050465;C4050466
any vascular efficacy,C1280519;C1707887
fatal bleed,C1302234;C0019080;C1705232
urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
nebivolol n $nmbr$,C0068475
any revascularization,C0581603
age years a,C1510829
bleeding,C0019080
trough seated sbp mmhg a,C0085805;C0439475
gusto moderate severe bleed,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
trough seated dbp mmhg a,C0277814;C0439475;C1283233
gusto severe bleed,C0205082;C0019080;C4050465;C4050466
trough seated hr bpm a,C0444506;C0277814;C1283233
fatal bleed,C1302234;C0019080;C1705232
all men,C0025266
nebivolol n $nmbr$,C0068475
all women,C0043210
age years a,C1510829
ethnicity t,C0015031;C0243103
trough seated sbp mmhg a,C0085805;C0439475
education y mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
trough seated dbp mmhg a,C0277814;C0439475;C1283233
treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
trough seated hr bpm a,C0444506;C0277814;C1283233
blood pressure mm hg mean sd,C0428886;C2699239
all men,C0025266
dbp $nmbr$ $nmbr$ $nmbr$ $nmbr$ baseline lipid profile mg dl mean sd,C0439269;C2699239
all women,C0043210
ethnicity t,C0015031;C0243103
total glucose mg dl,C0017725;C0439269
education y mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
diabetes mellitus classification,C0008902;C0008903;C0678229
diabetes mellitust,C0011847;C0011849
treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
normoglycemic^,C0580545
blood pressure mm hg mean sd,C0428886;C2699239
history of chd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
dbp $nmbr$ $nmbr$ $nmbr$ $nmbr$ baseline lipid profile mg dl mean sd,C0439269;C2699239
history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
total glucose mg dl,C0017725;C0439269
st t wavett,C0036056;C3272372
diabetes mellitus classification,C0008902;C0008903;C0678229
$nmbr$ $nmbr$ $nmbr$ continued,C0549178
diabetes mellitust,C0011847;C0011849
estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
normoglycemic^,C0580545
atrial fibrillation flutter n,C0155709
history of chd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
outcomes,C1274040
history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
$nmbr$ y rate per $nmbr$ persons se n,C0871208;C1521828
st t wavett,C0036056;C3272372
hazard ratio and $nmbr$ confidence interval,C2985465;C0009667
$nmbr$ $nmbr$ $nmbr$ continued,C0549178
a c,
estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
l c,C0439394;C1706495;C3642217
atrial fibrillation flutter n,C0155709
total randomized n,C0439175;C0034656;C3815594;C0439810
outcomes,C1274040
primary end point,C2986535
$nmbr$ y rate per $nmbr$ persons se n,C0871208;C1521828
chd nonfatal mi fatal chd,C0280604;C1302234;C1705232;C3542407
hazard ratio and $nmbr$ confidence interval,C2985465;C0009667
secondary end points,C0027627;C2349179;C0175668;C0205436
a c,
mortality outcomes,C0026565;C1274040;C0026566
l c,C0439394;C1706495;C3642217
combined fatal nonfatal outcomes,C1548228
total randomized n,C0439175;C0034656;C3815594;C0439810
heart failure treated hospitalized fatal,C1302234;C1705232
primary end point,C2986535
hospitalized fatal heart failure,C0018801;C0018802;C4554158
chd nonfatal mi fatal chd,C0280604;C1302234;C1705232;C3542407
hospitalized angina,C0701159;C0002962
secondary end points,C0027627;C2349179;C0175668;C0205436
coronary revascularization,C0877341
mortality outcomes,C0026565;C1274040;C0026566
insulin glargin arm,C0446516;C3715044;C4553528
combined fatal nonfatal outcomes,C1548228
insulin glargine slope lsm se mm year,C0439234;C0439508
heart failure treated hospitalized fatal,C1302234;C1705232
standard care slope lsm se mm year,C0439234;C0439508
hospitalized fatal heart failure,C0018801;C0018802;C4554158
difference glargine standard care lsm se mm year,C0439234;C0439508
hospitalized angina,C0701159;C0002962
p value for interaction by region,C1709380;C1704675;C0017446;C0205147
coronary revascularization,C0877341
north america n $nmbr$,C0028405
insulin glargin arm,C0446516;C3715044;C4553528
south america n $nmbr$,C0037713
insulin glargine slope lsm se mm year,C0439234;C0439508
n $nmbr$ fatty acit,C0369718;C0441922
standard care slope lsm se mm year,C0439234;C0439508
s arm,C0446516;C3715044;C4553528
difference glargine standard care lsm se mm year,C0439234;C0439508
p value for interaction by region,C1709380;C1704675;C0017446;C0205147
n $nmbr$ fatty acids slope lsm se mm year,C0439234;C0439508
north america n $nmbr$,C0028405
placebo slope lsm se mm year,C0439234;C0439508
south america n $nmbr$,C0037713
difference n $nmbr$ fa placebo lsm se mm year,C0439234;C0439508
n $nmbr$ fatty acit,C0369718;C0441922
other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers,C0015176;C0004340;C0021201;C2700456;C1511726;C3245479;C3714741;C0344329;C0392748
s arm,C0446516;C3715044;C4553528
sita $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cana $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
n $nmbr$ fatty acids slope lsm se mm year,C0439234;C0439508
other i,C0021966;C0221138
placebo slope lsm se mm year,C0439234;C0439508
a $nmbr$ c mmol mol,C3829066
difference n $nmbr$ fa placebo lsm se mm year,C0439234;C0439508
fpg mmol l mg dl,C1532980
other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers,C0015176;C0004340;C0021201;C2700456;C1511726;C3245479;C3714741;C0344329;C0392748
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
sita $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of type $nmbr$ diabetes years,C0449238;C2926735
cana $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1079230;C1515021
other i,C0021966;C0221138
ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0023189;C1710181;C1319635;C1418845
a $nmbr$ c mmol mol,C3829066
covariate,
fpg mmol l mg dl,C1532980
cluster $nmbr$ diuretic n $nmbr$,C1555715;C0012798;C1704332
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
cluster $nmbr$ reversible no diuretic n $nmbr$,C1555715;C0205343;C1704332;C0012798
duration of type $nmbr$ diabetes years,C0449238;C2926735
cluster $nmbr$ not reversible no diuretic n $nmbr$,C1555715;C1704332;C1518422;C0205343;C0012798
supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1079230;C1515021
age median years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0023189;C1710181;C1319635;C1418845
iqr,
covariate,
median m kg $nmbr$ iqr,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
cluster $nmbr$ diuretic n $nmbr$,C1555715;C0012798;C1704332
smoking mean,C0444504;C2347634;C2348143
cluster $nmbr$ reversible no diuretic n $nmbr$,C1555715;C0205343;C1704332;C0012798
pack years iqr,C1277691
cluster $nmbr$ not reversible no diuretic n $nmbr$,C1555715;C1704332;C1518422;C0205343;C0012798
fev $nmbr$ predicted sd,C0681842;C2699239;C1882327
age median years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
fev $nmbr$ reversibility sd,C0449261;C2699239
iqr,
reversibility stratum,C0449261
median m kg $nmbr$ iqr,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
[no yes],C1549445;C1705108;C1710701
smoking mean,C0444504;C2347634;C2348143
exacerbations requiring hospitalisation past year,C4086268;C0019993;C0439234;C0439508
pack years iqr,C1277691
exacerbations requiring oral steroids antibiotics past year,C4086268;C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
fev $nmbr$ predicted sd,C0681842;C2699239;C1882327
baseline medications,C0013227;C0802604;C2598133;C4284232
fev $nmbr$ reversibility sd,C0449261;C2699239
anti thrombotics,C0087086
reversibility stratum,C0449261
lipid modifiers,C0023779;C4284280
[no yes],C1549445;C1705108;C1710701
blockers,
exacerbations requiring hospitalisation past year,C4086268;C0019993;C0439234;C0439508
psycholeptics,C3653516
exacerbations requiring oral steroids antibiotics past year,C4086268;C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
anti histamines,C0019590
baseline medications,C0013227;C0802604;C2598133;C4284232
cardiac therapy,C3654025
anti thrombotics,C0087086
anti anaemics,C0857322
lipid modifiers,C0023779;C4284280
anti hypertensives,C0003364
blockers,
or $nmbr$ cl,C0596019
psycholeptics,C3653516
p for interaction,C0369773;C2603361
anti histamines,C0019590
age median,C0549183;C0876920;C2347635;C2348144;C2939193
cardiac therapy,C3654025
alcohol,C0001962;C0001975
anti anaemics,C0857322
alcohol $nmbr$ wk,C0332174;C0439230
anti hypertensives,C0003364
no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
or $nmbr$ cl,C0596019
depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
p for interaction,C0369773;C2603361
a $nmbr$ c median,C0549183;C0876920;C2347635;C2348144;C2939193
age median,C0549183;C0876920;C2347635;C2348144;C2939193
waist hip median,C0549183;C0876920;C2347635;C2348144;C2939193
alcohol,C0001962;C0001975
waisvhip median,C0549183;C0876920;C2347635;C2348144;C2939193
alcohol $nmbr$ wk,C0332174;C0439230
grip strength meidan,C0429271;C2598165
no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
grip strength median,C0549183;C0876920;C2347635;C2348144;C2939193
depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
urine acr median,C0549183;C0876920;C2347635;C2348144;C2939193
a $nmbr$ c median,C0549183;C0876920;C2347635;C2348144;C2939193
diabetic subjects n $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
waist hip median,C0549183;C0876920;C2347635;C2348144;C2939193
non diabetic subjects n $nmbr$,C1518422;C0241863
waisvhip median,C0549183;C0876920;C2347635;C2348144;C2939193
alcohol usef n,C0001962;C0001975
grip strength meidan,C0429271;C2598165
serum urate mg dl n,C0455272;C0439269
grip strength median,C0549183;C0876920;C2347635;C2348144;C2939193
years with gouty arthritis,C0439234;C0003868
urine acr median,C0549183;C0876920;C2347635;C2348144;C2939193
presence of tophi n,C0150312;C0392148;C3854307
diabetic subjects n $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
renal function n,C0232804
non diabetic subjects n $nmbr$,C1518422;C0241863
figure $nmbr$ achievement of sua,C0001072
alcohol usef n,C0001962;C0001975
higher target group n $nmbr$,C0441848
serum urate mg dl n,C0455272;C0439269
lower target group n $nmbr$,C0441848
years with gouty arthritis,C0439234;C0003868
blood pressure at entry mm hg,C0005823;C1271104;C1272641
presence of tophi n,C0150312;C0392148;C3854307
ischaemic heart disease,C0010054;C0151744
renal function n,C0232804
previous clinical stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
figure $nmbr$ achievement of sua,C0001072
current tobacco smoker,C3173209;C3241966
higher target group n $nmbr$,C0441848
qualifying event,C1514624;C0441471;C4019010
lower target group n $nmbr$,C0441848
ischaemic stroke,C0948008
blood pressure at entry mm hg,C0005823;C1271104;C1272641
tia,C0007787;C0917805;C1054154
ischaemic heart disease,C0010054;C0151744
number of antihypertensive medications at study entry,C1718138;C0557651;C1705654;C2603343
previous clinical stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
mean number of antihypertensive medications at $nmbr$ year,C0444504;C1718138;C2347634;C2348143;C0439234;C0439508
current tobacco smoker,C3173209;C3241966
types of antihypertensive medications at $nmbr$ year,C0457591;C0439234;C0439508
qualifying event,C1514624;C0441471;C4019010
ace inhibitor arb,C0003015;C3888198;C4541021
ischaemic stroke,C0948008
tia,C0007787;C0917805;C1054154
mean number of antihypertensive medication at last visit,C0444504;C0237753;C0449788;C2347634;C2348143;C0545082;C1512346;C2826704
number of antihypertensive medications at study entry,C1718138;C0557651;C1705654;C2603343
types of antihypertensive medications at last visit,C0457591;C0545082;C1512346;C2826704
mean number of antihypertensive medications at $nmbr$ year,C0444504;C1718138;C2347634;C2348143;C0439234;C0439508
statins used during follow up,C0360714;C1273517;C0589120;C1522577;C1704685;C3274571
number of events annualised rate [ ],C4330837
types of antihypertensive medications at $nmbr$ year,C0457591;C0439234;C0439508
ace inhibitor arb,C0003015;C3888198;C4541021
$nmbr$ o i $nmbr$ mm hg,C0021966;C0439475;C0221138
age p o $nmbr$,C0001779
mean number of antihypertensive medication at last visit,C0444504;C0237753;C0449788;C2347634;C2348143;C0545082;C1512346;C2826704
$nmbr$ years n $nmbr$,C0439234
types of antihypertensive medications at last visit,C0457591;C0545082;C1512346;C2826704
sex p $nmbr$,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
statins used during follow up,C0360714;C1273517;C0589120;C1522577;C1704685;C3274571
male n $nmbr$,C0086582;C1706180;C1706428;C1706429
number of events annualised rate [ ],C4330837
female n lll $nmbr$,C0043210;C1261077;C0086287;C1705497;C1705498
$nmbr$ o i $nmbr$ mm hg,C0021966;C0439475;C0221138
history of diabetes p $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
age p o $nmbr$,C0001779
non diabetic n $nmbr$,C1518422;C0241863
$nmbr$ years n $nmbr$,C0439234
diabetes n $nmbr$,C0011847;C0011849
sex p $nmbr$,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
race p o $nmbr$,C0034510;C1706779;C3853635
male n $nmbr$,C0086582;C1706180;C1706428;C1706429
hispanic n $nmbr$ l $nmbr$,C0086409
female n lll $nmbr$,C0043210;C1261077;C0086287;C1705497;C1705498
other mixed n $nmbr$,C0205430;C3160715
history of diabetes p $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
region of residence p $nmbr$ $nmbr$,C0017446;C0205147
non diabetic n $nmbr$,C1518422;C0241863
latin america n $nmbr$,C0023122
diabetes n $nmbr$,C0011847;C0011849
spain n $nmbr$,C0037747
race p o $nmbr$,C0034510;C1706779;C3853635
baseline sbp p o $nmbr$,C0168634;C0085805;C1442488
hispanic n $nmbr$ l $nmbr$,C0086409
normotensive n $nmbr$,C2712122
other mixed n $nmbr$,C0205430;C3160715
sbp median n $nmbr$,C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
region of residence p $nmbr$ $nmbr$,C0017446;C0205147
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
latin america n $nmbr$,C0023122
$nmbr$ $nmbr$ mga n $nmbr$,C0065879
spain n $nmbr$,C0037747
all n $nmbr$,C0369718;C0441922
baseline sbp p o $nmbr$,C0168634;C0085805;C1442488
male patients n,C0150904
normotensive n $nmbr$,C2712122
median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
sbp median n $nmbr$,C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
uc disease duration y,C0872146
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
extent of disease n,C0449279;C4553144
$nmbr$ $nmbr$ mga n $nmbr$,C0065879
limited to left side of colon,C0439801;C2674459;C3542948;C4050251
all n $nmbr$,C0369718;C0441922
mayo score $nmbr$ $nmbr$,C0449820;C4050231
male patients n,C0150904
endoscopy subscore n,C0014245
median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
uc disease duration y,C0872146
severe disease,C1836348
extent of disease n,C0449279;C4553144
crp mg l n,C3890735;C0439268;C4048285
limited to left side of colon,C0439801;C2674459;C3542948;C4050251
patients receiving any uc medication n,C0030705;C1514756;C0013227;C3244316;C4284232
mayo score $nmbr$ $nmbr$,C0449820;C4050231
corticosteroids excluding budesonide,C0001617;C3539185;C3540725;C3540726;C3540727
endoscopy subscore n,C0014245
$nmbr$ mg d peq,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
budesonide,C0054201
severe disease,C1836348
immunomodulatory drugs,C0013227;C3687832
crp mg l n,C3890735;C0439268;C4048285
$nmbr$ mercaptopurine azathioprine,C0000618;C0004482
patients receiving any uc medication n,C0030705;C1514756;C0013227;C3244316;C4284232
golimumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
corticosteroids excluding budesonide,C0001617;C3539185;C3540725;C3540726;C3540727
ne ne,C0027608;C0028219;C3538705
$nmbr$ mg d peq,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
normonatremic $nmbr$ meq l at baseline,C0439375;C0168634;C1442488
budesonide,C0054201
hyponatremic,C0857122
immunomodulatory drugs,C0013227;C3687832
p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo,C1709380;C1176308;C0857122;C0032042;C1696465;C1706408
$nmbr$ mercaptopurine azathioprine,C0000618;C0004482
placebo n $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
golimumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ne ne,C0027608;C0028219;C3538705
age y sd,C0001779;C2699239
normonatremic $nmbr$ meq l at baseline,C0439375;C0168634;C1442488
hyponatremic,C0857122
systolic blood pressure mm hg sd,C0488055;C2699239;C0871470;C1306620
p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo,C1709380;C1176308;C0857122;C0032042;C1696465;C1706408
diastolic blood pressure mm hg sd,C0428883;C2699239;C1305849
placebo n $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
heart rate sd,C0018810;C2699239
placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history of htn,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
age y sd,C0001779;C2699239
intravenous vasoactive drugs y,C0683092;C1980011
nesiritide z,C0054015
systolic blood pressure mm hg sd,C0488055;C2699239;C0871470;C1306620
edema z,C0013604;C1717255
diastolic blood pressure mm hg sd,C0428883;C2699239;C1305849
jvd $nmbr$ cm h $nmbr$ o,C0425687;C0455483
heart rate sd,C0018810;C2699239
duration of hf y,C0449238;C2926735
history of htn,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
prior hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
intravenous vasoactive drugs y,C0683092;C1980011
nyha iv,C0022326;C4265176
nesiritide z,C0054015
blood urea nitrogen mg dl,C0005845;C0439269;C0600137
edema z,C0013604;C1717255
jvd $nmbr$ cm h $nmbr$ o,C0425687;C0455483
non asian n $nmbr$ $nmbr$,C1518422;C0078988
$nmbr$ $nmbr$ n,C0369718;C0441922
duration of hf y,C0449238;C2926735
prior hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
$nmbr$ n weight kg,C0022718;C0439209;C4054209
nyha iv,C0022326;C4265176
systolic mean sd,C0039155;C2699239
diastolic mean sd,C0012000;C2699239
blood urea nitrogen mg dl,C0005845;C0439269;C0600137
type of atrial fibrillation,C0332307;C1547052
non asian n $nmbr$ $nmbr$,C1518422;C0078988
paroxysmal n,C0205311
$nmbr$ $nmbr$ n,C0369718;C0441922
persistent n,C0205322;C0332996
$nmbr$ n weight kg,C0022718;C0439209;C4054209
permanent n,C0205355
systolic mean sd,C0039155;C2699239
$nmbr$ n chads $nmbr$ score,C0449820;C4050231
diastolic mean sd,C0012000;C2699239
previous stroke yes n previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
type of atrial fibrillation,C0332307;C1547052
yes n,C1549445;C1705108;C1710701
paroxysmal n,C0205311
heat failure,C0231174;C0680095
persistent n,C0205322;C0332996
diabetes mellitus yes n hypertension,C0020538;C1963138
permanent n,C0205355
medication in use at the baseline,C0013227;C3244316;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
$nmbr$ n chads $nmbr$ score,C0449820;C4050231
aspirin n,C0004057
previous stroke yes n previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
arb n,C3888198
yes n,C1549445;C1705108;C1710701
ace i n,C0021966;C0221138
heat failure,C0231174;C0680095
blocker n,
diabetes mellitus yes n hypertension,C0020538;C1963138
amiodarone n,C0002598
medication in use at the baseline,C0013227;C3244316;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
verapamil n,C0042523
aspirin n,C0004057
proton pump inhibitor n,C0358591;C3536754;C4521480
arb n,C3888198
h $nmbr$ blocker n long term vka therapy,C0039798;C0087111;C1363945
ace i n,C0021966;C0221138
experience n,C0237607;C0596545
blocker n,
non asian,C1518422;C0078988
amiodarone n,C0002598
event number,C0237753;C0449788
verapamil n,C0042523
stroke or,C0038454;C4554100
proton pump inhibitor n,C0358591;C3536754;C4521480
systemic embolism,C0013922;C1704212
h $nmbr$ blocker n long term vka therapy,C0039798;C0087111;C1363945
hemorrhagic,C0333275
experience n,C0237607;C0596545
death from,C0011065;C1306577;C4082313;C4552775
non asian,C1518422;C0078988
any cause,C0015127;C1524003
event number,C0237753;C0449788
tcz $nmbr$ mg kg n $nmbr$,C0439272
stroke or,C0038454;C4554100
geographical region n,C0017446;C0205147
systemic embolism,C0013922;C1704212
rest of world,C0035253;C1622890
hemorrhagic,C0333275
positive hla b $nmbr$ status n,C1426226
death from,C0011065;C1306577;C4082313;C4552775
as duration y mean sd,C0444504;C2699239;C2347634;C2348143
any cause,C0015127;C1524003
swollen joints $nmbr$ n,C0152031
tcz $nmbr$ mg kg n $nmbr$,C0439272
basdai score mean sd,C0444504;C2699239;C2347634;C2348143
geographical region n,C0017446;C0205147
crp mg dl mean sd,C0439269;C2699239
rest of world,C0035253;C1622890
crp mg dl median,C0549183;C0876920;C2347635;C2348144;C2939193
positive hla b $nmbr$ status n,C1426226
rvalue for interaction,C1704675
as duration y mean sd,C0444504;C2699239;C2347634;C2348143
favors dabigatran,C0309049;C2348066
swollen joints $nmbr$ n,C0152031
no heart failure,C0018801;C0018802;C4554158
basdai score mean sd,C0444504;C2699239;C2347634;C2348143
prior stroke tia,C0007787;C0917805;C1054154
crp mg dl mean sd,C0439269;C2699239
no prior stroke tia,C0007787;C0917805;C1054154
crp mg dl median,C0549183;C0876920;C2347635;C2348144;C2939193
chadsa,
rvalue for interaction,C1704675
chadsj $nmbr$,
favors dabigatran,C0309049;C2348066
cha $nmbr$ ds $nmbr$ vasc $nmbr$ $nmbr$,C1420648;C3714751
no heart failure,C0018801;C0018802;C4554158
chajdsa vasc $nmbr$ $nmbr$,
prior stroke tia,C0007787;C0917805;C1054154
chajdsj vasc $nmbr$,
no prior stroke tia,C0007787;C0917805;C1054154
has bledo,C1019275
chadsa,
has bled $nmbr$ $nmbr$,C0019080
chadsj $nmbr$,
has bled $nmbr$,C0019080
cha $nmbr$ ds $nmbr$ vasc $nmbr$ $nmbr$,C1420648;C3714751
sbp $nmbr$ mm hg,C0085805;C0439475
chajdsa vasc $nmbr$ $nmbr$,
crcl,C1846718
chajdsj vasc $nmbr$,
crcl $nmbr$ ml min,C1846718;C0439445
has bledo,C1019275
history of cad mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
has bled $nmbr$ $nmbr$,C0019080
no cad mi,C1504769;C3810814;C2239547;C3813548;C4284121
has bled $nmbr$,C0019080
chadsj,
sbp $nmbr$ mm hg,C0085805;C0439475
chajdsrvasc $nmbr$ $nmbr$,
crcl,C1846718
chajdsj vasc $nmbr$ $nmbr$,
crcl $nmbr$ ml min,C1846718;C0439445
sbp $nmbr$ mmhg,C0085805;C0439475
history of cad mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
nocad mi,C3810814
no cad mi,C1504769;C3810814;C2239547;C3813548;C4284121
age s $nmbr$,C0001779
chadsj,
$nmbr$ e h,C0033727;C0369286;C0441932;C0564385;C4528284
chajdsrvasc $nmbr$ $nmbr$,
chad $nmbr$ $nmbr$,C0007928;C1413373
chajdsj vasc $nmbr$ $nmbr$,
h $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
sbp $nmbr$ mmhg,C0085805;C0439475
cha $nmbr$ ds $nmbr$ vasc $nmbr$,C1420648;C3714751
nocad mi,C3810814
sbp $nmbr$ mnn hg,C0025424;C0428257;C2347108;C2347109;C2348272
age s $nmbr$,C0001779
normal cognitive,C0205307;C0231683;C0439166;C2347086;C4553972;C1516691
$nmbr$ e h,C0033727;C0369286;C0441932;C0564385;C4528284
impaired cognitive,C0221099;C1516691
chad $nmbr$ $nmbr$,C0007928;C1413373
status spmsq,C0449438
h $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
status spmsq $nmbr$,C0449438
cha $nmbr$ ds $nmbr$ vasc $nmbr$,C1420648;C3714751
female gender,C0086287
sbp $nmbr$ mnn hg,C0025424;C0428257;C2347108;C2347109;C2348272
treatment arm zoledronate,C1522541;C0392938
normal cognitive,C0205307;C0231683;C0439166;C2347086;C4553972;C1516691
bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
impaired cognitive,C0221099;C1516691
total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0019552;C2699239;C0022122;C1505163;C3538851;C4284725
status spmsq,C0449438
femoral neck n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0015815;C2699239
status spmsq $nmbr$,C0449438
fn t score,C0449820;C4050231
female gender,C0086287
op concomitant medications,C0013227;C0802604;C2598133;C4284232
treatment arm zoledronate,C1522541;C0392938
charlson index,C0600653;C0918012;C1552854;C1637833;C2986546
bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
normal cognitive function spmsq,C4296962
total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0019552;C2699239;C0022122;C1505163;C3538851;C4284725
impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest,C0009240;C0679646;C0392335;C4050130
femoral neck n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0015815;C2699239
chi square p value,C1552646;C1709380
fn t score,C0449820;C4050231
clinical fracture,C0205210;C0016658
op concomitant medications,C0013227;C0802604;C2598133;C4284232
zoledronic acid arm,C0446516;C3715044;C4553528
charlson index,C0600653;C0918012;C1552854;C1637833;C2986546
placebo arm,C0446516;C3715044;C4553528
normal cognitive function spmsq,C4296962
death,C0011065;C1306577;C4082313;C4552775
impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest,C0009240;C0679646;C0392335;C4050130
vedolizumab,C2742797
chi square p value,C1552646;C1709380
cohort $nmbr$ n $nmbr$ f,C0009247;C0016327;C0599755
clinical fracture,C0205210;C0016658
cohort $nmbr$ n $nmbr$,C0009247;C0599755
zoledronic acid arm,C0446516;C3715044;C4553528
combined n $nmbr$,C0205195
placebo arm,C0446516;C3715044;C4553528
white race no,C0007457;C0043157
death,C0011065;C1306577;C4082313;C4552775
duration of disease yr,C0872146;C0439234
vedolizumab,C2742797
mayo clinic score,C0449820;C4050231
cohort $nmbr$ n $nmbr$ f,C0009247;C0016327;C0599755
partial mayo clinic scored,C0002424;C0442592;C0449820
cohort $nmbr$ n $nmbr$,C0009247;C0599755
ibdq score,C0449820;C4050231
combined n $nmbr$,C0205195
fecal calprotectin pg g,C0015733;C1638318
white race no,C0007457;C0043157
site of disease no,C2945843;C0012634
duration of disease yr,C0872146;C0439234
rectum and sigmoid colon only,C0034896;C0227391
mayo clinic score,C0449820;C4050231
left side of colon,C0227388
partial mayo clinic scored,C0002424;C0442592;C0449820
proximal to the splenic flexure,C0205107;C4489236
ibdq score,C0449820;C4050231
all of the colon,C0009368;C3888384
fecal calprotectin pg g,C0015733;C1638318
concomitant medications for ulcerative colitis no,C0013227;C0802604;C2598133;C4284232
site of disease no,C2945843;C0012634
immunosuppressants onlyff,C0021081
rectum and sigmoid colon only,C0034896;C0227391
glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778;C0021081
left side of colon,C0227388
no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778;C0021081
proximal to the splenic flexure,C0205107;C4489236
prednisone equivalent dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
all of the colon,C0009368;C3888384
prior anti tnf therapy no,C1514463
concomitant medications for ulcerative colitis no,C0013227;C0802604;C2598133;C4284232
prior failure of anti tnf therapy no,C0231174;C0680095;C0279936
immunosuppressants onlyff,C0021081
$nmbr$ failure,C0231174;C0680095
glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778;C0021081
inadequate response,C0871261;C1704632;C1706817;C2911692
no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778;C0021081
loss of response,C1517945;C0871261;C1704632;C1706817;C2911692
prednisone equivalent dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
unacceptable adverse events,C0877248;C1705413
prior anti tnf therapy no,C1514463
hemoglobin concentration g liter,C1319312;C0475211
prior failure of anti tnf therapy no,C0231174;C0680095;C0279936
white cell count x $nmbr$ _ $nmbr$ liter,C0023508;C0475211;C0427512
$nmbr$ failure,C0231174;C0680095
veflonzumao,
inadequate response,C0871261;C1704632;C1706817;C2911692
estimated difference,C1705241;C1705242
loss of response,C1517945;C0871261;C1704632;C1706817;C2911692
duration of ulcerative colitis,C0449238;C2926735
unacceptable adverse events,C0877248;C1705413
extent of disease,C0449279;C4553144
hemoglobin concentration g liter,C1319312;C0475211
extensive colitis,C0009319;C1963084
white cell count x $nmbr$ _ $nmbr$ liter,C0023508;C0475211;C0427512
pancolitis,C0868908
veflonzumao,
baseline composite mayo clinic score,C4055211;C0002424;C0442592
estimated difference,C1705241;C1705242
baseline fecal caicrctectin,C0168634;C0015733;C1442488
duration of ulcerative colitis,C0449238;C2926735
$nmbr$ ug g,C0439272
extent of disease,C0449279;C4553144
z $nmbr$ $nmbr$,
extensive colitis,C0009319;C1963084
prior treatment history $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pancolitis,C0868908
any prior anti tnf treatment failure,C1514463
baseline composite mayo clinic score,C4055211;C0002424;C0442592
prior immunnosupressive failure but no anti tnf failure,C0332152;C0231174;C0680095;C2826257
baseline fecal caicrctectin,C0168634;C0015733;C1442488
prior corticosteroid failure only,C0231174;C0680095
$nmbr$ ug g,C0439272
stratification variables,C1514983;C0439828
z $nmbr$ $nmbr$,
concomitant corticosteroid use,C0521115;C0239126
prior treatment history $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no concomitant cortcosteroid use,C0042153;C0457083;C1947944
any prior anti tnf treatment failure,C1514463
concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
prior immunnosupressive failure but no anti tnf failure,C0332152;C0231174;C0680095;C2826257
no concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
prior corticosteroid failure only,C0231174;C0680095
patients with deep vein thrombosis only,C0030705;C0149871
stratification variables,C1514983;C0439828
patients with pulmonary embolism,C0030705;C0034065
concomitant corticosteroid use,C0521115;C0239126
edoxaban n $nmbr$,C2975435
no concomitant cortcosteroid use,C0042153;C0457083;C1947944
creatinine clearance $nmbr$ to,C0812399
concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
patients receiving $nmbr$ mg of edoxaban at randomization no f,C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0034656;C0016327
no concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
anatomical extent of qualifying event no t,C0220784;C0439792;C1514624;C0441471;C4019010;C2603360
patients with deep vein thrombosis only,C0030705;C0149871
limited,C0439801;C2674459;C3542948;C4050251
patients with pulmonary embolism,C0030705;C0034065
intermediate,C0205103;C1550465;C2827755;C3889971
edoxaban n $nmbr$,C2975435
not assessable,C1883425
creatinine clearance $nmbr$ to,C0812399
concomitant dvt no baseline nt probnp no,C0149871;C2926618;C3899446;C0669479;C0754710
patients receiving $nmbr$ mg of edoxaban at randomization no f,C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0034656;C0016327
patients with measurement,C0030705;C0242485
anatomical extent of qualifying event no t,C0220784;C0439792;C1514624;C0441471;C4019010;C2603360
patients with level $nmbr$ pg ml,C0030705;C0439297
limited,C0439801;C2674459;C3542948;C4050251
intermediate,C0205103;C1550465;C2827755;C3889971
right ventricular dysfunction no total no,C0242707;C1556315;C0439175;C0439810
not assessable,C1883425
causes of dvt or pe no ^,C0015127;C1314792;C0070939;C1880476;C4284304
concomitant dvt no baseline nt probnp no,C0149871;C2926618;C3899446;C0669479;C0754710
temporary risk factor,C0205374;C0035648;C1548539;C3245481
patients with measurement,C0030705;C0242485
edoxaban,C2975435
patients with level $nmbr$ pg ml,C0030705;C0439297
presenting diagnosis,C0449450;C0011900;C1704338;C1704656
pe with without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
right ventricular dysfunction no total no,C0242707;C1556315;C0439175;C0439810
dvt only,C0149871;C2926618;C3899446
causes of dvt or pe no ^,C0015127;C1314792;C0070939;C1880476;C4284304
aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
temporary risk factor,C0205374;C0035648;C1548539;C3245481
gendar,
edoxaban,C2975435
baseline risk factors,C0035648;C1553898
presenting diagnosis,C0449450;C0011900;C1704338;C1704656
temporary factors,C1521761;C2827422
pe with without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
all others eteed for $nmbr$ mg edoxaban dose at,C1955473;C4086581;C3539125
dvt only,C0149871;C2926618;C3899446
ra ndosii zat ion,C0022023;C1700702
aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
no body weight at randomization ixrs,C0005910;C1305866
gendar,
baseline risk factors,C0035648;C1553898
$nmbr$ kg body weight at randomization,C0005910;C1305866
$nmbr$ is $nmbr$ $nmbr$,
temporary factors,C1521761;C2827422
creatinine clearance at randomization,C0812399;C0034656
all others eteed for $nmbr$ mg edoxaban dose at,C1955473;C4086581;C3539125
fragile,
ra ndosii zat ion,C0022023;C1700702
yaa,
no body weight at randomization ixrs,C0005910;C1305866
fl $nmbr$ b,C1300812;C1708024
$nmbr$ kg body weight at randomization,C0005910;C1305866
southern europe,C0037724
$nmbr$ is $nmbr$ $nmbr$,
nordic,C0331873
creatinine clearance at randomization,C0812399;C0034656
china japan,C0008115;C0022341
fragile,
other asian,C0078988
yaa,
south africa south america,C0037713
fl $nmbr$ b,C1300812;C1708024
usa canada,C0041703;C0006823
southern europe,C0037724
$nmbr$ t $nmbr$ $nmbr$,C2603360
nordic,C0331873
american indian or,C0002460
china japan,C0008115;C0022341
alaska native,C0682125
other asian,C0078988
native hawaiian or,C0337920
south africa south america,C0037713
other pacific islander,C0242191
usa canada,C0041703;C0006823
medical history cancer,C0006826;C0998265;C1306459
$nmbr$ t $nmbr$ $nmbr$,C2603360
no history of cancer,C0455471
american indian or,C0002460
active cancer at randomisation,C0006826;C0998265;C1306459
alaska native,C0682125
native hawaiian or,C0337920
no active cancer center level inr percent time,C0040223;C3541383
other pacific islander,C0242191
in therapeutic range for warfarin subjects,C0460097;C0043031
medical history cancer,C0006826;C0998265;C1306459
$nmbr$ ^ initial heparin treatment duration,C0444921;C3259042
no history of cancer,C0455471
on or after e^andomization,
$nmbr$ $nmbr$ days,C0439228
active cancer at randomisation,C0006826;C0998265;C1306459
$nmbr$ days,C0439228
no active cancer center level inr percent time,C0040223;C3541383
$nmbr$ day s initial heparin treatment duration,C0332173;C0439228;C0439505;C0444921;C3259042
in therapeutic range for warfarin subjects,C0460097;C0043031
medion $nmbr$ days,C0439228
$nmbr$ ^ initial heparin treatment duration,C0444921;C3259042
initial type of heparin treatment received,C0019134;C0455708;C0770546;C1514756
on or after e^andomization,
s $nmbr$ $nmbr$,
$nmbr$ $nmbr$ days,C0439228
concomitant aspirin use,C0042153;C0457083;C1947944
$nmbr$ days,C0439228
hazard ratio with,C2985465
$nmbr$ day s initial heparin treatment duration,C0332173;C0439228;C0439505;C0444921;C3259042
n t,C0369718;C0441922
medion $nmbr$ days,C0439228
warfarin s $nmbr$ cl,C0043031;C0596019
initial type of heparin treatment received,C0019134;C0455708;C0770546;C1514756
all others,C1955473;C3539125
s $nmbr$ $nmbr$,
need for $nmbr$ ng edoxaban dose at,C0017887;C0028074
concomitant aspirin use,C0042153;C0457083;C1947944
body weight at randonization ixrs,C0005910;C1305866
hazard ratio with,C2985465
body weight at randomization,C0005910;C1305866
n t,C0369718;C0441922
creatinine clearance at randomization ixrs,C0812399;C0034656
warfarin s $nmbr$ cl,C0043031;C0596019
all others,C1955473;C3539125
$nmbr$ $nmbr$ ml rain,C0439526;C0034640;C1705224;C3887665
ho,C0019905;C1832110;C3889614
need for $nmbr$ ng edoxaban dose at,C0017887;C0028074
hordic,
body weight at randonization ixrs,C0005910;C1305866
china tjapan,C0008115
body weight at randomization,C0005910;C1305866
$nmbr$ $nmbr$ b,
creatinine clearance at randomization ixrs,C0812399;C0034656
fl $nmbr$ $nmbr$,C1300812;C1708024
$nmbr$ $nmbr$ ml rain,C0439526;C0034640;C1705224;C3887665
active cancer at randomization,C0006826;C0998265;C1306459
ho,C0019905;C1832110;C3889614
ho active cancer,C0006826;C0998265;C1306459
hordic,
center level ihr percent time in therapeutic range for warfarin subjects,C1554109;C0681850;C1550501;C1706203;C2349001;C2697811
china tjapan,C0008115
initial heparin treatment duration on or after randomization,C0444921;C3259042;C0034656
$nmbr$ $nmbr$ b,
fl $nmbr$ $nmbr$,C1300812;C1708024
initial heparin treatment duration,C0444921;C3259042
median $nmbr$ days,C0549183;C0439228;C0876920;C2347635;C2348144;C2939193
active cancer at randomization,C0006826;C0998265;C1306459
ib $nmbr$ $nmbr$,C2744579;C3890035;C4283819
ho active cancer,C0006826;C0998265;C1306459
saxagliptin n $nmbr$,C1611934
center level ihr percent time in therapeutic range for warfarin subjects,C1554109;C0681850;C1550501;C1706203;C2349001;C2697811
hispanic ethnic group no i,C0015031;C1879937;C0021966;C0221138
initial heparin treatment duration on or after randomization,C0444921;C3259042;C0034656
weight^,C0005910;C0043100;C1305866;C1705104
initial heparin treatment duration,C0444921;C3259042
mean kg,C0022718;C0439209;C4054209
median $nmbr$ days,C0549183;C0439228;C0876920;C2347635;C2348144;C2939193
$nmbr$ kg no,C0022718;C0439209;C4054209
ib $nmbr$ $nmbr$,C2744579;C3890035;C4283819
duration of diabetes yr^,C0449238;C2926735
saxagliptin n $nmbr$,C1611934
established atherosclerotic disease no,C0333482;C0012634
hispanic ethnic group no i,C0015031;C1879937;C0021966;C0221138
dyslipidemia no,C0242339
weight^,C0005910;C0043100;C1305866;C1705104
prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
mean kg,C0022718;C0439209;C4054209
prior heart failure no,C0018801;C0018802;C4554158
$nmbr$ kg no,C0022718;C0439209;C4054209
prior coronary revascularization no,C0332152;C0877341;C2826257
duration of diabetes yr^,C0449238;C2926735
mean ml min,C0444504;C0439445;C2347634;C2348143
established atherosclerotic disease no,C0333482;C0012634
albumin to creatinine ratio i,C0021966;C0221138
dyslipidemia no,C0242339
$nmbr$ yr km rate,C0871208;C1521828
prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
saxagliptin,C1611934
prior heart failure no,C0018801;C0018802;C4554158
atherosclerosis,C0003850;C0004153
prior coronary revascularization no,C0332152;C0877341;C2826257
established,C0443211;C1272684
mean ml min,C0444504;C0439445;C2347634;C2348143
multiple risk factors,C0035648;C1553898
albumin to creatinine ratio i,C0021966;C0221138
a $nmbr$ years,C0439234
$nmbr$ yr km rate,C0871208;C1521828
region north america,C0017446;C0028405;C0205147
saxagliptin,C1611934
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
atherosclerosis,C0003850;C0004153
prior heart failure,C0018801;C0018802;C4554158
established,C0443211;C1272684
duration of diabetes,C0449238;C2926735
multiple risk factors,C0035648;C1553898
baseline glycated,C0168634;C1442488;C3666909
a $nmbr$ years,C0439234
hemoglobin,C0019046
region north america,C0017446;C0028405;C0205147
baseline insulin,C0021641;C1533581;C1579433;C3714501
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
baseline sulfonylurea yes,C1549445;C1705108;C1710701
prior heart failure,C0018801;C0018802;C4554158
baseline metformin,C0168634;C0025598;C1442488
duration of diabetes,C0449238;C2926735
thiazolidinedione,C0289779;C1257987;C3537039
baseline glycated,C0168634;C1442488;C3666909
baseline microalbumin,C0201838;C2362049
hemoglobin,C0019046
creatinine ratio,C0456603;C1547037
baseline insulin,C0021641;C1533581;C1579433;C3714501
_ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
baseline sulfonylurea yes,C1549445;C1705108;C1710701
p vaiue interaction,C0369773;C1704675;C2603361
baseline metformin,C0168634;C0025598;C1442488
saxagiiptin,
thiazolidinedione,C0289779;C1257987;C3537039
piacebo,
baseline microalbumin,C0201838;C2362049
non hishnic,C1518422
creatinine ratio,C0456603;C1547037
$nmbr$ $nmbr$ to $nmbr$ i iot,C0021966;C0006196;C0221138
_ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
prior hypertension,C0020538;C1963138
p vaiue interaction,C0369773;C1704675;C2603361
$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
saxagiiptin,
baseiine aspirin,C0004057
piacebo,
baseiine statin,C0360714
non hishnic,C1518422
baseiine acei arb,C3888198
$nmbr$ $nmbr$ to $nmbr$ i iot,C0021966;C0006196;C0221138
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$ t,C2603360
prior hypertension,C0020538;C1963138
baseiine ccb,C0006684
$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
baseiine diuretic,C0012798
baseiine aspirin,C0004057
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
baseiine statin,C0360714
overaii,
baseiine acei arb,C3888198
alogliptin n $nmbr$,C1958126
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$ t,C2603360
race or ethnic group no t,C0034510;C1706779;C3853635;C0015031;C1879937;C2603360
baseiine ccb,C0006684
region of world no,C0017446;C0205147
baseiine diuretic,C0012798
united states and canada,C0041703;C0006823
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
western europe australia new zealand and middle east,C0027978;C0324547;C0026068
overaii,
central and south america and mexico,C0205099;C1879652;C0037713;C0025885
alogliptin n $nmbr$,C1958126
eastern europe and africa,C0015177;C0001737
race or ethnic group no t,C0034510;C1706779;C3853635;C0015031;C1879937;C2603360
asia and pacific islands,C0003980;C0030168
region of world no,C0017446;C0205147
cardiovascular risk factors and history no,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
united states and canada,C0041703;C0006823
estimated glomerular filtration rate^,C3811844
western europe australia new zealand and middle east,C0027978;C0324547;C0026068
median ml min $nmbr$ $nmbr$ m $nmbr$,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
central and south america and mexico,C0205099;C1879652;C0037713;C0025885
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ no,C0439445
eastern europe and africa,C0015177;C0001737
index acs no,C0742343;C4318612
asia and pacific islands,C0003980;C0030168
unstable angina requiring hospitalization,C0002965;C0019993
cardiovascular risk factors and history no,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
time between index acs and randomization days,C0040223;C3541383;C0034656;C0439228
estimated glomerular filtration rate^,C3811844
alogliptin,C1958126
median ml min $nmbr$ $nmbr$ m $nmbr$,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
hazard,C0598697
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ no,C0439445
with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
index acs no,C0742343;C4318612
overall treatment effect,C0282416;C1518681;C1561607
unstable angina requiring hospitalization,C0002965;C0019993
index event,C0441471;C4019010
time between index acs and randomization days,C0040223;C3541383;C0034656;C0439228
history of ml before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
alogliptin,C1958126
history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0010055;C0441471;C4019010
hazard,C0598697
history of chf before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline bmi,C0168634;C0578022;C1442488
overall treatment effect,C0282416;C1518681;C1561607
$nmbr$ and $nmbr$ years,C0439234
index event,C0441471;C4019010
baseline glycemic control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
history of ml before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
hba $nmbr$ c $nmbr$ level,C0441889;C0456079;C1547707;C2946261
history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0010055;C0441471;C4019010
insulin use at baseline,C0240016;C0168634;C1442488
history of chf before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
biguanide use at baseline,C0042153;C0457083;C1947944
baseline bmi,C0168634;C0578022;C1442488
thiazolidinedione use at baseline,C0042153;C0457083;C1947944
$nmbr$ and $nmbr$ years,C0439234
sulfonylurea use at baseline,C0042153;C0457083;C1947944
baseline glycemic control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
united states canada,C0041703;C0006823
hba $nmbr$ c $nmbr$ level,C0441889;C0456079;C1547707;C2946261
mexico central south america,C0007674
insulin use at baseline,C0240016;C0168634;C1442488
western europe australia new zealand middle east,C0043128;C0026068
biguanide use at baseline,C0042153;C0457083;C1947944
eastern europe africa,C0001741
thiazolidinedione use at baseline,C0042153;C0457083;C1947944
renal function,C0232804
sulfonylurea use at baseline,C0042153;C0457083;C1947944
normalfunction or mild impairment,C0221099;C0684336
united states canada,C0041703;C0006823
placebo mtx,C0025677;C1417487
mexico central south america,C0007674
golimumab $nmbr$ mg kg mtx,C0025677;C1417487
western europe australia new zealand middle east,C0043128;C0026068
randomised patients n,C0030705
eastern europe africa,C0001741
median iq range,C1514721;C2348147;C3542016
renal function,C0232804
total vdh s score $nmbr$ $nmbr$ n,C2964552
normalfunction or mild impairment,C0221099;C0684336
erosion score $nmbr$ $nmbr$,C0449820;C4050231
placebo mtx,C0025677;C1417487
jsn score $nmbr$ $nmbr$,C0449820;C4050231
golimumab $nmbr$ mg kg mtx,C0025677;C1417487
crp normal,C0205307;C0231683;C0439166;C2347086;C4553972
randomised patients n,C0030705
cdai $nmbr$ $nmbr$,C0683448;C1413248;C3273706
median iq range,C1514721;C2348147;C3542016
disease activity n,C1292728
total vdh s score $nmbr$ $nmbr$ n,C2964552
low $nmbr$ $nmbr$ and,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
erosion score $nmbr$ $nmbr$,C0449820;C4050231
moderate $nmbr$ and,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
jsn score $nmbr$ $nmbr$,C0449820;C4050231
high $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
crp normal,C0205307;C0231683;C0439166;C2347086;C4553972
sdai $nmbr$ $nmbr$,C3871128
cdai $nmbr$ $nmbr$,C0683448;C1413248;C3273706
haq di $nmbr$ $nmbr$,C3826998;C4321476
disease activity n,C1292728
direction of hr,C0449738
low $nmbr$ $nmbr$ and,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
all subjects,C0681850;C1550501;C1706203;C2349001;C2697811
moderate $nmbr$ and,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
right,C0205090;C0444532
high $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
centre,C0205099;C3810851
sdai $nmbr$ $nmbr$,C3871128
causaslan,
haq di $nmbr$ $nmbr$,C3826998;C4321476
left,C0205091;C0443246;C1552822
direction of hr,C0449738
middle,C0444598;C0549183;C1552826
all subjects,C0681850;C1550501;C1706203;C2349001;C2697811
right,C0205090;C0444532
figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both,C0242492;C4554402;C0557651;C2603343;C0205195;C0947630;C0008107;C3259781;C0026175;C0338297;C0032042;C0031962;C1696465;C1706408;C0030705;C3272598;C1448177;C1456820;C1522669;C0008976;C0205171;C0439044;C0679994
centre,C0205099;C3810851
predictive factor,C0683956
causaslan,
age yr range,C1514721;C2348147;C3542016
left,C0205091;C0443246;C1552822
bmi no,C0578022
middle,C0444598;C0549183;C1552826
lifestyle behaviors,C0004927;C0677505
alcohol consumption no,C0001948
figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both,C0242492;C4554402;C0557651;C2603343;C0205195;C0947630;C0008107;C3259781;C0026175;C0338297;C0032042;C0031962;C1696465;C1706408;C0030705;C3272598;C1448177;C1456820;C1522669;C0008976;C0205171;C0439044;C0679994
comorbidities concomitant medications,C0013227;C0802604;C2598133;C4284232
predictive factor,C0683956
comorbidities no,C0009488
age yr range,C1514721;C2348147;C3542016
cardiovascular disorder,C0007222
bmi no,C0578022
cardiac disorder,C0018799
lifestyle behaviors,C0004927;C0677505
no antihypertensive medication,C0003364
alcohol consumption no,C0001948
one antihypertensive medication,C0205447;C0003364
comorbidities concomitant medications,C0013227;C0802604;C2598133;C4284232
two or more antihypertensive medications,C0205448;C0003364
comorbidities no,C0009488
statin s,C0360714
cardiovascular disorder,C0007222
ed characteristics,C3538926;C1521970
cardiac disorder,C0018799
ed $nmbr$ yr no,C3538926;C0439234
no antihypertensive medication,C0003364
ed etiology no,C0015127;C1314792;C1524003
one antihypertensive medication,C0205447;C0003364
ed severity no a,C0439793;C0522510
two or more antihypertensive medications,C0205448;C0003364
mild iief ef $nmbr$ $nmbr$,C2945599;C3641331
statin s,C0360714
moderate iief ef $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
ed characteristics,C3538926;C1521970
severe iief ef,C0205082;C3641331;C4050465;C4050466
ed $nmbr$ yr no,C3538926;C0439234
previous pde $nmbr$ i therapy no,C0039798;C0087111;C1363945
ed etiology no,C0015127;C1314792;C1524003
tadalafil $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ed severity no a,C0439793;C0522510
tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mild iief ef $nmbr$ $nmbr$,C2945599;C3641331
ls mean change,C0392747;C0443172;C1705241;C4319952
moderate iief ef $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
pbo adjusted ls mean change,C0392747;C0443172;C1705241;C4319952
severe iief ef,C0205082;C3641331;C4050465;C4050466
overally,
previous pde $nmbr$ i therapy no,C0039798;C0087111;C1363945
alcohol consumption at baseline,C0001948;C0168634;C1442488
tadalafil $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
smoker at baseline,C0337664;C0168634;C1442488
tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
antihypertensive use,C0042153;C0457083;C1947944
ls mean change,C0392747;C0443172;C1705241;C4319952
none at baseline,C0168634;C1442488
pbo adjusted ls mean change,C0392747;C0443172;C1705241;C4319952
one at baseline,C0205447;C0168634;C1442488
overally,
two or more at baseline,C0205448;C0168634;C1442488
alcohol consumption at baseline,C0001948;C0168634;C1442488
statin use,C0042153;C0457083;C1947944
smoker at baseline,C0337664;C0168634;C1442488
ed duration,C0449238;C2926735
antihypertensive use,C0042153;C0457083;C1947944
none at baseline,C0168634;C1442488
figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
one at baseline,C0205447;C0168634;C1442488
figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
two or more at baseline,C0205448;C0168634;C1442488
risedronate n $nmbr$,C0246719
statin use,C0042153;C0457083;C1947944
denosumab n $nmbr$,C1690432
ed duration,C0449238;C2926735
history of osteoporotic fracture n a,C4075937
figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
serum $nmbr$ hydroxyvitamin d ng ml,C0020337;C0439275
duration of prior alendronate use months,C1881378;C2826775
figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
$nmbr$ tob $nmbr$ months n,C1420851;C0439231
risedronate n $nmbr$,C0246719
$nmbr$ months n,C0439231
denosumab n $nmbr$,C1690432
time since prior alendronate use n,C1279919;C2362777
history of osteoporotic fracture n a,C4075937
$nmbr$ tob $nmbr$ months,C1420851;C0439231
serum $nmbr$ hydroxyvitamin d ng ml,C0020337;C0439275
never took alendronate,C2003901;C1515187;C0102118
duration of prior alendronate use months,C1881378;C2826775
still taking alendronate at study entry n,C0102118;C0557651;C2603343
$nmbr$ tob $nmbr$ months n,C1420851;C0439231
serum ctx $nmbr$ ng ml median iqr,C0010377;C0439275;C0631180;C3539598
$nmbr$ months n,C0439231
lower tertile b $nmbr$ $nmbr$,C0441994;C1548802;C2003888
time since prior alendronate use n,C1279919;C2362777
middle tertile $nmbr$ $nmbr$ to b $nmbr$ $nmbr$,C0444598;C0549183;C1552826
$nmbr$ tob $nmbr$ months,C1420851;C0439231
upper tertile $nmbr$ $nmbr$,C1282910
never took alendronate,C2003901;C1515187;C0102118
high dose edoxaban n $nmbr$,C0444956;C2975435
still taking alendronate at study entry n,C0102118;C0557651;C2603343
low dose edoxaban n $nmbr$,C0445550;C1708745
serum ctx $nmbr$ ng ml median iqr,C0010377;C0439275;C0631180;C3539598
asia pacific region and south africa,C0017446;C0205147;C0037712
lower tertile b $nmbr$ $nmbr$,C0441994;C1548802;C2003888
paroxysmal atrial fibrillation no,C0235480;C4050122
middle tertile $nmbr$ $nmbr$ to b $nmbr$ $nmbr$,C0444598;C0549183;C1552826
qualifying risk factor no,C1514624;C0035648
upper tertile $nmbr$ $nmbr$,C1282910
prior stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
high dose edoxaban n $nmbr$,C0444956;C2975435
hypertension requiring treatment,C0020538;C1963138;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
low dose edoxaban n $nmbr$,C0445550;C1708745
$nmbr$ $nmbr$ no,
asia pacific region and south africa,C0017446;C0205147;C0037712
dose reduction at randomization no i,C0301630;C0392756;C1293152;C4551656;C0021966;C0221138
paroxysmal atrial fibrillation no,C0235480;C4050122
use of verapamil or quinidine,C1524063;C0042523;C0034414
qualifying risk factor no,C1514624;C0035648
previous use of vitamin k antagonist for $nmbr$ days no,C1524063;C1096489;C2267235;C0439228
prior stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
medication at time of randomization no,C0013227;C3244316;C4284232
hypertension requiring treatment,C0020538;C1963138;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
digoxin or digitalis preparation,C0012265;C0304520
$nmbr$ $nmbr$ no,
hazard ratio with high $nmbr$ cl,C2985465;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
dose reduction at randomization no i,C0301630;C0392756;C1293152;C4551656;C0021966;C0221138
hazard ratio with low $nmbr$ cl,C2985465;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
use of verapamil or quinidine,C1524063;C0042523;C0034414
high dose edoxaban vs warfarin,C0444956;C2975435;C0043031
previous use of vitamin k antagonist for $nmbr$ days no,C1524063;C1096489;C2267235;C0439228
low dose edoxaban vs warfarin,C0445550;C2975435;C1708745;C0043031
medication at time of randomization no,C0013227;C3244316;C4284232
hale,
digoxin or digitalis preparation,C0012265;C0304520
af type,C0332307;C1547052
hazard ratio with high $nmbr$ cl,C2985465;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
prior stroke or tza,C0038454;C4554100;C0039298
hazard ratio with low $nmbr$ cl,C2985465;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
$nmbr$ p $nmbr$,C0369773;C2603361
high dose edoxaban vs warfarin,C0444956;C2975435;C0043031
congestive heart,C0742742;C0018787
low dose edoxaban vs warfarin,C0445550;C2975435;C1708745;C0043031
failure,C0231174;C0680095
hale,
cha $nmbr$ s $nmbr$ score,C1420648;C0449820;C4050231
af type,C0332307;C1547052
dose adjusted,C0178602;C0869039;C1114758;C0456081
prior stroke or tza,C0038454;C4554100;C0039298
vka naxve,
$nmbr$ p $nmbr$,C0369773;C2603361
amiodarone use at baseline,C0042153;C0457083;C1947944
congestive heart,C0742742;C0018787
center level ttr,C0032923;C1421224
failure,C0231174;C0680095
amiodarone ote at baseline,C0002598;C0168634;C1442488
cha $nmbr$ s $nmbr$ score,C1420648;C0449820;C4050231
$nmbr$ $nmbr$ ^,
dose adjusted,C0178602;C0869039;C1114758;C0456081
ff $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
vka naxve,
ff vi $nmbr$ $nmbr$ ig n $nmbr$,C0205999;C0021027;C0305052;C0360506
amiodarone use at baseline,C0042153;C0457083;C1947944
never smoked n,C2003901;C0037366;C0439994;C1881674
center level ttr,C0032923;C1421224
former smoker n,C0337671
amiodarone ote at baseline,C0002598;C0168634;C1442488
number of exacerbations in last $nmbr$ months,C0237753;C0449788;C0439231
$nmbr$ $nmbr$ ^,
duration of asthma years,C0449238;C2926735
ff $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
screening prebronchodilator fev $nmbr$ l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
ff vi $nmbr$ $nmbr$ ig n $nmbr$,C0205999;C0021027;C0305052;C0360506
screening predicted fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
never smoked n,C2003901;C0037366;C0439994;C1881674
screening reversibility fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
former smoker n,C0337671
screening absolute reversibility fev $nmbr$ ml,C0439526;C1705224;C3887665
number of exacerbations in last $nmbr$ months,C0237753;C0449788;C0439231
baseline acq $nmbr$ score,C0449820;C4050231
duration of asthma years,C0449238;C2926735
percentage of patients using ics or ics laba on entry,C0439165;C1549488;C1561533;C1524063;C0815320;C4551720;C1705654
screening prebronchodilator fev $nmbr$ l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
ics only,C0815320;C4551720
screening predicted fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
ics laba,C0815320;C4551720
screening reversibility fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
ff $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
screening absolute reversibility fev $nmbr$ ml,C0439526;C1705224;C3887665
ff vi $nmbr$ $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
baseline acq $nmbr$ score,C0449820;C4050231
total n $nmbr$ $nmbr$,C0439175;C0439810
percentage of patients using ics or ics laba on entry,C0439165;C1549488;C1561533;C1524063;C0815320;C4551720;C1705654
african american,C0085756
ics only,C0815320;C4551720
russia,C0035970
ics laba,C0815320;C4551720
ukraine,C0041580
ff $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
germany,C0017480
ff vi $nmbr$ $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
argentina,C0003761;C1504311
total n $nmbr$ $nmbr$,C0439175;C0439810
poland,C0032356
african american,C0085756
philippines,C0031529
russia,C0035970
romania,C0035826
ukraine,C0041580
japan,C0022341
germany,C0017480
australia,C0004340
argentina,C0003761;C1504311
baseline fev l,C0168634;C1442488
poland,C0032356
f,C0016327
philippines,C0031529
grouped region,C0017446;C0205147
romania,C0035826
australasia,C0282279;C1257882
japan,C0022341
participants no,C0679646
australia,C0004340
gi bleed,C1708130;C0019080;C3539617;C4050121
baseline fev l,C0168634;C1442488
no gi bleed,C1708130;C0019080;C3539617;C4050121
f,C0016327
participants randomized,C0679646;C0034656;C3815594
grouped region,C0017446;C0205147
no a,
australasia,C0282279;C1257882
black non black,C0005680;C0027567;C0085756;C0439541
participants no,C0679646
hispanic non hispanic,C0086409;C1518422
gi bleed,C1708130;C0019080;C3539617;C4050121
women taking estrogen,C0014939;C2936882;C4542544
no gi bleed,C1708130;C0019080;C3539617;C4050121
hdl mean sd mg dl,C0444504;C0439269;C2347634;C2348143
participants randomized,C0679646;C0034656;C3815594
diabetes classificationa,C0011847;C0011849
no a,
nondiabetes,
black non black,C0005680;C0027567;C0085756;C0439541
mean sd mg kg $nmbr$,C0444504;C0439272;C2347634;C2348143
hispanic non hispanic,C0086409;C1518422
yes no,C1512698
women taking estrogen,C0014939;C2936882;C4542544
history mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
hdl mean sd mg dl,C0444504;C0439269;C2347634;C2348143
history coronary,C0019664;C0018787;C0019665;C0262512;C0262926;C1705255;C2004062
diabetes classificationa,C0011847;C0011849
other atherosclerotic,C0333482
nondiabetes,
cvd,C0007222
mean sd mg kg $nmbr$,C0444504;C0439272;C2347634;C2348143
lvh by minnesota code,C0149721;C0009219;C0805701;C3889831
yes no,C1512698
unadjusted hr $nmbr$ ci a,C0008107;C3259781
history mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
lisinopril vs chlorthalidone,C0065374;C0008294
history coronary,C0019664;C0018787;C0019665;C0262512;C0262926;C1705255;C2004062
lisinopril vs amlodipineb,C0065374
other atherosclerotic,C0333482
aspirin at baseline,C0004057;C0168634;C1442488
cvd,C0007222
no aspirin at baseline,C0004057;C0168634;C1442488
lvh by minnesota code,C0149721;C0009219;C0805701;C3889831
qva $nmbr$ $nmbr$ pg once daily n $nmbr$,C0030827;C0072225;C1266240;C0332173
unadjusted hr $nmbr$ ci a,C0008107;C3259781
sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$,C0030827;C0585361;C0072225;C1266240
lisinopril vs chlorthalidone,C0065374;C0008294
duration of copd years,C0449238;C2926735
lisinopril vs amlodipineb,C0065374
copd severity n,C0024117;C0439793;C0522510;C1412502;C3714496
aspirin at baseline,C0004057;C0168634;C1442488
ics users at baseline,C1706077;C0168634;C1442488
no aspirin at baseline,C0004057;C0168634;C1442488
smoking history r,C0205090;C0684010;C2603358
qva $nmbr$ $nmbr$ pg once daily n $nmbr$,C0030827;C0072225;C1266240;C0332173
ex smokers,C0337671;C4555205
sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$,C0030827;C0585361;C0072225;C1266240
estimated number of pack years,C0237753;C0449788
duration of copd years,C0449238;C2926735
copd exacerbation history in the previous year n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
copd severity n,C0024117;C0439793;C0522510;C1412502;C3714496
pre bronchodilator fev l,C2599602;C3714541
ics users at baseline,C1706077;C0168634;C1442488
post bronchodilator fev l,C2599594;C3714541
smoking history r,C0205090;C0684010;C2603358
pre bronchodilator fev predicted,C2599602;C3714541;C0681842;C1882327
ex smokers,C0337671;C4555205
post bronchodilator fev predicted,C2599594;C3714541;C0681842;C1882327
estimated number of pack years,C0237753;C0449788
post bronchodilator fev reversibility,C2599594;C0449261
copd exacerbation history in the previous year n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
post bronchodilator fev fvc,C2599594;C3714541
pre bronchodilator fev l,C2599602;C3714541
lsm $nmbr$ cl,C0596019
post bronchodilator fev l,C2599594;C3714541
overall qvai $nmbr$ sfc,C0282416;C4521536;C1561607
pre bronchodilator fev predicted,C2599602;C3714541;C0681842;C1882327
ex smokers qvai $nmbr$ sfc,C0337671;C4521536;C4555205
post bronchodilator fev predicted,C2599594;C3714541;C0681842;C1882327
$nmbr$ o o $nmbr$ o $nmbr$,C0483204
post bronchodilator fev reversibility,C2599594;C0449261
smokers qva $nmbr$ $nmbr$ fc,C0337664;C2983605
post bronchodilator fev fvc,C2599594;C3714541
moderate cord qva $nmbr$ sfc,C0205081;C4521536;C1881878;C4049705;C4049706;C4085643;C4321335
lsm $nmbr$ cl,C0596019
severe cord qvai $nmbr$ sfc,C0205082;C4521536;C4050465;C4050466
overall qvai $nmbr$ sfc,C0282416;C4521536;C1561607
o $nmbr$ o oo $nmbr$ o $nmbr$ o,C0483204
ex smokers qvai $nmbr$ sfc,C0337671;C4521536;C4555205
men qvai $nmbr$ sfc,C0025266;C4521536
$nmbr$ o o $nmbr$ o $nmbr$,C0483204
women qva $nmbr$ sfc,C0043210;C4521536
smokers qva $nmbr$ $nmbr$ fc,C0337664;C2983605
ics non users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
moderate cord qva $nmbr$ sfc,C0205081;C4521536;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ oo $nmbr$ o $nmbr$,
severe cord qvai $nmbr$ sfc,C0205082;C4521536;C4050465;C4050466
ics users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
o $nmbr$ o oo $nmbr$ o $nmbr$ o,C0483204
age $nmbr$ qvai $nmbr$ sfc,C0001779;C4521536
men qvai $nmbr$ sfc,C0025266;C4521536
$nmbr$ ml min n $nmbr$,C0439445
women qva $nmbr$ sfc,C0043210;C4521536
median $nmbr$ th $nmbr$ th percentile,C0039725;C1264641;C0039738;C1420718;C4282123;C4285344
ics non users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
af duration n,C0344434;C0449238;C2926735;C4049859
$nmbr$ oo $nmbr$ o $nmbr$,
$nmbr$ mo $nmbr$ y,C0026544;C0332177
ics users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
chads $nmbr$ risk factors n,C0035648;C1553898
age $nmbr$ qvai $nmbr$ sfc,C0001779;C4521536
previous stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
$nmbr$ ml min n $nmbr$,C0439445
chads $nmbr$ score n,C0449820;C4050231
median $nmbr$ th $nmbr$ th percentile,C0039725;C1264641;C0039738;C1420718;C4282123;C4285344
any anticoagulant,C0003280;C0848112;C3536711
af duration n,C0344434;C0449238;C2926735;C4049859
events n y,C0441471;C3541888
$nmbr$ mo $nmbr$ y,C0026544;C0332177
dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
chads $nmbr$ risk factors n,C0035648;C1553898
dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C2348066;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
outcome according to renal function level in ml min,C1274040;C0232804;C0439445
chads $nmbr$ score n,C0449820;C4050231
dabigatran $nmbr$ mg bid events n y,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
any anticoagulant,C0003280;C0848112;C3536711
warfarin events n y,C0043031;C0441471;C3541888
events n y,C0441471;C3541888
p value inter,C1709380;C0205103;C1548610
dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
life threatening bleed,C1546953;C0019080;C2826244;C3537125
dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C2348066;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
intracranial bleed,C0151699
outcome according to renal function level in ml min,C1274040;C0232804;C0439445
net clinical benefit,C1456447;C4684590;C3853572;C3887809;C3890893
dabigatran $nmbr$ mg bid events n y,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
czp $nmbr$ mg every $nmbr$ weeks n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
warfarin events n y,C0043031;C0441471;C3541888
arthritis characteristics,C0003864;C1521970;C4552845
p value inter,C1709380;C0205103;C1548610
crp median range mg literl,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
life threatening bleed,C1546953;C0019080;C2826244;C3537125
esr median range mm hour,C0439227;C0564385
intracranial bleed,C0151699
tender joint count range $nmbr$ $nmbr$ joints,C0451530;C1514721;C2348147;C3542016
net clinical benefit,C1456447;C4684590;C3853572;C3887809;C3890893
swollen joint count range $nmbr$ $nmbr$ joints,C0451521;C1514721;C2348147;C3542016
czp $nmbr$ mg every $nmbr$ weeks n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
modified total sharp score,C0392747;C2964552;C3889737
arthritis characteristics,C0003864;C1521970;C4552845
joint space narrowing score,C0449820;C4050231
crp median range mg literl,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
physician s assessment of disease activity vas mm,C0031831;C0804815;C1261322;C1516048
esr median range mm hour,C0439227;C0564385
enthesitis,C1282952
tender joint count range $nmbr$ $nmbr$ joints,C0451530;C1514721;C2348147;C3542016
lei $nmbr$,C0023401;C0428209
swollen joint count range $nmbr$ $nmbr$ joints,C0451521;C1514721;C2348147;C3542016
dactylitis,C0239161
modified total sharp score,C0392747;C2964552;C3889737
ldi $nmbr$,
joint space narrowing score,C0449820;C4050231
psoriasis characteristics,C0033860;C1521970
physician s assessment of disease activity vas mm,C0031831;C0804815;C1261322;C1516048
$nmbr$ bsa psoriasis no,C0033860
enthesitis,C1282952
pasi median range,C1514721;C2348147;C3542016
lei $nmbr$,C0023401;C0428209
nail involvement,C0027342;C1314939;C1432728;C3538766
dactylitis,C0239161
mnapsi,
ldi $nmbr$,
patient reported outcomes,C2987124
psoriasis characteristics,C0033860;C1521970
patient assessment of disease activity mm,C0679830;C1292728
$nmbr$ bsa psoriasis no,C0033860
patient assessment of arthritis pain mm,C0679830
pasi median range,C1514721;C2348147;C3542016
fatigue range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
nail involvement,C0027342;C1314939;C1432728;C3538766
haq di range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
mnapsi,
sf $nmbr$ pcs,C1864389;C1882368
patient reported outcomes,C2987124
sf $nmbr$ mcs,C0037712
patient assessment of disease activity mm,C0679830;C1292728
psaqol,
patient assessment of arthritis pain mm,C0679830
dlqi,C3899393
fatigue range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
dlqi patients with $nmbr$ bsa psoriasis,C0030705;C0033860
haq di range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
prior tnf inhibitor exposure no,C0274281;C0332157
sf $nmbr$ pcs,C1864389;C1882368
adalimumab,C1122087
sf $nmbr$ mcs,C0037712
etanercept,C0717758
psaqol,
no prior tnf inhibitor exposure,C0274281;C0332157
dlqi,C3899393
prior tnf inhibitor exposure,C0274281;C0332157
dlqi patients with $nmbr$ bsa psoriasis,C0030705;C0033860
czp combined arms n $nmbr$,C0054841;C0205195;C1861828;C1872109
prior tnf inhibitor exposure no,C0274281;C0332157
pain mm,C4330985;C4554674
adalimumab,C1122087
fatigue,C0015672;C3463815;C4050243;C4554645
etanercept,C0717758
haq di,C3826998;C4321476
no prior tnf inhibitor exposure,C0274281;C0332157
figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c,C1709707;C0681850;C1550501;C1706203;C2349001;C2697811;C1521840;C2986546;C1704788;C3539106;C0332167;C0442804;C3272283;C4050568;C4319571;C4321397;C0596269;C0205210;C0205195;C1947911;C3811910;C0332257;C1552866;C2700399
prior tnf inhibitor exposure,C0274281;C0332157
abatacept $nmbr$ $nmbr$ n $nmbr$,C1619966
czp combined arms n $nmbr$,C0054841;C0205195;C1861828;C1872109
class iv glomerulonephritis,C0441888;C0017658;C2698970
pain mm,C4330985;C4554674
duration of current flare median range months n $nmbr$ $nmbr$ $nmbr$,C0449238;C2926735
fatigue,C0015672;C3463815;C4050243;C4554645
baseline creatinine median range mg dl,C0010294;C0439269;C1561535
haq di,C3826998;C4321476
baseline upgr mg mmole n $nmbr$ $nmbr$ $nmbr$,C0567349;C2348885
figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c,C1709707;C0681850;C1550501;C1706203;C2349001;C2697811;C1521840;C2986546;C1704788;C3539106;C0332167;C0442804;C3272283;C4050568;C4319571;C4321397;C0596269;C0205210;C0205195;C1947911;C3811910;C0332257;C1552866;C2700399
baseline upgr $nmbr$ gm gm $nmbr$ mg mmole,C0567349;C2348885
abatacept $nmbr$ $nmbr$ n $nmbr$,C1619966
prestudy treatment status,C0749659
class iv glomerulonephritis,C0441888;C0017658;C2698970
naive no treatment for current flare,C2827774;C1517205;C3540542
duration of current flare median range months n $nmbr$ $nmbr$ $nmbr$,C0449238;C2926735
recent treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline creatinine median range mg dl,C0010294;C0439269;C1561535
inadequate response $nmbr$ months mmf ggs,C0205412;C0083765;C0209368;C3848524;C0439856
baseline upgr mg mmole n $nmbr$ $nmbr$ $nmbr$,C0567349;C2348885
baseline prednisone or oral prednisone equivalent daily dose,C0168634;C0032952;C1442488;C2348070
baseline upgr $nmbr$ gm gm $nmbr$ mg mmole,C0567349;C2348885
mean sd mg n $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prestudy treatment status,C0749659
goncomitant treatment with age inhibitors angiotensin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
naive no treatment for current flare,C2827774;C1517205;C3540542
receptor blockers,C0597357
recent treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
premature discontinuation,C0457454;C1444662;C4552847
inadequate response $nmbr$ months mmf ggs,C0205412;C0083765;C0209368;C3848524;C0439856
adverse event,C0877248
baseline prednisone or oral prednisone equivalent daily dose,C0168634;C0032952;C1442488;C2348070
lack of efficacy,C0235828
mean sd mg n $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
withdrew consent,C2349954;C1511481;C1554192;C2923685
goncomitant treatment with age inhibitors angiotensin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no longer met study criteria,C0428210;C0243161;C1550543;C4317104
receptor blockers,C0597357
poor compliance noncompliance,C0376405;C0457432
premature discontinuation,C0457454;C1444662;C4552847
pregnancy,C0032961
adverse event,C0877248
revive i,C0021966;C0221138
lack of efficacy,C0235828
revive ii,
withdrew consent,C2349954;C1511481;C1554192;C2923685
levosimendan n $nmbr$,C0246904
no longer met study criteria,C0428210;C0243161;C1550543;C4317104
lv ejection fraction,C0489482;C2700378
poor compliance noncompliance,C0376405;C0457432
pulmonary rales,C0034642
pregnancy,C0032961
basal only,C0205112
revive i,C0021966;C0221138
$nmbr$ $nmbr$ lung fields,C0225759
revive ii,
peripheral edema,C0085649
levosimendan n $nmbr$,C0246904
legs only,C1140621
lv ejection fraction,C0489482;C2700378
sacral and or lumbar,C0036037;C0024090
pulmonary rales,C0034642
diastolic bp mm hg,C0428883;C0439475
basal only,C0205112
iv vasodilator,C0042402;C3537240
$nmbr$ $nmbr$ lung fields,C0225759
iv inotropic drug,C1971835
peripheral edema,C0085649
both iv vasodilator and inotrope,C0042402;C3537240
legs only,C1140621
figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization,C2985465;C0015127;C1524003;C0032042;C1696465;C1706408;C0005811;C0034656
sacral and or lumbar,C0036037;C0024090
table $nmbr$ selected baseline characteristics of the study patients,C4684572
diastolic bp mm hg,C0428883;C0439475
spironolactone n $nmbr$,C0037982
iv vasodilator,C0042402;C3537240
nyha functional classification no,C1275491;C0205245;C0542341;C2700217
iv inotropic drug,C1971835
eligibility stratum,C0013893;C1548635
both iv vasodilator and inotrope,C0042402;C3537240
hospitalization in previous year with management of heart failure as major component no,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539;C0449432;C1705248
figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization,C2985465;C0015127;C1524003;C0032042;C1696465;C1706408;C0005811;C0034656
elevated natriuretic peptides in previous $nmbr$ days no,C1144709;C0205156;C1552607
table $nmbr$ selected baseline characteristics of the study patients,C4684572
bnp pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
spironolactone n $nmbr$,C0037982
current smoker no blood pressure mm hg,C3173209;C3241966;C0005823;C0439475;C1271104;C1272641
nyha functional classification no,C1275491;C0205245;C0542341;C2700217
eligibility stratum,C0013893;C1548635
serum potassium mmol liter,C0302353;C0475211;C0543465
region of enrollment no,C0017446;C0205147
hospitalization in previous year with management of heart failure as major component no,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539;C0449432;C1705248
russia and georgia,C0035970;C0017452;C0017454
elevated natriuretic peptides in previous $nmbr$ days no,C1144709;C0205156;C1552607
quartiles of fgf $nmbr$ ru ml,C2828255;C0016026;C0919505
bnp pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
p value for trend,C1709380;C1521798;C4554533
current smoker no blood pressure mm hg,C3173209;C3241966;C0005823;C0439475;C1271104;C1272641
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
serum potassium mmol liter,C0302353;C0475211;C0543465
$nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
region of enrollment no,C0017446;C0205147
current tobacco use,C0040335;C0543414;C0841002;C3853727
russia and georgia,C0035970;C0017452;C0017454
prior pci or cabg,C0332152;C4049621;C2826257;C0010055
quartiles of fgf $nmbr$ ru ml,C2828255;C0016026;C0919505
apo a $nmbr$ mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
p value for trend,C1709380;C1521798;C4554533
$nmbr$ year km,C0439234;C3887676;C0439508
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
t $nmbr$ $nmbr$,C2603360
$nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
hr $nmbr$ $nmbr$,
current tobacco use,C0040335;C0543414;C0841002;C3853727
$nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0008107;C3259781
prior pci or cabg,C0332152;C4049621;C2826257;C0010055
risk categories,C0035647;C0683312;C4552904
apo a $nmbr$ mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
fgf $nmbr$ low egfr $nmbr$,C1739039;C3811844;C3812682
$nmbr$ year km,C0439234;C3887676;C0439508
fgf $nmbr$ low egfr,C1739039;C3811844;C3812682
t $nmbr$ $nmbr$,C2603360
fgf $nmbr$ high egfr $nmbr$,C1739039;C3811844;C3812682
hr $nmbr$ $nmbr$,
fgf $nmbr$ high egfr,C1739039;C3811844;C3812682
$nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0008107;C3259781
pinteraction $nmbr$ $nmbr$,
risk categories,C0035647;C0683312;C4552904
fgf $nmbr$ low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
fgf $nmbr$ low egfr $nmbr$,C1739039;C3811844;C3812682
fgf $nmbr$ low $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
fgf $nmbr$ low egfr,C1739039;C3811844;C3812682
fgf $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
fgf $nmbr$ high egfr $nmbr$,C1739039;C3811844;C3812682
fgf $nmbr$ high $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
fgf $nmbr$ high egfr,C1739039;C3811844;C3812682
p interaction $nmbr$ $nmbr$,C0369773;C1704675;C2603361
pinteraction $nmbr$ $nmbr$,
$nmbr$ mw distance m,C0024548;C0012751;C0026385;C0556966
fgf $nmbr$ low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
randomized treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fgf $nmbr$ low $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
nonwhite race,C0034510;C1706779;C3853635
fgf $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
weight lbs,C0439219;C3161851
fgf $nmbr$ high $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
ischemic hf etiology,C0015127;C1314792;C1524003
p interaction $nmbr$ $nmbr$,C0369773;C1704675;C2603361
pulmonary disease,C0024115
$nmbr$ mw distance m,C0024548;C0012751;C0026385;C0556966
ace i or arb,C0021966;C0221138;C3888198
randomized treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ yr km mortality rate,C0026565;C0205848
nonwhite race,C0034510;C1706779;C3853635
icd vs placebo,C0021122;C0032042;C1696465;C1706408
weight lbs,C0439219;C3161851
amiodarone vs placebo,C0002598;C0032042;C1696465;C1706408
ischemic hf etiology,C0015127;C1314792;C1524003
patients $nmbr$ y,C0030705
pulmonary disease,C0024115
pbo n $nmbr$,C0031962
ace i or arb,C0021966;C0221138;C3888198
duration of diabetes y,C0449238;C2926735
$nmbr$ yr km mortality rate,C0026565;C0205848
patients with cardiac disorders n,C0741926
icd vs placebo,C0021122;C0032042;C1696465;C1706408
patients on antihypertensive medications n,C0030705;C0003364
amiodarone vs placebo,C0002598;C0032042;C1696465;C1706408
number of patients randomized,C2360800;C0034656;C3815594
patients $nmbr$ y,C0030705
number of swollen joints $nmbr$ $nmbr$,C0449813
pbo n $nmbr$,C0031962
number of tender joints $nmbr$ $nmbr$,C0449813
duration of diabetes y,C0449238;C2926735
psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$,C0018563;C0016504;C0347981;C1552914
patients with cardiac disorders n,C0741926
all patients n,C0030705
patients on antihypertensive medications n,C0030705;C0003364
patients receiving mtx n,C0030705;C1514756;C0025677;C1417487
number of patients randomized,C2360800;C0034656;C3815594
patients not receiving mtx n,C0030705;C1518422;C1514756;C0025677;C1417487
number of swollen joints $nmbr$ $nmbr$,C0449813
patients with dactylitis,C0030705;C0239161
number of tender joints $nmbr$ $nmbr$,C0449813
dactylitis score $nmbr$ $nmbr$,C0449820;C4050231
psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$,C0018563;C0016504;C0347981;C1552914
patients with enthesitis,C0030705;C1282952
all patients n,C0030705
psa modified mases score $nmbr$ $nmbr$,C0449820;C4050231
patients receiving mtx n,C0030705;C1514756;C0025677;C1417487
patients with $nmbr$ bsa,C0030705
patients not receiving mtx n,C0030705;C1518422;C1514756;C0025677;C1417487
bsa,
patients with dactylitis,C0030705;C0239161
pasi score $nmbr$ $nmbr$,C0449820;C4050231
dactylitis score $nmbr$ $nmbr$,C0449820;C4050231
haq di score $nmbr$ $nmbr$,C0449820;C4050231
patients with enthesitis,C0030705;C1282952
patients with fingernail involvement,C0522476
psa modified mases score $nmbr$ $nmbr$,C0449820;C4050231
napsi score $nmbr$ $nmbr$ of target fingernail,C0449820;C4050231;C1521840;C0222001;C2986546
patients with $nmbr$ bsa,C0030705
sf $nmbr$ summary scores,C0037712;C0449820
bsa,
pcs score,C0449820;C4050231
pasi score $nmbr$ $nmbr$,C0449820;C4050231
mcs score,C0449820;C4050231
haq di score $nmbr$ $nmbr$,C0449820;C4050231
patients receiving mtx,C0030705;C1514756;C0025677;C1417487
patients with fingernail involvement,C0522476
eplerenone n $nmbr$,C0961485
napsi score $nmbr$ $nmbr$ of target fingernail,C0449820;C4050231;C1521840;C0222001;C2986546
race no b,C0034510;C1706779;C3853635
sf $nmbr$ summary scores,C0037712;C0449820
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C0017654;C0439445;C1424601;C0005902
pcs score,C0449820;C4050231
serum potassium mmol l,C0302353;C1532563;C0543465
mcs score,C0449820;C4050231
anterior mi,C3536746
patients receiving mtx,C0030705;C1514756;C0025677;C1417487
history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
eplerenone n $nmbr$,C0961485
concomitant treatments at randomization,C0087111;C0034656
race no b,C0034510;C1706779;C3853635
acetylsalicylic acid,C0004057
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C0017654;C0439445;C1424601;C0005902
p $nmbr$ y $nmbr$ antagonists,C0369773;C0243076;C2603361
serum potassium mmol l,C0302353;C1532563;C0543465
heparins and fondaparinux,C0019134;C1098510
anterior mi,C3536746
gp iib iiia inhibitors,C0016011;C0243077
history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fibrinolytics,C0040044
concomitant treatments at randomization,C0087111;C0034656
pci thrombolysis at randomization,C0520997;C0034656
acetylsalicylic acid,C0004057
thrombolysis,C0520997
p $nmbr$ y $nmbr$ antagonists,C0369773;C0243076;C2603361
no reperfusion,C0035124;C0684253
heparins and fondaparinux,C0019134;C1098510
subgroup level,C0441889;C0456079;C1547707;C2946261
gp iib iiia inhibitors,C0016011;C0243077
n participants,C0369718;C0679646;C0441922
fibrinolytics,C0040044
age group $nmbr$,C0027362;C2348001
pci thrombolysis at randomization,C0520997;C0034656
systolic blood pressure median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
thrombolysis,C0520997
pulse pressure median $nmbr$ $nmbr$ ],C0549183;C0876920;C2347635;C2348144;C2939193
no reperfusion,C0035124;C0684253
heart rate median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
subgroup level,C0441889;C0456079;C1547707;C2946261
prior bb plus acbi plus arb use,C0004739;C0332297;C0042153;C0457083;C1947944
n participants,C0369718;C0679646;C0441922
prior acbi or arb use,C0332152;C2826257;C0042153;C0457083;C1947944
age group $nmbr$,C0027362;C2348001
history of atrial fibrillation,C0729790
systolic blood pressure median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
history of diabetes mellitus,C0455488
pulse pressure median $nmbr$ $nmbr$ ],C0549183;C0876920;C2347635;C2348144;C2939193
anterior or non anterior ml,C0205094;C0439526;C1705224;C3887665
heart rate median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
non anterior,C1518422;C0205094
prior bb plus acbi plus arb use,C0004739;C0332297;C0042153;C0457083;C1947944
previous ml,C0439526;C1705224;C3887665
prior acbi or arb use,C0332152;C2826257;C0042153;C0457083;C1947944
acute reperfusion,C0035124;C0684253
history of atrial fibrillation,C0729790
$nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
history of diabetes mellitus,C0455488
not perfused,C1518422;C1549542
anterior or non anterior ml,C0205094;C0439526;C1705224;C3887665
use of pci or thrombolysis within one day of randomization,C1524063;C4049621;C0520997;C3844320
non anterior,C1518422;C0205094
first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms,C0178602;C0033727;C0369286;C0441932;C0564385;C4528284;C0869039;C1114758;C0687676;C4086878;C1704687;C3469826
previous ml,C0439526;C1705224;C3887665
$nmbr$ $nmbr$ hours,C0439227
acute reperfusion,C0035124;C0684253
cardiac enzyates raised,C0018787;C1522601;C0442818
$nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig,C2986535;C0205199;C1547335;C0961485;C0032042;C1696465;C1706408
not perfused,C1518422;C1549542
zoledronic acid n $nmbr$,C0257685
use of pci or thrombolysis within one day of randomization,C1524063;C4049621;C0520997;C3844320
age groups n,C0441848
first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms,C0178602;C0033727;C0369286;C0441932;C0564385;C4528284;C0869039;C1114758;C0687676;C4086878;C1704687;C3469826
baseline bmi kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ hours,C0439227
baseline t score at femoral neck n,C0449820;C4050231
cardiac enzyates raised,C0018787;C1522601;C0442818
entry hip fracture location n,C3260017
figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig,C2986535;C0205199;C1547335;C0961485;C0032042;C1696465;C1706408
intertrochanteric,C0745355
zoledronic acid n $nmbr$,C0257685
subtrochanteric,
age groups n,C0441848
fracture history n,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline bmi kg m $nmbr$,C0022718;C0439209;C4054209
hip fracture only,C0019557;C0149531;C4552776
baseline t score at femoral neck n,C0449820;C4050231
hip other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725;C0016658
entry hip fracture location n,C3260017
hip $nmbr$ vertebral fractures,C0019557
intertrochanteric,C0745355
hip nonvertebral vertebral,C0019552;C0549207;C0022122;C1505163;C3538851;C4284725
subtrochanteric,
fractures,C0016658
fracture history n,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
time to first infusion from hip surgery days n,C0040223;C3541383;C0596706;C0439228
hip fracture only,C0019557;C0149531;C4552776
$nmbr$ weeks,C0439230
hip other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725;C0016658
baseline serum calcium level n,C0036785;C0728876
hip $nmbr$ vertebral fractures,C0019557
prior use of osteoporosis medications n,C1524063
hip nonvertebral vertebral,C0019552;C0549207;C0022122;C1505163;C3538851;C4284725
bone mineral density g cm $nmbr$ mean sd,C0005938;C2699239;C0177804
fractures,C0016658
eq $nmbr$ dprofile mobility n,C0205163;C0080078;C0425245;C0449580;C4318935;C0439185
time to first infusion from hip surgery days n,C0040223;C3541383;C0596706;C0439228
walking,C0080331;C4283795;C4321241;C4321242
$nmbr$ weeks,C0439230
some walking,C0080331;C4283795;C4321241;C4321242
baseline serum calcium level n,C0036785;C0728876
mental status baseline spmsq scores n,C0278060;C0168634;C1442488
prior use of osteoporosis medications n,C1524063
charlson comobility score n,C0449820;C4050231
bone mineral density g cm $nmbr$ mean sd,C0005938;C2699239;C0177804
between treatment comparison of percentage change from baseline in total hip bmd,C1299575;C1707455;C0168634;C1442488
eq $nmbr$ dprofile mobility n,C0205163;C0080078;C0425245;C0449580;C4318935;C0439185
month $nmbr$ subgroup x treatment interaction p value,C0039798;C1709380;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
walking,C0080331;C4283795;C4321241;C4321242
age groups,C0027362
some walking,C0080331;C4283795;C4321241;C4321242
t score at femoral neck,C3854607;C0015815
mental status baseline spmsq scores n,C0278060;C0168634;C1442488
$nmbr$ $nmbr$ and,
charlson comobility score n,C0449820;C4050231
hip fracture,C0019557;C0149531;C4552776
between treatment comparison of percentage change from baseline in total hip bmd,C1299575;C1707455;C0168634;C1442488
fracture,C0016658
month $nmbr$ subgroup x treatment interaction p value,C0039798;C1709380;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
age groups,C0027362
hip fracture $nmbr$,C0019557;C0149531;C4552776
t score at femoral neck,C3854607;C0015815
time to first infusion,C0040223;C3541383
$nmbr$ $nmbr$ and,
calcium level,C0201925;C0428302
hip fracture,C0019557;C0149531;C4552776
prior medications,C0013227;C0802604;C2598133;C4284232
fracture,C0016658
charlson,
history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mental status,C0278060
hip fracture $nmbr$,C0019557;C0149531;C4552776
eq $nmbr$ d mobility,C0205163;C0439185;C0080078;C0425245;C0449580;C4318935
time to first infusion,C0040223;C3541383
age mean sd years n,C1510829;C0444504;C2347634;C2348143
calcium level,C0201925;C0428302
education mean sd years,C0013621;C0439234;C0013622;C0013658;C0039401
prior medications,C0013227;C0802604;C2598133;C4284232
weight mean sd lbs,C0439219;C3161851
charlson,
antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
mental status,C0278060
st t wave n,C0036056;C0429103;C3272372
eq $nmbr$ d mobility,C0205163;C0439185;C0080078;C0425245;C0449580;C4318935
lvh by ecg or echo n,C0232306;C0058928;C1655045
age mean sd years n,C1510829;C0444504;C2347634;C2348143
visit $nmbr$ blood pressures,C0545082;C1272641;C1512346;C2826704
education mean sd years,C0013621;C0439234;C0013622;C0013658;C0039401
sbp mean sd mm hg,C0085805;C0439475
weight mean sd lbs,C0439219;C3161851
dbp mean sd mm hg,C0444504;C0439475;C2347634;C2348143
antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bp,C0037623;C1415692;C1708288;C4318478
st t wave n,C0036056;C0429103;C3272372
serum potassium mean sd mmol l,C0302353;C1532563;C0543465
lvh by ecg or echo n,C0232306;C0058928;C1655045
fasting serum glucose mean sd mg dl,C0202041;C0439269;C3534430
visit $nmbr$ blood pressures,C0545082;C1272641;C1512346;C2826704
serum cholesterol mean sd mg dl,C0587184;C0439269
sbp mean sd mm hg,C0085805;C0439475
treatment groups n,C0039798;C0441848;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
dbp mean sd mm hg,C0444504;C0439475;C2347634;C2348143
history of mi or stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
bp,C0037623;C1415692;C1708288;C4318478
amlodipine vs chlorthalidone normal,C0051696;C0205307;C0231683;C0439166;C2347086;C4553972
serum potassium mean sd mmol l,C0302353;C1532563;C0543465
amlodipine vs chlorthalidone overweight,C0051696;C0008294;C0497406
fasting serum glucose mean sd mg dl,C0202041;C0439269;C3534430
amlodipine vs chlorthalidone obese,C0051696;C0008294;C0028754
serum cholesterol mean sd mg dl,C0587184;C0439269
favors amlodipine favors chlorthalidone,C0051696;C0008294
treatment groups n,C0039798;C0441848;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
favors favors amlodipine chlorthalidone,C0051696;C0008294
history of mi or stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
lisinopril vs chlorthalidone normal,C0065374;C0205307;C0231683;C0439166;C2347086;C4553972
amlodipine vs chlorthalidone normal,C0051696;C0205307;C0231683;C0439166;C2347086;C4553972
lisinopril vs chlorthalidone overweight,C0065374;C0008294;C0497406
amlodipine vs chlorthalidone overweight,C0051696;C0008294;C0497406
lisinopril vs chlorthalidone obese,C0065374;C0008294;C0028754
amlodipine vs chlorthalidone obese,C0051696;C0008294;C0028754
favors lisinopril favors chlorthalidone,C0065374;C0008294
favors amlodipine favors chlorthalidone,C0051696;C0008294
favors favors lisinopril chlorthalidone,C0065374;C0008294
favors favors amlodipine chlorthalidone,C0051696;C0008294
dulaglutide $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lisinopril vs chlorthalidone normal,C0065374;C0205307;C0231683;C0439166;C2347086;C4553972
metformin n $nmbr$,C0025598
lisinopril vs chlorthalidone overweight,C0065374;C0008294;C0497406
hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
lisinopril vs chlorthalidone obese,C0065374;C0008294;C0028754
fsg mg dl,C0439269
favors lisinopril favors chlorthalidone,C0065374;C0008294
prestudy treatment a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
favors favors lisinopril chlorthalidone,C0065374;C0008294
no oam,
dulaglutide $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ oam,
metformin n $nmbr$,C0025598
dulaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
oam,
fsg mg dl,C0439269
overall population n $nmbr$,C0282416;C0032659;C1257890;C1561607
prestudy treatment a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
tnf antagonist failure population n $nmbr$,C0231174;C0032659;C1257890;C0680095
no oam,
tnf antagonist naive subgroup n $nmbr$,C0231491;C1079230;C1515021
$nmbr$ oam,
median age y range,C1514721;C2348147;C3542016
dulaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean body weight kg range,C1514721;C2348147;C3542016
oam,
median body mass index kg m $nmbr$ range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
overall population n $nmbr$,C0282416;C0032659;C1257890;C1561607
median crohn s disease duration y range,C0549183;C0010346;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
tnf antagonist failure population n $nmbr$,C0231174;C0032659;C1257890;C0680095
mean cdai score sd,C3533236;C2699239
tnf antagonist naive subgroup n $nmbr$,C0231491;C1079230;C1515021
mean crp level mg l sd,C0439268;C2699239
median age y range,C1514721;C2348147;C3542016
mean fecal calprotectin level mg g stool sd,C1300563;C2699239
mean body weight kg range,C1514721;C2348147;C3542016
disease localization n,C0012634;C0475264;C1744691
median body mass index kg m $nmbr$ range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
ileocolonic both ileum and colon,C0020885;C0009368;C3888384
median crohn s disease duration y range,C0549183;C0010346;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
history of crohn s disease surgery n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634;C0038894;C0038895;C0543467;C1274039
mean cdai score sd,C3533236;C2699239
history of fistulizing disease n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
mean crp level mg l sd,C0439268;C2699239
corticosteroid use n,C0239126
mean fecal calprotectin level mg g stool sd,C1300563;C2699239
immunosuppressive use n,C0021081;C0042153;C0457083;C1947944
disease localization n,C0012634;C0475264;C1744691
mesalamine use n a,C0127615;C0042153;C0457083;C1947944
ileocolonic both ileum and colon,C0020885;C0009368;C3888384
prior immunosuppressive exposure n,C0021081;C0274281;C0332157
history of crohn s disease surgery n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634;C0038894;C0038895;C0543467;C1274039
prior tnf antagonist failure n b,C3887647;C0231174;C0680095
history of fistulizing disease n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
$nmbr$ prior tnf antagonist failure n b,C3887647;C0231174;C0680095
corticosteroid use n,C0239126
$nmbr$ prior tnf antagonist failures n b,C3887647;C0231174;C0680095
immunosuppressive use n,C0021081;C0042153;C0457083;C1947944
supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population,C0051767;C1279919;C0057671;C0012634;C3900351;C0032659;C1257890
mesalamine use n a,C0127615;C0042153;C0457083;C1947944
n $nmbr$ for etn mtx n $nmbr$ for dmards,C0369718;C0441922;C0014758;C0025677;C1417487;C0717758;C0242708
prior immunosuppressive exposure n,C0021081;C0274281;C0332157
supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara b $nmbr$ years disease duration population,C0051767;C1279919;C0057671;C0032659;C1257890
prior tnf antagonist failure n b,C3887647;C0231174;C0680095
$nmbr$ prior tnf antagonist failure n b,C3887647;C0231174;C0680095
bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards,C0005918;C0006413;C1552663;C2827109;C0014758;C0025677;C1417487;C0717758;C0242708
$nmbr$ prior tnf antagonist failures n b,C3887647;C0231174;C0680095
supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348;C3900351
supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population,C0051767;C1279919;C0057671;C0012634;C3900351;C0032659;C1257890
a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards,C0012634;C0032659;C1257890;C0014758;C0025677;C1417487;C0717758;C0242708
n $nmbr$ for etn mtx n $nmbr$ for dmards,C0369718;C0441922;C0014758;C0025677;C1417487;C0717758;C0242708
a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards,C1836348;C0005918;C0006413;C1552663;C2827109;C0014758;C0025677;C1417487;C0717758;C0242708
supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara b $nmbr$ years disease duration population,C0051767;C1279919;C0057671;C0032659;C1257890
race n a,C0034510;C1706779;C3853635
otherb,
bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards,C0005918;C0006413;C1552663;C2827109;C0014758;C0025677;C1417487;C0717758;C0242708
region n a,C0017446;C0205147
supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348;C3900351
central south america,C0007674
a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards,C0012634;C0032659;C1257890;C0014758;C0025677;C1417487;C0717758;C0242708
mean sd hba $nmbr$ c level,C0441889;C0456079;C1547707;C2946261
a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards,C1836348;C0005918;C0006413;C1552663;C2827109;C0014758;C0025677;C1417487;C0717758;C0242708
mean sd bmi kg m $nmbr$,C0022718;C0439209;C4054209
race n a,C0034510;C1706779;C3853635
mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
otherb,
mean sd duration of t $nmbr$ dm y,C0449238;C2926735
region n a,C0017446;C0205147
patients with microvascular complications n,C0030705;C0009566;C1171258
central south america,C0007674
patients with cardiac disorders n c,C0741926
mean sd hba $nmbr$ c level,C0441889;C0456079;C1547707;C2946261
mean treatment exposure wk,C0332174;C0439230
mean sd bmi kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ st tertile,C0036056;C3272372
mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
$nmbr$ nd tertile $nmbr$ to $nmbr$ $nmbr$ to,
mean sd duration of t $nmbr$ dm y,C0449238;C2926735
$nmbr$ rd tertile $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] d,C0439422
patients with microvascular complications n,C0030705;C0009566;C1171258
pbo,C0031962
patients with cardiac disorders n c,C0741926
cana $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean treatment exposure wk,C0332174;C0439230
baseline mg dl mmol l,C0439268
$nmbr$ st tertile,C0036056;C3272372
ls mean se,C0023668;C0036919
$nmbr$ nd tertile $nmbr$ to $nmbr$ $nmbr$ to,
change mg dl mmol l,C0439268
$nmbr$ rd tertile $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] d,C0439422
difference vs pbo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
pbo,C0031962
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
cana $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
percent change,C0392747;C0443172;C1705241;C4319952
baseline mg dl mmol l,C0439268
difference vs pbo,C1705241;C1705242;C0031962
ls mean se,C0023668;C0036919
tcz sc $nmbr$ mg every other week n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332174;C0439230
change mg dl mmol l,C0439268
pbo sc every other week n $nmbr$,C0031962;C0282380;C0332174;C0439230
difference vs pbo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
weight group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
concomitant medication no,C0013227;C3244316;C4284232
percent change,C0392747;C0443172;C1705241;C4319952
other dmards,C0242708
difference vs pbo,C1705241;C1705242;C0031962
previous dmards mean sd,C0205156;C2699239;C1552607
tcz sc $nmbr$ mg every other week n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332174;C0439230
previously failed anti tnf treatment no,C0231175;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pbo sc every other week n $nmbr$,C0031962;C0282380;C0332174;C0439230
laboratory tests,C0022885
weight group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
rf positive no,C0439178;C1446409;C1514241;C2825490;C3812269
concomitant medication no,C0013227;C3244316;C4284232
acpa positive no,C0439178;C1446409;C1514241;C2825490;C3812269
other dmards,C0242708
crp level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
previous dmards mean sd,C0205156;C2699239;C1552607
esr mean sd mg dl,C0444504;C0439269;C2347634;C2348143
previously failed anti tnf treatment no,C0231175;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
disease activity,C1292728
laboratory tests,C0022885
duration of ra mean sd years,C0449238;C2926735
rf positive no,C0439178;C1446409;C1514241;C2825490;C3812269
tender joints $nmbr$ joint count mean sd,C0451530;C2699239
acpa positive no,C0439178;C1446409;C1514241;C2825490;C3812269
swollen joints $nmbr$ joint count mean sd,C0451521;C2699239
crp level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
das $nmbr$ mean sd,C0051767;C2699239;C0057671
esr mean sd mg dl,C0444504;C0439269;C2347634;C2348143
shs mean sd,C0444504;C2699239;C2347634;C2348143
disease activity,C1292728
jsn mean sd,C0444504;C2699239;C2347634;C2348143
duration of ra mean sd years,C0449238;C2926735
erosion mean sd,C0333307;C2699239;C1880549;C1959609;C3887524
tender joints $nmbr$ joint count mean sd,C0451530;C2699239
quality of life,C0034380;C0518214
swollen joints $nmbr$ joint count mean sd,C0451521;C2699239
haq di score range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
das $nmbr$ mean sd,C0051767;C2699239;C0057671
pain vas range $nmbr$ $nmbr$ mean sd,C0042815;C2699239
shs mean sd,C0444504;C2699239;C2347634;C2348143
patient global assessment of disease,C4054229
jsn mean sd,C0444504;C2699239;C2347634;C2348143
activity range $nmbr$ $nmbr$ mean sd,C0205177;C2699239;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
erosion mean sd,C0333307;C2699239;C1880549;C1959609;C3887524
physician global assessment of disease,C4050369
quality of life,C0034380;C0518214
study $nmbr$ $nmbr$,C0557651;C2603343
haq di score range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
olodaterol,C2934193
pain vas range $nmbr$ $nmbr$ mean sd,C0042815;C2699239
$nmbr$ g n $nmbr$,C0439267
patient global assessment of disease,C4054229
mean sd age years,C0444504;C1510829;C2347634;C2348143
activity range $nmbr$ $nmbr$ mean sd,C0205177;C2699239;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
pre bronchodilator mean sd fev $nmbr$ l,C2599602;C0444504;C2347634;C2348143
physician global assessment of disease,C4050369
post bronchodilator,C2599594
study $nmbr$ $nmbr$,C0557651;C2603343
mean sd fev $nmbr$ l,C0444504;C2347634;C2348143
olodaterol,C2934193
mean sd predicted normal fev $nmbr$,C0205307;C3714541;C0231683;C0439166;C2347086;C4553972
$nmbr$ g n $nmbr$,C0439267
mean sd fev $nmbr$ fvc,C0444504;C3714541;C2347634;C2348143
mean sd age years,C0444504;C1510829;C2347634;C2348143
mean sd change from pre to post bronchodilator fev $nmbr$ l,C0392747;C0443172;C1705241;C4319952
pre bronchodilator mean sd fev $nmbr$ l,C2599602;C0444504;C2347634;C2348143
gold stage n,C0018026;C0205390;C1300072;C1306673;C1304897
post bronchodilator,C2599594
baseline pulmonary medications,C0013227;C0802604;C2598133;C4284232
mean sd fev $nmbr$ l,C0444504;C2347634;C2348143
any pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
mean sd predicted normal fev $nmbr$,C0205307;C3714541;C0231683;C0439166;C2347086;C4553972
sama b n,C1075468
mean sd fev $nmbr$ fvc,C0444504;C3714541;C2347634;C2348143
lama tiotropium b n,C0999593;C0213771;C1416775
mean sd change from pre to post bronchodilator fev $nmbr$ l,C0392747;C0443172;C1705241;C4319952
saba inhaled c n,C0004048
gold stage n,C0018026;C0205390;C1300072;C1306673;C1304897
laba inhaled d n,C0004048;C0369718;C0441922
baseline pulmonary medications,C0013227;C0802604;C2598133;C4284232
oral adrenergics n,C0442027;C0001637;C4521986
any pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
steroids n,C0038317
sama b n,C1075468
inhaledb,
lama tiotropium b n,C0999593;C0213771;C1416775
oralb,
saba inhaled c n,C0004048
xanthines b n,C0043318;C3541955
laba inhaled d n,C0004048;C0369718;C0441922
mean se auc^p l,C0036919;C0376690
oral adrenergics n,C0442027;C0001637;C4521986
olodaterol $nmbr$ jig,C2934193
steroids n,C0038317
tiotropium n $nmbr$ non tiotropium n $nmbr$,C0213771;C1518422
inhaledb,
non tiotropium,C1518422;C0213771
oralb,
mean se trough l,C0444504;C0036919;C2347634;C2348143
xanthines b n,C0043318;C3541955
tiotropium n $nmbr$ non tiotropium n $nmbr$ $nmbr$,C0213771;C1518422
mean se auc^p l,C0036919;C0376690
n unless otherwise specified,C0369718;C0441922;C0205369
olodaterol $nmbr$ jig,C2934193
a vs c,
tiotropium n $nmbr$ non tiotropium n $nmbr$,C0213771;C1518422
l vs c,C0439394;C1706495;C3642217
non tiotropium,C1518422;C0213771
education years mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
mean se trough l,C0444504;C0036919;C2347634;C2348143
type ii diabetes,C0011860
tiotropium n $nmbr$ non tiotropium n $nmbr$ $nmbr$,C0213771;C1518422
hx cabg,C0262926;C0010055;C3814444
n unless otherwise specified,C0369718;C0441922;C0205369
hx mi or stroke,C0262926;C3810814;C3814444;C0038454;C4554100
a vs c,
oascvd,
l vs c,C0439394;C1706495;C3642217
antihypertensive medication $nmbr$,C0003364
education years mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
estrogen,C0014939;C2936882;C4542544
type ii diabetes,C0011860
heart rate mean sd,C0018810;C2699239
hx cabg,C0262926;C0010055;C3814444
lvh by ecg minnesota code,C0232306;C0009219;C0805701;C3889831
hx mi or stroke,C0262926;C3810814;C3814444;C0038454;C4554100
cholesterol mg dl mean sd,C0439269;C2699239
oascvd,
fasting glucose mg dl mean sd,C0439269;C2699239
antihypertensive medication $nmbr$,C0003364
egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
estrogen,C0014939;C2936882;C4542544
heart rate mean sd,C0018810;C2699239
blood pressure mmhg mean sd,C0428886;C2699239
lvh by ecg minnesota code,C0232306;C0009219;C0805701;C3889831
systolic total,C0439175;C0439810
cholesterol mg dl mean sd,C0439269;C2699239
diastolic total,C0439175;C0439810
fasting glucose mg dl mean sd,C0439269;C2699239
systolic treated at baseline,C0039155;C1522326;C0168634;C1442488
egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
diastolic treated at baseline,C0012000;C1522326;C0168634;C1442488
pulse pressure,C0949236
blood pressure mmhg mean sd,C0428886;C2699239
systolic total,C0439175;C0439810
interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure,C1704675;C1709380;C0332283;C1719822;C4281991;C0051696;C0008294;C0001779;C0011847;C0065374;C0011849;C0085096;C1704436;C0008976;C0019993;C0184661;C2700391;C3274430;C3539779
diastolic total,C0439175;C0439810
no chd,C0280604;C3542407
systolic treated at baseline,C0039155;C1522326;C0168634;C1442488
$nmbr$ mg mtx,C0025677;C1417487
diastolic treated at baseline,C0012000;C1522326;C0168634;C1442488
patients with prior dmard use n a,C0030705;C0042153;C0457083;C1947944
pulse pressure,C0949236
hydroxychloroquine,C0020336
sulfasalazine,C0036078
interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure,C1704675;C1709380;C0332283;C1719822;C4281991;C0051696;C0008294;C0001779;C0011847;C0065374;C0011849;C0085096;C1704436;C0008976;C0019993;C0184661;C2700391;C3274430;C3539779
patients taking oral corticosteroids at baseline n,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
no chd,C0280604;C3542407
prednisone or equivalent dose mg day,C0032952;C0178602;C0439422;C0869039;C1114758
$nmbr$ mg mtx,C0025677;C1417487
anti ccp antibody positive n,C0432633
patients with prior dmard use n a,C0030705;C0042153;C0457083;C1947944
hydroxychloroquine,C0020336
total vdh s score,C2964552
sulfasalazine,C0036078
olodaterol $nmbr$ gg n $nmbr$,C0017454;C0018370
formoterol $nmbr$ gg n $nmbr$,C0017454;C0018370
patients taking oral corticosteroids at baseline n,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
pre bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
prednisone or equivalent dose mg day,C0032952;C0178602;C0439422;C0869039;C1114758
post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
anti ccp antibody positive n,C0432633
mean sd of predicted normal fev $nmbr$,C2699239;C0520835
total vdh s score,C2964552
$nmbr$ $nmbr$ a,
olodaterol $nmbr$ gg n $nmbr$,C0017454;C0018370
baseline pulmonary medication b n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
formoterol $nmbr$ gg n $nmbr$,C0017454;C0018370
samac,
pre bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
lamad,
post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
sabae,
mean sd of predicted normal fev $nmbr$,C2699239;C0520835
laba,
$nmbr$ $nmbr$ a,
icsf,
baseline pulmonary medication b n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
xanthinesg,
samac,
mean se auc $nmbr$ $nmbr$ l,C0036919;C0376690
lamad,
placebo tiotropium n $nmbr$ non tiotropium n $nmbr$,C0032042;C0213771;C1696465;C1706408
sabae,
olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$,C4032878;C0021027;C0305052;C0360506
laba,
icsf,
olodaterol $nmbr$ $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$,C4032878;C0021027;C0305052;C0360506
xanthinesg,
formoterol tiotropium n $nmbr$ non tiotropium n $nmbr$,C0060657;C0213771
mean se auc $nmbr$ $nmbr$ l,C0036919;C0376690
omalizumab,C0966225
placebo tiotropium n $nmbr$ non tiotropium n $nmbr$,C0032042;C0213771;C1696465;C1706408
age group n,C0441848
x $nmbr$ years,C0439234
olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$,C4032878;C0021027;C0305052;C0360506
o $nmbr$ kg n,C0022718;C0439209;C4054209
olodaterol $nmbr$ $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$,C4032878;C0021027;C0305052;C0360506
body mass index kgm _ $nmbr$,C0005893;C0578022;C1305855
formoterol tiotropium n $nmbr$ non tiotropium n $nmbr$,C0060657;C0213771
time since diagnosis of ciu csu years $nmbr$,C0556970;C0011900;C1704338;C1704656
omalizumab,C0966225
cu index test n $nmbr$,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
age group n,C0441848
x $nmbr$ years,C0439234
no of previous ciu csu medications,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
o $nmbr$ kg n,C0022718;C0439209;C4054209
median range total ige level iuml $nmbr$,C0439175;C0439810
body mass index kgm _ $nmbr$,C0005893;C0578022;C1305855
in clinic uas $nmbr$,C0150312;C0002424;C0442592;C0332285;C1707101
uas $nmbr$,
time since diagnosis of ciu csu years $nmbr$,C0556970;C0011900;C1704338;C1704656
weekly iss $nmbr$,C1740819;C1845118
cu index test n $nmbr$,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
weekly number of hives score $nmbr$,C0237753;C0449788
no of previous ciu csu medications,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
overall dlqi score $nmbr$,C0282416;C3897059;C1561607
median range total ige level iuml $nmbr$,C0439175;C0439810
angioedema present n $nmbr$,C0002994;C0150312;C0449450
in clinic uas $nmbr$,C0150312;C0002424;C0442592;C0332285;C1707101
lsm difference $nmbr$ cl,C1705241;C0596019;C1705242
uas $nmbr$,
sia,C1225105;C1551538
weekly iss $nmbr$,C1740819;C1845118
sack,
weekly number of hives score $nmbr$,C0237753;C0449788
non united states,C1518422;C0041703
overall dlqi score $nmbr$,C0282416;C3897059;C1561607
baseline weekly iss,C1740819;C1845118
angioedema present n $nmbr$,C0002994;C0150312;C0449450
baseline uas $nmbr$,C0168634;C1442488
lsm difference $nmbr$ cl,C1705241;C0596019;C1705242
a median,C0549183;C0876920;C2347635;C2348144;C2939193
sia,C1225105;C1551538
body weiqht,C0242821;C0460148;C1268086;C4082212
sack,
positive cu index test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
non united states,C1518422;C0041703
presence of angioedema at baseline,C0150312;C0392148;C3854307;C0168634;C1442488
baseline weekly iss,C1740819;C1845118
previous use of systemic steroids for ciu csu,C0281991;C0578870
baseline uas $nmbr$,C0168634;C1442488
a median,C0549183;C0876920;C2347635;C2348144;C2939193
level of thyroperoxidase antibody at baseline,C0428536;C0168634;C1442488
body weiqht,C0242821;C0460148;C1268086;C4082212
high $nmbr$ $nmbr$ u ml,C0439340;C1880521;C2945590
positive cu index test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
duration of disease before baseline,C0872146;C0168634;C1442488
presence of angioedema at baseline,C0150312;C0392148;C3854307;C0168634;C1442488
previous number of ciu csu medications,C0205156;C1718138;C1552607
figure $nmbr$,
previous use of systemic steroids for ciu csu,C0281991;C0578870
level of thyroperoxidase antibody at baseline,C0428536;C0168634;C1442488
b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug,C0018623;C0456603;C1610540;C0030705;C0441767;C1706317;C0009667;C0242708
high $nmbr$ $nmbr$ u ml,C0439340;C1880521;C2945590
baseline high density lipoprotein cholesterol mg dl,C0023822;C0439269
duration of disease before baseline,C0872146;C0168634;C1442488
no of cardiovascular events cardiovascular events $nmbr$ person years,C1320716;C0027361;C2347489
previous number of ciu csu medications,C0205156;C1718138;C1552607
hazard ratio,C2985465
figure $nmbr$,
pfor trend,C1521798;C4554533
chd plus cerebral infarction,C0280604;C3542407
b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug,C0018623;C0456603;C1610540;C0030705;C0441767;C1706317;C0009667;C0242708
total deaths,C0011065;C1306577
baseline high density lipoprotein cholesterol mg dl,C0023822;C0439269
prehospital ticagrelor n $nmbr$,C1999375
no of cardiovascular events cardiovascular events $nmbr$ person years,C1320716;C0027361;C2347489
in hospital ticagrelor n $nmbr$,C0019994;C1510665
hazard ratio,C2985465
bmi $nmbr$ no f,C0578022;C0016327
pfor trend,C1521798;C4554533
timi risk score no t,C0035647;C0449820;C4050231;C4552904;C2603360
chd plus cerebral infarction,C0280604;C3542407
killip class i no,C2697844
total deaths,C0011065;C1306577
first medical contact no,C0332158;C0337611;C1705415;C3812666
prehospital ticagrelor n $nmbr$,C1999375
in ambulance,C0002422;C3846685
in hospital ticagrelor n $nmbr$,C0019994;C1510665
in emergency department before ambulance transfer,C0562508;C0002422;C3846685
bmi $nmbr$ no f,C0578022;C0016327
procedures for index event,C0025664;C0184661;C2700391;C3538935
timi risk score no t,C0035647;C0449820;C4050231;C4552904;C2603360
coronary angiography no,C0085532;C1548829
killip class i no,C2697844
femoral access no total no,C0444454;C1554204;C0439175;C0439810
first medical contact no,C0332158;C0337611;C1705415;C3812666
radial access no total no,C0444454;C1554204;C0439175;C0439810
in ambulance,C0002422;C3846685
missing data no total no,C4684714;C0439175;C0439810
in emergency department before ambulance transfer,C0562508;C0002422;C3846685
thromboaspiration no,
procedures for index event,C0025664;C0184661;C2700391;C3538935
with stent^l,C0038257
coronary angiography no,C0085532;C1548829
drug eluting stent,C1322815
femoral access no total no,C0444454;C1554204;C0439175;C0439810
bare metal stent,C2825200
radial access no total no,C0444454;C1554204;C0439175;C0439810
without stent,C0038257
missing data no total no,C4684714;C0439175;C0439810
no pci or cabg no,C4049621;C0010055
thromboaspiration no,
study medication no,C0013227;C3244316;C4284232
with stent^l,C0038257
first loading dose,C0205435;C3714444;C1279901
drug eluting stent,C1322815
second loading dose,C0205436;C3714444;C0457385;C0565930;C1561503;C1705190
bare metal stent,C2825200
maintenance dose,C3714445
without stent,C0038257
aspirin no,C0004057
no pci or cabg no,C4049621;C0010055
any use,C0042153;C0457083;C1947944
study medication no,C0013227;C3244316;C4284232
other antithrombotic medication for index event no,C0013227;C3244316;C4284232
first loading dose,C0205435;C3714444;C1279901
glycoprotein ilb iiia inhibitor before pci],C0017968;C1999216
second loading dose,C0205436;C3714444;C0457385;C0565930;C1561503;C1705190
intravenous anticoagulant during hospitalization,C0003280;C0848112;C3536711
maintenance dose,C3714445
heparin,C0019134;C0770546
aspirin no,C0004057
combination therapy,C0009429;C0556895
any use,C0042153;C0457083;C1947944
total patients,C0439175;C0030705;C0439810
other antithrombotic medication for index event no,C0013227;C3244316;C4284232
endpoint rate,C0871208;C1521828
glycoprotein ilb iiia inhibitor before pci],C0017968;C1999216
p value int,C1709380;C3272375
intravenous anticoagulant during hospitalization,C0003280;C0848112;C3536711
pre h,C0033727;C0369286;C0441932;C0564385;C4528284
heparin,C0019134;C0770546
in h,C0033727;C0369286;C0441932;C0564385;C4528284
combination therapy,C0009429;C0556895
n nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
total patients,C0439175;C0030705;C0439810
pnorpci,
endpoint rate,C0871208;C1521828
pnorcabg,
p value int,C1709380;C3272375
so $nmbr$,
pre h,C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ j $nmbr$,
in h,C0033727;C0369286;C0441932;C0564385;C4528284
location of ml,C0450429;C1515974;C4284930;C4284931
n nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
tim $nmbr$ nsk score,C0449820;C4050231
pnorpci,
highest killip classiciation pre pci,C1522410;C0332152;C0740175;C2257086;C3669034
pnorcabg,
$nmbr$ ix,C0015491
so $nmbr$,
prior asa use,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ j $nmbr$,
gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944
location of ml,C0450429;C1515974;C4284930;C4284931
morphine use for index event pci,C0242000;C0441471;C4019010
tim $nmbr$ nsk score,C0449820;C4050231
heparin ondaparinux or brvalirudin use between rxjex event,C0019134;C0770546;C0042153;C0457083;C1947944
highest killip classiciation pre pci,C1522410;C0332152;C0740175;C2257086;C3669034
total atients,C0439175;C0439810
$nmbr$ ix,C0015491
tlmi risk score,C0035647;C0449820;C4050231;C4552904
prior asa use,C0042153;C0457083;C1947944
so,
gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944
gpifo llia inhibitor use before angography,C0042153;C0457083;C1947944
morphine use for index event pci,C0242000;C0441471;C4019010
heparin fondaparinux or brvalirudin use between oex event,C0019134;C1098510;C0770546;C0042153;C0457083;C1947944
heparin ondaparinux or brvalirudin use between rxjex event,C0019134;C0770546;C0042153;C0457083;C1947944
total by treatment,C0439175;C0439810
total atients,C0439175;C0439810
early,C1279919
tlmi risk score,C0035647;C0449820;C4050231;C4552904
delayed,C0205421;C1545665;C3272602
so,
vka n $nmbr$,
gpifo llia inhibitor use before angography,C0042153;C0457083;C1947944
creatinine clearance an,C0812399
heparin fondaparinux or brvalirudin use between oex event,C0019134;C1098510;C0770546;C0042153;C0457083;C1947944
prior non cns se,C0332152;C0036919;C2826257
total by treatment,C0439175;C0439810
prior tia,C0007787;C0917805;C1054154
early,C1279919
congestive hf,C0018488;C1313497;C1538440;C3273279
delayed,C0205421;C1545665;C3272602
nyha class iii iv,C0278962
vka n $nmbr$,
arterial hypertension,C0020538
creatinine clearance an,C0812399
vascular disease,C0042373
prior non cns se,C0332152;C0036919;C2826257
first diagnosed,C0205435;C1279901;C0011900
prior tia,C0007787;C0917805;C1054154
long standing persistent,C0205322;C0332996
congestive hf,C0018488;C1313497;C1538440;C3273279
cha $nmbr$ ds $nmbr$ vasc score n,C1420648;C0449820;C4050231
nyha class iii iv,C0278962
$nmbr$ or $nmbr$ if female only,C0043210;C0086287;C1705497;C1705498
arterial hypertension,C0020538
$nmbr$ except for female alone,C0043210;C0086287;C1705497;C1705498;C0205171;C0439044;C0679994
vascular disease,C0042373
oac experienced bn,C0005005;C0034700;C1706574;C4551963
first diagnosed,C0205435;C1279901;C0011900
antiarrhythmic drugs n,C0003195
long standing persistent,C0205322;C0332996
dronedarone,C0766326
cha $nmbr$ ds $nmbr$ vasc score n,C1420648;C0449820;C4050231
flecainide,C0016229
$nmbr$ or $nmbr$ if female only,C0043210;C0086287;C1705497;C1705498
propafenone,C0033429
$nmbr$ except for female alone,C0043210;C0086287;C1705497;C1705498;C0205171;C0439044;C0679994
others classes i and iiic,C0441885;C1319793;C2698967
oac experienced bn,C0005005;C0034700;C1706574;C4551963
efficacy n a,C1280519;C1707887
antiarrhythmic drugs n,C0003195
se,C0036919
dronedarone,C0766326
cardiovascular death,C0011065;C1306577;C4082313;C4552775
flecainide,C0016229
safety n b,C0036043;C1705187
propafenone,C0033429
fatal,C1302234;C1705232
others classes i and iiic,C0441885;C1319793;C2698967
critical site,C0205145;C1515974;C2825164
efficacy n a,C1280519;C1707887
ich,C0019191;C3272597;C3281105
se,C0036919
hb decrease $nmbr$ g dl,C0439267
cardiovascular death,C0011065;C1306577;C4082313;C4552775
transfusion $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C1879316;C0229664;C0370231;C1546552;C1608383
safety n b,C0036043;C1705187
mepolizumab,C0969324
fatal,C1302234;C1705232
intravenous n $nmbr$,C0348016
critical site,C0205145;C1515974;C2825164
subcutaneous n $nmbr$,C0443315
ich,C0019191;C3272597;C3281105
mean age range yr,C0001779;C0439234
hb decrease $nmbr$ g dl,C0439267
former smoker no,C0337671
transfusion $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C1879316;C0229664;C0370231;C1546552;C1608383
duration of asthma yr,C0449238;C2926735
mepolizumab,C0969324
use of oral glucocorticoids,C1524063
intravenous n $nmbr$,C0348016
maintenance use no,C0042153;C0457083;C1947944
subcutaneous n $nmbr$,C0443315
mean daily dose range mg i,C0024671;C0021966;C0221138;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean age range yr,C0001779;C0439234
allergic rhinitis no,C1334103;C2607914;C4552864
former smoker no,C0337671
fev $nmbr$,C3714541
duration of asthma yr,C0449238;C2926735
before bronchodilation liters,C1371299;C0475211;C3537072
use of oral glucocorticoids,C1524063
percent of predicted value before bronchodilation^,C1882327;C1371299;C3537072
maintenance use no,C0042153;C0457083;C1947944
reversibility,C0449261
mean daily dose range mg i,C0024671;C0021966;C0221138;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fevt fvc ratio,C0456603;C1547037
allergic rhinitis no,C1334103;C2607914;C4552864
morning peak expiratory flow liters min,C0702093;C1524029;C3813700
fev $nmbr$,C3714541
score on asthma control questionnaire,C4706265
before bronchodilation liters,C1371299;C0475211;C3537072
score on st george s respiratory questionnaire^^,C0449820;C4050231;C0521346;C0034394;C1546767
percent of predicted value before bronchodilation^,C1882327;C1371299;C3537072
geometric mean ige on loge scale u ml,C0439340;C1880521;C2945590
reversibility,C0449261
fevt fvc ratio,C0456603;C1547037
geometric mean blood eosinophil count on loge scale cells ^ljj,C2986759;C0200638
morning peak expiratory flow liters min,C0702093;C1524029;C3813700
asthma exacerbations,C0349790
score on asthma control questionnaire,C4706265
severe episodes in previous year no patient,C0205082;C0332189;C4050465;C4050466;C0030705
score on st george s respiratory questionnaire^^,C0449820;C4050231;C0521346;C0034394;C1546767
necessitating hospitalization in previous year no,C0019993;C0205156;C1552607
geometric mean ige on loge scale u ml,C0439340;C1880521;C2945590
history of asthma related intubation no,C0455544;C0021925
p $nmbr$ z $nmbr$ n $nmbr$,C0369773;C2603361
geometric mean blood eosinophil count on loge scale cells ^ljj,C2986759;C0200638
$nmbr$ to $nmbr$ n,C0369718;C0441922
asthma exacerbations,C0349790
north america oceania,C0282279;C4085681
severe episodes in previous year no patient,C0205082;C0332189;C4050465;C4050466;C0030705
femoral neck t score mean sd,C0015815;C2699239
necessitating hospitalization in previous year no,C0019993;C0205156;C1552607
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n,C0369718;C0441922
history of asthma related intubation no,C0455544;C0021925
mean bmd sd g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
p $nmbr$ z $nmbr$ n $nmbr$,C0369773;C2603361
lumbar,C0024090
$nmbr$ to $nmbr$ n,C0369718;C0441922
prior medication use n,C0332152;C0240320;C2826257
north america oceania,C0282279;C4085681
hormone therapy,C0279025
femoral neck t score mean sd,C0015815;C2699239
bisphosphonates,C0012544;C3541401
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n,C0369718;C0441922
calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
mean bmd sd g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
serms,C0732611
lumbar,C0024090
other osteoporosis medication,C0013227;C3244316;C4284232
prior medication use n,C0332152;C0240320;C2826257
mean sd days since,C0444504;C0439228;C2347634;C2348143
hormone therapy,C0279025
last infusion in the horizon pft,C0574032;C1827465
bisphosphonates,C0012544;C3541401
core study to first infusion,C0557651;C2603343
calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
in extension study,C0557651;C2603343
serms,C0732611
with ckd intensive n $nmbr$,C1561643
other osteoporosis medication,C0013227;C3244316;C4284232
with ckd standard n $nmbr$,C1561643;C1442989;C2828392
mean sd days since,C0444504;C0439228;C2347634;C2348143
no ckd intensive n $nmbr$,C1561643
last infusion in the horizon pft,C0574032;C1827465
no ckd standard n $nmbr$,C1561643;C1442989;C2828392
core study to first infusion,C0557651;C2603343
o $nmbr$ $nmbr$,C0483204
in extension study,C0557651;C2603343
race ethnicity,C0015031;C0243103
with ckd intensive n $nmbr$,C1561643
waist cm,C0230097
with ckd standard n $nmbr$,C1561643;C1442989;C2828392
uacr mg g,C1300563
no ckd intensive n $nmbr$,C1561643
o $nmbr$,C0483204
no ckd standard n $nmbr$,C1561643;C1442989;C2828392
no ckd,C1561643
o $nmbr$ $nmbr$,C0483204
ckd stage $nmbr$,C0205390;C1300072;C1306673
race ethnicity,C0015031;C0243103
serum glucose mg dl,C0202041;C0439269;C3534430
waist cm,C0230097
duration of dm years,C0449238;C2926735
uacr mg g,C1300563
heart rate,C0018810
o $nmbr$,C0483204
history of cvd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no ckd,C1561643
history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ckd stage $nmbr$,C0205390;C1300072;C1306673
merformin,
serum glucose mg dl,C0202041;C0439269;C3534430
any anti hypertensive agent,C0003364
duration of dm years,C0449238;C2926735
dihydropyridine ccbs,C0012315;C0006684;C0220821
heart rate,C0018810
non dihydropyridine ccbs,C0012315;C0006684;C0220821
history of cvd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fibrate,
history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
potassium,C0032821;C0202194;C0304475;C0597277;C3714637
merformin,
hdl female,C0043210;C0086287;C1705497;C1705498
any anti hypertensive agent,C0003364
hdl male,C0086582;C1706180;C1706428;C1706429
dihydropyridine ccbs,C0012315;C0006684;C0220821
ohs graduate,C0588053;C1547183
non dihydropyridine ccbs,C0012315;C0006684;C0220821
hs graduate ged,C0588053;C1880947;C1547183
fibrate,
some college tech,C0557806;C1826596
potassium,C0032821;C0202194;C0304475;C0597277;C3714637
college graduate or more,C0682187
hdl female,C0043210;C0086287;C1705497;C1705498
network,C0150775;C1513822;C1705739;C1882071
hdl male,C0086582;C1706180;C1706428;C1706429
e,
ohs graduate,C0588053;C1547183
$nmbr$ mg empagliflozin,C0024671;C3490348;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hs graduate ged,C0588053;C1880947;C1547183
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd,C1739039;C0439445;C3811844;C3812682;C3839656
some college tech,C0557806;C1826596
hba $nmbr$ c [mmol mol],C0019016;C1825777;C3538758;C3829066
college graduate or more,C0682187
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
network,C0150775;C1513822;C1705739;C1882071
years since diagnosis of type $nmbr$ diabetes n,C0439234;C1320657
e,
sbp office measurement mmhg,C0085805;C0439475
$nmbr$ mg empagliflozin,C0024671;C3490348;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd,C1739039;C0439445;C3811844;C3812682;C3839656
dbp office measurement mmhg,C0242485;C0439475
hba $nmbr$ c [mmol mol],C0019016;C1825777;C3538758;C3829066
dbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
pulse rate mean $nmbr$ h bpm,C0232117;C0033727;C0369286;C0441932;C0564385;C4528284
years since diagnosis of type $nmbr$ diabetes n,C0439234;C1320657
number of antihypertensive medications n,C1718138
sbp office measurement mmhg,C0085805;C0439475
daytime mean sbp abpm at week $nmbr$ mmhg,C0332169;C0085805
sbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
change from baseline mmhg,C0392747;C0443172;C1705241;C4319952
dbp office measurement mmhg,C0242485;C0439475
difference vs placebo,C1705241;C1705242;C0032042;C1696465;C1706408
dbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
nighttime mean sbp abpm at week $nmbr$ mmhg,C0240526;C0085805
pulse rate mean $nmbr$ h bpm,C0232117;C0033727;C0369286;C0441932;C0564385;C4528284
daytime mean dbp abpm at week $nmbr$ mmhg,C0332169;C0332174;C0439230
number of antihypertensive medications n,C1718138
nighttime mean dbp abpm at week $nmbr$ mmhg,C0240526;C0332174;C0439230
daytime mean sbp abpm at week $nmbr$ mmhg,C0332169;C0085805
mean $nmbr$ h sbp,C0033727;C0085805;C0369286;C0441932;C0564385;C4528284
change from baseline mmhg,C0392747;C0443172;C1705241;C4319952
patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0030705;C0037623;C1415692;C1708288;C4318478;C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
difference vs placebo,C1705241;C1705242;C0032042;C1696465;C1706408
change from baseline in mean $nmbr$ h sbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
nighttime mean sbp abpm at week $nmbr$ mmhg,C0240526;C0085805
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
daytime mean dbp abpm at week $nmbr$ mmhg,C0332169;C0332174;C0439230
mean $nmbr$ h dbp,C0536221;C3813197;C4281799
nighttime mean dbp abpm at week $nmbr$ mmhg,C0240526;C0332174;C0439230
mean $nmbr$ h sbp,C0033727;C0085805;C0369286;C0441932;C0564385;C4528284
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0030705;C0037623;C1415692;C1708288;C4318478;C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
change from baseline in mean $nmbr$ h dbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
change from baseline in mean $nmbr$ h sbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups,C0243132;C1554210;C2745955;C0332152;C1079230;C0740175;C2257086;C3669034
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C1696465;C1706408;C0168634;C1442488;C0332174;C0439230;C0871236;C0023824;C0086045;C0202117;C0178602;C1521801;C0743559;C1608199;C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0686905
mean $nmbr$ h dbp,C0536221;C3813197;C4281799
black or african,C0005680;C0027567;C0085756;C0439541
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
american,C0596070
change from baseline in mean $nmbr$ h dbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
region no c,C0017446;C0205147
figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups,C0243132;C1554210;C2745955;C0332152;C1079230;C0740175;C2257086;C3669034
central south,C0205099;C1710133;C1879652
america,C0002454
figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C1696465;C1706408;C0168634;C1442488;C0332174;C0439230;C0871236;C0023824;C0086045;C0202117;C0178602;C1521801;C0743559;C1608199;C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0686905
otherd,
black or african,C0005680;C0027567;C0085756;C0439541
duration of t $nmbr$ dm y,C0449238;C2926735
american,C0596070
taking antihypertensive medication at baseline no e,C0003364
region no c,C0017446;C0205147
dbp $nmbr$ mmhg,C0536221;C0439475;C3813197;C4281799
central south,C0205099;C1710133;C1879652
on antihypertensive medication at baseline n,C0003364;C0168634;C1442488
america,C0002454
secukinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
otherd,
age years $nmbr$,C1510829
duration of t $nmbr$ dm y,C0449238;C2926735
weight kg $nmbr$,C0022718;C0439209;C4054209
taking antihypertensive medication at baseline no e,C0003364
time since psoriasis diagnosis years $nmbr$,C0556970;C0011900;C1704338;C1704656
dbp $nmbr$ mmhg,C0536221;C0439475;C3813197;C4281799
pasi score $nmbr$,C0449820;C4050231
on antihypertensive medication at baseline n,C0003364;C0168634;C1442488
bsa involved $nmbr$,C1314939
secukinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
iga mod $nmbr$ score n,C0011860;C0449820;C4050231
age years $nmbr$,C1510829
$nmbr$ moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
weight kg $nmbr$,C0022718;C0439209;C4054209
$nmbr$ severe disease,C1836348
time since psoriasis diagnosis years $nmbr$,C0556970;C0011900;C1704338;C1704656
psa reported n,C0684224;C0700287;C4319718
pasi score $nmbr$,C0449820;C4050231
conventional agents,C0450442;C1254351;C1521826
bsa involved $nmbr$,C1314939
topical,C0332237
iga mod $nmbr$ score n,C0011860;C0449820;C4050231
phototherapy previous systemic treatment n,C0031765;C0678812
$nmbr$ moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
biologic,C0005515;C0205460
$nmbr$ severe disease,C1836348
anti p $nmbr$,
psa reported n,C0684224;C0700287;C4319718
anti tnf,C1448177
conventional agents,C0450442;C1254351;C1521826
efficacy endpoints,C1280519;C2349179;C1707887
topical,C0332237
visit,C0545082;C1512346;C2826704
phototherapy previous systemic treatment n,C0031765;C0678812
japanese subpopulation,C0376247;C1257890;C1556094
biologic,C0005515;C0205460
week,C0332174;C0439230
anti p $nmbr$,
secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
anti tnf,C1448177
pasi $nmbr$,C4528685
efficacy endpoints,C1280519;C2349179;C1707887
iga $nmbr$ $nmbr$,C2825347
visit,C0545082;C1512346;C2826704
japanese subpopulation,C0376247;C1257890;C1556094
figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use,C1274040;C1546471;C2825142;C0021641;C0008976;C1533581;C1579433;C3714501;C0392747;C0443172;C1709707;C0030705;C0019016;C2825507;C1825777;C3538758;C0005910;C1305866;C0007222;C0679831;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3538987;C0035648;C4048877;C4318503;C0020538;C1963138;C0360714;C0042153;C0457083;C1947944
week,C0332174;C0439230
abbreviations cv cardiovascular cvd cardiovascular disease glip glipizide hba $nmbr$ c glycated hemoglobin met metformin saxa saxagliptin se standard error,C0019045;C1710181
secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
amlodipine lisinopril chlorthalidone comparison,C0008294;C1707455
pasi $nmbr$,C4528685
no in trial stroke n $nmbr$ $nmbr$,C0008976;C0038454;C4554100
iga $nmbr$ $nmbr$,C2825347
in trial nonfatal or fatal stroke n $nmbr$ $nmbr$,C0150312;C0008976;C0332285;C1707101;C1302234;C0038454;C4554100;C1705232
figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use,C1274040;C1546471;C2825142;C0021641;C0008976;C1533581;C1579433;C3714501;C0392747;C0443172;C1709707;C0030705;C0019016;C2825507;C1825777;C3538758;C0005910;C1305866;C0007222;C0679831;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3538987;C0035648;C4048877;C4318503;C0020538;C1963138;C0360714;C0042153;C0457083;C1947944
education in years mean sd,C0013621;C0013622;C0013658;C0039401
lipids medications,C0013227;C0802604;C2598133;C4284232
abbreviations cv cardiovascular cvd cardiovascular disease glip glipizide hba $nmbr$ c glycated hemoglobin met metformin saxa saxagliptin se standard error,C0019045;C1710181
amlodipine lisinopril chlorthalidone comparison,C0008294;C1707455
blood pressure in mm hg mean sd,C0428886;C0488053
no in trial stroke n $nmbr$ $nmbr$,C0008976;C0038454;C4554100
sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
in trial nonfatal or fatal stroke n $nmbr$ $nmbr$,C0150312;C0008976;C0332285;C1707101;C1302234;C0038454;C4554100;C1705232
dbp at visit $nmbr$,C0536221;C3813197;C4281799
education in years mean sd,C0013621;C0013622;C0013658;C0039401
pulse in beats minute mean sd,C0232117;C0391850;C1947910
lipids medications,C0013227;C0802604;C2598133;C4284232
eligibility risk factors n,C0035648;C1553898
history coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
blood pressure in mm hg mean sd,C0428886;C0488053
major st depression or t wave inversion,C0041696;C1269683;C0520888
sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
hdl c $nmbr$ mg dl,C3715113;C0439269
dbp at visit $nmbr$,C0536221;C3813197;C4281799
lvh by echo or ecg,C0149721;C0058928;C1655045;C1623258
pulse in beats minute mean sd,C0232117;C0391850;C1947910
history chd,C0280604;C3542407
eligibility risk factors n,C0035648;C1553898
atrial fibrillation on baseline ecg n,C0344434;C0168634;C1442488
history coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0017654;C0439445;C1424601;C0369718;C0441922
major st depression or t wave inversion,C0041696;C1269683;C0520888
biochemical measures mean sd,C0079809;C2699239;C1879489
hdl c $nmbr$ mg dl,C3715113;C0439269
in trial $nmbr$ year rates per $nmbr$ se total events number at risk,C1264674;C1444641
lvh by echo or ecg,C0149721;C0058928;C1655045;C1623258
history chd,C0280604;C3542407
in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk,C0150312;C0008976;C0332285;C1707101;C1264674;C1444641
chlor,C0308648
atrial fibrillation on baseline ecg n,C0344434;C0168634;C1442488
$nmbr$ fe black,C0005680;C0027567;C0085756;C0439541
baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0017654;C0439445;C1424601;C0369718;C0441922
ment,C0084844;C1538994
biochemical measures mean sd,C0079809;C2699239;C1879489
women t,C0043210
in trial $nmbr$ year rates per $nmbr$ se total events number at risk,C1264674;C1444641
no atrial fibrillation,C0004238;C0344434;C1963067
in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk,C0150312;C0008976;C0332285;C1707101;C1264674;C1444641
chd at baseline,C0280604;C3542407
chlor,C0308648
no chd at baseline,C0280604;C3542407
$nmbr$ fe black,C0005680;C0027567;C0085756;C0439541
table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline,C4684572;C0034656;C3815594;C1524063;C0021641;C0439465;C1533581;C1579433;C3714501
ment,C0084844;C1538994
women t,C0043210
acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline,C0439165;C1549488;C1561533;C0439175;C0439810;C0332490;C0002460;C0238611;C0337920;C1165245;C0439064;C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0679646;C0205447;C0457464;C0168634;C1442488
no atrial fibrillation,C0004238;C0344434;C1963067
canagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
chd at baseline,C0280604;C3542407
age years median range,C1514721;C2348147;C3542016
no chd at baseline,C0280604;C3542407
othert,
table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline,C4684572;C0034656;C3815594;C1524063;C0021641;C0439465;C1533581;C1579433;C3714501
duration of diabetes years mean sd,C0449238;C2926735
insulin dose iu day median,C0549183;C0876920;C2347635;C2348144;C2939193
acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline,C0439165;C1549488;C1561533;C0439175;C0439810;C0332490;C0002460;C0238611;C0337920;C1165245;C0439064;C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0679646;C0205447;C0457464;C0168634;C1442488
insulin therapy n,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
canagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
basal plus bolus,C0205112;C1186706;C1511237;C1705509;C3812160
age years median range,C1514721;C2348147;C3542016
basal alone,C0205112;C0205171;C0439044;C0679994
othert,
bolus alone,C1186706;C1511237;C1705509;C3812160;C0205171;C0439044;C0679994
duration of diabetes years mean sd,C0449238;C2926735
other drug therapy n,C0013216;C0013217
insulin dose iu day median,C0549183;C0876920;C2347635;C2348144;C2939193
antithrombotic,
insulin therapy n,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
microvascular disease n,C0443258;C0012634
basal plus bolus,C0205112;C1186706;C1511237;C1705509;C3812160
retinopathy,C0035309;C1962966
basal alone,C0205112;C0205171;C0439044;C0679994
nephropathy,C0022658
bolus alone,C1186706;C1511237;C1705509;C3812160;C0205171;C0439044;C0679994
neuropathy,C0442874
other drug therapy n,C0013216;C0013217
atherosclerotic vascular disease n,C0004153
antithrombotic,
coronary,C0018787
microvascular disease n,C0443258;C0012634
cerebrovascular,C1880018
retinopathy,C0035309;C1962966
peripheral,C0205100
nephropathy,C0022658
sbp mmhg mean sd,C0085805;C2699239
neuropathy,C0442874
dbp mmhg mean sd,C0439475;C2699239
atherosclerotic vascular disease n,C0004153
hba $nmbr$ c mean sd,C0019016;C2699239;C1825777;C3538758
coronary,C0018787
mmol mol,C3829066
cerebrovascular,C1880018
total cholesterol mmol l mean sd,C0201950;C2699239;C0543421
peripheral,C0205100
triglycerides mmol l mean sd,C1532563;C2699239
sbp mmhg mean sd,C0085805;C2699239
hdl cholesterol mmol l mean sd,C0023822;C2699239;C0392885
dbp mmhg mean sd,C0439475;C2699239
ldl cholesterol mmol l mean sd,C0023824;C2699239;C0202117
hba $nmbr$ c mean sd,C0019016;C2699239;C1825777;C3538758
mmol mol,C3829066
ldl to hdl cholesterol ratio mean sd,C0428621;C1171408
total cholesterol mmol l mean sd,C0201950;C2699239;C0543421
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
triglycerides mmol l mean sd,C1532563;C2699239
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
hdl cholesterol mmol l mean sd,C0023822;C2699239;C0392885
acr mg g mean sd,C1300563;C2699239
microalbuminuria n,C0730345
ldl cholesterol mmol l mean sd,C0023824;C2699239;C0202117
macroalbuminuria n,
ldl to hdl cholesterol ratio mean sd,C0428621;C1171408
figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks,C1280500;C0178602;C0869039;C1114758;C1707455;C0032042;C1696465;C1706408;C0019016;C1079232;C1825777;C3538758
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
open label phase baseline week $nmbr$,C0332174;C0439230
acr mg g mean sd,C1300563;C2699239
randomized double blind reversal phase baseline week $nmbr$,C0332174;C0439230
microalbuminuria n,C0730345
total cohort,C0009247;C0599755
macroalbuminuria n,
azl ma,C0024443;C3887485
azl m cldb,
figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks,C1280500;C0178602;C0869039;C1114758;C1707455;C0032042;C1696465;C1706408;C0019016;C1079232;C1825777;C3538758
azl m,
open label phase baseline week $nmbr$,C0332174;C0439230
race no c,C0034510;C1706779;C3853635
randomized double blind reversal phase baseline week $nmbr$,C0332174;C0439230
baseline dbp mean sd mm hg,C0168634;C0439475;C1442488
total cohort,C0009247;C0599755
baseline sbp mean sd mm hg,C0085805;C0439475
azl ma,C0024443;C3887485
table $nmbr$ baseline demographics and clinical characteristics,C0011298;C1704791;C0683325
azl m cldb,
azl m,
all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation,C0030705;C3272598;C0332293;C0013175;C0168634;C1442488;C1299575;C0457987;C0871420
race no c,C0034510;C1706779;C3853635
linagliptin,C2746078
baseline dbp mean sd mm hg,C0168634;C0439475;C1442488
patients treated set n,C0030705;C0036849;C1442518;C1705195
baseline sbp mean sd mm hg,C0085805;C0439475
males n,C0086582
table $nmbr$ baseline demographics and clinical characteristics,C0011298;C1704791;C0683325
renal function egfr according to mdrd n,C1739039;C3811844;C3812682
normal $nmbr$ ml min,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation,C0030705;C3272598;C0332293;C0013175;C0168634;C1442488;C1299575;C0457987;C0871420
mild impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
linagliptin,C2746078
moderate impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
patients treated set n,C0030705;C0036849;C1442518;C1705195
severe to end stage impairment $nmbr$ ml min,C0205082;C4050465;C4050466
males n,C0086582
renal function egfr according to mdrd n,C1739039;C3811844;C3812682
patients full analysis sety n,C0030705;C0002778;C0936012;C1524024
normal $nmbr$ ml min,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
hba $nmbr$ c mmol mol mean sd,C3829066;C2699239
mild impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
time since diagnosis of diabetes mean sd,C0040223;C3541383
moderate impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
type of basal insulin n,C0457592
severe to end stage impairment $nmbr$ ml min,C0205082;C4050465;C4050466
insulin glargine,C0907402
patients full analysis sety n,C0030705;C0002778;C0936012;C1524024
insulin detemir,C0537270
nph,C0020258;C0027442
hba $nmbr$ c mmol mol mean sd,C3829066;C2699239
concomitant oads n,C0521115
time since diagnosis of diabetes mean sd,C0040223;C3541383
pioglitazone only,C0071097
type of basal insulin n,C0457592
metformin pioglitazone,C1635037
insulin glargine,C0907402
insulin detemir,C0537270
figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0457592;C0001779;C2986798;C0020258;C0332173;C0027442
nph,C0020258;C0027442
included in this study n $nmbr$,C0332257;C0557651;C2603343
concomitant oads n,C0521115
patients with early cd n $nmbr$,C0030705;C0007928;C0034283;C4552032
pioglitazone only,C0071097
age year median,C0549183;C0876920;C2347635;C2348144;C2939193
metformin pioglitazone,C1635037
disease duration year median,C0549183;C0876920;C2347635;C2348144;C2939193
crp median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0457592;C0001779;C2986798;C0020258;C0332173;C0027442
crp $nmbr$ $nmbr$ mg dl n,C3890735;C0439269;C4048285
included in this study n $nmbr$,C0332257;C0557651;C2603343
cdai score mean s d,C0449820;C0444504;C2347634;C2348143;C4050231
patients with early cd n $nmbr$,C0030705;C0007928;C0034283;C4552032
gastrointestinal area involved n total n,C0017446;C0205146
age year median,C0549183;C0876920;C2347635;C2348144;C2939193
upper gastrointestinal tract,C3203348
disease duration year median,C0549183;C0876920;C2347635;C2348144;C2939193
baseline crohn s disease medications,C0168634;C0010346;C1442488;C0013227;C0802604;C2598133;C4284232
crp median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
systemic corticosteroids n,C4053960
crp $nmbr$ $nmbr$ mg dl n,C3890735;C0439269;C4048285
budesonide n,C0054201
cdai score mean s d,C0449820;C0444504;C2347634;C2348143;C4050231
$nmbr$ asa compounds n,C0004057;C3853627
gastrointestinal area involved n total n,C0017446;C0205146
history of bowel resections n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
upper gastrointestinal tract,C3203348
early crohn s disease,C1279919;C0010346;C0012634
baseline crohn s disease medications,C0168634;C0010346;C1442488;C0013227;C0802604;C2598133;C4284232
non early crohn s disease,C1279919;C0010346;C0012634
systemic corticosteroids n,C4053960
remission component of variable,C0449432;C1705248
budesonide n,C0054201
azathioprine monotherapy,C0004482
$nmbr$ asa compounds n,C0004057;C3853627
infliximab monotherapy,C0666743
history of bowel resections n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
infliximab combination therapy,C4076075
early crohn s disease,C1279919;C0010346;C0012634
p valuer,C0369773;C0401806;C2603361
non early crohn s disease,C1279919;C0010346;C0012634
crj,
remission component of variable,C0449432;C1705248
mhi,
azathioprine monotherapy,C0004482
crpnonr,
infliximab monotherapy,C0666743
cr mh,C0026514;C2930980
infliximab combination therapy,C4076075
cr crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
p valuer,C0369773;C0401806;C2603361
mh crpnorr,C0026514;C2930980
crj,
cr mh crpnorr,C0201975;C0026514;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
mhi,
[ $nmbr$ ci],C0008107;C3259781
crpnonr,
a aza treatment ref,C0004482;C1425988
cr mh,C0026514;C2930980
ifx treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
cr crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
[ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
mh crpnorr,C0026514;C2930980
combination treatment ifx aza,C0020823;C0004482
cr mh crpnorr,C0201975;C0026514;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
previous cd related surgery ref a,C0007928;C1425988;C0034283;C4552032
[ $nmbr$ ci],C0008107;C3259781
no previous cd related surgery $nmbr$,C0038894;C0038895;C0543467;C1274039
a aza treatment ref,C0004482;C1425988
b aza treatment ref,C0004482;C1425988
ifx treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
history of bowel resection ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
[ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
combination treatment ifx aza,C0020823;C0004482
c kza treatment ref,C0039798;C1425988;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previous cd related surgery ref a,C0007928;C1425988;C0034283;C4552032
no hospitalization in the past $nmbr$ months prior to baseline ref,C0019993;C0439231;C0168634;C1425988;C1442488
no previous cd related surgery $nmbr$,C0038894;C0038895;C0543467;C1274039
hospitalization in the past $nmbr$ months prior to baseline,C0019993;C0439231;C0168634;C1442488
b aza treatment ref,C0004482;C1425988
no history of extra intestinal manifestations of ibd ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of bowel resection ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of extra intestinal manifestations of ibd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
d aza treatment ref,C0004482;C1425988
c kza treatment ref,C0039798;C1425988;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no steroid use at baseline ref,C0281991;C0168634;C1442488
no hospitalization in the past $nmbr$ months prior to baseline ref,C0019993;C0439231;C0168634;C1425988;C1442488
on steroid at baseline,C0038317;C0168634;C1442488
hospitalization in the past $nmbr$ months prior to baseline,C0019993;C0439231;C0168634;C1442488
e aza treatment ref,C0004482;C1425988
no history of extra intestinal manifestations of ibd ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
study $nmbr$,C0557651;C2603343
history of extra intestinal manifestations of ibd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
placebo $nmbr$ $nmbr$,C0032042;C1696465;C1706408
d aza treatment ref,C0004482;C1425988
reslizumab n $nmbr$,C1869620
no steroid use at baseline ref,C0281991;C0168634;C1442488
median age years iqr,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
on steroid at baseline,C0038317;C0168634;C1442488
mean body mass index kg mq,C0005893;C0024853;C0578022;C1305855
e aza treatment ref,C0004482;C1425988
$nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
study $nmbr$,C0557651;C2603343
mean time since diagnosis years,C0556970;C0011900;C1704338;C1704656
placebo $nmbr$ $nmbr$,C0032042;C1696465;C1706408
mean ics use at enrolment pg,C0042153;C0457083;C1947944
reslizumab n $nmbr$,C1869620
oral corticosteroid use at enrolmentt,C0239126
median age years iqr,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
laba use at enrolment,C0042153;C0457083;C1947944
mean body mass index kg mq,C0005893;C0024853;C0578022;C1305855
mean prebronchodilation l,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
mean predicted value prebronchodilation,C0444504;C0681842;C1882327;C2347634;C2348143
mean time since diagnosis years,C0556970;C0011900;C1704338;C1704656
mean reversibility,C0444504;C0449261;C2347634;C2348143
mean ics use at enrolment pg,C0042153;C0457083;C1947944
mean aqlq total score t,C3533236
oral corticosteroid use at enrolmentt,C0239126
mean acq $nmbr$ scores,C3533236;C2919686
laba use at enrolment,C0042153;C0457083;C1947944
mean asui scored,C0444504;C2347634;C2348143;C0449820
mean prebronchodilation l,C0444504;C2347634;C2348143
saba use in past $nmbr$ days,C0042153;C0457083;C1947944;C0439228
mean predicted value prebronchodilation,C0444504;C0681842;C1882327;C2347634;C2348143
mean number of puffs per day,C0444504;C0237753;C0449788;C2347634;C2348143;C0332173;C0439228;C0439505
mean reversibility,C0444504;C0449261;C2347634;C2348143
mean blood eosinophil count cells per pl,C0444504;C0200638;C2347634;C2348143
mean aqlq total score t,C3533236
mean acq $nmbr$ scores,C3533236;C2919686
mean number of caes in past $nmbr$ months number per patient ],C0444504;C0237753;C0449788;C2347634;C2348143;C0439231;C0030705
reslizumab,C1869620
mean asui scored,C0444504;C2347634;C2348143;C0449820
place,C0442504;C1533810;C1704765;C1882509
saba use in past $nmbr$ days,C0042153;C0457083;C1947944;C0439228
rate ratio $nmbr$ cl,C0456603;C0596019;C1547037
mean number of puffs per day,C0444504;C0237753;C0449788;C2347634;C2348143;C0332173;C0439228;C0439505
ocs at baseline,C0168634;C1442488
mean blood eosinophil count cells per pl,C0444504;C0200638;C2347634;C2348143
$nmbr$ $nmbr$ o $nmbr$ o $nmbr$,C0483204
mean number of caes in past $nmbr$ months number per patient ],C0444504;C0237753;C0449788;C2347634;C2348143;C0439231;C0030705
ics plus laba,C0815320;C4551720
reslizumab,C1869620
ics no laba,C0815320;C4551720
place,C0442504;C1533810;C1704765;C1882509
age s $nmbr$ years n $nmbr$ $nmbr$,C1510829
rate ratio $nmbr$ cl,C0456603;C0596019;C1547037
baseline tg level n $nmbr$ $nmbr$,C0168634;C0337445;C1442488
ocs at baseline,C0168634;C1442488
baseline tg level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
$nmbr$ $nmbr$ o $nmbr$ o $nmbr$,C0483204
statin only n $nmbr$ $nmbr$,C0360714;C0369718;C0441922
ics plus laba,C0815320;C4551720
statin ezetimibe n $nmbr$ $nmbr$,C0360714;C1142985
ics no laba,C0815320;C4551720
other n $nmbr$ $nmbr$ ],C0369718;C0441922
age s $nmbr$ years n $nmbr$ $nmbr$,C1510829
simvastatin n $nmbr$ $nmbr$,C0074554
baseline tg level n $nmbr$ $nmbr$,C0168634;C0337445;C1442488
atorvastatin n $nmbr$ $nmbr$,C0286651
baseline tg level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
rosuvastatin n $nmbr$ $nmbr$,C0965129
statin only n $nmbr$ $nmbr$,C0360714;C0369718;C0441922
diabetics yes n $nmbr$ $nmbr$,C0241863;C1549445;C1705108;C1710701
statin ezetimibe n $nmbr$ $nmbr$,C0360714;C1142985
diabetics no n $nmbr$ $nmbr$,C0241863;C0369718;C0441922
other n $nmbr$ $nmbr$ ],C0369718;C0441922
baseline ldlc level n $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
simvastatin n $nmbr$ $nmbr$,C0074554
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
atorvastatin n $nmbr$ $nmbr$,C0286651
baseline hdl c level n s $nmbr$ $nmbr$,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
rosuvastatin n $nmbr$ $nmbr$,C0965129
baseline hdl c level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
diabetics yes n $nmbr$ $nmbr$,C0241863;C1549445;C1705108;C1710701
baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0337445;C1442488;C0439269
diabetics no n $nmbr$ $nmbr$,C0241863;C0369718;C0441922
other n $nmbr$ $nmbr$,C0369718;C0441922
baseline ldlc level n $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
baseline hdl c level n s $nmbr$ $nmbr$,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
baseline hdl c level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
history of heart failure at baseline,C0455531;C0168634;C1442488
baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0337445;C1442488;C0439269
no history of heart failure at baseline,C0455531;C0168634;C1442488
other n $nmbr$ $nmbr$,C0369718;C0441922
baseline hba $nmbr$ c concentration,C0086045;C1446561;C3827302
baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
bodyweight kg,C0022718;C0439209;C4054209
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
cardiovascular risk factors and history,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
egfr ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
history of heart failure at baseline,C0455531;C0168634;C1442488
egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
no history of heart failure at baseline,C0455531;C0168634;C1442488
index acs event,C0441471;C4019010
baseline hba $nmbr$ c concentration,C0086045;C1446561;C3827302
time from index acs event to randomisation days,C0040223;C3541383;C0034656;C0439228
bodyweight kg,C0022718;C0439209;C4054209
nyha chf class,C1882083;C0018802
cardiovascular risk factors and history,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline bnp concentration pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
egfr ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
baseline concomitant cardiovascular medications,C0168634;C0007220;C1442488
egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
ace inhibitor arb or both,C0003015;C3888198;C4541021
index acs event,C0441471;C4019010
thiazide diuretics,C0012802
time from index acs event to randomisation days,C0040223;C3541383;C0034656;C0439228
loop diuretics,C0354100
nyha chf class,C1882083;C0018802
mras,C1335594;C1367476
baseline bnp concentration pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
primary mace endpoint,C2986535;C0349381;C0949745;C1445339
baseline concomitant cardiovascular medications,C0168634;C0007220;C1442488
non fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
ace inhibitor arb or both,C0003015;C3888198;C4541021
non fatal stroke,C0038454;C4554100
thiazide diuretics,C0012802
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ t,C2603360
loop diuretics,C0354100
pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0455531
mras,C1335594;C1367476
secondary mace endpoint,C4528314;C0349381;C0949745;C1445339
primary mace endpoint,C2986535;C0349381;C0949745;C1445339
urgent revascularisation due to unstable angina,C0581603;C0002965
non fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
cardiovascular death and hospital admission for heart failure,C0011065;C1306577;C4082313;C4552775;C0184666;C0018801;C0018802;C4554158
non fatal stroke,C0038454;C4554100
hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ t,C2603360
normal responder n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0455531
sensitive responder n $nmbr$,C0020517;C0332324;C1522640
secondary mace endpoint,C4528314;C0349381;C0949745;C1445339
highly sensitive responder n $nmbr$,C0439822
urgent revascularisation due to unstable angina,C0581603;C0002965
median age [interquartile range] yr,C0549183;C0001779;C0876920;C2347635;C2348144;C2939193;C1711350;C0439234
cardiovascular death and hospital admission for heart failure,C0011065;C1306577;C4082313;C4552775;C0184666;C0018801;C0018802;C4554158
atrial fibrillation no,C0004238;C0344434;C1963067
hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
qualifying risk factors no,C1514624;C0035648;C1553898
normal responder n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
chads $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
sensitive responder n $nmbr$,C0020517;C0332324;C1522640
previous exposure to a vitamin k antagonist no current or former never,C0332157;C1096489;C2267235;C0521116;C1705970;C0205156;C0750523
highly sensitive responder n $nmbr$,C0439822
medications at time of randomization no,C0013227;C0802604;C2598133;C4284232
median age [interquartile range] yr,C0549183;C0001779;C0876920;C2347635;C2348144;C2939193;C1711350;C0439234
digoxin or digitalis preparations,C0012265;C0304520
atrial fibrillation no,C0004238;C0344434;C1963067
asia pacific and south africa,C0003980;C0037712
qualifying risk factors no,C1514624;C0035648;C1553898
edoxaban higher dose vs warfarin,C2975435;C0444956;C0043031
chads $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
edoxaban lower dose vs warfarin,C2975435;C0445550;C1708745;C0043031
previous exposure to a vitamin k antagonist no current or former never,C0332157;C1096489;C2267235;C0521116;C1705970;C0205156;C0750523
higher dose,C0444956
medications at time of randomization no,C0013227;C0802604;C2598133;C4284232
lower dose,C0445550;C1708745
digoxin or digitalis preparations,C0012265;C0304520
pinteraction,
asia pacific and south africa,C0003980;C0037712
any overt bleed,C0019080
edoxaban higher dose vs warfarin,C2975435;C0444956;C0043031
normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
edoxaban lower dose vs warfarin,C2975435;C0445550;C1708745;C0043031
sensitive,C0020517;C0332324;C1522640
higher dose,C0444956
highly sensitive,C0439822
lower dose,C0445550;C1708745
major or clinically relevant non major bleed,C0205082;C0205164;C4318856;C4521762;C0019080
pinteraction,
clinically relevant non,C2347946;C1518422
any overt bleed,C0019080
background therapy,C0039798;C0087111;C1363945
normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
su,C0038642;C1705534
sensitive,C0020517;C0332324;C1522640
biguanide,C0005382;C3537187;C4317165
highly sensitive,C0439822
agi,C1299007
major or clinically relevant non major bleed,C0205082;C0205164;C4318856;C4521762;C0019080
dpp $nmbr$ inhibitor,C1414174;C1999216
clinically relevant non,C2347946;C1518422
glinide,C2266929
background therapy,C0039798;C0087111;C1363945
study drug,C0013175
su,C0038642;C1705534
empagliflozin,C3490348
biguanide,C0005382;C3537187;C4317165
metformin open label,C0025598;C1709323
agi,C1299007
time since diagnosis of t $nmbr$ dm,C0040223;C3541383
dpp $nmbr$ inhibitor,C1414174;C1999216
$nmbr$ year,C0439234;C0439508
glinide,C2266929
$nmbr$ to $nmbr$ years,C0439234
study drug,C0013175
systolic blood pressure mmhg,C0488055;C0439475;C0871470;C1306620
empagliflozin,C3490348
metformin open label,C0025598;C1709323
diastolic blood pressure mmhg,C0428883;C0439475;C1305849
time since diagnosis of t $nmbr$ dm,C0040223;C3541383
figure must be in supplement is not in paper,C0242295;C1947943;C2348609;C1518422;C0030351;C1547566
$nmbr$ year,C0439234;C0439508
heparin alone n $nmbr$,C0019134;C0205171;C0439044;C0679994;C0770546
$nmbr$ to $nmbr$ years,C0439234
heparin plus tirofiban n $nmbr$,C0019134;C0770546
systolic blood pressure mmhg,C0488055;C0439475;C0871470;C1306620
type of ml no,C0332307;C1547052
symptom onset to hospital arrival median iqr h,C4086878;C0019994;C1510665
diastolic blood pressure mmhg,C0428883;C0439475;C1305849
killip class $nmbr$ no,C1881332
figure must be in supplement is not in paper,C0242295;C1947943;C2348609;C1518422;C0030351;C1547566
anemia no total,C0002871;C1000483;C4554633;C0439175;C0439810
heparin alone n $nmbr$,C0019134;C0205171;C0439044;C0679994;C0770546
crusade bleeding score mean sd ^,C0019080;C2699239
heparin plus tirofiban n $nmbr$,C0019134;C0770546
$nmbr$ moderate or high bleeding risk no total,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0332167;C3272283;C4050568;C4319571;C0439175;C0439810
type of ml no,C0332307;C1547052
heparin tirofiban n $nmbr$,C0019134;C0247025;C0770546
symptom onset to hospital arrival median iqr h,C4086878;C0019994;C1510665
relative risk $nmbr$ ci,C0008107;C3259781
killip class $nmbr$ no,C1881332
no of events total no $nmbr$,C0439175;C0439810
anemia no total,C0002871;C1000483;C4554633;C0439175;C0439810
$nmbr$ years old,C0439234;C0580836
crusade bleeding score mean sd ^,C0019080;C2699239
class ll iv,C0456387;C1518526;C1705943;C0022326;C4265176
$nmbr$ moderate or high bleeding risk no total,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0332167;C3272283;C4050568;C4319571;C0439175;C0439810
arterial access,C0444454;C1554204
heparin tirofiban n $nmbr$,C0019134;C0247025;C0770546
transradial,
relative risk $nmbr$ ci,C0008107;C3259781
transfemoral,
no of events total no $nmbr$,C0439175;C0439810
previous cv events,C0441471;C3541888
$nmbr$ years old,C0439234;C0580836
crusade score,C0449820;C4050231
class ll iv,C0456387;C1518526;C1705943;C0022326;C4265176
target vessel,C0449618
arterial access,C0444454;C1554204
lad artery,C0003842;C0226004
transradial,
non lad artery,C0003842;C0226004
transfemoral,
no of events total no,C0439175;C0439810
previous cv events,C0441471;C3541888
killip ciass,
crusade score,C0449820;C4050231
ciass ll iv,C0022326;C4265176
target vessel,C0449618
ciass i,C0021966;C0221138
lad artery,C0003842;C0226004
creatinine ciearance,C0010294;C1561535
non lad artery,C0003842;C0226004
$nmbr$ mi min,C0702093;C1524029;C3813700
no of events total no,C0439175;C0439810
arteriai access,C0444454;C1554204
killip ciass,
no of events totol no,C0441471;C3541888
ciass ll iv,C0022326;C4265176
placebo golimumab $nmbr$ mg $nmbr$ mga b,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ciass i,C0021966;C0221138
$nmbr$ mg $nmbr$ mgc,C0024671;C3888239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
creatinine ciearance,C0010294;C1561535
$nmbr$ mg $nmbr$ mgb,C0024671;C0373680;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mi min,C0702093;C1524029;C3813700
randomized patients,C0034656;C0030705;C3815594
arteriai access,C0444454;C1554204
psa modified shs $nmbr$ $nmbr$,C3810537;C0392747;C3889737;C3813209
no of events totol no,C0441471;C3541888
ptga $nmbr$ $nmbr$ cm vas,C0042815;C3536884;C3827561
placebo golimumab $nmbr$ mg $nmbr$ mga b,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pasi score $nmbr$ $nmbr$ d,C0449820;C4050231
$nmbr$ mg $nmbr$ mgc,C0024671;C3888239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
methotrexate use at baseline,C0042153;C0457083;C1947944
$nmbr$ mg $nmbr$ mgb,C0024671;C0373680;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebofigolimumab $nmbr$ mg $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
randomized patients,C0034656;C0030705;C3815594
golimumab $nmbr$ mg $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
psa modified shs $nmbr$ $nmbr$,C3810537;C0392747;C3889737;C3813209
mtx use at baseline,C0042153;C0457083;C1947944
ptga $nmbr$ $nmbr$ cm vas,C0042815;C3536884;C3827561
no mtx use at baseline,C0042153;C0457083;C1947944
pasi score $nmbr$ $nmbr$ d,C0449820;C4050231
no patients with,C0030705
methotrexate use at baseline,C0042153;C0457083;C1947944
available data,C1511726;C3245479;C3714741
placebofigolimumab $nmbr$ mg $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction,C0021149;C0220856;C0446516;C3715044;C4553528;C0441833;C1706365;C1999270;C0155626;C3541950
golimumab $nmbr$ mg $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mitt population n $nmbr$,C0032659;C1257890
mtx use at baseline,C0042153;C0457083;C1947944
bmi $nmbr$ kg m $nmbr$ population n $nmbr$,C0022718;C0439209;C4054209;C0032659;C1257890
no mtx use at baseline,C0042153;C0457083;C1947944
race ethnicity no,C0015031;C0243103
no patients with,C0030705
canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
available data,C1511726;C3245479;C3714741
hba $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mm hg ldl c $nmbr$ mg dl,C0967300;C0439269
figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction,C0021149;C0220856;C0446516;C3715044;C4553528;C0441833;C1706365;C1999270;C0155626;C3541950
insulin lispro mix $nmbr$,C0205430;C1421951;C1720722;C4553942
mitt population n $nmbr$,C0032659;C1257890
caucasians n $nmbr$,C0007457;C0043157
bmi $nmbr$ kg m $nmbr$ population n $nmbr$,C0022718;C0439209;C4054209;C0032659;C1257890
asians n $nmbr$,C0078988
race ethnicity no,C0015031;C0243103
mg dl fpg mmol l,C0439268
canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
phg,
hba $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mm hg ldl c $nmbr$ mg dl,C0967300;C0439269
fhg,
insulin lispro mix $nmbr$,C0205430;C1421951;C1720722;C4553942
fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc,C0871261;C0168634;C1442488;C2349179;C2826544;C0205430;C1421951;C1720722;C4553942;C0019016;C2828255;C1825777;C3538758;C0015663;C0020456;C0376690;C4552833;C1855520
caucasians n $nmbr$,C0007457;C0043157
ranolazine n $nmbr$ $nmbr$,C0073633
asians n $nmbr$,C0078988
age years mean $nmbr$ sd,C1510829;C2699239
mg dl fpg mmol l,C0439268
not reported,C0684224;C0700287;C4319718
phg,
weight kg mean $nmbr$ sd,C0005910;C2699239;C0043100;C1305866;C1705104
fhg,
bmi kg m $nmbr$ mean $nmbr$ sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc,C0871261;C0168634;C1442488;C2349179;C2826544;C0205430;C1421951;C1720722;C4553942;C0019016;C2828255;C1825777;C3538758;C0015663;C0020456;C0376690;C4552833;C1855520
hba $nmbr$ c mean $nmbr$ sd,C0019016;C2699239;C1825777;C3538758
ranolazine n $nmbr$ $nmbr$,C0073633
hba $nmbr$ c mmol mol mean,C0444504;C2347634;C2348143
age years mean $nmbr$ sd,C1510829;C2699239
fsg mg dl mean sd,C0439269;C2699239
not reported,C0684224;C0700287;C4319718
diabetes duration years mean sd,C0011847;C2699239;C0011849
weight kg mean $nmbr$ sd,C0005910;C2699239;C0043100;C1305866;C1705104
took prior antihyperglycemic agent any,C1515187;C0450442;C1254351;C1521826
bmi kg m $nmbr$ mean $nmbr$ sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
sulfonylureas,C0038766;C3653359
hba $nmbr$ c mean $nmbr$ sd,C0019016;C2699239;C1825777;C3538758
concomitant lipid lowering therapy any,C0585943
hba $nmbr$ c mmol mol mean,C0444504;C2347634;C2348143
fibrates,C1449704;C3540783
fsg mg dl mean sd,C0439269;C2699239
niacin,C0027996;C1142562
diabetes duration years mean sd,C0011847;C2699239;C0011849
asteria i ii,C1710602;C4082587
took prior antihyperglycemic agent any,C1515187;C0450442;C1254351;C1521826
glacial $nmbr$,
sulfonylureas,C0038766;C3653359
placebo n [ $nmbr$,C0032042;C1696465;C1706408
concomitant lipid lowering therapy any,C0585943
omalizumab $nmbr$ mg n [ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fibrates,C1449704;C3540783
time since diagnosis of ciu csuf y,C0040223;C3541383
niacin,C0027996;C1142562
positive cu index test z n,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
asteria i ii,C1710602;C4082587
no of previous ciu csu medications mean median,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
glacial $nmbr$,
previous use of systemic steroids n,C0281991
placebo n [ $nmbr$,C0032042;C1696465;C1706408
total ige levelx iu ml median range,C1514721;C2348147;C3542016
omalizumab $nmbr$ mg n [ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
in clinic uask,C0150312;C0002424;C0442592;C0332285;C1707101
time since diagnosis of ciu csuf y,C0040223;C3541383
weekly iss,C1740819;C1845118
positive cu index test z n,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
weekly number of hives score,C0237753;C0449788
no of previous ciu csu medications mean median,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
weekly size of largest hives score,C0456389;C0042109
previous use of systemic steroids n,C0281991
overall dlqi score,C0282416;C3897059;C1561607
total ige levelx iu ml median range,C1514721;C2348147;C3542016
angioedema present n,C0002994;C0150312;C0449450
in clinic uask,C0150312;C0002424;C0442592;C0332285;C1707101
primary key efficacy endpoint,C2986535
weekly iss,C1740819;C1845118
change from baseline to week $nmbr$ in weekly iss,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C1740819;C1845118
weekly number of hives score,C0237753;C0449788
additional endpoints,C1524062;C2349179
weekly size of largest hives score,C0456389;C0042109
change from baseline to week $nmbr$ in uas $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
overall dlqi score,C0282416;C3897059;C1561607
change from baseline to week $nmbr$ in weekly no of hives score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0042109;C0449820;C4050231
angioedema present n,C0002994;C0150312;C0449450
median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f,C0040223;C3541383;C0871261;C1704632;C1706817;C2911692
primary key efficacy endpoint,C2986535
$nmbr$ $nmbr$ ne ne,C0027608;C0028219;C3538705
change from baseline to week $nmbr$ in weekly iss,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C1740819;C1845118
hr vs placebo $nmbr$ ci,C0008107;C3259781
additional endpoints,C1524062;C2349179
patients with weekly iss mid response n v,C0030705;C0332174;C0871261;C1704632;C1706817;C2911692
change from baseline to week $nmbr$ in uas $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
change from baseline to week $nmbr$ in weekly size of largest hive score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0456389;C0042109;C0221232
change from baseline to week $nmbr$ in weekly no of hives score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0042109;C0449820;C4050231
change from baseline to week $nmbr$ in dlqi scorez,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C3899393
median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f,C0040223;C3541383;C0871261;C1704632;C1706817;C2911692
proportion of angioedema free days from week $nmbr$ to week $nmbr$ x,C1709707;C0002994;C0332174;C0439230
$nmbr$ $nmbr$ ne ne,C0027608;C0028219;C3538705
ranotazine vs placebo km failure rate,C0231174;C0680095
hr vs placebo $nmbr$ ci,C0008107;C3259781
hr $nmbr$ s ci,C0008107;C3259781
patients with weekly iss mid response n v,C0030705;C0332174;C0871261;C1704632;C1706817;C2911692
primary ep cvd mi ri,C0035487;C1826843
change from baseline to week $nmbr$ in weekly size of largest hive score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0456389;C0042109;C0221232
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$,
change from baseline to week $nmbr$ in dlqi scorez,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C3899393
$nmbr$ $nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
proportion of angioedema free days from week $nmbr$ to week $nmbr$ x,C1709707;C0002994;C0332174;C0439230
no pci,C4049621
ranotazine vs placebo km failure rate,C0231174;C0680095
$nmbr$ $nmbr$ vi $nmbr$ $nmbr$,C0205999
hr $nmbr$ s ci,C0008107;C3259781
recurrent ischemia,C0022116;C4321499
primary ep cvd mi ri,C0035487;C1826843
ranolazine vs placebo km failure rate,C0073633;C0231174;C0680095
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$,
hr $nmbr$ s a,
$nmbr$ $nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
rec ischemia requiring revasc,C0022116;C4321499;C0378365
no pci,C4049621
rec ischemia leading to hosp,C0022116;C4321499;C0332152;C1522538
$nmbr$ $nmbr$ vi $nmbr$ $nmbr$,C0205999
rec ischemia,C0022116;C4321499
recurrent ischemia,C0022116;C4321499
due to ecg changes,C0855329
ranolazine vs placebo km failure rate,C0073633;C0231174;C0680095
due worsening angina,C0678226;C3146286;C0332271;C1457868;C1546960;C0002962
hr $nmbr$ s a,
de $nmbr$ mg bid n $nmbr$ $nmbr$,C0011198;C0017480;C3541240
rec ischemia requiring revasc,C0022116;C4321499;C0378365
warfarin n $nmbr$ $nmbr$,C0043031
rec ischemia leading to hosp,C0022116;C4321499;C0332152;C1522538
gfr ckd epi,C1561643;C0162734;C4281721
rec ischemia,C0022116;C4321499
ckd stages,C1561643;C1306673
due to ecg changes,C0855329
$nmbr$ $nmbr$ to $nmbr$ ml min,C0439445
due worsening angina,C0678226;C3146286;C0332271;C1457868;C1546960;C0002962
history of stroke see tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
de $nmbr$ mg bid n $nmbr$ $nmbr$,C0011198;C0017480;C3541240
history of heart failure,C0455531
warfarin n $nmbr$ $nmbr$,C0043031
documented coronary artery disease,C0010054;C0010068;C1956346
gfr ckd epi,C1561643;C0162734;C4281721
hypertension requiring medical treatment,C0020538;C1963138;C0679624
ckd stages,C1561643;C1306673
previous vka use stratified randomization,C0042153;C4687737;C0457083;C1947944
$nmbr$ $nmbr$ to $nmbr$ ml min,C0439445
naive,
history of stroke see tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
experienced,
history of heart failure,C0455531
duration of previous use of vka months,C1881378;C2826775
documented coronary artery disease,C0010054;C0010068;C1956346
q $nmbr$ q $nmbr$,
hypertension requiring medical treatment,C0020538;C1963138;C0679624
normal study termination,C1549081;C1692758
previous vka use stratified randomization,C0042153;C4687737;C0457083;C1947944
concomitant medication $nmbr$,C0013227;C3244316;C4284232
naive,
p gp inhibitor,C3898062
experienced,
vitamins,C0042890;C3540032;C3714649
duration of previous use of vka months,C1881378;C2826775
oral hypoglycemic,C0359086
q $nmbr$ q $nmbr$,
alpha blocker other vasodilator,C0001641;C0042402;C3537240
normal study termination,C1549081;C1692758
previous vka use,C0042153;C0457083;C1947944
concomitant medication $nmbr$,C0013227;C3244316;C4284232
mean se,C0444504;C0036919;C2347634;C2348143
p gp inhibitor,C3898062
$nmbr$ $nmbr$ _ $nmbr$ $nmbr$,
vitamins,C0042890;C3540032;C3714649
adjusted mean se change from baseline,C0392747;C0443172;C1705241;C4319952
oral hypoglycemic,C0359086
p value vs previous time point,C1709380;C0205156;C2348792;C1552607
alpha blocker other vasodilator,C0001641;C0042402;C3537240
calculated annual decline mean se,C0332181;C0036919
previous vka use,C0042153;C0457083;C1947944
adjusted mean _ se change from baseline,C0392747;C0443172;C1705241;C4319952
mean se,C0444504;C0036919;C2347634;C2348143
elderly patients n $nmbr$,C0870602
$nmbr$ $nmbr$ _ $nmbr$ $nmbr$,
very elderly patients n $nmbr$,C0442824;C0870602;C2984081
adjusted mean se change from baseline,C0392747;C0443172;C1705241;C4319952
p between age groups,C0441849;C1959644
p value vs previous time point,C1709380;C0205156;C2348792;C1552607
olmesartan along with ccb n $nmbr$,C1098320;C0006684
calculated annual decline mean se,C0332181;C0036919
olmesartan along with diuretic n $nmbr$,C1098320;C0012798
adjusted mean _ se change from baseline,C0392747;C0443172;C1705241;C4319952
grade of hypertension,C0441800;C0919553;C3244287
elderly patients n $nmbr$,C0870602
grade $nmbr$,C0441800;C0919553;C3244287
very elderly patients n $nmbr$,C0442824;C0870602;C2984081
previous history of cardiovascular events,C2004062
p between age groups,C0441849;C1959644
drinking,C0001948;C0684271
olmesartan along with ccb n $nmbr$,C1098320;C0006684
number of visits median,C1549755;C0549183;C0876920;C2347635;C2348144;C2939193
olmesartan along with diuretic n $nmbr$,C1098320;C0012798
number of visits mean sd,C1549755;C0444504;C2347634;C2348143
grade of hypertension,C0441800;C0919553;C3244287
sbp during the follow up period mmhg,C0085805;C0589120;C1522577;C1704685;C3274571
grade $nmbr$,C0441800;C0919553;C3244287
dbp during the follow up period mmhg,C0536221;C3813197;C4281799
previous history of cardiovascular events,C2004062
uncover $nmbr$,
drinking,C0001948;C0684271
etanercept n $nmbr$,C0717758
number of visits median,C1549755;C0549183;C0876920;C2347635;C2348144;C2939193
ixekizumab every $nmbr$ weeks n $nmbr$,C3489764;C0439230
number of visits mean sd,C1549755;C0444504;C2347634;C2348143
nx,C0445085
sbp during the follow up period mmhg,C0085805;C0589120;C1522577;C1704685;C3274571
bmi kg per m $nmbr$,C0022718;C0439209;C4054209
dbp during the follow up period mmhg,C0536221;C3813197;C4281799
psoriasis duration years,C0033860;C0439234
uncover $nmbr$,
percentage of bsa involved,C0439165;C1549488;C1561533;C1314939
etanercept n $nmbr$,C0717758
spga $nmbr$,
ixekizumab every $nmbr$ weeks n $nmbr$,C3489764;C0439230
pasi,C4528685
nx,C0445085
qids sr $nmbr$,C4331197
bmi kg per m $nmbr$,C0022718;C0439209;C4054209
napsit,
psoriasis duration years,C0033860;C0439234
itch nrs,C2240043;C4050142
percentage of bsa involved,C0439165;C1549488;C1561533;C1314939
previous therapy,C0039798;C0087111;C1363945
spga $nmbr$,
topical prescription,C0033080;C1521941
pasi,C4528685
topical non prescription,C0332237;C1518422;C0033080;C1521941
qids sr $nmbr$,C4331197
phototherapy,C0031765
napsit,
non biological systemic,C0445097;C0205373
itch nrs,C2240043;C4050142
biological,C0005532;C0205460
previous therapy,C0039798;C0087111;C1363945
diabetics n $nmbr$,C0241863
topical prescription,C0033080;C1521941
non diabetics n $nmbr$,C1518422;C0241863
topical non prescription,C0332237;C1518422;C0033080;C1521941
patients with dm n $nmbr$,C0030705;C0011816;C3250443
phototherapy,C0031765
patients without dm n $nmbr$,C0030705;C0011816;C3250443
non biological systemic,C0445097;C0205373
patients with dm vs patients without dm,C0030705;C0011816;C3250443
biological,C0005532;C0205460
age\\yr,C0001779;C0439234
diabetics n $nmbr$,C0241863
b $nmbr$ $nmbr$,
non diabetics n $nmbr$,C1518422;C0241863
year,C0439234;C0439508
patients with dm n $nmbr$,C0030705;C0011816;C3250443
male sex \ no,C0086582
patients without dm n $nmbr$,C0030705;C0011816;C3250443
body mass index \ kg m $nmbr$,C0022718;C0439209;C4054209
patients with dm vs patients without dm,C0030705;C0011816;C3250443
ischemic stroke incl uncertain,C0948008;C0087130;C4085655
age\\yr,C0001779;C0439234
hba $nmbr$ c \n,C0019016;C1825777;C3538758
b $nmbr$ $nmbr$,
hemorrhagic stroke,C0553692
year,C0439234;C0439508
\mean sd,C0444504;C2699239;C2347634;C2348143
male sex \ no,C0086582
af type no,C0332307;C1547052
body mass index \ kg m $nmbr$,C0022718;C0439209;C4054209
median crcl ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
ischemic stroke incl uncertain,C0948008;C0087130;C4085655
peripheral arterial disease no,C0085096;C1704436
hba $nmbr$ c \n,C0019016;C1825777;C3538758
baseline chads $nmbr$ a c,C0168634;C1442488
hemorrhagic stroke,C0553692
baseline cha $nmbr$ ds $nmbr$ vascb c,C0168634;C1420648;C1442488
\mean sd,C0444504;C2699239;C2347634;C2348143
patients without dm n $nmbr$ $nmbr$,C0030705;C0011816;C3250443
af type no,C0332307;C1547052
stroke or systemic,C0038454;C4554100;C0205373
median crcl ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
embolism,C0013922;C1704212
peripheral arterial disease no,C0085096;C1704436
incl uncertain,C0087130;C4085655
baseline chads $nmbr$ a c,C0168634;C1442488
ustekinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline cha $nmbr$ ds $nmbr$ vascb c,C0168634;C1420648;C1442488
duration of disease years,C0872146;C0439234
patients without dm n $nmbr$ $nmbr$,C0030705;C0011816;C3250443
psoriatic arthritis,C0003872
stroke or systemic,C0038454;C4554100;C0205373
psoriasis,C0033860
embolism,C0013922;C1704212
patients with psoriasis $nmbr$ of body surface area,C0030705;C0005902
incl uncertain,C0087130;C4085655
pasi score,C0449820;C4050231
ustekinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
dlqi score,C3897059
duration of disease years,C0872146;C0439234
swollen joint count,C0451521
psoriatic arthritis,C0003872
tender joint count,C0451530
psoriasis,C0033860
crp mg l,C3890735;C0439268;C4048285
patients with psoriasis $nmbr$ of body surface area,C0030705;C0005902
haq di score,C0449820;C4050231
pasi score,C0449820;C4050231
dactylitis in $nmbr$ digit,C0239161;C0582802;C3241971
dlqi score,C3897059
dactylitis score,C0449820;C4050231
swollen joint count,C0451521
enthesitis score,C0449820;C4050231
tender joint count,C0451530
mental component,C0449432;C1705248
crp mg l,C3890735;C0439268;C4048285
physical component,C0449432;C1705248
haq di score,C0449820;C4050231
dose mg week,C0332174;C0439230
dactylitis in $nmbr$ digit,C0239161;C0582802;C3241971
mean dose sd mg week,C0332174;C0439230
dactylitis score,C0449820;C4050231
oral corticosteroid,C0442027;C0001617;C3536709;C4521986
enthesitis score,C0449820;C4050231
dose mg day,C0178602;C0439422;C0869039;C1114758
mental component,C0449432;C1705248
mean dose sd mg day,C0178602;C0439422;C0869039;C1114758
physical component,C0449432;C1705248
non steroidal anti inflammatory drugs,C0003211
dose mg week,C0332174;C0439230
placebo to ustekinumab $nmbr$ mgt,C0032042;C1696465;C1706408
mean dose sd mg week,C0332174;C0439230
ustekinumab,C1608841
oral corticosteroid,C0442027;C0001617;C3536709;C4521986
patients randomized no,C0030705;C0034656;C3815594
dose mg day,C0178602;C0439422;C0869039;C1114758
clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
mean dose sd mg day,C0178602;C0439422;C0869039;C1114758
patients no,C0030705
non steroidal anti inflammatory drugs,C0003211
acr $nmbr$,C1412134;C1515941
placebo to ustekinumab $nmbr$ mgt,C0032042;C1696465;C1706408
acr response by baseline weight,C0871261;C1704632;C1706817;C2911692
ustekinumab,C1608841
no total no,C0439175;C0439810
patients randomized no,C0030705;C0034656;C3815594
acr response by baseline mtx use no total no acr $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C1412134;C1515941
clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
good moderate response,C0205170;C4085643
patients no,C0030705
remission,C0544452;C0687702
acr $nmbr$,C1412134;C1515941
change from baseline median iqr,C0392747;C0443172;C1705241;C4319952
acr response by baseline weight,C0871261;C1704632;C1706817;C2911692
patients with improvement $nmbr$ $nmbr$,C0030705;C2986411
no total no,C0439175;C0439810
patients with $nmbr$ bsa at baseline no,C0030705;C0168634;C1442488
acr response by baseline mtx use no total no acr $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C1412134;C1515941
pasi $nmbr$ at week $nmbr$,C4528685;C0332174;C0439230
good moderate response,C0205170;C4085643
no total no t,C0439175;C0439810;C2603360
remission,C0544452;C0687702
pasi $nmbr$ no total no $nmbr$,C4528685;C0439175;C0439810
change from baseline median iqr,C0392747;C0443172;C1705241;C4319952
pasi response by baseline weight no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
patients with improvement $nmbr$ $nmbr$,C0030705;C2986411
pasi response by baseline mtx use no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
patients with $nmbr$ bsa at baseline no,C0030705;C0168634;C1442488
$nmbr$ $nmbr$ $nmbr$ $nmbr$ continued,C0549178
pasi $nmbr$ at week $nmbr$,C4528685;C0332174;C0439230
patients with dactylitis at baseline no,C0030705;C0239161;C0168634;C1442488
no total no t,C0439175;C0439810;C2603360
dactylitis score at baseline median iqr week $nmbr$,C0449820;C4050231
pasi $nmbr$ no total no $nmbr$,C4528685;C0439175;C0439810
score improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
pasi response by baseline weight no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
percent improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
pasi response by baseline mtx use no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C0239161;C0332174;C1282952;C0439230
$nmbr$ $nmbr$ $nmbr$ $nmbr$ continued,C0549178
patients with enthesitis at baseline no,C0030705;C1282952;C0168634;C1442488
patients with dactylitis at baseline no,C0030705;C0239161;C0168634;C1442488
enthesitis score at baseline median iqr week $nmbr$,C0449820;C4050231
dactylitis score at baseline median iqr week $nmbr$,C0449820;C4050231
score improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score,C0030705;C1282952;C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
mean $nmbr$ sd,C0444504;C2699239;C2347634;C2348143
percent improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C0239161;C0332174;C1282952;C0439230
median iqr change from baseline to week $nmbr$ in psa modified total shs score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
patients with enthesitis at baseline no,C0030705;C1282952;C0168634;C1442488
median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight,C0444504;C0168634;C1442488;C2347634;C2348143;C0332174;C0439230;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0005910;C0043100;C1305866;C1705104
enthesitis score at baseline median iqr week $nmbr$,C0449820;C4050231
$nmbr$ kg mtx use,C0042153;C0457083;C1947944
patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score,C0030705;C1282952;C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
patients with change from baseline in psa modified total shs score $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
mean $nmbr$ sd,C0444504;C2699239;C2347634;C2348143
low risk n $nmbr$ $nmbr$,C3272281;C3538919
median iqr change from baseline to week $nmbr$ in psa modified total shs score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
high risk n $nmbr$ $nmbr$,C0332167;C3272283;C4050568;C4319571
median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight,C0444504;C0168634;C1442488;C2347634;C2348143;C0332174;C0439230;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0005910;C0043100;C1305866;C1705104
time since diagnosis of copd years,C0556970;C0011900;C1704338;C1704656
spirometry,C0037981
$nmbr$ kg mtx use,C0042153;C0457083;C1947944
fev $nmbr$ l,C3714541
patients with change from baseline in psa modified total shs score $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
respiratory medication taken at baseline n,C0418986;C1883727;C0168634;C1442488
low risk n $nmbr$ $nmbr$,C3272281;C3538919
anticholinergics,C0242896;C3537307;C3540711
high risk n $nmbr$ $nmbr$,C0332167;C3272283;C4050568;C4319571
ics,C0815320;C4551720
time since diagnosis of copd years,C0556970;C0011900;C1704338;C1704656
other steroids,C0038317
spirometry,C0037981
ics laba free or fdc,C0332296;C1880497;C1996904;C0340427;C1413520;C3539652
fev $nmbr$ l,C3714541
patient classification,C0008902;C0008903;C0678229
respiratory medication taken at baseline n,C0418986;C1883727;C0168634;C1442488
salmeterol,C0073992
anticholinergics,C0242896;C3537307;C3540711
tiotropium vs salmeterol,C0213771;C0073992
ics,C0815320;C4551720
number of patients with events,C2360800;C0441471;C3541888
other steroids,C0038317
low risk,C3272281;C3538919
ics laba free or fdc,C0332296;C1880497;C1996904;C0340427;C1413520;C3539652
infrequent exacerbator,C0521114
patient classification,C0008902;C0008903;C0678229
frequent exacerbator,C0332183
salmeterol,C0073992
low risk ics,C0815320;C4551720
tiotropium vs salmeterol,C0213771;C0073992
high risk ics,C0815320;C4551720
number of patients with events,C2360800;C0441471;C3541888
olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
low risk,C3272281;C3538919
tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
infrequent exacerbator,C0521114
tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
frequent exacerbator,C0332183
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
low risk ics,C0815320;C4551720
tiotropium olodaterol $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
high risk ics,C0815320;C4551720
gold $nmbr$ $nmbr$,C0018026;C1304897
olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
participants n,C0679646
tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
current smoker n post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
mean sd fevi ml,C0439526;C1705224;C3887665
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
mean sd change from pre to post bronchodilator fevi ml,C2599594;C3481639
tiotropium olodaterol $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
mean sd fevi fvc,C0802741;C3815113
gold $nmbr$ $nmbr$,C0018026;C1304897
participants n,C0679646
mean sd of predicted normal fevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
gold $nmbr$ $nmbr$ n $nmbr$,C0018026;C1304897
current smoker n post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
olodaterol sgg,C2934193
mean sd fevi ml,C0439526;C1705224;C3887665
tiotropium olodaterol $nmbr$ $nmbr$,C4032878
mean sd change from pre to post bronchodilator fevi ml,C2599594;C3481639
mean sd change from pre to post bronchodilator fevi nil,C2599594;C3481639
mean sd fevi fvc,C0802741;C3815113
gold $nmbr$ $nmbr$ $nmbr$,C0018026;C1304897
mean sd of predicted normal fevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
mean sd eevi ml,C0439526;C1705224;C3887665
gold $nmbr$ $nmbr$ n $nmbr$,C0018026;C1304897
mean sd fevi evc,C0013903;C0429711;C1414479
olodaterol sgg,C2934193
mean sd of predicted normal eevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
tiotropium olodaterol $nmbr$ $nmbr$,C4032878
treatment comparison,C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
mean sd change from pre to post bronchodilator fevi nil,C2599594;C3481639
adjusted mean se fevi auco_ $nmbr$ ml,C0439526;C1705224;C3887665
gold $nmbr$ $nmbr$ $nmbr$,C0018026;C1304897
adjusted mean se trough fevi ml,C0439526;C1705224;C3887665
mean sd eevi ml,C0439526;C1705224;C3887665
gold $nmbr$,C0018026;C1304897
mean sd fevi evc,C0013903;C0429711;C1414479
versus olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
mean sd of predicted normal eevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C4032878;C0030827;C0072225;C1266240
treatment comparison,C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
versus tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
adjusted mean se fevi auco_ $nmbr$ ml,C0439526;C1705224;C3887665
versus tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
adjusted mean se trough fevi ml,C0439526;C1705224;C3887665
bosentan,C0252643
gold $nmbr$,C0018026;C1304897
median interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
versus olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
brazil,C0006137
versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C4032878;C0030827;C0072225;C1266240
saudi arabia,C0036243
versus tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
time from pah diagnosis months,C0011900;C0556969;C1704338;C1704656
versus tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
aetiology of pah,C0015127;C1314792;C1524003
bosentan,C0252643
familial,C0015576;C0241888
median interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
repaired congenital shunts,C0232180;C0542331;C1442858
brazil,C0006137
drugs and toxins,C0013227;C3687832;C0040549
saudi arabia,C0036243
$nmbr$ min walk distance m,C0702093;C0429886;C1524029;C3813700
time from pah diagnosis months,C0011900;C0556969;C1704338;C1704656
who functional class,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
aetiology of pah,C0015127;C1314792;C1524003
nt probnp $nmbr$ pmol l $nmbr$,C0669479;C0439284;C0754710
familial,C0015576;C0241888
baseline sildenafil dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
repaired congenital shunts,C0232180;C0542331;C1442858
east asian,C1707877;C0078988
drugs and toxins,C0013227;C3687832;C0040549
non east asian,C1518422;C0078988
$nmbr$ min walk distance m,C0702093;C0429886;C1524029;C3813700
p value for east asian versus non east asian,C1709380;C0078988;C1518422
who functional class,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
age years mean _ sd,C1510829;C2699239
nt probnp $nmbr$ pmol l $nmbr$,C0669479;C0439284;C0754710
weight of $nmbr$ kg n,C0005910;C0043100;C1305866;C1705104
baseline sildenafil dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
crcl of $nmbr$ $nmbr$ ml min n,C1846718;C0439445
east asian,C1707877;C0078988
patients meeting the criteria to receive $nmbr$ mg of,C0030705;C0556656;C0243161;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
non east asian,C1518422;C0078988
edoxaban at randomization n,C2975435;C0034656
p value for east asian versus non east asian,C1709380;C0078988;C1518422
anatomic extent of qualifying event n x,C0220784;C0439792;C1514624;C0441471;C4019010
age years mean _ sd,C1510829;C2699239
concomitant dvt n,C0521115;C0149871;C2926618;C3899446
weight of $nmbr$ kg n,C0005910;C0043100;C1305866;C1705104
crcl of $nmbr$ $nmbr$ ml min n,C1846718;C0439445
right ventricular dysfunction n n j,C0242707;C1556315
patients meeting the criteria to receive $nmbr$ mg of,C0030705;C0556656;C0243161;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
causes of dvt or pe n,C0015127;C1314792;C0070939;C1880476;C4284304
edoxaban at randomization n,C2975435;C0034656
index event n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
anatomic extent of qualifying event n x,C0220784;C0439792;C1514624;C0441471;C4019010
non east asianf,C1518422;C1707877
concomitant dvt n,C0521115;C0149871;C2926618;C3899446
edoxaban n $nmbr$ n n,C2975435
warfarin n $nmbr$ n n,C0043031
right ventricular dysfunction n n j,C0242707;C1556315
hr with edoxaban $nmbr$ ci,C2975435;C0008107;C3259781
causes of dvt or pe n,C0015127;C1314792;C0070939;C1880476;C4284304
event during overall,C0441471;C4019010
index event n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
study period fatal pe,C0070939;C1880476;C4284304
non east asianf,C1518422;C1707877
death with pe not,C0011065;C1306577;C4082313;C4552775;C1518422
edoxaban n $nmbr$ n n,C2975435
ruled out non fatal pe with or,C1446409;C0070939;C1880476;C4284304
warfarin n $nmbr$ n n,C0043031
without dvt dvt alone,C0149871;C2926618;C3899446;C0205171;C0439044;C0679994
hr with edoxaban $nmbr$ ci,C2975435;C0008107;C3259781
event during on,C0441471;C4019010
event during overall,C0441471;C4019010
treatment period index dvt event,C0441471;C4019010
study period fatal pe,C0070939;C1880476;C4284304
during overall study period,C0439531;C1948053
death with pe not,C0011065;C1306577;C4082313;C4552775;C1518422
index pe event during,C0441471;C4019010
ruled out non fatal pe with or,C1446409;C0070939;C1880476;C4284304
overall study period,C0439531;C1948053
without dvt dvt alone,C0149871;C2926618;C3899446;C0205171;C0439044;C0679994
gaviscon da n $nmbr$,C0061146;C0011318;C3668815
event during on,C0441471;C4019010
bmi kg m $nmbr$ median range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
treatment period index dvt event,C0441471;C4019010
erd n,
during overall study period,C0439531;C1948053
la grade a n f,C0441800;C0919553;C3244287;C0369718;C0016327;C0441922
index pe event during,C0441471;C4019010
la grade b n f,C1881342;C0016327
overall study period,C0439531;C1948053
fdc $nmbr$ $nmbr$ g n $nmbr$,C0340427;C0439267;C1413520;C3539652
gaviscon da n $nmbr$,C0061146;C0011318;C3668815
aclidinium $nmbr$ g n $nmbr$,C2699757;C0439267
bmi kg m $nmbr$ median range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
formoterol $nmbr$ g n $nmbr$,C0060657;C0439267
erd n,
post bronchodilator fev $nmbr$ predicted,C0681842;C1882327
la grade a n f,C0441800;C0919553;C3244287;C0369718;C0016327;C0441922
number of exacerbations in previous $nmbr$ months,C0237753;C0449788;C0205156;C0439231;C1552607
la grade b n f,C1881342;C0016327
prior copd medicationa n,C0332152;C0024117;C1412502;C3714496;C2826257
fdc $nmbr$ $nmbr$ g n $nmbr$,C0340427;C0439267;C1413520;C3539652
any copd medication,C0013227;C3244316;C4284232
aclidinium $nmbr$ g n $nmbr$,C2699757;C0439267
laba ics,C0815320;C4551720
formoterol $nmbr$ g n $nmbr$,C0060657;C0439267
lama,C0999593;C1416775
post bronchodilator fev $nmbr$ predicted,C0681842;C1882327
bdi focal score,C0449820;C4050231
number of exacerbations in previous $nmbr$ months,C0237753;C0449788;C0205156;C0439231;C1552607
e rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
prior copd medicationa n,C0332152;C0024117;C1412502;C3714496;C2826257
overall night time copd symptom severity scorec,C0240526;C1319166
any copd medication,C0013227;C3244316;C4284232
overall early morning copd symptom severity scorec,C0024117;C1319166;C1412502;C3714496
laba ics,C0815320;C4551720
gold group n,C0018026;C0441848;C1304897
lama,C0999593;C1416775
gold group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
bdi focal score,C0449820;C4050231
fdc $nmbr$ $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
e rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
fdc $nmbr$ $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
overall night time copd symptom severity scorec,C0240526;C1319166
fdc $nmbr$ $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0072225;C1266240
overall early morning copd symptom severity scorec,C0024117;C1319166;C1412502;C3714496
aclidinium $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
gold group n,C0018026;C0441848;C1304897
formoterol $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
gold group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
hcru a,
fdc $nmbr$ $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
fdc $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
fdc $nmbr$ $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
rr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C4554402
fdc $nmbr$ $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0072225;C1266240
rro $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
aclidinium $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
formoterol $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
formoterol $nmbr$ pg,C0030827;C0072225;C1266240
hcru a,
exact b,C2828393;C4050514
fdc $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
outcome type,C0332307;C1547052
rr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C4554402
outcome severity,C0439793;C0522510
rro $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
any severity,C0439793;C0522510
aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
moderate severity,C0439793;C0522510
formoterol $nmbr$ pg,C0030827;C0072225;C1266240
baseline ics,C0815320;C4551720
exact b,C2828393;C4050514
with concomitant ics,C0815320;C4551720
outcome type,C0332307;C1547052
without concomitant ics,C0815320;C4551720
outcome severity,C0439793;C0522510
rr $nmbr$ $nmbr$,C4554402
any severity,C0439793;C0522510
teaes cases per $nmbr$ patient years ci,C0868928;C1533148
moderate severity,C0439793;C0522510
mtx $nmbr$ mg week,C0332174;C0439230
baseline ics,C0815320;C4551720
mtx $nmbr$ $nmbr$ mg week,C0332174;C0439230
with concomitant ics,C0815320;C4551720
czp $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
without concomitant ics,C0815320;C4551720
related to study druga,C0439849;C0445223
rr $nmbr$ $nmbr$,C4554402
leading to study withdrawal,C0332152;C0557651;C2603343;C1522538
teaes cases per $nmbr$ patient years ci,C0868928;C1533148
leading to death,C0332152;C0011065;C1306577;C4082313;C4552775;C1522538
mtx $nmbr$ mg week,C0332174;C0439230
gastrointestinal gi disorders,C0017178;C1708130;C3539617;C4050121
mtx $nmbr$ $nmbr$ mg week,C0332174;C0439230
infections,C3714514
czp $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
serious teaes,C0205404
related to study druga,C0439849;C0445223
most frequent gi disorders,C0332183;C0012634
leading to study withdrawal,C0332152;C0557651;C2603343;C1522538
nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
leading to death,C0332152;C0011065;C1306577;C4082313;C4552775;C1522538
most frequent infections,C0239998
gastrointestinal gi disorders,C0017178;C1708130;C3539617;C4050121
urinary tract infection,C0042029;C0262655;C4554638
infections,C3714514
nasopharyngitis,C0027441
serious teaes,C0205404
upper respiratory tract infection,C0041912
most frequent gi disorders,C0332183;C0012634
most frequent non infectious teaesb,C0332183;C1518422
nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
back pain,C0004604;C1963071;C4553945
most frequent infections,C0239998
rheumatoid arthritis,C0003873
urinary tract infection,C0042029;C0262655;C4554638
headache,C0018681;C4553197
nasopharyngitis,C0027441
pyrexia,C0015967
upper respiratory tract infection,C0041912
rash,C0015230
most frequent non infectious teaesb,C0332183;C1518422
contusion,C0009938
back pain,C0004604;C1963071;C4553945
cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
rheumatoid arthritis,C0003873
most frequent serious teaes,C0332183;C0205404
headache,C0018681;C4553197
serious infections,C0205404;C3714514
pyrexia,C0015967
serious gi disorder,C0205404;C0012634
rash,C0015230
pneumonia,C0032285
contusion,C0009938
erysipelas,C0014733
cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
disseminated tuberculosis,C0152915
most frequent serious teaes,C0332183;C0205404
investigations,C1261322
serious infections,C0205404;C3714514
alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708;C0205217;C0442805
serious gi disorder,C0205404;C0012634
aspartate aminotransferase increased,C0004002;C0205217;C0442805
pneumonia,C0032285
c group n $nmbr$,C0441848
erysipelas,C0014733
nc group n $nmbr$,C0027964;C0441848;C0028407;C0067895;C0265987
disseminated tuberculosis,C0152915
investigations,C1261322
systolic blood pressure mmhg mean sd,C0428886;C2699239
alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708;C0205217;C0442805
diastolic blood pressure mmhg mean sd,C0428886;C2699239
aspartate aminotransferase increased,C0004002;C0205217;C0442805
diabetes mellitus n,C0011849
c group n $nmbr$,C0441848
left ventricular systolic dysfunction n,C1277187;C1963159;C4553199
nc group n $nmbr$,C0027964;C0441848;C0028407;C0067895;C0265987
serum creatinine mg dl mean sd,C0201976;C2699239;C0600061
systolic blood pressure mmhg mean sd,C0428886;C2699239
ldl cholesterol mg dl mean sd,C0023824;C2699239;C0202117
diastolic blood pressure mmhg mean sd,C0428886;C2699239
hdl cholesterol mg dl mean sd,C0023822;C2699239;C0392885
diabetes mellitus n,C0011849
triglyceride mg dl mean sd,C0439269;C2699239
left ventricular systolic dysfunction n,C1277187;C1963159;C4553199
concomitant medications after randomization,C0013227;C0802604;C2598133;C4284232
aceis n,
serum creatinine mg dl mean sd,C0201976;C2699239;C0600061
b blockers n,
ldl cholesterol mg dl mean sd,C0023824;C2699239;C0202117
ca channel blockers n,C3887642;C0870261
hdl cholesterol mg dl mean sd,C0023822;C2699239;C0392885
nitrates n,C0028125
triglyceride mg dl mean sd,C0439269;C2699239
statins n,C0360714
concomitant medications after randomization,C0013227;C0802604;C2598133;C4284232
number of diseased vessels mean sd,C0237753;C0449788
aceis n,
b blockers n,
left main disease n,C0205091;C0012634;C0443246;C1552822
ca channel blockers n,C3887642;C0870261
type b $nmbr$ c lesions n,C4264484;C0221198
nitrates n,C0028125
des implantation for restenosis n,C0021107;C0029976
statins n,C0360714
sirolimus eluting stent use n,C0038257;C0042153;C0457083;C1947944
number of diseased vessels mean sd,C0237753;C0449788
paclitaxel eluting stent use n,C0038257;C0042153;C0457083;C1947944
number of implanted stents n mean sd,C0237753;C0449788
left main disease n,C0205091;C0012634;C0443246;C1552822
total length of implanted stents mm mean sd,C0439175;C0449462;C0439810
type b $nmbr$ c lesions n,C4264484;C0221198
rotablator use n,C0042153;C0457083;C1947944
des implantation for restenosis n,C0021107;C0029976
sirolimus eluting stent use n,C0038257;C0042153;C0457083;C1947944
aceis angiotensin converting enzyme inhibitors c candesartan des drug eluting stent egfr estimated glomerular filtration rate hdl high density lipoprotein ldl low density lipoprotein nc non candesartan,C0003015;C0151691;C2757044
paclitaxel eluting stent use n,C0038257;C0042153;C0457083;C1947944
total ipss,C1019118;C1998280;C2827405;C3811063
number of implanted stents n mean sd,C0237753;C0449788
age category n $nmbr$ years,C1510829;C0683312;C3889287
total length of implanted stents mm mean sd,C0439175;C0449462;C0439810
baseline subgroup,C1079230;C1515021
rotablator use n,C0042153;C0457083;C1947944
baseline sd,C0168634;C2699239;C1442488
end point sd,C2349179;C2699239;C2826544
aceis angiotensin converting enzyme inhibitors c candesartan des drug eluting stent egfr estimated glomerular filtration rate hdl high density lipoprotein ldl low density lipoprotein nc non candesartan,C0003015;C0151691;C2757044
ls mean change se,C0023668;C0036919
total ipss,C1019118;C1998280;C2827405;C3811063
pbo adjusted ls mean change se,C0023668;C0036919
age category n $nmbr$ years,C1510829;C0683312;C3889287
luts severity,C0439793;C0522510
baseline subgroup,C1079230;C1515021
mild moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
baseline sd,C0168634;C2699239;C1442488
mean age sd,C0001779;C2699239
end point sd,C2349179;C2699239;C2826544
severe ipss $nmbr$ age group,C0027362;C2348001
ls mean change se,C0023668;C0036919
lifestyle behaviours,C0004927;C0677505
pbo adjusted ls mean change se,C0023668;C0036919
body mass index bmi kg m $nmbr$ n $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
luts severity,C0439793;C0522510
$nmbr$ years bmi,C0439234;C0578022
mild moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
mean bmi sd,C0444504;C2699239;C2347634;C2348143
mean age sd,C0001779;C2699239
comorbidities and concomitant medications,C0009488;C0013227;C0802604;C2598133;C4284232
severe ipss $nmbr$ age group,C0027362;C2348001
diabetes mellitus n yes,C1549445;C1705108;C1710701
lifestyle behaviours,C0004927;C0677505
$nmbr$ kg m $nmbr$ smokers,C0022718;C0439209;C4054209;C0337664
body mass index bmi kg m $nmbr$ n $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
glycaemic control hba $nmbr$ c n,C0243148;C0019016;C1825777;C3538758;C1550141;C1882979;C2587213;C3274648;C4553389
$nmbr$ years bmi,C0439234;C0578022
diabetic therapy use n no therapy,C0039798;C0042153;C0457083;C1947944;C0087111;C1363945
mean bmi sd,C0444504;C2699239;C2347634;C2348143
oral agent,C0450442;C1254351;C1521826
comorbidities and concomitant medications,C0009488;C0013227;C0802604;C2598133;C4284232
glycaemic control group,C0009932
diabetes mellitus n yes,C1549445;C1705108;C1710701
oral agent and or insulin therapy,C0450442;C1254351;C1521826;C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
$nmbr$ kg m $nmbr$ smokers,C0022718;C0439209;C4054209;C0337664
hba $nmbr$ c $nmbr$ $nmbr$,C0019016;C1825777;C3538758
glycaemic control hba $nmbr$ c n,C0243148;C0019016;C1825777;C3538758;C1550141;C1882979;C2587213;C3274648;C4553389
hyperlipidaemia n yes,C1549445;C1705108;C1710701
diabetic therapy use n no therapy,C0039798;C0042153;C0457083;C1947944;C0087111;C1363945
hyperlipidaemia therapy use n no lipid lowering agent therapy,C0020473;C0039798;C0087111;C1363945;C0428465;C4555212;C0585943
oral agent,C0450442;C1254351;C1521826
combined insulin oral hypoglycaemic agent use,C0240016
glycaemic control group,C0009932
statin medication,C0013227;C3244316;C4284232
oral agent and or insulin therapy,C0450442;C1254351;C1521826;C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
other lipid lowering medication,C0023779;C0441994;C2003888;C0013227;C3244316;C4284232
hba $nmbr$ c $nmbr$ $nmbr$,C0019016;C1825777;C3538758
statin and or other lipid lowering agent therapy,C0360714;C0585943
hyperlipidaemia n yes,C1549445;C1705108;C1710701
hypertension n yes,C1549445;C1705108;C1710701
hyperlipidaemia therapy use n no lipid lowering agent therapy,C0020473;C0039798;C0087111;C1363945;C0428465;C4555212;C0585943
antihypertensive medication use n,C0003364;C0240320
combined insulin oral hypoglycaemic agent use,C0240016
number of antihypertensive medications used n no antihypertensive therapy,C1718138;C0585941
statin medication,C0013227;C3244316;C4284232
combined statin and other lipid lowering agent use,C0205195;C0360714;C0042153;C0457083;C1947944
other lipid lowering medication,C0023779;C0441994;C2003888;C0013227;C3244316;C4284232
statin and or other lipid lowering agent therapy,C0360714;C0585943
type of antihypertensive medication use among patients using antihypertensive medications n,C0457591;C0030705;C1524063;C0003364
hypertension n yes,C1549445;C1705108;C1710701
antihypertensive agent use,C0042153;C0457083;C1947944
centrally acting sympathomimetics,C3653511
antihypertensive medication use n,C0003364;C0240320
b blockers,
number of antihypertensive medications used n no antihypertensive therapy,C1718138;C0585941
number of antihypertensive agent reported,C0237753;C0449788;C0684224;C0700287;C4319718
combined statin and other lipid lowering agent use,C0205195;C0360714;C0042153;C0457083;C1947944
$nmbr$ med at baseline,C4321267;C0168634;C1442488
type of antihypertensive medication use among patients using antihypertensive medications n,C0457591;C0030705;C1524063;C0003364
other antihypertensive agents,C0003364
antihypertensive agent use,C0042153;C0457083;C1947944
$nmbr$ med at baseline cardiac disorder,C4321267;C0018799
centrally acting sympathomimetics,C3653511
cardiac disorder n,C0018799
b blockers,
cardiovascular disorder n,C0007222
number of antihypertensive agent reported,C0237753;C0449788;C0684224;C0700287;C4319718
no cardiovascular disorder $nmbr$,C0007222
$nmbr$ med at baseline,C4321267;C0168634;C1442488
ischaemic heart disease or cerebrovascular disorder n,C0010054;C0151744;C0007820
other antihypertensive agents,C0003364
cardiac arrhythmia n,C0003811;C0264886;C1560249
$nmbr$ med at baseline cardiac disorder,C4321267;C0018799
luts bph characteristics,C0005001;C1521970;C1704272
cardiac disorder n,C0018799
combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n,C0018801;C0878544;C0018802;C0521117;C1292730
cardiovascular disorder n,C0007222
combined ischaemic heart disease and or cerebrovascular disorder,C0010054;C0151744;C0007820
no cardiovascular disorder $nmbr$,C0007222
mild to moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
ischaemic heart disease or cerebrovascular disorder n,C0010054;C0151744;C0007820
mean total ipss sd,C0439175;C2699239;C0439810
cardiac arrhythmia n,C0003811;C0264886;C1560249
mean ipss voiding subscore sd,C0042034;C2699239;C4067975
luts bph characteristics,C0005001;C1521970;C1704272
mean ipss storage sub score sd,C3533236;C2699239
combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n,C0018801;C0878544;C0018802;C0521117;C1292730
mean ipss qol sd,C0444504;C2699239;C2347634;C2348143
combined ischaemic heart disease and or cerebrovascular disorder,C0010054;C0151744;C0007820
combined cardiac failure cardiomyopathy or other cardiac disorders,C0018801;C0878544;C0018802;C0018799
mild to moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
$nmbr$ uln,C1519815
mean total ipss sd,C0439175;C2699239;C0439810
pi,C0122626;C0429863;C3537219;C3539772
mean ipss voiding subscore sd,C0042034;C2699239;C4067975
ppci,
mean ipss storage sub score sd,C3533236;C2699239
prior chf,C0332152;C0018802;C2826257
mean ipss qol sd,C0444504;C2699239;C2347634;C2348143
systolic blood pressure,C0488055;C0871470;C1306620
combined cardiac failure cardiomyopathy or other cardiac disorders,C0018801;C0878544;C0018802;C0018799
mm hg,C0439475
$nmbr$ uln,C1519815
to $nmbr$,
pi,C0122626;C0429863;C3537219;C3539772
killip class i,C2697844
ppci,
timi risk score $nmbr$,C0035647;C0449820;C4050231;C4552904
prior chf,C0332152;C0018802;C2826257
inferior mi,C0340305;C3542426
systolic blood pressure,C0488055;C0871470;C1306620
baseline rst segment elevation mm,C4330985;C4554674
mm hg,C0439475
baseline rst segment,C0168634;C0441635;C1442488
to $nmbr$,
deviation mm,C4330985;C4554674
killip class i,C2697844
q waves in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
timi risk score $nmbr$,C0035647;C0449820;C4050231;C4552904
figure $nmbr$ relative risk plot of the $nmbr$ day composite endpoint of shock chf,C0242492;C0018802
inferior mi,C0340305;C3542426
baseline rst segment elevation mm,C4330985;C4554674
upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0013806;C0018802;C0449244;C0034656;C1442160;C0456081;C0027051;C0428953;C2926063;C3810814;C4552959;C0205307;C0231683;C0439166;C2347086;C4553972
baseline rst segment,C0168634;C0441635;C1442488
race n y,C0034510;C1706779;C3853635
deviation mm,C4330985;C4554674
otherz,
q waves in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
known duration of t $nmbr$ dm y,C0449238;C2926735
figure $nmbr$ relative risk plot of the $nmbr$ day composite endpoint of shock chf,C0242492;C0018802
history of cvd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
goal,C0018017;C1571704
upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0013806;C0018802;C0449244;C0034656;C1442160;C0456081;C0027051;C0428953;C2926063;C3810814;C4552959;C0205307;C0231683;C0439166;C2347086;C4553972
baseline n,C0168634;C1442488
race n y,C0034510;C1706779;C3853635
week $nmbr$ n,C0332174;C0439230
otherz,
or for cana vs pbo $nmbr$ ci,C1418845;C0008107;C3259781
known duration of t $nmbr$ dm y,C0449238;C2926735
p value nominal,C1709380
history of cvd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
body weight reduction $nmbr$,C1262477
goal,C0018017;C1571704
week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
baseline n,C0168634;C1442488
week $nmbr$ n or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
week $nmbr$ n,C0332174;C0439230
hdl c $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
or for cana vs pbo $nmbr$ ci,C1418845;C0008107;C3259781
composite endpoint a $nmbr$ c,C0205199;C1547335
p value nominal,C1709380
[ $nmbr$ $nmbr$ mmol l],C1532563
body weight reduction $nmbr$,C1262477
week $nmbr$ n ^,C0332174;C0439230
week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
male patients,C0150904
week $nmbr$ n or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
female patients^,C0150905
hdl c $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
week $nmbr$ n j,C0332174;C0439230
composite endpoint a $nmbr$ c,C0205199;C1547335
week $nmbr$ n $nmbr$,C0332174;C0439230
[ $nmbr$ $nmbr$ mmol l],C1532563
ef $nmbr$ n $nmbr$ $nmbr$,
week $nmbr$ n ^,C0332174;C0439230
ef $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,
male patients,C0150904
black race,C0005680
female patients^,C0150905
russia georgia,C0017452;C0017454
week $nmbr$ n j,C0332174;C0439230
history of hf hospitalization,C0551577;C0018488;C1313497;C1538440;C3273279
week $nmbr$ n $nmbr$,C0332174;C0439230
history of diabetes nyha class,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ef $nmbr$ n $nmbr$ $nmbr$,
heart rate b p m,C0018810
ef $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,
body mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
black race,C0005680
ace arb,C1452534;C3888198;C4284014
russia georgia,C0017452;C0017454
all patients n $nmbr$ $nmbr$,C0030705
history of hf hospitalization,C0551577;C0018488;C1313497;C1538440;C3273279
ejection fraction group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
history of diabetes nyha class,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
continuous lvef $nmbr$ treatment interaction,C0039798;C1704675;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
heart rate b p m,C0018810
primary endpoint,C2986535
body mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
event rate per $nmbr$,C0871208;C1521828
ace arb,C1452534;C3888198;C4284014
patient years hr unadjusted,C0030705;C0439234;C1439367
all patients n $nmbr$ $nmbr$,C0030705
referent,C1706462
ejection fraction group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
hr adjusteda,
continuous lvef $nmbr$ treatment interaction,C0039798;C1704675;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treatment effect hr,C1518681
primary endpoint,C2986535
hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
event rate per $nmbr$,C0871208;C1521828
no of hospitalised patients,C0030705
patient years hr unadjusted,C0030705;C0439234;C1439367
aplxaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
referent,C1706462
apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hr adjusteda,
pe with or without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
treatment effect hr,C1518681
apixaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
level of renal impairment,C0441889;C0456079;C1547707;C2946261
no of hospitalised patients,C0030705
severe or moderate,C0205082;C4050465;C4050466;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
aplxaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C4684572;C0205363;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0039601
apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
main effect baseline hormone,C0019932;C4521914
pe with or without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
baseline total ipss,C1019118;C1998280;C2827405;C3811063
apixaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
unadjusteda beta se,C0330390;C0036919;C0439096;C2004068
level of renal impairment,C0441889;C0456079;C1547707;C2946261
adjustedb c beta se,C0330390;C0036919;C0439096;C2004068
severe or moderate,C0205082;C4050465;C4050466;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
stratified by,C0205363
table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C4684572;C0205363;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0039601
linear regression,C0023733;C2346679
main effect baseline hormone,C0019932;C4521914
treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline total ipss,C1019118;C1998280;C2827405;C3811063
testosterone level nmol l,C0428412;C0439282;C0523912
unadjusteda beta se,C0330390;C0036919;C0439096;C2004068
testosterone nmol l,C0039601;C0439282
adjustedb c beta se,C0330390;C0036919;C0439096;C2004068
continuous,C0549178
stratified by,C0205363
low tt,C1452561;C4554543
linear regression,C0023733;C2346679
high tt $nmbr$ $nmbr$ n $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
estradiol pmol l,C0014912;C0439284
testosterone level nmol l,C0428412;C0439282;C0523912
baseline outcomes,C0168634;C1274040;C1442488
testosterone nmol l,C0039601;C0439282
logistic regression,C0206031
continuous,C0549178
odds ratios $nmbr$ ci,C0008107;C3259781
low tt,C1452561;C4554543
ipss v,C1019118;C1998280;C2827405;C3811063
high tt $nmbr$ $nmbr$ n $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
moderate $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
estradiol pmol l,C0014912;C0439284
ipss s,C1019118;C1998280;C2827405;C3811063
baseline outcomes,C0168634;C1274040;C1442488
severe $nmbr$,C0205082;C4050465;C4050466
logistic regression,C0206031
ipss categories,C1019118;C0683312;C1998280;C2827405;C3811063
odds ratios $nmbr$ ci,C0008107;C3259781
hormones,C0019932
ipss v,C1019118;C1998280;C2827405;C3811063
testosterone tt nmol l,C0039601;C0439282
moderate $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
estradiol e $nmbr$ pmol l,C0014912;C0439284
ipss s,C1019118;C1998280;C2827405;C3811063
estradiol quartiles,C0014912;C2828255
severe $nmbr$,C0205082;C4050465;C4050466
$nmbr$ st $nmbr$ $nmbr$ $nmbr$ pmol l,C0036056;C0439284;C3272372
ipss categories,C1019118;C0683312;C1998280;C2827405;C3811063
$nmbr$ nd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0439284
hormones,C0019932
$nmbr$ rd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0694666;C0439284;C4553350
testosterone tt nmol l,C0039601;C0439282
$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l,C0039725;C0439284;C0039738;C1420718;C4282123;C4285344
estradiol e $nmbr$ pmol l,C0014912;C0439284
american indian or alaskan,C0002460;C0238611
estradiol quartiles,C0014912;C2828255
alcohol useb,C0001962;C0001975
$nmbr$ st $nmbr$ $nmbr$ $nmbr$ pmol l,C0036056;C0439284;C3272372
smokingb,
$nmbr$ nd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0439284
obese $nmbr$ kg m $nmbr$ b,C0028754;C1532718
$nmbr$ rd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0694666;C0439284;C4553350
comorbid conditionsb,
$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l,C0039725;C0439284;C0039738;C1420718;C4282123;C4285344
cardiac diseasec,C0018787;C1522601
american indian or alaskan,C0002460;C0238611
medication useb,C0013227;C3244316;C4284232
alcohol useb,C0001962;C0001975
psychoactivesd,
smokingb,
diabetese,
obese $nmbr$ kg m $nmbr$ b,C0028754;C1532718
other lipid lowering drugs,C0086440
comorbid conditionsb,
alpha blockers,C0001641
cardiac diseasec,C0018787;C1522601
angiotensin receptive blocker,C0003018;C4521302
medication useb,C0013227;C3244316;C4284232
other antihypertensive medications,C0003364
psychoactivesd,
cyp $nmbr$ a $nmbr$ inhibitors,C1418793;C0243077;C2634343
diabetese,
alpha reductase inhibitors,C0597153;C1655741
other lipid lowering drugs,C0086440
previous pde $nmbr$ inhibitors,C0205156;C0031638;C1552607
alpha blockers,C0001641
laboratory measurements,C0681902
angiotensin receptive blocker,C0003018;C4521302
hemoglobin a $nmbr$ c,C0019020;C3889898
other antihypertensive medications,C0003364
good control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
cyp $nmbr$ a $nmbr$ inhibitors,C1418793;C0243077;C2634343
fair control $nmbr$ $nmbr$ $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
alpha reductase inhibitors,C0597153;C1655741
cholesterol nmol l,C0008377;C0439282
previous pde $nmbr$ inhibitors,C0205156;C0031638;C1552607
glucose non fasting or random nmol l,C0017725;C1518422;C0015663;C0034656;C0439282;C0439605
laboratory measurements,C0681902
standard bp lowering,C1442989;C2828392;C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
hemoglobin a $nmbr$ c,C0019020;C3889898
intensive bp lowering,C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
good control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
latino,C0086528
fair control $nmbr$ $nmbr$ $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
intensive glycemia lowering,C0005802;C0441994;C2003888
cholesterol nmol l,C0008377;C0439282
cornell index pv,C0030840;C0032463
glucose non fasting or random nmol l,C0017725;C1518422;C0015663;C0034656;C0439282;C0439605
standard bp lowering,C1442989;C2828392;C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure,C2986480;C0032664;C0149775;C0332152;C0023556;C2826257;C0030705;C0871208;C1521828;C0168634;C1442488;C0301630;C0392756;C1293152;C4551656;C0392360;C0444930;C2746065;C1264674;C0237753;C0449788;C0332293;C0377265;C3693636;C0657912;C0003299;C0751495;C0206132;C0332162
intensive bp lowering,C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
spirono n $nmbr$,
latino,C0086528
enrollment strata prior hospitalization,C0332152;C0019993;C2826257
intensive glycemia lowering,C0005802;C0441994;C2003888
physical characteristics,C0031809;C1521970;C0205485;C1509143
cornell index pv,C0030840;C0032463
heart rate beats per minute,C0439385
hematocrit,C0018935;C0518014
subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure,C2986480;C0032664;C0149775;C0332152;C0023556;C2826257;C0030705;C0871208;C1521828;C0168634;C1442488;C0301630;C0392756;C1293152;C4551656;C0392360;C0444930;C2746065;C1264674;C0237753;C0449788;C0332293;C0377265;C3693636;C0657912;C0003299;C0751495;C0206132;C0332162
prior hf hospitalization n $nmbr$,C0018488;C0019993;C1313497;C1538440;C3273279
spirono n $nmbr$,
elevated natriuretic peptide level n $nmbr$,C1144709;C2709270;C3537020
enrollment strata prior hospitalization,C0332152;C0019993;C2826257
p for inter act,C0369773;C2603361;C0205103;C1548610;C0079613;C1704930;C1869853;C3890007;C4048375
physical characteristics,C0031809;C1521970;C0205485;C1509143
lv heart structure,C0023128;C0018787;C0731033;C1881413
heart rate beats per minute,C0439385
lvedv ml,C0439526;C1705224;C3887665
hematocrit,C0018935;C0518014
lvesv ml,C0439526;C1705224;C3887665
prior hf hospitalization n $nmbr$,C0018488;C0019993;C1313497;C1538440;C3273279
mean wall thickness cm,C4054557;C0677535
elevated natriuretic peptide level n $nmbr$,C1144709;C2709270;C3537020
lv mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p for inter act,C0369773;C2603361;C0205103;C1548610;C0079613;C1704930;C1869853;C3890007;C4048375
relative wall thickness,C0080103;C0205345;C1547039
lv heart structure,C0023128;C0018787;C0731033;C1881413
lav ml,C0439526;C1705224;C3887665
lvedv ml,C0439526;C1705224;C3887665
la diameter,C0023031;C1301886;C0023749;C0230347;C2346906;C4553351
lvesv ml,C0439526;C1705224;C3887665
lv function,C0031843;C0542341;C0700205;C1705273
mean wall thickness cm,C4054557;C0677535
e a ratio,C0456603;C1547037
lv mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tdi e septal cm sec,C0205976;C0439392;C2674784;C3714807
relative wall thickness,C0080103;C0205345;C1547039
e e septal,C0442004
lav ml,C0439526;C1705224;C3887665
rv and pulmonary vascular,C0035190;C3889272;C0459963;C1508661
la diameter,C0023031;C1301886;C0023749;C0230347;C2346906;C4553351
tr jet velocity m sec,C0439830;C1547053;C0565930
lv function,C0031843;C0542341;C0700205;C1705273
rvfac,
e a ratio,C0456603;C1547037
enrolled in the americas,C4684790;C0002454;C0596070
tdi e septal cm sec,C0205976;C0439392;C2674784;C3714807
enrolled in russia or georgia,C4684790;C0035970;C0017452;C0017454
e e septal,C0442004
baseline adjusted hr,C0168634;C0456081;C1442488
rv and pulmonary vascular,C0035190;C3889272;C0459963;C1508661
alvedv per ml,C0439526;C1705224;C3887665
tr jet velocity m sec,C0439830;C1547053;C0565930
alvesv per ml,C0439526;C1705224;C3887665
rvfac,
alvmi per g m $nmbr$,C0439267
enrolled in the americas,C4684790;C0002454;C0596070
alvef per $nmbr$,
enrolled in russia or georgia,C4684790;C0035970;C0017452;C0017454
ae a ratio per $nmbr$ $nmbr$ unit,C3887670;C0456603;C1547037
baseline adjusted hr,C0168634;C0456081;C1442488
ae per cm s,C3887670
alvedv per ml,C0439526;C1705224;C3887665
ae e ratio per $nmbr$ unit,C0456603;C1547037
alvesv per ml,C0439526;C1705224;C3887665
alav per ml,C0439526;C1705224;C3887665
alvmi per g m $nmbr$,C0439267
apasp per mmhg,C0439475
alvef per $nmbr$,
arvfac per $nmbr$,
ae a ratio per $nmbr$ $nmbr$ unit,C3887670;C0456603;C1547037
sbp at baseline,C0085805;C0168634;C1442488
ae per cm s,C3887670
sd of sbp,C2699239;C0085805
ae e ratio per $nmbr$ unit,C0456603;C1547037
range of sbp,C1514721;C2348147;C3542016
alav per ml,C0439526;C1705224;C3887665
change in sbp,C0392747;C0443172;C1705241;C4319952
apasp per mmhg,C0439475
bp lowering treatment n $nmbr$,C0037623;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1415692;C1708288;C4318478
arvfac per $nmbr$,
treatment arm,C1522541
sbp at baseline,C0085805;C0168634;C1442488
r tpa,C0032143
sd of sbp,C2699239;C0085805
time to treatment h,C3494202;C0033727;C0369286;C0441932;C0564385;C4528284
range of sbp,C1514721;C2348147;C3542016
nihss score,C0449820;C4050231
change in sbp,C0392747;C0443172;C1705241;C4319952
stroke subtype,C0038454;C0449560;C4554100
bp lowering treatment n $nmbr$,C0037623;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1415692;C1708288;C4318478
taci,C0666480;C1425349;C4284230
treatment arm,C1522541
paci,C1165245
r tpa,C0032143
laci,C1420705;C3273314;C4281721
time to treatment h,C3494202;C0033727;C0369286;C0441932;C0564385;C4528284
poci,
nihss score,C0449820;C4050231
infarct size,C0021308;C0456389
stroke subtype,C0038454;C0449560;C4554100
no infarct visible,C0021308;C0205379
taci,C0666480;C1425349;C4284230
small medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
paci,C1165245
large very large,C0549177;C0442824;C2984081
laci,C1420705;C3273314;C4281721
symptomatic infarct swelling,C0013604;C0038999
poci,
symptomatic ich,C0019191;C3272597;C3281105
infarct size,C0021308;C0456389
nd not due to swelling or ich,C0678226;C0013604;C0038999;C0019191;C3272597;C3281105
no infarct visible,C0021308;C0205379
early ichaem ic stroke,C0038454;C4554100
small medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
any early adverse event,C1279919;C0877248
large very large,C0549177;C0442824;C2984081
early death,C1836407
symptomatic infarct swelling,C0013604;C0038999
poor outcome at $nmbr$ months,C3806166;C0439231
symptomatic ich,C0019191;C3272597;C3281105
numbers of events,C4330837
nd not due to swelling or ich,C0678226;C0013604;C0038999;C0019191;C3272597;C3281105
ors $nmbr$ cis,C1504308;C1742862
early ichaem ic stroke,C0038454;C4554100
any early adverse event,C1279919;C0877248
figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0178602;C0439542;C1707455;C0032042;C1696465;C1706408;C0030705;C0424092;C2349954;C2825032;C3853865;C0439228;C0034656;C1514624;C0439231;C0332152
early death,C1836407
western europe and other,C0043129
poor outcome at $nmbr$ months,C3806166;C0439231
hr bpm,
numbers of events,C4330837
creatinine mol l,C0010294;C0347982;C1561535
ors $nmbr$ cis,C1504308;C1742862
hemoglobin g l,C0635222
median bnp iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0178602;C0439542;C1707455;C0032042;C1696465;C1706408;C0030705;C0424092;C2349954;C2825032;C3853865;C0439228;C0034656;C1514624;C0439231;C0332152
median nt probnp iqr pg ml,C0669479;C0439297;C0754710
western europe and other,C0043129
ischaemic etiology n,C0475224;C0015127;C1314792;C1524003
hr bpm,
nyha,C1275491
creatinine mol l,C0010294;C0347982;C1561535
kccq score,C0449820;C4050231
hemoglobin g l,C0635222
hospitalization for heart failure n,C3898876
median bnp iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
median nt probnp iqr pg ml,C0669479;C0439297;C0754710
stroke n,C0038454;C4554100
ischaemic etiology n,C0475224;C0015127;C1314792;C1524003
coronary artery bypass grafting n,C0010055
nyha,C1275491
percutaneous coronary intervention n,C1532338
kccq score,C0449820;C4050231
diuretic n,C0012798
hospitalization for heart failure n,C3898876
beta blocker n,C0001645
myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
stroke n,C0038454;C4554100
mineralocorticoid receptor antagonist n,C1579268
oral anticoagulant n,C0354604
coronary artery bypass grafting n,C0010055
antiplatelet agent n,C0085826
percutaneous coronary intervention n,C1532338
lipid lowering agent n,C0086440
diuretic n,C0012798
implantable cardioverter defibrillator n,C0162589;C2825184
beta blocker n,C0001645
cardiac resynchronization therapy n,C1167956
mineralocorticoid receptor antagonist n,C1579268
enalapril,C0014025
oral anticoagulant n,C0354604
lcz $nmbr$,
antiplatelet agent n,C0085826
cv death or hf hosp,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
lipid lowering agent n,C0086440
hf hosp,C0018488;C1313497;C1538440;C3273279
implantable cardioverter defibrillator n,C0162589;C2825184
acd,C4554601
cardiac resynchronization therapy n,C1167956
enalapril,C0014025
bmi body mass index bnp brain natriuretic peptide dbp diastolic blood pressure gfr glomerular filtration rate hr heart rate iqr interquartile range kccq kansas city cardiomyopathy questionnaire n number nt n terminal nyha new york heart association sbp systolic blood pressure,C0488055;C0871470;C1306620
lcz $nmbr$,
fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy,C0349966;C1337208;C0237629;C1515119
cv death or hf hosp,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
tiotropium $nmbr$ g n $nmbr$,C0213771;C0439267
hf hosp,C0018488;C1313497;C1538440;C3273279
tiotropium $nmbr$ $nmbr$ g n $nmbr$,C0213771;C0439267
acd,C4554601
median range duration of asthma y,C0449238;C2926735
fev $nmbr$ at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
bmi body mass index bnp brain natriuretic peptide dbp diastolic blood pressure gfr glomerular filtration rate hr heart rate iqr interquartile range kccq kansas city cardiomyopathy questionnaire n number nt n terminal nyha new york heart association sbp systolic blood pressure,C0488055;C0871470;C1306620
actual l,C0237400
fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy,C0349966;C1337208;C0237629;C1515119
of predicted,C0681842;C1882327
tiotropium $nmbr$ g n $nmbr$,C0213771;C0439267
fev $nmbr$ at baseline randomization,C3714541;C0168634;C0034656;C1442488
tiotropium $nmbr$ $nmbr$ g n $nmbr$,C0213771;C0439267
fvc,C3714541
median range duration of asthma y,C0449238;C2926735
fev $nmbr$ fvc at baseline randomization,C3714541;C0034656
fev $nmbr$ at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
pefam l min,C0702093;C1524029;C3813700
actual l,C0237400
pefpm l min,C0702093;C1524029;C3813700
of predicted,C0681842;C1882327
acq $nmbr$ total score,C2919686;C2964552
fev $nmbr$ at baseline randomization,C3714541;C0168634;C0034656;C1442488
ics dose of stable maintenance treatment g,C3714445
fvc,C3714541
treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0549193;C1704769;C2350001
fev $nmbr$ fvc at baseline randomization,C3714541;C0034656
adjusted mean se ml,C0439526;C1705224;C3887665
pefam l min,C0702093;C1524029;C3813700
active vs placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
pefpm l min,C0702093;C1524029;C3813700
adjusted mean of difference se ml,C0444504;C2347634;C2348143
acq $nmbr$ total score,C2919686;C2964552
peak fev $nmbr$ $nmbr$ $nmbr$ h response,C0871261;C1704632;C1706817;C2911692
ics dose of stable maintenance treatment g,C3714445
trough fev $nmbr$ response,C0871261;C1704632;C1706817;C2911692
treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0549193;C1704769;C2350001
fev $nmbr$ of predicted normal post bronchodilator,C3714541;C0205307;C0231683;C0439166;C2347086;C4553972;C2599594
adjusted mean se ml,C0439526;C1705224;C3887665
dabigatran $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
active vs placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
enoxaparin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
adjusted mean of difference se ml,C0444504;C2347634;C2348143
number of treated patients,C2360800;C1522326
peak fev $nmbr$ $nmbr$ $nmbr$ h response,C0871261;C1704632;C1706817;C2911692
females n,C0086287
trough fev $nmbr$ response,C0871261;C1704632;C1706817;C2911692
body mass indexa,C0518010
fev $nmbr$ of predicted normal post bronchodilator,C3714541;C0205307;C0231683;C0439166;C2347086;C4553972;C2599594
previous vte n,C0205156;C0630906;C1552607
dabigatran $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
creatinine clearanceb ml min,C0010294;C0439445;C1561535
enoxaparin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
racec n,C4287599
number of treated patients,C2360800;C1522326
india,C0021201;C2700456
females n,C0086287
australia new zealand south africa,C0027978;C0037712;C0324547
body mass indexa,C0518010
patients treated and operated n,C0030705;C1522326;C3242339
previous vte n,C0205156;C0630906;C1552607
anesthesiad n,
creatinine clearanceb ml min,C0010294;C0439445;C1561535
general alone,C0205246;C3812897;C3891294;C4521767;C0205171;C0439044;C0679994
racec n,C4287599
neuraxial alonee,
india,C0021201;C2700456
combinationf,
australia new zealand south africa,C0027978;C0037712;C0324547
mean duration of surgery sd min,C0449238;C2926735
patients treated and operated n,C0030705;C1522326;C3242339
study treatment,C1521826
anesthesiad n,
mean time to first subcutaneous injectiong h in relation to surgery hr,C0040223;C3541383;C0038894;C0038895;C0543467;C1274039
general alone,C0205246;C3812897;C3891294;C4521767;C0205171;C0439044;C0679994
mean time to first oral dose postsurgeryh hr,C0040223;C3541383
neuraxial alonee,
combinationf,
median range duration of hospital stayi d,C0449238;C2926735
mean duration of surgery sd min,C0449238;C2926735
median range treatment duration d,C0444921;C3259042
study treatment,C1521826
monotherapy $nmbr$,
add on to met $nmbr$,C1883712;C0428210;C1550543;C4317104
mean time to first subcutaneous injectiong h in relation to surgery hr,C0040223;C3541383;C0038894;C0038895;C0543467;C1274039
add on to met su $nmbr$,C1883712;C0038642;C1705534
mean time to first oral dose postsurgeryh hr,C0040223;C3541383
mean sd age y race n,C0001779;C0034510;C1706779;C3853635
median range duration of hospital stayi d,C0449238;C2926735
othery ethnicity n,C0015031;C0243103
median range treatment duration d,C0444921;C3259042
mean sd hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
monotherapy $nmbr$,
latin american subgroup,C1079230;C1515021
add on to met $nmbr$,C1883712;C0428210;C1550543;C4317104
monotherapy,
add on to met su $nmbr$,C1883712;C0038642;C1705534
add on to met,C1883712;C0428210;C1550543;C4317104
mean sd age y race n,C0001779;C0034510;C1706779;C3853635
add on to met su,C1883712;C0038642;C1705534
othery ethnicity n,C0015031;C0243103
cana,C1418845
mean sd hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$,C1268766;C0032659;C1257890;C1553378;C1079230;C0031962;C0681867;C1706449
latin american subgroup,C1079230;C1515021
monotherapy,
bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified,C0038944;C1112705;C1705982;C1273937;C0031962;C1707455;C0884358;C0002778;C0936012;C1524024;C1518422
add on to met,C1883712;C0428210;C1550543;C4317104
bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478;C1274040;C1546471;C2825142
add on to met su,C1883712;C0038642;C1705534
ethnicity $nmbr$,C0015031;C0243103
cana,C1418845
mean change in sbp from baseline mmhg mean sd,C0392747;C0443172;C1705241;C4319952;C0168634;C2699239;C1442488
figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$,C1268766;C0032659;C1257890;C1553378;C1079230;C0031962;C0681867;C1706449
education yrs mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified,C0038944;C1112705;C1705982;C1273937;C0031962;C1707455;C0884358;C0002778;C0936012;C1524024;C1518422
receiving antihypertensive treatment n blood pressure mm hg mean sd,C1514756;C0428886;C2699239
bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478;C1274040;C1546471;C2825142
mean change in dbp from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952;C0439269;C2699239
ethnicity $nmbr$,C0015031;C0243103
baseline lipid profile mg dl mean sd,C0439269;C2699239
mean change in sbp from baseline mmhg mean sd,C0392747;C0443172;C1705241;C4319952;C0168634;C2699239;C1442488
participants at baseline n,C0679646;C0168634;C1442488
education yrs mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
fasting glucose mg dl diabetes classification,C0008902;C0008903;C0678229
diabetesz,
receiving antihypertensive treatment n blood pressure mm hg mean sd,C1514756;C0428886;C2699239
mean sd baseline,C0168634;C1442488
mean change in dbp from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952;C0439269;C2699239
impaired fasting glucosex,C0221099;C0015663
baseline lipid profile mg dl mean sd,C0439269;C2699239
baseline if have $nmbr$ yr follow up,C0168634;C1442488;C0589120;C1522577;C1704685;C3274571
participants at baseline n,C0679646;C0168634;C1442488
lipid trial participantsk,C0023779;C0008976
fasting glucose mg dl diabetes classification,C0008902;C0008903;C0678229
change from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952
diabetesz,
fasting glucose $nmbr$ mg dl n,C0015663;C0439269
mean sd baseline,C0168634;C1442488
st t waveft,C0036056;C3272372
impaired fasting glucosex,C0221099;C0015663
baseline if have $nmbr$ yr follow up,C0168634;C1442488;C0589120;C1522577;C1704685;C3274571
history of lvh on electrocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013798;C1547122;C1623258
lipid trial participantsk,C0023779;C0008976
history of lvh on echocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013516;C2243117
change from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
fasting glucose $nmbr$ mg dl n,C0015663;C0439269
additional antihypertensive subgroup,C1079230;C1515021
st t waveft,C0036056;C3272372
thiazide diuretic,C0012802;C3536861
dapagliflozin n $nmbr$,C2353951
history of lvh on electrocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013798;C1547122;C1623258
placebo n $nmbr$ l,C0032042;C1696465;C1706408
history of lvh on echocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013516;C2243117
women ethnic origin,C0043210;C0015031
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
$nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
additional antihypertensive subgroup,C1079230;C1515021
hbaj mmol mol,C3829066
thiazide diuretic,C0012802;C3536861
fasting plasma glucose mmol l,C0202042;C1532563;C0455280
dapagliflozin n $nmbr$,C2353951
participants taking insulin,C0679646;C3842788
placebo n $nmbr$ l,C0032042;C1696465;C1706408
l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
women ethnic origin,C0043210;C0015031
duration of hypertension years,C0449238;C2926735
$nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
selective vascular history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hbaj mmol mol,C3829066
stable angina,C0340288
fasting plasma glucose mmol l,C0202042;C1532563;C0455280
carotid artery disease,C0007273
participants taking insulin,C0679646;C3842788
amputation,C0002688;C0332840;C1546539
l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
history of dyslipidaemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
duration of hypertension years,C0449238;C2926735
recent cardiovascular eventf,C0332185;C0007226;C3887460
selective vascular history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
egfr ml min per $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
stable angina,C0340288
seated sbp n,C0277814;C0085805;C1283233
carotid artery disease,C0007273
baseline mean seated sbp mm hg sd,C0439475;C2699239
amputation,C0002688;C0332840;C1546539
sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
history of dyslipidaemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hba $nmbr$ c n,C0019016;C1825777;C3538758
recent cardiovascular eventf,C0332185;C0007226;C3887460
hba $nmbr$ c baseline mean hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
egfr ml min per $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
hba $nmbr$ c difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
seated sbp n,C0277814;C0085805;C1283233
ambulatory sbp n,C0439841;C0085805
baseline mean seated sbp mm hg sd,C0439475;C2699239
baseline mean ambulatory sbp mm hg sd,C0439475;C2699239
sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
ambulatory sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
hba $nmbr$ c n,C0019016;C1825777;C3538758
serum uric acid n,C0455272;C0700634
hba $nmbr$ c baseline mean hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
baseline mean serum uric acid pmol l sd,C0455272;C2699239;C0700634
hba $nmbr$ c difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
serum uric acid difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
ambulatory sbp n,C0439841;C0085805
$nmbr$ $nmbr$ $nmbr$ to $nmbr$,
baseline mean ambulatory sbp mm hg sd,C0439475;C2699239
dapagliflozin,C2353951
ambulatory sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
p blockersubgroup,C0369773;C2603361
serum uric acid n,C0455272;C0700634
o $nmbr$ o $nmbr$ loto $nmbr$ $nmbr$,C0483204
baseline mean serum uric acid pmol l sd,C0455272;C2699239;C0700634
$nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
serum uric acid difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
calcium channel blockersubgroup,C0006685
$nmbr$ $nmbr$ $nmbr$ to $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$,
dapagliflozin,C2353951
diuretic subgroup,C1079230;C1515021
p blockersubgroup,C0369773;C2603361
lixisenatide n $nmbr$,C2973895
o $nmbr$ o $nmbr$ loto $nmbr$ $nmbr$,C0483204
retinopathy no,C0035309;C1962966
$nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
neuropathy no,C0442874
calcium channel blockersubgroup,C0006685
race no t,C0034510;C1706779;C3853635;C2603360
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$,
hispanic ethnic group no t,C0015031;C1879937;C2603360
diuretic subgroup,C1079230;C1515021
geographic region no,C0017446
lixisenatide n $nmbr$,C2973895
africa or near east,C0001737;C1707877
retinopathy no,C0035309;C1962966
south or central america,C1710133;C0007674
neuropathy no,C0442874
current smoking no,C0037369;C0453996;C1881674
race no t,C0034510;C1706779;C3853635;C2603360
myocardial infarction before index acs no,C0027051;C0428953;C2926063;C3810814;C4552959
hispanic ethnic group no t,C0015031;C1879937;C2603360
medical history at randomization no,C0262926;C1704706
geographic region no,C0017446
qualifying acs event no,C1514624;C0441471;C4019010
africa or near east,C0001737;C1707877
unclassified,C0205426;C1546437;C2347854;C4085229
south or central america,C1710133;C0007674
days from acs to randomization,C0439228;C0742343;C4318612;C0034656
current smoking no,C0037369;C0453996;C1881674
urinary albumin creatinine ratio^,C0486293;C1318293
myocardial infarction before index acs no,C0027051;C0428953;C2926063;C3810814;C4552959
less than $nmbr$ y ears,C0013443;C0521421
medical history at randomization no,C0262926;C1704706
$nmbr$ years or older,C0439234;C0580836
qualifying acs event no,C1514624;C0441471;C4019010
racial category,C0683312;C3889287
unclassified,C0205426;C1546437;C2347854;C4085229
not hispanic,C1518424
days from acs to randomization,C0439228;C0742343;C4318612;C0034656
africa near east,C0001741
urinary albumin creatinine ratio^,C0486293;C1318293
south central america,C0037713
less than $nmbr$ y ears,C0013443;C0521421
days between acs and rand,C0439228;C0742343;C4318612;C1555436
$nmbr$ years or older,C0439234;C0580836
less than $nmbr$,
racial category,C0683312;C3889287
$nmbr$ to less than $nmbr$,
not hispanic,C1518424
$nmbr$ or greater,C1704243
africa near east,C0001741
region us,C0815353;C3889164
south central america,C0037713
non us,C0815353;C3889164
days between acs and rand,C0439228;C0742343;C4318612;C1555436
dm duration,C0449238;C2926735
less than $nmbr$,
$nmbr$ years or more,C0439234
$nmbr$ to less than $nmbr$,
hbalc,
$nmbr$ or greater,C1704243
less than $nmbr$ $nmbr$,
region us,C0815353;C3889164
$nmbr$ $nmbr$ or more,
non us,C0815353;C3889164
less than $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
dm duration,C0449238;C2926735
$nmbr$ kg m $nmbr$ or more,C0022718;C0439209;C4054209
$nmbr$ years or more,C0439234
acs event,C0441471;C4019010
hbalc,
pcr after acs,C0032520;C3853643;C4050242
less than $nmbr$ $nmbr$,
ace arb use,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ or more,
history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
less than $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
uacr,
$nmbr$ kg m $nmbr$ or more,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ mg g,C1300563
acs event,C0441471;C4019010
$nmbr$ mg g,C1300563
pcr after acs,C0032520;C3853643;C4050242
no previous diagnosis of diabetes mellitus,C0332132;C0011849
ace arb use,C0042153;C0457083;C1947944
previous diabetes mellitus,C0205156;C0011849;C1552607
history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0019016;C1825777;C3538758
uacr,
any hba $nmbr$ c,C0019016;C1825777;C3538758
$nmbr$ $nmbr$ mg g,C1300563
age mean,C0444504;C2347634;C2348143
$nmbr$ mg g,C1300563
lcz $nmbr$ treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no previous diagnosis of diabetes mellitus,C0332132;C0011849
hba $nmbr$ c median q $nmbr$ q $nmbr$,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
previous diabetes mellitus,C0205156;C0011849;C1552607
hf duration y n,C0018488;C0449238;C2926735;C1313497;C1538440;C3273279
hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0019016;C1825777;C3538758
nyha class n,C1882083
any hba $nmbr$ c,C0019016;C1825777;C3538758
jugular venous distension n,C0425687
age mean,C0444504;C2347634;C2348143
edema n,C0013604;C1717255
lcz $nmbr$ treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
rales n,C0034642;C0240859
hba $nmbr$ c median q $nmbr$ q $nmbr$,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
third heart sound n,C0232237;C0232278
hf duration y n,C0018488;C0449238;C2926735;C1313497;C1538440;C3273279
heart rate beats per min,C0425583;C0439385
nyha class n,C1882083
ckd egfr,C1739039;C3811844;C3812682
jugular venous distension n,C0425687
icd crt d n,C0021122
edema n,C0013604;C1717255
crt p d n,C0369718;C0441922
rales n,C0034642;C0240859
ischemic cause,C0015127;C1524003
third heart sound n,C0232237;C0232278
previous af,C0344434;C4049859
heart rate beats per min,C0425583;C0439385
medication n,C0013227;C3244316;C4284232
ckd egfr,C1739039;C3811844;C3812682
mra,C0243032;C1609165;C3891069
icd crt d n,C0021122
antiplatelets any,
crt p d n,C0369718;C0441922
hypoglycemic agent,C0020616
ischemic cause,C0015127;C1524003
normoglycemia,
previous af,C0344434;C4049859
pre diabetes mellitus,C0362046
medication n,C0013227;C3244316;C4284232
undiagnosed diabetes mellitus,C1408353;C0011849
mra,C0243032;C1609165;C3891069
p values for interaction,C1709380;C1704675
antiplatelets any,
hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279;C0011065;C1306577;C4082313;C4552775
hypoglycemic agent,C0020616
significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960;C0026544;C0332177
normoglycemia,
normal hba $nmbr$ c n $nmbr$,C0205307;C0019016;C1825777;C3538758;C0231683;C0439166;C2347086;C4553972
pre diabetes mellitus,C0362046
pre diabetes mellitus n $nmbr$,C0011849;C0362046
undiagnosed diabetes mellitus,C1408353;C0011849
undiagnosed diabetes mellitus n $nmbr$,C1408353;C0011849
p values for interaction,C1709380;C1704675
diabetes mellitus n $nmbr$,C0011849
hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279;C0011065;C1306577;C4082313;C4552775
p values of interaction,C1709380;C1704675
significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960;C0026544;C0332177
hypotension n,C0020649;C3163620
normal hba $nmbr$ c n $nmbr$,C0205307;C0019016;C1825777;C3538758;C0231683;C0439166;C2347086;C4553972
symptomatic hypotension,C0020649;C3163620
pre diabetes mellitus n $nmbr$,C0011849;C0362046
symptomatic hypotension with sbp,C0020649;C3163620
undiagnosed diabetes mellitus n $nmbr$,C1408353;C0011849
leading to study drug discontinuation,C0332152;C0013175;C1522538
diabetes mellitus n $nmbr$,C0011849
renal impairment n,C1565489
p values of interaction,C1709380;C1704675
serum creatinine $nmbr$ $nmbr$ mg dl,C0201976;C0439269;C0600061
hypotension n,C0020649;C3163620
hyperkalemia n,C0020461;C4552983
symptomatic hypotension,C0020649;C3163620
serum potassium $nmbr$ $nmbr$ mmol l,C0302353;C1532563;C0543465
symptomatic hypotension with sbp,C0020649;C3163620
cough n,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
leading to study drug discontinuation,C0332152;C0013175;C1522538
any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
renal impairment n,C1565489
angioedema adjudicated n,C0002994
serum creatinine $nmbr$ $nmbr$ mg dl,C0201976;C0439269;C0600061
no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0019590
hyperkalemia n,C0020461;C4552983
catecholamines or corticosteroids without hospitalization,C0007412;C0001617;C3539185;C3540725;C3540726;C3540727
serum potassium $nmbr$ $nmbr$ mmol l,C0302353;C1532563;C0543465
hospitalized without airway compromise,C0701159;C4055482
cough n,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
airway compromise,C4055482
any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
any adverse event leading to study drug discontinuation n,C0877248;C0332152;C0013175;C1522538
angioedema adjudicated n,C0002994
$nmbr$ $nmbr$ mm,C4330985;C4554674
no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0019590
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
catecholamines or corticosteroids without hospitalization,C0007412;C0001617;C3539185;C3540725;C3540726;C3540727
$nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
hospitalized without airway compromise,C0701159;C4055482
baseline ^ste mm,C4330985;C4554674
airway compromise,C4055482
baseline ste in worst lead mm,C1420459;C3811127
any adverse event leading to study drug discontinuation n,C0877248;C0332152;C0013175;C1522538
baseline std mm,C4330985;C4554674
$nmbr$ $nmbr$ mm,C4330985;C4554674
q wave in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
time from sx onset to baseline ecg min,C1519428;C0449244;C3539997;C3815196;C0702093;C1524029;C3813700
$nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
cana $nmbr$ met n $nmbr$,C1418845;C0428210;C1550543;C4317104
baseline ^ste mm,C4330985;C4554674
cana $nmbr$ n $nmbr$,C1418845
baseline ste in worst lead mm,C1420459;C3811127
met n $nmbr$,C0428210;C1550543;C4317104
baseline std mm,C4330985;C4554674
race n t,C0034510;C1706779;C3853635
q wave in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
baseline hba $nmbr$ c n,C0168634;C0019016;C1825777;C3538758;C1442488
time from sx onset to baseline ecg min,C1519428;C0449244;C3539997;C3815196;C0702093;C1524029;C3813700
$nmbr$ $nmbr$ $nmbr$ mmol mol,C3829066
cana $nmbr$ met n $nmbr$,C1418845;C0428210;C1550543;C4317104
type $nmbr$ diabetes duration years,C1320657;C0439234
cana $nmbr$ n $nmbr$,C1418845
figure $nmbr$ effects on ef cacy parameters,C1280500;C0449381
met n $nmbr$,C0428210;C1550543;C4317104
c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C1079230;C3829066;C0332174;C0439230
race n t,C0034510;C1706779;C3853635
apremilast,C1678805
baseline hba $nmbr$ c n,C0168634;C0019016;C1825777;C3538758;C1442488
$nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ mmol mol,C3829066
duration mean sd years,C0444504;C0439234;C2347634;C2348143
type $nmbr$ diabetes duration years,C1320657;C0439234
prior use of conventional dmards only biologic nai ve n,C1524063;C0242708;C0005515;C3537218;C0205460;C0369718;C0441922
figure $nmbr$ effects on ef cacy parameters,C1280500;C0449381
prior use of biologics n,C1524063;C0005515;C0005522;C4553887
c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C1079230;C3829066;C0332174;C0439230
prior biologic therapeutic failures n,C0005515;C0087111;C0302350;C0205460
apremilast,C1678805
baseline dmard use n,C0168634;C0042153;C0457083;C1947944;C1442488
$nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mtx mean dose $nmbr$ $nmbr$ mg wk,C0366550;C1881833
duration mean sd years,C0444504;C0439234;C2347634;C2348143
leflunomide mean dose $nmbr$ $nmbr$ mg day,C0063041;C0439422
prior use of conventional dmards only biologic nai ve n,C1524063;C0242708;C0005515;C3537218;C0205460;C0369718;C0441922
sulfasalazine mean dose $nmbr$ $nmbr$ g day,C0036078;C0439417
prior use of biologics n,C1524063;C0005515;C0005522;C4553887
baseline corticosteroidst mean dose $nmbr$ $nmbr$ mg day n,C0168634;C0439422;C1442488
prior biologic therapeutic failures n,C0005515;C0087111;C0302350;C0205460
sjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
baseline dmard use n,C0168634;C0042153;C0457083;C1947944;C1442488
tjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
mtx mean dose $nmbr$ $nmbr$ mg wk,C0366550;C1881833
haq di $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
leflunomide mean dose $nmbr$ $nmbr$ mg day,C0063041;C0439422
crp normal range $nmbr$ $nmbr$ $nmbr$ mg dl mean sd,C0086715;C2699239
sulfasalazine mean dose $nmbr$ $nmbr$ g day,C0036078;C0439417
patient s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0030705;C0281858;C1292728
baseline corticosteroidst mean dose $nmbr$ $nmbr$ mg day n,C0168634;C0439422;C1442488
sjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0031831;C0804815;C0281858;C1292728
tjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
das $nmbr$ crp mean sd,C0051767;C2699239;C0057671
haq di $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
bsa $nmbr$ n t,
pasi score $nmbr$ $nmbr$ t mean sd,C0444504;C2699239;C2347634;C2348143
crp normal range $nmbr$ $nmbr$ $nmbr$ mg dl mean sd,C0086715;C2699239
presence of enthesitis n,C0150312;C0392148;C3854307
patient s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0030705;C0281858;C1292728
mases $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0031831;C0804815;C0281858;C1292728
presence of dactylitis n,C0150312;C0392148;C3854307
das $nmbr$ crp mean sd,C0051767;C2699239;C0057671
dactylitis count $nmbr$ $nmbr$ mean sd,C0239161;C2699239
bsa $nmbr$ n t,
week $nmbr$ itt population,C0032659;C1257890
pasi score $nmbr$ $nmbr$ t mean sd,C0444504;C2699239;C2347634;C2348143
apremilast $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
presence of enthesitis n,C0150312;C0392148;C3854307
concomitant conventional dmard use,C0042153;C0457083;C1947944
mases $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
prior biologic exposure,C0274281;C0332157
presence of dactylitis n,C0150312;C0392148;C3854307
biologic naive,C0005515;C0205460
dactylitis count $nmbr$ $nmbr$ mean sd,C0239161;C2699239
prior biologic use,C0042153;C0457083;C1947944
week $nmbr$ itt population,C0032659;C1257890
biologic therapeutic failure,C0231174;C0680095
apremilast $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
trial,C0008976
concomitant conventional dmard use,C0042153;C0457083;C1947944
trial $nmbr$,C0008976
prior biologic exposure,C0274281;C0332157
scale obesity and prediabetes,C0028754;C1963185;C0362046
biologic naive,C0005515;C0205460
scale diabetes,C0011847;C0011849
prior biologic use,C0042153;C0457083;C1947944
phase $nmbr$ dose finding trial,C0037088;C0008976;C0243095;C2825141
biologic therapeutic failure,C0231174;C0680095
biometric parameters,C0449381
trial,C0008976
[sd],C2699239
trial $nmbr$,C0008976
[ $nmbr$ ],
scale obesity and prediabetes,C0028754;C1963185;C0362046
mean bmi kg m $nmbr$,C0022718;C0439209;C4054209
scale diabetes,C0011847;C0011849
glycaemic parameters,C0449381
phase $nmbr$ dose finding trial,C0037088;C0008976;C0243095;C2825141
mean hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
biometric parameters,C0449381
[ $nmbr$ $nmbr$ ],
[sd],C2699239
mean hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
[ $nmbr$ ],
individuals with pre diabetes n,C0027361;C0237401
mean bmi kg m $nmbr$,C0022718;C0439209;C4054209
individuals with type $nmbr$ diabetes n,C0027361;C0237401
glycaemic parameters,C0449381
normoglycaemic individuals n,C0580545;C0027361;C0237401
mean hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
figure $nmbr$ liraglutide exposure and body weight loss in men and women,C0274281;C0332157;C2911645;C0025266;C0043210
[ $nmbr$ $nmbr$ ],
mean hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0005911;C0025266;C0043210;C0042295;C1180280;C0444504;C2347634;C2348143;C0205120;C0205119;C1552595;C1882932;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602;C0205132;C0750572;C0032659;C1257890;C0205452;C0032042;C1696465;C1706408;C1456408;C0023693;C1306462;C1570446;C1881376;C3842678;C4050248;C4521367;C0028754;C1963185;C0008976;C0011847;C0011849;C0282460
individuals with pre diabetes n,C0027361;C0237401
figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c,C0274281;C0332157;C0019020;C3889898
individuals with type $nmbr$ diabetes n,C0027361;C0237401
normoglycaemic individuals n,C0580545;C0027361;C0237401
exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0392747;C0443172;C1705241;C4319952;C0027361;C0237401;C0497406;C0028754;C1963185;C1320657;C0205363;C0008976;C0444504;C0042295;C2347634;C2348143;C0205423;C0032042;C0205132;C1696465;C1706408;C1882932;C0750572;C0057717;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602
figure $nmbr$ liraglutide exposure and body weight loss in men and women,C0274281;C0332157;C2911645;C0025266;C0043210
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
mean lvef,C0428772;C0488728
liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0005911;C0025266;C0043210;C0042295;C1180280;C0444504;C2347634;C2348143;C0205120;C0205119;C1552595;C1882932;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602;C0205132;C0750572;C0032659;C1257890;C0205452;C0032042;C1696465;C1706408;C1456408;C0023693;C1306462;C1570446;C1881376;C3842678;C4050248;C4521367;C0028754;C1963185;C0008976;C0011847;C0011849;C0282460
new york heart association class,C1882083
figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c,C0274281;C0332157;C0019020;C3889898
prior hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
ischemic cardiomyopathy,C0349782
exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0392747;C0443172;C1705241;C4319952;C0027361;C0237401;C0497406;C0028754;C1963185;C1320657;C0205363;C0008976;C0444504;C0042295;C2347634;C2348143;C0205423;C0032042;C0205132;C1696465;C1706408;C1882932;C0750572;C0057717;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602
history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
icd or crt d,C0021122
mean lvef,C0428772;C0488728
hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
new york heart association class,C1882083
breakfastb,
prior hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
lunchb,
ischemic cardiomyopathy,C0349782
evening mealb,C0587117
history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
lm $nmbr$ bid n $nmbr$,C1261082;C1551056
icd or crt d,C0021122
igl n $nmbr$,C0021037;C0314619;C2247518
hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
glycemic variability mmol lc,C2827666;C0439190
breakfastb,
insulin glargine dose at screening visit iu,C0366513
lunchb,
evening mealb,C0587117
figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1550335;C0332293;C0982221;C0907402;C0332173;C0293359;C0021037;C0314619;C2247518;C0439745;C4319846;C1998602;C0020456;C0521095;C0205449;C0005803;C1979963;C2003903;C0237881;C0750502;C1546944
lm $nmbr$ bid n $nmbr$,C1261082;C1551056
data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values,C1511726;C3245479;C3714741;C0449450;C1706992;C0683607;C0444504;C0039725;C1532337;C0039738;C1420718;C4282123;C4285344
igl n $nmbr$,C0021037;C0314619;C2247518
table $nmbr$ characteristics of the patients at baseline,C0039224;C0815172;C1706074;C0168634;C1442488
glycemic variability mmol lc,C2827666;C0439190
fluticasone salmeterol n $nmbr$,C0939232
insulin glargine dose at screening visit iu,C0366513
fluticasone alone n $nmbr$,C0082607;C0205171;C0439044;C0679994
africa,C0001737
figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1550335;C0332293;C0982221;C0907402;C0332173;C0293359;C0021037;C0314619;C2247518;C0439745;C4319846;C1998602;C0020456;C0521095;C0205449;C0005803;C1979963;C2003903;C0237881;C0750502;C1546944
figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding,C0475224;C0085415;C1518681;C0749659;C0439231;C0030705;C1274040;C3897493;C0441471;C3541888;C0205082;C4050465;C4050466;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values,C1511726;C3245479;C3714741;C0449450;C1706992;C0683607;C0444504;C0039725;C1532337;C0039738;C1420718;C4282123;C4285344
reslizumab $nmbr$ $nmbr$ mg kg n $nmbr$,C1869620;C0439272
table $nmbr$ characteristics of the patients at baseline,C0039224;C0815172;C1706074;C0168634;C1442488
bmi mean kg m $nmbr$,C0022718;C0439209;C4054209
fluticasone salmeterol n $nmbr$,C0939232
years since diagnosis mean,C0439234;C0011900;C1704338;C1704656
fluticasone alone n $nmbr$,C0082607;C0205171;C0439044;C0679994
ics use at enrollment mean mg d,C0042153;C0457083;C1947944
africa,C0001737
exacerbation within previous $nmbr$ mo no,C4086268;C0026544;C0332177
figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding,C0475224;C0085415;C1518681;C0749659;C0439231;C0030705;C1274040;C3897493;C0441471;C3541888;C0205082;C4050465;C4050466;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
acq score mean,C0444504;C2347634;C2348143
reslizumab $nmbr$ $nmbr$ mg kg n $nmbr$,C1869620;C0439272
airway reversibility,C0178987;C0449261;C0458827
bmi mean kg m $nmbr$,C0022718;C0439209;C4054209
fev $nmbr$ mean l,C0444504;C2347634;C2348143
years since diagnosis mean,C0439234;C0011900;C1704338;C1704656
rescue medication use mean inhalations previous $nmbr$ d,C0004048;C0354922;C0205156;C1552607
ics use at enrollment mean mg d,C0042153;C0457083;C1947944
blood eosinophils mean range cells ml,C2699156
exacerbation within previous $nmbr$ mo no,C4086268;C0026544;C0332177
treated with laba,C0332293
acq score mean,C0444504;C2347634;C2348143
baricitinib $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
airway reversibility,C0178987;C0449261;C0458827
positive for anti cyclic citrullinated peptide antibody no f,C0741132;C1320283;C0016327
fev $nmbr$ mean l,C0444504;C2347634;C2348143
positive for rheumatoid factor no t,C0439178;C1446409;C1514241;C2825490;C3812269;C2603360
rescue medication use mean inhalations previous $nmbr$ d,C0004048;C0354922;C0205156;C1552607
no of previous biologic dmards no,C0205156;C4055380;C1552607
blood eosinophils mean range cells ml,C2699156
tnf inhibitors,C1448177;C0243077
treated with laba,C0332293
non tnf inhibitors,C1448177;C0243077
baricitinib $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
swollen joint count of $nmbr$ joints examined,C0451521;C0332128
positive for anti cyclic citrullinated peptide antibody no f,C0741132;C1320283;C0016327
tender joint count of $nmbr$ joints examined,C0451530;C0332128
positive for rheumatoid factor no t,C0439178;C1446409;C1514241;C2825490;C3812269;C2603360
scores for global and pain assessments,C0449820;C0205246;C2348867;C0030198
no of previous biologic dmards no,C0205156;C4055380;C1552607
physician s global assessment,C0031831;C0804815;C0281858
tnf inhibitors,C1448177;C0243077
patient s global assessment,C0030705;C0281858
non tnf inhibitors,C1448177;C0243077
patient s assessment of pain,C0030705;C0030198
swollen joint count of $nmbr$ joints examined,C0451521;C0332128
haq di scored,C3826998;C4321476;C0449820
tender joint count of $nmbr$ joints examined,C0451530;C0332128
high sensitivity crp mg liter,C1441604;C0475211
scores for global and pain assessments,C0449820;C0205246;C2348867;C0030198
esr mm hr,C3811131;C4330985;C4554674
physician s global assessment,C0031831;C0804815;C0281858
das $nmbr$ esr,C0051767;C3811131;C0057671
patient s global assessment,C0030705;C0281858
simplified disease activity index score,C4706353
patient s assessment of pain,C0030705;C0030198
n n,C0369718;C0441922
haq di scored,C3826998;C4321476;C0449820
baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
high sensitivity crp mg liter,C1441604;C0475211
of prior bdmards,C0332152;C2826257
esr mm hr,C3811131;C4330985;C4554674
of prior tnfi among non tnfi naive,C0332152;C1518422;C2826257
das $nmbr$ esr,C0051767;C3811131;C0057671
of prior non tnfi bdmards,C0332152;C1518422;C2826257
simplified disease activity index score,C4706353
n n,C0369718;C0441922
white race no y left ventricular ejection fraction,C0007457;C0043157;C0428772;C0488728
baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nyha functional classification no i,C1275491;C0205245;C0542341;C2700217;C0021966;C0221138
of prior bdmards,C0332152;C2826257
hospitalization in previous year with management of heart failure,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539
of prior tnfi among non tnfi naive,C0332152;C1518422;C2826257
as major component no,C0449432;C1705248
of prior non tnfi bdmards,C0332152;C1518422;C2826257
qrs,
qrs $nmbr$ ms $nmbr$ cl n $nmbr$,C2349943;C0596019;C3539704;C3713294
white race no y left ventricular ejection fraction,C0007457;C0043157;C0428772;C0488728
hr $nmbr$ cl pvalue,C0596019
nyha functional classification no i,C1275491;C0205245;C0542341;C2700217;C0021966;C0221138
adjusted hr $nmbr$ cl pvalue,C0456081;C0596019
hospitalization in previous year with management of heart failure,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539
primary outcome,C0205225;C1274040;C0439612;C0439631
as major component no,C0449432;C1705248
$nmbr$ events,C0441471;C3541888
qrs,
$nmbr$ $nmbr$ per $nmbr$ py,C0030428;C3538810
qrs $nmbr$ ms $nmbr$ cl n $nmbr$,C2349943;C0596019;C3539704;C3713294
aborted cardiac arrest,C0018790;C4553105
hr $nmbr$ cl pvalue,C0596019
$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C3541888;C0030428;C3538810
adjusted hr $nmbr$ cl pvalue,C0456081;C0596019
$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C4019010;C0030428;C3538810
primary outcome,C0205225;C1274040;C0439612;C0439631
heart failure hospitalizations,C3898876
$nmbr$ events,C0441471;C3541888
persistent faol n [ $nmbr$,C0205322;C0332996
$nmbr$ $nmbr$ per $nmbr$ py,C0030428;C3538810
persistent faod n [ $nmbr$,C0205322;C0332996
aborted cardiac arrest,C0018790;C4553105
inconsistent fao n [ $nmbr$,C0442809;C0016457
$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C3541888;C0030428;C3538810
total n [ $nmbr$,C0439175;C0439810
$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C4019010;C0030428;C3538810
duration of asthma y,C0449238;C2926735
heart failure hospitalizations,C3898876
predose fev $nmbr$ l,C0439565;C3714541;C3812758
persistent faol n [ $nmbr$,C0205322;C0332996
fevj predicted t,C0681842;C1882327
persistent faod n [ $nmbr$,C0205322;C0332996
fvc predicted t,C0681842;C1882327
inconsistent fao n [ $nmbr$,C0442809;C0016457
baseline ics dose n,C0168634;C0178602;C0869039;C1114758;C1442488
total n [ $nmbr$,C0439175;C0439810
moderatex,
duration of asthma y,C0449238;C2926735
highjj,
predose fev $nmbr$ l,C0439565;C3714541;C3812758
rescue medication use inh d,C0240320;C0022209
fevj predicted t,C0681842;C1882327
asthma control days,C0004096;C0439228;C2984299
fvc predicted t,C0681842;C1882327
figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status,C0439565;C2986411;C3812758;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0016457;C0449438
baseline ics dose n,C0168634;C0178602;C0869039;C1114758;C1442488
baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol,C0168634;C1442488;C1704788;C3539106;C0444706;C3541902;C0220908;C1522609;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C1551351;C0205436;C0060657;C0457385;C0565930;C1561503;C1705190
moderatex,
prior mi n $nmbr$ $nmbr$,C0332152;C2826257
highjj,
index mi n $nmbr$ $nmbr$,C0600653;C0918012;C1552854;C1637833;C2986546
rescue medication use inh d,C0240320;C0022209
any mi n $nmbr$ $nmbr$,C3810814
asthma control days,C0004096;C0439228;C2984299
no mi n $nmbr$ $nmbr$,C3810814
figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status,C0439565;C2986411;C3812758;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0016457;C0449438
pvaluefor any mi versus no mi,C3810814
baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol,C0168634;C1442488;C1704788;C3539106;C0444706;C3541902;C0220908;C1522609;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C1551351;C0205436;C0060657;C0457385;C0565930;C1561503;C1705190
race nonwhitet,C0034510;C1706779;C3853635
prior mi n $nmbr$ $nmbr$,C0332152;C2826257
oral medications,C0304289
index mi n $nmbr$ $nmbr$,C0600653;C0918012;C1552854;C1637833;C2986546
diet controlled or no,C0743195
any mi n $nmbr$ $nmbr$,C3810814
stroke tia,C0007787;C0917805;C1054154
no mi n $nmbr$ $nmbr$,C3810814
history of major bleeding,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pvaluefor any mi versus no mi,C3810814
peripheral artery disease,C1704436;C4025272
race nonwhitet,C0034510;C1706779;C3853635
indication for index procedure,C2315323;C0600653;C0918012;C1552854;C1637833;C2986546
oral medications,C0304289
unstable anginat,C0443343;C1883468
diet controlled or no,C0743195
any mi,C3810814
stroke tia,C0007787;C0917805;C1054154
ischemic outcomes,C0475224;C1274040
history of major bleeding,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
continue thienopyridine n $nmbr$,C0549178;C1120149
peripheral artery disease,C1704436;C4025272
stratified hazard ratio $nmbr$ ci,C0008107;C3259781
indication for index procedure,C2315323;C0600653;C0918012;C1552854;C1637833;C2986546
stratified log rank p value,C0205363;C1709380
unstable anginat,C0443343;C1883468
stent thrombosis arc definite probable,C0033204;C0332148
any mi,C3810814
macce death mi stroke,C0038454;C4554100
ischemic outcomes,C0475224;C1274040
stent thrombosis related mi,C3897493;C3810814
continue thienopyridine n $nmbr$,C0549178;C1120149
non stent thrombosis related mi,C3897493;C3810814
stratified hazard ratio $nmbr$ ci,C0008107;C3259781
bleeding outcomes,C0019080;C1274040
stratified log rank p value,C0205363;C1709380
log rank p value,C0667477;C1709380;C0699794
stent thrombosis arc definite probable,C0033204;C0332148
gusto severe moderate,C1299393
macce death mi stroke,C0038454;C4554100
gusto moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
stent thrombosis related mi,C3897493;C3810814
barc types $nmbr$ $nmbr$ or $nmbr$,C0332307
non stent thrombosis related mi,C3897493;C3810814
no mi,C3810814
bleeding outcomes,C0019080;C1274040
log rank,C0667477;C0699794
log rank p value,C0667477;C1709380;C0699794
figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes,C0871208;C1521828;C1709595;C1999375;C2349200;C4522255;C0206655;C0446516;C2681631;C3715044;C4553528;C0011847;C0011849
gusto severe moderate,C1299393
central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results,C1999375;C0030705;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657;C1274040;C1546471;C2825142
gusto moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
peripheral artery disease pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
barc types $nmbr$ $nmbr$ or $nmbr$,C0332307
adolescents aged $nmbr$ $nmbr$ y no,C0001779;C0001792;C1999167
no mi,C3810814
adults aged $nmbr$ y no,C0001675;C0001779;C0001792;C1999167
log rank,C0667477;C0699794
othera,
figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes,C0871208;C1521828;C1709595;C1999375;C2349200;C4522255;C0206655;C0446516;C2681631;C3715044;C4553528;C0011847;C0011849
non hispanic non latino,C1518424;C0086528
central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results,C1999375;C0030705;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657;C1274040;C1546471;C2825142
disease characteristics,C0599878
peripheral artery disease pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
mean time since diagnosis y,C0040223;C3541383
adolescents aged $nmbr$ $nmbr$ y no,C0001779;C0001792;C1999167
exacerbation within $nmbr$ mo,C4086268;C0026544;C0332177
adults aged $nmbr$ y no,C0001675;C0001779;C0001792;C1999167
aqlq score mean,C0444504;C2347634;C2348143
othera,
asui score mean,C0444504;C2347634;C2348143
non hispanic non latino,C1518424;C0086528
airway reversibility mean,C0444504;C2347634;C2348143
disease characteristics,C0599878
fev $nmbr$ mean predicted,C0444504;C2347634;C2348143;C0681842;C1882327
mean time since diagnosis y,C0040223;C3541383
rescue use mean no of inhalations d,C0444504;C2347634;C2348143;C0004048;C0354922
exacerbation within $nmbr$ mo,C4086268;C0026544;C0332177
blood eosinophils mean range cells mlb,C0005773
aqlq score mean,C0444504;C2347634;C2348143
total daily dose of ics mean gc,C2348070;C0444504;C2347634;C2348143
asui score mean,C0444504;C2347634;C2348143
a reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
airway reversibility mean,C0444504;C2347634;C2348143
b reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
fev $nmbr$ mean predicted,C0444504;C2347634;C2348143;C0681842;C1882327
eos count cells pl,C3897966;C4049765
rescue use mean no of inhalations d,C0444504;C2347634;C2348143;C0004048;C0354922
mensa,
blood eosinophils mean range cells mlb,C0005773
sirius,
total daily dose of ics mean gc,C2348070;C0444504;C2347634;C2348143
prior oma use,C0042153;C0457083;C1947944
a reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
no prior oma use,C0042153;C0457083;C1947944
b reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
mepo n $nmbr$,
eos count cells pl,C3897966;C4049765
prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
mensa,
no prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
sirius,
annual exacerbation rate,C0871208;C1521828
prior oma use,C0042153;C0457083;C1947944
age mean range years,C1510829;C0444504;C2347634;C2348143
no prior oma use,C0042153;C0457083;C1947944
rate ratio mepo pbo $nmbr$ ci,C0008107;C3259781
mepo n $nmbr$,
female n race n,C0043210;C0034510;C1706779;C3853635;C0086287;C1705497;C1705498
prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
change from baseline in acq $nmbr$,C0392747;C0443172;C1705241;C4319952;C2919686
no prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
score at week $nmbr$ mean se difference mepo pbo $nmbr$ ci,C3533236;C0008107;C3259781
annual exacerbation rate,C0871208;C1521828
change from baseline in sgrq,C0392747;C0443172;C1705241;C4319952
age mean range years,C1510829;C0444504;C2347634;C2348143
change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se,C0392747;C0443172;C1705241;C4319952;C0030771;C1518922;C1542834
rate ratio mepo pbo $nmbr$ ci,C0008107;C3259781
hispanic ethnicity n,C0086409;C0015031;C0243103
female n race n,C0043210;C0034510;C1706779;C3853635;C0086287;C1705497;C1705498
difference mepo pbo $nmbr$ ci,C0008107;C3259781
change from baseline in acq $nmbr$,C0392747;C0443172;C1705241;C4319952;C2919686
change from baseline in pre bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
score at week $nmbr$ mean se difference mepo pbo $nmbr$ ci,C3533236;C0008107;C3259781
fev $nmbr$ at week $nmbr$ mean ml se difference mepo pbo $nmbr$ ci,C3714541;C0008107;C3259781
change from baseline in sgrq,C0392747;C0443172;C1705241;C4319952
duration of asthma,C0449238;C2926735
change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se,C0392747;C0443172;C1705241;C4319952;C0030771;C1518922;C1542834
change from baseline in post bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
hispanic ethnicity n,C0086409;C0015031;C0243103
mean sd years daily ocs use n,C0332173;C0042153;C0457083;C1947944
difference mepo pbo $nmbr$ ci,C0008107;C3259781
ocs dose mean sd,C0178602;C2699239;C0869039;C1114758
change from baseline in pre bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll,C0456603;C1547037;C0200638;C0750879;C0007584;C0007634
fev $nmbr$ at week $nmbr$ mean ml se difference mepo pbo $nmbr$ ci,C3714541;C0008107;C3259781
mg day,C0439422
duration of asthma,C0449238;C2926735
ratio mepo pbo $nmbr$ ci,C0008107;C3259781
change from baseline in post bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
eosinophils cells ll inclusion criteria n,C0007584;C0007634;C1512693
mean sd years daily ocs use n,C0332173;C0042153;C0457083;C1947944
ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml,C0456603;C1547037;C0806481;C2986759;C0439340;C1880521;C2945590
ocs dose mean sd,C0178602;C2699239;C0869039;C1114758
$nmbr$ in previous,C0205156;C1552607
ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll,C0456603;C1547037;C0200638;C0750879;C0007584;C0007634
$nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
mg day,C0439422
predicted pre bd,C0005126;C2344255;C4050145
ratio mepo pbo $nmbr$ ci,C0008107;C3259781
fev $nmbr$ mean sd pre bd fev $nmbr$ fvc,C0005126;C3714541;C2344255;C4050145
eosinophils cells ll inclusion criteria n,C0007584;C0007634;C1512693
mean sd reversibility fev $nmbr$ at,C0444504;C3714541;C2347634;C2348143
ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml,C0456603;C1547037;C0806481;C2986759;C0439340;C1880521;C2945590
screening mean sd morning pef mean,C0220908;C0030771;C1518922;C1542834;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
$nmbr$ in previous,C0205156;C1552607
sd l min acq $nmbr$ score mean sd,C0449820;C0444504;C2347634;C2348143;C4050231
$nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
sgrq score mean sd,C0444504;C2699239;C2347634;C2348143
predicted pre bd,C0005126;C2344255;C4050145
total ige geometric,C0439175;C0439810
fev $nmbr$ mean sd pre bd fev $nmbr$ fvc,C0005126;C3714541;C2344255;C4050145
mean sd on loge scale u ml,C2699239;C0439340;C1880521;C2945590
mean sd reversibility fev $nmbr$ at,C0444504;C3714541;C2347634;C2348143
blood eosinophil count geometric mean sd loge scale cells ll,C0005773
screening mean sd morning pef mean,C0220908;C0030771;C1518922;C1542834;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
severe exacerbations,C0205082;C4086268;C4050465;C4050466
sd l min acq $nmbr$ score mean sd,C0449820;C0444504;C2347634;C2348143;C4050231
in previous year mean sd,C0205156;C2699239;C1552607
sgrq score mean sd,C0444504;C2699239;C2347634;C2348143
exacerbations in previous year requiring hospitalization and or ed visit n,C4086268;C0205156;C1552607;C0019993;C0545082;C1512346;C2826704
total ige geometric,C0439175;C0439810
exacerbations in previous year requiring hospitalization n,C4086268;C0205156;C1552607;C0019993
mean sd on loge scale u ml,C2699239;C0439340;C1880521;C2945590
spondylitis,C0038012
blood eosinophil count geometric mean sd loge scale cells ll,C0005773
non spondylitis,C1518422;C0038012
severe exacerbations,C0205082;C4086268;C4050465;C4050466
ustekinumab combined,C1608841;C0205195
in previous year mean sd,C0205156;C2699239;C1552607
randomised patients with spondylitis at baseline n,C0030705;C0038012;C0168634;C1442488
exacerbations in previous year requiring hospitalization and or ed visit n,C4086268;C0205156;C1552607;C0019993;C0545082;C1512346;C2826704
patients randomised n,C0030705
exacerbations in previous year requiring hospitalization n,C4086268;C0205156;C1552607;C0019993
randomised patients with basdai assessment at baseline and week $nmbr$ n,C1998004;C0679830;C0168634;C1442488;C0332174;C0439230
spondylitis,C0038012
mean sd improvement from baseline to week $nmbr$ in basdai,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004
non spondylitis,C1518422;C0038012
number of swollen joints $nmbr$ $nmbr$ mean sd,C0449813
ustekinumab combined,C1608841;C0205195
mean sd improvement from baseline to week $nmbr$ in basdai questions,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004;C1522634
randomised patients with spondylitis at baseline n,C0030705;C0038012;C0168634;C1442488
number of tender joints $nmbr$ $nmbr$ mean sd,C0449813
patients randomised n,C0030705
question $nmbr$ fatigue tiredness,C0015672;C4553152
randomised patients with basdai assessment at baseline and week $nmbr$ n,C1998004;C0679830;C0168634;C1442488;C0332174;C0439230
haq di score $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
mean sd improvement from baseline to week $nmbr$ in basdai,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004
question $nmbr$ neck back hip pain,C0007859;C1963180;C4553909
number of swollen joints $nmbr$ $nmbr$ mean sd,C0449813
crp mg l mean sd,C0439268;C2699239
mean sd improvement from baseline to week $nmbr$ in basdai questions,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004;C1522634
question $nmbr$ pain swelling in joints other than neck back hips,C0152031;C0004600;C0019552;C0205095;C0460009;C1995000
number of tender joints $nmbr$ $nmbr$ mean sd,C0449813
psa subtypes n,C3810537;C0449560;C3813209
question $nmbr$ fatigue tiredness,C0015672;C4553152
question $nmbr$ discomfort from any areas tender to touch pressure,C2364135;C0205146;C4319729;C0033095;C0460139;C1306345;C4284008
haq di score $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
dip joint arthritis,C0003864;C4552845
question $nmbr$ neck back hip pain,C0007859;C1963180;C4553909
question $nmbr$ morning stiffness since arising,C1522634;C0457086;C0332284;C4019053;C4318616
crp mg l mean sd,C0439268;C2699239
arthritis mutilans,C0702102
question $nmbr$ pain swelling in joints other than neck back hips,C0152031;C0004600;C0019552;C0205095;C0460009;C1995000
question $nmbr$ length of morning stiffness since arising,C1444754;C1706316;C0332284;C4019053;C4318616
psa subtypes n,C3810537;C0449560;C3813209
asymmetric peripheral arthritis,C0332514;C0238694
question $nmbr$ discomfort from any areas tender to touch pressure,C2364135;C0205146;C4319729;C0033095;C0460139;C1306345;C4284008
basdai responses at week $nmbr$,C0871261;C0332174;C0439230
dip joint arthritis,C0003864;C4552845
polyarticular arthritis no rheumatoid nodules,C0162323;C0035450
question $nmbr$ morning stiffness since arising,C1522634;C0457086;C0332284;C4019053;C4318616
basdai $nmbr$ n,C1998004
arthritis mutilans,C0702102
spondylitis with peripheral arthritis,C0038012;C0238694
question $nmbr$ length of morning stiffness since arising,C1444754;C1706316;C0332284;C4019053;C4318616
psa duration years mean sd,C0439234;C2699239
asymmetric peripheral arthritis,C0332514;C0238694
psoriasis duration years mean sd,C0033860;C2699239
basdai responses at week $nmbr$,C0871261;C0332174;C0439230
patients taking mtx n,C0030705;C0025677;C1417487
polyarticular arthritis no rheumatoid nodules,C0162323;C0035450
patients with digits with dactylitis n,C0030705;C0582802;C0239161
basdai $nmbr$ n,C1998004
haq di improvement from baseline to week $nmbr$,C3826998;C2986411;C4321476;C0332174;C0439230
spondylitis with peripheral arthritis,C0038012;C0238694
dactylitis score $nmbr$ $nmbr$ mean sd,C0239161;C2699239
psa duration years mean sd,C0439234;C2699239
patients with enthesitis n,C0030705;C1282952
psoriasis duration years mean sd,C0033860;C2699239
enthesitis score mases $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
patients taking mtx n,C0030705;C0025677;C1417487
patients with radiographic erosion n n,C0030705;C0333307;C1880549;C1959609;C3887524
patients with digits with dactylitis n,C0030705;C0582802;C0239161
randomised patients with $nmbr$ bsa psoriasis skin involvement at baseline,C0522476;C0168634;C1442488
haq di improvement from baseline to week $nmbr$,C3826998;C2986411;C4321476;C0332174;C0439230
basdai score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
dactylitis score $nmbr$ $nmbr$ mean sd,C0239161;C2699239
dlqi improvement from baseline to week $nmbr$,C2986411;C0168634;C1442488;C0332174;C0439230
patients with enthesitis n,C0030705;C1282952
basdai question $nmbr$ score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
enthesitis score mases $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
patients with $nmbr$ bsa psoriasis skin involvement n,C0522476
patients with radiographic erosion n n,C0030705;C0333307;C1880549;C1959609;C3887524
bsa mean sd,C0444504;C2699239;C2347634;C2348143
randomised patients with $nmbr$ bsa psoriasis skin involvement at baseline,C0522476;C0168634;C1442488
pasi score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
basdai score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
randomised patients with dactylitis at baseline,C0030705;C0239161;C0168634;C1442488
dlqi improvement from baseline to week $nmbr$,C2986411;C0168634;C1442488;C0332174;C0439230
dlqi $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
basdai question $nmbr$ score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
improvement in dactylitis score at week $nmbr$ n,C2986411;C0239161;C0332174;C0439230
patients with $nmbr$ bsa psoriasis skin involvement n,C0522476
patients with dactylitis at week $nmbr$ n,C0030705;C0239161;C0332174;C0439230
bsa mean sd,C0444504;C2699239;C2347634;C2348143
randomised patients with enthesitis at baselinet,C0030705;C1282952
pasi score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
improvement in enthesitis score at week $nmbr$ n,C2986411;C0449820;C4050231;C0332174;C0439230
randomised patients with dactylitis at baseline,C0030705;C0239161;C0168634;C1442488
patients with enthesitis at week $nmbr$ n,C0030705;C1282952;C0332174;C0439230
dlqi $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
standard treatment n $nmbr$,C4684780
improvement in dactylitis score at week $nmbr$ n,C2986411;C0239161;C0332174;C0439230
mra regimen n $nmbr$,C0243032;C0040808;C2945654;C1609165;C3891069
patients with dactylitis at week $nmbr$ n,C0030705;C0239161;C0332174;C0439230
risk factors and medical history,C0035648;C1553898;C0262926;C1704706
randomised patients with enthesitis at baselinet,C0030705;C1282952
prior cancer,C0006826;C0998265;C1306459
improvement in enthesitis score at week $nmbr$ n,C2986411;C0449820;C4050231;C0332174;C0439230
presentation,C0449450
patients with enthesitis at week $nmbr$ n,C0030705;C1282952;C0332174;C0439230
creatinine clearance ml min $nmbr$,C0812399;C0439445
standard treatment n $nmbr$,C4684780
potassium at admission mmol l $nmbr$,C0032821;C0202194;C0304475;C0597277;C3714637
mra regimen n $nmbr$,C0243032;C0040808;C2945654;C1609165;C3891069
admission grace score,C0449820;C4050231
risk factors and medical history,C0035648;C1553898;C0262926;C1704706
in hospital medication,C0013227;C3244316;C4284232
prior cancer,C0006826;C0998265;C1306459
p $nmbr$ y $nmbr$ antagonist,C0369773;C0231491;C2603361
presentation,C0449450
fibrinolysist,
creatinine clearance ml min $nmbr$,C0812399;C0439445
glycoprotein iib iiia inhibitort,C0016011
potassium at admission mmol l $nmbr$,C0032821;C0202194;C0304475;C0597277;C3714637
interventional or surgical procedures,C0184661;C3274035;C0543467
admission grace score,C0449820;C4050231
primary pcit,C0205225;C0439612;C0439631
in hospital medication,C0013227;C3244316;C4284232
demographic characteristic,C0011298;C1521970
p $nmbr$ y $nmbr$ antagonist,C0369773;C0231491;C2603361
umec $nmbr$ $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
fibrinolysist,
tio $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
glycoprotein iib iiia inhibitort,C0016011
umec $nmbr$ $nmbr$ mcg n $nmbr$,C0439211;C3463985
interventional or surgical procedures,C0184661;C3274035;C0543467
tio i $nmbr$ mcg n $nmbr$,C0021966;C0221138
primary pcit,C0205225;C0439612;C0439631
treatment diff vs tio $nmbr$ ci,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0008107;C3259781
demographic characteristic,C0011298;C1521970
gold grade $nmbr$,C0441800;C0919553;C3244287
umec $nmbr$ $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
ls mean change from baseline ml se a,C0392747;C0443172;C1705241;C4319952
tio $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
$nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
umec $nmbr$ $nmbr$ mcg n $nmbr$,C0439211;C3463985
current smoker at screening n,C3173209;C3241966
tio i $nmbr$ mcg n $nmbr$,C0021966;C0221138
smoking pack yearsa,C0037369;C0453996;C1881674
treatment diff vs tio $nmbr$ ci,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0008107;C3259781
post salbutamol fev $nmbr$ l b mean sd,C0001927;C2699239
gold grade $nmbr$,C0441800;C0919553;C3244287
gold group b,C0018026;C4522078;C1304897
ls mean change from baseline ml se a,C0392747;C0443172;C1705241;C4319952
post salbutamol fev $nmbr$ fvcb mean sd,C0001927;C2699239
$nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
reversibility to salbutamolc d mean sd,C0449261;C0444504;C2699239;C2347634;C2348143
current smoker at screening n,C3173209;C3241966
gold group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
smoking pack yearsa,C0037369;C0453996;C1881674
reversible,C0205343
post salbutamol fev $nmbr$ l b mean sd,C0001927;C2699239
nonreversible,
gold group b,C0018026;C4522078;C1304897
ics users at screening,C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
post salbutamol fev $nmbr$ fvcb mean sd,C0001927;C2699239
gold grades $nmbr$ $nmbr$ percent predicted fev n,C0018026;C0439165;C1304897
reversibility to salbutamolc d mean sd,C0449261;C0444504;C2699239;C2347634;C2348143
grade $nmbr$ moderate copd n,C0205081;C0024117;C1412502;C3714496;C1881878;C4049705;C4049706;C4085643;C4321335
gold group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
ics non users at screening,C1518422;C1706077
reversible,C0205343
grade $nmbr$ severe copd n,C0205082;C0024117;C1412502;C3714496;C4050465;C4050466
nonreversible,
gold groups a d using mmrcb,C0441838;C1524063
ics users at screening,C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
gold grade $nmbr$ and ics users at screening,C0441800;C0919553;C3244287;C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
gold grades $nmbr$ $nmbr$ percent predicted fev n,C0018026;C0439165;C1304897
group b low risk more symptoms n,C3272281;C3538919;C0683368;C1457887
grade $nmbr$ moderate copd n,C0205081;C0024117;C1412502;C3714496;C1881878;C4049705;C4049706;C4085643;C4321335
group d high risk more symptoms n,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0332167;C3272283;C4050568;C4319571;C0683368;C1457887
ics non users at screening,C1518422;C1706077
gold grade $nmbr$ and ics non users at screening,C0441800;C0919553;C3244287;C1518422;C1706077
grade $nmbr$ severe copd n,C0205082;C0024117;C1412502;C3714496;C4050465;C4050466
ics use at screening,C0042153;C0457083;C1947944
gold groups a d using mmrcb,C0441838;C1524063
ics users n,C0815320;C1706077;C4551720
gold grade $nmbr$ and ics users at screening,C0441800;C0919553;C3244287;C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
ics nonusers n,C0815320;C4551720
group b low risk more symptoms n,C3272281;C3538919;C0683368;C1457887
proportion of patients with trough fevi $nmbr$ ml above baseline n,C1709707;C0030705;C0439526;C1705224;C3887665
group d high risk more symptoms n,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0332167;C3272283;C4050568;C4319571;C0683368;C1457887
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
gold grade $nmbr$ and ics non users at screening,C0441800;C0919553;C3244287;C1518422;C1706077
odds ratio $nmbr$ cl,C0028873;C0596019
ics use at screening,C0042153;C0457083;C1947944
heterogeneity test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
ics users n,C0815320;C1706077;C4551720
y $nmbr$,
ics nonusers n,C0815320;C4551720
previous statin use,C0042153;C0457083;C1947944
proportion of patients with trough fevi $nmbr$ ml above baseline n,C1709707;C0030705;C0439526;C1705224;C3887665
troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
$nmbr$ $nmbr$ ng ml,C0439275
odds ratio $nmbr$ cl,C0028873;C0596019
duration of assigned regimen before surgery,C0449238;C2926735;C0038894;C0038895;C0543467;C1274039
heterogeneity test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
surgical technique,C0683469
y $nmbr$,
on pump,C3842462
previous statin use,C0042153;C0457083;C1947944
off pump,C1518543;C0182537
troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
procedure,C0184661;C2700391;C3274430;C3539779
$nmbr$ $nmbr$ ng ml,C0439275
aortic valve replacement,C0003506
duration of assigned regimen before surgery,C0449238;C2926735;C0038894;C0038895;C0543467;C1274039
postoperative glucocorticoid use,C0042153;C0457083;C1947944
surgical technique,C0683469
postoperative nsaid or glucocorticoid use,C0003211;C3536840;C0042153;C0457083;C1947944
on pump,C3842462
dulaglutide $nmbr$ $nmbr$ mgf,C1366394;C3712803;C3887684
off pump,C1518543;C0182537
age $nmbr$ vears n $nmbr$,C0001779
procedure,C0184661;C2700391;C3274430;C3539779
previous oral antidiabetic medication use n,C1527415
aortic valve replacement,C0003506
no oral antidiabetic medication,C0175795
postoperative glucocorticoid use,C0042153;C0457083;C1947944
$nmbr$ oral antidiabetic medication,C0175795
postoperative nsaid or glucocorticoid use,C0003211;C3536840;C0042153;C0457083;C1947944
insulin oral antidiabetic medication s,C0175795
dulaglutide $nmbr$ $nmbr$ mgf,C1366394;C3712803;C3887684
figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study,C0392747;C0443172;C1705241;C4319952;C0439230;C0027361;C0237401
age $nmbr$ vears n $nmbr$,C0001779
data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years,C1511726;C3245479;C3714741;C0449450;C0023668;C2708217;C2708218;C0017853;C0439234
previous oral antidiabetic medication use n,C1527415
pbo mtx n $nmbr$,C0031962;C0025677;C1417487
no oral antidiabetic medication,C0175795
czp mtx n $nmbr$,C0054841;C0025677;C1417487;C1861828;C1872109
$nmbr$ oral antidiabetic medication,C0175795
europe and australia,C0015176;C0004340
insulin oral antidiabetic medication s,C0175795
latin and north america,C0028405
figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study,C0392747;C0443172;C1705241;C4319952;C0439230;C0027361;C0237401
systemic corticosteroids n a,C4053960
data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years,C1511726;C3245479;C3714741;C0449450;C0023668;C2708217;C2708218;C0017853;C0439234
das $nmbr$ esr mean sd,C0051767;C2699239;C0057671
pbo mtx n $nmbr$,C0031962;C0025677;C1417487
moderate disease activity $nmbr$ $nmbr$ to,C1513375;C3833417
czp mtx n $nmbr$,C0054841;C0025677;C1417487;C1861828;C1872109
high disease activity $nmbr$ $nmbr$ n,C4699623
europe and australia,C0015176;C0004340
sdai mean sd,C0444504;C2699239;C2347634;C2348143
latin and north america,C0028405
cdai mean sd,C0444504;C2699239;C2347634;C2348143
systemic corticosteroids n a,C4053960
haq di mean sd,C3826998;C2699239;C4321476
das $nmbr$ esr mean sd,C0051767;C2699239;C0057671
tjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
moderate disease activity $nmbr$ $nmbr$ to,C1513375;C3833417
sjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
high disease activity $nmbr$ $nmbr$ n,C4699623
esr mm h median min max,C3642211
sdai mean sd,C0444504;C2699239;C2347634;C2348143
crp mg l median min max,C0439420
cdai mean sd,C0444504;C2699239;C2347634;C2348143
months since ra was first diagnosed mean sd,C0439231;C3538806;C4048756;C0011900;C2699239
haq di mean sd,C3826998;C2699239;C4321476
$nmbr$ months mean sd,C0439231;C2699239
tjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
months since first ra symptom mean sd f,C0439231;C0016327
sjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
rf positive $nmbr$ iu ml n,C0035448;C0439458;C0201660;C0748398;C1547111
esr mm h median min max,C3642211
acpa positive $nmbr$ iu ml n,C0439178;C0439458;C1446409;C1514241;C2825490;C3812269
crp mg l median min max,C0439420
mtss median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
months since ra was first diagnosed mean sd,C0439231;C3538806;C4048756;C0011900;C2699239
$nmbr$ months median min max,C0439231;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ months mean sd,C0439231;C2699239
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
months since first ra symptom mean sd f,C0439231;C0016327
erosion score median min max,C0333307;C0449820;C4050231;C1880549;C1959609;C3887524
rf positive $nmbr$ iu ml n,C0035448;C0439458;C0201660;C0748398;C1547111
jsn median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
acpa positive $nmbr$ iu ml n,C0439178;C0439458;C1446409;C1514241;C2825490;C3812269
presence of erosions n,C0150312;C0392148;C3854307
mtss median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot,C2986480;C0205363;C0040223;C3541383;C0011900;C1704338;C1704656;C0025677;C1417487;C0441837;C0028873;C0086312
$nmbr$ months median min max,C0439231;C0549183;C0876920;C2347635;C2348144;C2939193
included in analysis,C0332257;C0002778;C0936012;C1524024
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
total sample $nmbr$,C0370003;C2347026
erosion score median min max,C0333307;C0449820;C4050231;C1880549;C1959609;C3887524
age at baseline in years mean sd,C0001779;C0168634;C1442488;C0439234;C2699239
jsn median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
$nmbr$ $nmbr$ lo i,C0021966;C0221138
presence of erosions n,C0150312;C0392148;C3854307
time from parkinson s disease diagnosis in months mean sd,C0040223;C3541383;C0439231;C2699239
supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot,C2986480;C0205363;C0040223;C3541383;C0011900;C1704338;C1704656;C0025677;C1417487;C0441837;C0028873;C0086312
total updrs score baseline mean sd,C2964552;C2699239
included in analysis,C0332257;C0002778;C0936012;C1524024
activities of daily living updrs subscore baseline mean sd,C0001288;C4050548
total sample $nmbr$,C0370003;C2347026
motor updrs subscore baseline mean sd,C0168634;C2699239;C1442488
age at baseline in years mean sd,C0001779;C0168634;C1442488;C0439234;C2699239
mental activities updrs subscore baseline mean sd,C0168634;C2699239;C1442488
$nmbr$ $nmbr$ lo i,C0021966;C0221138
hoehn and yahr stage baseline mean sd,C0168634;C2699239;C1442488
time from parkinson s disease diagnosis in months mean sd,C0040223;C3541383;C0439231;C2699239
initial treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
total updrs score baseline mean sd,C2964552;C2699239
$nmbr$ mg $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
activities of daily living updrs subscore baseline mean sd,C0001288;C4050548
placebo $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
motor updrs subscore baseline mean sd,C0168634;C2699239;C1442488
gentype,
mental activities updrs subscore baseline mean sd,C0168634;C2699239;C1442488
weeks,C0439230
hoehn and yahr stage baseline mean sd,C0168634;C2699239;C1442488
weeks_measured,C0444706;C3541902
initial treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0443172;C1705241;C4319952;C0456081;C0168634;C1442488
$nmbr$ mg $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ to $nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
placebo $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
$nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
gentype,
event rate vr,C0441471;C3476815;C4019010
weeks,C0439230
edoxaban vs warfarin,C2975435;C0043031
weeks_measured,C0444706;C3541902
$nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
edo,
mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0443172;C1705241;C4319952;C0456081;C0168634;C1442488
$nmbr$ to $nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
p int,C0369773;C3272375;C2603361
$nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
stroke see,C0042789;C1947903
event rate vr,C0441471;C3476815;C4019010
type of af,C0332307;C1547052
edoxaban vs warfarin,C2975435;C0043031
persisent,
$nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
fatal stroke,C0038454;C4554100
edo,
crcl ml min at randomization,C0439445;C0034656
p int,C0369773;C3272375;C2603361
cha $nmbr$ ds $nmbr$ vasc score,C0449820;C4050231
stroke see,C0042789;C1947903
has bled score $nmbr$,C0449820;C4050231
type of af,C0332307;C1547052
major gl bleeding,C0018229;C0019080;C1423073;C1427674
persisent,
time in therapeutic range,C1554109
fatal stroke,C0038454;C4554100
dose reduction at randomization,C0301630;C0392756;C1293152;C4551656
crcl ml min at randomization,C0439445;C0034656
prior vka experience,C0237607;C0596545
cha $nmbr$ ds $nmbr$ vasc score,C0449820;C4050231
medication at time of randomization,C0013227;C3244316;C4284232
has bled score $nmbr$,C0449820;C4050231
gly $nmbr$ $nmbr$ mg b i d n $nmbr$,C0439422
major gl bleeding,C0018229;C0019080;C1423073;C1427674
ind $nmbr$ mg q d n $nmbr$,C4049864;C0439422
time in therapeutic range,C1554109
smoking history n,C1519384
dose reduction at randomization,C0301630;C0392756;C1293152;C4551656
number of pack years,C0237753;C0449788
prior vka experience,C0237607;C0596545
severity of copd airflow limitation n,C0439793;C0522510
medication at time of randomization,C0013227;C3244316;C4284232
moderate gold $nmbr$,C0018026;C1304897
gly $nmbr$ $nmbr$ mg b i d n $nmbr$,C0439422
severe gold $nmbr$,C0018026;C1304897
ind $nmbr$ mg q d n $nmbr$,C4049864;C0439422
very severe gold $nmbr$,C0018026;C1304897
smoking history n,C1519384
severity of copd combined assessment n,C0439793;C0522510
number of pack years,C0237753;C0449788
group b,C4522078
severity of copd airflow limitation n,C0439793;C0522510
group c,C0441837
moderate gold $nmbr$,C0018026;C1304897
group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
severe gold $nmbr$,C0018026;C1304897
copd exacerbation history n,C0740304;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
very severe gold $nmbr$,C0018026;C1304897
ics use at baseline n,C0042153;C0457083;C1947944
severity of copd combined assessment n,C0439793;C0522510
mmrc dyspnea scale n,C0013404;C0175659;C0349674;C1947916;C1963100
group b,C4522078
copd assessment test cat score,C0237855;C0237856
group c,C0441837
pre bronchodilator fev $nmbr$ l,C2599602;C3714541
group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
post bronchodilator fev $nmbr$ l,C2599594;C3714541
copd exacerbation history n,C0740304;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
post bronchodilator fev $nmbr$ reversibility a,C2599594;C0449261
ics use at baseline n,C0042153;C0457083;C1947944
ccv history condition,C0683519
mmrc dyspnea scale n,C0013404;C0175659;C0349674;C1947916;C1963100
gly $nmbr$ $nmbr$ gg b i d n n,C1415124;C0152277
copd assessment test cat score,C0237855;C0237856
ind $nmbr$ gg q d n n,C0017454;C0018370
pre bronchodilator fev $nmbr$ l,C2599602;C3714541
severity of airflow obstruction,C0439793;C0522510
post bronchodilator fev $nmbr$ l,C2599594;C3714541
mild or moderate copd,C2945599;C0024117;C1412502;C3714496
post bronchodilator fev $nmbr$ reversibility a,C2599594;C0449261
severe or very severe copd,C0205082;C4050465;C4050466;C0024117;C1412502;C3714496
ccv history condition,C0683519
ics use at baseline,C0042153;C0457083;C1947944
gly $nmbr$ $nmbr$ gg b i d n n,C1415124;C0152277
ccv history condition at baseline,C0683519;C0168634;C1442488
ind $nmbr$ gg q d n n,C0017454;C0018370
history of atrial fibrillation flutter,C0729790
severity of airflow obstruction,C0439793;C0522510
history of cardiac arrhythmia,C3494593
mild or moderate copd,C2945599;C0024117;C1412502;C3714496
long acting bronchodilator use at screening,C0042153;C0457083;C1947944
severe or very severe copd,C0205082;C4050465;C4050466;C0024117;C1412502;C3714496
attain,
ics use at baseline,C0042153;C0457083;C1947944
augment copd,C0205217;C0024117;C1412502;C3714496
ccv history condition at baseline,C0683519;C0168634;C1442488
pooled analysis sample,C1709595
history of atrial fibrillation flutter,C0729790
aclidinium $nmbr$ g n $nmbr$ a,C2699757;C0439267
history of cardiac arrhythmia,C3494593
placebo n $nmbr$ a,C0032042;C1696465;C1706408
long acting bronchodilator use at screening,C0042153;C0457083;C1947944
aclidinium $nmbr$ g n $nmbr$ b,C2699757;C0439267
attain,
placebo n $nmbr$ b,C0032042;C1696465;C1706408
augment copd,C0205217;C0024117;C1412502;C3714496
all patients n $nmbr$ b,C0030705
pooled analysis sample,C1709595
caucasian n,C0007457;C0043157
aclidinium $nmbr$ g n $nmbr$ a,C2699757;C0439267
smoking history pack years mean sd,C1277691;C2699239
placebo n $nmbr$ a,C0032042;C1696465;C1706408
post bronchodilator fev $nmbr$ l mean sd c,C2599594;C0444504;C2347634;C2348143
aclidinium $nmbr$ g n $nmbr$ b,C2699757;C0439267
post bronchodilator fev $nmbr$ predicted mean sd c,C2599594;C0444504;C2347634;C2348143
placebo n $nmbr$ b,C0032042;C1696465;C1706408
bronchial reversibility sd,C0205039;C2699239;C1442216
all patients n $nmbr$ b,C0030705
number of exacerbations in previous year mean sd,C0237753;C0449788;C0205156;C2699239;C1552607
caucasian n,C0007457;C0043157
rs breathlessnessb,C0035970;C3714753;C3813325
smoking history pack years mean sd,C1277691;C2699239
rs cough sputumc,C0035970;C0010200;C1961131;C3274924;C4084725;C4084726;C4084727;C3714753;C3813325
post bronchodilator fev $nmbr$ l mean sd c,C2599594;C0444504;C2347634;C2348143
rs chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
post bronchodilator fev $nmbr$ predicted mean sd c,C2599594;C0444504;C2347634;C2348143
rs totala,C0035970;C3714753;C3813325
bronchial reversibility sd,C0205039;C2699239;C1442216
aclidinium $nmbr$ g bid n $nmbr$,C2699757;C0439267
number of exacerbations in previous year mean sd,C0237753;C0449788;C0205156;C2699239;C1552607
gold group a,C0441835;C4522145
rs breathlessnessb,C0035970;C3714753;C3813325
gold group c,C0018026;C0441837;C1304897
rs cough sputumc,C0035970;C0010200;C1961131;C3274924;C4084725;C4084726;C4084727;C3714753;C3813325
fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f,C0392747;C0443172;C1705241;C4319952;C0035970;C0449820;C3714753;C3813325;C1709707;C0282416;C1561607;C0441835;C4522145;C2964552;C0013404;C0119082;C0016327
rs chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
rs cough sputum domain g and h rs chest symptoms domain p,C0370205;C0119082;C0150618;C0035970;C3714753;C3813325
rs totala,C0035970;C3714753;C3813325
lixisenatide,C2973895
aclidinium $nmbr$ g bid n $nmbr$,C2699757;C0439267
high i $nmbr$ baseline hba $nmbr$ c,C0021966;C0019016;C1825777;C3538758;C0221138
gold group a,C0441835;C4522145
high i $nmbr$ kg m $nmbr$ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
gold group c,C0018026;C0441837;C1304897
short,C1282927;C1806781;C2350002
fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f,C0392747;C0443172;C1705241;C4319952;C0035970;C0449820;C3714753;C3813325;C1709707;C0282416;C1561607;C0441835;C4522145;C2964552;C0013404;C0119082;C0016327
long i $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
rs cough sputum domain g and h rs chest symptoms domain p,C0370205;C0119082;C0150618;C0035970;C3714753;C3813325
i $nmbr$ years of age,C0021966;C1510829;C0221138
lixisenatide,C2973895
getgoal l asia,C0003980
high i $nmbr$ baseline hba $nmbr$ c,C0021966;C0019016;C1825777;C3538758;C0221138
getgoal s,
high i $nmbr$ kg m $nmbr$ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
high $nmbr$ baseline hbalc,C0205250;C0168634;C1442488;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
short,C1282927;C1806781;C2350002
high $nmbr$ kg m^ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
long i $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
long $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
i $nmbr$ years of age,C0021966;C1510829;C0221138
$nmbr$ years of age,C1510829
getgoal l asia,C0003980
suit quartile $nmbr$ b $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
getgoal s,
suit quartile $nmbr$ $nmbr$ $nmbr$,C2828255
high $nmbr$ baseline hbalc,C0205250;C0168634;C1442488;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
suit quartile $nmbr$ $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
high $nmbr$ kg m^ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
t $nmbr$ d duration years,C2603360;C0449238;C0439234;C2926735
long $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
oad use n,C0042153;C0457083;C1947944
$nmbr$ years of age,C1510829
oad history years,C0019664;C0439234;C0019665;C0262512;C0262926;C1705255;C2004062
suit quartile $nmbr$ b $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
ppg post meal test mmol l,C0376674;C1532563
suit quartile $nmbr$ $nmbr$ $nmbr$,C2828255
suit index nmol mmol,C1532564;C1533073
suit quartile $nmbr$ $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
no cv event n $nmbr$ $nmbr$,C3538987;C0441471;C4019010;C4048877;C4318503
t $nmbr$ d duration years,C2603360;C0449238;C0439234;C2926735
nonfatal mi n $nmbr$,C3810814
oad use n,C0042153;C0457083;C1947944
hhf n $nmbr$,
oad history years,C0019664;C0439234;C0019665;C0262512;C0262926;C1705255;C2004062
nonfatal stroke n $nmbr$,C0038454;C4554100
ppg post meal test mmol l,C0376674;C1532563
ua n $nmbr$,C0041580;C0042014
suit index nmol mmol,C1532564;C1533073
baseline glycated hemoglobin,C0168634;C0017853;C1442488
no cv event n $nmbr$ $nmbr$,C3538987;C0441471;C4019010;C4048877;C4318503
cv risk factors and history,C0035648;C1553898;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
nonfatal mi n $nmbr$,C3810814
coronary artery bypass graft,C0010055;C1260596
hhf n $nmbr$,
placebo n,C0032042;C1696465;C1706408
nonfatal stroke n $nmbr$,C0038454;C4554100
alogliptin n,C1958126
ua n $nmbr$,C0041580;C0042014
$nmbr$ kg ma $nmbr$,C0024443;C3887485
baseline glycated hemoglobin,C0168634;C0017853;C1442488
$nmbr$ years and $nmbr$ years,C0439234
cv risk factors and history,C0035648;C1553898;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hba $nmbr$ c $nmbr$,C0019016;C1825777;C3538758
coronary artery bypass graft,C0010055;C1260596
western europe australia new zealand middle eai,C0043128;C0027978;C0324547
placebo n,C0032042;C1696465;C1706408
normal function or mild impairment,C4296962;C0221099;C0684336
alogliptin n,C1958126
table $nmbr$ characteristics of the patients at baseline according,C0039224;C0815172;C1706074;C0168634;C1442488;C0680240
$nmbr$ kg ma $nmbr$,C0024443;C3887485
to the estimated glomerular filtration r,C0205090;C0684010;C2603358
$nmbr$ years and $nmbr$ years,C0439234
ate egfr,C1739039;C3811844;C3812682
hba $nmbr$ c $nmbr$,C0019016;C1825777;C3538758
western europe australia new zealand middle eai,C0043128;C0027978;C0324547
normal function or mild impairment,C4296962;C0221099;C0684336
table $nmbr$ characteristics of the patients at baseline according,C0039224;C0815172;C1706074;C0168634;C1442488;C0680240
p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition,C1709380;C1704970;C2699239;C0017654;C1424601;C0750572;C3839656;C1739039;C3811844;C3812682;C0686905;C0030705;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0237881;C0750502;C1546944;C0041420;C0681848;C0023822;C1704436;C4025272;C0439232;C0700321;C0702093;C1282918;C2347166;C0042295;C0008377;C1532563;C1719797;C2911648;C0041004;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0017853;C1522609;C1551393;C1705492;C3272743;C0456603;C1547037;C0444706;C3541902;C0439208;C0065055;C0032042;C1696465;C1706408;C0017351;C0021034;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0205447;C0439526;C1705224;C3887665;C0231174;C0680095;C0521095;C1140263;C0012634;C0348080;C1705253;C3864998
to the estimated glomerular filtration r,C0205090;C0684010;C2603358
patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less,C0030705;C0439526;C1705224;C3887665;C0439232;C0700321;C0702093;C1282918;C2347166
ate egfr,C1739039;C3811844;C3812682
patients with minute per,C0030705;C0439232;C0700321;C0702093;C1282918;C2347166
egfr of $nmbr$ ml per $nmbr$ $nmbr$ m $nmbr$ or more,C1739039;C3811844;C3812682
empagliflozin n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C3490348
interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no,C1272706;C1552654;C1552713;C1550351
p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition,C1709380;C1704970;C2699239;C0017654;C1424601;C0750572;C3839656;C1739039;C3811844;C3812682;C0686905;C0030705;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0237881;C0750502;C1546944;C0041420;C0681848;C0023822;C1704436;C4025272;C0439232;C0700321;C0702093;C1282918;C2347166;C0042295;C0008377;C1532563;C1719797;C2911648;C0041004;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0017853;C1522609;C1551393;C1705492;C3272743;C0456603;C1547037;C0444706;C3541902;C0439208;C0065055;C0032042;C1696465;C1706408;C0017351;C0021034;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0205447;C0439526;C1705224;C3887665;C0231174;C0680095;C0521095;C1140263;C0012634;C0348080;C1705253;C3864998
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less,C0030705;C0439526;C1705224;C3887665;C0439232;C0700321;C0702093;C1282918;C2347166
urinary albumin to creatinine ratio no,C0486293;C1318293
patients with minute per,C0030705;C0439232;C0700321;C0702093;C1282918;C2347166
low density lipoprotein^,C0023823
egfr of $nmbr$ ml per $nmbr$ $nmbr$ m $nmbr$ or more,C1739039;C3811844;C3812682
high density lipoprotein],C0023821
empagliflozin n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C3490348
cardiac failure,C0018801;C0018802
interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no,C1272706;C1552654;C1552713;C1550351
angiotensin converting enzyme inhibitor or angiotensin,C0003015;C2757044;C3536837;C4541021;C0003018;C4521302
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
receptor blocker,C0597357
urinary albumin to creatinine ratio no,C0486293;C1318293
urine albumin to creatinine ratio,C0455271;C1318330
low density lipoprotein^,C0023823
time since diagnosis of type $nmbr$ diabetes,C0040223;C3541383
high density lipoprotein],C0023821
sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
cardiac failure,C0018801;C0018802
cardiovascular risk,C0007226;C0035647;C4552904;C3887460
angiotensin converting enzyme inhibitor or angiotensin,C0003015;C2757044;C3536837;C4541021;C0003018;C4521302
only cerebrovascular disease,C0007820
receptor blocker,C0597357
only coronary artery disease,C0010054;C0010068;C1956346
urine albumin to creatinine ratio,C0455271;C1318330
only peripheral artery disease,C1704436;C4025272
time since diagnosis of type $nmbr$ diabetes,C0040223;C3541383
$nmbr$ or $nmbr$ high cardiovascular risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
statin and or ezetimibe,C0360714;C1142985
cardiovascular risk,C0007226;C0035647;C4552904;C3887460
anti hypertensive therapy,C0585941
only cerebrovascular disease,C0007820
ace inhibitor and or arb,C0003015;C4541021;C3888198
only coronary artery disease,C0010054;C0010068;C1956346
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C1304897;C0012634
only peripheral artery disease,C1704436;C4025272
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C0012634;C1304897
$nmbr$ or $nmbr$ high cardiovascular risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
statin and or ezetimibe,C0360714;C1142985
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408
anti hypertensive therapy,C0585941
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C1514756;C1518422
ace inhibitor and or arb,C0003015;C4541021;C3888198
rotigotine n $nmbr$,C1700683;C4318637
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C1304897;C0012634
stage of pda,C0205390;C1300072;C1306673
early n,C1279919
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C0012634;C1304897
advanced n,C0205179
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408
time since pd diagnosis mean sd,C0040223;C3541383
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C1514756;C1518422
years modified hoehn and yahr stage n,C0439234;C0679846
rotigotine n $nmbr$,C1700683;C4318637
renal function at randomization,C0232804;C0034656
stage of pda,C0205390;C1300072;C1306673
moderate dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274776;C0439445
early n,C1279919
mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],C2945599;C0031847;C0439445;C0277785;C3887504;C3887505
advanced n,C0205179
mild dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274775;C0439445
time since pd diagnosis mean sd,C0040223;C3541383
normal function crcl $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C4296962;C0439445
years modified hoehn and yahr stage n,C0439234;C0679846
weight median iqr kg,C0022718;C0439209;C4054209
renal function at randomization,C0232804;C0034656
bmi median iqr kg m $nmbr$,C0022718;C0439209;C4054209
moderate dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274776;C0439445
crcl median iqr ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],C2945599;C0031847;C0439445;C0277785;C3887504;C3887505
current or prior smoking,C0521116;C1705970;C0037369;C0453996;C1881674
mild dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274775;C0439445
other vascular disease cvd or pad,C0042373;C0007222;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
normal function crcl $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C4296962;C0439445
asia pacific and africa,C0003980;C0001737
weight median iqr kg,C0022718;C0439209;C4054209
chads $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
bmi median iqr kg m $nmbr$,C0022718;C0439209;C4054209
cha $nmbr$ ds $nmbr$ vasc mean sd,C0444504;C2699239;C2347634;C2348143
crcl median iqr ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
modified has bled score mean sd,C0392747;C3889737;C0444504;C2699239;C2347634;C2348143
current or prior smoking,C0521116;C1705970;C0037369;C0453996;C1881674
intermediate $nmbr$,C0205103;C1550465;C2827755;C3889971
other vascular disease cvd or pad,C0042373;C0007222;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
potent phosphorylated glycoprotein inhibitor use,C0042153;C0457083;C1947944
asia pacific and africa,C0003980;C0001737
prior vka use for $nmbr$ d,C0042153;C0457083;C1947944
chads $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
medication at randomization,C0013227;C3244316;C4284232
cha $nmbr$ ds $nmbr$ vasc mean sd,C0444504;C2699239;C2347634;C2348143
time in therapeutic range median iqr,C1554109
modified has bled score mean sd,C0392747;C3889737;C0444504;C2699239;C2347634;C2348143
n n yr,C0369718;C0439234;C0441922
intermediate $nmbr$,C0205103;C1550465;C2827755;C3889971
warf,C0043031
potent phosphorylated glycoprotein inhibitor use,C0042153;C0457083;C1947944
hder,C3898895
prior vka use for $nmbr$ d,C0042153;C0457083;C1947944
stroke or se s se,C0038454;C4554100;C0036919
medication at randomization,C0013227;C3244316;C4284232
crcl $nmbr$ $nmbr$,C1846718
time in therapeutic range median iqr,C1554109
crci $nmbr$,
major bleeding mb,C0019080;C0024853
n n yr,C0369718;C0439234;C0441922
s se mb or death,C0036919;C0024853;C0011065;C1306577;C4082313;C4552775
warf,C0043031
hder,C3898895
previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
stroke or se s se,C0038454;C4554100;C0036919
no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
crcl $nmbr$ $nmbr$,C1846718
warfarin n $nmbr$ n y,C0043031
crci $nmbr$,
higher dose edoxaban n $nmbr$ n y,C0444956;C2975435
major bleeding mb,C0019080;C0024853
higher dose edoxaban vs warfarin,C0444956;C2975435;C0043031
s se mb or death,C0036919;C0024853;C0011065;C1306577;C4082313;C4552775
ard per $nmbr$ $nmbr$ patient years $nmbr$ ci,C1817569;C1826411
previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
previous stroke tia,C0007787;C0917805;C1054154
no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
no previous stroke tia,C0007787;C0917805;C1054154
warfarin n $nmbr$ n y,C0043031
cvd stroke see,C0042789;C1947903
higher dose edoxaban n $nmbr$ n y,C0444956;C2975435
all cause death stroke see,C0042789;C1947903
higher dose edoxaban vs warfarin,C0444956;C2975435;C0043031
atrial fibrillation type n,C0004238;C0344434;C1963067
ard per $nmbr$ $nmbr$ patient years $nmbr$ ci,C1817569;C1826411
mace,C0349381;C0949745;C1445339
previous stroke tia,C0007787;C0917805;C1054154
paroxysmal af,C0235480
no previous stroke tia,C0007787;C0917805;C1054154
persistent af,C0344434;C4049859
cvd stroke see,C0042789;C1947903
permanent af,C0344434;C4049859
all cause death stroke see,C0042789;C1947903
qualifying risk factor n,C1514624;C0035648
atrial fibrillation type n,C0004238;C0344434;C1963067
chads $nmbr$ score $nmbr$ $nmbr$ n,C0449820;C4050231
mace,C0349381;C0949745;C1445339
nonfatal stroke,C0038454;C4554100
paroxysmal af,C0235480
dose reduction n,C0178602;C0301630;C0392756;C1293152;C4551656;C0869039;C1114758
persistent af,C0344434;C4049859
renal impairment crcl,C1565489;C1846718
permanent af,C0344434;C4049859
low body weight,C0041667
qualifying risk factor n,C1514624;C0035648
nondisabling nonfatal stroke,C0038454;C4554100
chads $nmbr$ score $nmbr$ $nmbr$ n,C0449820;C4050231
vka naive n,
nonfatal stroke,C0038454;C4554100
medication at randomization n,C0013227;C3244316;C4284232
dose reduction n,C0178602;C0301630;C0392756;C1293152;C4551656;C0869039;C1114758
disabling stroke,C0038454;C4554100
renal impairment crcl,C1565489;C1846718
disabling or fatal stroke,C0038454;C4554100
low body weight,C0041667
primary hemorrhagic stroke,C0205225;C0553692;C0439612;C0439631
nondisabling nonfatal stroke,C0038454;C4554100
primary ischemic stroke,C0205225;C0948008;C0439612;C0439631
vka naive n,
figure $nmbr$ treatment effect of sacubitril valsartan therapy,C1518681
medication at randomization n,C0013227;C3244316;C4284232
note have already got interaction values from the paper itself,C1316572;C1317574;C0042295;C0030351;C1547566
disabling stroke,C0038454;C4554100
vildagliptin metformin vldm,C1570906;C0025598
disabling or fatal stroke,C0038454;C4554100
metformin hdm,C0025598
primary hemorrhagic stroke,C0205225;C0553692;C0439612;C0439631
mean s d age years,C0444504;C1510829;C2347634;C2348143
primary ischemic stroke,C0205225;C0948008;C0439612;C0439631
mean s d weight kg,C0022718;C0439209;C4054209
figure $nmbr$ treatment effect of sacubitril valsartan therapy,C1518681
mean s d bmi kg m $nmbr$,C0022718;C0439209;C4054209
note have already got interaction values from the paper itself,C1316572;C1317574;C0042295;C0030351;C1547566
age distribution n,C0001782
vildagliptin metformin vldm,C1570906;C0025598
bmi distribution n,C0578022;C0520511;C1704711
metformin hdm,C0025598
mean s d duration of t $nmbr$ dm years,C0449238;C2926735
mean s d age years,C0444504;C1510829;C2347634;C2348143
mean s d baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
mean s d weight kg,C0022718;C0439209;C4054209
mean s d baseline fpg mmol l,C0168634;C1532563;C1442488
mean s d bmi kg m $nmbr$,C0022718;C0439209;C4054209
mean s d metformin dose mg day,C0025598;C0439422
age distribution n,C0001782
age $nmbr$ years and bmi,C1510829;C0578022
bmi distribution n,C0578022;C0520511;C1704711
age $nmbr$ years and bmi $nmbr$ kg m $nmbr$,C1510829;C0022718;C0439209;C4054209
mean s d duration of t $nmbr$ dm years,C0449238;C2926735
vldm n $nmbr$,
mean s d baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
hdm n $nmbr$,
mean s d baseline fpg mmol l,C0168634;C1532563;C1442488
hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
mean s d metformin dose mg day,C0025598;C0439422
hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions,C0019016;C1825777;C3538758;C1708130;C0559546;C3539617;C4050121
age $nmbr$ years and bmi,C1510829;C0578022
reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$,C0301630;C0392756;C1293152;C4551656;C0168634;C1442488
age $nmbr$ years and bmi $nmbr$ kg m $nmbr$,C1510829;C0022718;C0439209;C4054209
mean age y median range,C1514721;C2348147;C3542016
vldm n $nmbr$,
systolic blood pressure mm hg median range,C1514721;C2348147;C3542016
hdm n $nmbr$,
diastolic blood pressure mm hg median range,C1514721;C2348147;C3542016
hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
previous ischemic stroke n,C0205156;C0948008;C1552607
hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions,C0019016;C1825777;C3538758;C1708130;C0559546;C3539617;C4050121
previous coronary artery disease n,C0010054;C0010068;C1956346
reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$,C0301630;C0392756;C1293152;C4551656;C0168634;C1442488
history of diabetes mellitus n,C0455488
mean age y median range,C1514721;C2348147;C3542016
history of hypercholesterolemia n,C1533076
systolic blood pressure mm hg median range,C1514721;C2348147;C3542016
baseline scales median range,C1514721;C2348147;C3542016
diastolic blood pressure mm hg median range,C1514721;C2348147;C3542016
nihss at randomization,C1697238;C0034656
previous ischemic stroke n,C0205156;C0948008;C1552607
stroke subtype n,C0038454;C0449560;C4554100
previous coronary artery disease n,C0010054;C0010068;C1956346
laa,
history of diabetes mellitus n,C0455488
soe or sue,
history of hypercholesterolemia n,C1533076
extracranial carotid stenosis n,C0580586;C0007282
baseline scales median range,C1514721;C2348147;C3542016
medications at timing of randomization n,C2359859;C0034656
nihss at randomization,C1697238;C0034656
antiplatelet within $nmbr$ mo before randomization,C0026544;C0332177;C0034656
stroke subtype n,C0038454;C0449560;C4554100
antihypertensive agents,C0003364
laa,
antidiabetic agents,C0935929
soe or sue,
time from onset to randomization h mean sd,C0449244;C0033727;C2699239;C0369286;C0441932;C0564385;C4528284
extracranial carotid stenosis n,C0580586;C0007282
time from onset to medication h mean sd,C0449244;C0013227;C2699239;C3244316;C4284232
medications at timing of randomization n,C2359859;C0034656
event rates,C0871208;C1521828
antiplatelet within $nmbr$ mo before randomization,C0026544;C0332177;C0034656
p value for variance,C1709380;C1711260;C2348152
antihypertensive agents,C0003364
clopidogrel plus aspirin,C0070166;C0004057
antidiabetic agents,C0935929
placebo plus aspirin,C0032042;C1696465;C1706408
time from onset to randomization h mean sd,C0449244;C0033727;C2699239;C0369286;C0441932;C0564385;C4528284
history of hypercholesterolemia,C1533076
time from onset to medication h mean sd,C0449244;C0013227;C2699239;C3244316;C4284232
history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
event rates,C0871208;C1521828
time to treatment,C3494202
p value for variance,C1709380;C1711260;C2348152
hospital factor $nmbr$,C1521761;C2827422
clopidogrel plus aspirin,C0070166;C0004057
$nmbr$ enroll,
placebo plus aspirin,C0032042;C1696465;C1706408
$nmbr$ beds,C0004916
history of hypercholesterolemia,C1533076
lesion location,C0450429;C1515974;C4284930;C4284931
history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cortical only,C0001613;C0007776;C0022655
time to treatment,C3494202
non cortical,C0001613;C0007776;C0022655
hospital factor $nmbr$,C1521761;C2827422
vascular territory $nmbr$,C1301808;C2983136
$nmbr$ enroll,
anterior circulation,C0005775;C1516559
$nmbr$ beds,C0004916
posterior circulation,C0005775;C1516559
lesion location,C0450429;C1515974;C4284930;C4284931
mca,C0149566
cortical only,C0001613;C0007776;C0022655
aclidinium formoterol $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
non cortical,C0001613;C0007776;C0022655
salmeterol fluticasone $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
vascular territory $nmbr$,C1301808;C2983136
caucasians,C0007457;C0043157
anterior circulation,C0005775;C1516559
gold classification,C0008902;C0008903;C0678229
posterior circulation,C0005775;C1516559
smoking consumption pack years,C0425291;C1277691
mca,C0149566
exacerbation in previous year,C4086268;C0205156;C1552607
aclidinium formoterol $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
exacerbations in previous year,C4086268;C0205156;C1552607
salmeterol fluticasone $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
prior copd medication,C0013227;C3244316;C4284232
caucasians,C0007457;C0043157
laba lama,C0999593;C1416775
gold classification,C0008902;C0008903;C0678229
laba lama ics,C0815320;C4551720
smoking consumption pack years,C0425291;C1277691
fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
exacerbation in previous year,C4086268;C0205156;C1552607
post bronchodilator fevi $nmbr$ predicted,C0681842;C1882327
exacerbations in previous year,C4086268;C0205156;C1552607
bronchial reversibility,C0205039;C0449261;C1442216
prior copd medication,C0013227;C3244316;C4284232
bdi focal score $nmbr$,C0449820;C4050231
laba lama,C0999593;C1416775
cat total score $nmbr$,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
laba lama ics,C0815320;C4551720
sgrq total score $nmbr$,C2964552
fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p,C4055223;C0030705;C1279919;C3538806;C4048756
post bronchodilator fevi $nmbr$ predicted,C0681842;C1882327
acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis,C0035452;C4706353;C0014779;C0003873
bronchial reversibility,C0205039;C0449261;C1442216
a no vhd n $nmbr$ $nmbr$,
bdi focal score $nmbr$,C0449820;C4050231
b vhd n $nmbr$,
cat total score $nmbr$,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
sgrq total score $nmbr$,C2964552
c right sided vhd n $nmbr$,C0205090;C0444532
d mitral stenosis vhd n $nmbr$,C0026269;C0264766
figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p,C4055223;C0030705;C1279919;C3538806;C4048756
bonferroni adjusted p value b vs a,C0456081;C1709380
acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis,C0035452;C4706353;C0014779;C0003873
bonferroni adjusted p value c vs a,C0456081;C1709380
a no vhd n $nmbr$ $nmbr$,
bonferroni adjusted p value d vs a,C0456081;C1709380
b vhd n $nmbr$,
vhd event rate year n,C0439234;C0439508
c right sided vhd n $nmbr$,C0205090;C0444532
no vhd event rate year n,C0439234;C0439508
d mitral stenosis vhd n $nmbr$,C0026269;C0264766
adiusted hazard ratio,C2985465
bonferroni adjusted p value b vs a,C0456081;C1709380
persistent af n,C0205322;C0332996
bonferroni adjusted p value c vs a,C0456081;C1709380
[ $nmbr$ cl],C0596019
bonferroni adjusted p value d vs a,C0456081;C1709380
strokezsee,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
vhd event rate year n,C0439234;C0439508
crcl at baseline ml min,C1846718;C0439445
no vhd event rate year n,C0439234;C0439508
moderate renal impairment n,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
adiusted hazard ratio,C2985465
persistent af n,C0205322;C0332996
history of heart failure n,C0455531
[ $nmbr$ cl],C0596019
coronary artery disease n,C0010054;C0010068;C1956346
strokezsee,
history of myocardial infarction n,C1275835
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
vitamin k antagonist experienced n,C1096489;C2267235
crcl at baseline ml min,C1846718;C0439445
history of stroke see tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
moderate renal impairment n,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i,C1705241;C1705242;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0168634;C1442488;C0439230;C0021966;C0221138
history of heart failure n,C0455531
colchicine n $nmbr$,C0009262
coronary artery disease n,C0010054;C0010068;C1956346
no colchicine n $nmbr$,C0009262
history of myocardial infarction n,C1275835
age y mean range,C1514721;C2348147;C3542016
vitamin k antagonist experienced n,C1096489;C2267235
creatinine mg dl mean sd,C0439269;C2699239
history of stroke see tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ef mean sd,C0444504;C2699239;C2347634;C2348143
fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i,C1705241;C1705242;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0168634;C1442488;C0439230;C0021966;C0221138
ef b $nmbr$,
colchicine n $nmbr$,C0009262
valvular heart disease,C0018824;C1963123
no colchicine n $nmbr$,C0009262
$nmbr$ $nmbr$ range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
age y mean range,C1514721;C2348147;C3542016
age y n $nmbr$,C0001779
creatinine mg dl mean sd,C0439269;C2699239
age $nmbr$ $nmbr$ y n $nmbr$,C0001779
ef mean sd,C0444504;C2699239;C2347634;C2348143
age $nmbr$ y n $nmbr$,C0001779
ef b $nmbr$,
$nmbr$ y kaplan meier rate $nmbr$ ci,C0008107;C3259781
valvular heart disease,C0018824;C1963123
female race white,C0007457;C0043157;C0220938
$nmbr$ $nmbr$ range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
vorapaxar,C2974521
age y n $nmbr$,C0001779
cv death mi stroke recurrent ischemia,C0022116;C4321499
age $nmbr$ $nmbr$ y n $nmbr$,C0001779
with rehospitalization urgent coronary revascularization,C0439609;C0877341;C3272275
age $nmbr$ y n $nmbr$,C0001779
age b $nmbr$ y n $nmbr$,C0001779
$nmbr$ y kaplan meier rate $nmbr$ ci,C0008107;C3259781
cv death mi stroke,C0038454;C4554100
female race white,C0007457;C0043157;C0220938
bmi kg m $nmbr$ median q $nmbr$ q $nmbr$,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
vorapaxar,C2974521
gusto moderate severe bleeding,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
cv death mi stroke recurrent ischemia,C0022116;C4321499
gusto moderate bleeding ich,C0019191;C3272597;C3281105
with rehospitalization urgent coronary revascularization,C0439609;C0877341;C3272275
hyperlipidmemia,
age b $nmbr$ y n $nmbr$,C0001779
net clinical benefit cv death mi stroke gusto moderate severe bleeding,C4684590;C0019080
cv death mi stroke,C0038454;C4554100
thienopyridine at baseline,C1120149;C0168634;C1442488
bmi kg m $nmbr$ median q $nmbr$ q $nmbr$,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
aspirin dose at baseline mg,C4696290
gusto moderate severe bleeding,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
secukinumab $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gusto moderate bleeding ich,C0019191;C3272597;C3281105
range race n,C1514721;C0034510;C1706779;C3853635;C2348147;C3542016
hyperlipidmemia,
height cm mean sd a,C0444504;C2699239;C2347634;C2348143
net clinical benefit cv death mi stroke gusto moderate severe bleeding,C4684590;C0019080
bmi kg m $nmbr$ mean sd a,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
thienopyridine at baseline,C1120149;C0168634;C1442488
pasi score mean sd,C0444504;C2699239;C2347634;C2348143
aspirin dose at baseline mg,C4696290
range iga modified $nmbr$ score n,C0392747;C0449820;C4050231;C3889737
secukinumab $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time since first psoriasis diagnosis y mean sd,C0040223;C3541383
range race n,C1514721;C0034510;C1706779;C3853635;C2348147;C3542016
previous exposure to systemic psoriasis therapyb yes n,C0332157;C0033860
height cm mean sd a,C0444504;C2699239;C2347634;C2348143
previous exposure to biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
bmi kg m $nmbr$ mean sd a,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
previous exposure to non biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
pasi score mean sd,C0444504;C2699239;C2347634;C2348143
tpasi $nmbr$,
range iga modified $nmbr$ score n,C0392747;C0449820;C4050231;C3889737
ulpasi $nmbr$,
time since first psoriasis diagnosis y mean sd,C0040223;C3541383
llpasi $nmbr$,
previous exposure to systemic psoriasis therapyb yes n,C0332157;C0033860
no stroke n $nmbr$ $nmbr$,C0038454;C4554100
previous exposure to biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
stroke n $nmbr$,C0038454;C4554100
age median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
previous exposure to non biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
weight in kg median iqr,C0005910;C0043100;C1305866;C1705104
tpasi $nmbr$,
ulpasi $nmbr$,
bmi median iqr,C0578022;C0549183;C0876920;C2347635;C2348144;C2939193
llpasi $nmbr$,
sbp mm hg median iqr,C0085805;C0439475
no stroke n $nmbr$ $nmbr$,C0038454;C4554100
dbp mm hg median iqr,C0536221;C0439475;C3813197;C4281799
stroke n $nmbr$,C0038454;C4554100
hypercholesterolemia n,C0020443;C1522133
age median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
current smoking n,C0037369;C0453996;C1881674
weight in kg median iqr,C0005910;C0043100;C1305866;C1705104
cardiovascular history,C1880008
bmi median iqr,C0578022;C0549183;C0876920;C2347635;C2348144;C2939193
history of second prior mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
sbp mm hg median iqr,C0085805;C0439475
multivessel cad n,C1504769;C2239547;C3813548;C4284121
dbp mm hg median iqr,C0536221;C0439475;C3813197;C4281799
history of cabg n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hypercholesterolemia n,C0020443;C1522133
history of pci n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
current smoking n,C0037369;C0453996;C1881674
qualifying nstemi n,C1514624;C3537184;C4255010
cardiovascular history,C1880008
history of chf n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of second prior mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of atrial fibrillation n,C0729790
multivessel cad n,C1504769;C2239547;C3813548;C4284121
history of tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of cabg n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of pci n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
medical therapies,C0418981
qualifying nstemi n,C1514624;C3537184;C4255010
ace inhibitor n,C0003015;C4541021
history of chf n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ticagrelor $nmbr$ mg $nmbr$ yr km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history of atrial fibrillation n,C0729790
placebo $nmbr$ yr km,C0032042;C3887676;C1696465;C1706408
history of tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0008107;C3259781
history of stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
p interactio n,C0369773;C2603361
medical therapies,C0418981
no renal dysfunction,C1565489;C3279454
ace inhibitor n,C0003015;C4541021
renal dysfunction,C1565489;C3279454
ticagrelor $nmbr$ mg $nmbr$ yr km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
placebo $nmbr$ yr km,C0032042;C3887676;C1696465;C1706408
no history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0008107;C3259781
low dose,C0445550;C1708745
p interactio n,C0369773;C2603361
high dose,C0444956
no renal dysfunction,C1565489;C3279454
budesonide formoterol $nmbr$ $nmbr$ $nmbr$ ^g n $nmbr$,C1276807;C0439267
renal dysfunction,C1565489;C3279454
budesonide $nmbr$ ^g n $nmbr$,C0054201;C0439267
no history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
budesonide formoterol $nmbr$ ^g $nmbr$ $nmbr$ ^g n $nmbr$,C1276807
no history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
budesonide formoterol n $nmbr$,C1276807
low dose,C0445550;C1708745
budesonide n $nmbr$,C0054201
high dose,C0444956
age yr age group no,C0027362;C2348001
budesonide formoterol $nmbr$ $nmbr$ $nmbr$ ^g n $nmbr$,C1276807;C0439267
female sex no race no f,C0086287;C0034510;C1706779;C3853635;C0016327
budesonide $nmbr$ ^g n $nmbr$,C0054201;C0439267
mean time since asthma,C0040223;C3541383
budesonide formoterol $nmbr$ ^g $nmbr$ $nmbr$ ^g n $nmbr$,C1276807
diagnosis yr,C0011900;C0439234;C1704338;C1704656
budesonide formoterol n $nmbr$,C1276807
mean acq $nmbr$ score at randomization,C3533236;C0034656
budesonide n $nmbr$,C0054201
asthma control status at randomization no,C0004096;C0449438;C2984299
age yr age group no,C0027362;C2348001
controlled acq $nmbr$,C2587213;C2919686;C2911690
female sex no race no f,C0086287;C0034510;C1706779;C3853635;C0016327
uncontrolled acq $nmbr$ $nmbr$ $nmbr$,C0205318;C2919686
mean time since asthma,C0040223;C3541383
exacerbations in past $nmbr$ mo no,C4086268;C0026544;C0332177
diagnosis yr,C0011900;C0439234;C1704338;C1704656
daily dose of inhaled glucocorticoid no,C2348070;C0004048
mean acq $nmbr$ score at randomization,C3533236;C0034656
medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
asthma control status at randomization no,C0004096;C0449438;C2984299
monitoring group n $nmbr$,C0150369;C0441848;C1283169
controlled acq $nmbr$,C2587213;C2919686;C2911690
body mass index kg m,C0022718;C0439209;C4054209
uncontrolled acq $nmbr$ $nmbr$ $nmbr$,C0205318;C2919686
medical history and risk factors,C0262926;C1704706;C0035648;C1553898
exacerbations in past $nmbr$ mo no,C4086268;C0026544;C0332177
dyslipidaemia,C0242339
daily dose of inhaled glucocorticoid no,C2348070;C0004048
previous cancer,C0006826;C0998265;C1306459
medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
chronic respiratory failure,C0264492
monitoring group n $nmbr$,C0150369;C0441848;C1283169
inflammatory disease,C1290884
body mass index kg m,C0022718;C0439209;C4054209
previous cardiovascular events,C0205156;C1320716;C1552607
medical history and risk factors,C0262926;C1704706;C0035648;C1553898
concomitant medication after randomisation,C0013227;C3244316;C4284232
dyslipidaemia,C0242339
mra spironolactone or eplerenone,C0243032;C0037982;C1609165;C3891069;C0961485
previous cancer,C0006826;C0998265;C1306459
clinical presentation,C2708283
chronic respiratory failure,C0264492
secondary pci,C0027627;C4049621;C0175668;C0205436
inflammatory disease,C1290884
coronary angiography and intervention,C0085532;C1548829;C0184661;C0886296;C1273869
previous cardiovascular events,C0205156;C1320716;C1552607
radial access,C0444454;C1554204
concomitant medication after randomisation,C0013227;C3244316;C4284232
one vessel disease,C3275121
mra spironolactone or eplerenone,C0243032;C0037982;C1609165;C3891069;C0961485
two vessel disease,C0581375
clinical presentation,C2708283
three vessel disease,C3272265
secondary pci,C0027627;C4049621;C0175668;C0205436
left main,C0205091;C0205225;C1542147;C0443246;C1552822
coronary angiography and intervention,C0085532;C1548829;C0184661;C0886296;C1273869
multivessel two vessel three vessel or left main,C0205448;C0005847;C0205091;C0205225;C1542147;C0443246;C1552822
radial access,C0444454;C1554204
number of stents implanted,C0237753;C0449788;C0021102;C2828363
one vessel disease,C3275121
drug eluting stent implanted at least one,C1322815;C0205447
two vessel disease,C0581375
stented vessels,C0038257;C0005847
three vessel disease,C3272265
left main artery,C0205091;C0003842;C0226004;C0443246;C1552822
left main,C0205091;C0205225;C1542147;C0443246;C1552822
multivessel two vessel three vessel or left main,C0205448;C0005847;C0205091;C0205225;C1542147;C0443246;C1552822
left anterior descending coronary artery,C0226032
number of stents implanted,C0237753;C0449788;C0021102;C2828363
left circumflex coronary artery,C0226037
drug eluting stent implanted at least one,C1322815;C0205447
right coronary artery,C1261316
stented vessels,C0038257;C0005847
coronary bypass graft,C1260596
left main artery,C0205091;C0003842;C0226004;C0443246;C1552822
creatinine clearance at admission ml min,C0184666;C0151280;C0809949
haemoglobin g dl,C0439267
left anterior descending coronary artery,C0226032
monitoring treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
left circumflex coronary artery,C0226037
conventional treatment,C2945704
right coronary artery,C1261316
full population,C0032659;C1257890
coronary bypass graft,C1260596
t $nmbr$,C2603360
creatinine clearance at admission ml min,C0184666;C0151280;C0809949
weight $nmbr$ kg,C0022718;C0439209;C4054209
haemoglobin g dl,C0439267
no hypertension,C0020538;C1963138
monitoring treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no current smoking,C0037369;C0453996;C1881674
conventional treatment,C2945704
st,C0036056;C3272372
full population,C0032659;C1257890
creat clearance,C0449297;C1382187;C2825073;C4554548
t $nmbr$,C2603360
creat clearance $nmbr$ ml min,C0201975;C0439445
weight $nmbr$ kg,C0022718;C0439209;C4054209
no prior cancer,C0006826;C0998265;C1306459
no hypertension,C0020538;C1963138
no prior heart failure,C0018801;C0018802;C4554158
no current smoking,C0037369;C0453996;C1881674
one vessel,C0205447;C0005847
st,C0036056;C3272372
multi vessel or left main,C0439064;C0005847;C3266262;C0205091;C0205225;C1542147;C0443246;C1552822
creat clearance,C0449297;C1382187;C2825073;C4554548
des,C0011702;C4551552
creat clearance $nmbr$ ml min,C0201975;C0439445
bms,
no prior cancer,C0006826;C0998265;C1306459
length of stent median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
no prior heart failure,C0018801;C0018802;C4554158
number of stent l or $nmbr$ or $nmbr$,C0237753;C0449788
one vessel,C0205447;C0005847
number stent $nmbr$,C0237753;C0038257;C0449788
multi vessel or left main,C0439064;C0005847;C3266262;C0205091;C0205225;C1542147;C0443246;C1552822
roflumilast n $nmbr$ $nmbr$,C0965618
des,C0011702;C4551552
age mean sd yr,C0001779;C0439234
bms,
total cigarette pack years mean sd,C1303175;C2699239
length of stent median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
very severe,C3641272;C4050419
number of stent l or $nmbr$ or $nmbr$,C0237753;C0449788
copd duration mean sd yr,C0024117;C0439234;C1412502;C3714496
number stent $nmbr$,C0237753;C0038257;C0449788
prebronchodilator fev $nmbr$ mean sd l,C0444504;C2347634;C2348143
roflumilast n $nmbr$ $nmbr$,C0965618
post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
age mean sd yr,C0001779;C0439234
predicted prebronchodilator fev $nmbr$ mean sd l,C0681842;C0444504;C2347634;C2348143;C1882327
total cigarette pack years mean sd,C1303175;C2699239
predicted post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
very severe,C3641272;C4050419
post bronchodilator fev $nmbr$ fvc ratio mean sd,C2599594;C2699239
copd duration mean sd yr,C0024117;C0439234;C1412502;C3714496
no of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
prebronchodilator fev $nmbr$ mean sd l,C0444504;C2347634;C2348143
$nmbr$ mo mean sd x,C0026544;C0332177
post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
year n,C0439234;C0439508
predicted prebronchodilator fev $nmbr$ mean sd l,C0681842;C0444504;C2347634;C2348143;C1882327
prior hospitalizations n,C0332152;C0019993;C2826257
predicted post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
cat score mean sd,C0007450;C2699239;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
post bronchodilator fev $nmbr$ fvc ratio mean sd,C2599594;C2699239
exact pro total score mean sd,C2964552;C2699239
no of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
ics laba therapy n,C0039798;C0087111;C1363945
$nmbr$ mo mean sd x,C0026544;C0332177
fluticasone propionate salmeterol fdc,C0340427;C1413520;C3539652
year n,C0439234;C0439508
budesonide formoterol fdc,C0340427;C1413520;C3539652
prior hospitalizations n,C0332152;C0019993;C2826257
lama use n,C0042153;C0457083;C1947944
cat score mean sd,C0007450;C2699239;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
brv $nmbr$ mg day,C0155502;C0439422
exact pro total score mean sd,C2964552;C2699239
brv overall,C0155502;C0282416;C1561607
ics laba therapy n,C0039798;C0087111;C1363945
mean bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
fluticasone propionate salmeterol fdc,C0340427;C1413520;C3539652
etiology n,C0015127;C1314792;C1524003
budesonide formoterol fdc,C0340427;C1413520;C3539652
cryptogenic,C0332240
lama use n,C0042153;C0457083;C1947944
$nmbr$ b,
brv $nmbr$ mg day,C0155502;C0439422
mean sd [range] duration of epilepsy years,C0444504;C2699239;C2347634;C2348143;C1514721;C2348147;C3542016;C0449238;C2926735
brv overall,C0155502;C0282416;C1561607
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
mean bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
median minimum maximum focal seizure frequency $nmbr$ days at baseline,C0149775;C0439228
etiology n,C0015127;C1314792;C1524003
number of prior aeds n,C0237753;C0449788
cryptogenic,C0332240
prior lev treatment n,C1514463;C0023556
$nmbr$ b,
concomitant aedsb n,C0521115
mean sd [range] duration of epilepsy years,C0444504;C2699239;C2347634;C2348143;C1514721;C2348147;C3542016;C0449238;C2926735
oxcarbazepine,C0069751
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
carbamazepine,C0006949;C0006950;C0682993
median minimum maximum focal seizure frequency $nmbr$ days at baseline,C0149775;C0439228
lamotrigine,C0064636;C0524166
number of prior aeds n,C0237753;C0449788
lacosamide,C0893761
$nmbr$ teae,
prior lev treatment n,C1514463;C0023556
concomitant aedsb n,C0521115
teaes leading to discontinuation of study drug,C0332152;C0013175;C1522538
oxcarbazepine,C0069751
drug related teaes,C0013227;C0439849;C0445223;C1254351
carbamazepine,C0006949;C0006950;C0682993
saes,C1519255;C1622657;C4553214
lamotrigine,C0064636;C0524166
drug related saes,C1519255;C1622657;C4553214
lacosamide,C0893761
deaths,C0011065;C1306577
$nmbr$ teae,
teaes reported by $nmbr$ patients in the overall brv group n,C1709908;C0155502;C0441848
teaes leading to discontinuation of study drug,C0332152;C0013175;C1522538
paresthesia,C0030554;C4553220
drug related teaes,C0013227;C0439849;C0445223;C1254351
somnolence,C0013144;C2830004;C4553740
saes,C1519255;C1622657;C4553214
cataract,C0086543;C4555209
drug related saes,C1519255;C1622657;C4553214
constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
deaths,C0011065;C1306577
convulsion,C0036572;C4048158
teaes reported by $nmbr$ patients in the overall brv group n,C1709908;C0155502;C0441848
cystitis,C0010692;C0600041;C1963088
paresthesia,C0030554;C4553220
hyponatremia,C0020625;C4553967
somnolence,C0013144;C2830004;C4553740
hot climate subset,C0178683;C1515021
cataract,C0086543;C4555209
other climate subset,C0008946;C1515021
constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
sex n b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
convulsion,C0036572;C4048158
race n b,C0034510;C1706779;C3853635
cystitis,C0010692;C0600041;C1963088
otherc,
hyponatremia,C0020625;C4553967
duration of t $nmbr$ dm years,C0449238;C2926735
hot climate subset,C0178683;C1515021
high dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
other climate subset,C0008946;C1515021
high dosage ics plus laba with baseline blood eosinophils,C0815320;C4551720;C0168634;C0014467;C1442488
sex n b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
race n b,C0034510;C1706779;C3853635
age group years,C1510829
otherc,
body mass index kg m $nmbr$ t,C0005893;C1532718;C0578022;C1305855
duration of t $nmbr$ dm years,C0449238;C2926735
local eosinophil count cells per pl t,C0007584
high dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
central eosinophil count cells per pl t,C0007584
high dosage ics plus laba with baseline blood eosinophils,C0815320;C4551720;C0168634;C0014467;C1442488
prebronchodilator fev $nmbr$ l t,C2599602;C3714541
benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prebronchodilator fev $nmbr$ predicted normal t,C0520835;C0681842;C1882327
age group years,C1510829
fev $nmbr$ fvc prebronchodilatort,C3714541
body mass index kg m $nmbr$ t,C0005893;C1532718;C0578022;C1305855
reversibility t,C0449261
local eosinophil count cells per pl t,C0007584
acq $nmbr$ score,C0449820;C4050231
central eosinophil count cells per pl t,C0007584
time since asthma diagnosis years,C0556970;C0004096;C2984299
prebronchodilator fev $nmbr$ l t,C2599602;C3714541
number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C0439231
prebronchodilator fev $nmbr$ predicted normal t,C0520835;C0681842;C1882327
number resulting in emergency department visit,C0237753;C0449788;C0332294;C0562508
fev $nmbr$ fvc prebronchodilatort,C3714541
patients with $nmbr$ exacerbations resulting in emergency department visit,C0030705;C4086268;C0332294;C0562508
reversibility t,C0449261
number resulting in hospital admission,C0237753;C0449788;C0184666
acq $nmbr$ score,C0449820;C4050231
patients with $nmbr$ exacerbations resulting in hospital admission,C0030705;C4086268;C0184666
time since asthma diagnosis years,C0556970;C0004096;C2984299
total asthma symptom score,C3533163;C0004096;C2984299
number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C0439231
diagnosis of allergic rhinitis,C0011900;C1704338;C1704656
number resulting in emergency department visit,C0237753;C0449788;C0332294;C0562508
nasal polyps,C0027430
patients with $nmbr$ exacerbations resulting in emergency department visit,C0030705;C4086268;C0332294;C0562508
atopic based on phadiatop test,C0392707;C1527178;C1705938
number resulting in hospital admission,C0237753;C0449788;C0184666
history of omalizumab treatment,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
patients with $nmbr$ exacerbations resulting in hospital admission,C0030705;C4086268;C0184666
aqlq s $nmbr$ scorets,C4055434
total asthma symptom score,C3533163;C0004096;C2984299
smoking pack year years fl,C1300812;C1708024
diagnosis of allergic rhinitis,C0011900;C1704338;C1704656
empty,C1880497
nasal polyps,C0027430
a beuralizuinab $nmbr$ ing q $nmbr$ w,
atopic based on phadiatop test,C0392707;C1527178;C1705938
b benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history of omalizumab treatment,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
estimate $nmbr$ ci,C0008107;C3259781
aqlq s $nmbr$ scorets,C4055434
baseline ocs use yes,C1549445;C1705108;C1710701
smoking pack year years fl,C1300812;C1708024
age groiro,C0001779
empty,C1880497
geo graphic region asia,C0017446;C0003980;C0205147
a beuralizuinab $nmbr$ ing q $nmbr$ w,
$nmbr$ kg nr,C0027496;C3844738
b benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
exacerbations in the prev year $nmbr$,C4086268;C0439234;C0439508
estimate $nmbr$ ci,C0008107;C3259781
nasal polyps at baseline yes,C0027430;C0168634;C1442488
baseline ocs use yes,C1549445;C1705108;C1710701
iee at baseline,C0168634;C1442488
age groiro,C0001779
$nmbr$ iu l,C0439457
geo graphic region asia,C0017446;C0003980;C0205147
atopic at baseline yes,C0392707;C0168634;C1442488
$nmbr$ kg nr,C0027496;C3844738
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$,
exacerbations in the prev year $nmbr$,C4086268;C0439234;C0439508
prior therapy with omalizumab yes,C1514463;C0966225
nasal polyps at baseline yes,C0027430;C0168634;C1442488
high dosage ics plus laba with baseline blood eosinophils $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
iee at baseline,C0168634;C1442488
eosinophil count cells per pl,C0007584
$nmbr$ iu l,C0439457
central eosinophil count cells per pl,C0007584
atopic at baseline yes,C0392707;C0168634;C1442488
prebronchodilator fev $nmbr$ l,C2599602;C3714541
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$,
predicted normal,C0205307;C0231683;C0439166;C2347086;C4553972
prior therapy with omalizumab yes,C1514463;C0966225
prebronchodilator fev $nmbr$ fvc,C2599602;C3714541
high dosage ics plus laba with baseline blood eosinophils $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
acq $nmbr$ scoret,C2919686
eosinophil count cells per pl,C0007584
number resulting in ed visit,C0237753;C0449788;C0332294
central eosinophil count cells per pl,C0007584
patients with $nmbr$ exacerbations resulting in ed visit,C0030705;C4086268;C0332294
prebronchodilator fev $nmbr$ l,C2599602;C3714541
aqlq s $nmbr$ scored,C4055434;C0449820
predicted normal,C0205307;C0231683;C0439166;C2347086;C4553972
nicotine pack years,C0028040;C1277691
prebronchodilator fev $nmbr$ fvc,C2599602;C3714541
appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l,C0871208;C0456603;C1547037;C1521828;C1079230;C1515021;C0032042;C1696465;C1706408;C2982078;C1514756;C0014467;C0347983
acq $nmbr$ scoret,C2919686
at increased fall risk n $nmbr$,C4699158
number resulting in ed visit,C0237753;C0449788;C0332294
notatincreased fall risk n $nmbr$ $nmbr$,C1268740
patients with $nmbr$ exacerbations resulting in ed visit,C0030705;C4086268;C0332294
randomization group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
aqlq s $nmbr$ scored,C4055434;C0449820
higher dose edoxaban regimen,C2348331
nicotine pack years,C0028040;C1277691
lower dose edoxaban regimen,C2348331
appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l,C0871208;C0456603;C1547037;C1521828;C1079230;C1515021;C0032042;C1696465;C1706408;C2982078;C1514756;C0014467;C0347983
age $nmbr$ yrs,C0001779
at increased fall risk n $nmbr$,C4699158
has bled score,C0449820;C4050231
notatincreased fall risk n $nmbr$ $nmbr$,C1268740
history of stroke or tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
randomization group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
crcl at randomization ml min,C1846718;C0439445
higher dose edoxaban regimen,C2348331
aspirin use at randomization,C0042153;C0457083;C1947944
lower dose edoxaban regimen,C2348331
dose reduced at randomization,C0178602;C0869039;C1114758;C0392756;C0034656
age $nmbr$ yrs,C0001779
ttr warfarin arm only,C0446516;C3715044;C4553528
has bled score,C0449820;C4050231
charlson comorbidity index,C4546361
history of stroke or tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
increased risk for falls,C4699158
crcl at randomization ml min,C1846718;C0439445
no increased risk for falls,C4699158
aspirin use at randomization,C0042153;C0457083;C1947944
univariable,
dose reduced at randomization,C0178602;C0869039;C1114758;C0392756;C0034656
multivariable,
ttr warfarin arm only,C0446516;C3715044;C4553528
bone fracture,C0016658
charlson comorbidity index,C4546361
bone fracture due to fall,C0016658;C0678226
increased risk for falls,C4699158
malignancy death,C0011065;C1306577;C4082313;C4552775
no increased risk for falls,C4699158
net ep $nmbr$,C1880476;C4321526
univariable,
major crnm bleed,C0205082;C0019080;C0205164;C4318856;C4521762
multivariable,
death or ich,C0011065;C1306577;C4082313;C4552775;C0019191;C3272597;C3281105
bone fracture,C0016658
abaloparatide sc n,C4042342;C0282380
bone fracture due to fall,C0016658;C0678226
all participantsa,
malignancy death,C0011065;C1306577;C4082313;C4552775
t score categories lumbar spineb,C3854607
net ep $nmbr$,C1880476;C4321526
total hipc,C0439175;C0439810
major crnm bleed,C0205082;C0019080;C0205164;C4318856;C4521762
femoral neckc,C0015811
death or ich,C0011065;C1306577;C4082313;C4552775;C0019191;C3272597;C3281105
fracture status prevalent vertebral fractured,C0016658;C0549207;C4554413
abaloparatide sc n,C4042342;C0282380
prior nonvertebral fracture,C0332152;C0016658;C2826257
all participantsa,
age categories,C2916832
t score categories lumbar spineb,C3854607
abl sc n n,C0023139;C0282380;C1704928;C3890208
total hipc,C0439175;C0439810
\bl sc n n,C0439394;C0282380;C1706495;C3642217
femoral neckc,C0015811
interaction j $nmbr$ valuet,C1704675
fracture status prevalent vertebral fractured,C0016658;C0549207;C4554413
lumbar spine bmd t,C0024091;C3887615
prior nonvertebral fracture,C0332152;C0016658;C2826257
score,C0449820;C4050231
age categories,C2916832
total hip bmi t score,C2964552;C0019552;C0022122;C1505163;C3538851;C4284725
abl sc n n,C0023139;C0282380;C1704928;C3890208
placebo mean,C0444504;C2347634;C2348143
\bl sc n n,C0439394;C0282380;C1706495;C3642217
abl sc mean,C0444504;C2347634;C2348143
interaction j $nmbr$ valuet,C1704675
least squares mean difference $nmbr$ ci,C0008107;C3259781
lumbar spine bmd t,C0024091;C3887615
interaction p valuef,C1704675
score,C0449820;C4050231
o os,C2673162
total hip bmi t score,C2964552;C0019552;C0022122;C1505163;C3538851;C4284725
lavolta $nmbr$,
placebo mean,C0444504;C2347634;C2348143
lavolta ii,C1710602;C4082587
abl sc mean,C0444504;C2347634;C2348143
lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
least squares mean difference $nmbr$ ci,C0008107;C3259781
lebrikizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
interaction p valuef,C1704675
body mass index kg mq,C0005893;C0024853;C0578022;C1305855
o os,C2673162
median range duration of asthma years,C0449238;C2926735
lavolta $nmbr$,
baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba,C2827928;C0117996;C0205163;C0439185
lavolta ii,C1710602;C4082587
mean ics fluticasone propionate dpi or equivalent pg per day,C0444504;C0117996;C2347634;C2348143;C0205163;C2827928;C0439185
lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pre bronchodilator fevj,C2599602
lebrikizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
absolute l,C0205344
body mass index kg mq,C0005893;C0024853;C0578022;C1305855
t jj $nmbr$ $nmbr$,C2603360
median range duration of asthma years,C0449238;C2926735
median serum periostin ng ml t,C0219433;C0439275;C1424662;C3812270
baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba,C2827928;C0117996;C0205163;C0439185
median feno ppb f,C0549183;C0016327;C0876920;C2347635;C2348144;C2939193
mean ics fluticasone propionate dpi or equivalent pg per day,C0444504;C0117996;C2347634;C2348143;C0205163;C2827928;C0439185
tj $nmbr$ $nmbr$,C0039247
pre bronchodilator fevj,C2599602
median blood eosinophil count cells per pl t,C0549183;C0200638;C0876920;C2347635;C2348144;C2939193
absolute l,C0205344
$nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
t jj $nmbr$ $nmbr$,C2603360
biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl t,C0005516;C0439275;C0005773
median serum periostin ng ml t,C0219433;C0439275;C1424662;C3812270
patients with $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C4086268;C0205156;C0439231;C1552607
median feno ppb f,C0549183;C0016327;C0876920;C2347635;C2348144;C2939193
adjusted exacerbation rate per patient peryear,C0871208;C1521828
tj $nmbr$ $nmbr$,C0039247
rate difference lebrikizumab placebo,C0032042;C1696465;C1706408
median blood eosinophil count cells per pl t,C0549183;C0200638;C0876920;C2347635;C2348144;C2939193
rate reduction,C0301630;C0392756;C1293152;C4551656
$nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
rate ratio lebrikizumab vs placebo $nmbr$ cl,C0456603;C2981360;C1547037;C0032042;C0596019;C1696465;C1706408
biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl t,C0005516;C0439275;C0005773
biomarker high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
patients with $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C4086268;C0205156;C0439231;C1552607
lebrikizumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
adjusted exacerbation rate per patient peryear,C0871208;C1521828
lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rate difference lebrikizumab placebo,C0032042;C1696465;C1706408
biomarker low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
rate reduction,C0301630;C0392756;C1293152;C4551656
periostin high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
rate ratio lebrikizumab vs placebo $nmbr$ cl,C0456603;C2981360;C1547037;C0032042;C0596019;C1696465;C1706408
periostin low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
biomarker high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
eosinophil high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
lebrikizumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
eosinophil low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
change from baseline in fevj mb,C0392747;C0443172;C1705241;C4319952;C0024853
biomarker low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
adjusted mean se,C0444504;C0036919;C2347634;C2348143
periostin high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
difference in means $nmbr$ cl,C1705241;C1705242
periostin low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
time to first exacerbation,C0040223;C3541383
eosinophil high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
patients with event n,C0030705;C0441471;C4019010
eosinophil low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
median time to event weeks,C0040223;C3541383
change from baseline in fevj mb,C0392747;C0443172;C1705241;C4319952;C0024853
asthma related health,C0004096;C0018684;C2984299
adjusted mean se,C0444504;C0036919;C2347634;C2348143
care use,C0042153;C0457083;C1947944
difference in means $nmbr$ cl,C1705241;C1705242
health care use rate peryear,C0814514;C0871208;C1521828
time to first exacerbation,C0040223;C3541383
rate difference events year,C0439234;C0439508
patients with event n,C0030705;C0441471;C4019010
oil,C0028908;C0032085;C1517288;C3541397
median time to event weeks,C0040223;C3541383
change from baseline in aqlq s score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
asthma related health,C0004096;C0018684;C2984299
change from baseline in rescue medication use puffs per day,C0392747;C0443172;C1705241;C4319952;C0240320;C1533107
care use,C0042153;C0457083;C1947944
change from baseline in acq $nmbr$ score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
health care use rate peryear,C0814514;C0871208;C1521828
difference in means,C1705241;C1705242
rate difference events year,C0439234;C0439508
evolocumab,C3529352
oil,C0028908;C0032085;C1517288;C3541397
p value $nmbr$,C1709380
change from baseline in aqlq s score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
safety,C0036043;C1705187
change from baseline in rescue medication use puffs per day,C0392747;C0443172;C1705241;C4319952;C0240320;C1533107
dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
change from baseline in acq $nmbr$ score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
no dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
difference in means,C1705241;C1705242
all subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
evolocumab,C3529352
evomab n $nmbr$,
p value $nmbr$,C1709380
postbaseline new onset diabetes n,C0746890;C0011847;C0011849
safety,C0036043;C1705187
any adverse event ae,C0877248;C3887670
dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
baseline normoglycaemia fpg $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
no dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
most common aes in any group,C1412268;C2699274
all subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
baseline ifg fpg $nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
evomab n $nmbr$,
influenza,C0021400;C0021403
postbaseline new onset diabetes n,C0746890;C0011847;C0011849
serious,C0205404
any adverse event ae,C0877248;C3887670
leading to discontinuation,C0332152;C0457454;C1444662;C4552847;C1522538
baseline normoglycaemia fpg $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
ck $nmbr$ x uln $nmbr$,C0009212;C1519815;C0010287;C1872855
most common aes in any group,C1412268;C2699274
alt or ast $nmbr$ x uln $nmbr$,C1266129;C4553172;C1415181;C1519815;C3891303
baseline ifg fpg $nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
total bilirubin $nmbr$ x uln $nmbr$,C0005437;C1519815;C0368753
influenza,C0021400;C0021403
potential injection site reactions,C3245505;C0151735
serious,C0205404
postbaseline binding antibodies,C1145667;C0003241;C1167622
leading to discontinuation,C0332152;C0457454;C1444662;C4552847;C1522538
semaglutide n $nmbr$,C3885068
ck $nmbr$ x uln $nmbr$,C0009212;C1519815;C0010287;C1872855
low density lipoprotein cholesterol mg dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alt or ast $nmbr$ x uln $nmbr$,C1266129;C4553172;C1415181;C1519815;C3891303
never smoked no,C0037366;C0439994;C1881674
total bilirubin $nmbr$ x uln $nmbr$,C0005437;C1519815;C0368753
tnf naive patientsa,C1448177
potential injection site reactions,C3245505;C0151735
tnf failure patientsa,C0231174;C0680095
postbaseline binding antibodies,C1145667;C0003241;C1167622
vedolizumab cohort $nmbr$ n $nmbr$,C0009247;C0599755
semaglutide n $nmbr$,C3885068
disease duration y mean sd,C0872146;C2699239
low density lipoprotein cholesterol mg dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mayo clinic score mean sd,C0002424;C2699239;C0442592
never smoked no,C0037366;C0439994;C1881674
fcal mg g mean sd,C1300563;C2699239
tnf naive patientsa,C1448177
concomitant medications n,C0521115;C0013227;C0802604;C2598133;C4284232
tnf failure patientsa,C0231174;C0680095
cs only,C0010182;C0271160;C3540510;C4085345
vedolizumab cohort $nmbr$ n $nmbr$,C0009247;C0599755
is only,
disease duration y mean sd,C0872146;C2699239
cs and is,C0010182;C0271160;C3540510;C4085345
mayo clinic score mean sd,C0002424;C2699239;C0442592
no cs and is,C0010182;C0271160;C3540510;C4085345
fcal mg g mean sd,C1300563;C2699239
median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
concomitant medications n,C0521115;C0013227;C0802604;C2598133;C4284232
type of tnf failure n b,C0332307;C1547052
cs only,C0010182;C0271160;C3540510;C4085345
intolerance,C0231199;C1744706;C2355652
is only,
tnf naivea,C1448177
cs and is,C0010182;C0271160;C3540510;C4085345
tnf failurea,C1448177
no cs and is,C0010182;C0271160;C3540510;C4085345
all patientsb,
median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
point difference $nmbr$ ci c,C1552961;C0008107;C3259781;C2347617;C3714763
type of tnf failure n b,C0332307;C1547052
rr $nmbr$ ci c,C0008107;C3259781
intolerance,C0231199;C1744706;C2355652
clinical responsed,C0205210
tnf naivea,C1448177
clinical remissione,C0205210
tnf failurea,C1448177
mucosal healingf,C0026724
all patientsb,
durable clinical responseg,C0205210
point difference $nmbr$ ci c,C1552961;C0008107;C3259781;C2347617;C3714763
durable clinical remissionh,C0205210
rr $nmbr$ ci c,C0008107;C3259781
corticosteroid free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
clinical responsed,C0205210
patients not receiving statin,C0030705;C1518422;C1514756;C0360714
clinical remissione,C0205210
patients receiving statin,C0030705;C1514756;C0360714
mucosal healingf,C0026724
alirocumab,C3491162
durable clinical responseg,C0205210
$nmbr$ q $nmbr$ w n $nmbr$,
durable clinical remissionh,C0205210
baseline demographics,C0011298;C1704791
corticosteroid free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
race white n,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
patients not receiving statin,C0030705;C1518422;C1514756;C0360714
race black or african american n,C0005680;C0027567;C0085756;C0439541
patients receiving statin,C0030705;C1514756;C0360714
ethnicity hispanic latino n,C0015031;C0086409;C0243103
alirocumab,C3491162
diagnosis of hefh n,C0011900;C1704338;C1704656
$nmbr$ q $nmbr$ w n $nmbr$,
by genotyping,C1285573
baseline demographics,C0011298;C1704791
by who simon broome criteria,C0443058;C0243161
race white n,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
diabetes mellitus type $nmbr$ n,C1320657
race black or african american n,C0005680;C0027567;C0085756;C0439541
cardiovascular risk n,C0007226;C0035647;C4552904;C3887460
ethnicity hispanic latino n,C0015031;C0086409;C0243103
very high,C0442804;C4321397
diagnosis of hefh n,C0011900;C1704338;C1704656
lipid treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
by genotyping,C1285573
patients on atorvastatin rosuvastatin or simvastatin at,C0030705;C0286651;C0074554
by who simon broome criteria,C0443058;C0243161
randomization n,C0034656
diabetes mellitus type $nmbr$ n,C1320657
any llt other than statins n b,C2347090;C0360714
cardiovascular risk n,C0007226;C0035647;C4552904;C3887460
any llt other than nutraceuticals n,C2347090;C1518478
very high,C0442804;C4321397
ezetimibe n,C1142985
lipid treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
nutraceuticals n,C1518478
patients on atorvastatin rosuvastatin or simvastatin at,C0030705;C0286651;C0074554
baseline lipid parameters mg dl mmol l or g l,C0439268;C0439294;C0456615
randomization n,C0034656
ldl c calculated mean sd,C0444504;C2699239;C2347634;C2348143
any llt other than statins n b,C2347090;C0360714
ldl c measured mean sd,C0444504;C2699239;C2347634;C2348143
any llt other than nutraceuticals n,C2347090;C1518478
non hdl c mean sd,C0444504;C2699239;C2347634;C2348143
ezetimibe n,C1142985
total cholesterol mean sd,C0201950;C2699239;C0543421
nutraceuticals n,C1518478
apo b mean sd,C0003593;C2699239;C3252643
baseline lipid parameters mg dl mmol l or g l,C0439268;C0439294;C0456615
lp a median q $nmbr$ q $nmbr$,C0065058;C1439335;C4553379
ldl c calculated mean sd,C0444504;C2699239;C2347634;C2348143
fasting tgs median q $nmbr$ q $nmbr$,C0015663;C0549183;C0876920;C2347635;C2348144;C2939193
ldl c measured mean sd,C0444504;C2699239;C2347634;C2348143
apo a $nmbr$ mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
non hdl c mean sd,C0444504;C2699239;C2347634;C2348143
change from baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
total cholesterol mean sd,C0201950;C2699239;C0543421
no statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
apo b mean sd,C0003593;C2699239;C3252643
statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
lp a median q $nmbr$ q $nmbr$,C0065058;C1439335;C4553379
$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fasting tgs median q $nmbr$ q $nmbr$,C0015663;C0549183;C0876920;C2347635;C2348144;C2939193
not hispanic latino,C1518424;C0086528
apo a $nmbr$ mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
moderate chronic kidney disease,C1561643;C4553188
change from baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
baseline total pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
no statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
below median,C0549183;C0876920;C2347635;C2348144;C2939193
statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
baseline free pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
statin intolerant,C0360714;C0231200
not hispanic latino,C1518424;C0086528
baseline ldl c mg dl,C0168634;C0439269;C1442488
moderate chronic kidney disease,C1561643;C4553188
baseline hdl c mg dl,C0168634;C0439269;C1442488
baseline total pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
baseline fasting tgs mg dl,C0168634;C1442488;C0015663;C1156212;C0439269;C1537574
below median,C0549183;C0876920;C2347635;C2348144;C2939193
baseline lp a mg dl,C0065058;C0439269;C1439335;C4553379
baseline free pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
inter p value,C0205103;C1548610;C1709380
statin intolerant,C0360714;C0231200
any gusto bleeding,C0019080
baseline ldl c mg dl,C0168634;C0439269;C1442488
acs,C0742343;C4318612
baseline hdl c mg dl,C0168634;C0439269;C1442488
severe life ttireatening,C0205082;C0376558;C4050465;C4050466
baseline fasting tgs mg dl,C0168634;C1442488;C0015663;C1156212;C0439269;C1537574
sa acs,C0742343;C4318612
baseline lp a mg dl,C0065058;C0439269;C1439335;C4553379
severe moderate,C1299393
inter p value,C0205103;C1548610;C1709380
any timi bleeding,C0019080
any gusto bleeding,C0019080
major,C0205082;C0205164;C4318856;C4521762
acs,C0742343;C4318612
any acuity bleeding,C0750509;C0019080
severe life ttireatening,C0205082;C0376558;C4050465;C4050466
any blood product transfusion,C0005841;C0281867
sa acs,C0742343;C4318612
fvc $nmbr$ predicted,C0681842;C1882327
severe moderate,C1299393
nintedanib n $nmbr$,C2930789
any timi bleeding,C0019080
time since diagnosis years,C0556970;C0011900;C1704338;C1704656
major,C0205082;C0205164;C4318856;C4521762
centrilobular emphysema,C0221227
any acuity bleeding,C0750509;C0019080
fvc ml,C0439526;C1705224;C3887665
any blood product transfusion,C0005841;C0281867
fvc predicted,C3714541;C0681842;C1882327
fvc $nmbr$ predicted,C0681842;C1882327
fev $nmbr$ fvc ratio,C0456603;C1547037
nintedanib n $nmbr$,C2930789
diffusion capacity of the lung for carbon monoxide predicted,C0231971;C0007018;C4520712;C0681842;C1882327
time since diagnosis years,C0556970;C0011900;C1704338;C1704656
st george s respiratory questionnaire total score,C1553316;C0034394;C2964552
centrilobular emphysema,C0221227
composite physiologic index,C0600653;C0918012;C1552854;C1637833;C2986546
fvc ml,C0439526;C1705224;C3887665
absolute decline in fvc $nmbr$ predicted or death n,C0205344;C0681842;C1882327;C0011065;C1306577;C4082313;C4552775
fvc predicted,C3714541;C0681842;C1882327
treatment by subgroup interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fev $nmbr$ fvc ratio,C0456603;C1547037
criterion reached first n,C0243161;C0205435;C1279901
diffusion capacity of the lung for carbon monoxide predicted,C0231971;C0007018;C4520712;C0681842;C1882327
absolute decline in fvc $nmbr$ predicted,C0205344;C0681842;C1882327
st george s respiratory questionnaire total score,C1553316;C0034394;C2964552
baricitinib $nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
composite physiologic index,C0600653;C0918012;C1552854;C1637833;C2986546
duration of rheumatoid arthritis year,C0449238;C2926735
absolute decline in fvc $nmbr$ predicted or death n,C0205344;C0681842;C1882327;C0011065;C1306577;C4082313;C4552775
anticyclic citrullinated peptide positive^ n,C1320283;C0439178;C1446409;C1514241;C2825490;C3812269
treatment by subgroup interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
rheumatoid factor positive n,C0035448;C0201660
criterion reached first n,C0243161;C0205435;C1279901
$nmbr$ erosion n,C0333307;C1880549;C1959609;C3887524
absolute decline in fvc $nmbr$ predicted,C0205344;C0681842;C1882327
mtss units,C0439148;C1519795;C3853603
baricitinib $nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior conventional synthetic dmards n,C0332152;C0242708;C2826257
duration of rheumatoid arthritis year,C0449238;C2926735
swollen joint count of $nmbr$,C0451521
anticyclic citrullinated peptide positive^ n,C1320283;C0439178;C1446409;C1514241;C2825490;C3812269
tender joint count of $nmbr$,C0451530
rheumatoid factor positive n,C0035448;C0201660
high sensitivity c reactive protein mg ltt,C0006560;C1413716;C4048285
$nmbr$ erosion n,C0333307;C1880549;C1959609;C3887524
erythrocyte sedimentation rate mm hour,C0439227;C0564385
mtss units,C0439148;C1519795;C3853603
simplified disease activity index,C3869582
prior conventional synthetic dmards n,C0332152;C0242708;C2826257
a acr $nmbr$,C1412134;C1515941
swollen joint count of $nmbr$,C0451521
week $nmbr$ overall population,C0032659;C1257890
tender joint count of $nmbr$,C0451530
background csdmard category,C0683312;C3889287
high sensitivity c reactive protein mg ltt,C0006560;C1413716;C4048285
mtx only,C0025677;C1417487
erythrocyte sedimentation rate mm hour,C0439227;C0564385
non mtx csdmards,C0025677;C1417487
simplified disease activity index,C3869582
mtx other csdmards,C0025677;C1417487
a acr $nmbr$,C1412134;C1515941
$nmbr$ $nmbr$ i,C0021966;C0221138
week $nmbr$ overall population,C0032659;C1257890
b acr $nmbr$,C1412134;C1515941
background csdmard category,C0683312;C3889287
nteraction p value,C1709380
mtx only,C0025677;C1417487
c das $nmbr$ crp,C3890735;C4048285
non mtx csdmards,C0025677;C1417487
figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone,C0086312;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0332174;C0439230;C1079230
mtx other csdmards,C0025677;C1417487
fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction,C1280500;C1518681;C2348382;C0669479;C3538926;C0754710;C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675
$nmbr$ $nmbr$ i,C0021966;C0221138
figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline,C0871208;C1521828;C0589120;C1522577;C1704685;C3274571;C0002688;C0332840;C1546539
b acr $nmbr$,C1412134;C1515941
mod sev exacerbation rate,C0871208;C1521828
nteraction p value,C1709380
ff vi $nmbr$ $nmbr$,C4554348;C0205999
c das $nmbr$ crp,C3890735;C4048285
current smoker n $nmbr$ $nmbr$,C3173209;C3241966
figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone,C0086312;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0332174;C0439230;C1079230
former smoker n $nmbr$ $nmbr$,C0337671
fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction,C1280500;C1518681;C2348382;C0669479;C3538926;C0754710;C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675
cv entry criteria,C1705654;C0243161
figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline,C0871208;C1521828;C0589120;C1522577;C1704685;C3274571;C0002688;C0332840;C1546539
$nmbr$ $nmbr$ cv disease n $nmbr$ $nmbr$,C0007222
mod sev exacerbation rate,C0871208;C1521828
$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$,C0035647;C4552904;C1518422;C0012634
ff vi $nmbr$ $nmbr$,C4554348;C0205999
hispanic latino n $nmbr$,C0086409;C0086528
current smoker n $nmbr$ $nmbr$,C3173209;C3241966
not hispanic latino n $nmbr$ $nmbr$,C1518424;C0086528
former smoker n $nmbr$ $nmbr$,C0337671
asian n $nmbr$ $nmbr$,C0078988
cv entry criteria,C1705654;C0243161
african american african heritage n $nmbr$,C0085756;C2986513
$nmbr$ $nmbr$ cv disease n $nmbr$ $nmbr$,C0007222
usa n $nmbr$ $nmbr$,C0041703
$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$,C0035647;C4552904;C1518422;C0012634
asia n $nmbr$ $nmbr$,C0003980
hispanic latino n $nmbr$,C0086409;C0086528
europe $nmbr$ n $nmbr$ $nmbr$,C0015176
not hispanic latino n $nmbr$ $nmbr$,C1518424;C0086528
rest of world n $nmbr$,C0035253;C1622890
asian n $nmbr$ $nmbr$,C0078988
moderate severe exacerbation,C0205081;C4086268;C1881878;C4049705;C4049706;C4085643;C4321335
african american african heritage n $nmbr$,C0085756;C2986513
hospitalized for an exacerbation,C0701159;C4086268
usa n $nmbr$ $nmbr$,C0041703
hospitalized exacerbation rates,C0871208;C1521828
asia n $nmbr$ $nmbr$,C0003980
mod sev exacerbation rates,C0871208;C1521828
europe $nmbr$ n $nmbr$ $nmbr$,C0015176
favors ffa i favors placebo,C0032042;C1696465;C1706408
rest of world n $nmbr$,C0035253;C1622890
ff vi,C4554348;C0205999
moderate severe exacerbation,C0205081;C4086268;C1881878;C4049705;C4049706;C4085643;C4321335
b_ $nmbr$,
hospitalized for an exacerbation,C0701159;C4086268
$nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
hospitalized exacerbation rates,C0871208;C1521828
h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
mod sev exacerbation rates,C0871208;C1521828
$nmbr$ t i,C0021966;C0221138
favors ffa i favors placebo,C0032042;C1696465;C1706408
predicted fev,C0681842;C3714541;C1882327
ff vi,C4554348;C0205999
t n $nmbr$ $nmbr$,C2986835
b_ $nmbr$,
favors ff vi favors placebo,C0032042;C1696465;C1706408
$nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
current smoker n $nmbr$ $nmbr$ former smoker n $nmbr$ $nmbr$,C3173209;C3241966
h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
ijb^,
$nmbr$ t i,C0021966;C0221138
$nmbr$ bh i,C0021966;C0221138
predicted fev,C0681842;C3714541;C1882327
i ^w i $nmbr$,C0021966;C0221138
t n $nmbr$ $nmbr$,C2986835
predicted fev^,C0681842;C3714541;C1882327
favors ff vi favors placebo,C0032042;C1696465;C1706408
itt population,C0032659;C1257890
current smoker n $nmbr$ $nmbr$ former smoker n $nmbr$ $nmbr$,C3173209;C3241966
mn population,C0032659;C1257890
ijb^,
umec vi $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205999
$nmbr$ bh i,C0021966;C0221138
tio n $nmbr$ $nmbr$,
i ^w i $nmbr$,C0021966;C0221138
current smoker at screeninga n,C3173209;C3241966
predicted fev^,C0681842;C3714541;C1882327
smoking pack yearsb n,C0037369;C0453996;C1881674
itt population,C0032659;C1257890
reversible to albuterolc d n,C0205343;C0369718;C0441922
mn population,C0032659;C1257890
post albuterol predicted fev $nmbr$ mean sd e,C0001927;C0444504;C2347634;C2348143
umec vi $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205999
gold stage nf,C0018026;C0205390;C1300072;C1306673;C1304897
tio n $nmbr$ $nmbr$,
ics use at screeningg n,C0042153;C0457083;C1947944
current smoker at screeninga n,C3173209;C3241966
exacerbation historyh n,C4086268
smoking pack yearsb n,C0037369;C0453996;C1881674
required corticosteroid and or antibiotic without hospitalization,C0001617;C3536709;C0003232;C0019993
reversible to albuterolc d n,C0205343;C0369718;C0441922
required hospitalization,C1708385
post albuterol predicted fev $nmbr$ mean sd e,C0001927;C0444504;C2347634;C2348143
components of the first cid,C0449432;C0205435;C1279901
gold stage nf,C0018026;C0205390;C1300072;C1306673;C1304897
umec vi $nmbr$ $nmbr$ $nmbr$,C0205999
ics use at screeningg n,C0042153;C0457083;C1947944
tio,
exacerbation historyh n,C4086268
hazard ratio umec vi vs tio $nmbr$ ci,C2985465;C0205999;C0008107;C3259781
required corticosteroid and or antibiotic without hospitalization,C0001617;C3536709;C0003232;C0019993
itt population n,C0032659;C1257890
required hospitalization,C1708385
c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0547047
components of the first cid,C0449432;C0205435;C1279901
c $nmbr$ unit sgrq total score increase,C2964552;C0442805
umec vi $nmbr$ $nmbr$ $nmbr$,C0205999
moderate to severe copd exacerbation,C1299393;C0740304
tio,
mn population n,C0026327;C0026405;C4285072
hazard ratio umec vi vs tio $nmbr$ ci,C2985465;C0205999;C0008107;C3259781
re cover re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
itt population n,C0032659;C1257890
re medy,
c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0547047
thrombophilia,C0398623
c $nmbr$ unit sgrq total score increase,C2964552;C0442805
not tested,C1518422;C0392366
moderate to severe copd exacerbation,C1299393;C0740304
de n $nmbr$,C0011198;C0017480;C3541240
mn population n,C0026327;C0026405;C4285072
age mean years sd,C1510829;C2699239
re cover re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
bmi mean kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
re medy,
crcl mean ml min sd,C0439445;C2699239
thrombophilia,C0398623
qualifying symptomatic event n a,C1514624;C0231220;C0441471;C4019010
not tested,C1518422;C0392366
pe and dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
de n $nmbr$,C0011198;C0017480;C3541240
pe only,C0070939;C1880476;C4284304
age mean years sd,C1510829;C2699239
neither pe nor dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
bmi mean kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
non transient risk factors for recurrent vte n,C0035648;C1553898
crcl mean ml min sd,C0439445;C2699239
active cancer at any timeb,C0006826;C0998265;C1306459
qualifying symptomatic event n a,C1514624;C0231220;C0441471;C4019010
concomitant anticoagulant antithrombotic or nsaid n,C0521115;C0003280;C0848112;C3536711;C0003211;C3536840
pe and dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
vte vte related deathsa n n,C0439849;C0445223
pe only,C0070939;C1880476;C4284304
pulmonary embolisma n n,C0024109;C2707265;C2709248;C4522268
neither pe nor dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
vte vte related deathsb n n,C0439849;C0445223
non transient risk factors for recurrent vte n,C0035648;C1553898
pulmonary embolismb n n,C0024109;C2707265;C2709248;C4522268
active cancer at any timeb,C0006826;C0998265;C1306459
de,C0011198;C0017480;C3541240
concomitant anticoagulant antithrombotic or nsaid n,C0521115;C0003280;C0848112;C3536711;C0003211;C3536840
total study population,C3258257
vte vte related deathsa n n,C0439849;C0445223
treatment de vs warfarin by thrombophilia interaction,C0011198;C0017480;C3541240;C0043031;C0398623
pulmonary embolisma n n,C0024109;C2707265;C2709248;C4522268
mbesc n n,
vte vte related deathsb n n,C0439849;C0445223
mbes crbesc,
pulmonary embolismb n n,C0024109;C2707265;C2709248;C4522268
mbesb n n,
de,C0011198;C0017480;C3541240
mbes crbesb n n,
chlorthalidone $nmbr$,C0008294
total study population,C3258257
amlodipine lisinopril $nmbr$,C0051696;C0065374
treatment de vs warfarin by thrombophilia interaction,C0011198;C0017480;C3541240;C0043031;C0398623
total $nmbr$,C0439175;C0439810
mbesc n n,
mbes crbesc,
white non hispanic n,C1533020;C1533021
mbesb n n,
black non hispanic n,C1533017;C1533018
mbes crbesb n n,
white hispanic n,C1533020;C1533021
chlorthalidone $nmbr$,C0008294
black hispanic n,C1533017;C1533018
amlodipine lisinopril $nmbr$,C0051696;C0065374
receiving antihypertensive treatment,C1514756;C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
total $nmbr$,C0439175;C0439810
n blood pressure mean sd mm hg,C0428886;C0439475
white non hispanic n,C1533020;C1533021
major st depression or t wave,C0041696;C1269683;C0429103
black non hispanic n,C1533017;C1533018
inversion,C0021943;C0021945;C1705687;C2349984
white hispanic n,C1533020;C1533021
diabetes t,C0011847;C0011849
black hispanic n,C1533017;C1533018
medication use at baseline n,C0240320;C0168634;C1442488
receiving antihypertensive treatment,C1514756;C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
females only,C0086287
n blood pressure mean sd mm hg,C0428886;C0439475
atenolol use at $nmbr$ month,C0042153;C0457083;C1947944
major st depression or t wave,C0041696;C1269683;C0429103
cholesterol mean sd n,C0008377;C0444504;C2347634;C2348143
inversion,C0021943;C0021945;C1705687;C2349984
serum creatinine mean sd n,C0201976;C0600061
diabetes t,C0011847;C0011849
egfr mean sd n,C1739039;C0444504;C2347634;C2348143;C3811844;C3812682
medication use at baseline n,C0240320;C0168634;C1442488
baseline mdrd,C0168634;C3839656;C1442488
females only,C0086287
baseline ckd epi,C1561643;C0162734;C4281721
atenolol use at $nmbr$ month,C0042153;C0457083;C1947944
lipid trial participants n,C1997894;C2242969
cholesterol mean sd n,C0008377;C0444504;C2347634;C2348143
baseline mdrd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
serum creatinine mean sd n,C0201976;C0600061
baseline mdrd egfr,C1739039;C3811844;C3812682
egfr mean sd n,C1739039;C0444504;C2347634;C2348143;C3811844;C3812682
baseline ckd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
baseline mdrd,C0168634;C3839656;C1442488
baseline ckd egfr,C1739039;C3811844;C3812682
baseline ckd epi,C1561643;C0162734;C4281721
no cvd,C0007222
lipid trial participants n,C1997894;C2242969
prevalent cvd,C0007222
baseline mdrd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
healthy weight,C0005910;C0043100;C1305866;C1705104
baseline mdrd egfr,C1739039;C3811844;C3812682
overweight,C0497406
baseline ckd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
obese,C0028754
baseline ckd egfr,C1739039;C3811844;C3812682
no estrogen,C0014939;C2936882;C4542544
no cvd,C0007222
budesonide symptom days a week,C0054201;C0439228;C0332174;C0439230
prevalent cvd,C0007222
placebo symptom days a week,C0032042;C0439228;C1696465;C1706408;C0332174;C0439230
healthy weight,C0005910;C0043100;C1305866;C1705104
$nmbr$ tol n $nmbr$,
lto,
overweight,C0497406
obese,C0028754
$nmbr$ n $nmbr$ l $nmbr$,C0369718;C0441922
no estrogen,C0014939;C2936882;C4542544
age mean age years sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
budesonide symptom days a week,C0054201;C0439228;C0332174;C0439230
$nmbr$ u,C0439148
oriental,C0078988;C0699027
placebo symptom days a week,C0032042;C0439228;C1696465;C1706408;C0332174;C0439230
$nmbr$ tol n $nmbr$,
passive smoker,C0425309
lto,
prebronchodilator fevj predicted,C2599602;C0681842;C1882327
$nmbr$ n $nmbr$ l $nmbr$,C0369718;C0441922
postbronchodilator fevj predicted,C2599594;C0681842;C1882327
age mean age years sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
controllertreatment before entry,C1705654
$nmbr$ u,C0439148
inhaled corticosteroid,C0004048;C0001617;C3536709
oriental,C0078988;C0699027
oral or other systemic corticosteroid,C0442027;C4521986;C4053960
passive smoker,C0425309
xanthine,C0043314;C0043318
prebronchodilator fevj predicted,C2599602;C0681842;C1882327
cromoglicate,C0010347
postbronchodilator fevj predicted,C2599594;C0681842;C1882327
leukotriene modifier,C0205349;C1514623;C1516451;C3542952
controllertreatment before entry,C1705654
$nmbr$ to $nmbr$ n $nmbr$,C0369718;C0441922
inhaled corticosteroid,C0004048;C0001617;C3536709
time to first sare,C0040223;C3541383
oral or other systemic corticosteroid,C0442027;C4521986;C4053960
cumulative incidence lyear,C0021149;C0220856
xanthine,C0043314;C0043318
cumulative incidence $nmbr$ years,C0021149;C0439234;C0220856
cromoglicate,C0010347
rate of sares,C0871208;C1521828
leukotriene modifier,C0205349;C1514623;C1516451;C3542952
rate per $nmbr$ patient years,C0871208;C1521828
$nmbr$ to $nmbr$ n $nmbr$,C0369718;C0441922
$nmbr$ year mean change from baseline,C0392747;C0443172;C1705241;C4319952
time to first sare,C0040223;C3541383
$nmbr$ to $nmbr$ $nmbr$,
cumulative incidence lyear,C0021149;C0220856
prebronchodilator fevi predicted,C0849974;C1561566;C4528367;C0681842;C1882327
cumulative incidence $nmbr$ years,C0021149;C0439234;C0220856
lyear mean change from baseline,C0392747;C0443172;C1705241;C4319952
rate of sares,C0871208;C1521828
time to first inhaled corticosteroid,C0040223;C3541383
rate per $nmbr$ patient years,C0871208;C1521828
time to first oral or systemic corticosteroid,C0040223;C3541383;C4053960
$nmbr$ year mean change from baseline,C0392747;C0443172;C1705241;C4319952
rate of oral or systemic corticosteroid,C0871208;C1521828;C4053960
$nmbr$ to $nmbr$ $nmbr$,
asthma symptoms in the past $nmbr$ weeks,C0683368;C1457887
prebronchodilator fevi predicted,C0849974;C1561566;C4528367;C0681842;C1882327
mean proportion,C0444504;C1709707;C2347634;C2348143
lyear mean change from baseline,C0392747;C0443172;C1705241;C4319952
restriction in normal activities in the past $nmbr$ weeks,C0443288;C4697852;C0439230
time to first inhaled corticosteroid,C0040223;C3541383
sleeping problems in the past $nmbr$ weeks,C0037313;C0424522;C4050403;C1546466;C0439230
time to first oral or systemic corticosteroid,C0040223;C3541383;C4053960
symptom free days in the past $nmbr$ weeks,C0332296;C0677547;C1880497;C1996904
rate of oral or systemic corticosteroid,C0871208;C1521828;C4053960
$nmbr$ to $nmbr$ symptom days per week,C1457887;C0677547;C3854129
asthma symptoms in the past $nmbr$ weeks,C0683368;C1457887
lto $nmbr$ symptom days per week,C1457887;C0677547;C3854129
mean proportion,C0444504;C1709707;C2347634;C2348143
$nmbr$ symptom days per week,C1457887;C0677547;C3854129
restriction in normal activities in the past $nmbr$ weeks,C0443288;C4697852;C0439230
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$,C0596019
sleeping problems in the past $nmbr$ weeks,C0037313;C0424522;C4050403;C1546466;C0439230
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
symptom free days in the past $nmbr$ weeks,C0332296;C0677547;C1880497;C1996904
a prebronchodilator fevl predicted,C2599602;C0681842;C1882327
$nmbr$ to $nmbr$ symptom days per week,C1457887;C0677547;C3854129
baseline symptom days perweek,C0168634;C0439228;C1442488
lto $nmbr$ symptom days per week,C1457887;C0677547;C3854129
mean difference $nmbr$ cl,C0444504;C0596019;C2347634;C2348143
$nmbr$ symptom days per week,C1457887;C0677547;C3854129
yearl,
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$,C0596019
b postbronchodilator fevl predicted,C2599594;C0681842;C1882327
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
baseline feature,C1521970;C1706388;C2346469;C2348519
a prebronchodilator fevl predicted,C2599602;C0681842;C1882327
pioglitazone,C0071097
baseline symptom days perweek,C0168634;C0439228;C1442488
hispanic ethnicity,C0015031;C0243103
mean difference $nmbr$ cl,C0444504;C0596019;C2347634;C2348143
lived alone,C0205171;C0439044;C0679994
yearl,
stroke at entry,C0038454;C4554100
b postbronchodilator fevl predicted,C2599594;C0681842;C1882327
nih stroke scale,C1697238;C3484372
baseline feature,C1521970;C1706388;C2346469;C2348519
modified rankin score,C0392747;C0449820;C4050231;C3889737
pioglitazone,C0071097
health practices,C0018684;C0237607
hispanic ethnicity,C0015031;C0243103
$nmbr$ $nmbr$ drinks day if male female,C0332173;C0439228;C0439505;C0043210;C0086287;C1705497;C1705498
lived alone,C0205171;C0439044;C0679994
aerobic exercise,C0001701
stroke at entry,C0038454;C4554100
cognitive,C1516691
nih stroke scale,C1697238;C3484372
and physical examination,C0031809;C1744699
modified rankin score,C0392747;C0449820;C4050231;C3889737
$nmbr$ ms score,C0449820;C4050231
health practices,C0018684;C0237607
antidepressant,C0003289
$nmbr$ $nmbr$ drinks day if male female,C0332173;C0439228;C0439505;C0043210;C0086287;C1705497;C1705498
benzodiazepine or bzra,C0005064;C3536850;C4048284
aerobic exercise,C0001701
epilepsy drug,C0013227;C1254351
cognitive,C1516691
osteoporosis drug,C0013227;C1254351
and physical examination,C0031809;C1744699
vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
$nmbr$ ms score,C0449820;C4050231
group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
antidepressant,C0003289
risk at,C0035647;C4552904
benzodiazepine or bzra,C0005064;C3536850;C4048284
fxs,C0016667
epilepsy drug,C0013227;C1254351
risk,C0035647;C4552904
osteoporosis drug,C0013227;C1254351
any site,C0205145;C1515974;C2825164
vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
upper limb,C1140618
group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
distal lower,C0441994;C1548802;C2003888
risk at,C0035647;C4552904
limb,C0015385
fxs,C0016667
hip femur,C0019552;C0015811;C0022122;C1505163;C3538851;C4284725
risk,C0035647;C4552904
rib,C0035561
any site,C0205145;C1515974;C2825164
id,C0009450;C0600091;C1441613
upper limb,C1140618
figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison,C1705241;C1705242;C0008107;C3259781;C1079231;C1079232;C3715113;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1707455;C1696465;C1706408
distal lower,C0441994;C1548802;C2003888
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
limb,C0015385
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
hip femur,C0019552;C0015811;C0022122;C1505163;C3538851;C4284725
uniti $nmbr$,
rib,C0035561
im uniti,
id,C0009450;C0600091;C1441613
ustekinu,
figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison,C1705241;C1705242;C0008107;C3259781;C1079231;C1079232;C3715113;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1707455;C1696465;C1706408
mab,C0003250;C0369637
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
usteki,
numab,
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
$nmbr$ mg kgf n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
uniti $nmbr$,
$nmbr$ mg $nmbr$ wk n $nmbr$,C1881833
im uniti,
ustekinu,
duration of disease yr t,C0872146;C0439234
mab,C0003250;C0369637
cdai,C0683448;C1413248;C3273706
usteki,
median c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
numab,
median fecal calprotectin mg kg gi areas involved no,C0205146;C4319729;C1314939
$nmbr$ mg kgf n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
proximal gi tract,C0205107;C0017189;C4489236
$nmbr$ mg $nmbr$ wk n $nmbr$,C1881833
perianal gi tract,C0442158;C0017189
duration of disease yr t,C0872146;C0439234
medications for crohn s disease taken at baseline no,C0013227;C0802604;C2598133;C4284232;C0012634;C1883727;C0168634;C1442488
cdai,C0683448;C1413248;C3273706
one or more medications,C0205447;C0013227;C0802604;C2598133;C4284232
median c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
immunosuppressant^,C0021081
median fecal calprotectin mg kg gi areas involved no,C0205146;C4319729;C1314939
aminosalicylate,C0368663;C2825094
proximal gi tract,C0205107;C0017189;C4489236
glucocorticoid],C0017710
perianal gi tract,C0442158;C0017189
history of disease refractory to treatment with tnf antagonist no,C0683519;C0730226;C0850708;C0944983;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
medications for crohn s disease taken at baseline no,C0013227;C0802604;C2598133;C4284232;C0012634;C1883727;C0168634;C1442488
no history of tnf antagonist treatment no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
one or more medications,C0205447;C0013227;C0802604;C2598133;C4284232
history of tnf antagonist treatment failure no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
immunosuppressant^,C0021081
patients who received $nmbr$ drug,C0013227;C1254351
aminosalicylate,C0368663;C2825094
patients who received $nmbr$ or $nmbr$ drugs,C0030705;C3272598;C1514756;C0013227;C3687832
glucocorticoid],C0017710
primary nonresponse,C0205225;C0439612;C0439631
history of disease refractory to treatment with tnf antagonist no,C0683519;C0730226;C0850708;C0944983;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
secondary nonresponse,C0027627;C0175668;C0205436
no history of tnf antagonist treatment no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
unacceptable side effects,C0001688;C0877248;C0879626
history of tnf antagonist treatment failure no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
uistekinumab,
patients who received $nmbr$ drug,C0013227;C1254351
$nmbr$ mq kq,C0024853
while,
patients who received $nmbr$ or $nmbr$ drugs,C0030705;C3272598;C1514756;C0013227;C3687832
primary nonresponse,C0205225;C0439612;C0439631
weight at baseline,C1303013
secondary nonresponse,C0027627;C0175668;C0205436
$nmbr$ st quartile,C0036056;C2828255;C3272372
unacceptable side effects,C0001688;C0877248;C0879626
$nmbr$ st and $nmbr$ nd quartile,C0036056;C3272372;C2828255
uistekinumab,
$nmbr$ nd and $nmbr$ rd quartile,C0694666;C2828255;C4553350
$nmbr$ mq kq,C0024853
$nmbr$ rd quartile,C0694666;C2828255;C4553350
while,
crohn s disease duration,C0010346;C0872146
weight at baseline,C1303013
s $nmbr$ yrs,
$nmbr$ st quartile,C0036056;C2828255;C3272372
$nmbr$ to s $nmbr$ yrs,
$nmbr$ st and $nmbr$ nd quartile,C0036056;C3272372;C2828255
involved gastrointestinal,C1314939;C0521362
$nmbr$ nd and $nmbr$ rd quartile,C0694666;C2828255;C4553350
areas,C0205146;C4319729
$nmbr$ rd quartile,C0694666;C2828255;C4553350
secukinumab intravenous $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
crohn s disease duration,C0010346;C0872146
time since as diagnosis mean sd years,C0040223;C3541383;C0011900;C0439234;C1704338;C1704656
s $nmbr$ yrs,
hla b $nmbr$ positive n,C1426226
$nmbr$ to s $nmbr$ yrs,
anti tnf naive n,C1448177
involved gastrointestinal,C1314939;C0521362
hscrp median min max mg l,C0549183;C2827895;C0876920;C2347635;C2348144;C2939193
areas,C0205146;C4319729
elevated hscrp $nmbr$ mg l n,C0205250;C0439268;C3163633
secukinumab intravenous $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total basdai mean sd,C0439175;C2699239;C0439810
time since as diagnosis mean sd years,C0040223;C3541383;C0011900;C0439234;C1704338;C1704656
basfi mean sd,C0444504;C2699239;C2347634;C2348143
hla b $nmbr$ positive n,C1426226
basmi linear mean sd,C0205132;C2699239
anti tnf naive n,C1448177
msasss mean sd,C0444504;C2699239;C2347634;C2348143
hscrp median min max mg l,C0549183;C2827895;C0876920;C2347635;C2348144;C2939193
syndesmophyte present n,C0221690;C0150312;C0449450
elevated hscrp $nmbr$ mg l n,C0205250;C0439268;C3163633
total back pain mean sd,C0004604;C2699239;C1963071;C4553945
total basdai mean sd,C0439175;C2699239;C0439810
patient s global assessment of disease activity mean sd,C0030705;C0281858;C1292728
basfi mean sd,C0444504;C2699239;C2347634;C2348143
placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
basmi linear mean sd,C0205132;C2699239
placebo secukinumab pooled,C0032042;C3179547;C1696465;C1706408;C1709595;C2349200;C4522255
msasss mean sd,C0444504;C2699239;C2347634;C2348143
change at week $nmbr$,C0392747;C0443172;C1705241;C4319952
syndesmophyte present n,C0221690;C0150312;C0449450
patients with syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
total back pain mean sd,C0004604;C2699239;C1963071;C4553945
patients without syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
patient s global assessment of disease activity mean sd,C0030705;C0281858;C1292728
elevated hscrp,C0205250;C3163633
placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
placebo secukinumab pooled,C0032042;C3179547;C1696465;C1706408;C1709595;C2349200;C4522255
smokers at baseline,C0337664;C0168634;C1442488
change at week $nmbr$,C0392747;C0443172;C1705241;C4319952
non smokers at baseline,C0337672;C4554605
patients with syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
empagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients without syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
elevated hscrp,C0205250;C3163633
sbp mm hg office measurement mean sd,C0439475;C2699239
normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
sbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
smokers at baseline,C0337664;C0168634;C1442488
dbp mm hg office measurement mean sd,C0439475;C2699239
non smokers at baseline,C0337672;C4554605
dbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
empagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pulse rate bpm mean $nmbr$ h mean sd,C0232117;C2699239
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
time since diagnosis of t $nmbr$ dm y n,C0040223;C3541383
sbp mm hg office measurement mean sd,C0439475;C2699239
use of diuretics n,C1524063;C0012798
sbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
use of ace inhibitors arbs n,C1524063;C0003015
dbp mm hg office measurement mean sd,C0439475;C2699239
$nmbr$ antihypertensive medication,C0003364
dbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
$nmbr$ antihypertensive medications,C0003364
pulse rate bpm mean $nmbr$ h mean sd,C0232117;C2699239
$nmbr$ aes,C1412268;C2699274
time since diagnosis of t $nmbr$ dm y n,C0040223;C3541383
$nmbr$ drug related aes,C1412268;C2699274
use of diuretics n,C1524063;C0012798
$nmbr$ aes leading to discontinuation,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
use of ace inhibitors arbs n,C1524063;C0003015
$nmbr$ serious aes,C1412268;C2699274
$nmbr$ antihypertensive medication,C0003364
special interest categories,C0205555;C0683312
$nmbr$ antihypertensive medications,C0003364
hypoglycemiat,
$nmbr$ aes,C1412268;C2699274
events requiring assistance,C0441471;C3541888;C0018896;C1269765
$nmbr$ drug related aes,C1412268;C2699274
events consistent with uti,C0441471;C3541888;C0332290;C0042029;C0077906;C1412376
$nmbr$ aes leading to discontinuation,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
events consistent with genital infection,C0441471;C3541888;C0332290;C0729552
$nmbr$ serious aes,C1412268;C2699274
events consistent with volume depletion,C0441471;C3541888;C0332290;C0546884
special interest categories,C0205555;C0683312
positive orthostatic test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
hypoglycemiat,
no diuretic therapy,C0948575
events requiring assistance,C0441471;C3541888;C0018896;C1269765
diuretic therapy,C0948575
events consistent with uti,C0441471;C3541888;C0332290;C0042029;C0077906;C1412376
no ace inhibitor arb,C0003015;C3888198;C4541021
events consistent with genital infection,C0441471;C3541888;C0332290;C0729552
ace inhibitor arb therapy,C1444755;C3888198
events consistent with volume depletion,C0441471;C3541888;C0332290;C0546884
therapy,C0039798;C0087111;C1363945
positive orthostatic test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
empa,C2699863
no diuretic therapy,C0948575
$nmbr$ drug related,C0013227;C0439849;C0445223;C1254351
diuretic therapy,C0948575
aes,C1412268;C2699274
no ace inhibitor arb,C0003015;C3888198;C4541021
hypoglycemia^,C0020615;C4553659
ace inhibitor arb therapy,C1444755;C3888198
requiring assistance,C0018896;C1269765
therapy,C0039798;C0087111;C1363945
orthostatic test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
empa,C2699863
non cana n $nmbr$,C1518422;C1418845
$nmbr$ drug related,C0013227;C0439849;C0445223;C1254351
baseline hbalc,C0168634;C1442488
aes,C1412268;C2699274
baseline hbalc $nmbr$ to,C0168634;C1442488
hypoglycemia^,C0020615;C4553659
baseline hbalc $nmbr$,C0168634;C1442488
requiring assistance,C0018896;C1269765
genital mycotic infections male $nmbr$,C0564768
orthostatic test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
female $nmbr$,C0043210;C0086287;C1705497;C1705498
non cana n $nmbr$,C1518422;C1418845
utis,C0042029
baseline hbalc,C0168634;C1442488
osmotic diuresis related aes,C1412268;C2699274
baseline hbalc $nmbr$ to,C0168634;C1442488
volume depletion related aes,C1412268;C2699274
baseline hbalc $nmbr$,C0168634;C1442488
olodaterol $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
genital mycotic infections male $nmbr$,C0564768
tiotropium $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
female $nmbr$,C0043210;C0086287;C1705497;C1705498
tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$,C4032878;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
utis,C0042029
co morbidities a n,C0009488;C0369718;C0441922
osmotic diuresis related aes,C1412268;C2699274
cardiac history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
volume depletion related aes,C1412268;C2699274
cardiac rhythm disorders,C0264886
olodaterol $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vascular disordersb,C0005847;C1558950;C1801960
tiotropium $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gold n,C0018026;C1304897
tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$,C4032878;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ e,
co morbidities a n,C0009488;C0369718;C0441922
baseline pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
cardiac history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
sama,C1075468
cardiac rhythm disorders,C0264886
saba,
vascular disordersb,C0005847;C1558950;C1801960
xanthines,C0043318;C3541955
gold n,C0018026;C1304897
baseline cardiovascular medication c n,C0168634;C0007220;C1442488
$nmbr$ $nmbr$ e,
mean sd extent of exposure days,C0439792;C0274281;C0332157
baseline pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
cardiac rhythm disorder at baseline no,C0264886;C0168634;C1442488
sama,C1075468
cardiac rhythm disorder at baseline yes,C0264886;C0168634;C1442488
saba,
meddra smq,C1140263
xanthines,C0043318;C3541955
olodaterol $nmbr$ m g,C2934193;C0439267
baseline cardiovascular medication c n,C0168634;C0007220;C1442488
tiotropium $nmbr$ m g,C0213771;C0439267
mean sd extent of exposure days,C0439792;C0274281;C0332157
tiotropium olodaterol $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cardiac rhythm disorder at baseline no,C0264886;C0168634;C1442488
total patients n,C0439175;C0030705;C0439810
cardiac rhythm disorder at baseline yes,C0264886;C0168634;C1442488
any aes n,C1412268;C2699274
meddra smq,C1140263
tachyarrhythmias n,C0080203
olodaterol $nmbr$ m g,C2934193;C0439267
supraventricular tachyarrhythmias incl atrial,C1698480;C3853833
tiotropium $nmbr$ m g,C0213771;C0439267
fibrillation flutter,C0016385;C2242390
tiotropium olodaterol $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ventricular tachyarrhythmias,C3827656
total patients n,C0439175;C0030705;C0439810
ischaemic heart disease n,C0010054;C0151744
any aes n,C1412268;C2699274
other ischaemic heart disease non infarction,C0027051;C1518422
tachyarrhythmias n,C0080203
cardiac failure n,C0018801;C0018802
supraventricular tachyarrhythmias incl atrial,C1698480;C3853833
cerebrovascular disorders n,C0007820
fibrillation flutter,C0016385;C2242390
haemorrhagic,C0333275
ventricular tachyarrhythmias,C3827656
olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ischaemic heart disease n,C0010054;C0151744
tiotropium $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
other ischaemic heart disease non infarction,C0027051;C1518422
tiotropium $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cardiac failure n,C0018801;C0018802
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cerebrovascular disorders n,C0007820
racea,
haemorrhagic,C0333275
copd disease severity,C0024117;C0521117;C1412502;C3714496
olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vonoprazan $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropium $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aget y,
tiotropium $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bmit,
previous smoker,C0337671
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
racea,
every day,C0332173;C0439228;C0439505
copd disease severity,C0024117;C0521117;C1412502;C3714496
$nmbr$ or $nmbr$ d wk,C0332174;C0439230
$nmbr$ or $nmbr$ d mo,C0026544;C0332177
vonoprazan $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aget y,
never drink,C2003901;C0452428
bmit,
caffeine consumption,C0948365
previous smoker,C0337671
modi fied la grade,C0441800;C0919553;C3244287
every day,C0332173;C0439228;C0439505
heartburn severity during the run in periodt,C0439793;C0522510
$nmbr$ or $nmbr$ d wk,C0332174;C0439230
esophageal hiatal hernia,C3489393
$nmbr$ or $nmbr$ d mo,C0026544;C0332177
yes z $nmbr$ cm,C1549445;C1705108;C1710701
never drink,C2003901;C0452428
yes o $nmbr$ cm,C1549445;C1705108;C1710701
caffeine consumption,C0948365
h pylori serology,C0036745;C0220911;C0455278
modi fied la grade,C0441800;C0919553;C3244287
history of h pylori eradication,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
heartburn severity during the run in periodt,C0439793;C0522510
yes r $nmbr$ y,C1549445;C1705108;C1710701;C0205090;C0684010;C2603358
esophageal hiatal hernia,C3489393
yes $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
yes z $nmbr$ cm,C1549445;C1705108;C1710701
serum gastrint pg ml,C0229671;C0439297;C1546774;C1550100
yes o $nmbr$ cm,C1549445;C1705108;C1710701
serum pepsinogen i iit,C0077923;C0523816
h pylori serology,C0036745;C0220911;C0455278
czp mtx^mtx,C0054841;C0025677;C1417487;C1861828;C1872109
history of h pylori eradication,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pbo mtx^mtx,C0031962;C0025677;C1417487
yes r $nmbr$ y,C1549445;C1705108;C1710701;C0205090;C0684010;C2603358
total patients n $nmbr$,C0439175;C0030705;C0439810
yes $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
patients entering pt period n $nmbr$,C0030705;C1522196;C0032743;C0439531;C1948053;C0699718
serum gastrint pg ml,C0229671;C0439297;C1546774;C1550100
db baseline week $nmbr$,C0332174;C0439230
serum pepsinogen i iit,C0077923;C0523816
pt baseline week $nmbr$,C0332174;C0439230
czp mtx^mtx,C0054841;C0025677;C1417487;C1861828;C1872109
ra duration months,C0449238;C0439231;C2926735
pbo mtx^mtx,C0031962;C0025677;C1417487
rf positive n,C0035448;C0201660;C0748398;C1547111
total patients n $nmbr$,C0439175;C0030705;C0439810
bone erosion judged by physician n,C0587240;C0221191;C0031831;C0804815
patients entering pt period n $nmbr$,C0030705;C1522196;C0032743;C0439531;C1948053;C0699718
tjc $nmbr$ joints,C0022417;C0392905
db baseline week $nmbr$,C0332174;C0439230
sjc $nmbr$ joints,C0022417;C0392905
pt baseline week $nmbr$,C0332174;C0439230
mmp $nmbr$ ng ml,C0623362;C0439275;C0919336
ra duration months,C0449238;C0439231;C2926735
sdai,C3871128
rf positive n,C0035448;C0201660;C0748398;C1547111
mtss,
bone erosion judged by physician n,C0587240;C0221191;C0031831;C0804815
average weekly mtx dose mg week t,C0366550;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tjc $nmbr$ joints,C0022417;C0392905
czp mtx to mtx,C0054841;C0025677;C1417487;C1861828;C1872109
sjc $nmbr$ joints,C0022417;C0392905
pbo mtx to mtx,C0031962;C0025677;C1417487
mmp $nmbr$ ng ml,C0623362;C0439275;C0919336
mtss cfb,C0009002;C1824728
sdai,C3871128
baseline factor,C1521761;C2827422
mtss,
baseline erosion,C0333307;C1880549;C1959609;C3887524
average weekly mtx dose mg week t,C0366550;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
das $nmbr$,C0051767;C0057671
czp mtx to mtx,C0054841;C0025677;C1417487;C1861828;C1872109
rf iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
pbo mtx to mtx,C0031962;C0025677;C1417487
tnf alpha pg ml,C1448177;C0439297;C1456820;C1522669
mtss cfb,C0009002;C1824728
il $nmbr$ pg ml,C0020898;C0439297;C0021764;C0022271
baseline factor,C1521761;C2827422
baseline steroids,C0168634;C0038317;C1442488
baseline erosion,C0333307;C1880549;C1959609;C3887524
mtx exposure mg week,C0332174;C0439230
das $nmbr$,C0051767;C0057671
age of onset,C0206132;C3175530
rf iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
age of onset $nmbr$ years n $nmbr$,C0206132;C3175530
tnf alpha pg ml,C1448177;C0439297;C1456820;C1522669
icsa plus laba n,
il $nmbr$ pg ml,C0020898;C0439297;C0021764;C0022271
geographical location n,C4545686
baseline steroids,C0168634;C0038317;C1442488
ocs n,
mtx exposure mg week,C0332174;C0439230
fev $nmbr$ l mean sd,C0444504;C2699239;C2347634;C2348143
age of onset,C0206132;C3175530
fev $nmbr$ predicted mean sd,C0444504;C2699239;C2347634;C2348143
age of onset $nmbr$ years n $nmbr$,C0206132;C3175530
acq $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
icsa plus laba n,
aqlq score mean sd,C0444504;C2699239;C2347634;C2348143
geographical location n,C4545686
asui score mean sd,C0444504;C2699239;C2347634;C2348143
ocs n,
blood eosinophils cells ml,C2699156
fev $nmbr$ l mean sd,C0444504;C2699239;C2347634;C2348143
allergic disease by historyb n,C0020517;C0851444
fev $nmbr$ predicted mean sd,C0444504;C2699239;C2347634;C2348143
atopy specific ige c n,C0392707;C0205369;C1552740;C3539705
acq $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
chronic sinusitis nasal polypsd n,C0149516;C0028429;C4520890
aqlq score mean sd,C0444504;C2699239;C2347634;C2348143
age of asthma onset years,C0206132;C3175530
asui score mean sd,C0444504;C2699239;C2347634;C2348143
rr,
blood eosinophils cells ml,C2699156
resllzumab,
allergic disease by historyb n,C0020517;C0851444
demographic data,C4684639
atopy specific ige c n,C0392707;C0205369;C1552740;C3539705
alprostadil n $nmbr$,C0002335
chronic sinusitis nasal polypsd n,C0149516;C0028429;C4520890
gender male female number,C0237753;C0449788
age of asthma onset years,C0206132;C3175530
risk factors and diabetes status,C0035648;C1553898;C1317301
rr,
caffeine,C0006644;C0236734
resllzumab,
complete healinga,C0205197;C0725685;C3853530;C4283785
demographic data,C4684639
major amputationsb,C0205082;C0205164;C4318856;C4521762
alprostadil n $nmbr$,C0002335
alprostadil n n,C0002335
gender male female number,C0237753;C0449788
interim analysis,C4684691
risk factors and diabetes status,C0035648;C1553898;C1317301
diabetics,C0241863
caffeine,C0006644;C0236734
non diabetics,C1518422;C0241863
complete healinga,C0205197;C0725685;C3853530;C4283785
overall analysis,C0002778;C0936012;C1524024
major amputationsb,C0205082;C0205164;C4318856;C4521762
cochranemantelehaenszel repeated $nmbr$ $nmbr$ ci c,C0205341;C0008107;C3259781
alprostadil n n,C0002335
statistic,C2348149;C2828391
interim analysis,C4684691
statisticd,
diabetics,C0241863
interim analysis all patients,C4684691;C0030705
non diabetics,C1518422;C0241863
e $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
overall analysis,C0002778;C0936012;C1524024
final analysis all patients,C0002778;C0936012;C1524024;C0030705
cochranemantelehaenszel repeated $nmbr$ $nmbr$ ci c,C0205341;C0008107;C3259781
characteristica,
statistic,C2348149;C2828391
serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
statisticd,
serum mg $nmbr$ $nmbr$ mmol l normal mg hvpermagnesemia,C2827881
interim analysis all patients,C4684691;C0030705
pbo n $nmbr$ $nmbr$,C0031962
e $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
cana $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
final analysis all patients,C0002778;C0936012;C1524024;C0030705
ethnicity n b,C0015031;C0243103
characteristica,
hba $nmbr$ c mmol mole,C0019016;C3829066;C1825777;C3538758
serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
serum mg $nmbr$ $nmbr$ mmol l normal mg hvpermagnesemia,C2827881
baseline serum mg $nmbr$ $nmbr$ mmol l,C0439268
pbo n $nmbr$ $nmbr$,C0031962
baseline mmol l,C0168634;C1532563;C1442488
cana $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
week $nmbr$ mmol l,C0332174;C1532563;C0439230
ethnicity n b,C0015031;C0243103
total number of patients,C2360800
hba $nmbr$ c mmol mole,C0019016;C3829066;C1825777;C3538758
egfr mean sd,C0444504;C2699239;C2347634;C2348143
baseline serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
egfr $nmbr$ to,C1739039;C3811844;C3812682
baseline serum mg $nmbr$ $nmbr$ mmol l,C0439268
egfr $nmbr$ ml min n,C1739039;C0439445;C3811844;C3812682
baseline mmol l,C0168634;C1532563;C1442488
af first diagnosis $nmbr$ years n,C0205435;C0011900;C1704338;C1704656;C1279901
week $nmbr$ mmol l,C0332174;C1532563;C0439230
af on baseline ecg n,C0344434;C4049859
total number of patients,C2360800
$nmbr$ or $nmbr$ n,C0369718;C0441922
egfr mean sd,C0444504;C2699239;C2347634;C2348143
cha $nmbr$ ds $nmbr$ vasc score mean sd,C0444504;C2699239;C2347634;C2348143
egfr $nmbr$ to,C1739039;C3811844;C3812682
risk factors for stroke,C0035648;C1553898
egfr $nmbr$ ml min n,C1739039;C0439445;C3811844;C3812682
previous stroke or tia n,C0038454;C4554100;C0007787;C0917805;C1054154
af first diagnosis $nmbr$ years n,C0205435;C0011900;C1704338;C1704656;C1279901
heart failure n,C0018801;C0018802;C4554158
af on baseline ecg n,C0344434;C4049859
hypertension receiving treatment n,C0020538;C1963138;C1514756;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ or $nmbr$ n,C0369718;C0441922
peripheral arterial disease n,C0085096;C1704436
cha $nmbr$ ds $nmbr$ vasc score mean sd,C0444504;C2699239;C2347634;C2348143
valvular heart disease n,C0018824;C1963123
risk factors for stroke,C0035648;C1553898
concomitant medications at baseline,C0013227;C0802604;C2598133;C4284232
previous stroke or tia n,C0038454;C4554100;C0007787;C0917805;C1054154
arb or ace inhibitor n,C3888198;C0003015;C4541021
heart failure n,C0018801;C0018802;C4554158
ppi or h $nmbr$ receptor antagonist n,C0358591;C0871125;C3811894;C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
hypertension receiving treatment n,C0020538;C1963138;C1514756;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
on oac at time of randomisation n,C0040223;C0034656;C3541383
peripheral arterial disease n,C0085096;C1704436
dabigatran $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
valvular heart disease n,C0018824;C1963123
dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
concomitant medications at baseline,C0013227;C0802604;C2598133;C4284232
dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
arb or ace inhibitor n,C3888198;C0003015;C4541021
clinical outcome,C0205210;C1274040
ppi or h $nmbr$ receptor antagonist n,C0358591;C0871125;C3811894;C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
number of events,C4330837
on oac at time of randomisation n,C0040223;C0034656;C3541383
event rate year,C0439234;C0439508
dabigatran $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p value for interaction age groups,C1709380
dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
p value for interaction age continuous,C1709380;C0001779;C0549178
dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
stroke non,C0038454;C1518422;C4554100
clinical outcome,C0205210;C1274040
cns systemic embolism,C0013922;C1704212
number of events,C4330837
all cause,C0015127;C1524003
event rate year,C0439234;C0439508
mortality,C0026565;C0026566
p value for interaction age groups,C1709380
$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$,C0024671;C3254570;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
p value for interaction age continuous,C1709380;C0001779;C0549178
age range years,C1510829;C1514721;C2348147;C3542016
stroke non,C0038454;C1518422;C4554100
duration of rheumatoid arthritis years,C0449238;C2926735
cns systemic embolism,C0013922;C1704212
anti ccp antibody positive,C0741132
all cause,C0015127;C1524003
das $nmbr$ c reactive protein,C0006560;C1413716;C4048285
mortality,C0026565;C0026566
clinical disease activity index score $nmbr$ $nmbr$,C4706353
$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$,C0024671;C3254570;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
simplified disease activity index score $nmbr$ $nmbr$,C4706353
age range years,C1510829;C1514721;C2348147;C3542016
duration of morning,C0449238;C2926735
duration of rheumatoid arthritis years,C0449238;C2926735
stiffness min,C0702093;C1524029;C3813700
anti ccp antibody positive,C0741132
conventional synthetic dmard use at baseline,C0042153;C0457083;C1947944
das $nmbr$ c reactive protein,C0006560;C1413716;C4048285
methotrexate dose at baseline,C0178602;C0869039;C1114758
clinical disease activity index score $nmbr$ $nmbr$,C4706353
$nmbr$ $nmbr$ mg week,C0332174;C0439230
simplified disease activity index score $nmbr$ $nmbr$,C4706353
sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of morning,C0449238;C2926735
evaluable for acr $nmbr$ at week $nmbr$ n,C1516986;C1412134;C1515941;C0332174;C0439230
stiffness min,C0702093;C1524029;C3813700
acr $nmbr$ response at week $nmbr$ n,C0871261;C1704632;C1706817;C2911692
conventional synthetic dmard use at baseline,C0042153;C0457083;C1947944
prior anti tnf therapy,C1514463
methotrexate dose at baseline,C0178602;C0869039;C1114758
received $nmbr$ prior anti tnf therapy n,C1514463
$nmbr$ $nmbr$ mg week,C0332174;C0439230
received $nmbr$ prior anti tnf therapies n,C1514463
sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior biologic therapy including anti tnfs,C0278947;C1448177
evaluable for acr $nmbr$ at week $nmbr$ n,C1516986;C1412134;C1515941;C0332174;C0439230
received $nmbr$ prior biologic therapy n,C1514756;C0278947
acr $nmbr$ response at week $nmbr$ n,C0871261;C1704632;C1706817;C2911692
received $nmbr$ prior biologic therapies n,C1514756;C0278947
prior anti tnf therapy,C1514463
baseline hstni,C0168634;C1442488
received $nmbr$ prior anti tnf therapy n,C1514463
$nmbr$ ng l n $nmbr$,C0439297
received $nmbr$ prior anti tnf therapies n,C1514463
p value trend,C1521798;C4554533
prior biologic therapy including anti tnfs,C0278947;C1448177
glycohemoglobin,C0202054;C0696092
received $nmbr$ prior biologic therapy n,C1514756;C0278947
prior coronary intervention or coronary artery bypass grafting,C0184661;C0886296;C1273869;C0010055
received $nmbr$ prior biologic therapies n,C1514756;C0278947
index inclusion acute coronary syndrome,C0007637;C0948089;C1512693
baseline hstni,C0168634;C1442488
time from acute coronary syndrome to randomization days,C0040223;C3541383;C0034656;C0439228
$nmbr$ ng l n $nmbr$,C0439297
median egfr interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
p value trend,C1521798;C4554533
$nmbr$ ng l n $nmbr$ n,C0439297
glycohemoglobin,C0202054;C0696092
cardiovascular death nonfatal myocardial infarction nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959
prior coronary intervention or coronary artery bypass grafting,C0184661;C0886296;C1273869;C0010055
nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
index inclusion acute coronary syndrome,C0007637;C0948089;C1512693
cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
time from acute coronary syndrome to randomization days,C0040223;C3541383;C0034656;C0439228
hospitalization for heart failure,C3898876
median egfr interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
cardiovascular death or nonfatal myocardial infarction,C0011065;C1306577;C4082313;C4552775;C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ ng l n $nmbr$ n,C0439297
number of prior aeds,C0237753;C0449788
cardiovascular death nonfatal myocardial infarction nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959
lev exposed,C0023556;C0332157
nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ responder rate n,C0871208;C1521828
cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
lev naive,C0023556
hospitalization for heart failure,C3898876
cbz exposed,C0006949;C0332157
cardiovascular death or nonfatal myocardial infarction,C0011065;C1306577;C4082313;C4552775;C0027051;C0428953;C2926063;C3810814;C4552959
cbz naive,C0006949
number of prior aeds,C0237753;C0449788
tpm exposed,C0076829;C0332157
lev exposed,C0023556;C0332157
tpm naive,C0076829
$nmbr$ responder rate n,C0871208;C1521828
ltg exposed,C1420817;C4521367;C4521846;C0332157
lev naive,C0023556
ltg naive,C1420817;C4521367;C4521846
cbz exposed,C0006949;C0332157
placebo no diabetes n $nmbr$,C0032042;C1696465;C1706408;C0011847;C0011849
cbz naive,C0006949
placebo diabetes n $nmbr$,C0011847;C0011849
tpm exposed,C0076829;C0332157
ticagrelor $nmbr$ mg no diabetes n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0011847;C0011849
tpm naive,C0076829
ticagrelor $nmbr$ mg diabetes n $nmbr$,C0011847;C0011849
ltg exposed,C1420817;C4521367;C4521846;C0332157
caucasian race,C0007457
ltg naive,C1420817;C4521367;C4521846
body mass index median,C0549183;C0876920;C2347635;C2348144;C2939193
placebo no diabetes n $nmbr$,C0032042;C1696465;C1706408;C0011847;C0011849
kg m $nmbr$,C0022718;C0439209;C4054209
placebo diabetes n $nmbr$,C0011847;C0011849
prior mi diagnosis,C0332132;C3810814
ticagrelor $nmbr$ mg no diabetes n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0011847;C0011849
years since mi median,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
ticagrelor $nmbr$ mg diabetes n $nmbr$,C0011847;C0011849
years,C0439234
caucasian race,C0007457
hypercholesterolaemia,C0020443;C1522133
body mass index median,C0549183;C0876920;C2347635;C2348144;C2939193
prior transient ischaemic,C0040704;C0475224;C0205374
kg m $nmbr$,C0022718;C0439209;C4054209
attack,C0277793;C1261512;C1304680
prior mi diagnosis,C0332132;C3810814
multivessel cad,C1504769;C2239547;C3813548;C4284121
years since mi median,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
time since last dose of,C0946444
years,C0439234
study medication pre dose,C0801821;C3174092
hypercholesterolaemia,C0020443;C1522133
median h,C0033727;C0369286;C0441932;C0564385;C4528284
prior transient ischaemic,C0040704;C0475224;C0205374
chronic kidney disease,C1561643;C4553188
attack,C0277793;C1261512;C1304680
ace inhibitor use,C0042153;C0457083;C1947944
multivessel cad,C1504769;C2239547;C3813548;C4284121
beta blocker use,C0042153;C0457083;C1947944
time since last dose of,C0946444
hypoglycaemic therapy,C0039798;C0087111;C1363945
study medication pre dose,C0801821;C3174092
diet controlled,C0743195
median h,C0033727;C0369286;C0441932;C0564385;C4528284
ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
chronic kidney disease,C1561643;C4553188
lta max response to $nmbr$ pm adp defined hpr patients,C2611142;C0030266;C4049155
ace inhibitor use,C0042153;C0457083;C1947944
pre dose,C0439565;C3812758
beta blocker use,C0042153;C0457083;C1947944
p value for dm vs no dm,C1709380;C0011816;C3250443
hypoglycaemic therapy,C0039798;C0087111;C1363945
post dose,C0439568
diet controlled,C0743195
verifynow pru defined hpr patients,C1337105;C0030705
ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vasp pri defined hpr patients,C0034044;C0030705;C1826843;C3539761;C3539762
lta max response to $nmbr$ pm adp defined hpr patients,C2611142;C0030266;C4049155
vhd,
pre dose,C0439565;C3812758
no vhd,
p value for dm vs no dm,C1709380;C0011816;C3250443
aspirin use at randomization n,C0042153;C0457083;C1947944
post dose,C0439568
history of coronary artery disease n,C1881055
verifynow pru defined hpr patients,C1337105;C0030705
history of carotid disease n,C0683519;C0730226;C0850708;C0944983
vasp pri defined hpr patients,C0034044;C0030705;C1826843;C3539761;C3539762
history of diabetes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
vhd,
history of stroke or tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
no vhd,
itt cohort overall study period,C0439531;C1948053
aspirin use at randomization n,C0042153;C0457083;C1947944
hd n $nmbr$,
history of coronary artery disease n,C1881055
ld,C0694649
history of carotid disease n,C0683519;C0730226;C0850708;C0944983
hd edoxaban vs warfarin,C2975435;C0043031
history of diabetes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ld edoxaban vs warfarin,C0694649;C2975435;C0043031
history of stroke or tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
stroke or see,C0038454;C4554100;C0042789;C1947903
itt cohort overall study period,C0439531;C1948053
ischemic stroke or see,C0948008;C0042789;C1947903
hd n $nmbr$,
disabling or fatal,C1302234;C1705232
ld,C0694649
key secondary end points,C0027627;C2349179;C0175668;C0205436
hd edoxaban vs warfarin,C2975435;C0043031
stroke see or cv death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
ld edoxaban vs warfarin,C0694649;C2975435;C0043031
stroke see or death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
stroke or see,C0038454;C4554100;C0042789;C1947903
other end points,C2349179
ischemic stroke or see,C0948008;C0042789;C1947903
death or disabling stroke,C0011065;C1306577;C4082313;C4552775;C0038454;C4554100
disabling or fatal,C1302234;C1705232
cv,C3538987;C4048877;C4318503
key secondary end points,C0027627;C2349179;C0175668;C0205436
aspirin $nmbr$ mg n $nmbr$,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
stroke see or cv death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
weight no,C0005910;C0043100;C1305866;C1705104
stroke see or death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
index event no,C0441471;C4019010
other end points,C2349179
isolated deep vein thrombosis,C0205409;C0149871;C1548221
death or disabling stroke,C0011065;C1306577;C4082313;C4552775;C0038454;C4554100
isolated pulmonary embolism,C0205409;C0034065;C1548221
cv,C3538987;C4048877;C4318503
index event asymptomatic or unconfirmed,C0441471;C0231221;C4019010;C1547326
aspirin $nmbr$ mg n $nmbr$,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
classification of index venous thromboembolism no,C0008902;C0008903;C0678229
weight no,C0005910;C0043100;C1305866;C1705104
provoked,C1444748
index event no,C0441471;C4019010
hormonal therapy no,C0279025
isolated deep vein thrombosis,C0205409;C0149871;C1548221
estrogens,C0014939;C3537250;C3541386;C3714615
isolated pulmonary embolism,C0205409;C0034065;C1548221
progestins,C0033306
index event asymptomatic or unconfirmed,C0441471;C0231221;C4019010;C1547326
median duration of study drug administration iqr days,C0920470;C2348354
classification of index venous thromboembolism no,C0008902;C0008903;C0678229
individual intended study duration no,C0027361;C0489652;C0237401
provoked,C1444748
rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hormonal therapy no,C0279025
aspirin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
estrogens,C0014939;C3537250;C3541386;C3714615
presentation of index event,C0449450;C0441471;C4019010
progestins,C0033306
pulmonary embolism deep vein thrombosis,C0392108;C0852030
median duration of study drug administration iqr days,C0920470;C2348354
extent of index event,C0439792;C0441471;C4019010
individual intended study duration no,C0027361;C0489652;C0237401
history of recurrent venous thromboembolism,C0455533
rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
risk factor profile index event,C0441471;C4019010
aspirin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of pre randomization anticoagulant therapy,C2711563
presentation of index event,C0449450;C0441471;C4019010
s $nmbr$ months,C0439231
pulmonary embolism deep vein thrombosis,C0392108;C0852030
s $nmbr$ ml min,C0439445
extent of index event,C0439792;C0441471;C4019010
known thrombophilia,C0205309;C0398623
history of recurrent venous thromboembolism,C0455533
history of cv disease,C0683519;C0730226;C0850708;C0944983
risk factor profile index event,C0441471;C4019010
any ae,C3887670
duration of pre randomization anticoagulant therapy,C2711563
aes leading to,C1412268;C2699274;C0332152;C1522538
s $nmbr$ months,C0439231
discontinu ation,
s $nmbr$ ml min,C0439445
aes related to,C1412268;C2699274;C0439849;C0445223
known thrombophilia,C0205309;C0398623
study druga,C0557651;C2603343
history of cv disease,C0683519;C0730226;C0850708;C0944983
serious aes,C1412268;C2699274
any ae,C3887670
baseline statin use,C0042153;C0457083;C1947944
aes leading to,C1412268;C2699274;C0332152;C1522538
cv risk factors,C0035648;C1553898
discontinu ation,
uncontrolled on oad s,C0205318
aes related to,C1412268;C2699274;C0439849;C0445223
uncontrolled on basal insulin,C0205318;C0650607
study druga,C0557651;C2603343
dual i extension,C0231448;C1880641
serious aes,C1412268;C2699274
dual iv,C0022326;C4265176
baseline statin use,C0042153;C0457083;C1947944
dual ii,C1710602;C4082587
cv risk factors,C0035648;C1553898
global trial population,C0032659;C1257890
uncontrolled on oad s,C0205318
indian subpopulation,C1524069;C1257890
uncontrolled on basal insulin,C0205318;C0650607
ideglira,C4308663
dual i extension,C0231448;C1880641
ideg,
dual iv,C0022326;C4265176
lira,C1555441
dual ii,C1710602;C4082587
number of people n,C0237753;C0449788
global trial population,C0032659;C1257890
oad at screening n,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
indian subpopulation,C1524069;C1257890
metformin su,C0038642;C1705534
ideglira,C4308663
np tercile $nmbr$ bnp,C0054015;C1095989;C1417808;C2982014
ideg,
nptercile $nmbr$ bnp $nmbr$ $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
lira,C1555441
np tercile $nmbr$ bnp $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
number of people n,C0237753;C0449788
pvaluefor trend,C1521798;C4554533
oad at screening n,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
nt probnp median pg ml,C0669479;C0439297;C0754710
metformin su,C0038642;C1705534
i or ii,C0021966;C0221138
np tercile $nmbr$ bnp,C0054015;C1095989;C1417808;C2982014
copd or asthma,C0024117;C1412502;C3714496;C0004096;C2984299
nptercile $nmbr$ bnp $nmbr$ $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
physical examination,C0031809;C1744699
np tercile $nmbr$ bnp $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
hf symptoms and signs,C0683368;C1457887;C0220912;C0220913;C0311392
pvaluefor trend,C1521798;C4554533
pnd,C1417807;C1956415;C4552608
nt probnp median pg ml,C0669479;C0439297;C0754710
orthopnea,C0085619
i or ii,C0021966;C0221138
dyspnea t,C0013404;C1963100
copd or asthma,C0024117;C1412502;C3714496;C0004096;C2984299
jvp $nmbr$ cm h $nmbr$ o,C0455483
physical examination,C0031809;C1744699
ankle edema,C0235439
hf symptoms and signs,C0683368;C1457887;C0220912;C0220913;C0311392
pulmonary congestion cxr,C0006888;C0039985
pnd,C1417807;C1956415;C4552608
laboratory variables,C0022877;C0439828;C3244292;C4283904
orthopnea,C0085619
sodium meq l,C0037473;C0439375;C0597484;C3541959;C3714642
dyspnea t,C0013404;C1963100
potassium meq l,C0032821;C0439375;C0202194;C0304475;C0597277;C3714637
jvp $nmbr$ cm h $nmbr$ o,C0455483
microalbuminuria mg g cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
ankle edema,C0235439
total bilirubin mg dl,C0005437;C0439269;C0368753
pulmonary congestion cxr,C0006888;C0039985
albumin g dl,C0001924;C0439267
laboratory variables,C0022877;C0439828;C3244292;C4283904
lvh on ecg,C0232306
sodium meq l,C0037473;C0439375;C0597484;C3541959;C3714642
diuretic agents,C0450442;C1254351;C1521826
potassium meq l,C0032821;C0439375;C0202194;C0304475;C0597277;C3714637
ace inhibitors or arbs,C0003015;C3888198
microalbuminuria mg g cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
long acting nitrate agents,C0450442;C1254351;C1521826
total bilirubin mg dl,C0005437;C0439269;C0368753
no of events patients,C0441471;C0030705;C3541888
albumin g dl,C0001924;C0439267
bnp ntbnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
lvh on ecg,C0232306
terlile $nmbr$,
diuretic agents,C0450442;C1254351;C1521826
tertile $nmbr$,
ace inhibitors or arbs,C0003015;C3888198
bnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
long acting nitrate agents,C0450442;C1254351;C1521826
ntbnp n $nmbr$,
no of events patients,C0441471;C0030705;C3541888
dyspnoea n $nmbr$,C0013404;C1963100
bnp ntbnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
no dyspnoea n $nmbr$,C0013404;C1963100
terlile $nmbr$,
non usa,C1518422;C0041703
tertile $nmbr$,
with dyspnoea,C0013404;C1963100
bnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
without dyspnoea,C0013404;C1963100
ntbnp n $nmbr$,
cangrelor dyspnoea vs no dyspnoea,C0013404;C1963100
dyspnoea n $nmbr$,C0013404;C1963100
clopidogrel dyspnoea vs no dyspnoea,C0013404;C1963100
no dyspnoea n $nmbr$,C0013404;C1963100
cangrelor n $nmbr$,C1121991
non usa,C1518422;C0041703
clopidogrel n $nmbr$,C0070166
with dyspnoea,C0013404;C1963100
death mi idr st,C0036056;C3272372
without dyspnoea,C0013404;C1963100
idr,
cangrelor dyspnoea vs no dyspnoea,C0013404;C1963100
p inter action,C0205103;C0441472;C3266814;C1548610
clopidogrel dyspnoea vs no dyspnoea,C0013404;C1963100
non cabg related bleeding at $nmbr$ h,C0010055;C0019080
cangrelor n $nmbr$,C1121991
severe life threatening,C1546953;C2826244;C3537125
clopidogrel n $nmbr$,C0070166
minor,C0026193;C0205165
death mi idr st,C0036056;C3272372
fixed triple n $nmbr$,C0443218;C0205174;C2827483;C3714578
idr,
open triple n $nmbr$,C0175566;C0205174
p inter action,C0205103;C0441472;C3266814;C1548610
blood leucocyte concentration $nmbr$ cells per l,C0005773;C0347983
non cabg related bleeding at $nmbr$ h,C0010055;C0019080
blood eosinophil concentration $nmbr$ cells per l,C0005773;C0347983
severe life threatening,C1546953;C2826244;C3537125
blood eosinophil proportion,C0014467;C1709707
minor,C0026193;C0205165
time since first copd diagnosis years,C0556970;C0011900;C1704338;C1704656
fixed triple n $nmbr$,C0443218;C0205174;C2827483;C3714578
of predicted normal value,C0681842;C0086715;C1882327
open triple n $nmbr$,C0175566;C0205174
$nmbr$ and,
blood leucocyte concentration $nmbr$ cells per l,C0005773;C0347983
inspiratory capacity l,C0021610;C0802663
blood eosinophil concentration $nmbr$ cells per l,C0005773;C0347983
chronic bronchitist,C0205191
blood eosinophil proportion,C0014467;C1709707
exacerbation rate in the previous year range,C0871208;C1521828
time since first copd diagnosis years,C0556970;C0011900;C1704338;C1704656
cat total score,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
of predicted normal value,C0681842;C0086715;C1882327
copd medication at study entry,C0024117;C0013175;C1412502;C3714496
$nmbr$ and,
ics lama,C0999593;C1416775
inspiratory capacity l,C0021610;C0802663
spacer use during the study,C0221874;C0869040
chronic bronchitist,C0205191
patients with at least one concomitant disease,C0683521
exacerbation rate in the previous year range,C0871208;C1521828
myocardial ischaemia,C0010054;C0151744
cat total score,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
ischaemic cardiomyopathy,C0349782
copd medication at study entry,C0024117;C0013175;C1412502;C3714496
arteriosclerosis,C0003850
ics lama,C0999593;C1416775
coronary artery osteochondrosis,C0029376;C0029429;C0729346
spacer use during the study,C0221874;C0869040
cholecystitis chronic,C0008325;C0205191;C1963083;C4553186
patients with at least one concomitant disease,C0683521
subgroup levels,C1079230;C0441889;C1515021
myocardial ischaemia,C0010054;C0151744
estimate,C0750572
ischaemic cardiomyopathy,C0349782
overall itt n $nmbr$,C0282416;C1561607
arteriosclerosis,C0003850
mar imputation random n $nmbr$,C0034656;C0439605
coronary artery osteochondrosis,C0029376;C0029429;C0729346
cr imputation random n $nmbr$,C0201975;C0034656;C0439605;C3539604;C3711669;C4084730;C4553336;C4553337
cholecystitis chronic,C0008325;C0205191;C1963083;C4553186
very severe itt n $nmbr$,C3641272;C4050419
subgroup levels,C1079230;C0441889;C1515021
severe itt n $nmbr$,C0205082;C4050465;C4050466
estimate,C0750572
ex smokers itt n $nmbr$,C0337671;C4555205
overall itt n $nmbr$,C0282416;C1561607
current smokers itt n $nmbr$,C3173209;C3241966
mar imputation random n $nmbr$,C0034656;C0439605
males itt n $nmbr$,C0086582
cr imputation random n $nmbr$,C0201975;C0034656;C0439605;C3539604;C3711669;C4084730;C4553336;C4553337
females itt n $nmbr$,C0086287
very severe itt n $nmbr$,C3641272;C4050419
reversibility s $nmbr$ itt n $nmbr$,C0449261
severe itt n $nmbr$,C0205082;C4050465;C4050466
reversibility $nmbr$ itt n $nmbr$,C0449261
ex smokers itt n $nmbr$,C0337671;C4555205
chronic bronchitis itt n $nmbr$,C0008677
current smokers itt n $nmbr$,C3173209;C3241966
emphysema itt n $nmbr$,C0013990;C0034067
males itt n $nmbr$,C0086582
mixed itt n $nmbr$,C0205430;C3160715
females itt n $nmbr$,C0086287
$nmbr$ exacerbation in prev $nmbr$ m n $nmbr$,C4086268;C1552852;C0369718;C0441922
reversibility s $nmbr$ itt n $nmbr$,C0449261
cardiovascular disease n $nmbr$,C0007222
reversibility $nmbr$ itt n $nmbr$,C0449261
no cardiovascular disease n $nmbr$,C0007222
chronic bronchitis itt n $nmbr$,C0008677
eosinophils,C0014467;C0200638
emphysema itt n $nmbr$,C0013990;C0034067
eosinophils $nmbr$ n $nmbr$,C0014467;C0200638
mixed itt n $nmbr$,C0205430;C3160715
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
$nmbr$ exacerbation in prev $nmbr$ m n $nmbr$,C4086268;C1552852;C0369718;C0441922
age $nmbr$ $nmbr$ years n $nmbr$,C1510829
cardiovascular disease n $nmbr$,C0007222
age $nmbr$ years n $nmbr$,C1510829
no cardiovascular disease n $nmbr$,C0007222
i $nmbr$ $nmbr$,C0021966;C0221138
eosinophils,C0014467;C0200638
overall per protocol n $nmbr$,C0282416;C1698058;C1561607
eosinophils $nmbr$ n $nmbr$,C0014467;C0200638
bocf iike imputation random n $nmbr$,C0034656;C0439605
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
eosinophils $nmbr$ itt n $nmbr$,C0014467;C0200638
age $nmbr$ $nmbr$ years n $nmbr$,C1510829
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^ itt n $nmbr$,C0014467;C0200638
age $nmbr$ years n $nmbr$,C1510829
age $nmbr$ $nmbr$ years itt n $nmbr$,C1510829
i $nmbr$ $nmbr$,C0021966;C0221138
age $nmbr$ years itt n $nmbr$,C1510829
overall per protocol n $nmbr$,C0282416;C1698058;C1561607
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^^ itt n $nmbr$,C0014467;C0200638
bocf iike imputation random n $nmbr$,C0034656;C0439605
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ itt n $nmbr$,C0014467;C0200638
eosinophils $nmbr$ itt n $nmbr$,C0014467;C0200638
pool of fh i and ii studies,C0337051;C1509144;C2349200;C1710602;C0947630;C4082587
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^ itt n $nmbr$,C0014467;C0200638
pool of long term hefh patients only and high fh,C0337051;C1509144;C2349200;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
age $nmbr$ $nmbr$ years itt n $nmbr$,C1510829
alirocumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age $nmbr$ years itt n $nmbr$,C1510829
alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^^ itt n $nmbr$,C0014467;C0200638
q $nmbr$ w n $nmbr$ $nmbr$,
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ itt n $nmbr$,C0014467;C0200638
race n white,C0007457;C0043157;C0220938
pool of fh i and ii studies,C0337051;C1509144;C2349200;C1710602;C0947630;C4082587
diabetes type ii n,C0011860
pool of long term hefh patients only and high fh,C0337051;C1509144;C2349200;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
family history of premature,C0241889;C0151526;C0205252;C4018905
alirocumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
coronary heart disease n cardiovascular risk per protocol n very high,C0442804;C4321397
alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients with no prior cvd primary,C0030705;C1335497
q $nmbr$ w n $nmbr$ $nmbr$,
prevention n patients on llt other than statin n,C0199176;C0030705;C1706420;C2700409;C0360714
race n white,C0007457;C0043157;C0220938
ldl c calculated mg dl mean sd,C0439269;C2699239
diabetes type ii n,C0011860
apo b mg dl mean sd,C0003593;C2699239;C3252643
family history of premature,C0241889;C0151526;C0205252;C4018905
non hdl c mg dl mean sd,C0439269;C2699239
coronary heart disease n cardiovascular risk per protocol n very high,C0442804;C4321397
total cholesterol mg dl mean sd,C0201950;C2699239;C0543421
patients with no prior cvd primary,C0030705;C1335497
lp a mg dl median q $nmbr$ q $nmbr$,C0065058;C0439269;C1439335;C4553379
prevention n patients on llt other than statin n,C0199176;C0030705;C1706420;C2700409;C0360714
triglycerides mg dl median q $nmbr$ q $nmbr$,C0041004;C0439269
ldl c calculated mg dl mean sd,C0439269;C2699239
hdl c mg dl mean sd,C0439269;C2699239
apo b mg dl mean sd,C0003593;C2699239;C3252643
apo a $nmbr$ mg dl mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
non hdl c mg dl mean sd,C0439269;C2699239
factor at baseline,C1521761;C2827422
total cholesterol mg dl mean sd,C0201950;C2699239;C0543421
percentage of patients receiving dose adjustment,C0439165;C1549488;C1561533;C1514756;C2826232
lp a mg dl median q $nmbr$ q $nmbr$,C0065058;C0439269;C1439335;C4553379
distance to ldl c goal,C0012751;C0018017;C1571704
triglycerides mg dl median q $nmbr$ q $nmbr$,C0041004;C0439269
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
hdl c mg dl mean sd,C0439269;C2699239
$nmbr$ i,C0021966;C0221138
apo a $nmbr$ mg dl mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
ltt other than statin,C0360714
factor at baseline,C1521761;C2827422
no reference,C1514811;C1706462
percentage of patients receiving dose adjustment,C0439165;C1549488;C1561533;C1514756;C2826232
$nmbr$ $nmbr$ $nmbr$ $nmbr$ o $nmbr$,C0483204
distance to ldl c goal,C0012751;C0018017;C1571704
mepolizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
number of exacerbations in the $nmbr$ months before screening,C0237753;C0449788;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
$nmbr$ i,C0021966;C0221138
patients with $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0545082;C1512346;C2826704;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
ltt other than statin,C0360714
patients with $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
no reference,C1514811;C1706462
current oral corticosteroid use,C1527415
$nmbr$ $nmbr$ $nmbr$ $nmbr$ o $nmbr$,C0483204
oral corticosteroid dose mg day,C0001617;C0439422;C3536709
mepolizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current inhaled corticosteroid use,C0004048;C0239126
number of exacerbations in the $nmbr$ months before screening,C0237753;C0449788;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
th $nmbr$,C0039725;C0039738;C1420718;C4282123;C4285344
patients with $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0545082;C1512346;C2826704;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
current laba use,C0042153;C0457083;C1947944
patients with $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
current lra use,C0042153;C0457083;C1947944
current oral corticosteroid use,C1527415
current xanthine derivative use,C0042153;C0457083;C1947944
oral corticosteroid dose mg day,C0001617;C0439422;C3536709
current lama use,C0042153;C0457083;C1947944
current inhaled corticosteroid use,C0004048;C0239126
measures of lung function,C0079809;C1879489
th $nmbr$,C0039725;C0039738;C1420718;C4282123;C4285344
pre bronchodilator fev^ l,C2599602;C3714541
current laba use,C0042153;C0457083;C1947944
percentage of predicted pre bronchodilator fev^,C0439165;C1549488;C1561533
current lra use,C0042153;C0457083;C1947944
percentage of fevj reversibility,C0439165;C1549488;C1561533
current xanthine derivative use,C0042153;C0457083;C1947944
pre bronchodilator fvc l,C2599602;C3714541
current lama use,C0042153;C0457083;C1947944
pre bronchodilator fef $nmbr$ $nmbr$ ml s baseline blood eosinophil count,C0200638;C0750879
measures of lung function,C0079809;C1879489
baseline geometric mean $nmbr$ l,C0168634;C2986759;C1442488
pre bronchodilator fev^ l,C2599602;C3714541
$nmbr$ per pl at screening,C3897966;C4049765
percentage of predicted pre bronchodilator fev^,C0439165;C1549488;C1561533
$nmbr$ per pl in $nmbr$ months before screening,C3897966;C4049765;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
percentage of fevj reversibility,C0439165;C1549488;C1561533
total sgrq score,C2964552
pre bronchodilator fvc l,C2599602;C3714541
baseline presence of nasal polyps,C0150312;C0392148;C3854307
pre bronchodilator fef $nmbr$ $nmbr$ ml s baseline blood eosinophil count,C0200638;C0750879
positive atopic status,C0392707;C0449438
baseline geometric mean $nmbr$ l,C0168634;C2986759;C1442488
eosinophil count,C0200638;C0750879
$nmbr$ per pl at screening,C3897966;C4049765
mean change in sgrq,C0392747;C0443172;C1705241;C4319952
$nmbr$ per pl in $nmbr$ months before screening,C3897966;C4049765;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
$nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0596019
total sgrq score,C2964552
mean change in fev $nmbr$,C0392747;C0443172;C1705241;C4319952
baseline presence of nasal polyps,C0150312;C0392148;C3854307
$nmbr$ $nmbr$ cl $nmbr$ to $nmbr$,C0596019
positive atopic status,C0392707;C0449438
mean change in acq score,C0392747;C0443172;C1705241;C4319952
eosinophil count,C0200638;C0750879
exacerbation rate per year,C0871208;C1521828
mean change in sgrq,C0392747;C0443172;C1705241;C4319952
baricitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0596019
patient characteristics,C0815172
mean change in fev $nmbr$,C0392747;C0443172;C1705241;C4319952
female patients n,C0150905
$nmbr$ $nmbr$ cl $nmbr$ to $nmbr$,C0596019
duration of ra time from symptom onset years,C0449238;C2926735;C4086878;C0439234
mean change in acq score,C0392747;C0443172;C1705241;C4319952
concomitant corticosteroid use n,C0521115;C0239126
exacerbation rate per year,C0871208;C1521828
concomitant mtx use n,C0025677;C0042153;C0457083;C1947944;C1417487
baricitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd mtx dose mg week,C0332174;C0439230
patient characteristics,C0815172
number of prior csdmards n,C0237753;C0449788
female patients n,C0150905
number of concomitant csdmards n,C0237753;C0449788
duration of ra time from symptom onset years,C0449238;C2926735;C4086878;C0439234
non mtx,C0025677;C1417487
concomitant corticosteroid use n,C0521115;C0239126
mtx non mtx,C0025677;C1417487
concomitant mtx use n,C0025677;C0042153;C0457083;C1947944;C1417487
$nmbr$ non mtx,C0025677;C1417487
mean sd mtx dose mg week,C0332174;C0439230
das $nmbr$ hscrp,C0051767;C0057671
number of prior csdmards n,C0237753;C0449788
patient reported outcome measures,C4277735
number of concomitant csdmards n,C0237753;C0449788
health assessment questionnaire disability index,C4321476
non mtx,C0025677;C1417487
patient s global assessment of disease,C0030705;C0281858
mtx non mtx,C0025677;C1417487
activity $nmbr$ $nmbr$ vas,C0042815;C3536884;C3827561
$nmbr$ non mtx,C0025677;C1417487
patient s assessment of pain $nmbr$ $nmbr$ vas,C0030705;C0030198
das $nmbr$ hscrp,C0051767;C0057671
functional assessment of chronic illness,C0278372;C0008679
patient reported outcome measures,C4277735
therapy fatigue facit f $nmbr$ $nmbr$,C0015672;C3272505;C3463815;C4050243;C4554645
health assessment questionnaire disability index,C4321476
short form $nmbr$ sf $nmbr$,C2964478;C0037712
patient s global assessment of disease,C0030705;C0281858
physical component score pcs,C1864389;C1882368
activity $nmbr$ $nmbr$ vas,C0042815;C3536884;C3827561
mental component score mcs,C0229992;C0449432;C1705248
patient s assessment of pain $nmbr$ $nmbr$ vas,C0030705;C0030198
european quality of life $nmbr$ dimensions $nmbr$ level eq $nmbr$ d,C0205163;C0439185
functional assessment of chronic illness,C0278372;C0008679
health state index score uk algorithm,C0002045;C1553907
therapy fatigue facit f $nmbr$ $nmbr$,C0015672;C3272505;C3463815;C4050243;C4554645
vas $nmbr$ $nmbr$,C0042815;C3536884;C3827561
short form $nmbr$ sf $nmbr$,C2964478;C0037712
mtx other csomards,C0025677;C1417487
physical component score pcs,C1864389;C1882368
mtx othetcsdmards,C0025677;C1417487
mental component score mcs,C0229992;C0449432;C1705248
iglarlixi,
european quality of life $nmbr$ dimensions $nmbr$ level eq $nmbr$ d,C0205163;C0439185
iglar,
health state index score uk algorithm,C0002045;C1553907
lixi,
vas $nmbr$ $nmbr$,C0042815;C3536884;C3827561
week $nmbr$ changea,C0332174;C4349366;C0439230
mtx other csomards,C0025677;C1417487
p valuec,C0369773;C2603361
mtx othetcsdmards,C0025677;C1417487
$nmbr$ hour ppg mmol l,C0439227;C1532563;C0564385
iglarlixi,
hypoglycaemiad,
iglar,
events patient year n,C0030705;C0439234;C0439508
lixi,
octave induction $nmbr$,C0205263;C0857127
week $nmbr$ changea,C0332174;C4349366;C0439230
octave sustain,C0443318;C2732140
p valuec,C0369773;C2603361
male sex no f,C0086582;C0016327
$nmbr$ hour ppg mmol l,C0439227;C1532563;C0564385
induction trial group assignment no,C1320290;C1516050
hypoglycaemiad,
tofacitinib $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
events patient year n,C0030705;C0439234;C0439508
remission at maintenance trial entry no,C0544452;C0687702
octave induction $nmbr$,C0205263;C0857127
extent of disease no total no ^,C0449279;C4553144;C0439175;C0439810
octave sustain,C0443318;C2732140
extensive colitis or pancolitis,C0009319;C1963084;C0868908
male sex no f,C0086582;C0016327
total mayo score,C2964552;C0454788;C1077578
induction trial group assignment no,C1320290;C1516050
partial mayo score,C0449820;C4050231
tofacitinib $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
c reactive protein mg literj,C0006560;C1413716;C4048285
remission at maintenance trial entry no,C0544452;C0687702
oral glucocorticoid use at baseline no t,C1527415;C0017710;C2603360
extent of disease no total no ^,C0449279;C4553144;C0439175;C0439810
previous treatment with tnf antagonist no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
extensive colitis or pancolitis,C0009319;C1963084;C0868908
previous treatment failure no,C0162643;C0235828;C0521983;C1547544
total mayo score,C2964552;C0454788;C1077578
tnf antagonist,C1448177;C0231491
partial mayo score,C0449820;C4050231
glucocorticoid,C0017710
c reactive protein mg literj,C0006560;C1413716;C4048285
immunosuppressant^^,C0021081
oral glucocorticoid use at baseline no t,C1527415;C0017710;C2603360
tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous treatment with tnf antagonist no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
difference,C1705241;C1705242
previous treatment failure no,C0162643;C0235828;C0521983;C1547544
prior tnf antagonist treatment yes,C1549445;C1705108;C1710701
tnf antagonist,C1448177;C0231491
prior tnf antagonist treatment no,C1514463;C0231491
glucocorticoid,C0017710
prior tnf antagonist failure yes,C1549445;C1705108;C1710701
immunosuppressant^^,C0021081
prior tnf antagonist failure no,C0231174;C0680095
tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
corticosteroid use at baseline yes,C0239126;C0168634;C1442488
difference,C1705241;C1705242
corticosteroid use at baseline no,C0239126;C0168634;C1442488
prior tnf antagonist treatment yes,C1549445;C1705108;C1710701
geographic region europe,C0017446;C0015176
prior tnf antagonist treatment no,C1514463;C0231491
geographic region north america,C0017446;C0028405
prior tnf antagonist failure yes,C1549445;C1705108;C1710701
geographic region other,C0017446
prior tnf antagonist failure no,C0231174;C0680095
lvh n $nmbr$,C0149721
corticosteroid use at baseline yes,C0239126;C0168634;C1442488
non cns embolism,C0013922;C1704212
corticosteroid use at baseline no,C0239126;C0168634;C1442488
medication use at entry,C0240320;C1705654
geographic region europe,C0017446;C0015176
antiplateletsa,
geographic region north america,C0017446;C0028405
arbs or ace inhibitors,C3888198;C0003015
geographic region other,C0017446
_ $nmbr$,
lvh n $nmbr$,C0149721
electrocardiography,C0013798;C1623258
non cns embolism,C0013922;C1704212
r wave in avl mm,C0429091;C0449216
medication use at entry,C0240320;C1705654
s wave in v $nmbr$ mm,C0429094;C4330985;C4554674
antiplateletsa,
strain,C0080194;C0456178;C1518614;C2987481
arbs or ace inhibitors,C3888198;C0003015
lv ejection fractionb,C0023128;C0302131;C0336969;C0812388;C0731033;C1881413
_ $nmbr$,
lvh,C0149721
electrocardiography,C0013798;C1623258
p value d $nmbr$ mg vs warfarin,C1709380;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
r wave in avl mm,C0429091;C0449216
yr,C0439234
s wave in v $nmbr$ mm,C0429094;C4330985;C4554674
d $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
strain,C0080194;C0456178;C1518614;C2987481
absent,C0332197;C4285062
lv ejection fractionb,C0023128;C0302131;C0336969;C0812388;C0731033;C1881413
present,C0150312;C0449450
lvh,C0149721
vascular,C0005847;C1558950;C1801960
p value d $nmbr$ mg vs warfarin,C1709380;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
$nmbr$ $nmbr$ y,
yr,C0439234
pravastatin sodium,C0700474
d $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
female no,C0043210;C0086287;C1705497;C1705498
absent,C0332197;C4285062
medication use no total no,C0240320;C0439175;C0439810
present,C0150312;C0449450
current cigarette smoking no,C0239059;C0700219
vascular,C0005847;C1558950;C1801960
type $nmbr$ diabetes no,C1320657
$nmbr$ $nmbr$ y,
lipid values,C0023779;C0042295
pravastatin sodium,C0700474
ldl c mean sd mg dl,C0444504;C0439269;C2347634;C2348143
female no,C0043210;C0086287;C1705497;C1705498
hdl c mean sd mg dl,C0444504;C0439269;C2347634;C2348143
medication use no total no,C0240320;C0439175;C0439810
antihypertensive randomization no a,C0003364;C0034656
current cigarette smoking no,C0239059;C0700219
years of follow up mean sd [maximum],C0439234;C0589120;C1522577;C1704685;C3274571;C0806909;C1552615;C2826546
type $nmbr$ diabetes no,C1320657
cumulative events,C0441471;C3541888
lipid values,C0023779;C0042295
$nmbr$ y incidence rate se per $nmbr$ participants,C1708485;C0036919
ldl c mean sd mg dl,C0444504;C0439269;C2347634;C2348143
pravastatin vs usual care,C0085542;C3538928;C1947933
hdl c mean sd mg dl,C0444504;C0439269;C2347634;C2348143
cvd deaths,C0011065;C1306577
antihypertensive randomization no a,C0003364;C0034656
chd deaths,C0011065;C1306577
years of follow up mean sd [maximum],C0439234;C0589120;C1522577;C1704685;C3274571;C0806909;C1552615;C2826546
stroke deaths,C0011065;C1306577
cumulative events,C0441471;C3541888
non cvd deaths,C0011065;C1306577
$nmbr$ y incidence rate se per $nmbr$ participants,C1708485;C0036919
cause of death unknown,C0277589
pravastatin vs usual care,C0085542;C3538928;C1947933
fatal chd and nonfatal mia,C0280604;C3542407;C1417154
cvd deaths,C0011065;C1306577
stroke fatal and nonfatal,C0038454;C4554100;C1302234;C1705232
chd deaths,C0011065;C1306577
heart failure hospitalized or fatal,C0018801;C0018802;C4554158;C0701159;C1302234;C1705232
stroke deaths,C0011065;C1306577
cancer fatal and nonfatal,C0006826;C0998265;C1306459;C1302234;C1705232
non cvd deaths,C0011065;C1306577
secukinumab pooled n $nmbr$,C1709595;C2349200;C4522255
cause of death unknown,C0277589
current smoker at baseline n,C3173209;C3241966
fatal chd and nonfatal mia,C0280604;C3542407;C1417154
methotrexate use at randomization n,C0042153;C0457083;C1947944
stroke fatal and nonfatal,C0038454;C4554100;C1302234;C1705232
sulfasalazine use at randomization n,C0042153;C0457083;C1947944
heart failure hospitalized or fatal,C0018801;C0018802;C4554158;C0701159;C1302234;C1705232
corticosteroid use at randomization n,C0239126;C0034656
cancer fatal and nonfatal,C0006826;C0998265;C1306459;C1302234;C1705232
total back pain $nmbr$ $nmbr$ mm vas mean sd,C0042815;C2699239
secukinumab pooled n $nmbr$,C1709595;C2349200;C4522255
nocturnal back pain $nmbr$ $nmbr$ mm vas mean sd,C1970122;C2699239
current smoker at baseline n,C3173209;C3241966
basdai total mean sd,C0439175;C2699239;C0439810
methotrexate use at randomization n,C0042153;C0457083;C1947944
hscrp mg l median min max,C0439420
sulfasalazine use at randomization n,C0042153;C0457083;C1947944
mean time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
corticosteroid use at randomization n,C0239126;C0034656
anti tnf na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
total back pain $nmbr$ $nmbr$ mm vas mean sd,C0042815;C2699239
endpoints,C2349179
nocturnal back pain $nmbr$ $nmbr$ mm vas mean sd,C1970122;C2699239
hscrp exp ls mean change se,C0023668;C0036919
basdai total mean sd,C0439175;C2699239;C0439810
asas $nmbr$ $nmbr$ n,C0004057;C3853627
hscrp mg l median min max,C0439420
sf $nmbr$ pcs ls mean change se,C0023668;C0036919
mean time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
asqol ls mean change se,C0023668;C0036919
anti tnf na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
asas partial remission n,C1521726;C4552913;C4552914
endpoints,C2349179
criterion,C0243161
hscrp exp ls mean change se,C0023668;C0036919
placebo controlled period,C0439531;C1948053
asas $nmbr$ $nmbr$ n,C0004057;C3853627
any secukinumab n $nmbr$,C3179547
sf $nmbr$ pcs ls mean change se,C0023668;C0036919
no of patients with events,C0030705;C0441471;C3541888
asqol ls mean change se,C0023668;C0036919
any sae,C1519255;C1622657;C4553214
asas partial remission n,C1521726;C4552913;C4552914
infections and infestations,C3714514;C0851341
criterion,C0243161
most common aes,C1412268;C2699274
placebo controlled period,C0439531;C1948053
urti,
any secukinumab n $nmbr$,C3179547
mouth ulceration,C0149745
no of patients with events,C0030705;C0441471;C3541888
leukopenia,C0023530;C0750394
any sae,C1519255;C1622657;C4553214
pharyngitis,C0031350;C4553308
infections and infestations,C3714514;C0851341
osteoprotegerin decreased,C0538161;C1308614;C1336645;C0205216;C0392756;C0442797
most common aes,C1412268;C2699274
oropharyngeal pain,C2363731;C4554669
urti,
lymphadenopathy,C0497156;C4282165
mouth ulceration,C0149745
rhinitis,C0035455
leukopenia,C0023530;C0750394
neutropenia,C0023530;C0027947;C0853697
pharyngitis,C0031350;C4553308
gastroenteritis,C0017160
osteoprotegerin decreased,C0538161;C1308614;C1336645;C0205216;C0392756;C0442797
oropharyngeal pain,C2363731;C4554669
includes patients originally randomized to placebo who were switched to secukinumab per the study designs aes that occurred in at least $nmbr$ $nmbr$ of the patients in the any secukinumab group during the $nmbr$ week placebo controlled period and events with an eair of at least $nmbr$ $nmbr$ cases per $nmbr$ patient years in the any secukinumab group during the entire treatment period events listed according to preferred term in the medical dictionary for regulatory activities meddra version $nmbr$ $nmbr$ sorted in descending order of eair in the any secukinumab group for the entire treatment period the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies ae adverse event as ankylosing spondylitis eair exposure adjusted incidence rates n number of randomized patients sae serious adverse event urti upper respiratory tract infection,C0332257;C1552866;C2700399;C0030705;C0034656;C3815594;C1707719;C3179547;C1412268;C2699274;C1709305;C0009932;C0441471;C3541888;C0439234;C0374505;C0439531;C1948053;C0745732;C3272378;C0237886;C0700314;C1947906;C0205386;C1547177;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072;C0168634;C1442488;C0545082;C1512346;C2826704;C4684790;C0877248;C0038013;C1264674;C1519255;C0041912
lymphadenopathy,C0497156;C4282165
fig $nmbr$ analysis of time to first cid event in patients who a received treatment with a laba and or lama and b did not receive treatment with a laba and or lama prior to the study,C0349966;C1718396;C1337208;C0441471;C4019010;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0999593;C1416775;C1518422;C1514756
rhinitis,C0035455
neutropenia,C0023530;C0027947;C0853697
fig $nmbr$ analysis of time to first cid event in patients with a moderate and b severe copd at baseline itt population,C0349966;C1718396;C1337208;C0441471;C4019010;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0024117;C1412502;C3714496
gastroenteritis,C0017160
incidence rate of cv events n,C1708485;C0441471;C3541888
hazard ratio $nmbr$ ci $nmbr$ with vs without psoriasis,C0008107;C3259781;C0033860
without psoriasis n $nmbr$ $nmbr$,C0033860
includes patients originally randomized to placebo who were switched to secukinumab per the study designs aes that occurred in at least $nmbr$ $nmbr$ of the patients in the any secukinumab group during the $nmbr$ week placebo controlled period and events with an eair of at least $nmbr$ $nmbr$ cases per $nmbr$ patient years in the any secukinumab group during the entire treatment period events listed according to preferred term in the medical dictionary for regulatory activities meddra version $nmbr$ $nmbr$ sorted in descending order of eair in the any secukinumab group for the entire treatment period the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies ae adverse event as ankylosing spondylitis eair exposure adjusted incidence rates n number of randomized patients sae serious adverse event urti upper respiratory tract infection,C0332257;C1552866;C2700399;C0030705;C0034656;C3815594;C1707719;C3179547;C1412268;C2699274;C1709305;C0009932;C0441471;C3541888;C0439234;C0374505;C0439531;C1948053;C0745732;C3272378;C0237886;C0700314;C1947906;C0205386;C1547177;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072;C0168634;C1442488;C0545082;C1512346;C2826704;C4684790;C0877248;C0038013;C1264674;C1519255;C0041912
with psoriasis n $nmbr$,C0033860
fig $nmbr$ analysis of time to first cid event in patients who a received treatment with a laba and or lama and b did not receive treatment with a laba and or lama prior to the study,C0349966;C1718396;C1337208;C0441471;C4019010;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0999593;C1416775;C1518422;C1514756
total v $nmbr$ $nmbr$,C0439175;C0439810
fig $nmbr$ analysis of time to first cid event in patients with a moderate and b severe copd at baseline itt population,C0349966;C1718396;C1337208;C0441471;C4019010;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0024117;C1412502;C3714496
unadjusted,C1439367
incidence rate of cv events n,C1708485;C0441471;C3541888
all treatments,C0087111
hazard ratio $nmbr$ ci $nmbr$ with vs without psoriasis,C0008107;C3259781;C0033860
atorvastatin $nmbr$ mg and simvastatin $nmbr$ $nmbr$ mg zi $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043476
without psoriasis n $nmbr$ $nmbr$,C0033860
atorvastatin $nmbr$ mg zi $nmbr$,C0024671;C0043476;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with psoriasis n $nmbr$,C0033860
characteristic no,C1521970
total v $nmbr$ $nmbr$,C0439175;C0439810
digoxin n $nmbr$ $nmbr$,C0012265
unadjusted,C1439367
no digoxin n $nmbr$ $nmbr$ $nmbr$,C0012265
all treatments,C0087111
white race n $nmbr$ $nmbr$,C0007457;C0043157
atorvastatin $nmbr$ mg and simvastatin $nmbr$ $nmbr$ mg zi $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043476
type of atrial fibrillation n $nmbr$ $nmbr$,C0332307;C1547052
atorvastatin $nmbr$ mg zi $nmbr$,C0024671;C0043476;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
qualifying risk factor,C1514624;C0035648
characteristic no,C1521970
coronary artery disease n $nmbr$ $nmbr$,C0010054;C0010068;C1956346
digoxin n $nmbr$ $nmbr$,C0012265
nyha iii or iv n $nmbr$ $nmbr$,C0439070;C1705160;C0022326;C4265176
no digoxin n $nmbr$ $nmbr$ $nmbr$,C0012265
peripheral arterial disease n $nmbr$ $nmbr$,C0085096;C1704436
white race n $nmbr$ $nmbr$,C0007457;C0043157
former current smoker n $nmbr$ $nmbr$,C0337671
type of atrial fibrillation n $nmbr$ $nmbr$,C0332307;C1547052
copd,C0024117;C1412502;C3714496
qualifying risk factor,C1514624;C0035648
mitral valve disease n $nmbr$ $nmbr$,C0026265;C4553832
coronary artery disease n $nmbr$ $nmbr$,C0010054;C0010068;C1956346
aortic valve disease n $nmbr$ $nmbr$,C1260873;C4553103
nyha iii or iv n $nmbr$ $nmbr$,C0439070;C1705160;C0022326;C4265176
prior electrical cardioversion for af n $nmbr$ $nmbr$,C0013778;C0542380
peripheral arterial disease n $nmbr$ $nmbr$,C0085096;C1704436
charlson comorbidity index mean sd,C4546361;C2699239
former current smoker n $nmbr$ $nmbr$,C0337671
heart rate mean sd bpm n $nmbr$ $nmbr$,C0018810;C0444504;C2347634;C2348143
copd,C0024117;C1412502;C3714496
hypertrophy per ecg n $nmbr$ $nmbr$,C0020564;C1623258
mitral valve disease n $nmbr$ $nmbr$,C0026265;C4553832
vitamin k antagonist experiencedk n $nmbr$ $nmbr$,C1096489;C2267235
aortic valve disease n $nmbr$ $nmbr$,C1260873;C4553103
aspirin n $nmbr$ $nmbr$,C0004057
prior electrical cardioversion for af n $nmbr$ $nmbr$,C0013778;C0542380
lipid lowering,C0023779;C0441994;C2003888
charlson comorbidity index mean sd,C4546361;C2699239
antiarrhythmics,C0003195
heart rate mean sd bpm n $nmbr$ $nmbr$,C0018810;C0444504;C2347634;C2348143
class ii b blockers,C0441886;C2698968
hypertrophy per ecg n $nmbr$ $nmbr$,C0020564;C1623258
raas inhibitor,C1999216
vitamin k antagonist experiencedk n $nmbr$ $nmbr$,C1096489;C2267235
high dose edoxaban,C0444956;C2975435
aspirin n $nmbr$ $nmbr$,C0004057
low dose edoxaban,C0445550;C2975435;C1708745
lipid lowering,C0023779;C0441994;C2003888
digoxin scd no y,C0012265
antiarrhythmics,C0003195
no digoxin scd no y,C0012265
class ii b blockers,C0441886;C2698968
adjusted hr $nmbr$ ci,C0008107;C3259781
raas inhibitor,C1999216
persistent permanent,C0205322;C0205355;C0332996
high dose edoxaban,C0444956;C2975435
lv hypertrophy per ecg,C0232306
low dose edoxaban,C0445550;C2975435;C1708745
b blockers at baseline,C0168634;C1442488
digoxin scd no y,C0012265
diuretic use at baseline,C0042153;C0457083;C1947944
no digoxin scd no y,C0012265
normal responders n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
adjusted hr $nmbr$ ci,C0008107;C3259781
sensitive responders n $nmbr$,C0020517;C0332324;C1522640
persistent permanent,C0205322;C0205355;C0332996
highly sensitive responders n $nmbr$,C0439822
lv hypertrophy per ecg,C0232306
age year mean sd,C0001779;C2699239
b blockers at baseline,C0168634;C1442488
creatinine clearance ml min mean sd,C0439445;C2699239
diuretic use at baseline,C0042153;C0457083;C1947944
edoxaban dose adjusted at randomisation n,C0178602;C0869039;C1114758;C0456081;C0034656
normal responders n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
bleeding events during first $nmbr$ days of treatmen,C0441471;C3541888
sensitive responders n $nmbr$,C0020517;C0332324;C1522640
t,C2603360
highly sensitive responders n $nmbr$,C0439822
bleeding events during the entire study,C0441471;C3541888
age year mean sd,C0001779;C2699239
adj hr $nmbr$ cl a,C0001552;C0596019;C2826286
creatinine clearance ml min mean sd,C0439445;C2699239
p b int,C1539794;C3272375
edoxaban dose adjusted at randomisation n,C0178602;C0869039;C1114758;C0456081;C0034656
edoxaban warfarin,C2975435;C0043031
bleeding events during first $nmbr$ days of treatmen,C0441471;C3541888
total bleeds,C0232100
t,C2603360
major and crnm bleeds,C0205082;C0205164;C4318856;C4521762;C0019080
bleeding events during the entire study,C0441471;C3541888
laba ics n $nmbr$,C0815320;C4551720
adj hr $nmbr$ cl a,C0001552;C0596019;C2826286
ind gly n $nmbr$,C0017890;C0523677
p b int,C1539794;C3272375
laba or lamab n $nmbr$,
edoxaban warfarin,C2975435;C0043031
ind glyb n $nmbr$,C4049864;C1415124
total bleeds,C0232100
post bronchodilator fev $nmbr$ predicted of normal value,C0681842;C1882327
major and crnm bleeds,C0205082;C0205164;C4318856;C4521762;C0019080
dyspnoea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
laba ics n $nmbr$,C0815320;C4551720
number of exacerbation in the previous $nmbr$ months n,C0237753;C0449788;C0205156;C0439231;C1552607
ind gly n $nmbr$,C0017890;C0523677
baseline treatments n a,C0168634;C0087111;C1442488
laba or lamab n $nmbr$,
lama only monotherapy,C0999593;C1416775
ind glyb n $nmbr$,C4049864;C1415124
laba only monotherapy,
post bronchodilator fev $nmbr$ predicted of normal value,C0681842;C1882327
laba ics free or fixed dose combination,C0332296;C1880497;C1996904;C0178602;C0205195;C1947911;C3811910;C0869039;C1114758
dyspnoea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
othersc,
number of exacerbation in the previous $nmbr$ months n,C0237753;C0449788;C0205156;C0439231;C1552607
laba ics versus indzgly lsm difference $nmbr$ cl,C0815320;C4551720;C1705241;C0596019;C1705242
baseline treatments n a,C0168634;C0087111;C1442488
indzgly,
lama only monotherapy,C0999593;C1416775
exacerbations in the previous year,C4086268;C0205156;C1552607
laba only monotherapy,
fev $nmbr$ at baseline,C3714541;C0168634;C1442488
laba ics free or fixed dose combination,C0332296;C1880497;C1996904;C0178602;C0205195;C1947911;C3811910;C0869039;C1114758
mmrc at baseline,C3826977;C0168634;C1442488
othersc,
form bud,C2700462;C2945744
laba ics versus indzgly lsm difference $nmbr$ cl,C0815320;C4551720;C1705241;C0596019;C1705242
sfc,C4521536
indzgly,
laba or lama versus ind gly lsm difference $nmbr$ cl,C0999593;C1416775;C0017890;C0596019;C0523677
exacerbations in the previous year,C4086268;C0205156;C1552607
laba or lama,C0999593;C1416775
fev $nmbr$ at baseline,C3714541;C0168634;C1442488
ind gly,C0017890;C0523677
mmrc at baseline,C3826977;C0168634;C1442488
ex smokers $nmbr$,C0337671;C4555205
form bud,C2700462;C2945744
fev at baseline,C3714541;C0168634;C1442488
sfc,C4521536
pooled itt,C1709595;C2349200;C4522255
laba or lama versus ind gly lsm difference $nmbr$ cl,C0999593;C1416775;C0017890;C0596019;C0523677
cat $nmbr$ n $nmbr$ $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
laba or lama,C0999593;C1416775
median y range,C1514721;C2348147;C3542016
ind gly,C0017890;C0523677
mean mmrc grade units sd,C0439148;C2699239;C1519795;C3853603
ex smokers $nmbr$,C0337671;C4555205
mean sgrq total score,C3533236
fev at baseline,C3714541;C0168634;C1442488
use of ics at baseline,C1524063;C0815320;C4551720;C0168634;C1442488
pooled itt,C1709595;C2349200;C4522255
mean copd duration y sd,C0024117;C2699239;C1412502;C3714496
cat $nmbr$ n $nmbr$ $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
copd severity,C0439793;C0522510
median y range,C1514721;C2348147;C3542016
mean number of exacerbations in previous y sd,C0444504;C0237753;C0449788;C2347634;C2348143;C0205156;C2699239;C1552607
mean mmrc grade units sd,C0439148;C2699239;C1519795;C3853603
mean postbronchodilatora fev $nmbr$ predicted sd,C0444504;C2699239;C2347634;C2348143
mean sgrq total score,C3533236
reversible to bronchodilator b,C0205343;C0006280
use of ics at baseline,C1524063;C0815320;C4551720;C0168634;C1442488
favors comparator,C1707454;C4553389;C4553390
mean copd duration y sd,C0024117;C2699239;C1412502;C3714496
gff mdi,C0993596;C1839839;C4049613
copd severity,C0439793;C0522510
gp mdi,C0993596;C1839839;C4049613
mean number of exacerbations in previous y sd,C0444504;C0237753;C0449788;C2347634;C2348143;C0205156;C2699239;C1552607
ff mdi,C0993596;C1839839;C4049613
mean postbronchodilatora fev $nmbr$ predicted sd,C0444504;C2699239;C2347634;C2348143
placebo mdi,C0993596;C1839839;C4049613
reversible to bronchodilator b,C0205343;C0006280
cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
favors comparator,C1707454;C4553389;C4553390
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
gff mdi,C0993596;C1839839;C4049613
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
gp mdi,C0993596;C1839839;C4049613
empagliflozin $nmbr$ mg day n $nmbr$,C3490348;C0439422
ff mdi,C0993596;C1839839;C4049613
parameters at baseline,C0449381;C0168634;C1442488
placebo mdi,C0993596;C1839839;C4049613
a bmi subgroups,C0578022;C1079230
cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
b age subgroups,C1304659;C0001779
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
fpg,
empagliflozin $nmbr$ mg day n $nmbr$,C3490348;C0439422
n $nmbr$ l $nmbr$,C0369718;C0441922
parameters at baseline,C0449381;C0168634;C1442488
n l $nmbr$,C0369718;C0441922
a bmi subgroups,C0578022;C1079230
p value nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
b age subgroups,C1304659;C0001779
efficacy,C1280519;C1707887
empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
death mi idr or st,C0011065;C1306577;C4082313;C4552775;C0036056;C3272372
fpg,
ischemia driven revascularization,C0022116;C0581603;C4321499
n $nmbr$ l $nmbr$,C0369718;C0441922
stent thrombosis,C3897493
n l $nmbr$,C0369718;C0441922
gusto moderate severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
p value nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
timi major minor,C4441842
efficacy,C1280519;C1707887
timi major,C0205082;C0205164;C4318856;C4521762
death mi idr or st,C0011065;C1306577;C4082313;C4552775;C0036056;C3272372
acuity major,C0205082;C0205164;C4318856;C4521762
ischemia driven revascularization,C0022116;C0581603;C4321499
net composite,C0205199;C1547335
stent thrombosis,C3897493
death mi idr st or gusto severe bleeding,C0036056;C3272372;C0205082;C0019080;C4050465;C4050466
gusto moderate severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
death mi idr st or gusto mod sev bleeding,C0036056;C3272372;C0011860;C0019080
timi major minor,C4441842
death mi idr st or any timi bleeding,C0036056;C3272372;C0019080
timi major,C0205082;C0205164;C4318856;C4521762
death mi idr st or gusto moderate severe bleeding,C0036056;C3272372;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
acuity major,C0205082;C0205164;C4318856;C4521762
pah ctd,C1335071;C1442905
net composite,C0205199;C1547335
pah ssc,C0030123;C3897657;C3203102;C4284467
death mi idr st or gusto severe bleeding,C0036056;C3272372;C0205082;C0019080;C4050465;C4050466
pah sle,C0030123;C0024141;C3203102;C4284467
death mi idr st or gusto mod sev bleeding,C0036056;C3272372;C0011860;C0019080
pah mctd ctd other,C1335071;C1442905
death mi idr st or any timi bleeding,C0036056;C3272372;C0019080
selexipag,C2000145
death mi idr st or gusto moderate severe bleeding,C0036056;C3272372;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
age years geographic region,C1510829;C0017446
pah ctd,C1335071;C1442905
western europe australia,C0043128
pah ssc,C0030123;C3897657;C3203102;C4284467
time since diagnosis of pah years,C0556970;C0011900;C1704338;C1704656
pah sle,C0030123;C0024141;C3203102;C4284467
use of medication for pah,C1524063;C0030123;C3203102;C4284467
pah mctd ctd other,C1335071;C1442905
era,C1521863;C3495919
selexipag,C2000145
pde $nmbr$ i,C0021966;C0221138
age years geographic region,C1510829;C0017446
era and pde $nmbr$ i,C1521863;C3495919;C0021966;C0221138
western europe australia,C0043128
other medications,C0013227;C0802604;C2598133;C4284232
time since diagnosis of pah years,C0556970;C0011900;C1704338;C1704656
immunosuppressants,C0021081
use of medication for pah,C1524063;C0030123;C3203102;C4284467
corticosteroids $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
era,C1521863;C3495919
placebo patients events n,C0032042;C0030705;C1696465;C1706408
pde $nmbr$ i,C0021966;C0221138
selexipag patients events n,C0030705;C0441471;C3541888
era and pde $nmbr$ i,C1521863;C3495919;C0021966;C0221138
overall study population,C0282416;C2348561;C1561607
other medications,C0013227;C0802604;C2598133;C4284232
overall ctd,C1335071;C1442905
immunosuppressants,C0021081
pah therapy at baseline,C0039798;C0087111;C1363945
corticosteroids $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
era monotherapy,C1521863;C3495919
placebo patients events n,C0032042;C0030705;C1696465;C1706408
pde $nmbr$ i monotherapy,C0021966;C0221138
selexipag patients events n,C0030705;C0441471;C3541888
no pah specific therapy,C0039798;C0087111;C1363945
overall study population,C0282416;C2348561;C1561607
ctd population subgroup,C1079230;C1515021
overall ctd,C1335071;C1442905
pooled pah mctd and pah,C0030123;C0026272;C3203102;C4284467
pah therapy at baseline,C0039798;C0087111;C1363945
years since pd diagnosis mean sd,C0439234;C0011900;C1704338;C1704656
era monotherapy,C1521863;C3495919
duration of disease n,C0872146
pde $nmbr$ i monotherapy,C0021966;C0221138
hoehn yahr stage on n,C0205390;C1300072;C1306673
no pah specific therapy,C0039798;C0087111;C1363945
hoehn yahr stage off n,C0205390;C1300072;C1306673
ctd population subgroup,C1079230;C1515021
levodopa dose mean sd mg day,C0023570;C0439422
pooled pah mctd and pah,C0030123;C0026272;C3203102;C4284467
concomitant pd medications at baseline n c d,C0013227;C0802604;C2598133;C4284232
years since pd diagnosis mean sd,C0439234;C0011900;C1704338;C1704656
tertiary amines,C3653356
duration of disease n,C0872146
dopa and dopa derivativese,C0013023
hoehn yahr stage on n,C0205390;C1300072;C1306673
adamantane derivatives,C3653470
hoehn yahr stage off n,C0205390;C1300072;C1306673
entacapone,C0165921
levodopa dose mean sd mg day,C0023570;C0439422
monoamine oxidase b inhibitors,C2917290;C3653412
concomitant pd medications at baseline n c d,C0013227;C0802604;C2598133;C4284232
daily off time mean sd h dayf,C0332173;C0033727;C0369286;C0441932;C0564385;C4528284
tertiary amines,C3653356
mean sd baseline score,C3533236;C0168634;C1442488
dopa and dopa derivativese,C0013023
mean sd change from,C0392747;C0443172;C1705241;C4319952
adamantane derivatives,C3653470
ls mean [ $nmbr$ ci] treatment difference vs placebo,C0444504;C2347634;C2348143;C0008107;C3259781;C1705241;C1705242;C0032042;C1696465;C1706408
entacapone,C0165921
p value ancova treatment difference a,C1705241;C1705242
monoamine oxidase b inhibitors,C2917290;C3653412
baseline to eom placebo n $nmbr$,C0168634;C1442488
daily off time mean sd h dayf,C0332173;C0033727;C0369286;C0441932;C0564385;C4528284
number of off periods,C0237753;C0449788;C0439531;C1948053
mean sd baseline score,C3533236;C0168634;C1442488
absolute time spent on h day,C0439546;C0680968;C0033727;C0369286;C0441932;C0564385;C4528284
mean sd change from,C0392747;C0443172;C1705241;C4319952
absolute time spent on without troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
ls mean [ $nmbr$ ci] treatment difference vs placebo,C0444504;C2347634;C2348143;C0008107;C3259781;C1705241;C1705242;C0032042;C1696465;C1706408
absolute time spent on with troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
p value ancova treatment difference a,C1705241;C1705242
patient status after wake up of days patient woke,C0449437;C1170730;C0442696;C0585034
baseline to eom placebo n $nmbr$,C0168634;C1442488
off,
number of off periods,C0237753;C0449788;C0439531;C1948053
on without troublesome dyskinesia,C0013384
absolute time spent on h day,C0439546;C0680968;C0033727;C0369286;C0441932;C0564385;C4528284
on with troublesome dyskinesia,C0013384
absolute time spent on without troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
updrs iii motor,C1513492;C1705994
absolute time spent on with troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
overall $nmbr$ $nmbr$,C0282416;C1561607
patient status after wake up of days patient woke,C0449437;C1170730;C0442696;C0585034
with ckd $nmbr$,C1561643
off,
without ckd $nmbr$,C1561643
on without troublesome dyskinesia,C0013384
mean or n,C0444504;C2347634;C2348143;C0369718;C0441922
on with troublesome dyskinesia,C0013384
sd or,C2699239
updrs iii motor,C1513492;C1705994
latin,
overall $nmbr$ $nmbr$,C0282416;C1561607
urine acr mg g,C0042036;C1300563;C0042037;C2963137
with ckd $nmbr$,C1561643
median urine acr mg g iqr,C0042036;C1300563;C0042037;C2963137
without ckd $nmbr$,C1561643
median fasting serum glucose mg dl iqr,C0202041;C0439269;C3534430
mean or n,C0444504;C2347634;C2348143;C0369718;C0441922
glycemic status,C0449438
sd or,C2699239
prior dm,C0011816;C3250443
latin,
new dm,C0011816;C3250443
urine acr mg g,C0042036;C1300563;C0042037;C2963137
igt ifg,C1334085;C1708411
median urine acr mg g iqr,C0042036;C1300563;C0042037;C2963137
other glucose status,C0017725;C0449438
median fasting serum glucose mg dl iqr,C0202041;C0439269;C3534430
dcct a $nmbr$ c,
glycemic status,C0449438
duration dm in dm years,C0011816;C0439234;C3250443
prior dm,C0011816;C3250443
pulse pressure mm hg,C0949236;C0439475
new dm,C0011816;C3250443
median pulse pressure mm hg iqr,C0949236;C0439475
igt ifg,C1334085;C1708411
n $nmbr$ fatty acids,C0369718;C0015684;C0441922
other glucose status,C0017725;C0449438
dcct a $nmbr$ c,
previous cv event,C0441471;C4019010
other drugs,C0013227;C3687832
duration dm in dm years,C0011816;C0439234;C3250443
no glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
pulse pressure mm hg,C0949236;C0439475
other bp drug,C0013227;C1254351
median pulse pressure mm hg iqr,C0949236;C0439475
median tg iqr,C0549183;C0337445;C0876920;C2347635;C2348144;C2939193
n $nmbr$ fatty acids,C0369718;C0015684;C0441922
ckd rate events,C0441471;C3541888
previous cv event,C0441471;C4019010
no ckd rate events,C0441471;C3541888
other drugs,C0013227;C3687832
cv death non fatal mi or non fatal stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
no glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
secondary outcome,C0027627;C1274040;C0175668;C0205436
other bp drug,C0013227;C1254351
median tg iqr,C0549183;C0337445;C0876920;C2347635;C2348144;C2939193
non fatal mi,C1302234;C3810814;C1705232
stroke any,C0038454;C4554100
ckd rate events,C0441471;C3541888
no ckd rate events,C0441471;C3541888
stroke non fatal,C0038454;C4554100;C1518422;C1302234;C1705232
cardiovascular,C0007226;C3887460
cv death non fatal mi or non fatal stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
primary outcome plus revascularization or nonfatal hf,C0205225;C1274040;C0439612;C0439631;C0018488;C1313497;C1538440;C3273279
secondary outcome,C0027627;C1274040;C0175668;C0205436
non fatal mi,C1302234;C3810814;C1705232
major coronary disease event fatal non fatal mi,C0741923;C3810814
stroke any,C0038454;C4554100
ckd n,C1561643
stroke non fatal,C0038454;C4554100;C1518422;C1302234;C1705232
no ckd n,C1561643
cardiovascular,C0007226;C3887460
$nmbr$ yrs or more,
diabetes melitus,C0011847;C0011849
primary outcome plus revascularization or nonfatal hf,C0205225;C1274040;C0439612;C0439631;C0018488;C1313497;C1538440;C3273279
treatment glargine,C0039798;C0907402;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
major coronary disease event fatal non fatal mi,C0741923;C3810814
socalone n $nmbr$,
ckd n,C1561643
evolocumab soc n $nmbr$,C3529352
no ckd n,C1561643
type $nmbr$ diabetes mellitus $nmbr$,C1320657
$nmbr$ yrs or more,
high risk of diabetes,C0332167
diabetes melitus,C0011847;C0011849
treatment glargine,C0039798;C0907402;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
cerebrovascular or peripheral arterial disease,C1880018;C0085096;C1704436
socalone n $nmbr$,
ldl cholesterol mmol l,C0023824;C1532563;C0202117
evolocumab soc n $nmbr$,C3529352
fasting plasma glucose mmol l $nmbr$,C0202042;C1532563;C0455280
type $nmbr$ diabetes mellitus $nmbr$,C1320657
fasting plasma glucose mg dl $nmbr$,C0202042;C0439269;C0455280
high risk of diabetes,C0332167
ldl c in mmol l baseline mean sd [n] wk $nmbr$ and change mean se [n],C1532563;C0168634;C1442488;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
cerebrovascular or peripheral arterial disease,C1880018;C0085096;C1704436
fasting plasma glucose in mmol l median q $nmbr$ q $nmbr$ [n],C0583513;C1532563
ldl cholesterol mmol l,C0023824;C1532563;C0202117
hba $nmbr$ c in median q $nmbr$ q $nmbr$ [n],C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
fasting plasma glucose mmol l $nmbr$,C0202042;C1532563;C0455280
weight in kg baseline mean sd [n] wk $nmbr$ and change mean se [n],C0022718;C1303013;C0439209;C4054209;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
fasting plasma glucose mg dl $nmbr$,C0202042;C0439269;C0455280
soc,
ldl c in mmol l baseline mean sd [n] wk $nmbr$ and change mean se [n],C1532563;C0168634;C1442488;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
evomab soc,
fasting plasma glucose in mmol l median q $nmbr$ q $nmbr$ [n],C0583513;C1532563
change to week $nmbr$,C0392747;C0443172;C1705241;C4319952
[ $nmbr$ [,
hba $nmbr$ c in median q $nmbr$ q $nmbr$ [n],C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
ldl c in mmol l mean sd for baseline [n] mean se for week $nmbr$ [n],C1532563;C0444504;C2347634;C2348143;C0168634;C1442488;C0369718;C0441922;C0036919;C0332174;C0439230
weight in kg baseline mean sd [n] wk $nmbr$ and change mean se [n],C0022718;C1303013;C0439209;C4054209;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
any placebo,C0032042;C1696465;C1706408
soc,
ezetimibe,C1142985
evomab soc,
evomab,
change to week $nmbr$,C0392747;C0443172;C1705241;C4319952
[ $nmbr$,
[ $nmbr$ [,
high risk for diabetes,C0332167;C3272283;C4050568;C4319571
ldl c in mmol l mean sd for baseline [n] mean se for week $nmbr$ [n],C1532563;C0444504;C2347634;C2348143;C0168634;C1442488;C0369718;C0441922;C0036919;C0332174;C0439230
enrolled into osler,C4684790
any placebo,C0032042;C1696465;C1706408
did not enrol into osler,C1518422
ezetimibe,C1142985
gly $nmbr$ $nmbr$ pg b i d n $nmbr$,C2827928
evomab,
[ $nmbr$,
severity of copda airflow limitation n,C0439793;C0522510
high risk for diabetes,C0332167;C3272283;C4050568;C4319571
severity of copda combined assessment of copd n,C0439793;C0522510
enrolled into osler,C4684790
gold b,C0018026;C1304897
did not enrol into osler,C1518422
gold d,C0018026;C1304897
gly $nmbr$ $nmbr$ pg b i d n $nmbr$,C2827928
discontinuation of lama prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
severity of copda airflow limitation n,C0439793;C0522510
discontinuation of ics laba prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
severity of copda combined assessment of copd n,C0439793;C0522510
sgrq total score,C2964552
gold b,C0018026;C1304897
cat score,C0449820;C4050231
gold d,C0018026;C1304897
pre bronchodilator fev i l,C2599602;C0021966;C0221138
discontinuation of lama prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
post bronchodilator fevx l,C2599594
discontinuation of ics laba prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
post bronchodilator fev i reversibility b,C2599594;C0021966;C0221138
sgrq total score,C2964552
fev auc i $nmbr$ h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
cat score,C0449820;C4050231
ics use yes,C1549445;C1705108;C1710701
pre bronchodilator fev i l,C2599602;C0021966;C0221138
ics use no,C0042153;C0457083;C1947944
post bronchodilator fevx l,C2599594
tiotropium group n $nmbr$,C0213771;C0441848
post bronchodilator fev i reversibility b,C2599594;C0021966;C0221138
former smoking,C0037369;C0453996;C1881674
fev auc i $nmbr$ h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
smoking index pack yr,C0037369;C0439234;C0453996;C1881674
ics use yes,C1549445;C1705108;C1710701
duration of copd days^,C0449238;C2926735
ics use no,C0042153;C0457083;C1947944
previous respiratory disease other than copd no,C0035204;C0035242
tiotropium group n $nmbr$,C0213771;C0441848
previous medication for respiratory disease no,C0418986
former smoking,C0037369;C0453996;C1881674
traditional chinese medicine for respiratory disease no,C0025124;C1515884
smoking index pack yr,C0037369;C0439234;C0453996;C1881674
spirometric values at baseline,C0042295;C0168634;C1442488
duration of copd days^,C0449238;C2926735
before bronchodilator use,C0042153;C0457083;C1947944
previous respiratory disease other than copd no,C0035204;C0035242
after bronchodilator use,C0042153;C0457083;C1947944
previous medication for respiratory disease no,C0418986
airflow reversibility no,C0231999;C0449261
traditional chinese medicine for respiratory disease no,C0025124;C1515884
gold stage no,C0205390;C1300072;C1306673
spirometric values at baseline,C0042295;C0168634;C1442488
cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
before bronchodilator use,C0042153;C0457083;C1947944
mmrc dyspnea scale score t t,C0013404;C4049715;C1963100
after bronchodilator use,C0042153;C0457083;C1947944
ccq score,C0449820;C4050231
airflow reversibility no,C0231999;C0449261
follow up,C0589120;C1522577;C1704685;C3274571
gold stage no,C0205390;C1300072;C1306673
cat,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
difference tiotropium placebo ml $nmbr$ ci,C0008107;C3259781
mmrc dyspnea scale score t t,C0013404;C4049715;C1963100
pre bronchodilation fev $nmbr$,C0439566;C3714541
ccq score,C0449820;C4050231
month $nmbr$,C0332177;C0439231
follow up,C0589120;C1522577;C1704685;C3274571
post bronchodilation fev $nmbr$,C0439576;C3714541
cat,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
pre bronchodilation fvc,C0439566;C3714541
difference tiotropium placebo ml $nmbr$ ci,C0008107;C3259781
post bronchodilation fvc,C0439576;C3714541
pre bronchodilation fev $nmbr$,C0439566;C3714541
table $nmbr$ baseline characteristics of early dmard naive patients with ra participating in the swefot trial,C4684572;C3538806;C4048756;C0679823;C0008976
month $nmbr$,C0332177;C0439231
post bronchodilation fev $nmbr$,C0439576;C3714541
patients with available bmi for univariate analyses or with all data available for the multivariate model did not differ from the original swefot trial population proportions n were compared with pearson s $nmbr$ continuous variables medians iqr were compared with independent samples mann whitney u tests all patients who originally participated in the swefot missing data were as follows in number n bmi $nmbr$ smoking status $nmbr$ rf status $nmbr$ anti acpa status $nmbr$ concurrent prednisolone use $nmbr$ haq $nmbr$ univariate model where the das $nmbr$ at $nmbr$ months and baseline bmi were required missing data n were as follows smoking status $nmbr$ rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ and haq $nmbr$ multivariate model shown in table $nmbr$ and gure $nmbr$ a missing data points n were as follows rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ acpa anticitrullinated protein antibody bmi body mass index das $nmbr$ $nmbr$ joint count disease activity score dmard disease modifying rheumatic drug haq health assessment questionnaire ra rheumatoid arthritis rf rheumatoid factor swefot swedish pharmacotherapy trial,C0030705;C0470187;C0683962;C1511726;C3245479;C3714741;C3161035;C3274659;C3714583;C3853906;C1518422;C0008976;C0032659;C1257890;C1707455;C0549178;C0439828;C0242927;C3272598;C4684714;C1519386;C0035448;C0201660;C0748398;C1547111;C0051767;C0057671;C0439231;C0168634;C0578022;C1442488;C1514873;C0332283;C1719822;C4281991;C0042153;C0457083;C1947944;C1547282;C0039224;C1706074;C1552961;C2347617;C3714763;C1537044;C1954799;C0392747;C0304229
pre bronchodilation fvc,C0439566;C3714541
swefot n $nmbr$,
post bronchodilation fvc,C0439576;C3714541
univariatet n $nmbr$,
table $nmbr$ baseline characteristics of early dmard naive patients with ra participating in the swefot trial,C4684572;C3538806;C4048756;C0679823;C0008976
multivariate^ n $nmbr$,
proportions n,C1709707
patients with available bmi for univariate analyses or with all data available for the multivariate model did not differ from the original swefot trial population proportions n were compared with pearson s $nmbr$ continuous variables medians iqr were compared with independent samples mann whitney u tests all patients who originally participated in the swefot missing data were as follows in number n bmi $nmbr$ smoking status $nmbr$ rf status $nmbr$ anti acpa status $nmbr$ concurrent prednisolone use $nmbr$ haq $nmbr$ univariate model where the das $nmbr$ at $nmbr$ months and baseline bmi were required missing data n were as follows smoking status $nmbr$ rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ and haq $nmbr$ multivariate model shown in table $nmbr$ and gure $nmbr$ a missing data points n were as follows rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ acpa anticitrullinated protein antibody bmi body mass index das $nmbr$ $nmbr$ joint count disease activity score dmard disease modifying rheumatic drug haq health assessment questionnaire ra rheumatoid arthritis rf rheumatoid factor swefot swedish pharmacotherapy trial,C0030705;C0470187;C0683962;C1511726;C3245479;C3714741;C3161035;C3274659;C3714583;C3853906;C1518422;C0008976;C0032659;C1257890;C1707455;C0549178;C0439828;C0242927;C3272598;C4684714;C1519386;C0035448;C0201660;C0748398;C1547111;C0051767;C0057671;C0439231;C0168634;C0578022;C1442488;C1514873;C0332283;C1719822;C4281991;C0042153;C0457083;C1947944;C1547282;C0039224;C1706074;C1552961;C2347617;C3714763;C1537044;C1954799;C0392747;C0304229
obese bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
swefot n $nmbr$,
overweight bmi $nmbr$ $nmbr$ $nmbr$,C0497406;C0578022
univariatet n $nmbr$,
normal bmi,C4229017
multivariate^ n $nmbr$,
acpa positive,C0439178;C1446409;C1514241;C2825490;C3812269
proportions n,C1709707
concurrent prednisolone,C0205420;C0032950
obese bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
medians iqr,C0549183
overweight bmi $nmbr$ $nmbr$ $nmbr$,C0497406;C0578022
symptom duration months,C0449238;C0439231;C2926735
normal bmi,C4229017
haq score,C0449820;C4050231
acpa positive,C0439178;C1446409;C1514241;C2825490;C3812269
ticagrelor $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
concurrent prednisolone,C0205420;C0032950
multivessel coronary artery disease no total no,C0010054;C0010068;C1956346;C0439175;C0439810
medians iqr,C0549183
history of pci no total no t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439175;C0439810;C2603360
symptom duration months,C0449238;C0439231;C2926735
$nmbr$ prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
haq score,C0449820;C4050231
qualifying events,C1514624;C0441471;C3541888
ticagrelor $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
years since myocardial infarction,C0439234;C0027051;C0428953;C2926063;C3810814;C4552959
multivessel coronary artery disease no total no,C0010054;C0010068;C1956346;C0439175;C0439810
type of myocardial infarction no,C0332307;C1547052
history of pci no total no t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439175;C0439810;C2603360
unknown type,C0332307;C1547052
$nmbr$ prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
medication at enrollment no,C0013227;C3244316;C4284232
qualifying events,C1514624;C0441471;C3541888
aspirin at any dose,C4696290
years since myocardial infarction,C0439234;C0027051;C0428953;C2926063;C3810814;C4552959
year from randomization,C0439234;C0439508
type of myocardial infarction no,C0332307;C1547052
first year,C0439234;C0439508
unknown type,C0332307;C1547052
chd death,C0011065;C1306577;C4082313;C4552775
medication at enrollment no,C0013227;C3244316;C4284232
second year,C0439234;C0439508
aspirin at any dose,C4696290
third yeart,C0205437
year from randomization,C0439234;C0439508
chd disease death,C0011065;C1306577;C4082313;C4552775
first year,C0439234;C0439508
placebo km,C0032042;C3887676;C1696465;C1706408
chd death,C0011065;C1306577;C4082313;C4552775
ticagrelor $nmbr$ mg km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
second year,C0439234;C0439508
cv death myocardial infarction stroke,C0038454;C4554100
third yeart,C0205437
timi major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
chd disease death,C0011065;C1306577;C4082313;C4552775
sotagliflozin n $nmbr$,C3896939
placebo km,C0032042;C3887676;C1696465;C1706408
race or ethnic group no white,C0034510;C1706779;C3853635;C0015031;C1879937;C0007457;C0043157;C0220938
ticagrelor $nmbr$ mg km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
native american or alaska native,C0282204;C1515945;C0682125
cv death myocardial infarction stroke,C0038454;C4554100
bmij,
timi major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
bmi $nmbr$ no,C0578022
sotagliflozin n $nmbr$,C3896939
systolic blood pressure $nmbr$ mm hg no,C0488055;C0439475;C0871470;C1306620
race or ethnic group no white,C0034510;C1706779;C3853635;C0015031;C1879937;C0007457;C0043157;C0220938
daily total dose of insulin lu kg,C2348070
native american or alaska native,C0282204;C1515945;C0682125
insulin dose lu day,C0332173;C0439228;C0439505
bmij,
basal,C0205112
bmi $nmbr$ no,C0578022
bolus and corrections,C1186706;C1511237;C1705509;C3812160;C1705565;C1947976
systolic blood pressure $nmbr$ mm hg no,C0488055;C0439475;C0871470;C1306620
type of insulin therapy no $nmbr$,C0457592;C0039798;C0087111;C1363945
daily total dose of insulin lu kg,C2348070
subcutaneous injections,C0021499
insulin dose lu day,C0332173;C0439228;C0439505
pump,C0182537
basal,C0205112
sotagliflozin,C3896939
bolus and corrections,C1186706;C1511237;C1705509;C3812160;C1705565;C1947976
difference $nmbr$ cl,C1705241;C0596019;C1705242
type of insulin therapy no $nmbr$,C0457592;C0039798;C0087111;C1363945
no totalno,
subcutaneous injections,C0021499
percentage points,C1552961;C2347617;C3714763
pump,C0182537
patients with glycated hemoglobin,C0030705;C0017853
sotagliflozin,C3896939
patients who used insulin pump,C0030705;C1140609
difference $nmbr$ cl,C1705241;C0596019;C1705242
patients who did not use insulin pump,C0030705;C3272598;C1140609
no totalno,
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode of severe hypoglycemia,C0030705;C0017853;C0332189;C0020615;C4553659
percentage points,C1552961;C2347617;C3714763
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode ofdiabetic ketoacidosis,C0030705;C0017853;C0022638;C0220982
patients with glycated hemoglobin,C0030705;C0017853
randomization groups $nmbr$ and $nmbr$,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
patients who used insulin pump,C0030705;C1140609
pfo closure group n $nmbr$,C0185003;C0441848;C1521802
patients who did not use insulin pump,C0030705;C3272598;C1140609
antiplatelet only group n $nmbr$,C0441848
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode of severe hypoglycemia,C0030705;C0017853;C0332189;C0020615;C4553659
anticoagulant group n $nmbr$,C0003280;C0441848;C0848112;C3536711
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode ofdiabetic ketoacidosis,C0030705;C0017853;C0022638;C0220982
antiplatelet onl group n $nmbr$,C0441848
randomization groups $nmbr$ and $nmbr$,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
body mass index $nmbr$ no f,C0005893;C0578022;C1305855;C0016327
pfo closure group n $nmbr$,C0185003;C0441848;C1521802
oral contraceptive pills no total no,C0009905;C0009906;C0029151;C0439175;C0439810
antiplatelet only group n $nmbr$,C0441848
migraine no,C0149931
anticoagulant group n $nmbr$,C0003280;C0441848;C0848112;C3536711
stroke no,C0038454;C4554100
antiplatelet onl group n $nmbr$,C0441848
myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
body mass index $nmbr$ no f,C0005893;C0578022;C1305855;C0016327
deep vein thrombosis or pulmonary embolism no,C0149871;C0034065
oral contraceptive pills no total no,C0009905;C0009906;C0029151;C0439175;C0439810
qualifying event no,C1514624;C0441471;C4019010
migraine no,C0149931
carotid infarct,C0741968;C0021308
stroke no,C0038454;C4554100
vertebrobasilar infarct,C0545733;C0021308
myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
modified rankin scale no,C2984908;C3854213
deep vein thrombosis or pulmonary embolism no,C0149871;C0034065
rope score,C0449820;C4050231
qualifying event no,C1514624;C0441471;C4019010
septal anomaly no,C0332447;C1704258
carotid infarct,C0741968;C0021308
pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
vertebrobasilar infarct,C0545733;C0021308
pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
modified rankin scale no,C2984908;C3854213
pfo with mild to moderate shunt and atrial septal aneurysm,C1299392;C0232180;C0542331;C1442858;C0521533
rope score,C0449820;C4050231
pfo closure,C0185003;C1521802
septal anomaly no,C0332447;C1704258
antiplatelet therapy,C1096021
pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
no of strokes,C0038454
pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
age at randomisation,C0001779;C0034656
pfo with mild to moderate shunt and atrial septal aneurysm,C1299392;C0232180;C0542331;C1442858;C0521533
patent foramen ovale,C0016522;C0344724
pfo closure,C0185003;C1521802
large shunt,C0232180;C0542331;C1442858
antiplatelet therapy,C1096021
pfo asa,C0004057;C3853627
no of strokes,C0038454
usual care n $nmbr$,C3538928;C1947933
age at randomisation,C0001779;C0034656
fluticasone furoate and vilanterol n $nmbr$,C1948374;C2935023
patent foramen ovale,C0016522;C0344724
body mass index $nmbr$ kg nrn,C0005893;C1425210;C0578022;C1305855
large shunt,C0232180;C0542331;C1442858
asthma control test score at baseline,C2733224;C0168634;C1442488
pfo asa,C0004057;C3853627
duration of asthma $nmbr$ years,C0449238;C2926735
usual care n $nmbr$,C3538928;C1947933
daytime symptoms more than twice per week,C0683368;C1457887;C1720725;C1948050;C0332174;C0439230
fluticasone furoate and vilanterol n $nmbr$,C1948374;C2935023
nocturnal symptoms in past week,C0683368;C1457887;C0332174;C0439230
body mass index $nmbr$ kg nrn,C0005893;C1425210;C0578022;C1305855
number of exacerbations $nmbr$ months before randomisation,C0237753;C0449788;C0034656
asthma control test score at baseline,C2733224;C0168634;C1442488
cardiac,C0018787;C1522601
duration of asthma $nmbr$ years,C0449238;C2926735
figure s $nmbr$ baseline subgroups and act scores at week $nmbr$ pea population,C0168634;C1079230;C1442488;C0449820;C0030738;C0069964;C0070939;C1262903;C3257529
daytime symptoms more than twice per week,C0683368;C1457887;C1720725;C1948050;C0332174;C0439230
baseline hba $nmbr$ c median $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
nocturnal symptoms in past week,C0683368;C1457887;C0332174;C0439230
ls mean $nmbr$ ci,C0008107;C3259781
number of exacerbations $nmbr$ months before randomisation,C0237753;C0449788;C0034656
ls mean $nmbr$ ci mmol mol,C0008107;C3829066;C3259781
cardiac,C0018787;C1522601
difference in ls mean vs placebo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
figure s $nmbr$ baseline subgroups and act scores at week $nmbr$ pea population,C0168634;C1079230;C1442488;C0449820;C0030738;C0069964;C0070939;C1262903;C3257529
difference in ls mean vs placebo $nmbr$ ci mmol mol,C1705241;C1705242;C0008107;C3829066;C3259781
baseline hba $nmbr$ c median $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
ls mean $nmbr$ ci,C0008107;C3259781
baseline hba $nmbr$ c $nmbr$ $nmbr$ to,C0168634;C0019016;C1825777;C3538758;C1442488
ls mean $nmbr$ ci mmol mol,C0008107;C3829066;C3259781
baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
difference in ls mean vs placebo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
pravastatin n $nmbr$,C0085542
difference in ls mean vs placebo $nmbr$ ci mmol mol,C1705241;C1705242;C0008107;C3829066;C3259781
control n $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
$nmbr$ month n $nmbr$,C0332177;C0439231
baseline hba $nmbr$ c $nmbr$ $nmbr$ to,C0168634;C0019016;C1825777;C3538758;C1442488
ischemic stroke subtype,C0948008;C0449560
baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
atherothrombotic stroke n,C0038454;C4554100
pravastatin n $nmbr$,C0085542
lacunar infarction n,C0333559
control n $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
undetermined etiology n,C0478157
$nmbr$ month n $nmbr$,C0332177;C0439231
use of antiplatelet agents n,C1524063;C0085826
ischemic stroke subtype,C0948008;C0449560
use of anti hypertensive agents n,C1524063;C0003364
atherothrombotic stroke n,C0038454;C4554100
incidence of each outcome,C0021149;C0220856
lacunar infarction n,C0333559
stroke and tia n,C0038454;C4554100;C0007787;C0917805;C1054154
undetermined etiology n,C0478157
incidence $nmbr$ person year,C0027361;C0439234;C0439508;C2347489
use of antiplatelet agents n,C1524063;C0085826
all strokes n,C0038454
use of anti hypertensive agents n,C1524063;C0003364
atherothrombotic infarction n,C0021308
incidence of each outcome,C0021149;C0220856
cardioembolic infarction n,C0021308
stroke and tia n,C0038454;C4554100;C0007787;C0917805;C1054154
intracranial hemorrhage n,C0151699;C4554169
incidence $nmbr$ person year,C0027361;C0439234;C0439508;C2347489
tia n,C0007787;C0917805;C1054154
all strokes n,C0038454
vascular accidents n,C0005847;C0000924;C1558950;C1801960
atherothrombotic infarction n,C0021308
death n,C0011065;C1306577;C4082313;C4552775
cardioembolic infarction n,C0021308
hospitalization n,C0019993
intracranial hemorrhage n,C0151699;C4554169
bmi kg m $nmbr$ median iqr,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
tia n,C0007787;C0917805;C1054154
patient s history of,C0030705;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
vascular accidents n,C0005847;C0000924;C1558950;C1801960
prior non haemorrhagic stroke,C0332152;C0553692;C2826257
death n,C0011065;C1306577;C4082313;C4552775
chronic obstructive pulmonary disease,C0024117
hospitalization n,C0019993
chronic renal disease,C0022661;C1561643
bmi kg m $nmbr$ median iqr,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
index event information,C0441471;C1533716;C4019010
patient s history of,C0030705;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
first medical contact in ambulance,C0332158;C0337611;C1705415;C3812666
prior non haemorrhagic stroke,C0332152;C0553692;C2826257
minutes from symptom onset to prehospital ecg median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
chronic obstructive pulmonary disease,C0024117
minutes from prehospital ecg to pci median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
chronic renal disease,C0022661;C1561643
minutes from pre pci angiography to post pci angiography median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0002978;C0549183;C0876920;C2347635;C2348144;C2939193
index event information,C0441471;C1533716;C4019010
received first loading dose,C0205435;C3714444;C1279901
first medical contact in ambulance,C0332158;C0337611;C1705415;C3812666
risk level at admission,C2923839;C0184666;C0809949
minutes from symptom onset to prehospital ecg median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
culprit vessel,C0005847
minutes from prehospital ecg to pci median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
left anterior descending artery,C0226032
minutes from pre pci angiography to post pci angiography median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0002978;C0549183;C0876920;C2347635;C2348144;C2939193
left circumflex,C0205091;C1880089;C0443246;C1552822
received first loading dose,C0205435;C3714444;C1279901
no culprit vessel identified,C0005847;C0205396;C1550043
risk level at admission,C2923839;C0184666;C0809949
normal coronary angiography,C0853522
culprit vessel,C0005847
femoral access,C0444454;C1554204
left anterior descending artery,C0226032
thromboaspiration,
left circumflex,C0205091;C1880089;C0443246;C1552822
with any stent,C0038257
no culprit vessel identified,C0005847;C0205396;C1550043
with des,C0011702;C4551552
no revascularisation,C0581603
normal coronary angiography,C0853522
femoral access,C0444454;C1554204
any glycoprotein iib iiia inhibitor use,C0042153;C0457083;C1947944
thromboaspiration,
glycoprotein iib iiia inhibitor use before angiography,C0042153;C0457083;C1947944
with any stent,C0038257
intravenous anticoagulant prior to pre pci angiography,C0003280;C0848112;C3536711
with des,C0011702;C4551552
intravenous anticoagulant during hospitalisation,C0003280;C0848112;C3536711
no revascularisation,C0581603
heparin only,C0019134;C0770546
any glycoprotein iib iiia inhibitor use,C0042153;C0457083;C1947944
bivalirudin only,C0168273
glycoprotein iib iiia inhibitor use before angiography,C0042153;C0457083;C1947944
pre hospital ticagrelor n $nmbr$,C0332152;C0019994;C1510665;C0740175;C2257086;C3669034
intravenous anticoagulant prior to pre pci angiography,C0003280;C0848112;C3536711
model n,C3161035;C3274659;C3714583;C3853906
intravenous anticoagulant during hospitalisation,C0003280;C0848112;C3536711
patients with endpoin t n,C0030705
heparin only,C0019134;C0770546
composite of death mi stro ke urgent revasc definit e acute stent thrombosis,C0205199;C1547335
bivalirudin only,C0168273
composite of death mi urg ent revasc,C0205199;C1547335
pre hospital ticagrelor n $nmbr$,C0332152;C0019994;C1510665;C0740175;C2257086;C3669034
nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038;C0750572
model n,C3161035;C3274659;C3714583;C3853906
urgent revascularizati on,C0439609;C3272275
patients with endpoin t n,C0030705
definite acute stent thrombosis,C0205178;C3897493
composite of death mi stro ke urgent revasc definit e acute stent thrombosis,C0205199;C1547335
acute stent thrombosis definite or probable,C0205178;C3897493;C0439544;C1704787;C0033204;C0332148
composite of death mi urg ent revasc,C0205199;C1547335
fig $nmbr$ acr $nmbr$ $nmbr$ and $nmbr$ response rates by baseline tnf status at weeks $nmbr$ $nmbr$ and $nmbr$,C1412134;C1515941;C0237629;C0168634;C1442488;C0439230
nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038;C0750572
fig $nmbr$ acr $nmbr$ acr $nmbr$ and acr $nmbr$ response rates by baseline mtx use at weeks $nmbr$ $nmbr$ and $nmbr$,C0349966;C1337208;C0237629;C0025677;C1417487;C0439230
urgent revascularizati on,C0439609;C3272275
placebo [n $nmbr$ ],C0032042;C1696465;C1706408;C0369718;C0441922
definite acute stent thrombosis,C0205178;C3897493
tofacitinib $nmbr$ mg bid [n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
acute stent thrombosis definite or probable,C0205178;C3897493;C0439544;C1704787;C0033204;C0332148
placebo [n $nmbr$,C0032042;C1696465;C1706408;C0369718;C0441922
fig $nmbr$ acr $nmbr$ $nmbr$ and $nmbr$ response rates by baseline tnf status at weeks $nmbr$ $nmbr$ and $nmbr$,C1412134;C1515941;C0237629;C0168634;C1442488;C0439230
age mean years [sd],C1510829;C0444504;C2347634;C2348143;C2699239
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
fig $nmbr$ acr $nmbr$ acr $nmbr$ and acr $nmbr$ response rates by baseline mtx use at weeks $nmbr$ $nmbr$ and $nmbr$,C0349966;C1337208;C0237629;C0025677;C1417487;C0439230
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$,
placebo [n $nmbr$ ],C0032042;C1696465;C1706408;C0369718;C0441922
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ a,
tofacitinib $nmbr$ mg bid [n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
gender n [ ] male,C0079399;C1522384;C0086582;C1706180;C1706428;C1706429
placebo [n $nmbr$,C0032042;C1696465;C1706408;C0369718;C0441922
$nmbr$ [ $nmbr$ $nmbr$,
age mean years [sd],C1510829;C0444504;C2347634;C2348143;C2699239
duration of disease median,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
years [range],C0439234;C1514721;C2348147;C3542016
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$,
previous anti tnf therapy n [ ],C0205156;C1552607
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ a,
$nmbr$ [ $nmbr$ $nmbr$ a,
gender n [ ] male,C0079399;C1522384;C0086582;C1706180;C1706428;C1706429
$nmbr$ [ $nmbr$ $nmbr$,
concomitant aminosalicylates n [ ] concomitant corticosteroids n [ ] mayo score mean [sd],C0521115;C0368663;C0001617;C3539185;C3540725;C3540726;C3540727;C0444504;C2347634;C2348143;C2699239
duration of disease median,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ _ $nmbr$ s,
years [range],C0439234;C1514721;C2348147;C3542016
ibdq total score mean [sd],C0444504;C2347634;C2348143;C2699239
previous anti tnf therapy n [ ],C0205156;C1552607
ibdq domain scores mean [sd],C0444504;C2347634;C2348143;C2699239
$nmbr$ [ $nmbr$ $nmbr$ a,
bowel function,C0011135
concomitant aminosalicylates n [ ] concomitant corticosteroids n [ ] mayo score mean [sd],C0521115;C0368663;C0001617;C3539185;C3540725;C3540726;C3540727;C0444504;C2347634;C2348143;C2699239
systemic symptoms,C0683368;C1457887
$nmbr$ _ $nmbr$ s,
emotional status,C0013987;C0449438;C0849912
ibdq total score mean [sd],C0444504;C2347634;C2348143;C2699239
social function,C0037395
ibdq domain scores mean [sd],C0444504;C2347634;C2348143;C2699239
sf $nmbr$ v $nmbr$ pcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
bowel function,C0011135
sf $nmbr$ v $nmbr$ mcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
systemic symptoms,C0683368;C1457887
sf $nmbr$ v $nmbr$ domain scores mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
emotional status,C0013987;C0449438;C0849912
physical function,C0516981;C4049916
social function,C0037395
role physical,C0035820;C0031809;C0205485;C1509143;C1705810;C3871154
sf $nmbr$ v $nmbr$ pcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
bodily pain,C3890602
sf $nmbr$ v $nmbr$ mcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
general health,C0424575;C4018875
sf $nmbr$ v $nmbr$ domain scores mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
vitality,C0424589
physical function,C0516981;C4049916
social functioning,C0037395
role physical,C0035820;C0031809;C0205485;C1509143;C1705810;C3871154
role emotional,C0035820;C0013987;C0849912;C1705810;C3871154
bodily pain,C3890602
mental health,C0025353
octave induction $nmbr$ and $nmbr$,C0205263;C0857127
general health,C0424575;C4018875
vitality,C0424589
ls mean change from baseline,C0392747;C0443172;C1705241;C4319952
social functioning,C0037395
in ibdq total score at week $nmbr$ mean [se],C2964552;C0036919
role emotional,C0035820;C0013987;C0849912;C1705810;C3871154
corticosteroid use at baseline,C0239126;C0168634;C1442488
mental health,C0025353
placebo n $nmbr$ i,C0021966;C0221138
octave induction $nmbr$ and $nmbr$,C0205263;C0857127
patient demographics age yr,C4698447;C0439234
ls mean change from baseline,C0392747;C0443172;C1705241;C4319952
disease characteristics duration of psoriatic arthritis yr,C0872146;C0003872
in ibdq total score at week $nmbr$ mean [se],C2964552;C0036919
$nmbr$ $nmbr$ o $nmbr$,C0483204
corticosteroid use at baseline,C0239126;C0168634;C1442488
leeds enthesitis index^ score $nmbr$ no,C0449820;C4050231
placebo n $nmbr$ i,C0021966;C0221138
dactylitis severity score score $nmbr$ no,C0239161;C0457451
patient demographics age yr,C4698447;C0439234
swollen joint count of $nmbr$ joints assessed no,C0451521;C1516048
disease characteristics duration of psoriatic arthritis yr,C0872146;C0003872
tender or painful joint count of $nmbr$ joints assessed no,C0234234;C0750480;C1705566;C1516048
$nmbr$ $nmbr$ o $nmbr$,C0483204
elevated high sensitivity crp no,C0742906;C1441604
leeds enthesitis index^ score $nmbr$ no,C0449820;C4050231
affected body surface area $nmbr$ no,C0005902;C1879646
dactylitis severity score score $nmbr$ no,C0239161;C0457451
median pasi score range i i,C0021966;C0221138
swollen joint count of $nmbr$ joints assessed no,C0451521;C1516048
day $nmbr$ oral glucocorticoid use no,C1527415;C0017710
tender or painful joint count of $nmbr$ joints assessed no,C0234234;C0750480;C1705566;C1516048
concomitant use of conventional synthetic dmard up to $nmbr$ mo no methotrexate,C1524063;C0242708;C0026544;C0332177;C0025677
elevated high sensitivity crp no,C0742906;C1441604
leflunomide,C0063041
otherj^,
affected body surface area $nmbr$ no,C0005902;C1879646
methotrexate dose on day $nmbr$ mg per wl,C4086581
median pasi score range i i,C0021966;C0221138
no of previous tne inhibitors,C0205156;C0243077;C1552607
day $nmbr$ oral glucocorticoid use no,C1527415;C0017710
previous use of other biologic agents in addition to tne,C1524063;C0005515;C3896585
concomitant use of conventional synthetic dmard up to $nmbr$ mo no methotrexate,C1524063;C0242708;C0026544;C0332177;C0025677
inhibitors no se $nmbr$ physical functioning score^^,C0243077;C4483112
leflunomide,C0063041
otherj^,
eacit e total score,C2964552
methotrexate dose on day $nmbr$ mg per wl,C4086581
figure s $nmbr$ american college of rheumatology $nmbr$ response rate and change from baseline in health assessment questionnaire disability index at month $nmbr$ by number of prior tnfi inadequate responses,C0035452;C0237629;C0392747;C0443172;C1705241;C4319952;C4321476;C0332177;C0439231;C0237753;C0449788
no of previous tne inhibitors,C0205156;C0243077;C1552607
high sensitivity c reactive protein stratification,C0006560;C1514983;C1413716;C4048285
previous use of other biologic agents in addition to tne,C1524063;C0005515;C3896585
$nmbr$ to $nmbr$ mg l n $nmbr$,C0439268
inhibitors no se $nmbr$ physical functioning score^^,C0243077;C4483112
$nmbr$ mg l n $nmbr$,C0439268
eacit e total score,C2964552
high sensitivity c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
figure s $nmbr$ american college of rheumatology $nmbr$ response rate and change from baseline in health assessment questionnaire disability index at month $nmbr$ by number of prior tnfi inadequate responses,C0035452;C0237629;C0392747;C0443172;C1705241;C4319952;C4321476;C0332177;C0439231;C0237753;C0449788
coronary bypass surgery,C0010055
high sensitivity c reactive protein stratification,C0006560;C1514983;C1413716;C4048285
glycated haemoglobin,C0017853
$nmbr$ to $nmbr$ mg l n $nmbr$,C0439268
triglyceride mg dl,C0041004;C0439269
$nmbr$ mg l n $nmbr$,C0439268
index acs,C0742343;C4318612
high sensitivity c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
major adverse cardiovascular events,C0877248;C1705413
coronary bypass surgery,C0010055
death from cardiovascular causes,C0007465;C0007226;C3887460
glycated haemoglobin,C0017853
urgent revascularization because of unstable angina,C0581603;C0002965
triglyceride mg dl,C0041004;C0439269
central illustration dual antiplatelet therapy with complex lesions cumulative incidence of endpoint events from $nmbr$ to $nmbr$ months after randomization,C0205173;C1096021;C1554184;C0439231;C0034656
index acs,C0742343;C4318612
the endpoint events were strati ed by randomized treatment arm and number of anatomical complexity characteristics outcomes were analyzed comparing randomized treatments among subgroups of subjects with $nmbr$ n $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$ or $nmbr$ or more n $nmbr$ anatomic complexity characteristics to assess whether treatment effects differed depending on the number of complexity factors,C0441471;C3541888;C3538926;C1522541;C0237753;C0449788;C0936012;C1707455;C0034656;C0087111;C3815594;C0369718;C0441922;C0220784;C1521970;C1516048;C1518681
major adverse cardiovascular events,C0877248;C1705413
calima japandhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$ y,C0178602;C0815320;C4551720;C2986497;C0005773
death from cardiovascular causes,C0007465;C0007226;C3887460
urgent revascularization because of unstable angina,C0581603;C0002965
calima overalldhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$,C0178602;C0815320;C4551720;C2986497;C0005773
central illustration dual antiplatelet therapy with complex lesions cumulative incidence of endpoint events from $nmbr$ to $nmbr$ months after randomization,C0205173;C1096021;C1554184;C0439231;C0034656
benralizumab q $nmbr$ w n $nmbr$,C2982078
age [years] median range,C0001779;C0439234;C1514721;C2348147;C3542016
the endpoint events were strati ed by randomized treatment arm and number of anatomical complexity characteristics outcomes were analyzed comparing randomized treatments among subgroups of subjects with $nmbr$ n $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$ or $nmbr$ or more n $nmbr$ anatomic complexity characteristics to assess whether treatment effects differed depending on the number of complexity factors,C0441471;C3541888;C3538926;C1522541;C0237753;C0449788;C0936012;C1707455;C0034656;C0087111;C3815594;C0369718;C0441922;C0220784;C1521970;C1516048;C1518681
$nmbr$ $nmbr$ e $nmbr$,
calima japandhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$ y,C0178602;C0815320;C4551720;C2986497;C0005773
body mass index [kg m $nmbr$ ] mean sd,C0005893;C0578022;C1305855;C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
calima overalldhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$,C0178602;C0815320;C4551720;C2986497;C0005773
time since asthma diagnosis [years] median range,C0040223;C3541383;C0439234;C1514721;C2348147;C3542016
benralizumab q $nmbr$ w n $nmbr$,C2982078
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e $nmbr$ $nmbr$,
age [years] median range,C0001779;C0439234;C1514721;C2348147;C3542016
oral corticosteroid use n,C1527415
$nmbr$ $nmbr$ e $nmbr$,
number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C0439231
body mass index [kg m $nmbr$ ] mean sd,C0005893;C0578022;C1305855;C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
ed visit related to exacerbation n,C0545082;C1512346;C2826704;C0439849;C0445223
time since asthma diagnosis [years] median range,C0040223;C3541383;C0439234;C1514721;C2348147;C3542016
hospitalisation related to exacerbation n,C0019993;C0439849;C0445223
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e $nmbr$ $nmbr$,
fev $nmbr$ prebronchodilator [l] mean sd,C3714541;C2599602;C0439394;C1706495;C3642217;C0444504;C2699239;C2347634;C2348143
oral corticosteroid use n,C1527415
fev $nmbr$ prebronchodilator [ pn] mean sd,C3714541;C2599602;C0219433;C1549735;C3541307;C4049640;C4049767;C0444504;C2699239;C2347634;C2348143
number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C0439231
fev $nmbr$ fvc prebronchodilator mean sd,C0444504;C2699239;C2347634;C2348143
ed visit related to exacerbation n,C0545082;C1512346;C2826704;C0439849;C0445223
reversibility [ ] median range,C0449261;C1514721;C2348147;C3542016
hospitalisation related to exacerbation n,C0019993;C0439849;C0445223
total asthma symptom score mean sdz,C3533163;C0004096;C2984299
fev $nmbr$ prebronchodilator [l] mean sd,C3714541;C2599602;C0439394;C1706495;C3642217;C0444504;C2699239;C2347634;C2348143
local eosinophil count [cells ml] median range,C0200638;C0750879;C2699156;C1514721;C2348147;C3542016
fev $nmbr$ prebronchodilator [ pn] mean sd,C3714541;C2599602;C0219433;C1549735;C3541307;C4049640;C4049767;C0444504;C2699239;C2347634;C2348143
calima japan n $nmbr$,C0022341
fev $nmbr$ fvc prebronchodilator mean sd,C0444504;C2699239;C2347634;C2348143
calima overall n $nmbr$,C0282416;C1561607
reversibility [ ] median range,C0449261;C1514721;C2348147;C3542016
benralizumab,C2982078
total asthma symptom score mean sdz,C3533163;C0004096;C2984299
q $nmbr$ w n $nmbr$,
local eosinophil count [cells ml] median range,C0200638;C0750879;C2699156;C1514721;C2348147;C3542016
number of exacerbations in the last $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
calima japan n $nmbr$,C0022341
total asthma symptom score mean sd,C3533163;C2699239
calima overall n $nmbr$,C0282416;C1561607
local eosinophil count [cells l] median range,C0200638;C0750879;C0347983;C1514721;C2348147;C3542016
benralizumab,C2982078
japanese subgroup n $nmbr$,C0376247;C1079230;C1515021;C1556094
q $nmbr$ w n $nmbr$,
any ae n,C3887670
number of exacerbations in the last $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
aes in $nmbr$ japanese patients in a study arm n,C1412268;C2699274;C0557651;C0446516;C3715044;C4553528;C2603343
total asthma symptom score mean sd,C3533163;C2699239
bronchitis,C0006277
local eosinophil count [cells l] median range,C0200638;C0750879;C0347983;C1514721;C2348147;C3542016
allergic rhinitis,C1334103;C2607914;C4552864
japanese subgroup n $nmbr$,C0376247;C1079230;C1515021;C1556094
asthma,C0004096;C2984299
any ae n,C3887670
eczema,C0013595;C4553957
bacterial pneumonia,C0004626
aes in $nmbr$ japanese patients in a study arm n,C1412268;C2699274;C0557651;C0446516;C3715044;C4553528;C2603343
sinusitis,C0037199;C4553555
bronchitis,C0006277
urticaria,C0042109;C1559188
allergic rhinitis,C1334103;C2607914;C4552864
asthma,C0004096;C2984299
upper respiratory tract inflammation,C0877266
eczema,C0013595;C4553957
epistaxis,C0014591;C4554627
bacterial pneumonia,C0004626
dermatitis atopic,C0011603;C0392707
sinusitis,C0037199;C4553555
injection site reaction n,C0151735;C4551923
urticaria,C0042109;C1559188
hypersensitivity n,C0020517;C0520946
upper respiratory tract inflammation,C0877266
any drug related ae n,C0013227;C0439849;C0445223;C1254351
epistaxis,C0014591;C4554627
any ae leading to discontinuation n,C3887670;C0332152;C0457454;C1444662;C4552847;C1522538
dermatitis atopic,C0011603;C0392707
any serious ae n,C0205404;C3887670
injection site reaction n,C0151735;C4551923
deaths n,C0011065;C1306577
hypersensitivity n,C0020517;C0520946
low dose rivaroxaban aspirin n n,C2608320;C1739768
any drug related ae n,C0013227;C0439849;C0445223;C1254351
aspirin alone n n,C0004057;C0205171;C0439044;C0679994
any ae leading to discontinuation n,C3887670;C0332152;C0457454;C1444662;C4552847;C1522538
west europe,C1705493;C0015176
any serious ae n,C0205404;C3887670
east europe,C1707877;C0015176
deaths n,C0011065;C1306577
asia pacific and other,C0003980
low dose rivaroxaban aspirin n n,C2608320;C1739768
baseline diabetes,C0011847;C0011849
aspirin alone n n,C0004057;C0205171;C0439044;C0679994
no previous myocardial infarction $nmbr$ $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
west europe,C1705493;C0015176
history of pci ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
east europe,C1707877;C0015176
history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
asia pacific and other,C0003980
myocardial infarction cabg pci,C0027051;C4049621;C0428953;C2926063;C3810814;C4552959
baseline diabetes,C0011847;C0011849
baseline total cholesterol,C0201950;C0543421
no previous myocardial infarction $nmbr$ $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ mmol l,C1532563
history of pci ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
non smokers receiving lipid lowering drugs $nmbr$ blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
f emale,C0016327
myocardial infarction cabg pci,C0027051;C4049621;C0428953;C2926063;C3810814;C4552959
w est europe,C3811127;C0015176;C3890902
baseline total cholesterol,C0201950;C0543421
w hite,
$nmbr$ mmol l,C1532563
y es,C0013754;C0205944
non smokers receiving lipid lowering drugs $nmbr$ blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
non smokers receiving lipid lowering drugs p blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
f emale,C0016327
o $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0483204
w est europe,C3811127;C0015176;C3890902
timi risk scoret,C0035647;C4552904
w hite,
age categories n,C2916832
y es,C0013754;C0205944
bmi categories n,C0578022;C0683312
non smokers receiving lipid lowering drugs p blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
duration of type $nmbr$ diabetes categories n,C1547660;C1320657
o $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0483204
hba $nmbr$ c categories n,C0019016;C0683312;C1825777;C3538758
timi risk scoret,C0035647;C4552904
fasting plasma glucose categories n,C0202042;C0455280
age categories n,C2916832
metformin use n,C0025598;C0042153;C0457083;C1947944
bmi categories n,C0578022;C0683312
total daily insulin dose u,C2348070;C0439148
duration of type $nmbr$ diabetes categories n,C1547660;C1320657
insulin type n,C0457592
hba $nmbr$ c categories n,C0019016;C0683312;C1825777;C3538758
intermediate acting,C0205103;C1550465;C2827755;C3889971
fasting plasma glucose categories n,C0202042;C0455280
long acting,C0205166;C1706317
metformin use n,C0025598;C0042153;C0457083;C1947944
intermediate long acting fast acting,C0015663;C0456962;C2985769
total daily insulin dose u,C2348070;C0439148
long acting intermediate long acting fast acting,C0015663;C0456962;C2985769
insulin type n,C0457592
secondary cardiovascular endpoint,C4528314;C0007226;C3887460
intermediate acting,C0205103;C1550465;C2827755;C3889971
incidence rate per $nmbr$ person years,C1708485;C0027361;C2347489
long acting,C0205166;C1706317
canakinumab,C2718773
intermediate long acting fast acting,C0015663;C0456962;C2985769
sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
long acting intermediate long acting fast acting,C0015663;C0456962;C2985769
$nmbr$ sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
secondary cardiovascular endpoint,C4528314;C0007226;C3887460
pulse pressure mmhg,C0949236;C0439475
randomization to,C0034656
incidence rate per $nmbr$ person years,C1708485;C0027361;C2347489
canakinumab,C2718773
spironolactone n,C0037982
sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
nyha class iii or iv n,C1882086;C0022326;C4265176
$nmbr$ sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
enrolment through hf,C1516879;C1696073;C3888021
pulse pressure mmhg,C0949236;C0439475
hospitalization stratum n,C0019993
randomization to,C0034656
co morbidities n,C0009488
spironolactone n,C0037982
acei and or arb,C3888198
nyha class iii or iv n,C1882086;C0022326;C4265176
other anti hypertensive,C0003364
enrolment through hf,C1516879;C1696073;C3888021
medication,C0013227;C3244316;C4284232
hospitalization stratum n,C0019993
anti hypertensive,C0003364
co morbidities n,C0009488
laboratory testing,C0022885
acei and or arb,C3888198
rate ml min $nmbr$ $nmbr$ m $nmbr$,C0871208;C0439445;C1521828
other anti hypertensive,C0003364
haemoglobin mg dl,C0019046;C0439269
medication,C0013227;C3244316;C4284232
ecg and imaging data,C1623258;C1511726;C3245479;C3714741
anti hypertensive,C0003364
ecg left ventricular,C1623258;C0225897
laboratory testing,C0022885
hypertrophy n,C0020564
rate ml min $nmbr$ $nmbr$ m $nmbr$,C0871208;C0439445;C1521828
ecg atrial fibrillation n,C0004238;C0344434;C1963067
haemoglobin mg dl,C0019046;C0439269
composite endpoint,C2349179;C2826544
ecg and imaging data,C1623258;C1511726;C3245479;C3714741
event rate per $nmbr$ person years,C0871208;C1521828
ecg left ventricular,C1623258;C0225897
crude model hr $nmbr$ ci,C0008107;C3259781
hypertrophy n,C0020564
multivariable adjusted model hr $nmbr$ ci,C0008107;C3259781
ecg atrial fibrillation n,C0004238;C0344434;C1963067
recurrent hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
composite endpoint,C2349179;C2826544
hyperkalaemia,C0020461;C4552983
event rate per $nmbr$ person years,C0871208;C1521828
hypokalaemia,C0020621;C4553966
crude model hr $nmbr$ ci,C0008107;C3259781
doubling of creatinine,C0205173;C1705764
multivariable adjusted model hr $nmbr$ ci,C0008107;C3259781
ertugliflozin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
recurrent hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
medical history of cv disease or heart failure n,C0262926;C0018801;C0018802;C4554158
hyperkalaemia,C0020461;C4552983
background aha therapy at screening n,C0039798;C0087111;C1363945
hypokalaemia,C0020621;C4553966
currently on aha therapy,C0050451;C0039798;C0087111;C1363945;C0772110
doubling of creatinine,C0205173;C1705764
dpp $nmbr$ inhibitors,C1414174;C0243077
ertugliflozin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glp $nmbr$ receptor agonists,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
medical history of cv disease or heart failure n,C0262926;C0018801;C0018802;C4554158
insulins and analogs,C0021641;C3537244;C4049919;C0243071
background aha therapy at screening n,C0039798;C0087111;C1363945
ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
currently on aha therapy,C0050451;C0039798;C0087111;C1363945;C0772110
overall cohort primary analysis,C0086027;C0205225;C0439612;C0439631
dpp $nmbr$ inhibitors,C1414174;C0243077
difference in ls means $nmbr$ ci versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408
glp $nmbr$ receptor agonists,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
stage $nmbr$ a ckd cohort secondary analysis,C0205390;C1300072;C1306673;C0086027;C0027627;C0175668;C0205436
insulins and analogs,C0021641;C3537244;C4049919;C0243071
p valueb,C0369773;C2603361
ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
overall cohort post hoc analysis excluding metformin users,C0086027;C0025598
overall cohort primary analysis,C0086027;C0205225;C0439612;C0439631
stage $nmbr$ a ckd cohort post hoc analysis excluding metformin users,C0205390;C1300072;C1306673;C0086027;C0025598
difference in ls means $nmbr$ ci versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408
week $nmbr$ a,C0332174;C0439230
stage $nmbr$ a ckd cohort secondary analysis,C0205390;C1300072;C1306673;C0086027;C0027627;C0175668;C0205436
table $nmbr$ baseline characteristics in america between patients w wo resistant htn,C4684572;C0002454;C0030705;C1980014
p valueb,C0369773;C2603361
overall cohort post hoc analysis excluding metformin users,C0086027;C0025598
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker bb beta blocker bmi body mass index bnp brain natriuretic peptide ccb calcium channel blocker dbp diastolic blood pressure egfr estimated glomerular ltration rate hr heart rate sbp systolic blood pressure w wo with or without,C4528226;C1980014
stage $nmbr$ a ckd cohort post hoc analysis excluding metformin users,C0205390;C1300072;C1306673;C0086027;C0025598
america all patients,C0002454;C0030705
week $nmbr$ a,C0332174;C0439230
america rhtn only,C0002454
table $nmbr$ baseline characteristics in america between patients w wo resistant htn,C4684572;C0002454;C0030705;C1980014
no resistant htn n $nmbr$ $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
resistant htn n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker bb beta blocker bmi body mass index bnp brain natriuretic peptide ccb calcium channel blocker dbp diastolic blood pressure egfr estimated glomerular ltration rate hr heart rate sbp systolic blood pressure w wo with or without,C4528226;C1980014
resistant htn placebo n $nmbr$,C0020538;C0032042;C1696465;C1706408
america all patients,C0002454;C0030705
resistant htn spiro n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
america rhtn only,C0002454
race_white,C0007457;C0043157;C0220938
no resistant htn n $nmbr$ $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
nyha_class,C1882083
resistant htn n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
eligibility strata,C0013893;C1548635
resistant htn placebo n $nmbr$,C0020538;C0032042;C1696465;C1706408
elevated bnp,C0054015;C1095989;C1417808;C2982014
resistant htn spiro n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
ace or arb,C1452534;C4284014;C3888198
race_white,C0007457;C0043157;C0220938
ccb,C0006684
bb,C0004739;C0332297
nyha_class,C1882083
eligibility strata,C0013893;C1548635
k mmol l,C0597277;C1532563;C1708601
elevated bnp,C0054015;C1095989;C1417808;C2982014
hb g dl,C0439267
ace or arb,C1452534;C4284014;C3888198
table $nmbr$ outcom,C0039224;C1706074
ccb,C0006684
es in americas according to the presence absence of rhtn,C0013754;C0205944;C0332197;C1689985
bb,C0004739;C0332297
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker ci con dence interval cvd cardiovascular death hf heart failure hr hazard ratio rhtn resistant hypertension afrom unadjusted model bstrati ed by eligibility strata cfurther adjusted for age ace arb diabetes,C0596525;C3538926;C0013893;C1548635;C4300468
k mmol l,C0597277;C1532563;C1708601
rhtn,
hb g dl,C0439267
no rhtn,
table $nmbr$ outcom,C0039224;C1706074
number and of participants with events and incidence rate per $nmbr$ person year,C0237753;C0449788;C0679646;C0441471;C3541888;C1708485;C0027361;C2347489
es in americas according to the presence absence of rhtn,C0013754;C0205944;C0332197;C1689985
unadjusted model hr $nmbr$ ci p value,C0008107;C1709380;C3259781
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker ci con dence interval cvd cardiovascular death hf heart failure hr hazard ratio rhtn resistant hypertension afrom unadjusted model bstrati ed by eligibility strata cfurther adjusted for age ace arb diabetes,C0596525;C3538926;C0013893;C1548635;C4300468
strata modelb hr $nmbr$ ci p value,C0008107;C1709380;C3259781
rhtn,
adjusted modelc hr $nmbr$ ci p value,C0008107;C1709380;C3259781
no rhtn,
p for interaction between rhtn and no rhtn and treatmenta,C0369773;C2603361
number and of participants with events and incidence rate per $nmbr$ person year,C0237753;C0449788;C0679646;C0441471;C3541888;C1708485;C0027361;C2347489
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr,
unadjusted model hr $nmbr$ ci p value,C0008107;C1709380;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
strata modelb hr $nmbr$ ci p value,C0008107;C1709380;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per pyr $nmbr$ pyr,
adjusted modelc hr $nmbr$ ci p value,C0008107;C1709380;C3259781
recurrent hf,C0018488;C1313497;C1538440;C3273279
$nmbr$ $nmbr$ per $nmbr$ pyr,
p for interaction between rhtn and no rhtn and treatmenta,C0369773;C2603361
$nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr pyr,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr,
itca $nmbr$ $nmbr$ mg day n $nmbr$,C0165330;C0439422
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
femalesex,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per pyr $nmbr$ pyr,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
recurrent hf,C0018488;C1313497;C1538440;C3273279
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
$nmbr$ $nmbr$ per $nmbr$ pyr,
egfr ml min bsa,C1739039;C0439445;C3811844;C3812682
$nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr pyr,
medications at baselinet,C0013227;C0802604;C2598133;C4284232
itca $nmbr$ $nmbr$ mg day n $nmbr$,C0165330;C0439422
metforminmonotherapy,
femalesex,
metformin su tzd,C0025598;C0038642;C1705534
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
tah n $nmbr$,C0404079
egfr ml min bsa,C1739039;C0439445;C3811844;C3812682
ta n $nmbr$,C0039297;C1506978;C1705538;C3272501;C4553364
medications at baselinet,C0013227;C0802604;C2598133;C4284232
anthropometrics mean sd,C0444504;C2699239;C2347634;C2348143
metforminmonotherapy,
vital signs mean sd,C0150404;C2699239;C0518766
metformin su tzd,C0025598;C0038642;C1705534
baseline sitting sbp $nmbr$ mm hg,C0085805;C0439475
tah n $nmbr$,C0404079
baseline sitting dbp mm hg,C0168634;C0439475;C1442488
ta n $nmbr$,C0039297;C1506978;C1705538;C3272501;C4553364
comorbidity no,C0009488
anthropometrics mean sd,C0444504;C2699239;C2347634;C2348143
dm or ckd,C0011816;C3250443;C1561643
vital signs mean sd,C0150404;C2699239;C0518766
female gender n,C0086287
baseline sitting sbp $nmbr$ mm hg,C0085805;C0439475
crcl ml min mean sd,C0439445;C2699239
baseline sitting dbp mm hg,C0168634;C0439475;C1442488
prespecified medical conditions n f,C0199168;C0016327;C0205476
comorbidity no,C0009488
cardiovascular disease n,C0007222
dm or ckd,C0011816;C3250443;C1561643
cerebrovascular disease n,C0007820
female gender n,C0086287
cancer n,C0006826;C0998265;C1306459
crcl ml min mean sd,C0439445;C2699239
number of medications n,C1718138
prespecified medical conditions n f,C0199168;C0016327;C0205476
aspirin use n,C0004057;C0042153;C0457083;C1947944
cardiovascular disease n,C0007222
dose adjustment n,C2826232
cerebrovascular disease n,C0007820
dose adjustment reason $nmbr$ kg,C0022718;C0439209;C4054209
cancer n,C0006826;C0998265;C1306459
crcl $nmbr$ $nmbr$ ml min,C1846718;C0439445
number of medications n,C1718138
p gp use,C0042153;C0457083;C1947944
aspirin use n,C0004057;C0042153;C0457083;C1947944
two or more,C0205448
dose adjustment n,C2826232
treatment duration mean sd,C0444921;C2699239;C3259042
dose adjustment reason $nmbr$ kg,C0022718;C0439209;C4054209
unprovoked vte n,C0630906
crcl $nmbr$ $nmbr$ ml min,C1846718;C0439445
index events dvt n,C0441471;C0149871;C2926618;C3899446;C3541888
p gp use,C0042153;C0457083;C1947944
extent of index dvt n of dvt patients,C0439792;C0030705
two or more,C0205448
index events pe dvt n,C0070939;C0149871;C2926618;C3899446;C1880476;C4284304
treatment duration mean sd,C0444921;C2699239;C3259042
extent of index pe n of pe patients,C0439792;C0030705
unprovoked vte n,C0630906
nt probnp $nmbr$ ng ml n,C4284038;C0439275
index events dvt n,C0441471;C0149871;C2926618;C3899446;C3541888
edoxaban n n rate,C0871208;C1521828
extent of index dvt n of dvt patients,C0439792;C0030705
warfarin n n rate,C0871208;C1521828
index events pe dvt n,C0070939;C0149871;C2926618;C3899446;C1880476;C4284304
primary efficacy outcome,C0205225;C1274040;C0439612;C0439631
extent of index pe n of pe patients,C0439792;C0030705
recurrent vte during overall study period,C0630906;C0282416;C1561607
nt probnp $nmbr$ ng ml n,C4284038;C0439275
primary safety outcome,C0036043;C1274040;C1705187
edoxaban n n rate,C0871208;C1521828
major or clinically relevant non major bleeding,C0205082;C0205164;C4318856;C4521762;C0019080
warfarin n n rate,C0871208;C1521828
net clinical benefit on treatment vte or major bleeding,C1516635;C0630906;C0205082;C0019080;C0205164;C4318856;C4521762
primary efficacy outcome,C0205225;C1274040;C0439612;C0439631
end points,C2349179
recurrent vte during overall study period,C0630906;C0282416;C1561607
placebo simvastatin,C0032042;C0074554;C1696465;C1706408
primary safety outcome,C0036043;C1274040;C1705187
ezetimibe simvastatin,C1532737
major or clinically relevant non major bleeding,C0205082;C0205164;C4318856;C4521762;C0019080
km event at $nmbr$ y,C0441471;C4019010
net clinical benefit on treatment vte or major bleeding,C1516635;C0630906;C0205082;C0019080;C0205164;C4318856;C4521762
primary end points,C0205225;C2349179;C0439612;C0439631
end points,C2349179
secondary end points $nmbr$,C0027627;C2349179;C0175668;C0205436
placebo simvastatin,C0032042;C0074554;C1696465;C1706408
secondary end points ii,C1710602;C4082587
ezetimibe simvastatin,C1532737
secondary end points iii,C0439070;C1705160
km event at $nmbr$ y,C0441471;C4019010
tertiary end points,C0205372;C2349179
primary end points,C0205225;C2349179;C0439612;C0439631
e $nmbr$ n $nmbr$,
secondary end points $nmbr$,C0027627;C2349179;C0175668;C0205436
s $nmbr$ n $nmbr$,C2986823
secondary end points ii,C1710602;C4082587
e $nmbr$ s $nmbr$ n $nmbr$,C3846405
secondary end points iii,C0439070;C1705160
duration of type $nmbr$ diabetes mellitus years,C0449238;C2926735
tertiary end points,C0205372;C2349179
testing order,C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
e $nmbr$ n $nmbr$,
hba $nmbr$ c change from baseline,C0392747;C0443172;C1705241;C4319952
s $nmbr$ n $nmbr$,C2986823
$nmbr$ a,
e $nmbr$ s $nmbr$ n $nmbr$,C3846405
e $nmbr$ s $nmbr$ vs s $nmbr$,C3846405
duration of type $nmbr$ diabetes mellitus years,C0449238;C2926735
e $nmbr$ s $nmbr$ vs e $nmbr$,C3846405
testing order,C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
body weight change from baseline,C0005911
hba $nmbr$ c change from baseline,C0392747;C0443172;C1705241;C4319952
fasting plasma glucose change from baseline,C0392747;C0443172;C1705241;C4319952
$nmbr$ a,
systolic blood pressure change from baseline,C1268766
e $nmbr$ s $nmbr$ vs s $nmbr$,C3846405
hba $nmbr$ c patients,C0019016;C0030705;C1825777;C3538758
e $nmbr$ s $nmbr$ vs e $nmbr$,C3846405
dynamic measure of cell function s change from baseline assessed for mmtt subset only,C0079809;C0242485;C0392747;C0443172;C1705241;C4319952;C1516048;C1515021
body weight change from baseline,C0005911
liraglutide $nmbr$,C1456408
fasting plasma glucose change from baseline,C0392747;C0443172;C1705241;C4319952
hbaie mean sd,C0444504;C2699239;C2347634;C2348143
systolic blood pressure change from baseline,C1268766
$nmbr$ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
hba $nmbr$ c patients,C0019016;C0030705;C1825777;C3538758
hbajc mmol mol mean sd,C3829066;C2699239
dynamic measure of cell function s change from baseline assessed for mmtt subset only,C0079809;C0242485;C0392747;C0443172;C1705241;C4319952;C1516048;C1515021
diabetes duration mean sd,C0011847;C2699239;C0011849
liraglutide $nmbr$,C1456408
caleitonin ng l males mean sd,C0439297;C2699239
hbaie mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ $nmbr$ lo $nmbr$ $nmbr$,C0206579;C1232424
$nmbr$ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
caleitonin ng l females mean sd,C0439297;C2699239
hbajc mmol mol mean sd,C3829066;C2699239
lo lo lo,C0206579;C1232424
diabetes duration mean sd,C0011847;C2699239;C0011849
egfr n normal egfr $nmbr$ ml min em^,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
caleitonin ng l males mean sd,C0439297;C2699239
mild impairment egfr $nmbr$ $nmbr$ ml min m^,C0221099;C0439445;C0684336
$nmbr$ $nmbr$ lo $nmbr$ $nmbr$,C0206579;C1232424
moderate impairment egfr $nmbr$ $nmbr$ ml min m^,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335
caleitonin ng l females mean sd,C0439297;C2699239
severe impairment egfr,C1739039;C3811844;C3812682
lo lo lo,C0206579;C1232424
patients with established cv disease aged $nmbr$ years,C0683521
egfr n normal egfr $nmbr$ ml min em^,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
n patients with risk faetors for cv disease aged $nmbr$,C0030705;C0035647;C4552904;C0007222;C0001779;C0001792;C1999167
mild impairment egfr $nmbr$ $nmbr$ ml min m^,C0221099;C0439445;C0684336
years n smoking n current,C0521116;C1705970
moderate impairment egfr $nmbr$ $nmbr$ ml min m^,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335
use of proton inhibitors n,C1524063;C0033727
severe impairment egfr,C1739039;C3811844;C3812682
use of h $nmbr$ bloekers n,C1524063;C0033727;C0369286;C0441932;C0564385;C4528284
patients with established cv disease aged $nmbr$ years,C0683521
history of thyroid disease n,C0683519;C0730226;C0850708;C0944983
n patients with risk faetors for cv disease aged $nmbr$,C0030705;C0035647;C4552904;C0007222;C0001779;C0001792;C1999167
ct calcitonin cv cardiovascular egfr estimated glomerular filtration rate hbalc glycated hemoglobin h $nmbr$ histamine $nmbr$ iqr interquartile range n number of patients sd standard deviation,C2986735;C0030705;C0871420
years n smoking n current,C0521116;C1705970
liraglutide,C1456408
use of proton inhibitors n,C1524063;C0033727
high uln,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
use of h $nmbr$ bloekers n,C1524063;C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ ng l,C0439297
history of thyroid disease n,C0683519;C0730226;C0850708;C0944983
ulnand,
ct calcitonin cv cardiovascular egfr estimated glomerular filtration rate hbalc glycated hemoglobin h $nmbr$ histamine $nmbr$ iqr interquartile range n number of patients sd standard deviation,C2986735;C0030705;C0871420
figure $nmbr$ acr response rates at $nmbr$ weeks in patients treated with pbo ixeq $nmbr$ w or ixeq $nmbr$ w alone or in combination with cdmards or mtx the proportions of patients achieving acr $nmbr$ a acr $nmbr$ b and acr $nmbr$ c are shown,C0237629;C0439230;C0030705;C0332293;C0031962;C0205171;C0439044;C0679994;C0205195;C1947911;C3811910;C0025677;C1417487;C1709707;C1412134;C1515941;C1547282
liraglutide,C1456408
fig $nmbr$ continuous and categorical baseline predictors of disease activity score based on $nmbr$ joints das $nmbr$ a simplified disease activity index sdai b and clinical disease activity index cdai c remission using univariate logistic regression unadjusted if the $nmbr$ ci does not contain the value $nmbr$ $nmbr$ the predictor is statistically significant at $nmbr$ $nmbr$ non significant predictors black significant predictors gray,C0349966;C1337208;C0549178;C0035648;C1527178;C1705938;C3869582;C3871128;C0544452;C1524063;C0206031;C1439367;C0008107;C3259781;C1518422;C0332256;C2700400;C1522609;C2698872;C0237881;C0005680;C0027567;C0085756;C0439541
high uln,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
figure $nmbr$ ef cacy of ticagrelor,C1419788;C3274822
$nmbr$ ng l,C0439297
supplementary figure s $nmbr$ mda response through $nmbr$ weeks by disease duration,C0871261;C1704632;C1706817;C2911692;C0872146
ulnand,
met atopy and ige $nmbr$ $nmbr$ ku l criteria n $nmbr$,C0392707;C3539705;C0439340;C0243161
figure $nmbr$ acr response rates at $nmbr$ weeks in patients treated with pbo ixeq $nmbr$ w or ixeq $nmbr$ w alone or in combination with cdmards or mtx the proportions of patients achieving acr $nmbr$ a acr $nmbr$ b and acr $nmbr$ c are shown,C0237629;C0439230;C0030705;C0332293;C0031962;C0205171;C0439044;C0679994;C0205195;C1947911;C3811910;C0025677;C1417487;C1709707;C1412134;C1515941;C1547282
did not meet atopy and ige $nmbr$ $nmbr$ ku lcriteriaa n $nmbr$ $nmbr$,C0392707;C3539705;C0022804;C1337080;C1532717;C1881335
fig $nmbr$ continuous and categorical baseline predictors of disease activity score based on $nmbr$ joints das $nmbr$ a simplified disease activity index sdai b and clinical disease activity index cdai c remission using univariate logistic regression unadjusted if the $nmbr$ ci does not contain the value $nmbr$ $nmbr$ the predictor is statistically significant at $nmbr$ $nmbr$ non significant predictors black significant predictors gray,C0349966;C1337208;C0549178;C0035648;C1527178;C1705938;C3869582;C3871128;C0544452;C1524063;C0206031;C1439367;C0008107;C3259781;C1518422;C0332256;C2700400;C1522609;C2698872;C0237881;C0005680;C0027567;C0085756;C0439541
ige high $nmbr$ ku l n $nmbr$ $nmbr$,C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
figure $nmbr$ ef cacy of ticagrelor,C1419788;C3274822
igelow n $nmbr$ $nmbr$,
supplementary figure s $nmbr$ mda response through $nmbr$ weeks by disease duration,C0871261;C1704632;C1706817;C2911692;C0872146
atopy n $nmbr$ $nmbr$,C0392707;C3539705
met atopy and ige $nmbr$ $nmbr$ ku l criteria n $nmbr$,C0392707;C3539705;C0439340;C0243161
no atopy n $nmbr$,C0392707;C3539705
did not meet atopy and ige $nmbr$ $nmbr$ ku lcriteriaa n $nmbr$ $nmbr$,C0392707;C3539705;C0022804;C1337080;C1532717;C1881335
body mass index kg m $nmbr$ mean sd c,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
ige high $nmbr$ ku l n $nmbr$ $nmbr$,C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
eosinophil count cells pl median range c,C0200638;C0750879
igelow n $nmbr$ $nmbr$,
fev $nmbr$ pre bronchodilator l mean sd c,C2599602;C0444504;C2347634;C2348143
atopy n $nmbr$ $nmbr$,C0392707;C3539705
fev $nmbr$ pre bronchodilator predicted normal mean sd c d,C0520835;C2599602
no atopy n $nmbr$,C0392707;C3539705
reversibility median range c,C0449261;C0549183;C0876920;C2347635;C2348144;C2939193
body mass index kg m $nmbr$ mean sd c,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
exacerbations in previous $nmbr$ mo n mean sd,C4086268;C0026544;C0332177
eosinophil count cells pl median range c,C0200638;C0750879
acq $nmbr$ score mean sd e,C0449820;C0444504;C2347634;C2348143;C4050231
fev $nmbr$ pre bronchodilator l mean sd c,C2599602;C0444504;C2347634;C2348143
aqlq s $nmbr$ score mean sd c f,C0444504;C0016327;C2347634;C2348143
fev $nmbr$ pre bronchodilator predicted normal mean sd c d,C0520835;C2599602
atopy by phadiatop test n,C0392707;C3539705
reversibility median range c,C0449261;C0549183;C0876920;C2347635;C2348144;C2939193
ige ku l median range c,C0439340;C0549183;C0876920;C2347635;C2348144;C2939193
exacerbations in previous $nmbr$ mo n mean sd,C4086268;C0026544;C0332177
nasal polyps n,C0027430
acq $nmbr$ score mean sd e,C0449820;C0444504;C2347634;C2348143;C4050231
maintenance ocs use n,C0024501;C0042153;C0457083;C1947944
aqlq s $nmbr$ score mean sd c f,C0444504;C0016327;C2347634;C2348143
igehigh i $nmbr$ ku l n i $nmbr$,C0021966;C0439340;C0221138
atopy by phadiatop test n,C0392707;C3539705
igelow,
ige ku l median range c,C0439340;C0549183;C0876920;C2347635;C2348144;C2939193
placebo n $nmbr$ i $nmbr$,C0021966;C0221138
annual asthma exacerbation rates,C0871208;C1521828
nasal polyps n,C0027430
patients analyzed n,C0030705;C0936012
maintenance ocs use n,C0024501;C0042153;C0457083;C1947944
i $nmbr$,C0021966;C0221138
igehigh i $nmbr$ ku l n i $nmbr$,C0021966;C0439340;C0221138
rate estimate $nmbr$ ci,C0008107;C3259781
igelow,
i $nmbr$ $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
placebo n $nmbr$ i $nmbr$,C0021966;C0221138
i $nmbr$ i $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
annual asthma exacerbation rates,C0871208;C1521828
absolute difference estimate vs placebo $nmbr$ ci,C1549031;C0750572;C0008107;C3259781
patients analyzed n,C0030705;C0936012
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ i $nmbr$,C0021966;C0221138
i $nmbr$,C0021966;C0221138
rate ratio vs placebo $nmbr$ ci,C0871208;C0456603;C1547037;C1521828;C0008107;C3259781
rate estimate $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
i $nmbr$ $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
nominal p vs placebo,C0032042;C1696465;C1706408
i $nmbr$ i $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
pre bronchodilator fevi change,C2599602;C3481639
absolute difference estimate vs placebo $nmbr$ ci,C1549031;C0750572;C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ i $nmbr$,C0021966;C0221138
patients in analysis n,C0030705;C0002778;C0936012;C1524024
rate ratio vs placebo $nmbr$ ci,C0871208;C0456603;C1547037;C1521828;C0008107;C3259781
patients with eot data n,C2707520
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
i $nmbr$ i,C0021966;C0221138
nominal p vs placebo,C0032042;C1696465;C1706408
ls mean difference vs placebo $nmbr$ ci,C0444504;C1705241;C1705242;C2347634;C2348143;C0008107;C3259781
pre bronchodilator fevi change,C2599602;C3481639
$nmbr$ i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
$nmbr$ i $nmbr$ $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
patients in analysis n,C0030705;C0002778;C0936012;C1524024
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$ i,C0021966;C0221138
patients with eot data n,C2707520
absolutedifferenceestimate vs placebo $nmbr$ ci,C0008107;C3259781
i $nmbr$ i,C0021966;C0221138
ls mean difference vs placebo $nmbr$ ci,C0444504;C1705241;C1705242;C2347634;C2348143;C0008107;C3259781
fig $nmbr$ absolute change in fev $nmbr$ from baseline at week $nmbr$ mitt patients top biomarker high group middle biomarker low group bottom,C0349966;C1549031;C1337208;C0168634;C1442488
$nmbr$ i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
ltg subgroup n $nmbr$,C1420817;C1079230;C1515021;C4521367;C4521846
$nmbr$ i $nmbr$ $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
tpm subgroup n $nmbr$,C0076829;C1079230;C1515021
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$ i,C0021966;C0221138
brv $nmbr$ mg day n $nmbr$,C0155502;C0439422
absolutedifferenceestimate vs placebo $nmbr$ ci,C0008107;C3259781
brv overalla n $nmbr$,C0155502
fig $nmbr$ absolute change in fev $nmbr$ from baseline at week $nmbr$ mitt patients top biomarker high group middle biomarker low group bottom,C0349966;C1549031;C1337208;C0168634;C1442488
whiteb,
regions n,C0017446;C0205147
ltg subgroup n $nmbr$,C1420817;C1079230;C1515021;C4521367;C4521846
asia pacific other,C0003980
tpm subgroup n $nmbr$,C0076829;C1079230;C1515021
age at time of first seizure,C0001779;C0036572;C1959629;C4553401
brv $nmbr$ mg day n $nmbr$,C0155502;C0439422
lev status,C0023556;C0449438
brv overalla n $nmbr$,C0155502
whiteb,
previous lev only,C0205156;C0023556;C1552607
regions n,C0017446;C0205147
never used lev,C1273517;C0023556
asia pacific other,C0003980
number of concomitant aedsc,C0237753;C0449788
age at time of first seizure,C0001779;C0036572;C1959629;C4553401
aed inducer status,C0887457;C0449438
lev status,C0023556;C0449438
no inducer at core study entry,C3898767;C0444669;C1167518;C1706352;C1882467;C3274653
previous lev only,C0205156;C0023556;C1552607
no of prior aedsd,C0332152;C2826257
never used lev,C1273517;C0023556
seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
number of concomitant aedsc,C0237753;C0449788
type ia,C0020980;C0694634;C1947960
aed inducer status,C0887457;C0449438
type ib,C2744579;C3890035;C4283819
no inducer at core study entry,C3898767;C0444669;C1167518;C1706352;C1882467;C3274653
type ic,C0020750;C4554818
no of prior aedsd,C0332152;C2826257
bdp ff g n $nmbr$,C0004906;C0439267;C1422585;C1538710
seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
blood leukocyte count $nmbr$ cells per l,C0005771;C0009555
type ia,C0020980;C0694634;C1947960
blood eosinophil count $nmbr$ cells per l,C0200638
type ib,C2744579;C3890035;C4283819
blood eosinophil,C0014467
type ic,C0020750;C4554818
fev_ l,C3714541
bdp ff g n $nmbr$,C0004906;C0439267;C1422585;C1538710
proportion of predicted normal fev $nmbr$ value,C1709707;C0086715
blood leukocyte count $nmbr$ cells per l,C0005771;C0009555
clinical copd phenotype^,C0031437;C1285572
blood eosinophil count $nmbr$ cells per l,C0200638
chronic bronchitis,C0008677
blood eosinophil,C0014467
emphysema,C0013990;C0034067
fev_ l,C3714541
mixed chronic bronchitis and emphysema,C0205430;C0008677;C3160715;C0013990;C0034067
proportion of predicted normal fev $nmbr$ value,C1709707;C0086715
moderate or severe exacerbations in the previous year range,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
clinical copd phenotype^,C0031437;C1285572
copd medication taken for at least $nmbr$ months before st,C0013227;C3244316;C4284232;C1883727;C0439231;C0036056;C3272372
chronic bronchitis,C0008677
udy entry,C1705654
emphysema,C0013990;C0034067
benign prostatic hyperplasia,C1704272
mixed chronic bronchitis and emphysema,C0205430;C0008677;C3160715;C0013990;C0034067
gastroesophageal reflux disease,C0017168;C4553201
moderate or severe exacerbations in the previous year range,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
overall pp n $nmbr$,C0030375;C0063017;C4319755
copd medication taken for at least $nmbr$ months before st,C0013227;C3244316;C4284232;C1883727;C0439231;C0036056;C3272372
sensitivity analyses,C0020517;C0036667;C0312418;C0427965;C1511883;C1522640;C2346484;C2349185
udy entry,C1705654
mar itt n $nmbr$,C3829202;C4255469
benign prostatic hyperplasia,C1704272
or itt n $nmbr$,
gastroesophageal reflux disease,C0017168;C4553201
post bronchodilator fev $nmbr$ at screening,C2599594;C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
overall pp n $nmbr$,C0030375;C0063017;C4319755
males n $nmbr$,C0086582
sensitivity analyses,C0020517;C0036667;C0312418;C0427965;C1511883;C1522640;C2346484;C2349185
females n $nmbr$,C0086287
mar itt n $nmbr$,C3829202;C4255469
ex smokers n $nmbr$,C0337671;C4555205
or itt n $nmbr$,
current smokers n $nmbr$,C3173209;C3241966
post bronchodilator fev $nmbr$ at screening,C2599594;C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
reversibility $nmbr$ n $nmbr$,C0449261
males n $nmbr$,C0086582
chronic bronchitis n $nmbr$,C0008677
females n $nmbr$,C0086287
emphysema n $nmbr$,C0013990;C0034067
ex smokers n $nmbr$,C0337671;C4555205
mixed n $nmbr$,C0205430;C3160715
current smokers n $nmbr$,C3173209;C3241966
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
reversibility $nmbr$ n $nmbr$,C0449261
prediabetese,
prior admb,C0332152;C2826257
chronic bronchitis n $nmbr$,C0008677
no prior admc,C0332152;C2826257
emphysema n $nmbr$,C0013990;C0034067
all diabetesd,
mixed n $nmbr$,C0205430;C3160715
dmab n $nmbr$,C0012411
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
white or caucasian n,C0007457;C0043157;C0220938
prediabetese,
prior admb,C0332152;C2826257
serum ctx i ng ml,C0631180;C0439275
no prior admc,C0332152;C2826257
$nmbr$ oh vitamin d ng ml,C0014695;C0439275;C0042866;C2936842;C3537249;C3714503
all diabetesd,
baseline use of adm n,C0168634;C1524063;C1442488
dmab n $nmbr$,C0012411
insulins,C0021641;C3537244;C4049919
white or caucasian n,C0007457;C0043157;C0220938
a glucosidase inhibitors,C1512211
serum ctx i ng ml,C0631180;C0439275
meglitinides glinides,C0065880;C3537178;C1579432
thiazolidinediones,C1257987;C3541957
$nmbr$ oh vitamin d ng ml,C0014695;C0439275;C0042866;C2936842;C3537249;C3714503
baseline use of adm n,C0168634;C1524063;C1442488
baseline numberf of adm classes n,C0168634;C0215825;C4521767;C1442488
insulins,C0021641;C3537244;C4049919
all dulaglutide $nmbr$ $nmbr$ mg insulin lispro insulin glargine n $nmbr$,C0907402
a glucosidase inhibitors,C1512211
insulin glargine insulin lispro award $nmbr$ n $nmbr$,C0293359
meglitinides glinides,C0065880;C3537178;C1579432
placebo insulin glargine award $nmbr$ n $nmbr$,C0907402;C0004446
thiazolidinediones,C1257987;C3541957
azl m $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline numberf of adm classes n,C0168634;C0215825;C4521767;C1442488
age mean sd yearsa,C0001779;C0444504;C2347634;C2348143
all dulaglutide $nmbr$ $nmbr$ mg insulin lispro insulin glargine n $nmbr$,C0907402
weight mean sd kgb,C0005910;C0043100;C1305866;C1705104
insulin glargine insulin lispro award $nmbr$ n $nmbr$,C0293359
bmi mean sd kg m $nmbr$ c,C0444504;C1532718;C2347634;C2348143
placebo insulin glargine award $nmbr$ n $nmbr$,C0907402;C0004446
egfr mean sd ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
azl m $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diabetes status n,C1317301
age mean sd yearsa,C0001779;C0444504;C2347634;C2348143
concomitant medication n d,C0521115;C0013227;C3244316;C4284232
weight mean sd kgb,C0005910;C0043100;C1305866;C1705104
medication continued into double blind treatment period,C0013227;C3244316;C4284232;C0549178;C0013072
bmi mean sd kg m $nmbr$ c,C0444504;C1532718;C2347634;C2348143
initiated use during double blind treatment period,C0042153;C0457083;C1947944
egfr mean sd ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
smoking classification n,C0008902;C0008903;C0678229
diabetes status n,C1317301
scsbp mean sd mmhge,C0444504;C2347634;C2348143
concomitant medication n d,C0521115;C0013227;C3244316;C4284232
scdbp mean sd mmhgf,C0444504;C2347634;C2348143
medication continued into double blind treatment period,C0013227;C3244316;C4284232;C0549178;C0013072
prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
initiated use during double blind treatment period,C0042153;C0457083;C1947944
no prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
smoking classification n,C0008902;C0008903;C0678229
age median $nmbr$ th $nmbr$ th y,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
scsbp mean sd mmhge,C0444504;C2347634;C2348143
history of diabetes mellitus no,C0455488
scdbp mean sd mmhgf,C0444504;C2347634;C2348143
prior mi within $nmbr$ y no,C0332152;C3810814;C2826257
prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
history of pvd no,C4534349
no prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
history of hf or lvef b $nmbr$ with index event no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0428772;C0441471;C4019010;C0488728
age median $nmbr$ th $nmbr$ th y,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
history of impaired renal function no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of diabetes mellitus no,C0455488
no revascularization for index acs event no,C0581603;C0441471;C4019010
prior mi within $nmbr$ y no,C0332152;C3810814;C2826257
other medical history no,C0262926;C1704706
history of pvd no,C4534349
hf,C0018488;C1313497;C1538440;C3273279
history of hf or lvef b $nmbr$ with index event no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0428772;C0441471;C4019010;C0488728
revascularization history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of impaired renal function no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no revascularization for index acs event no,C0581603;C0441471;C4019010
cabg history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
other medical history no,C0262926;C1704706
acs management no,C0001554;C0376636;C1273870;C3273539
hf,C0018488;C1313497;C1538440;C3273279
medical therapy,C0418981
revascularization history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
dual antiplatelet therapy,C0205173;C1096021;C1554184
pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cardiovascular death mi or stroke,C0007226;C3810814;C3887460;C0038454;C4554100
cabg history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
timi major minor bleeding,C4441842;C0019080
acs management no,C0001554;C0376636;C1273870;C3273539
any bleeding,C0019080
medical therapy,C0418981
all death,C0011065;C1306577;C4082313;C4552775
dual antiplatelet therapy,C0205173;C1096021;C1554184
six study placebo controlled set,C0036849;C1442518;C1705195
cardiovascular death mi or stroke,C0007226;C3810814;C3887460;C0038454;C4554100
ra beam,C0338248;C2347880;C4521565
timi major minor bleeding,C4441842;C0019080
all baricitinib ra n $nmbr$,C4044947;C3538806;C4048756
any bleeding,C0019080
adalimumab n $nmbr$,C1122087
all death,C0011065;C1306577;C4082313;C4552775
$nmbr$ years of age n,C1510829
six study placebo controlled set,C0036849;C1442518;C1705195
tobacco use yes n,C0040335;C0543414;C0841002;C3853727
ra beam,C0338248;C2347880;C4521565
duration of rat years,C0449238;C2926735
all baricitinib ra n $nmbr$,C4044947;C3538806;C4048756
central south america and mexico,C0007674;C0025885
adalimumab n $nmbr$,C1122087
asia excluding japan,C0003980;C0022341
$nmbr$ years of age n,C1510829
european union,C0015179
tobacco use yes n,C0040335;C0543414;C0841002;C3853727
hscrp mg l median first third quartiles,C0439268;C2828255
duration of rat years,C0449238;C2926735
baricitinib $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
central south america and mexico,C0007674;C0025885
non statin n $nmbr$,C1518422;C0360714
asia excluding japan,C0003980;C0022341
statin n $nmbr$,C0360714
european union,C0015179
triglycerides mmol l,C0041004;C1532563
hscrp mg l median first third quartiles,C0439268;C2828255
patients with draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
baricitinib $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients without draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
non statin n $nmbr$,C1518422;C0360714
vdz pbo [n $nmbr$ ],C0031962;C0369718;C0441922
statin n $nmbr$,C0360714
vdz vdz [n $nmbr$ ],C0369718;C0441922
triglycerides mmol l,C0041004;C1532563
age [year] mean sda,C0001779;C0439234;C0439508;C0276477;C1428349;C1553165
patients with draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
male sex n [ ],C0086582
patients without draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
current smoker n [ ],C3173209;C3241966
vdz pbo [n $nmbr$ ],C0031962;C0369718;C0441922
disease duration [year] mean sda,C0872146;C0439234;C0439508;C0276477;C1428349;C1553165
vdz vdz [n $nmbr$ ],C0369718;C0441922
cdai score mean sda,C0276477;C1428349;C1553165
age [year] mean sda,C0001779;C0439234;C0439508;C0276477;C1428349;C1553165
crp [mg l] median,C3890735;C4048285;C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
male sex n [ ],C0086582
disease site n [ ],C0012634;C0205145;C1515974;C2825164
current smoker n [ ],C3173209;C3241966
prior surgery for cd n [ ],C0455610;C0007928;C0034283;C4552032
disease duration [year] mean sda,C0872146;C0439234;C0439508;C0276477;C1428349;C1553165
prior tnf antagonist failure n [ ],C0231491;C0231174;C0680095
cdai score mean sda,C0276477;C1428349;C1553165
concomitant medication n [ ],C0521115;C0013227;C3244316;C4284232
crp [mg l] median,C3890735;C4048285;C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
cs,C0010182;C0271160;C3540510;C4085345
disease site n [ ],C0012634;C0205145;C1515974;C2825164
imm,C0205470
prior surgery for cd n [ ],C0455610;C0007928;C0034283;C4552032
cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
prior tnf antagonist failure n [ ],C0231491;C0231174;C0680095
neither cs nor imm,C0010182;C0271160;C3540510;C4085345;C0205470
concomitant medication n [ ],C0521115;C0013227;C3244316;C4284232
history of fistulising disease n [ ],C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
cs,C0010182;C0271160;C3540510;C4085345
concomitant antibiotic use n [ ],C0003232;C0042153;C0457083;C1947944
imm,C0205470
number of draining fistulae per patient n,C0237753;C0449788;C0013103;C0180499;C4265177;C0016169;C0030705
cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
[ ],
neither cs nor imm,C0010182;C0271160;C3540510;C4085345;C0205470
patients with perianal fistulae n [ ],C0030705;C0267561
history of fistulising disease n [ ],C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
psa ng ml,C3810537;C0439275;C3813209
concomitant antibiotic use n [ ],C0003232;C0042153;C0457083;C1947944
drinker n,C0556338
number of draining fistulae per patient n,C0237753;C0449788;C0013103;C0180499;C4265177;C0016169;C0030705
ex drinker,C0337679
[ ],
underlying disease,C4067746;C0012634
patients with perianal fistulae n [ ],C0030705;C0267561
erectile dysfunction,C0242350;C1961100
psa ng ml,C3810537;C0439275;C3813209
$nmbr$ c,
drinker n,C0556338
pde $nmbr$ inhibitors,C0031638
ex drinker,C0337679
irritative subscore,
underlying disease,C4067746;C0012634
obstructive subscore,C0549186
qol,C0518214
erectile dysfunction,C0242350;C1961100
$nmbr$ c,
voided volume ml,C0439526;C1705224;C3887665
pde $nmbr$ inhibitors,C0031638
pvr ml,C0439526;C1705224;C3887665
irritative subscore,
tamsulosin $nmbr$ $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
obstructive subscore,C0549186
tamsulosin $nmbr$ $nmbr$ mg vs $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
qol,C0518214
t $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
voided volume ml,C0439526;C1705224;C3887665
week $nmbr$ baseline,C0168634;C1442488
pvr ml,C0439526;C1705224;C3887665
ancova result,C1274040;C1546471;C2825142
tamsulosin $nmbr$ $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ls mean difference se,C0023668;C0036919
tamsulosin $nmbr$ $nmbr$ mg vs $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
participants with heart failure,C0679646;C0018801;C0018802;C4554158
t $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
participants without heart failure,C0679646;C0018801;C0018802;C4554158
week $nmbr$ baseline,C0168634;C1442488
p value heart failure vs no heart failure,C0018801;C0018802;C4554158
ancova result,C1274040;C1546471;C2825142
canagliflozin n $nmbr$,C2974540
ls mean difference se,C0023668;C0036919
duration of diabetes mellitus y mean sd,C0449238;C2926735
participants with heart failure,C0679646;C0018801;C0018802;C4554158
microvascular disease history n,C0443258;C0683519
participants without heart failure,C0679646;C0018801;C0018802;C4554158
atherosclerotic vascular disease history n t,C0004153
p value heart failure vs no heart failure,C0018801;C0018802;C4554158
cardiovascular disease history n,C1880008
canagliflozin n $nmbr$,C2974540
history of amputation n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
duration of diabetes mellitus y mean sd,C0449238;C2926735
systolic blood pressure mm hg mean sd,C0428886;C2699239
microvascular disease history n,C0443258;C0683519
diastolic blood pressure mm hg mean sd,C0428886;C2699239
atherosclerotic vascular disease history n t,C0004153
glycated hemoglobin mean sd,C0017853;C2699239
cardiovascular disease history n,C1880008
ldl hdl cholesterol ratio mean sd,C0428621;C2699239
history of amputation n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C3811844;C0439445;C0444504;C2699239;C2347634;C2348143
systolic blood pressure mm hg mean sd,C0428886;C2699239
micro or macroalbuminuria n,C0085672;C1553035;C3811161;C4049106
diastolic blood pressure mm hg mean sd,C0428886;C2699239
concomitant drug therapies n,C0013216
glycated hemoglobin mean sd,C0017853;C2699239
renin angiotensin aldosterone system blocker,C0086907
ldl hdl cholesterol ratio mean sd,C0428621;C2699239
dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C3811844;C0439445;C0444504;C2699239;C2347634;C2348143
glucagon like peptide $nmbr$ receptor agonist,C0014361;C4543206
micro or macroalbuminuria n,C0085672;C1553035;C3811161;C4049106
patients per $nmbr$ patient years,C0030705;C0439234
concomitant drug therapies n,C0013216
ard $nmbr$ cl per $nmbr$ patient years,C0596019;C0030705
renin angiotensin aldosterone system blocker,C0086907
canagliflozin,C2974540
dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
cardiovascular death or hospitalized hf,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
glucagon like peptide $nmbr$ receptor agonist,C0014361;C4543206
no history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
patients per $nmbr$ patient years,C0030705;C0439234
fatal or nonlatal myocardial inlarctlon,C1302234;C1705232;C0027061;C1522564
ard $nmbr$ cl per $nmbr$ patient years,C0596019;C0030705
fatal or nonlatal stroke,C1302234;C1705232;C0038454;C4554100
canagliflozin,C2974540
serious decline in kidney function $nmbr$,C0205404;C0232804
cardiovascular death or hospitalized hf,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
number of previous anti tnf treatments for psa n,C0237753;C0449788;C1448177;C0087111
no history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
time since diagnosis of psa years mean sd,C0556970;C0011900;C1704338;C1704656
fatal or nonlatal myocardial inlarctlon,C1302234;C1705232;C0027061;C1522564
mtx use at randomization n,C0042153;C0457083;C1947944
fatal or nonlatal stroke,C1302234;C1705232;C0038454;C4554100
systemic glucocorticoid use at randomization n,C0042153;C0457083;C1947944
serious decline in kidney function $nmbr$,C0205404;C0232804
patients with specific disease characteristics n,C0683521;C0815172
number of previous anti tnf treatments for psa n,C0237753;C0449788;C1448177;C0087111
psoriasis $nmbr$ of bsa,C0033860
time since diagnosis of psa years mean sd,C0556970;C0011900;C1704338;C1704656
presence of dactylitis,C0150312;C0392148;C3854307
mtx use at randomization n,C0042153;C0457083;C1947944
presence of enthesitis,C0150312;C0392148;C3854307
systemic glucocorticoid use at randomization n,C0042153;C0457083;C1947944
disease and quality of life scores mean sd,C0012634;C3476431;C2699239
patients with specific disease characteristics n,C0683521;C0815172
pasia,
psoriasis $nmbr$ of bsa,C0033860
physician s global assessment vas,C0031831;C0804815;C0042815;C3536884;C3827561
presence of dactylitis,C0150312;C0392148;C3854307
psa pain vas,C3810537;C0042815;C3813209
presence of enthesitis,C0150312;C0392148;C3854307
patient s global assessment vas,C0030705;C0042815;C3536884;C3827561
disease and quality of life scores mean sd,C0012634;C3476431;C2699239
all doses n $nmbr$,C0178602
pasia,
past smoking,C0037369;C0453996;C1881674
physician s global assessment vas,C0031831;C0804815;C0042815;C3536884;C3827561
never smoker,C0425293
psa pain vas,C3810537;C0042815;C3813209
alcohol use $nmbr$ day,C0332173;C0439228;C0439505
patient s global assessment vas,C0030705;C0042815;C3536884;C3827561
daily exercise,C0015259;C1522704
all doses n $nmbr$,C0178602
interleukin $nmbr$ ng l,C0021764;C0439297;C1527200
past smoking,C0037369;C0453996;C1881674
impaired fasting glucose $nmbr$ mg dl,C1272092;C0439269
never smoker,C0425293
canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alcohol use $nmbr$ day,C0332173;C0439228;C0439505
all canakinumab,C2718773
daily exercise,C0015259;C1522704
n events n at risk,C0369718;C0441471;C3541888;C0441922;C1444641
interleukin $nmbr$ ng l,C0021764;C0439297;C1527200
incidence rate,C1708485
impaired fasting glucose $nmbr$ mg dl,C1272092;C0439269
hazard ratio $nmbr$ ci vs placebo,C0008107;C3259781;C0032042;C1696465;C1706408
canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p value vs placebo,C1709380;C0032042;C1696465;C1706408
all canakinumab,C2718773
baseline prediabetes,C0168634;C0362046;C1442488
n events n at risk,C0369718;C0441471;C3541888;C0441922;C1444641
baseline normoglycemia,C0168634;C1442488
incidence rate,C1708485
hazard ratio vs placebo,C2985465;C0032042;C1696465;C1706408
hazard ratio $nmbr$ ci vs placebo,C0008107;C3259781;C0032042;C1696465;C1706408
p heterogeneity,C0019409;C0242960
p value vs placebo,C1709380;C0032042;C1696465;C1706408
hazard ratio $nmbr$ ci for adjudicated type $nmbr$ diabetes,C0008107;C3259781
baseline prediabetes,C0168634;C0362046;C1442488
risk marker and model,C1519104;C3161035;C3274659;C3714583;C3853906
baseline normoglycemia,C0168634;C1442488
hscrp range mg l,C1514721;C0439268;C2348147;C3542016
hazard ratio vs placebo,C2985465;C0032042;C1696465;C1706408
model $nmbr$,C3161035;C3274659;C3714583;C3853906
p heterogeneity,C0019409;C0242960
model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
hazard ratio $nmbr$ ci for adjudicated type $nmbr$ diabetes,C0008107;C3259781
il $nmbr$ range ng l,C0020898;C0439297;C0021764;C0022271
risk marker and model,C1519104;C3161035;C3274659;C3714583;C3853906
czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hscrp range mg l,C1514721;C0439268;C2348147;C3542016
week $nmbr$ czp $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
model $nmbr$,C3161035;C3274659;C3714583;C3853906
pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
demographic characteristics mean sd unless otherwise indicated,C0683970;C2699239;C1444656
il $nmbr$ range ng l,C0020898;C0439297;C0021764;C0022271
mean sd unless otherwise indicated,C0444504;C2699239;C2347634;C2348143;C1444656
czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time from psoriatic arthritis diagnosis [a] years,C0040223;C3541383;C0439234
week $nmbr$ czp $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
crp mg l [b] median min max,C3890735;C0439268;C4048285;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tender joint count $nmbr$ $nmbr$ joints,C0451530
demographic characteristics mean sd unless otherwise indicated,C0683970;C2699239;C1444656
swollen joint count $nmbr$ $nmbr$ joints,C0451521
mean sd unless otherwise indicated,C0444504;C2699239;C2347634;C2348143;C1444656
psoriasis bsa $nmbr$ n,C0033860
time from psoriatic arthritis diagnosis [a] years,C0040223;C3541383;C0439234
pasi [c] median min max,C4528685;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
crp mg l [b] median min max,C3890735;C0439268;C4048285;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
prior use of synthetic dmards n,C1524063;C0242708
tender joint count $nmbr$ $nmbr$ joints,C0451530
concomitant use of nsaids to week $nmbr$,C1524063;C0003211;C0332174;C0439230
swollen joint count $nmbr$ $nmbr$ joints,C0451521
prior anti tnf exposure,C0332152;C2826257
psoriasis bsa $nmbr$ n,C0033860
concomitant use of mtx to week $nmbr$,C1524063;C0025677;C1417487;C0332174;C0439230
pasi [c] median min max,C4528685;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior use of synthetic dmards n,C1524063;C0242708
week $nmbr$ czp dose combined,C0178602;C0869039;C1114758;C0205195
concomitant use of nsaids to week $nmbr$,C1524063;C0003211;C0332174;C0439230
pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C1861828;C1872109;C0205195
prior anti tnf exposure,C0332152;C2826257
baseline mtss subgroup,C1079230;C1515021
concomitant use of mtx to week $nmbr$,C1524063;C0025677;C1417487;C0332174;C0439230
mtss at baseline observed case,C0168634;C0868928;C1706255;C1706256;C1442488
week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
n observed,C0369718;C0441922;C1441672
week $nmbr$ czp dose combined,C0178602;C0869039;C1114758;C0205195
[min max],C0702093;C1524029;C3813700
pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C1861828;C1872109;C0205195
mmrm estimates ls mean se [ $nmbr$ ci],C0008107;C3259781
baseline mtss subgroup,C1079230;C1515021
mtss at,
mtss at baseline observed case,C0168634;C0868928;C1706255;C1706256;C1442488
czp baseline,C0168634;C1442488
n observed,C0369718;C0441922;C1441672
cfb at week $nmbr$,C0009002;C1824728
[min max],C0702093;C1524029;C3813700
observed case,C0868928;C1706255;C1706256
mmrm estimates ls mean se [ $nmbr$ ci],C0008107;C3259781
rate of non progression defined as cfb in mtss $nmbr$ $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
mtss at,
rate of non progression defined as cfb in mtss $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
czp baseline,C0168634;C1442488
blisibimod n $nmbr$,C3713826
cfb at week $nmbr$,C0009002;C1824728
gender female male,C0086582;C1706180;C1706428;C1706429
observed case,C0868928;C1706255;C1706256
central and south america,C0205099;C1879652;C0037713
rate of non progression defined as cfb in mtss $nmbr$ $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
selena sledai mean score sd,C3533236;C2699239
rate of non progression defined as cfb in mtss $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
selena sledai activity n,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
blisibimod n $nmbr$,C3713826
total score $nmbr$,C2964552
gender female male,C0086582;C1706180;C1706428;C1706429
dermal,C0221928;C1522447
central and south america,C0205099;C1879652;C0037713
immunologic,C0152036;C0205470
musculoskeletal,C0497254;C2707260
selena sledai mean score sd,C3533236;C2699239
renal,C0022646
selena sledai activity n,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
bilag a b or c domain score n,C1880389;C0449820;C4050231;C1883221;C3541951
total score $nmbr$,C2964552
mucocutaneous,
dermal,C0221928;C1522447
haematological,
immunologic,C0152036;C0205470
constitutional,C1511487
musculoskeletal,C0497254;C2707260
renal,C0022646
pga score mean sd,C0016410;C2699239;C3541266;C4050369
pga score range,C1514721;C2348147;C3542016
bilag a b or c domain score n,C1880389;C0449820;C4050231;C1883221;C3541951
mucocutaneous,
corticosteroid dose prednisone,C0001617;C0032952;C3536709
haematological,
dose equivalent mg sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
constitutional,C1511487
smedian prednisone dose n,C0032952;C0178602;C0869039;C1114758
pga score mean sd,C0016410;C2699239;C3541266;C4050369
systemic sle medications n,C0024141;C0013227;C0802604;C2598133;C4284232
pga score range,C1514721;C2348147;C3542016
any including corticosteroid,C0001617;C3536709
corticosteroid dose prednisone,C0001617;C0032952;C3536709
antimalarial,C0003374;C3536844;C4552582
dose equivalent mg sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
any immunosuppressive agent,C0021081
smedian prednisone dose n,C0032952;C0178602;C0869039;C1114758
mycophenolate any derivative,C0883242;C1527240
systemic sle medications n,C0024141;C0013227;C0802604;C2598133;C4284232
sle markers n,C0024141;C0005516
any including corticosteroid,C0001617;C3536709
anti dsdna positive,C0439178;C1446409;C1514241;C2825490;C3812269
antimalarial,C0003374;C3536844;C4552582
low c $nmbr$ c $nmbr$ and anti dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0012854;C0311474
any immunosuppressive agent,C0021081
upcr n,
mycophenolate any derivative,C0883242;C1527240
s $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
sle markers n,C0024141;C0005516
s $nmbr$ mg mmol,C0567349;C2348885
anti dsdna positive,C0439178;C1446409;C1514241;C2825490;C3812269
patients without diabetes,C0030705;C0011847;C0011849
low c $nmbr$ c $nmbr$ and anti dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0012854;C0311474
patients with diabetes,C0030705;C0011847;C0011849
upcr n,
enalapril n $nmbr$,C0014025
s $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
sacubitril valsartan n $nmbr$,C4033631
s $nmbr$ mg mmol,C0567349;C2348885
previous hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
patients without diabetes,C0030705;C0011847;C0011849
ntprobnp pg ml,C0669479;C0439297;C0754710
patients with diabetes,C0030705;C0011847;C0011849
treatments at randomisation,C0087111;C0034656
enalapril n $nmbr$,C0014025
mineralocorticoid receptor antagonist,C1579268
sacubitril valsartan n $nmbr$,C4033631
with diabetes,C0011847;C0011849
previous hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
without diabetes,C0011847;C0011849
ntprobnp pg ml,C0669479;C0439297;C0754710
sacubitril valsartan,C4033631
treatments at randomisation,C0087111;C0034656
difference $nmbr$ ci p value,C0008107;C1709380;C3259781
mineralocorticoid receptor antagonist,C1579268
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p,C0369773;C2603361
with diabetes,C0011847;C0011849
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
without diabetes,C0011847;C0011849
characteristic outcome,C1521970;C1274040
sacubitril valsartan,C4033631
nonblack n $nmbr$,
difference $nmbr$ ci p value,C0008107;C1709380;C3259781
standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p,C0369773;C2603361
bnp nt probnp,C0669479;C0754710
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
qrs duration ms,C2349943;C3539704;C3713294
characteristic outcome,C1521970;C1274040
serum potassium meq l,C0302353;C0439375;C0543465
nonblack n $nmbr$,
egfr ml kg per $nmbr$ $nmbr$ m $nmbr$,C1739039;C1300574;C3811844;C3812682
standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
hf signs and symptoms,C0220912;C0220913;C0311392;C0683368;C1457887
bnp nt probnp,C0669479;C0754710
paroxysmal nocturnal dyspnea,C1956415
qrs duration ms,C2349943;C3539704;C3713294
not present at screening but within previous year,C0150312;C0449450;C0205156;C0439234;C0439508;C1552607
serum potassium meq l,C0302353;C0439375;C0543465
present at screening,C0150312;C0449450
egfr ml kg per $nmbr$ $nmbr$ m $nmbr$,C1739039;C1300574;C3811844;C3812682
chest x ray,C0039985
hf signs and symptoms,C0220912;C0220913;C0311392;C0683368;C1457887
comorbid illnesses,C0221423
paroxysmal nocturnal dyspnea,C1956415
any cvd history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
not present at screening but within previous year,C0150312;C0449450;C0205156;C0439234;C0439508;C1552607
insulin treated dm,C0011816;C3250443
present at screening,C0150312;C0449450
non insulin treated dm,C0011816;C3250443
chest x ray,C0039985
prior revascularization,C0332152;C0581603;C2826257
comorbid illnesses,C0221423
adjusted hazard ratio,C0456081;C2985465
any cvd history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
outcomes by treatment spironolactone vs placebo,C0085415;C0037982;C0032042;C1696465;C1706408
insulin treated dm,C0011816;C3250443
black n $nmbr$ adjusted hazard ratio,C0456081;C2985465
non insulin treated dm,C0011816;C3250443
nonblack n $nmbr$ adjusted hazard ratio,C0456081;C2985465
prior revascularization,C0332152;C0581603;C2826257
sc belimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
adjusted hazard ratio,C0456081;C2985465
sri $nmbr$ response rate,C1420401;C0237629
outcomes by treatment spironolactone vs placebo,C0085415;C0037982;C0032042;C1696465;C1706408
$nmbr$ point reduction in selena sledai score,C0301630;C0392756;C1293152;C4551656
black n $nmbr$ adjusted hazard ratio,C0456081;C2985465
no worsening in pga,C0332271;C0016410;C3541266;C4050369;C1457868;C1546960
nonblack n $nmbr$ adjusted hazard ratio,C0456081;C2985465
no new a or and no more than $nmbr$ new bilag b domain score,C0205314;C0449820;C4050231
sc belimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baricitinib $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sri $nmbr$ response rate,C1420401;C0237629
us w $nmbr$,C0815353;C3889164
$nmbr$ point reduction in selena sledai score,C0301630;C0392756;C1293152;C4551656
row n $nmbr$,C1552840;C1552846
no worsening in pga,C0332271;C0016410;C3541266;C4050369;C1457868;C1546960
us n $nmbr$,C0815353;C3889164
no new a or and no more than $nmbr$ new bilag b domain score,C0205314;C0449820;C4050231
body mass index kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
baricitinib $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time from symptom onset of ra years median,C1320528
us w $nmbr$,C0815353;C3889164
time from ra diagnosis years median,C0556970;C0011900;C1704338;C1704656
row n $nmbr$,C1552840;C1552846
seropositivity status n,C0449438
us n $nmbr$,C0815353;C3889164
rf and acpa positive n,C0035448;C0201660;C0748398;C1547111;C0439178;C1446409;C1514241;C2825490;C3812269
body mass index kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
rf negative and acpa positive n,C0205160;C1513916;C2825415;C2825491;C3853545;C0439178;C1446409;C1514241;C2825490;C3812269
time from symptom onset of ra years median,C1320528
rf positive and acpa negative n,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
time from ra diagnosis years median,C0556970;C0011900;C1704338;C1704656
rf and acpa negative n,C0035448;C0201660;C0748398;C1547111;C0205160;C1513916;C2825415;C2825491;C3853545
seropositivity status n,C0449438
no of previous csdmards n,C0205156;C1552607
rf and acpa positive n,C0035448;C0201660;C0748398;C1547111;C0439178;C1446409;C1514241;C2825490;C3812269
current corticosteroid use n,C0521116;C0239126;C1705970
rf negative and acpa positive n,C0205160;C1513916;C2825415;C2825491;C3853545;C0439178;C1446409;C1514241;C2825490;C3812269
mtx average weekly dose mg week mean sd,C0366550;C2699239
rf positive and acpa negative n,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
tender joint count $nmbr$ mean sd,C0451530;C2699239
rf and acpa negative n,C0035448;C0201660;C0748398;C1547111;C0205160;C1513916;C2825415;C2825491;C3853545
swollen joint count $nmbr$ mean sd,C0451521;C2699239
no of previous csdmards n,C0205156;C1552607
patient global assessment of disease activity mean sd,C4054228;C0444504;C2347634;C2348143
current corticosteroid use n,C0521116;C0239126;C1705970
patient assessment of pain $nmbr$ $nmbr$ mm mean sd,C0679830
mtx average weekly dose mg week mean sd,C0366550;C2699239
physician global assessment of disease activity mean sd,C4050369;C0444504;C2347634;C2348143
tender joint count $nmbr$ mean sd,C0451530;C2699239
hscrp mean sd,C0444504;C2699239;C2347634;C2348143
swollen joint count $nmbr$ mean sd,C0451521;C2699239
das $nmbr$ hscrp mean sd,C0051767;C2699239;C0057671
patient global assessment of disease activity mean sd,C4054228;C0444504;C2347634;C2348143
esr mm h mean sd,C0456680;C2699239
patient assessment of pain $nmbr$ $nmbr$ mm mean sd,C0679830
bone erosion score mean sd,C0587240;C2699239
physician global assessment of disease activity mean sd,C4050369;C0444504;C2347634;C2348143
joint space narrowing score mean sd,C1859695;C2699239
hscrp mean sd,C0444504;C2699239;C2347634;C2348143
table baseline characteristics by study and blood pressure intervention in participants with baseline egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ or higher,C4684572;C0184661;C0886296;C1273869;C0168634;C0439445;C1442488;C0205250
das $nmbr$ hscrp mean sd,C0051767;C2699239;C0057671
esr mm h mean sd,C0456680;C2699239
bone erosion score mean sd,C0587240;C2699239
data are number of patients mean sd or median iqr accord action to control cardiovascular risk in diabetes acr albumin creatinine ratio egfr estimated glomerular filtration rate mdrd modification of diet in renal disease n a not applicable n r not reported sprint systolic blood pressure intervention trial defined in the accord trial as one or more of myocardial infarction stroke angina coronary artery bypass graft percutaneous transluminal coronary intervention or other revascularisation procedure defined in sprint as one or more of myocardial infarction acute coronary syndrome coronary revascularisation carotid revascularisation peripheral arterial disease with revascularisation greater than $nmbr$ stenosis of coronary carotid or lower extremity artery or abdominal aortic aneurysm $nmbr$ mm or larger $nmbr$ participants assigned the standard intervention and $nmbr$ allocated the intensive intervention had a fasting plasma glucose greater than $nmbr$ $nmbr$ mmol l at baseline estimated by four variable mdrd equation,C1511726;C3245479;C3714741;C2360800;C0444504;C2347634;C2348143;C0441472;C3266814;C0086153;C3671772;C0022658;C0205090;C0684010;C2603358;C0814861;C1704788;C3539106;C0205447;C0010055;C1260596;C0184661;C2700391;C3274430;C3539779;C0948089;C0085096;C1704436;C0581603;C0439093;C0007282;C0226415;C4330985;C4554674;C0549177;C0679646;C1704243;C1516050;C1552601;C0886296;C1273869;C0202042;C0455280;C1532563;C0168634;C1442488;C0750572;C0205450
joint space narrowing score mean sd,C1859695;C2699239
accord trial,C0680240;C0008976
sprint,
table baseline characteristics by study and blood pressure intervention in participants with baseline egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ or higher,C4684572;C0184661;C0886296;C1273869;C0168634;C0439445;C1442488;C0205250
standard n $nmbr$,C1442989;C2828392
intensive n $nmbr$,
data are number of patients mean sd or median iqr accord action to control cardiovascular risk in diabetes acr albumin creatinine ratio egfr estimated glomerular filtration rate mdrd modification of diet in renal disease n a not applicable n r not reported sprint systolic blood pressure intervention trial defined in the accord trial as one or more of myocardial infarction stroke angina coronary artery bypass graft percutaneous transluminal coronary intervention or other revascularisation procedure defined in sprint as one or more of myocardial infarction acute coronary syndrome coronary revascularisation carotid revascularisation peripheral arterial disease with revascularisation greater than $nmbr$ stenosis of coronary carotid or lower extremity artery or abdominal aortic aneurysm $nmbr$ mm or larger $nmbr$ participants assigned the standard intervention and $nmbr$ allocated the intensive intervention had a fasting plasma glucose greater than $nmbr$ $nmbr$ mmol l at baseline estimated by four variable mdrd equation,C1511726;C3245479;C3714741;C2360800;C0444504;C2347634;C2348143;C0441472;C3266814;C0086153;C3671772;C0022658;C0205090;C0684010;C2603358;C0814861;C1704788;C3539106;C0205447;C0010055;C1260596;C0184661;C2700391;C3274430;C3539779;C0948089;C0085096;C1704436;C0581603;C0439093;C0007282;C0226415;C4330985;C4554674;C0549177;C0679646;C1704243;C1516050;C1552601;C0886296;C1273869;C0202042;C0455280;C1532563;C0168634;C1442488;C0750572;C0205450
clinical atherosclerotic disease,C0205210;C0012634
accord trial,C0680240;C0008976
antihypertensive agents n per patient,C0003364
sprint,
n r,C0205090;C0684010;C2603358
standard n $nmbr$,C1442989;C2828392
urinary acr mg mmol,C0567349;C2348885
intensive n $nmbr$,
sprint acr,C1412134;C1515941
clinical atherosclerotic disease,C0205210;C0012634
sprint acr $nmbr$ $nmbr$,C1412134;C1515941
antihypertensive agents n per patient,C0003364
accord acr,C1412134;C1515941
n r,C0205090;C0684010;C2603358
accord acr $nmbr$ $nmbr$,C1412134;C1515941
urinary acr mg mmol,C0567349;C2348885
sustain $nmbr$,C0443318;C2732140
sprint acr,C1412134;C1515941
pooled analysis of sustain $nmbr$ $nmbr$ trials,C0002778;C0936012;C1524024;C0443318;C2732140;C0008976
sprint acr $nmbr$ $nmbr$,C1412134;C1515941
semaglutide,C3885068
accord acr,C1412134;C1515941
sitagliptin,C1565750
accord acr $nmbr$ $nmbr$,C1412134;C1515941
semaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sustain $nmbr$,C0443318;C2732140
exenatide er,C3810541;C3811131
pooled analysis of sustain $nmbr$ $nmbr$ trials,C0002778;C0936012;C1524024;C0443318;C2732140;C0008976
placebo add on to basal insulin,C1883712;C0650607
semaglutide,C3885068
non elderly,C1518422;C0001792;C1999167
sitagliptin,C1565750
elderly,C0001792;C1999167
semaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bw kg,C0022718;C0439209;C4054209
exenatide er,C3810541;C3811131
mdrd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
placebo add on to basal insulin,C1883712;C0650607
blood pressure mmhg systolic,C0005823;C0039155;C1271104;C1272641
non elderly,C1518422;C0001792;C1999167
dyspnea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
elderly,C0001792;C1999167
number of patients with exacerbations in the previous $nmbr$ months n,C2360800;C4086268;C0205156;C1552607
bw kg,C0022718;C0439209;C4054209
ccq total score,C2964552
mdrd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
tofacitinib $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
blood pressure mmhg systolic,C0005823;C0039155;C1271104;C1272641
induction study treatment,C4049995
dyspnea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
in remission at maintenance study baseline,C0544452;C0687702
number of patients with exacerbations in the previous $nmbr$ months n,C2360800;C4086268;C0205156;C1552607
ibdq total score,C2964552
ccq total score,C2964552
baseline crp category mg l,C0168634;C0439268;C1442488
tofacitinib $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior anti tnf treatment,C1514463;C1448177
induction study treatment,C4049995
prior anti tnf failure,C0332152;C2826257
in remission at maintenance study baseline,C0544452;C0687702
prior immunosuppressant failure,C0231174;C0680095
ibdq total score,C2964552
prior corticosteroid treatment,C1514463;C0001617;C3536709
baseline crp category mg l,C0168634;C0439268;C1442488
steroid use at baseline mg day,C0281991;C0439422
prior anti tnf treatment,C1514463;C1448177
subsets,C1515021
prior anti tnf failure,C0332152;C2826257
dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior immunosuppressant failure,C0231174;C0680095
semaglutide exposure nmol l,C0274281;C0439282;C0332157
prior corticosteroid treatment,C1514463;C0001617;C3536709
mean change from baseline points,C0392747;C0443172;C1705241;C4319952
steroid use at baseline mg day,C0281991;C0439422
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg points,C0392747;C0443172;C1705241;C4319952;C1552961;C2347617;C3714763
subsets,C1515021
mean change from baseline,C0392747;C0443172;C1705241;C4319952
dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg,C0392747;C0443172;C1705241;C4319952;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
semaglutide exposure nmol l,C0274281;C0439282;C0332157
all participants,C0679646
mean change from baseline points,C0392747;C0443172;C1705241;C4319952
$nmbr$ participants,C0679646
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg points,C0392747;C0443172;C1705241;C4319952;C1552961;C2347617;C3714763
with highest bwa,C1522410;C0006041
mean change from baseline,C0392747;C0443172;C1705241;C4319952
with lowest bwb,C1708760
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg,C0392747;C0443172;C1705241;C4319952;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with highest hba $nmbr$ cc,C0008318;C3538933
all participants,C0679646
with lowest hba $nmbr$ cd,C0007928;C0034283;C4552032
$nmbr$ participants,C0679646
sustain $nmbr$ semaglutide vs placebo,C0443318;C2732140;C3885068;C0032042;C1696465;C1706408
with highest bwa,C1522410;C0006041
sustain $nmbr$ semaglutide vs sitagliptin $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with lowest bwb,C1708760
sustain $nmbr$ semaglutide vs exenatide er $nmbr$ $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with highest hba $nmbr$ cc,C0008318;C3538933
sustain $nmbr$ semaglutide vs iglar,C0443318;C2732140;C3885068
with lowest hba $nmbr$ cd,C0007928;C0034283;C4552032
sustain $nmbr$ semaglutide add on to insulin vs placebo,C0443318;C2732140;C1883712;C0021641;C1533581;C1579433;C3714501;C0032042;C1696465;C1706408
sustain $nmbr$ semaglutide vs placebo,C0443318;C2732140;C3885068;C0032042;C1696465;C1706408
$nmbr$ wk,C0332174;C0439230
sustain $nmbr$ semaglutide vs sitagliptin $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline characteristics mean sd a,C4684572;C2699239
sustain $nmbr$ semaglutide vs exenatide er $nmbr$ $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
subject disposition n,C0681850;C0743223;C1705555;C1550501;C1706203;C2349001;C2697811
sustain $nmbr$ semaglutide vs iglar,C0443318;C2732140;C3885068
exposed,C0332157
sustain $nmbr$ semaglutide add on to insulin vs placebo,C0443318;C2732140;C1883712;C0021641;C1533581;C1579433;C3714501;C0032042;C1696465;C1706408
trial completers,C0008976
$nmbr$ wk,C0332174;C0439230
premature treatment discontinuation,C0457454;C1444662;C4552847
baseline characteristics mean sd a,C4684572;C2699239
subjects with imputed value for end of treatment body weight,C0681850;C1550501;C1706203;C2349001;C2697811;C2983672;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
subject disposition n,C0681850;C0743223;C1705555;C1550501;C1706203;C2349001;C2697811
number of subjects,C0237753;C0449788
exposed,C0332157
adverse events any grade,C0877248;C1705413;C0441800;C0919553;C3244287
trial completers,C0008976
serious adverse events,C1519255
premature treatment discontinuation,C0457454;C1444662;C4552847
gastrointestinal disorders,C0017178
subjects with imputed value for end of treatment body weight,C0681850;C1550501;C1706203;C2349001;C2697811;C2983672;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
adverse events leading to premature treatment discontinuation,C0877248;C1705413;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
number of subjects,C0237753;C0449788
nausea and or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767;C0877248;C1705413
adverse events any grade,C0877248;C1705413;C0441800;C0919553;C3244287
participants with a history of cabg,C0679646;C0010055
serious adverse events,C1519255
participants without a history of cabg,C0679646;C0010055
gastrointestinal disorders,C0017178
empagliflozin n $nmbr$,C3490348
adverse events leading to premature treatment discontinuation,C0877248;C1705413;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
other missing,C1551393;C1705492;C3272743
nausea and or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767;C0877248;C1705413
north america plus australia and new zealand,C0028405;C0004340;C0027978;C0324547
participants with a history of cabg,C0679646;C0010055
time since cabg,C0040223;C3541383
participants without a history of cabg,C0679646;C0010055
cv disease,C0007222
empagliflozin n $nmbr$,C3490348
multi vessel coronary artery disease,C1299432
other missing,C1551393;C1705492;C3272743
history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
north america plus australia and new zealand,C0028405;C0004340;C0027978;C0324547
peripheral artery diseaseb,C0489868
time since cabg,C0040223;C3541383
single vessel coronary artery diseasea,C0265903;C0005847
cv disease,C0007222
cardiac failurec,C0018787;C1522601
multi vessel coronary artery disease,C1299432
hba $nmbr$ c mmol mold,C0019016;C0369241;C1825777;C3538758
history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hba $nmbr$ c d,C0019016;C1825777;C3538758
peripheral artery diseaseb,C0489868
glucose lowering therapy,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
single vessel coronary artery diseasea,C0265903;C0005847
medication taken alone or in combination,C0205171;C0439044;C0679994;C0205195;C1947911;C3811910
cardiac failurec,C0018787;C1522601
dual therapy,C0039798;C0087111;C1363945
hba $nmbr$ c mmol mold,C0019016;C0369241;C1825777;C3538758
angiotensin converting enzyme inhibitor angiotensin receptor blocker,C0034787;C1622222
hba $nmbr$ c d,C0019016;C1825777;C3538758
renin inhibitor,C1960108;C3537174;C4521920
glucose lowering therapy,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
lipid lowering therapy,C0585943
medication taken alone or in combination,C0205171;C0439044;C0679994;C0205195;C1947911;C3811910
vitamin k antagonist,C1096489;C2267235
dual therapy,C0039798;C0087111;C1363945
total cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
angiotensin converting enzyme inhibitor angiotensin receptor blocker,C0034787;C1622222
ldl cholesterol mmol lf,C1416933;C2986618;C4554443
renin inhibitor,C1960108;C3537174;C4521920
hdl cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
lipid lowering therapy,C0585943
triacylglycerol mmol le,C0023190;C0439090;C1423767;C2697858
vitamin k antagonist,C1096489;C2267235
egfr mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
total cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
placebo $nmbr$ $nmbr$ ml n $nmbr$,C0032042;C0439526;C1705224;C3887665;C1696465;C1706408
ldl cholesterol mmol lf,C1416933;C2986618;C4554443
dupiiumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hdl cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
prebronchodilator fevi liters,C0429706;C0475211;C0849974;C1561566;C4528367
triacylglycerol mmol le,C0023190;C0439090;C1423767;C2697858
percent of predicted normal value,C1882327
egfr mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
fevi reversibility,C3830088
placebo $nmbr$ $nmbr$ ml n $nmbr$,C0032042;C0439526;C1705224;C3887665;C1696465;C1706408
no of exacerbations in past year,C4086268;C0439234;C0439508
dupiiumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
use of high dose inhaled glucocorticoid no,C1524063;C0444956
prebronchodilator fevi liters,C0429706;C0475211;C0849974;C1561566;C4528367
ongoing atopic or allergic condition no,C0549178;C0392707;C0851444
percent of predicted normal value,C1882327
nasal polyposis or chronic rhinosinusitis no,C0027430;C0149516
fevi reversibility,C3830088
no of pack yr,C1968515;C0439234;C2825051;C2828395
no of exacerbations in past year,C4086268;C0439234;C0439508
biomarker levels,C0005516;C0441889
use of high dose inhaled glucocorticoid no,C1524063;C0444956
blood eosinophil count cells mm,C4330985;C4554674
ongoing atopic or allergic condition no,C0549178;C0392707;C0851444
feno ppb,C1415800
nasal polyposis or chronic rhinosinusitis no,C0027430;C0149516
total ige lu ml,C0439175;C2697941;C0439810
no of pack yr,C1968515;C0439234;C2825051;C2828395
relative risk vs placebo $nmbr$ cl,C0242492;C0032042;C0596019;C1696465;C1706408
biomarker levels,C0005516;C0441889
dupilumab $nmbr$,C3660996
blood eosinophil count cells mm,C4330985;C4554674
$nmbr$ cells mm^,C4330985;C4554674
feno ppb,C1415800
$nmbr$ ppb,C1415800
total ige lu ml,C0439175;C2697941;C0439810
eosinoohil count,C0750480;C1705566
relative risk vs placebo $nmbr$ cl,C0242492;C0032042;C0596019;C1696465;C1706408
gene,C0017337
dupilumab $nmbr$,C3660996
snp,C0752046;C1527094
$nmbr$ cells mm^,C4330985;C4554674
short term n $nmbr$,C0443303
$nmbr$ ppb,C1415800
long term n $nmbr$,C0443252
eosinoohil count,C0750480;C1705566
p $nmbr$ cl,C0369773;C0596019;C2603361
gene,C0017337
octi,
snp,C0752046;C1527094
rs $nmbr$,C0035970;C3714753;C3813325
short term n $nmbr$,C0443303
atm locus,C3711796;C1708726
long term n $nmbr$,C0443252
atm locm,C3711796
ocn,C1412791;C2347392
p $nmbr$ cl,C0369773;C0596019;C2603361
octi,
octi mate $nmbr$,C0682323;C1260875
rs $nmbr$,C0035970;C3714753;C3813325
short term^,C0443303
atm locus,C3711796;C1708726
long term,C0443252
atm locm,C3711796
rs $nmbr$ rs $nmbr$,C0035970;C3714753;C3813325
ocn,C1412791;C2347392
rs $nmbr$ aa rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C4554792;C3714753;C3813325
octi mate $nmbr$,C0682323;C1260875
rs $nmbr$ ac rs $nmbr$,C0001246;C0003354;C1412573;C2000891;C3539770
short term^,C0443303
rs $nmbr$ cc rs $nmbr$,C0035970;C0008318;C3538933;C3714753;C3813325
long term,C0443252
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
rs $nmbr$ rs $nmbr$,C0035970;C3714753;C3813325
active canakinumab n $nmbr$ $nmbr$,C0205177;C2718773;C3853793;C3888249
rs $nmbr$ aa rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C4554792;C3714753;C3813325
history of congestive heart failure,C0455531
rs $nmbr$ ac rs $nmbr$,C0001246;C0003354;C1412573;C2000891;C3539770
serum creatinine mol l,C0201976;C0347982;C0600061
rs $nmbr$ cc rs $nmbr$,C0035970;C0008318;C3538933;C3714753;C3813325
serum albumin g l,C0439294;C0456615
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
serum calcium mmol l,C0036785;C1532563;C0728876
active canakinumab n $nmbr$ $nmbr$,C0205177;C2718773;C3853793;C3888249
serum phosphate mmol l,C0036820;C1532563
history of congestive heart failure,C0455531
protein in urine $nmbr$,C0033687
serum creatinine mol l,C0201976;C0347982;C0600061
glucose in urine $nmbr$,C0004076
serum albumin g l,C0439294;C0456615
urine albumin creatinine ratio mg mmol,C0567349;C2348885
serum calcium mmol l,C0036785;C1532563;C0728876
canakinumab dose,C0178602;C0869039;C1114758
serum phosphate mmol l,C0036820;C1532563
ptrend across doses,C0178602
protein in urine $nmbr$,C0033687
all doses,C0178602
glucose in urine $nmbr$,C0004076
incidence rate n,C1708485
urine albumin creatinine ratio mg mmol,C0567349;C2348885
uacr $nmbr$ mg mmol,C0567349;C2348885
canakinumab dose,C0178602;C0869039;C1114758
figure $nmbr$ clinical remission from week $nmbr$ through week $nmbr$ of treatment among a all randomised patients entering the long term extension and b by induction study subgroups sc subcutaneous tnf tumour necrosis factor q $nmbr$ w every $nmbr$ weeks q $nmbr$ w every $nmbr$ weeks,C0205210;C0544452;C0687702;C0332174;C0439230;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0030705;C1522196;C0443252;C0231448;C1880641;C0033453;C0046774;C1824728
ptrend across doses,C0178602
tnf antagonist naive,C1448177;C0231491
all doses,C0178602
tnf antagonist exposed,C1448177;C0231491;C0332157
incidence rate n,C1708485
vedolizumab n $nmbr$,C2742797
uacr $nmbr$ mg mmol,C0567349;C2348885
age y median min max,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
figure $nmbr$ clinical remission from week $nmbr$ through week $nmbr$ of treatment among a all randomised patients entering the long term extension and b by induction study subgroups sc subcutaneous tnf tumour necrosis factor q $nmbr$ w every $nmbr$ weeks q $nmbr$ w every $nmbr$ weeks,C0205210;C0544452;C0687702;C0332174;C0439230;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0030705;C1522196;C0443252;C0231448;C1880641;C0033453;C0046774;C1824728
sex male n,C0086582
tnf antagonist naive,C1448177;C0231491
weight kg median min max,C0005910;C1532757;C0043100;C1305866;C1705104
tnf antagonist exposed,C1448177;C0231491;C0332157
duration of disease y median min max,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
vedolizumab n $nmbr$,C2742797
complete mayo clinic score median min max,C0205197;C0002424;C0442592;C0725685;C3853530;C4283785
age y median min max,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
history of elms n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
sex male n,C0086582
elms n,C0330531;C2980688
weight kg median min max,C0005910;C1532757;C0043100;C1305866;C1705104
concomitant medications yes n,C0521115;C0013227;C0802604;C2598133;C4284232
duration of disease y median min max,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
imm only,C0205470
complete mayo clinic score median min max,C0205197;C0002424;C0442592;C0725685;C3853530;C4283785
no cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
history of elms n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
type of tnf antagonist failure n o,C0332307;C1547052
elms n,C0330531;C2980688
weight kg median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
concomitant medications yes n,C0521115;C0013227;C0802604;C2598133;C4284232
disease duration y median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
imm only,C0205470
cdai score median min max,C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
no cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
prior surgery for cd n,C0455610;C0007928;C0034283;C4552032
type of tnf antagonist failure n o,C0332307;C1547052
history of fistullzing disease n,C0683519;C0730226;C0850708;C0944983
weight kg median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
draining fistulae n,C0013103;C0180499;C4265177;C0016169
disease duration y median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
type of tnf antagonist failure n,C0332307;C1547052
cdai score median min max,C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
inadequate response ^,C0871261;C1704632;C1706817;C2911692
prior surgery for cd n,C0455610;C0007928;C0034283;C4552032
loss of response s,C1517945;C0871261;C1704632;C1706817;C2911692
history of fistullzing disease n,C0683519;C0730226;C0850708;C0944983
figure $nmbr$ rbs and sfs in patients with uc percentage change from baseline in rbs in the overall itt a tnf antagonist naive b and tnf antagonist exposed c populations and in sfs in the overall itt d tnf antagonist naive e and tnf antagonist exposed f populations after vdz or pbo administration adata points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se bdifference adjusted o f c $nmbr$ h $nmbr$ a ngcei[v,C0392475;C0030705;C0392747;C0443172;C1705241;C4319952;C0282416;C1561607;C3887647;C0231491;C2348484;C1448177;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0033727;C0369286;C0441932;C0564385;C4528284
draining fistulae n,C0013103;C0180499;C4265177;C0016169
type of tnf antagonist failure n,C0332307;C1547052
figure $nmbr$ proportion of patients with uc who achieved the composite score rbs $nmbr$ and sfs $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance cl confidence interval ns nonsignificance pbo placebo rbs rectal bleeding subscore sfs stool frequency subscore vdz vedolizumab,C1709707;C0030705;C3272598;C4055211;C0392475;C0814896;C0237881;C1709380;C0009667;C2742797
inadequate response ^,C0871261;C1704632;C1706817;C2911692
figure $nmbr$ abdominal pain subscores in patients with cd percentage change from baseline in aps in overall itt a tnf antagonist naive s and tnf antagonist exposed c populations and percentage change from baseline in lsfs in overall itt d tnf antagonist naive and tnf antagonist exposed f populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0000737;C4554323;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C1448177;C0231491;C2348484;C0243902;C1456377;C3538776;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
loss of response s,C1517945;C0871261;C1704632;C1706817;C2911692
figure $nmbr$ combined score of abdominal pain and loose stool frequency in patients with cd percentage change from baseline in aps and lsfs in the overall itt a tnf antagonist naive s and tnf antagonist exposed c populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0582148;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C0243902;C1456377;C3538776;C1448177;C0231491;C2348484;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
figure $nmbr$ rbs and sfs in patients with uc percentage change from baseline in rbs in the overall itt a tnf antagonist naive b and tnf antagonist exposed c populations and in sfs in the overall itt d tnf antagonist naive e and tnf antagonist exposed f populations after vdz or pbo administration adata points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se bdifference adjusted o f c $nmbr$ h $nmbr$ a ngcei[v,C0392475;C0030705;C0392747;C0443172;C1705241;C4319952;C0282416;C1561607;C3887647;C0231491;C2348484;C1448177;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0033727;C0369286;C0441932;C0564385;C4528284
figure $nmbr$ proportion of patients with cd gemini $nmbr$ and $nmbr$ who achieved the average daily composite score of aps $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance aps abdominal pain subscore cl confidence interval lsfs loose stool frequency subscore ns nonsignificance pbo placebo vdz vedolizumab,C1709707;C0030705;C0007928;C0034283;C4552032;C3272598;C4055211;C0001468;C1706670;C0814896;C0237881;C1709380;C0518090;C2742797;C4082250
figure $nmbr$ proportion of patients with uc who achieved the composite score rbs $nmbr$ and sfs $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance cl confidence interval ns nonsignificance pbo placebo rbs rectal bleeding subscore sfs stool frequency subscore vdz vedolizumab,C1709707;C0030705;C3272598;C4055211;C0392475;C0814896;C0237881;C1709380;C0009667;C2742797
tnf na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
figure $nmbr$ abdominal pain subscores in patients with cd percentage change from baseline in aps in overall itt a tnf antagonist naive s and tnf antagonist exposed c populations and percentage change from baseline in lsfs in overall itt d tnf antagonist naive and tnf antagonist exposed f populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0000737;C4554323;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C1448177;C0231491;C2348484;C0243902;C1456377;C3538776;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
pain vas mean change from baselinea,C0392747;C0443172;C1705241;C4319952
sf $nmbr$ bodily pain mean change from baselineb,C0392747;C0443172;C1705241;C4319952
figure $nmbr$ combined score of abdominal pain and loose stool frequency in patients with cd percentage change from baseline in aps and lsfs in the overall itt a tnf antagonist naive s and tnf antagonist exposed c populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0582148;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C0243902;C1456377;C3538776;C1448177;C0231491;C2348484;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
eq $nmbr$ d $nmbr$ l no pain or discomfortc,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
figure $nmbr$ proportion of patients with cd gemini $nmbr$ and $nmbr$ who achieved the average daily composite score of aps $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance aps abdominal pain subscore cl confidence interval lsfs loose stool frequency subscore ns nonsignificance pbo placebo vdz vedolizumab,C1709707;C0030705;C0007928;C0034283;C4552032;C3272598;C4055211;C0001468;C1706670;C0814896;C0237881;C1709380;C0518090;C2742797;C4082250
tnf ir,C0022065;C0022071;C1448132
tnf na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
pain vas mean change from baselined,C0392747;C0443172;C1705241;C4319952
pain vas mean change from baselinea,C0392747;C0443172;C1705241;C4319952
sf $nmbr$ bodily pain mean change from baselinee,C0392747;C0443172;C1705241;C4319952
sf $nmbr$ bodily pain mean change from baselineb,C0392747;C0443172;C1705241;C4319952
eq $nmbr$ d $nmbr$ l no pain or discomfortf,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
eq $nmbr$ d $nmbr$ l no pain or discomfortc,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
low nfs nfs,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
tnf ir,C0022065;C0022071;C1448132
indeterminate nfs $nmbr$ $nmbr$ nfs,C0205258;C1555018
pain vas mean change from baselined,C0392747;C0443172;C1705241;C4319952
high nfs nfs $nmbr$ $nmbr$ n $nmbr$,C0205250;C1513839;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
sf $nmbr$ bodily pain mean change from baselinee,C0392747;C0443172;C1705241;C4319952
p value low vs high nfs^,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205250;C1555018;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
eq $nmbr$ d $nmbr$ l no pain or discomfortf,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
p j $nmbr$ trend,C1521798;C4554533
low nfs nfs,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
body mass index kg m^^,C0022718;C0439209;C4054209
indeterminate nfs $nmbr$ $nmbr$ nfs,C0205258;C1555018
smoking current,C0521116;C1705970
high nfs nfs $nmbr$ $nmbr$ n $nmbr$,C0205250;C1513839;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
ezetimibe simvastatin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
p value low vs high nfs^,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205250;C1555018;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
past cardiovascular history no,C1880008
p j $nmbr$ trend,C1521798;C4554533
any lipid lowering agent use,C0042153;C0457083;C1947944
body mass index kg m^^,C0022718;C0439209;C4054209
at index event no,C0441471;C4019010
smoking current,C0521116;C1705970
type of event,C1561488
ezetimibe simvastatin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
ml with st segment elevation,C0439526;C1705224;C3887665
past cardiovascular history no,C1880008
ml without st segment elevation,C0439526;C1705224;C3887665
any lipid lowering agent use,C0042153;C0457083;C1947944
diagnostic catheterization,C0596429
at index event no,C0441471;C4019010
prerandomization pci,C4049621
type of event,C1561488
laboratory parameters median iqr,C0022877;C0449381;C3244292;C4283904
ml with st segment elevation,C0439526;C1705224;C3887665
alanine aminotransferase u l,C0001899;C0439339;C0057041;C1415274;C3887708
ml without st segment elevation,C0439526;C1705224;C3887665
aspartate aminotransferase u l,C0004002;C0439339
diagnostic catheterization,C0596429
gamma glutamyltransferase u l,C0017040;C0439339
prerandomization pci,C4049621
c reactive protein u l,C0006560;C0439339;C1413716;C4048285
laboratory parameters median iqr,C0022877;C0449381;C3244292;C4283904
platelets xlooo mm^,C4330985;C4554674
alanine aminotransferase u l,C0001899;C0439339;C0057041;C1415274;C3887708
total cholesterol mg dl ^,C0201950;C0439269;C0543421
aspartate aminotransferase u l,C0004002;C0439339
apolipoprotein b mg dl,C0003593;C0439269
gamma glutamyltransferase u l,C0017040;C0439339
hemoglobin ale,C0678386;C2632076
c reactive protein u l,C0006560;C0439339;C1413716;C4048285
outcome n,C1274040
platelets xlooo mm^,C4330985;C4554674
high nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
total cholesterol mg dl ^,C0201950;C0439269;C0543421
low nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
apolipoprotein b mg dl,C0003593;C0439269
placebo simva,C0032042;C1696465;C1706408
hemoglobin ale,C0678386;C2632076
eze simva,
outcome n,C1274040
death from cv causes major coronary event or nonfatal stroke,C0376297;C0038454;C4554100
high nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
secondary endpoints,C4528314
low nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
$nmbr$ death from any cause major coronary event or nonfatal stroke,C0007465;C0376297;C0038454;C4554100
placebo simva,C0032042;C1696465;C1706408
ii death from coronary heart disease nonfatal mi coronary revascularization $nmbr$ days,C0376297
eze simva,
iii death from cv causes nonfatal mi hospitalization for ua all revascularization $nmbr$ days nonfatal stroke,C0007465;C0019993;C0041580;C0042014;C0038454;C4554100
death from cv causes major coronary event or nonfatal stroke,C0376297;C0038454;C4554100
tertiary endpoints,C0205372;C2349179
secondary endpoints,C4528314
death from coronary heart disease,C0376297
$nmbr$ death from any cause major coronary event or nonfatal stroke,C0007465;C0376297;C0038454;C4554100
nonfatal ml,C0439526;C1705224;C3887665
ii death from coronary heart disease nonfatal mi coronary revascularization $nmbr$ days,C0376297
urgent coronaiy revascularization $nmbr$ days,C0439609;C0439228;C3272275
iii death from cv causes nonfatal mi hospitalization for ua all revascularization $nmbr$ days nonfatal stroke,C0007465;C0019993;C0041580;C0042014;C0038454;C4554100
hospitalization for unstable angina,C0019993;C0002965
tertiary endpoints,C0205372;C2349179
clinical endpoint,C2347784
death from coronary heart disease,C0376297
km rates p s,C0234833;C0722388
nonfatal ml,C0439526;C1705224;C3887665
km rates e s,C3887676;C0871208;C1521828
urgent coronaiy revascularization $nmbr$ days,C0439609;C0439228;C3272275
hr $nmbr$ c,
hospitalization for unstable angina,C0019993;C0002965
primary endpoint^,C2986535
clinical endpoint,C2347784
nfs,C1555018
km rates p s,C0234833;C0722388
nfs $nmbr$ $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
km rates e s,C3887676;C0871208;C1521828
secondary p,C0027627;C0175668;C0205436
hr $nmbr$ c,
secondary ip,C1308226;C4049997
primary endpoint^,C2986535
secondary iii,C0439070;C1705160
nfs,C1555018
p inte faction,C0369773;C2603361
nfs $nmbr$ $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
arr,C2170357;C4084934
secondary p,C0027627;C0175668;C0205436
nnt,C1417750
secondary ip,C1308226;C4049997
upa $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
secondary iii,C0439070;C1705160
characteristic_name,C0027365;C1547383;C4522128
p inte faction,C0369773;C2603361
characteristic_level,C0441889;C0456079;C1547707;C2946261
arr,C2170357;C4084934
n america,C0369718;C0002454;C0441922
nnt,C1417750
w europe,C0015176
upa $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
e europe,C0015176
characteristic_name,C0027365;C1547383;C4522128
placebo n l $nmbr$,C0032042;C1696465;C1706408
characteristic_level,C0441889;C0456079;C1547707;C2946261
upadacitinib $nmbr$ mg n l $nmbr$,C0439268
n america,C0369718;C0002454;C0441922
time since rheumatoid arthritis diagnosis years,C0556970;C0003873
w europe,C0015176
u $nmbr$ $nmbr$ $nmbr$,C0439148
e europe,C0015176
tj $nmbr$,C0039247
placebo n l $nmbr$,C0032042;C1696465;C1706408
age years geographical distribution of patients,C0001782
upadacitinib $nmbr$ mg n l $nmbr$,C0439268
previous bdmard received,C0205156;C1552607;C1514756
time since rheumatoid arthritis diagnosis years,C0556970;C0003873
stratum $nmbr$ inadequate response or intolerance to $nmbr$ $nmbr$ bdmards of same moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
u $nmbr$ $nmbr$ $nmbr$,C0439148
stratum $nmbr$ inadequate response or intolerance to $nmbr$ bdmards of same moa or $nmbr$ of multiple moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652;C0439064;C4551881
tj $nmbr$,C0039247
inadequate response or intolerance to $nmbr$ anti tnfdrug,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
age years geographical distribution of patients,C0001782
lack of efficacy with $nmbr$ bdmard,C0235828
previous bdmard received,C0205156;C1552607;C1514756
lack of efficacy with $nmbr$ anti interleukin $nmbr$,C0235828;C0021764;C1527200
stratum $nmbr$ inadequate response or intolerance to $nmbr$ $nmbr$ bdmards of same moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
t] $nmbr$,C2603360
stratum $nmbr$ inadequate response or intolerance to $nmbr$ bdmards of same moa or $nmbr$ of multiple moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652;C0439064;C4551881
csdmard use at baseline^,C0042153;C0457083;C1947944
inadequate response or intolerance to $nmbr$ anti tnfdrug,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
methotrexate alone^,C0025677;C0205171;C0439044;C0679994
lack of efficacy with $nmbr$ bdmard,C0235828
methotrexate plus other csdmardfl,C0025677
lack of efficacy with $nmbr$ anti interleukin $nmbr$,C0235828;C0021764;C1527200
methotrexate dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
t] $nmbr$,C2603360
csdmard otherthan methotrexate,C0025677
csdmard use at baseline^,C0042153;C0457083;C1947944
chloroquine,C0008269
methotrexate alone^,C0025677;C0205171;C0439044;C0679994
oral glucocorticoid use,C1527415;C0017710
methotrexate plus other csdmardfl,C0025677
oral glucocorticoid dose mg prednisone equivalent,C0205163;C0439185
methotrexate dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rheumatoid factor and acpa positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
csdmard otherthan methotrexate,C0025677
rheumatoid factor or acpa positive or both,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
chloroquine,C0008269
tender joint count of $nmbr$ joints,C0451530
oral glucocorticoid use,C1527415;C0017710
swollen joint count of $nmbr$ joints,C0451521
oral glucocorticoid dose mg prednisone equivalent,C0205163;C0439185
patient s ga $nmbr$ $nmbr$ mm vas,C0030705;C0042815;C3536884;C3827561
rheumatoid factor and acpa positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
pain $nmbr$ $nmbr$ mm vas,C0042815;C4330985;C4554674
rheumatoid factor or acpa positive or both,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
physician s ga $nmbr$ $nmbr$ mmvas,C0031831;C0804815;C0016993
tender joint count of $nmbr$ joints,C0451530
clinical disease activity index,C3869583
swollen joint count of $nmbr$ joints,C0451521
morning stiffness severity $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
patient s ga $nmbr$ $nmbr$ mm vas,C0030705;C0042815;C3536884;C3827561
morning stiffness duration min,C0702093;C1524029;C3813700
pain $nmbr$ $nmbr$ mm vas,C0042815;C4330985;C4554674
uniti $nmbr$ and uniti $nmbr$ im uniti,
physician s ga $nmbr$ $nmbr$ mmvas,C0031831;C0804815;C0016993
ustekinumab n $nmbr$,C1608841
clinical disease activity index,C3869583
cd duration y,C0007928;C0034283;C4552032
morning stiffness severity $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
involved gl areas,C1879646;C0018229;C1423073;C1427674
morning stiffness duration min,C0702093;C1524029;C3813700
ileum only n,C0020885;C0369718;C0441922
uniti $nmbr$ and uniti $nmbr$ im uniti,
colon only n,C0009368;C3888384;C0369718;C0441922
ustekinumab n $nmbr$,C1608841
ileum and colon n,C0020885;C0009368;C3888384
cd duration y,C0007928;C0034283;C4552032
proximal gl tract n,C0205107;C0018229;C1423073;C1427674;C4489236
involved gl areas,C1879646;C0018229;C1423073;C1427674
perianal n,C0442158
ileum only n,C0020885;C0369718;C0441922
cd complications,C0009566;C1171258
colon only n,C0009368;C3888384;C0369718;C0441922
intra abdominal abscess past,C0243001
ileum and colon n,C0020885;C0009368;C3888384
$nmbr$ [ $nmbr$,
proximal gl tract n,C0205107;C0018229;C1423073;C1427674;C4489236
sinus tracts perforation ^ n,C0854572
perianal n,C0442158
fistula n,C0016169
cd complications,C0009566;C1171258
current n,C0521116;C1705970
intra abdominal abscess past,C0243001
bowel stricturing n,C0021853;C4083257;C1261287;C0369718;C0441922
$nmbr$ [ $nmbr$,
patients with evaluable endoscopy,C2986511;C0014245
sinus tracts perforation ^ n,C0854572
data n,C1511726;C3245479;C3714741
fistula n,C0016169
patients with eligible ses cd score,C0030705;C0007928;C0034283;C4552032
current n,C0521116;C1705970
or ulcerations n,C0041582
bowel stricturing n,C0021853;C4083257;C1261287;C0369718;C0441922
ses cd mean sd,C0007928;C2699239;C0034283;C4552032
patients with evaluable endoscopy,C2986511;C0014245
endoscopic disease severity,C0014245;C0521117;C0442418
data n,C1511726;C3245479;C3714741
total ses cd score at,C2964552;C0007928;C0034283;C4552032
patients with eligible ses cd score,C0030705;C0007928;C0034283;C4552032
baseline of induction n,C0168634;C1442488
or ulcerations n,C0041582
mild $nmbr$ $nmbr$,C2945599
ses cd mean sd,C0007928;C2699239;C0034283;C4552032
patients who had ulcerations at,C0030705;C3272598;C0041582
endoscopic disease severity,C0014245;C0521117;C0442418
baseline of induction,C0168634;C1442488
total ses cd score at,C2964552;C0007928;C0034283;C4552032
lieum only n,C0369718;C0441922
baseline of induction n,C0168634;C1442488
ileum ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
mild $nmbr$ $nmbr$,C2945599
nd,
patients who had ulcerations at,C0030705;C3272598;C0041582
colon ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
baseline of induction,C0168634;C1442488
lieum only n,C0369718;C0441922
figure $nmbr$ endoscopy as sessments at week $nmbr$ pooled ustekinumab vs placebo a by induction study b randomized pa tients with eligible ses cd score or ulcerations at in duction baseline note $nmbr$ pooled ustekinumab group comprises patients receiving ustekinumab $nmbr$ mg and tiered ustekinu mab doses approximating $nmbr$ mg kg combined for analyses patients who prior to the designated analysis timepoint had a cd related surgery due to lack of ef cacy or had an initiation of speci ed prohibited medication had their baseline value carried forward or were considered to not have mucosal healing patients with missing segments at the designated analysis timepoint had their base line score or ulceration status at baseline for the missing segment s carried forward $nmbr$ clinically meaningful endoscopic improvement ses cd reduction $nmbr$ from induction baseline endoscopic response ses cd reduc tion $nmbr$ from induction baseline endoscopic remission ses cd total score $nmbr$ mucosal healing complete absence of ul cers in patients with ulcers at baseline cd crohn s disease ses simpli ed endoscopic disease severity score,C0014245;C0332174;C1608841;C0439230;C0032042;C1696465;C1706408;C0034656;C0030428;C3541314;C3815594;C0449820;C4050231;C0041582;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2700400;C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0003250;C0178602;C0369637;C0332232;C0439272;C0205195;C0002778;C2348792;C0936012;C1524024;C0038894;C0038895;C0543467;C1274039;C0138547;C4288398;C0168634;C0439780;C1442488;C0750591;C1518422;C0026724;C0449438;C1963256;C3887532;C1551393;C0441635;C1705492;C3272743;C0301630;C0392756;C1293152;C4551656;C0007928;C0034283;C4552032;C0442418;C0332197;C1689985;C0010346;C0521117
ileum ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
insulin glargine n $nmbr$,C0907402
nd,
sex women men,C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
colon ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
race or ethnic origin,C0034510;C1706779;C3853635;C0015031
native american or alaskan native,C0282204;C1515945;C0238611;C0302891
figure $nmbr$ endoscopy as sessments at week $nmbr$ pooled ustekinumab vs placebo a by induction study b randomized pa tients with eligible ses cd score or ulcerations at in duction baseline note $nmbr$ pooled ustekinumab group comprises patients receiving ustekinumab $nmbr$ mg and tiered ustekinu mab doses approximating $nmbr$ mg kg combined for analyses patients who prior to the designated analysis timepoint had a cd related surgery due to lack of ef cacy or had an initiation of speci ed prohibited medication had their baseline value carried forward or were considered to not have mucosal healing patients with missing segments at the designated analysis timepoint had their base line score or ulceration status at baseline for the missing segment s carried forward $nmbr$ clinically meaningful endoscopic improvement ses cd reduction $nmbr$ from induction baseline endoscopic response ses cd reduc tion $nmbr$ from induction baseline endoscopic remission ses cd total score $nmbr$ mucosal healing complete absence of ul cers in patients with ulcers at baseline cd crohn s disease ses simpli ed endoscopic disease severity score,C0014245;C0332174;C1608841;C0439230;C0032042;C1696465;C1706408;C0034656;C0030428;C3541314;C3815594;C0449820;C4050231;C0041582;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2700400;C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0003250;C0178602;C0369637;C0332232;C0439272;C0205195;C0002778;C2348792;C0936012;C1524024;C0038894;C0038895;C0543467;C1274039;C0138547;C4288398;C0168634;C0439780;C1442488;C0750591;C1518422;C0026724;C0449438;C1963256;C3887532;C1551393;C0441635;C1705492;C3272743;C0301630;C0392756;C1293152;C4551656;C0007928;C0034283;C4552032;C0442418;C0332197;C1689985;C0010346;C0521117
hba $nmbr$ c mmol mol [se],C0019016;C3829066;C1825777;C3538758;C0036919
insulin glargine n $nmbr$,C0907402
sitting systolic blood pressure mm hg,C1319893;C0439475
sex women men,C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
sitting diastolic blood pressure mm hg,C1319894;C0439475
race or ethnic origin,C0034510;C1706779;C3853635;C0015031
total daily insulin dose u day,C2348070;C0456683
native american or alaskan native,C0282204;C1515945;C0238611;C0302891
duration of chronic kidney disease years,C0872146
hba $nmbr$ c mmol mol [se],C0019016;C3829066;C1825777;C3538758;C0036919
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
sitting systolic blood pressure mm hg,C1319893;C0439475
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
sitting diastolic blood pressure mm hg,C1319894;C0439475
baseline egfr $nmbr$ to,C1739039;C3811844;C3812682
total daily insulin dose u day,C2348070;C0456683
baseline egfr,C1739039;C3811844;C3812682
duration of chronic kidney disease years,C0872146
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ mean [se],C1739039;C3811844;C3812682;C0444504;C2347634;C2348143;C0036919
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
uacr mg g median [iqr],C0549183;C0876920;C2347635;C2348144;C2939193
baseline egfr $nmbr$ to,C1739039;C3811844;C3812682
normal albuminuria uacr,C0205307;C0001925;C0231683;C0439166;C2347086;C4553972
baseline egfr,C1739039;C3811844;C3812682
microalbuminuria uacr $nmbr$ $nmbr$,C0730345
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ mean [se],C1739039;C3811844;C3812682;C0444504;C2347634;C2348143;C0036919
macroalbuminuria uacr $nmbr$,
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
angiotensin converting enzyme inhibitor or angiotensin receptor blocker use mitt population,C0003015;C2757044;C3536837;C4541021;C0032659;C1257890
uacr mg g median [iqr],C0549183;C0876920;C2347635;C2348144;C2939193
indacaterol glycopyrronium $nmbr$ $nmbr$ g o d,C1722260;C0439267
normal albuminuria uacr,C0205307;C0001925;C0231683;C0439166;C2347086;C4553972
salmeterol fluticasone $nmbr$ $nmbr$ g b i d,C0439417
microalbuminuria uacr $nmbr$ $nmbr$,C0730345
copd severitya n,C0024117;C1412502;C3714496
macroalbuminuria uacr $nmbr$,
high risk and more symptoms group d,C0332167;C3272283;C4050568;C4319571;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
angiotensin converting enzyme inhibitor or angiotensin receptor blocker use mitt population,C0003015;C2757044;C3536837;C4541021;C0032659;C1257890
number of copd exacerbations in the previous year n,C0237753;C0449788;C0205156;C0439234;C0439508;C1552607
indacaterol glycopyrronium $nmbr$ $nmbr$ g o d,C1722260;C0439267
sgrq c total scoreb,C3826872;C0439175;C0439810
salmeterol fluticasone $nmbr$ $nmbr$ g b i d,C0439417
post bronchodilator fev $nmbr$ fvc,C2599594;C3714541
copd severitya n,C0024117;C1412502;C3714496
data presented as mean sd unless otherwise specified acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ] gold $nmbr$ [ $nmbr$ ] bon a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status the mcid is a change of $nmbr$ units on a scale of $nmbr$ $nmbr$ with higher scores indicating more severe dyspnea on a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status,C1511726;C3245479;C3714741;C0449450;C0444504;C2347634;C2348143;C0439793;C0522510;C1527178;C1705938;C0018026;C1304897;C1552041;C2986536;C0175659;C0349674;C1947916;C0205250;C0449820;C0332271;C0018759;C1279889;C1457868;C0392747;C0443172;C1705241;C4319952;C2080700
high risk and more symptoms group d,C0332167;C3272283;C4050568;C4319571;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
number of copd exacerbations in the previous year n,C0237753;C0449788;C0205156;C0439234;C0439508;C1552607
b i d twice daily cat copd assessment test copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s fvc forced vital capacity gold global initiative for chronic obstructive lung disease ics inhaled corticosteroid mcid minimum clinically important difference mmrc modified medical research council o d once daily sd standard deviation sgrq c st george s respiratory questionnaire for copd,C0016529;C1306036;C0205246;C0424093;C2348867;C0024117;C0079816;C0871420;C1553316;C0034394;C1412502;C3714496
sgrq c total scoreb,C3826872;C0439175;C0439810
baseline eosinophil $nmbr$ cells pl,C3897966;C4049765
post bronchodilator fev $nmbr$ fvc,C2599594;C3714541
baseline eosinophil,C0168634;C0014467;C1442488
data presented as mean sd unless otherwise specified acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ] gold $nmbr$ [ $nmbr$ ] bon a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status the mcid is a change of $nmbr$ units on a scale of $nmbr$ $nmbr$ with higher scores indicating more severe dyspnea on a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status,C1511726;C3245479;C3714741;C0449450;C0444504;C2347634;C2348143;C0439793;C0522510;C1527178;C1705938;C0018026;C1304897;C1552041;C2986536;C0175659;C0349674;C1947916;C0205250;C0449820;C0332271;C0018759;C1279889;C1457868;C0392747;C0443172;C1705241;C4319952;C2080700
very severe copd,C0024117;C1412502;C3714496
severe copd,C0024117;C1412502;C3714496
b i d twice daily cat copd assessment test copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s fvc forced vital capacity gold global initiative for chronic obstructive lung disease ics inhaled corticosteroid mcid minimum clinically important difference mmrc modified medical research council o d once daily sd standard deviation sgrq c st george s respiratory questionnaire for copd,C0016529;C1306036;C0205246;C0424093;C2348867;C0024117;C0079816;C0871420;C1553316;C0034394;C1412502;C3714496
moderate copd,C0024117;C1412502;C3714496
baseline eosinophil $nmbr$ cells pl,C3897966;C4049765
egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
baseline eosinophil,C0168634;C0014467;C1442488
drug therapy,C0013216;C0013217
very severe copd,C0024117;C1412502;C3714496
renin angiotensin system inhibitor,C1960108;C3537174;C4521920
severe copd,C0024117;C1412502;C3714496
microvascular disease history,C0443258;C0683519
moderate copd,C0024117;C1412502;C3714496
atherosclerotic vascular disease history,C0683519
egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
history of amputation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
drug therapy,C0013216;C0013217
ratio of ldl to hdl cholesterol,C0456603;C1547037;C0023822;C0392885
renin angiotensin system inhibitor,C1960108;C3537174;C4521920
urinary albumin to creatinine ratio,C0486293;C1318293
microvascular disease history,C0443258;C0683519
mg g,C1300563
atherosclerotic vascular disease history,C0683519
mg mmol,C0567349;C2348885
history of amputation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
normoalbuminuria,
ratio of ldl to hdl cholesterol,C0456603;C1547037;C0023822;C0392885
microalbuminuria or macroalbuminuria,C0730345
urinary albumin to creatinine ratio,C0486293;C1318293
composite of doubling of serum creatinine end stage kidney disease or death from renal causes,C0205199;C1547335;C0007465;C0022646
mg g,C1300563
composite of $nmbr$ reduction in egfr end stage kidney disease or death from renal causes,C0205199;C1547335;C0022661;C2316810;C0007465;C0022646
mg mmol,C0567349;C2348885
pvaluefor interaction $nmbr$ $nmbr$,C1704675
normoalbuminuria,
canvas,C3281223
microalbuminuria or macroalbuminuria,C0730345
canvas r,C0205090;C0684010;C2603358
composite of doubling of serum creatinine end stage kidney disease or death from renal causes,C0205199;C1547335;C0007465;C0022646
$nmbr$ $nmbr$ o $nmbr$ s o $nmbr$,C0483204
composite of $nmbr$ reduction in egfr end stage kidney disease or death from renal causes,C0205199;C1547335;C0022661;C2316810;C0007465;C0022646
central or south america,C0205099;C1879652;C0037713
pvaluefor interaction $nmbr$ $nmbr$,C1704675
$nmbr$ $nmbr$ o $nmbr$ o o $nmbr$,C0483204
canvas,C3281223
rest ofthe world,C0035253;C2700280;C1622890
canvas r,C0205090;C0684010;C2603358
$nmbr$ $nmbr$ o $nmbr$ i $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ o $nmbr$ s o $nmbr$,C0483204
^ $nmbr$,
central or south america,C0205099;C1879652;C0037713
$nmbr$ $nmbr$ o $nmbr$ i o $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ o $nmbr$ o o $nmbr$,C0483204
systolic blood pressure $nmbr$ mm hg or diastolic,C0488055;C0439475;C0871470;C1306620;C0012000
rest ofthe world,C0035253;C2700280;C1622890
blood pressure $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
$nmbr$ $nmbr$ o $nmbr$ i $nmbr$,C0021966;C0221138
$nmbr$ o $nmbr$ o $nmbr$,C0483204
^ $nmbr$,
hbai,
$nmbr$ $nmbr$ o $nmbr$ i o $nmbr$,C0021966;C0221138
ecfr ml min per $nmbr$ $nmbr$ m,C0439445
systolic blood pressure $nmbr$ mm hg or diastolic,C0488055;C0439475;C0871470;C1306620;C0012000
baseline albuminuria,C0168634;C0001925;C1442488
blood pressure $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
renin angiotensin system inhibitor use,C0042153;C0457083;C1947944
$nmbr$ o $nmbr$ o $nmbr$,C0483204
loop diuretic use,C0042153;C0457083;C1947944
hbai,
sotagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ecfr ml min per $nmbr$ $nmbr$ m,C0439445
race or ethnic group n,C0034510;C1706779;C3853635;C0441848
baseline albuminuria,C0168634;C0001925;C1442488
hispanic latino ethnicity,C0015031;C0243103
renin angiotensin system inhibitor use,C0042153;C0457083;C1947944
alc mmol mol,C1424945;C3829066;C3811058
loop diuretic use,C0042153;C0457083;C1947944
mg dl sd,C0439269;C2699239
sotagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
body mass index $nmbr$ kg m n,C0022718;C0439209;C4054209;C0369718;C0441922
race or ethnic group n,C0034510;C1706779;C3853635;C0441848
systolic blood pressure $nmbr$ mm hg n,C0488055;C0871470;C1306620
hispanic latino ethnicity,C0015031;C0243103
total daily insulin dose lu kg,C0022718;C0439209;C4054209
alc mmol mol,C1424945;C3829066;C3811058
mdi,C0993596;C1839839;C4049613
mg dl sd,C0439269;C2699239
csii,
body mass index $nmbr$ kg m n,C0022718;C0439209;C4054209;C0369718;C0441922
figure $nmbr$ lsm percent a and absolute b change from baseline in insulin dose at $nmbr$ and $nmbr$ weeks baseline values are iu day,C0439165;C1549031;C0168634;C1442488;C0366513;C0042295;C0439465
systolic blood pressure $nmbr$ mm hg n,C0488055;C0871470;C1306620
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
total daily insulin dose lu kg,C0022718;C0439209;C4054209
history of heart failure no,C0455531
mdi,C0993596;C1839839;C4049613
duration of diabetes y mean sd,C0449238;C2926735
csii,
drug therapy no,C0013216;C0013217
figure $nmbr$ lsm percent a and absolute b change from baseline in insulin dose at $nmbr$ and $nmbr$ weeks baseline values are iu day,C0439165;C1549031;C0168634;C1442488;C0366513;C0042295;C0439465
glp $nmbr$ receptor agonist,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
microvascular disease history no,C0443258;C0683519
history of heart failure no,C0455531
atherosclerotic vascular disease history no,C0683519
duration of diabetes y mean sd,C0449238;C2926735
cv disease history no,C0683519
drug therapy no,C0013216;C0013217
history of amputation no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
glp $nmbr$ receptor agonist,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
systolic bp mm hg mean sd,C0488053;C2699239
microvascular disease history no,C0443258;C0683519
diastolic bp mm hg mean sd,C0488053;C2699239
atherosclerotic vascular disease history no,C0683519
glycohemoglobin mean sd,C0202054;C2699239;C0696092
cv disease history no,C0683519
hdl c mmol l mean sd,C1532563;C2699239
history of amputation no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ldl c mmol l mean sd,C1532563;C2699239
systolic bp mm hg mean sd,C0488053;C2699239
ldl c hdl c ratio mean sd,C0428621;C2699239
diastolic bp mm hg mean sd,C0488053;C2699239
uacr mg g median iqr,C1300563;C0549183;C0876920;C2347635;C2348144;C2939193
glycohemoglobin mean sd,C0202054;C2699239;C0696092
albuminuria,C0001925
hdl c mmol l mean sd,C1532563;C2699239
normoalbuminuria no,
ldl c mmol l mean sd,C1532563;C2699239
micro or macroalbuminuria no,C0085672;C1553035;C3811161;C4049106
ldl c hdl c ratio mean sd,C0428621;C2699239
patients with an event per $nmbr$ patient years,C0030705;C0441471;C4019010;C0439234
uacr mg g median iqr,C1300563;C0549183;C0876920;C2347635;C2348144;C2939193
number of participants with an event,C0237753;C0449788;C0441471;C4019010
albuminuria,C0001925
canagiiflozin,
normoalbuminuria no,
interaction p vaiue,C1704675
micro or macroalbuminuria no,C0085672;C1553035;C3811161;C4049106
fatal nonfatal ml,C0439526;C1705224;C3887665
patients with an event per $nmbr$ patient years,C0030705;C0441471;C4019010;C0439234
fatal nonfatal stroke,C0038454;C4554100
number of participants with an event,C0237753;C0449788;C0441471;C4019010
hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
canagiiflozin,
renal composite,C0205199;C1547335
interaction p vaiue,C1704675
dabigatran $nmbr$ mg b i d,C0439422
fatal nonfatal ml,C0439526;C1705224;C3887665
nsaid at least once,C0003211;C3536840
fatal nonfatal stroke,C0038454;C4554100
never nsaid,C0003211;C3536840
hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
hr vs warfarin $nmbr$ ci,C0008107;C3259781
renal composite,C0205199;C1547335
gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
dabigatran $nmbr$ mg b i d,C0439422
stroke se,C0038454;C0036919;C4554100
nsaid at least once,C0003211;C3536840
duration of disease y,C0872146
never nsaid,C0003211;C3536840
stool frequency subscore,C0015733;C0183622
hr vs warfarin $nmbr$ ci,C0008107;C3259781
rectal bleeding subscore,C0018932;C0267596
gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
daily bowel movements,C0332173;C0011135
stroke se,C0038454;C0036919;C4554100
$nmbr$ mg l,C0439268
duration of disease y,C0872146
oral corticosteroid use at baseline,C0239126
stool frequency subscore,C0015733;C0183622
mean dose,C0444504;C0178602;C0869039;C1114758;C2347634;C2348143
rectal bleeding subscore,C0018932;C0267596
median dose range,C0178602;C0869039;C1114758
daily bowel movements,C0332173;C0011135
dapagliflozin $nmbr$ mg insulin n $nmbr$,C0024671;C0021641;C1533581;C1579433;C3714501;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mg l,C0439268
placebo insulin n $nmbr$,C0032042;C0021641;C1533581;C1579433;C3714501;C1696465;C1706408
oral corticosteroid use at baseline,C0239126
duration of t $nmbr$ d years,C0449238;C2926735;C0439234
mean dose,C0444504;C0178602;C0869039;C1114758;C2347634;C2348143
total baseline insulin dose,C2986497
median dose range,C0178602;C0869039;C1114758
dose iu,C0049272;C0439453;C0694756
dapagliflozin $nmbr$ mg insulin n $nmbr$,C0024671;C0021641;C1533581;C1579433;C3714501;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
dose weight iu kg,C0005910;C0439463;C0043100;C1305866;C1705104
placebo insulin n $nmbr$,C0032042;C0021641;C1533581;C1579433;C3714501;C1696465;C1706408
method of insulin administration,C0087111;C1547585
duration of t $nmbr$ d years,C0449238;C2926735;C0439234
use of cgm yes,C1524063;C1549445;C1705108;C1710701
total baseline insulin dose,C2986497
hba $nmbr$ c at randomization,C0019016;C0034656;C1825777;C3538758
dose iu,C0049272;C0439453;C0694756
$nmbr$ $nmbr$ and $nmbr$ $nmbr$,
dose weight iu kg,C0005910;C0439463;C0043100;C1305866;C1705104
subgroup statistics,C0038215;C0600673
method of insulin administration,C0087111;C1547585
for patients using personal cgm,C0030705;C1524063;C1519021
use of cgm yes,C1524063;C1549445;C1705108;C1710701
baseline mean sd,C0168634;C2699239;C1442488
hba $nmbr$ c at randomization,C0019016;C0034656;C1825777;C3538758
adjusted mean change from baseline,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ and $nmbr$ $nmbr$,
difference from placebo $nmbr$ cl,C1705241;C1705242
subgroup statistics,C0038215;C0600673
for patients not using personal cgm,C0030705;C1518422;C1524063;C1519021
for patients using personal cgm,C0030705;C1524063;C1519021
use of cgm interaction test p value^,C1524063;C1709380
baseline mean sd,C0168634;C2699239;C1442488
adjusted mean change from baseline se,C0392747;C0443172;C1705241;C4319952
adjusted mean change from baseline,C0392747;C0443172;C1705241;C4319952
patients n n a,C0030705
difference from placebo $nmbr$ cl,C1705241;C1705242
overall pea population,C0032659;C1257890
for patients not using personal cgm,C0030705;C1518422;C1524063;C1519021
ics subset,C0815320;C1515021;C4551720
use of cgm interaction test p value^,C1524063;C1709380
ics laba subset,C0815320;C1515021;C4551720
adjusted mean change from baseline se,C0392747;C0443172;C1705241;C4319952
ff vi n $nmbr$,C4554348;C0205999
patients n n a,C0030705
uc n $nmbr$,
overall pea population,C0032659;C1257890
adjusted or $nmbr$ ci b,C0456081;C0008107;C3259781
ics subset,C0815320;C1515021;C4551720
adjusted or $nmbr$ ci c,C0456081;C0008107;C3259781
ics laba subset,C0815320;C1515021;C4551720
act total score $nmbr$ and or improvement from baseline $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375;C2986411;C0168634;C1442488
ff vi n $nmbr$,C4554348;C0205999
act total score $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375
uc n $nmbr$,
improvement from baseline $nmbr$,C2986411;C0168634;C1442488
adjusted or $nmbr$ ci b,C0456081;C0008107;C3259781
ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
adjusted or $nmbr$ ci c,C0456081;C0008107;C3259781
difference ff vi versus uc,C1705241;C0205999;C1705242
act total score $nmbr$ and or improvement from baseline $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375;C2986411;C0168634;C1442488
$nmbr$ ci b,C0008107;C3259781
act total score $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375
$nmbr$ ci c,C0008107;C3259781
improvement from baseline $nmbr$,C2986411;C0168634;C1442488
percent work time missed due to asthma,C0043227;C0040223;C3541383;C1705492;C0678226
ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
percent impairment while working due to asthma,C0221099;C0684336;C0043227;C0678226
difference ff vi versus uc,C1705241;C0205999;C1705242
percent overall work impairment due to asthma,C0221099;C0684336
$nmbr$ ci b,C0008107;C3259781
percent activity impairment due to asthma,C0221099;C0684336
$nmbr$ ci c,C0008107;C3259781
secukinumab $nmbr$ mg no load n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1550025;C1704782;C1708715
percent work time missed due to asthma,C0043227;C0040223;C3541383;C1705492;C0678226
time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
percent impairment while working due to asthma,C0221099;C0684336;C0043227;C0678226
hla b $nmbr$ positive at baseline n,C0439178;C1446409;C1514241;C2825490;C3812269
percent overall work impairment due to asthma,C0221099;C0684336
tnfi na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
percent activity impairment due to asthma,C0221099;C0684336
total basdai score mean sd,C2964552;C2699239
secukinumab $nmbr$ mg no load n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1550025;C1704782;C1708715
total back pain score $nmbr$ $nmbr$ mm scale mean sd,C1504479;C2699239
time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
previous systemic treatment n,C0205156;C0678812;C1552607
hla b $nmbr$ positive at baseline n,C0439178;C1446409;C1514241;C2825490;C3812269
methotrexate use at randomization,C0042153;C0457083;C1947944
tnfi na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
sulfasalazine use at randomization,C0042153;C0457083;C1947944
total basdai score mean sd,C2964552;C2699239
corticosteroid use at randomization,C0239126;C0034656
total back pain score $nmbr$ $nmbr$ mm scale mean sd,C1504479;C2699239
cumulative nsaid score mean sd,C0003211;C2699239;C3536840
previous systemic treatment n,C0205156;C0678812;C1552607
uveitis,C0042164;C1963266
methotrexate use at randomization,C0042153;C0457083;C1947944
tnfi naive,
sulfasalazine use at randomization,C0042153;C0457083;C1947944
tnfi ir,C0022065;C0022071;C1448132
corticosteroid use at randomization,C0239126;C0034656
asas $nmbr$,C0004057;C3853627
cumulative nsaid score mean sd,C0003211;C2699239;C3536840
hscrp post baseline baseline ratio ls mean se,C0023668;C0036919
uveitis,C0042164;C1963266
asas $nmbr$ $nmbr$,C0004057;C3853627
tnfi naive,
basdai ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
tnfi ir,C0022065;C0022071;C1448132
sf $nmbr$ pcs ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
asas $nmbr$,C0004057;C3853627
asqol ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
hscrp post baseline baseline ratio ls mean se,C0023668;C0036919
benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
asas $nmbr$ $nmbr$,C0004057;C3853627
a $nmbr$ $nmbr$ $nmbr$ a $nmbr$,
basdai ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
a $nmbr$ $nmbr$,
sf $nmbr$ pcs ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
$nmbr$ nil,C0442734
other^,
asqol ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
bmp kg m $nmbr$,C0022718;C0439209;C4054209
benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
a $nmbr$ $nmbr$ $nmbr$ a $nmbr$,
eosinophil counf cells pl,C3897966;C4049765
a $nmbr$ $nmbr$,
pre bronchodilator fevr l,C2599602;C1708033
$nmbr$ nil,C0442734
pre bronchodilator fevr pred,C0032952;C0044955
other^,
$nmbr$ $nmbr$ $nmbr$ a $nmbr$,
bmp kg m $nmbr$,C0022718;C0439209;C4054209
pre bronchodilator fevi fvc,C0802741;C3815113
eosinophil counf cells pl,C3897966;C4049765
$nmbr$ i $nmbr$ $nmbr$ ai,C0003504;C4551710
pre bronchodilator fevr l,C2599602;C1708033
pre bronchodilator fvc pred,C0032952;C0044955
pre bronchodilator fevr pred,C0032952;C0044955
age at asthma diagnosis years,C1828181;C3173302
$nmbr$ $nmbr$ $nmbr$ a $nmbr$,
exacerbations in the past $nmbr$ months n,C4086268;C0439231
pre bronchodilator fevi fvc,C0802741;C3815113
tass,C0559483
$nmbr$ i $nmbr$ $nmbr$ ai,C0003504;C4551710
aqlq si $nmbr$ score,C0449820;C4050231
pre bronchodilator fvc pred,C0032952;C0044955
atopic,C0392707
age at asthma diagnosis years,C1828181;C3173302
ocs use,C0042153;C0457083;C1947944
exacerbations in the past $nmbr$ months n,C4086268;C0439231
subgroup name level,C0441889;C0456079;C1547707;C2946261
tass,C0559483
estimate $nmbr$ cl,C0750572;C0596019
aqlq si $nmbr$ score,C0449820;C4050231
ocs,
atopic,C0392707
no ocs,
ocs use,C0042153;C0457083;C1947944
no nasal polyps,C0027430
subgroup name level,C0441889;C0456079;C1547707;C2946261
pre bd fvc,C0005126;C3714541;C2344255;C4050145
estimate $nmbr$ cl,C0750572;C0596019
pre bd fvc s $nmbr$ of predicted,C0005126;C3714541;C2344255;C4050145;C0681842;C1882327
ocs,
s $nmbr$ exacerbations,C4086268
no ocs,
$nmbr$ exacerbations,C4086268
no nasal polyps,C0027430
age at diagnosis s $nmbr$ years,C1828181;C3173302;C0439234
pre bd fvc,C0005126;C3714541;C2344255;C4050145
age at diagnosis,C1828181;C3173302
pre bd fvc s $nmbr$ of predicted,C0005126;C3714541;C2344255;C4050145;C0681842;C1882327
either ocs use nasal polyps pre bd fvc,C0027430;C3714541
s $nmbr$ exacerbations,C4086268
no ocs use no nasal polyps pre bd fvc s $nmbr$ of predicted and age at diagnosis,C0042153;C0457083;C1947944;C0027430;C3714541;C0681842;C1882327;C1828181;C3173302
$nmbr$ exacerbations,C4086268
aspirin group n $nmbr$,C0004057;C0441848
age at diagnosis s $nmbr$ years,C1828181;C3173302;C0439234
white race no i,C0007457;C0043157;C0021966;C0221138
age at diagnosis,C1828181;C3173302
participant reported hypertension no,C0020538;C1963138
either ocs use nasal polyps pre bd fvc,C0027430;C3714541
aspirin use before screening no,C0042153;C0457083;C1947944
no ocs use no nasal polyps pre bd fvc s $nmbr$ of predicted and age at diagnosis,C0042153;C0457083;C1947944;C0027430;C3714541;C0681842;C1882327;C1828181;C3173302
statin use no,C0042153;C0457083;C1947944
aspirin group n $nmbr$,C0004057;C0441848
median interquartile range yr,C1711350;C0439234
white race no i,C0007457;C0043157;C0021966;C0221138
mean mm hg,C0444504;C0439475;C2347634;C2348143
participant reported hypertension no,C0020538;C1963138
vascular risk score no ^,C0449820;C4050231
aspirin use before screening no,C0042153;C0457083;C1947944
aspirin n $nmbr$ no of participants with events,C0004057;C0679646;C0441471;C3541888
statin use no,C0042153;C0457083;C1947944
piacebo n $nmbr$ no of participants with events,C0679646;C0441471;C3541888
median interquartile range yr,C1711350;C0439234
rate ratio $nmbr$ ci,C0008107;C3259781
mean mm hg,C0444504;C0439475;C2347634;C2348143
heterogeneity or trend p vaiue,C0019409;C0242960;C1521798;C4554533
vascular risk score no ^,C0449820;C4050231
body mass index kg m ^,C0022718;C0439209;C4054209
aspirin n $nmbr$ no of participants with events,C0004057;C0679646;C0441471;C3541888
weight at randomization kg,C2985844;C0022718;C0439209;C4054209
piacebo n $nmbr$ no of participants with events,C0679646;C0441471;C3541888
prior aspirin use,C0042153;C0457083;C1947944
rate ratio $nmbr$ ci,C0008107;C3259781
vascular risk score,C0449820;C4050231
heterogeneity or trend p vaiue,C0019409;C0242960;C1521798;C4554533
other treatment assignment,C0039798;C1516050;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
body mass index kg m ^,C0022718;C0439209;C4054209
omega $nmbr$ fatty acids,C1719844;C0015684
weight at randomization kg,C2985844;C0022718;C0439209;C4054209
moderate s $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
prior aspirin use,C0042153;C0457083;C1947944
fatty acid group n $nmbr$,C0015684;C0441848
vascular risk score,C0449820;C4050231
body mass indexj,C0518010
other treatment assignment,C0039798;C1516050;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
unknown no,C0439673;C3541433;C4050014
omega $nmbr$ fatty acids,C1719844;C0015684
patient reported hypertension no,C0020538;C1963138
moderate s $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
medication use no,C0240320
fatty acid group n $nmbr$,C0015684;C0441848
median iqr yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
body mass indexj,C0518010
systolic blood pressure^,C0488055;C0871470;C1306620
unknown no,C0439673;C3541433;C4050014
$nmbr$ mm hg no,C0439475
patient reported hypertension no,C0020538;C1963138
omega $nmbr$ fa n $nmbr$,C1719844
medication use no,C0240320
heterogeneity or trend p value,C0019409;C0242960;C1521798;C1709380;C4554533
median iqr yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
percentage,C0439165;C1549488;C1561533
systolic blood pressure^,C0488055;C0871470;C1306620
body mass index kg m^ ^,C0022718;C0439209;C4054209
$nmbr$ mm hg no,C0439475
canakinumab $nmbr$ month on treatment il $nmbr$ above the median value $nmbr$ $nmbr$ ng l n $nmbr$,C0020898;C0021764;C0022271;C0549183;C0439297;C0876920;C2347635;C2348144;C2939193
omega $nmbr$ fa n $nmbr$,C1719844
canakinumab $nmbr$ month on treatment il $nmbr$ below the median value,C0020898;C0021764;C0022271;C0549183;C0876920;C2347635;C2348144;C2939193
heterogeneity or trend p value,C0019409;C0242960;C1521798;C1709380;C4554533
non stemi,C3537184
percentage,C0439165;C1549488;C1561533
unknown missing,C0439673;C3541433;C4050014;C1551393;C1705492;C3272743
body mass index kg m^ ^,C0022718;C0439209;C4054209
history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
canakinumab $nmbr$ month on treatment il $nmbr$ above the median value $nmbr$ $nmbr$ ng l n $nmbr$,C0020898;C0021764;C0022271;C0549183;C0439297;C0876920;C2347635;C2348144;C2939193
renin angiotensin inhibitors,C2917241;C3653375
canakinumab $nmbr$ month on treatment il $nmbr$ below the median value,C0020898;C0021764;C0022271;C0549183;C0876920;C2347635;C2348144;C2939193
anti ischaemia agents,C0450442;C1254351;C1521826
non stemi,C3537184
randomized to canakinumab $nmbr$ mg,C0034656;C3815594
unknown missing,C0439673;C3541433;C4050014;C1551393;C1705492;C3272743
treatment group on treatment il $nmbr$ threshold,C0020898;C0449864;C0021764;C0022271
history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
incidence rate n a,C1708485
renin angiotensin inhibitors,C2917241;C3653375
hradjusted $nmbr$ ci b,C0008107;C3259781
anti ischaemia agents,C0450442;C1254351;C1521826
$nmbr$ ref,C1425988
randomized to canakinumab $nmbr$ mg,C0034656;C3815594
canakinumab il $nmbr$ top tertilec,C0020898;C0021764;C0022271
treatment group on treatment il $nmbr$ threshold,C0020898;C0449864;C0021764;C0022271
canakinumab il $nmbr$ middle tertile,C0020898;C0021764;C0022271
incidence rate n a,C1708485
canakinumab il $nmbr$ lowest tertile,C0020898;C0021764;C0022271
hradjusted $nmbr$ ci b,C0008107;C3259781
p value for trend across categories,C1709380;C1521798;C4554533;C0683312
$nmbr$ ref,C1425988
experimental intervention group n $nmbr$,C0441848
canakinumab il $nmbr$ top tertilec,C0020898;C0021764;C0022271
mean body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
canakinumab il $nmbr$ middle tertile,C0020898;C0021764;C0022271
insulin dependent diabetes mellitus,C0011854
canakinumab il $nmbr$ lowest tertile,C0020898;C0021764;C0022271
previous major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
p value for trend across categories,C1709380;C1521798;C4554533;C0683312
previous coronary artery bypass grafting,C2144990
experimental intervention group n $nmbr$,C0441848
stable coronary artery disease,C0010054;C0010068;C1956346
mean body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
non st elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
insulin dependent diabetes mellitus,C0011854
st elevation myocardial infarction,C1536220;C3538872
previous major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
percutaneous coronary intervention done,C1532338;C1272695
previous coronary artery bypass grafting,C2144990
vascular access site,C0589360
stable coronary artery disease,C0010054;C0010068;C1956346
radial,C0442038;C0920847
non st elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
femoral,C0015811
st elevation myocardial infarction,C1536220;C3538872
brachial,C0445456
percutaneous coronary intervention done,C1532338;C1272695
lesions treated per patient,C0221198;C1522326;C0030705
vascular access site,C0589360
one lesion,C0221198;C1546698
radial,C0442038;C0920847
two lesions,C0205448;C0221198
femoral,C0015811
three or more lesions,C0205449;C0221198
brachial,C0445456
treated lesions,C1522326;C0221198
lesions treated per patient,C0221198;C1522326;C0030705
n lesions,C0369718;C0221198;C0441922
one lesion,C0221198;C1546698
left main coronary artery,C1261082
two lesions,C0205448;C0221198
three or more lesions,C0205449;C0221198
left circumflex artery,C0226037
treated lesions,C1522326;C0221198
bypass graft,C0185098
n lesions,C0369718;C0221198;C0441922
stented lesions,C0038257;C0221198
index percutaneous coronary intervention,C0600653;C1532338;C0918012;C1552854;C1637833;C2986546
left main coronary artery,C1261082
n stented lesions,C0038257;C0221198
left circumflex artery,C0226037
mean stents per lesion sd,C0038257;C0221198;C1546698
bypass graft,C0185098
biolimus a $nmbr$ eluting stent,C0038257
stented lesions,C0038257;C0221198
other stent,C0038257
index percutaneous coronary intervention,C0600653;C1532338;C0918012;C1552854;C1637833;C2986546
mean total stent length per lesion mm sd,C1444754;C1706316
n stented lesions,C0038257;C0221198
mean stent diameter per lesion mm sd,C0038257;C0552409
mean stents per lesion sd,C0038257;C0221198;C1546698
direct stenting per lesion,C0038257;C2348535
biolimus a $nmbr$ eluting stent,C0038257
bifurcation per lesion,C0184906;C3146289
other stent,C0038257
thrombus aspiration done per lesion,C0220787;C0349707;C0700198;C2712334;C2827071;C1272695;C0221198;C1546698
mean total stent length per lesion mm sd,C1444754;C1706316
timi flow,C3272266
mean stent diameter per lesion mm sd,C0038257;C0552409
pre procedure,C3272300
direct stenting per lesion,C0038257;C2348535
post procedure,C3272301
bifurcation per lesion,C0184906;C3146289
experimental treatment group,C0949266;C2585119
thrombus aspiration done per lesion,C0220787;C0349707;C0700198;C2712334;C2827071;C1272695;C0221198;C1546698
control group,C0009932
timi flow,C3272266
indication,C0392360;C3146298
pre procedure,C3272300
s $nmbr$ years,C0439234
post procedure,C3272301
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
experimental treatment group,C0949266;C2585119
renal failure,C0035078;C1963154
control group,C0009932
left main treated,C0205091;C1522326;C0443246;C1552822
indication,C0392360;C3146298
type of reference treatment strategy,C0455708;C0679199
s $nmbr$ years,C0439234
use of ticagrelor,C1524063;C1999375
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
use of clopidogrel,C1524063;C0070166
renal failure,C0035078;C1963154
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ o $nmbr$,C0483204
left main treated,C0205091;C1522326;C0443246;C1552822
cld $nmbr$ mg n l $nmbr$,C0439268
type of reference treatment strategy,C0455708;C0679199
azl m $nmbr$ mg $nmbr$ cld $nmbr$ mg n l $nmbr$,C2827881
use of ticagrelor,C1524063;C1999375
$nmbr$ $nmbr$ $nmbr$ l l,C3539687
use of clopidogrel,C1524063;C0070166
non hispanic and latino,C1518424;C0086528
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ o $nmbr$,C0483204
not collected^,C1516695;C1516698
cld $nmbr$ mg n l $nmbr$,C0439268
bmi kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
azl m $nmbr$ mg $nmbr$ cld $nmbr$ mg n l $nmbr$,C2827881
anti hypertensive treatment history n,C0432633
$nmbr$ $nmbr$ $nmbr$ l l,C3539687
raas inhibitors,C0243077
non hispanic and latino,C1518424;C0086528
antihypertensives,C0003364
not collected^,C1516695;C1516698
change from baseline to final apbm,C0392747;C0443172;C1705241;C4319952;C0205088;C1546485;C3853528
bmi kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
anti hypertensive treatment history n,C0432633
azl m $nmbr$ mg cld $nmbr$ mg,C1319635
raas inhibitors,C0243077
p value overall,C1709380;C0282416;C1561607
antihypertensives,C0003364
baseline $nmbr$ hour mean sbp mm hg,C0085805;C0439475
change from baseline to final apbm,C0392747;C0443172;C1705241;C4319952;C0205088;C1546485;C3853528
median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cgfr ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
azl m $nmbr$ mg cld $nmbr$ mg,C1319635
people with diabetes n $nmbr$,C0027361;C0011847;C0011849
p value overall,C1709380;C0282416;C1561607
people without diabetes n $nmbr$,C0027361;C0011847;C0011849
baseline $nmbr$ hour mean sbp mm hg,C0085805;C0439475
alirocumab n $nmbr$,C3491162
median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
cgfr ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
atherosclerotic coronary heart disease ischaemic stroke or peripheral arterial disease n n number of people in phase $nmbr$ studies only high intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily,C0010054;C0948008;C0237753;C0449788;C0205390;C0947630;C1710475;C4081854;C0360714;C1704788;C3539106;C0024671;C0965129;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
people with diabetes n $nmbr$,C0027361;C0011847;C0011849
heterozygous familial hypercholesterolemia,C0020445;C0745103;C1366529
people without diabetes n $nmbr$,C0027361;C0011847;C0011849
high intensity statins,C4081854;C0360714
alirocumab n $nmbr$,C3491162
any other lipid lowering therapy n,C0585943
anti hyperglycaemic agent n,C0432633;C1321567
atherosclerotic coronary heart disease ischaemic stroke or peripheral arterial disease n n number of people in phase $nmbr$ studies only high intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily,C0010054;C0948008;C0237753;C0449788;C0205390;C0947630;C1710475;C4081854;C0360714;C1704788;C3539106;C0024671;C0965129;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
injectable anti hyperglycaemic n,C1272883;C0432633
heterozygous familial hypercholesterolemia,C0020445;C0745103;C1366529
insulin n,C0021641;C1533581;C1579433;C3714501
high intensity statins,C4081854;C0360714
non hdl cholesterol,C0729627;C1535899
any other lipid lowering therapy n,C0585943
triglycerides median q $nmbr$ q $nmbr$,C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
anti hyperglycaemic agent n,C0432633;C1321567
duration of total exposure to study treatment weeks,C0439175;C2826870;C0439810;C1521826;C0439230
injectable anti hyperglycaemic n,C1272883;C0432633
teaes of special interest,C0205555;C0543488
insulin n,C0021641;C1533581;C1579433;C3714501
study population,C2348561
non hdl cholesterol,C0729627;C1535899
proportion of individuals a alirocumab placebo,C1709707;C0027361;C0237401;C0032042;C1696465;C1706408
triglycerides median q $nmbr$ q $nmbr$,C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
rate per $nmbr$ patient years control vs alirocumab i,C0489879;C0030705;C0021966;C0221138
duration of total exposure to study treatment weeks,C0439175;C2826870;C0439810;C1521826;C0439230
hr vs control $nmbr$ cl,C0243148;C0596019;C1550141;C1882979;C2587213;C3274648;C4553389
teaes of special interest,C0205555;C0543488
lisrs,
study population,C2348561
non dm,C1518422;C0011816;C3250443
proportion of individuals a alirocumab placebo,C1709707;C0027361;C0237401;C0032042;C1696465;C1706408
neurocognitive disorders,C0029227;C4041080
rate per $nmbr$ patient years control vs alirocumab i,C0489879;C0030705;C0021966;C0221138
neurologicai events,C0441471;C3541888
hr vs control $nmbr$ cl,C0243148;C0596019;C1550141;C1882979;C2587213;C3274648;C4553389
hepatic disorders,C0023895
lisrs,
general allergic events,C0441471;C3541888
non dm,C1518422;C0011816;C3250443
ophthalmologic events,C0441471;C3541888
neurocognitive disorders,C0029227;C4041080
dm or diabetic complications,C0011816;C3250443;C0342257
neurologicai events,C0441471;C3541888
adjudicated mace $nmbr$,C0349381;C0949745;C1445339
hepatic disorders,C0023895
week $nmbr$ czp dose combined n $nmbr$,C0054841;C0178602;C0869039;C1114758;C1861828;C1872109
general allergic events,C0441471;C3541888
dmard n $nmbr$,C0242708
ophthalmologic events,C0441471;C3541888
demographic characteristics mean sd unless otherwise stated,C0683970;C2699239;C1301808;C1442792
dm or diabetic complications,C0011816;C3250443;C0342257
age [years],C0001779;C0439234
adjudicated mace $nmbr$,C0349381;C0949745;C1445339
weight [kg],C0005910;C0043100;C1305866;C1705104;C0022718;C0439209;C4054209
week $nmbr$ czp dose combined n $nmbr$,C0054841;C0178602;C0869039;C1114758;C1861828;C1872109
bmi [kg m $nmbr$ ],C0578022;C0022718;C0439209;C4054209
dmard n $nmbr$,C0242708
disease characteristics n unless otherwise stated,C0599878;C1301808;C1442792
demographic characteristics mean sd unless otherwise stated,C0683970;C2699239;C1301808;C1442792
prior use of synthetic dmards,C1524063;C0242708
age [years],C0001779;C0439234
concomitant use of corticosteroids,C1524063
weight [kg],C0005910;C0043100;C1305866;C1705104;C0022718;C0439209;C4054209
tender joint count $nmbr$ $nmbr$ joints mean sd,C0451530;C2699239
bmi [kg m $nmbr$ ],C0578022;C0022718;C0439209;C4054209
swollen joint count $nmbr$ $nmbr$ joints mean sd,C0451521;C2699239
disease characteristics n unless otherwise stated,C0599878;C1301808;C1442792
patients with psoriasis bsa $nmbr$,C0030705;C0033860
prior use of synthetic dmards,C1524063;C0242708
pasi mean sd,C0444504;C2699239;C2347634;C2348143
concomitant use of corticosteroids,C1524063
patients with enthesitis lei $nmbr$,C0030705;C1282952
tender joint count $nmbr$ $nmbr$ joints mean sd,C0451530;C2699239
lei mean sd,C0444504;C2699239;C2347634;C2348143
swollen joint count $nmbr$ $nmbr$ joints mean sd,C0451521;C2699239
patients with dactylitisa,C0030705
patients with psoriasis bsa $nmbr$,C0030705;C0033860
ldi mean sd a,C0444504;C2699239;C2347634;C2348143
pasi mean sd,C0444504;C2699239;C2347634;C2348143
patients with nail psoriasis mnapsi $nmbr$,C0030705;C0406322
patients with enthesitis lei $nmbr$,C0030705;C1282952
mnapsi mean sd,C0444504;C2699239;C2347634;C2348143
lei mean sd,C0444504;C2699239;C2347634;C2348143
observed,C1441672
patients with dactylitisa,C0030705
imputed,C2699638
ldi mean sd a,C0444504;C2699239;C2347634;C2348143
clinical and patient reported outcomes observed n unless otherwise indicated,C0205210;C2987124;C1441672;C1444656
patients with nail psoriasis mnapsi $nmbr$,C0030705;C0406322
pasi $nmbr$ a,C4528685
mnapsi mean sd,C0444504;C2699239;C2347634;C2348143
ldi mean [sd]b,C0444504;C2347634;C2348143;C2699239
observed,C1441672
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ] n $nmbr$,C0369718;C0441922
imputed,C2699638
total resolution of dactylitisb,C1514893;C1706463;C2699488
clinical and patient reported outcomes observed n unless otherwise indicated,C0205210;C2987124;C1441672;C1444656
lei mean [sd]c,C0444504;C2347634;C2348143;C2699239
pasi $nmbr$ a,C4528685
total resolution of enthesitisc,C1514893;C1706463;C2699488
ldi mean [sd]b,C0444504;C2347634;C2348143;C2699239
mnapsi mean [sd]d,C0444504;C2347634;C2348143;C2699239
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ] n $nmbr$,C0369718;C0441922
total resolution of nail psoriasisd,C1514893;C1706463;C2699488
total resolution of dactylitisb,C1514893;C1706463;C2699488
haq di mean [sd],C0444504;C2347634;C2348143;C2699239
lei mean [sd]c,C0444504;C2347634;C2348143;C2699239
haq di mcide,C3826998;C4321476
total resolution of enthesitisc,C1514893;C1706463;C2699488
uc [gemini $nmbr$ ],
mnapsi mean [sd]d,C0444504;C2347634;C2348143;C2699239
cd [gemini $nmbr$ ],C0007928;C0034283;C4552032
total resolution of nail psoriasisd,C1514893;C1706463;C2699488
vdz n \ $nmbr$,
haq di mean [sd],C0444504;C2347634;C2348143;C2699239
vdz pla n $nmbr$,C0456170
haq di mcide,C3826998;C4321476
pla n $nmbr$,C0456170
uc [gemini $nmbr$ ],
vdz n $nmbr$,
cd [gemini $nmbr$ ],C0007928;C0034283;C4552032
pla $nmbr$,C0456170
vdz n \ $nmbr$,
disease duration mean [sd] years,C0444504;C2347634;C2348143;C2699239;C0439234
vdz pla n $nmbr$,C0456170
disease duration $nmbr$ years $nmbr$ [ ] disease activity s,C0872146;C0439234;C1292728
pla n $nmbr$,C0456170
cdai mean [sd],C0444504;C2347634;C2348143;C2699239
vdz n $nmbr$,
cdai $nmbr$ n [ ],C0683448;C1413248;C3273706
pla $nmbr$,C0456170
ms mean [sd],C0444504;C2347634;C2348143;C2699239
disease duration mean [sd] years,C0444504;C2347634;C2348143;C2699239;C0439234
ms,C2349943;C3539704;C3713294
disease duration $nmbr$ years $nmbr$ [ ] disease activity s,C0872146;C0439234;C1292728
ms $nmbr$ $nmbr$ n [ ],C2349943;C3539704;C3713294
cdai mean [sd],C0444504;C2347634;C2348143;C2699239
crp mean [sd] mg $nmbr$,C0444504;C2347634;C2348143;C2699239;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cdai $nmbr$ n [ ],C0683448;C1413248;C3273706
crp $nmbr$ mg $nmbr$ n [ ],C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ms mean [sd],C0444504;C2347634;C2348143;C2699239
concomitant therapy n [ ],C1707479
ms,C2349943;C3539704;C3713294
cs and im,C0010182;C0271160;C3540510;C4085345
ms $nmbr$ $nmbr$ n [ ],C2349943;C3539704;C3713294
im on]y,
crp mean [sd] mg $nmbr$,C0444504;C2347634;C2348143;C2699239;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior tnf antagonist n [ ],C0332152;C0231491;C2826257
crp $nmbr$ mg $nmbr$ n [ ],C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
smoking status n [ ],C1519386
concomitant therapy n [ ],C1707479
cs and im,C0010182;C0271160;C3540510;C4085345
supplementary figure $nmbr$ incidence of arthritis arthralgia in patients receiving corticosteroids at baseline according to tapering of corticosteroids in the previous $nmbr$ weeks in a patients with crohn s disease n $nmbr$ and b patients with ulcerative colitis n $nmbr$ this analysis includes patients who received $nmbr$ mg prednisone equivalent per day at baseline,C0021149;C0220856;C0030705;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727;C0441640;C1548969;C0439230;C0010346;C0012634;C0009324;C0002778;C0936012;C1524024;C0332257;C1552866;C2700399;C0205163;C0439185;C0168634;C1442488
im on]y,
aii participants n $nmbr$,C1424250;C0679646;C2698414
prior tnf antagonist n [ ],C0332152;C0231491;C2826257
anti gad positive n $nmbr$,C0270549;C0439178;C1446409;C1514241;C2825490;C3812269;C1414925
smoking status n [ ],C1519386
anti gad negative n $nmbr$,C0270549;C0205160;C1513916;C2825415;C2825491;C3853545;C1414925
prior diabetes,C0011847;C0011849
supplementary figure $nmbr$ incidence of arthritis arthralgia in patients receiving corticosteroids at baseline according to tapering of corticosteroids in the previous $nmbr$ weeks in a patients with crohn s disease n $nmbr$ and b patients with ulcerative colitis n $nmbr$ this analysis includes patients who received $nmbr$ mg prednisone equivalent per day at baseline,C0021149;C0220856;C0030705;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727;C0441640;C1548969;C0439230;C0010346;C0012634;C0009324;C0002778;C0936012;C1524024;C0332257;C1552866;C2700399;C0205163;C0439185;C0168634;C1442488
new diabetes,C0011847;C0011849
aii participants n $nmbr$,C1424250;C0679646;C2698414
prior cvd,C0332152;C0007222;C2826257
anti gad positive n $nmbr$,C0270549;C0439178;C1446409;C1514241;C2825490;C3812269;C1414925
thyroid disease,C0040128
anti gad negative n $nmbr$,C0270549;C0205160;C1513916;C2825415;C2825491;C3853545;C1414925
ethnic background,C0015031
prior diabetes,C0011847;C0011849
south asian,C1519427
new diabetes,C0011847;C0011849
prior gestational diabetes,C0332152;C0085207;C2826257
prior cvd,C0332152;C0007222;C2826257
alcohol $nmbr$ drinks per week,C0556297;C0332174;C0439230
thyroid disease,C0040128
education level,C0013621;C0013658
ethnic background,C0015031
education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
south asian,C1519427
education $nmbr$ y,C0013621;C0013622;C0013658;C0039401
prior gestational diabetes,C0332152;C0085207;C2826257
creatinine pmol l,C0010294;C0439284;C1561535
alcohol $nmbr$ drinks per week,C0556297;C0332174;C0439230
acr $nmbr$ mg g,C1412134;C1300563;C1515941
education level,C0013621;C0013658
hbalc mmol mol,C3829066
education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
f plasma glucose mmol l,C0202042;C1532563;C0455280
education $nmbr$ y,C0013621;C0013622;C0013658;C0039401
statin users,C0360714;C1706077
creatinine pmol l,C0010294;C0439284;C1561535
ace arb users,C1452534;C1706077;C4284014
acr $nmbr$ mg g,C1412134;C1300563;C1515941
beta blocker users,C0001645;C1706077
hbalc mmol mol,C3829066
thiazide users,C0541746;C1706077
f plasma glucose mmol l,C0202042;C1532563;C0455280
statin users,C0360714;C1706077
c peptide nmol l,C0607868
ace arb users,C1452534;C1706077;C4284014
overall n n loopy,C0282416;C1561607
glargine n n loopy,C0907402
beta blocker users,C0001645;C1706077
std n n loopy,
thiazide users,C0541746;C1706077
person years,C0027361;C0439234;C2347489
c peptide nmol l,C0607868
first co primary,C0205225;C0439612;C0439631
overall n n loopy,C0282416;C1561607
anti gad positive,C0439178;C1446409;C1514241;C2825490;C3812269
glargine n n loopy,C0907402
anti gad negative,C0205160;C1513916;C2825415;C2825491;C3853545
std n n loopy,
second co primary,C0205225;C0439612;C0439631
person years,C0027361;C0439234;C2347489
microvascular outcome,C0443258;C1274040
first co primary,C0205225;C0439612;C0439631
non severe hypoglycaemia,C0020615;C4553659
anti gad positive,C0439178;C1446409;C1514241;C2825490;C3812269
hbalc $nmbr$ $nmbr$ mmol mol,C3829066
anti gad negative,C0205160;C1513916;C2825415;C2825491;C3853545
iglarlixi n $nmbr$,
second co primary,C0205225;C0439612;C0439631
iglar n $nmbr$,
microvascular outcome,C0443258;C1274040
beam values mg dl mean sd,C0439269;C2699239
non severe hypoglycaemia,C0020615;C4553659
beam,C0338248;C2347880;C4521565
hbalc $nmbr$ $nmbr$ mmol mol,C3829066
sample statistics,C2348149
iglarlixi n $nmbr$,
nilvadipine,C0132512
iglar n $nmbr$,
years since diagnosis,C0439234;C0011900;C1704338;C1704656
beam values mg dl mean sd,C0439269;C2699239
years since symptom onset,C0439234;C4086878
beam,C0338248;C2347880;C4521565
apoe $nmbr$ carrier,C0007294;C0560175;C1325398;C1706209;C3273162
sample statistics,C2348149
smmse,
nilvadipine,C0132512
smmse $nmbr$,
years since diagnosis,C0439234;C0011900;C1704338;C1704656
baseline adas cog $nmbr$,C0168634;C3539026;C1442488
years since symptom onset,C0439234;C4086878
baseline cdr sb n $nmbr$ $nmbr$,C0168634;C0038111;C3811240;C1442488
apoe $nmbr$ carrier,C0007294;C0560175;C1325398;C1706209;C3273162
baseline dad n $nmbr$ $nmbr$,C0168634;C1442488
smmse,
d $nmbr$ ci,C0008107;C3259781
smmse $nmbr$,
group difference,C1705241;C1705242
baseline adas cog $nmbr$,C0168634;C3539026;C1442488
female n $nmbr$,C0043210;C0086287;C1705497;C1705498
baseline cdr sb n $nmbr$ $nmbr$,C0168634;C0038111;C3811240;C1442488
non carrier n $nmbr$,C2986416
baseline dad n $nmbr$ $nmbr$,C0168634;C1442488
carrier n $nmbr$,C0007294;C0560175;C1325398;C1706209;C3273162
d $nmbr$ ci,C0008107;C3259781
mild n $nmbr$,C2945599
group difference,C1705241;C1705242
moderate n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
female n $nmbr$,C0043210;C0086287;C1705497;C1705498
ease $nmbr$,C1331418
non carrier n $nmbr$,C2986416
empaglifiozin $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
carrier n $nmbr$,C0007294;C0560175;C1325398;C1706209;C3273162
placebo w $nmbr$,C0032042;C1696465;C1706408
mild n $nmbr$,C2945599
empaglifiozin $nmbr$ $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
moderate n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
femaie,
ease $nmbr$,C1331418
pacific,
empaglifiozin $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
egfr ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
placebo w $nmbr$,C0032042;C1696465;C1706408
total daily insulin dose units kgt,C2348070
empaglifiozin $nmbr$ $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
femaie,
basal insulin doset,C0650607
pacific,
bolus insulin doseh,C1186706;C0021641;C1533581;C1579433;C3714501;C1511237;C1705509;C3812160
egfr ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
type of insulin,C0457592
total daily insulin dose units kgt,C2348070
figure $nmbr$ hba $nmbr$ c ef cacy analysis data are from patients treated with $nmbr$ dose of study drug who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement c placebo corrected change from baseline in hba $nmbr$ c with empagli ozin at week $nmbr$ in subgroups by baseline hba $nmbr$ c $nmbr$ and $nmbr$ data are based on mixed model repeated measures analysis p $nmbr$ $nmbr$ for difference vs placebo p $nmbr$ $nmbr$ for difference vs placebo,C1511726;C3245479;C3714741;C0030705;C0332293;C0013175;C0168634;C1442488;C1299575;C0019016;C1825777;C3538758;C0332174;C0439230;C1079232;C1527178;C1705938;C1705241;C1705242;C0032042;C1696465;C1706408
basal insulin doset,C0650607
permanent users,C0205355;C1706077
bolus insulin doseh,C1186706;C0021641;C1533581;C1579433;C3714501;C1511237;C1705509;C3812160
fp,C0016704;C1419068;C1419906;C3541238;C3541412
type of insulin,C0457592
other ics,C0815320;C4551720
no ics,C0815320;C4551720
figure $nmbr$ hba $nmbr$ c ef cacy analysis data are from patients treated with $nmbr$ dose of study drug who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement c placebo corrected change from baseline in hba $nmbr$ c with empagli ozin at week $nmbr$ in subgroups by baseline hba $nmbr$ c $nmbr$ and $nmbr$ data are based on mixed model repeated measures analysis p $nmbr$ $nmbr$ for difference vs placebo p $nmbr$ $nmbr$ for difference vs placebo,C1511726;C3245479;C3714741;C0030705;C0332293;C0013175;C0168634;C1442488;C1299575;C0019016;C1825777;C3538758;C0332174;C0439230;C1079232;C1527178;C1705938;C1705241;C1705242;C0032042;C1696465;C1706408
non inhaled steroid use n,C1518422;C0586793
permanent users,C0205355;C1706077
fp,C0016704;C1419068;C1419906;C3541238;C3541412
anticholinergic use n,C0242896;C0042153;C0457083;C1947944;C3537004
other ics,C0815320;C4551720
fvc l mean sd,C0444504;C2699239;C2347634;C2348143
no ics,C0815320;C4551720
fvc predicted mean sd,C0444504;C2699239;C2347634;C2348143
non inhaled steroid use n,C1518422;C0586793
fev $nmbr$ fvc mean sd,C0444504;C2699239;C2347634;C2348143
anticholinergic use n,C0242896;C0042153;C0457083;C1947944;C3537004
post bronchodilator fev $nmbr$ l mean sd,C2599594;C2699239
fvc l mean sd,C0444504;C2699239;C2347634;C2348143
post bronchodilator fev $nmbr$ predicted mean sd,C2599594;C2699239
fvc predicted mean sd,C0444504;C2699239;C2347634;C2348143
treatment throughout study,C1521826;C3161471
fev $nmbr$ fvc mean sd,C0444504;C2699239;C2347634;C2348143
fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
post bronchodilator fev $nmbr$ l mean sd,C2599594;C2699239
fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
post bronchodilator fev $nmbr$ predicted mean sd,C2599594;C2699239
other ics versus no ics,C0815320;C4551720
treatment throughout study,C1521826;C3161471
hr or rr $nmbr$ ci,C0008107;C3259781
fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
permanent users n,C0205355;C1706077
fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
patients with pneumonia events n,C0030705;C0032285
other ics versus no ics,C0815320;C4551720
pneumonia events n,C0032285;C0441471;C3541888
hr or rr $nmbr$ ci,C0008107;C3259781
adjusted rate of pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
permanent users n,C0205355;C1706077
patients with hospitalized pneumonia events n,C0870668;C0032285
patients with pneumonia events n,C0030705;C0032285
hospitalized pneumonia events n,C0032285;C0441471;C3541888
pneumonia events n,C0032285;C0441471;C3541888
adjusted rate of hospitalized pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
adjusted rate of pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
patients with pneumonia resulting in death n,C0030705;C0032285;C0332294;C0011065;C1306577;C4082313;C4552775
patients with hospitalized pneumonia events n,C0870668;C0032285
treatment at baseline,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
hospitalized pneumonia events n,C0032285;C0441471;C3541888
hr or rr,
adjusted rate of hospitalized pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
use at baseline n,C0042153;C0457083;C1947944
patients with pneumonia resulting in death n,C0030705;C0032285;C0332294;C0011065;C1306577;C4082313;C4552775
patients with pneumonia event n,C0030705;C0032285
treatment at baseline,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
albiglutide n $nmbr$,C2607479
hr or rr,
race or ethnicity,C0034510;C1706779;C3853635;C0015031;C0243103
use at baseline n,C0042153;C0457083;C1947944
non hispanic white,C0007457;C0043157;C0220938
patients with pneumonia event n,C0030705;C0032285
non hispanic black or african american,C0005680;C0027567;C0085756;C0439541
albiglutide n $nmbr$,C2607479
eastern and central europe,C1707877;C0682369
race or ethnicity,C0034510;C1706779;C3853635;C0015031;C0243103
coronary artery bypass surgery,C0010055
non hispanic white,C0007457;C0043157;C0220938
history of microvascular disease,C0683519;C0730226;C0850708;C0944983
non hispanic black or african american,C0005680;C0027567;C0085756;C0439541
diabetic eye disease,C0342245
eastern and central europe,C1707877;C0682369
peripheral sensory neuropathy,C0151313;C4554142
coronary artery bypass surgery,C0010055
autonomic neuropathy,C0259749
history of microvascular disease,C0683519;C0730226;C0850708;C0944983
cardiovascular medications,C0007220
diabetic eye disease,C0342245
p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
peripheral sensory neuropathy,C0151313;C4554142
glucose lowering medications,C0017725;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
autonomic neuropathy,C0259749
none or diet,C0012155;C0012159;C1519433;C2983588;C3668949
cardiovascular medications,C0007220
sodium glucose cotransporter $nmbr$ inhibitor,C0017725;C1999216
p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
glucosidase inhibitor,C1512211
glucose lowering medications,C0017725;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
albiglutide events patients,C0441471;C0030705;C3541888
none or diet,C0012155;C0012159;C1519433;C2983588;C3668949
placebo events patients,C0032042;C0030705;C1696465;C1706408
sodium glucose cotransporter $nmbr$ inhibitor,C0017725;C1999216
hazard ratio $nmbr$,C2985465
glucosidase inhibitor,C1512211
primary analysis,C0002778;C0936012;C1524024
non hispanicwhite,C1518422
albiglutide events patients,C0441471;C0030705;C3541888
placebo events patients,C0032042;C0030705;C1696465;C1706408
non hispanic black,C0005680;C0027567;C0085756;C0439541
hazard ratio $nmbr$,C2985465
$nmbr$ $nmbr$ o $nmbr$ s i $nmbr$,C0021966;C0221138
primary analysis,C0002778;C0936012;C1524024
$nmbr$ $nmbr$ o $nmbr$ o i i $nmbr$,C0021966;C0221138
non hispanicwhite,C1518422
$nmbr$ o $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$ ^,
non hispanic black,C0005680;C0027567;C0085756;C0439541
number of arterial beds involved,C0237753;C0449788;C1314939
$nmbr$ $nmbr$ o $nmbr$ s i $nmbr$,C0021966;C0221138
heart failure history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ $nmbr$ o $nmbr$ o i i $nmbr$,C0021966;C0221138
$nmbr$ o $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
baseline egfr ml min per $nmbr$ $nmbr$ m,C0168634;C0439445;C1442488
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$ ^,
baseline bmi kg m^,C0022718;C0439209;C4054209
number of arterial beds involved,C0237753;C0449788;C1314939
$nmbr$ years to,C0439234
heart failure history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline hba^c,C0168634;C0019016;C1825777;C3538758;C1442488
baseline egfr ml min per $nmbr$ $nmbr$ m,C0168634;C0439445;C1442488
baseline dipeptidyl peptidase $nmbr$,C0168634;C0022709;C1442488
baseline bmi kg m^,C0022718;C0439209;C4054209
baseline statin,C0168634;C0360714;C1442488
$nmbr$ years to,C0439234
normoalbuminuria uacr,
baseline hba^c,C0168634;C0019016;C1825777;C3538758;C1442488
macroalbuminuria,
lixisenatide n $nmbr$ o,C2973895
baseline dipeptidyl peptidase $nmbr$,C0168634;C0022709;C1442488
$nmbr$ tq fi i,C0021966;C0221138
baseline statin,C0168634;C0360714;C1442488
normoalbuminuria uacr,
$nmbr$ f $nmbr$ q,C0016327
macroalbuminuria,
$nmbr$ l $nmbr$,C0439394;C1706495;C3642217
lixisenatide n $nmbr$ o,C2973895
$nmbr$ f $nmbr$ l $nmbr$,C0016327
$nmbr$ tq fi i,C0021966;C0221138
$nmbr$ f $nmbr$ $nmbr$,C0016327
$nmbr$ f $nmbr$ q,C0016327
hba,C0019016;C1825777;C3538758
$nmbr$ l $nmbr$,C0439394;C1706495;C3642217
ldl mmol l,C1532563
$nmbr$ f $nmbr$ l $nmbr$,C0016327
egfr ml min per $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
$nmbr$ f $nmbr$ $nmbr$,C0016327
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
hba,C0019016;C1825777;C3538758
renal impairment,C1565489
ldl mmol l,C1532563
$nmbr$ ^ f $nmbr$ $nmbr$,C0016327
egfr ml min per $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
therapies,C0087111
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
angiotensin converting enzyme inhibitors,C0003015;C2757044
renal impairment,C1565489
angiotensin ii receptor blocker,C0521942;C3536793
$nmbr$ ^ f $nmbr$ $nmbr$,C0016327
other blood pressure lowering drugs,C0003364
therapies,C0087111
overall n $nmbr$ $nmbr$,C0282416;C1561607
angiotensin converting enzyme inhibitors,C0003015;C2757044
no diabetes n $nmbr$ $nmbr$,C0011847;C0011849
angiotensin ii receptor blocker,C0521942;C3536793
amann whitney u test wilcoxon sum rank test,C0439148;C0683443
other blood pressure lowering drugs,C0003364
age group $nmbr$ no,C0027362;C2348001
overall n $nmbr$ $nmbr$,C0282416;C1561607
bpearson s chi square test,C0008041
no diabetes n $nmbr$ $nmbr$,C0011847;C0011849
body mass index group kg m $nmbr$ $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
amann whitney u test wilcoxon sum rank test,C0439148;C0683443
dyslipidaemia including hypercholesterol no,C0242339
age group $nmbr$ no,C0027362;C2348001
chronic renal disease no,C0022661;C1561643
bpearson s chi square test,C0008041
cfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
body mass index group kg m $nmbr$ $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
mi no,C3810814
dyslipidaemia including hypercholesterol no,C0242339
coronary artery bypass graft no,C0010055;C1260596
chronic renal disease no,C0022661;C1561643
chronic obstructive pulmonary disease no,C0024117
cfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
transient ischaemic attack no,C0007787;C0917805
mi no,C3810814
haemorrhagic stroke no,C0553692
coronary artery bypass graft no,C0010055;C1260596
non haemorrhagic stroke no,C1518422;C0553692
chronic obstructive pulmonary disease no,C0024117
timi risk score category no,C0683312;C3889287
transient ischaemic attack no,C0007787;C0917805
gp iib iiia inhibitor before pci no,C0016011;C1999216
haemorrhagic stroke no,C0553692
ticagrelor in hosp n $nmbr$,C1999375
non haemorrhagic stroke no,C1518422;C0553692
ticagrelor pre hosp n $nmbr$,C0332152;C0740175;C2257086;C3669034
timi risk score category no,C0683312;C3889287
atwo sample t test,C0370003;C0871472;C2347026
gp iib iiia inhibitor before pci no,C0016011;C1999216
age group $nmbr$ years no,C1510829
ticagrelor in hosp n $nmbr$,C1999375
cmann whitney u test wilcoxon sum rank test,C0439148;C0683443
ticagrelor pre hosp n $nmbr$,C0332152;C0740175;C2257086;C3669034
body mass index group $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
atwo sample t test,C0370003;C0871472;C2347026
dyslipidaemia no,C0242339
age group $nmbr$ years no,C1510829
$nmbr$ $nmbr$ d,
cmann whitney u test wilcoxon sum rank test,C0439148;C0683443
dfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
body mass index group $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
univariate logistic modela,C0242415
dyslipidaemia no,C0242339
multivariate logistic modelb,C0242415
$nmbr$ $nmbr$ d,
aunivariate logistic regression,C0206031
dfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828;C0441722;C0443221
univariate logistic modela,C0242415
mi previous pci and chronic obstructive pulmonary disease,C0205156;C4049621;C1552607;C0024117
multivariate logistic modelb,C0242415
pre hospital ticagrelor,C0019994;C1999375;C1510665
aunivariate logistic regression,C0206031
in hospital ticagrelor,C0019994;C1999375;C1510665
bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828;C0441722;C0443221
the p value is from the test statistic for testing the interaction between the treatment group and diabetes group,C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675;C0374505;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
mi previous pci and chronic obstructive pulmonary disease,C0205156;C4049621;C1552607;C0024117
$nmbr$ days composite of death new mi urgent revascularization and definite st,C0205199;C1547335;C0036056;C3272372
pre hospital ticagrelor,C0019994;C1999375;C1510665
$nmbr$ days new mi or definite acute st,C0205314;C3810814;C0036056;C3272372
in hospital ticagrelor,C0019994;C1999375;C1510665
$nmbr$ days new mi,C0205314;C3810814
the p value is from the test statistic for testing the interaction between the treatment group and diabetes group,C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675;C0374505;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ days definite st,C0036056;C3272372
$nmbr$ days composite of death new mi urgent revascularization and definite st,C0205199;C1547335;C0036056;C3272372
$nmbr$ days urgent revascularization,C0439228;C0581603
$nmbr$ days new mi or definite acute st,C0205314;C3810814;C0036056;C3272372
$nmbr$ days stroke ischemic,C0038454;C0475224;C4554100
$nmbr$ days new mi,C0205314;C3810814
timi flow grade $nmbr$ of mi culprit vessel pre pci,C0441800;C0919553;C3244287;C3810814;C0005847;C0332152;C0740175;C2257086;C3669034
$nmbr$ days definite st,C0036056;C3272372
st str $nmbr$ pre ci,C0008107;C3259781
$nmbr$ days urgent revascularization,C0439228;C0581603
timi flow grade $nmbr$ of mi culprit vessel post pci,C0441800;C0919553;C3244287;C0856742;C4049621
$nmbr$ days stroke ischemic,C0038454;C0475224;C4554100
st str $nmbr$ post pci,C0036056;C4049621;C3272372
timi flow grade $nmbr$ of mi culprit vessel pre pci,C0441800;C0919553;C3244287;C3810814;C0005847;C0332152;C0740175;C2257086;C3669034
bail out use of glycoprotein iib iiia inhibitors,C1524063;C0016011
st str $nmbr$ pre ci,C0008107;C3259781
timi minor bleeding,C0026193;C0019080;C0205165
timi flow grade $nmbr$ of mi culprit vessel post pci,C0441800;C0919553;C3244287;C0856742;C4049621
evolocumab n $nmbr$,C3529352
st str $nmbr$ post pci,C0036056;C4049621;C3272372
antiplatelet use,C0042153;C0457083;C1947944
bail out use of glycoprotein iib iiia inhibitors,C1524063;C0016011
high intensity statin use,C0042153;C0457083;C1947944
timi minor bleeding,C0026193;C0019080;C0205165
moderate intensity statin use,C0042153;C0457083;C1947944
evolocumab n $nmbr$,C3529352
imaged artery,C0003842;C0226004
antiplatelet use,C0042153;C0457083;C1947944
left anterior descending,C0441998;C0205386;C1547177
high intensity statin use,C0042153;C0457083;C1947944
right coronary,C0225808
moderate intensity statin use,C0042153;C0457083;C1947944
ramus,C3538818
imaged artery,C0003842;C0226004
p value between groups,C1709380
left anterior descending,C0441998;C0205386;C1547177
normalized volume measures,C0079809;C1879489
right coronary,C0225808
necrotic core mm^,C4330985;C4554674
ramus,C3538818
nominal change,C0392747;C0443172;C1705241;C4319952
p value between groups,C1709380
fibrofatty mm^,C4330985;C4554674
normalized volume measures,C0079809;C1879489
fibrous mm,C4330985;C4554674
necrotic core mm^,C4330985;C4554674
dense calcium mm,C4330985;C4554674
nominal change,C0392747;C0443172;C1705241;C4319952
necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
fibrofatty mm^,C4330985;C4554674
volume change mm^,C4330985;C4554674
fibrous mm,C4330985;C4554674
fibrofatty,
dense calcium mm,C4330985;C4554674
fibrous,C0016059;C0439709
necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
dense calcium,C0006675;C0006726;C2936886;C3540037;C3714611
volume change mm^,C4330985;C4554674
fig $nmbr$ proportion of patients achieving das de ned remission over time by symptom duration in each treatment arm a abatacept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci das de ned remission is de ned as das $nmbr$ crp $nmbr$ $nmbr$ das $nmbr$ crp disease activity score in $nmbr$ joints with c reactive pro tein das $nmbr$ crp mtx methotrexate,C1709707;C0030705;C0544452;C0687702;C0444921;C3259042;C0743559;C1608199;C1882932;C1518340;C4706353;C0022417;C0392905
fibrofatty,
fibrous,C0016059;C0439709
fig $nmbr$ proportion of patients achieving haq response over time by baseline symptom duration in each treatment arm a abata cept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci haq response is de ned as a reduction of at least $nmbr$ $nmbr$ units from baseline haq h ealth assessment question naire mtx methotrexate,C1709707;C0030705;C0102923;C0034746;C0451208;C0444921;C3259042;C0743559;C1608199;C1882932;C0871261;C1704632;C1706817;C2911692;C0011198;C1518340;C0017480;C3541240;C4684571;C0025677
dense calcium,C0006675;C0006726;C2936886;C3540037;C3714611
dapaglifloiin n,
[ ifrerence vs placebo $nmbr$ cl,C0032042;C0596019;C1696465;C1706408
fig $nmbr$ proportion of patients achieving das de ned remission over time by symptom duration in each treatment arm a abatacept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci das de ned remission is de ned as das $nmbr$ crp $nmbr$ $nmbr$ das $nmbr$ crp disease activity score in $nmbr$ joints with c reactive pro tein das $nmbr$ crp mtx methotrexate,C1709707;C0030705;C0544452;C0687702;C0444921;C3259042;C0743559;C1608199;C1882932;C1518340;C4706353;C0022417;C0392905
baseline hbalc^,C0168634;C1442488
fig $nmbr$ proportion of patients achieving haq response over time by baseline symptom duration in each treatment arm a abata cept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci haq response is de ned as a reduction of at least $nmbr$ $nmbr$ units from baseline haq h ealth assessment question naire mtx methotrexate,C1709707;C0030705;C0102923;C0034746;C0451208;C0444921;C3259042;C0743559;C1608199;C1882932;C0871261;C1704632;C1706817;C2911692;C0011198;C1518340;C0017480;C3541240;C4684571;C0025677
s $nmbr$ $nmbr$ s $nmbr$ $nmbr$,C0565930;C2603362
dapaglifloiin n,
s $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
[ ifrerence vs placebo $nmbr$ cl,C0032042;C0596019;C1696465;C1706408
insulin administration,C0199782
baseline hbalc^,C0168634;C1442488
cgm use,C0042153;C0457083;C1947944
s $nmbr$ $nmbr$ s $nmbr$ $nmbr$,C0565930;C2603362
dapaglifloz in n,
s $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
insulin administration,C0199782
baseline hba $nmbr$ c^,C0168634;C0019016;C1825777;C3538758;C1442488
cgm use,C0042153;C0457083;C1947944
difference vs placebo kg $nmbr$ cl,C1705241;C1705242;C0022718;C0596019;C0439209;C4054209
dapaglifloz in n,
s $nmbr$ kg m^,C0022718;C0439209;C4054209
difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
$nmbr$ ^ $nmbr$ kg m,C0022718;C0439209;C4054209
baseline hba $nmbr$ c^,C0168634;C0019016;C1825777;C3538758;C1442488
$nmbr$ kg m,C0022718;C0439209;C4054209
difference vs placebo kg $nmbr$ cl,C1705241;C1705242;C0022718;C0596019;C0439209;C4054209
dapagliflozin n,C2353951
s $nmbr$ kg m^,C0022718;C0439209;C4054209
$nmbr$ s $nmbr$ kg m,C0022718;C0439209;C4054209
$nmbr$ ^ $nmbr$ kg m,C0022718;C0439209;C4054209
n liraglutide $nmbr$ placebo,C0032042;C1696465;C1706408
$nmbr$ kg m,C0022718;C0439209;C4054209
ldl c $nmbr$ $nmbr$ mg dl,C0439269
dapagliflozin n,C2353951
ldl c $nmbr$ mg dl,C0439269
$nmbr$ s $nmbr$ kg m,C0022718;C0439209;C4054209
non fatal ml,C0439526;C1705224;C3887665
n liraglutide $nmbr$ placebo,C0032042;C1696465;C1706408
expanded mace,C0349381;C0949745;C1445339
ldl c $nmbr$ $nmbr$ mg dl,C0439269
race nonwhite,C0034510;C1706779;C3853635
ldl c $nmbr$ mg dl,C0439269
pci indication,C0392360;C3146298
non fatal ml,C0439526;C1705224;C3887665
thienopyridine at discharge,C1120149;C0012621;C0030685;C2926602
expanded mace,C0349381;C0949745;C1445339
any risk factor for stent thrombosis,C0035648;C3897493
race nonwhite,C0034510;C1706779;C3853635
$nmbr$ lesions per vessel,C0221198;C0005847
pci indication,C0392360;C3146298
lesion length $nmbr$ mm,C4330985;C4554674
thienopyridine at discharge,C1120149;C0012621;C0030685;C2926602
bifurcation lesion with side branch $nmbr$ $nmbr$ mm stented,C0221198;C1546698;C0038257
any risk factor for stent thrombosis,C0035648;C3897493
vein bypass stented,C0042449;C0741847;C0038257
$nmbr$ lesions per vessel,C0221198;C0005847
thrombus containing lesion,C0087086;C0302148;C3146237;C0332256;C2700400;C0221198;C1546698
lesion length $nmbr$ mm,C4330985;C4554674
lesions,C0221198
bifurcation lesion with side branch $nmbr$ $nmbr$ mm stented,C0221198;C1546698;C0038257
native coronary,C0302891;C0018787
vein bypass stented,C0042449;C0741847;C0038257
venous graft,C0181074;C0332835;C1961139
thrombus containing lesion,C0087086;C0302148;C3146237;C0332256;C2700400;C0221198;C1546698
arterial graft,C0450140
lesions,C0221198
modified acc or aha lesion class b $nmbr$ or c,C0175754;C0282160;C3541413;C0050451;C0221198;C1546698;C0772110
native coronary,C0302891;C0018787
continued thienopyridine n $nmbr$,C0549178;C1120149
venous graft,C0181074;C0332835;C1961139
stent thrombosis or mi,C3897493;C3810814
arterial graft,C0450140
definite probable stent thrombosis,C0033204;C3897493;C0332148
modified acc or aha lesion class b $nmbr$ or c,C0175754;C0282160;C3541413;C0050451;C0221198;C1546698;C0772110
definite stent thrombosis,C0439544;C3897493;C1704787
continued thienopyridine n $nmbr$,C0549178;C1120149
probable stent thrombosis,C0033204;C3897493;C0332148
stent thrombosis or mi,C3897493;C3810814
cardiac death,C0376297
definite probable stent thrombosis,C0033204;C3897493;C0332148
noncardiac death,C0011065;C1306577;C4082313;C4552775
definite stent thrombosis,C0439544;C3897493;C1704787
gusto moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
probable stent thrombosis,C0033204;C3897493;C0332148
mean sd n,C0444504;C2347634;C2348143
cardiac death,C0376297
genetic subgroup,C1079230;C1515021
noncardiac death,C0011065;C1306577;C4082313;C4552775
total aim high study,C0557651;C2603343
gusto moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
statin placebo n $nmbr$,C0360714;C0032042;C1696465;C1706408
mean sd n,C0444504;C2347634;C2348143
statin er niacin n $nmbr$,C0360714;C0027996;C1142562
genetic subgroup,C1079230;C1515021
baseline tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
total aim high study,C0557651;C2603343
baseline tg mg dl median iqr,C0168634;C0439269;C1442488
statin placebo n $nmbr$,C0360714;C0032042;C1696465;C1706408
baseline lipoprotein a nmol l median iqr,C0065058;C0125953;C1096202;C1439335
statin er niacin n $nmbr$,C0360714;C0027996;C1142562
change in ldl c,C0392747;C0443172;C1705241;C4319952
baseline tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
baseline tg mg dl median iqr,C0168634;C0439269;C1442488
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
baseline lipoprotein a nmol l median iqr,C0065058;C0125953;C1096202;C1439335
change in hdl c,C0392747;C0443172;C1705241;C4319952
change in ldl c,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ b,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
change in tc,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
change in tg,C0392747;C0443172;C1705241;C4319952
change in hdl c,C0392747;C0443172;C1705241;C4319952
change in lp a,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ b,
gene chr snp,C0752046;C1527094
change in tc,C0392747;C0443172;C1705241;C4319952
alleles,C0002085
change in tg,C0392747;C0443172;C1705241;C4319952
placebo statin,C0032042;C0360714;C1696465;C1706408
change in lp a,C0392747;C0443172;C1705241;C4319952
niacin statin,C0027996;C0360714;C1142562
gene chr snp,C0752046;C1527094
maf,
alleles,C0002085
minor major,C0205082;C0205164;C4318856;C4521762
placebo statin,C0032042;C0360714;C1696465;C1706408
trait,C0599883
niacin statin,C0027996;C0360714;C1142562
frequency of events,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
maf,
freqency of events,C0441471;C3541888
minor major,C0205082;C0205164;C4318856;C4521762
lipc,C1416867
trait,C0599883
aa g,C0282379;C0439267;C1235746;C1882141;C4554792
frequency of events,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
cad death,C0011065;C1306577;C4082313;C4552775
freqency of events,C0441471;C3541888
p value by gt,C1709380;C1435727;C1704693;C2697657
lipc,C1416867
ampd $nmbr$,
aa g,C0282379;C0439267;C1235746;C1882141;C4554792
ga a,C0016993
cad death,C0011065;C1306577;C4082313;C4552775
cyp $nmbr$ a $nmbr$,C1418793;C2634343
p value by gt,C1709380;C1435727;C1704693;C2697657
a ga,C0016993
ampd $nmbr$,
ga,C0016993
ga a,C0016993
male sex^,C0086582
cyp $nmbr$ a $nmbr$,C1418793;C2634343
diabetes duration years^,C0011847;C0439234;C0011849
a ga,C0016993
geographic region^,C0017446
ga,C0016993
hbau,
male sex^,C0086582
body weight kg^,C0022718;C0439209;C4054209
diabetes duration years^,C0011847;C0439234;C0011849
systolic blood pressure mm hg^,C0488055;C0439475;C0871470;C1306620
geographic region^,C0017446
diastolic blood pressure mm hg^,C0428883;C0439475;C1305849
hbau,
established cvd chronic kidney disease age $nmbr$ ^,C1561643;C0001779;C4553188
body weight kg^,C0022718;C0439209;C4054209
cvd risk factors age $nmbr$ ^ ^,C0001783
systolic blood pressure mm hg^,C0488055;C0439475;C0871470;C1306620
antihyperglycaemic medication at baseline,C0013227;C3244316;C4284232
diastolic blood pressure mm hg^,C0428883;C0439475;C1305849
$nmbr$ oad,
established cvd chronic kidney disease age $nmbr$ ^,C1561643;C0001779;C4553188
$nmbr$ oads,
cvd risk factors age $nmbr$ ^ ^,C0001783
insulin oad,C0021641;C1533581;C1579433;C3714501
antihyperglycaemic medication at baseline,C0013227;C3244316;C4284232
insulin dose u,C0366513;C0439148
$nmbr$ oad,
per body weight u kg,C0005910;C1300561;C1305866
$nmbr$ oads,
fig s $nmbr$ change in hba $nmbr$ c from baseline stratified by hba $nmbr$ c at baseline i first quartile hba $nmbr$ c,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0205363;C0019016;C1825777;C3538758;C0021966;C0221138
insulin oad,C0021641;C1533581;C1579433;C3714501
table $nmbr$ baseline characteristics of the liraglutide and placebo groups including concomitant antihyperglycaemic treatment,C0039224;C4684572;C1706074;C0032042;C0374505;C1696465;C1706408
insulin dose u,C0366513;C0439148
per body weight u kg,C0005910;C1300561;C1305866
fig s $nmbr$ change in hba $nmbr$ c from baseline stratified by hba $nmbr$ c at baseline i first quartile hba $nmbr$ c,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0205363;C0019016;C1825777;C3538758;C0021966;C0221138
full analysis set data are the mean standard deviation or the number of patients percentage of either liraglutide or placebo group percentage data refer to the proportion of patients a data rst published in the leader primary publication marso et al [ $nmbr$ ] b established cvd was de ned as prior myocardial infarction or prior stroke or transient ischaemic attack or prior revascularisation or [ $nmbr$ stenosis of coronary carotid or lower extremity arteries or documented symptomatic coronary heart disease or documented asymptomatic cardiac ischaemia or heart failure or chronic kidney disease c cvd risk factors included microalbuminuria or proteinuria hypertension and left ventricular hypertrophy left ven tricular systolic or diastolic dysfunction or ankle brachial index \ $nmbr$ $nmbr$ bmi body mass index cvd cardiovascular disease hba $nmbr$ c glycated haemoglobin oad oral antihyperglycaemic drug,C1511726;C3245479;C3714741;C1828170;C2360800;C0439165;C1549488;C1561533;C0205543;C0030705;C1425219;C0034037;C1704324;C0443211;C0007222;C1272684;C1518340;C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0007787;C0917805;C0332152;C0581603;C2826257;C0007282;C0242231;C0226415;C0010054;C0010068;C1956346;C1279369;C2062869;C0018801;C0018802;C4554158;C0679238;C0730345;C0020538;C1963138;C0149721;C0039155;C3484363;C0520863;C0007220
table $nmbr$ baseline characteristics of the liraglutide and placebo groups including concomitant antihyperglycaemic treatment,C0039224;C4684572;C1706074;C0032042;C0374505;C1696465;C1706408
age years^,C1510829
diabetes duration ycars,C0011847;C0011849
no polyvascular disease n $nmbr$ $nmbr$,C0012634
full analysis set data are the mean standard deviation or the number of patients percentage of either liraglutide or placebo group percentage data refer to the proportion of patients a data rst published in the leader primary publication marso et al [ $nmbr$ ] b established cvd was de ned as prior myocardial infarction or prior stroke or transient ischaemic attack or prior revascularisation or [ $nmbr$ stenosis of coronary carotid or lower extremity arteries or documented symptomatic coronary heart disease or documented asymptomatic cardiac ischaemia or heart failure or chronic kidney disease c cvd risk factors included microalbuminuria or proteinuria hypertension and left ventricular hypertrophy left ven tricular systolic or diastolic dysfunction or ankle brachial index \ $nmbr$ $nmbr$ bmi body mass index cvd cardiovascular disease hba $nmbr$ c glycated haemoglobin oad oral antihyperglycaemic drug,C1511726;C3245479;C3714741;C1828170;C2360800;C0439165;C1549488;C1561533;C0205543;C0030705;C1425219;C0034037;C1704324;C0443211;C0007222;C1272684;C1518340;C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0007787;C0917805;C0332152;C0581603;C2826257;C0007282;C0242231;C0226415;C0010054;C0010068;C1956346;C1279369;C2062869;C0018801;C0018802;C4554158;C0679238;C0730345;C0020538;C1963138;C0149721;C0039155;C3484363;C0520863;C0007220
polyvascular disease n $nmbr$,C0012634
age years^,C1510829
cardiac catheterisation or pci for index event,C0018795;C4049621;C0441471;C4019010
diabetes duration ycars,C0011847;C0011849
medications at enrolment,C0013227;C0802604;C2598133;C4284232
no polyvascular disease n $nmbr$ $nmbr$,C0012634
aspirin any dose,C0004057;C0178602;C0869039;C1114758
polyvascular disease n $nmbr$,C0012634
polyvascular disease status,C3176928
cardiac catheterisation or pci for index event,C0018795;C4049621;C0441471;C4019010
polyvascular disease and type $nmbr$ diabetes status,C0012634;C1317301
medications at enrolment,C0013227;C0802604;C2598133;C4284232
polyvascular disease and type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
aspirin any dose,C0004057;C0178602;C0869039;C1114758
polyvascular disease and no type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
polyvascular disease status,C3176928
cardiovascular death myocardial infarction or stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
polyvascular disease and type $nmbr$ diabetes status,C0012634;C1317301
coronary revascularisation,C0877341
polyvascular disease and type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
cardiovascular hospitalisation,C0007226;C0019993;C3887460
polyvascular disease and no type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
peripheral revascularisation,C0205100;C0581603
cardiovascular death myocardial infarction or stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
central and eastern europe,C0205099;C1879652;C0015177
coronary revascularisation,C0877341
canada or united states,C0006823;C0041703
cardiovascular hospitalisation,C0007226;C0019993;C3887460
rest ofworld,C0035253;C1622890
peripheral revascularisation,C0205100;C0581603
medical history before index acute coronary syndrome no,C0262926;C1704706
central and eastern europe,C0205099;C1879652;C0015177
family history of premature coronary heart disease,C0260520;C1313980;C2317524
canada or united states,C0006823;C0041703
index acute coronary syndrome no,C0600653;C0948089;C0918012;C1552854;C1637833;C2986546
rest ofworld,C0035253;C1622890
st segment elevation myocardial infarction,C1536220
medical history before index acute coronary syndrome no,C0262926;C1704706
non st segment elevation myocardial infarction,C1536220
family history of premature coronary heart disease,C0260520;C1313980;C2317524
percutaneous coronary intervention or coronary artery bypass grafting for index acute coronary syndrome no,C1532338;C0010055
index acute coronary syndrome no,C0600653;C0948089;C0918012;C1552854;C1637833;C2986546
median time from index acute coronary syndrome to randomization iqr mo,C0040223;C3541383;C0026544;C0332177
st segment elevation myocardial infarction,C1536220
median duration oftype $nmbr$ diabetes iqr yr,C0011847;C0439234;C0011849
non st segment elevation myocardial infarction,C1536220
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m^,C3811844;C0439445
percutaneous coronary intervention or coronary artery bypass grafting for index acute coronary syndrome no,C1532338;C0010055
established atherosclerotic cardiovascular disease no,C0443211;C0004153;C1272684
median time from index acute coronary syndrome to randomization iqr mo,C0040223;C3541383;C0026544;C0332177
history of coronary artery disease no,C1881055
median duration oftype $nmbr$ diabetes iqr yr,C0011847;C0439234;C0011849
history of peripheral artery disease no,C0683519;C0730226;C0850708;C0944983
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m^,C3811844;C0439445
history of cerebrovascular disease no,C0585890
established atherosclerotic cardiovascular disease no,C0443211;C0004153;C1272684
glucose lowering therapies no,C0017725;C0441994;C2003888;C0087111
history of coronary artery disease no,C1881055
dpp $nmbr$,C1414174
history of peripheral artery disease no,C0683519;C0730226;C0850708;C0944983
cardiovascular therapies no,C0587038
history of cerebrovascular disease no,C0585890
statin or ezetimibe,C0360714;C1142985
glucose lowering therapies no,C0017725;C0441994;C2003888;C0087111
dapagliflozin placebo no of events no of patients,C0032042;C1696465;C1706408;C0441471;C3541888;C0030705
dpp $nmbr$,C1414174
hazard ratio $nmbr$ c,C2985465
cardiovascular therapies no,C0587038
a cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
statin or ezetimibe,C0360714;C1142985
risk group,C0242444
dapagliflozin placebo no of events no of patients,C0032042;C1696465;C1706408;C0441471;C3541888;C0030705
[,
hazard ratio $nmbr$ c,C2985465
mrf,C0312443;C1412879
$nmbr$ em,
a cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
i h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
risk group,C0242444
[,
$nmbr$ ml min $nmbr$ $nmbr$ m^,C0439445
mrf,C0312443;C1412879
b mace,C0349381;C0949745;C1445339
$nmbr$ em,
$nmbr$ ml min $nmbr$ $nmbr$,C0439445
i h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
icosapent ethyl events n,C0058978;C0441471;C3541888
$nmbr$ ml min $nmbr$ $nmbr$ m^,C0439445
placebo events n,C0032042;C0441471;C3541888;C1696465;C1706408
b mace,C0349381;C0949745;C1445339
risk stratum,C0035647;C4552904
$nmbr$ ml min $nmbr$ $nmbr$,C0439445
secondary prevention cohort,C0009247;C0599755
icosapent ethyl events n,C0058978;C0441471;C3541888
primary prevention cohort,C0009247;C0599755
placebo events n,C0032042;C0441471;C3541888;C1696465;C1706408
the netherlands australia new zealand and south africa,C0027978;C0324547;C0037712
risk stratum,C0035647;C4552904
ezetimibe use,C0042153;C0457083;C1947944
secondary prevention cohort,C0009247;C0599755
$nmbr$ yr from the united states,C0439234;C0041703
primary prevention cohort,C0009247;C0599755
diabetes at baseline,C0011847;C0011849
the netherlands australia new zealand and south africa,C0027978;C0324547;C0037712
baseline estimated gfr,C0017654;C1424601
ezetimibe use,C0042153;C0457083;C1947944
baseline triglycerides,C0168634;C0041004;C1442488
$nmbr$ yr from the united states,C0439234;C0041703
baseline triglycerides $nmbr$ mg dl and,C0041004;C0439269
diabetes at baseline,C0011847;C0011849
h dl cholesterol,C0033727;C0008377;C0369286;C0441932;C0564385;C4528284
baseline estimated gfr,C0017654;C1424601
baseline statin intensity,C0168634;C0522510;C1442488
baseline triglycerides,C0168634;C0041004;C1442488
baseline ldl cholesterol derived,C0023824;C0202117;C1441547;C3245521
baseline triglycerides $nmbr$ mg dl and,C0041004;C0439269
in thirds,C0205437
h dl cholesterol,C0033727;C0008377;C0369286;C0441932;C0564385;C4528284
$nmbr$ mg dl baseline high sensitivity crp,C3890735;C4048285
baseline statin intensity,C0168634;C0522510;C1442488
$nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline ldl cholesterol derived,C0023824;C0202117;C1441547;C3245521
linagliptin n $nmbr$,C2746078
in thirds,C0205437
black af rican american,C0085756;C0344434;C4049859
$nmbr$ mg dl baseline high sensitivity crp,C3890735;C4048285
europe plus south africa,C0015176;C0037712
$nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ischemic heart disease no,C0010054;C0151744
linagliptin n $nmbr$,C2746078
egfr mdrd ml min $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
black af rican american,C0085756;C0344434;C4049859
uacr median iqr mg g,C0549183;C1300563;C0876920;C2347635;C2348144;C2939193
europe plus south africa,C0015176;C0037712
hemoglobin a^c,C0019020;C3889898
ischemic heart disease no,C0010054;C0151744
heart rate min,C0702093;C1524029;C3813700
egfr mdrd ml min $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
low density lipoprotein cholesterol mg dl,C0023824;C0439269
uacr median iqr mg g,C0549183;C1300563;C0876920;C2347635;C2348144;C2939193
$nmbr$ glucose lowering medication no,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
hemoglobin a^c,C0019020;C3889898
no of background glucose lowering therapies no,C1706907;C0017725;C0441994;C2003888;C0087111
heart rate min,C0702093;C1524029;C3813700
$nmbr$ antihypertensive medication no,C0003364
low density lipoprotein cholesterol mg dl,C0023824;C0439269
statins no,C0360714
$nmbr$ glucose lowering medication no,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
incidence rate difference linagliptin placebo $nmbr$ cl,C1708485;C0596019
no of background glucose lowering therapies no,C1706907;C0017725;C0441994;C2003888;C0087111
primary outcome $nmbr$ point mace,C0349381;C0949745;C1445339
$nmbr$ antihypertensive medication no,C0003364
cardiovascular death nonfatal myocardial infarction or nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
statins no,C0360714
secondary kidney composite outcome,C0022646;C1274040;C0227665
incidence rate difference linagliptin placebo $nmbr$ cl,C1708485;C0596019
sustained esrd death due to kidney failure or sustained decrease of $nmbr$ in egfr from baseline,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047;C1739039;C3811844;C3812682
primary outcome $nmbr$ point mace,C0349381;C0949745;C1445339
death due to renal failure,C0011065;C1306577;C4082313;C4552775
cardiovascular death nonfatal myocardial infarction or nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
sustained decrease of $nmbr$ in egfr,C0392756;C0547047;C1739039;C3811844;C3812682
secondary kidney composite outcome,C0022646;C1274040;C0227665
exploratory cardiovascular and death outcomes,C0007226;C3887460;C0011065;C1274040;C1306577;C4082313;C4552775
sustained esrd death due to kidney failure or sustained decrease of $nmbr$ in egfr from baseline,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047;C1739039;C3811844;C3812682
noncardiovascular death,C0011065;C1306577;C4082313;C4552775
death due to renal failure,C0011065;C1306577;C4082313;C4552775
fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
sustained decrease of $nmbr$ in egfr,C0392756;C0547047;C1739039;C3811844;C3812682
fatal or nonfatal myocardial infarction,C1302234;C1705232;C0027051;C0428953;C2926063;C3810814;C4552959
exploratory cardiovascular and death outcomes,C0007226;C3887460;C0011065;C1274040;C1306577;C4082313;C4552775
fatal or nonfatal stroke,C1302234;C1705232;C0038454;C4554100
noncardiovascular death,C0011065;C1306577;C4082313;C4552775
$nmbr$ point mace $nmbr$ point mace plus hospitalization for unstable angina,C0349381;C0019993;C0949745;C1445339;C0002965
fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
coronary revascularization procedure,C0877341
fatal or nonfatal myocardial infarction,C1302234;C1705232;C0027051;C0428953;C2926063;C3810814;C4552959
exploratory kidney and microvascular outcomes,C0022646;C0227665;C0443258;C1274040
fatal or nonfatal stroke,C1302234;C1705232;C0038454;C4554100
death due to renal failure or sustained esrd,C0011065;C1306577;C4082313;C4552775;C0022661;C0035078;C2316810
$nmbr$ point mace $nmbr$ point mace plus hospitalization for unstable angina,C0349381;C0019993;C0949745;C1445339;C0002965
albuminuria progression,C0242656;C0449258
coronary revascularization procedure,C0877341
composite microvascular end point,C2349179;C2826544
exploratory kidney and microvascular outcomes,C0022646;C0227665;C0443258;C1274040
composite ocular end point^,C2349179;C2826544
death due to renal failure or sustained esrd,C0011065;C1306577;C4082313;C4552775;C0022661;C0035078;C2316810
nonsevere hypoglycemia,C0020615;C4553659
albuminuria progression,C0242656;C0449258
no nonsevere hypoglycemia,C0020615;C4553659
composite microvascular end point,C2349179;C2826544
mean bmi,C0444504;C0578022;C2347634;C2348143
composite ocular end point^,C2349179;C2826544
previous cvd^,C0205156;C0007222;C1552607
nonsevere hypoglycemia,C0020615;C4553659
alcohol^,C0001962;C0001975
no nonsevere hypoglycemia,C0020615;C4553659
previous dm,C0011816;C3250443
mean bmi,C0444504;C0578022;C2347634;C2348143
dm duration years,C0011816;C0439234;C3250443
previous cvd^,C0205156;C0007222;C1552607
mean alc,C1424945;C3811058
alcohol^,C0001962;C0001975
mean fpg mmol l,C0444504;C1532563;C2347634;C2348143
previous dm,C0011816;C3250443
glargine allocation,C0907402;C1706778
dm duration years,C0011816;C0439234;C3250443
standard allocation,C1442989;C1706778;C2828392
mean alc,C1424945;C3811058
n $nmbr$ allocation,C0369718;C1706778;C0441922
mean fpg mmol l,C0444504;C1532563;C2347634;C2348143
placebo allocation,C0032042;C1706778;C1696465;C1706408
glargine allocation,C0907402;C1706778
other glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
standard allocation,C1442989;C1706778;C2828392
mean mmse score,C3533236;C0451306
n $nmbr$ allocation,C0369718;C1706778;C0441922
itch nrs $nmbr$ v $nmbr$,C2240043;C4050142
placebo allocation,C0032042;C1706778;C1696465;C1706408
itch nrs $nmbr$ $nmbr$ at $nmbr$,C2240043;C4050142
other glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
itch nrs $nmbr$ $nmbr$ v $nmbr$,C2240043;C4050142
mean mmse score,C3533236;C0451306
itch nrs $nmbr$ $nmbr$ \ $nmbr$,C2240043;C4050142
itch nrs $nmbr$ v $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ a $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ at $nmbr$,C2240043;C4050142
geographic region n,C0017446
itch nrs $nmbr$ $nmbr$ v $nmbr$,C2240043;C4050142
baseline pssi score mean sd,C0168634;C2699239;C1442488
itch nrs $nmbr$ $nmbr$ \ $nmbr$,C2240043;C4050142
baseline ppasi score mean sd,C0168634;C2699239;C1442488
itch nrs $nmbr$ $nmbr$ a $nmbr$,C2240043;C4050142
baseline skin pain vas mean sd,C0042815;C2699239
geographic region n,C0017446
baseline bsa mean sd,C0168634;C2699239;C1442488
baseline pssi score mean sd,C0168634;C2699239;C1442488
baseline spga mean sd,C0168634;C2699239;C1442488
baseline ppasi score mean sd,C0168634;C2699239;C1442488
baseline pasi mean sd,C0168634;C2699239;C1442488
baseline skin pain vas mean sd,C0042815;C2699239
baseline dlqi mean sd,C0168634;C2699239;C1442488
baseline bsa mean sd,C0168634;C2699239;C1442488
age at enrollment years mean sd,C1510829;C0444504;C2347634;C2348143
baseline spga mean sd,C0168634;C2699239;C1442488
duration of psoriasis years mean sd,C0449238;C2926735
baseline pasi mean sd,C0168634;C2699239;C1442488
previous use of nonbiologic systemic therapy n,C1524063;C1515119
baseline dlqi mean sd,C0168634;C2699239;C1442488
previous use of biologic systemic therapy n,C1524063;C1515119
age at enrollment years mean sd,C1510829;C0444504;C2347634;C2348143
facial psoriasis n,C1276112
duration of psoriasis years mean sd,C0449238;C2926735
scalp psoriasis n,C0406326
previous use of nonbiologic systemic therapy n,C1524063;C1515119
previous use of biologic systemic therapy n,C1524063;C1515119
fig $nmbr$ impact of baseline psoriasis associated itch severity on the itch numeric rating scale changes from baseline during the induction period pooled data from uncover $nmbr$ and $nmbr$ lsm in patients with psoriasis associated itch nrs c $nmbr$ at baseline the lsm difference $nmbr$ con dence interval and p values were derived from a mixed effects model for repeated measures analysis including the xed effects treatment study visit and treatment $nmbr$ visit with the variance covariance structure set to unstructured intent to treat population itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs scores at baseline etn etanercept ixe ixekizumab lsm least squares mean nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks,C1825598;C4049986;C0392747;C0443172;C1511726;C3245479;C3714741;C0030705;C0033860;C0033774;C1422257;C0168634;C1442488;C1272706;C1552654;C1552713;C1709380;C1441547;C3245521;C0002778;C0936012;C1524024;C2359836;C0036849;C1442518;C1705195;C2240043;C4050142;C0449820;C0023189;C0439230
facial psoriasis n,C1276112
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for a clinically meaningful improvement in itch i e c $nmbr$ point reduction in itch nrs at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treat ment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033774;C1422257;C0301630;C0392756;C1293152;C4551656;C0332174;C0439230;C0030705;C0332281;C0032659;C1257890;C4049715;C0014758;C0717758;C0031962
scalp psoriasis n,C0406326
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for complete itch resolution i e itch nrs $nmbr$ at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2240043;C4050142;C0332174;C0439230;C0030705;C0332281;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C0449820;C4050231;C0014758;C0717758;C0031962
fig $nmbr$ impact of baseline psoriasis associated itch severity on the itch numeric rating scale changes from baseline during the induction period pooled data from uncover $nmbr$ and $nmbr$ lsm in patients with psoriasis associated itch nrs c $nmbr$ at baseline the lsm difference $nmbr$ con dence interval and p values were derived from a mixed effects model for repeated measures analysis including the xed effects treatment study visit and treatment $nmbr$ visit with the variance covariance structure set to unstructured intent to treat population itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs scores at baseline etn etanercept ixe ixekizumab lsm least squares mean nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks,C1825598;C4049986;C0392747;C0443172;C1511726;C3245479;C3714741;C0030705;C0033860;C0033774;C1422257;C0168634;C1442488;C1272706;C1552654;C1552713;C1709380;C1441547;C3245521;C0002778;C0936012;C1524024;C2359836;C0036849;C1442518;C1705195;C2240043;C4050142;C0449820;C0023189;C0439230
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for c $nmbr$ improvement in psoriasis area and severity index from baseline at the end of the induction period week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population pooled data from uncover $nmbr$ and $nmbr$ nri treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pasi $nmbr$ c $nmbr$ improvement in pasi from baseline pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033860;C0017446;C0205146;C0444930;C2746065;C0336604;C1511726;C3245479;C3714741;C0039798;C0033774;C1422257;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0449820;C4050231;C4050142;C4528685;C0031962;C0439230;C0014758;C0717758
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for a clinically meaningful improvement in itch i e c $nmbr$ point reduction in itch nrs at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treat ment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033774;C1422257;C0301630;C0392756;C1293152;C4551656;C0332174;C0439230;C0030705;C0332281;C0032659;C1257890;C4049715;C0014758;C0717758;C0031962
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for absolute psoriasis area and severity index score b $nmbr$ at week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C0457451;C0332174;C0439230;C0336604;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C2240043;C4050142;C0449820;C4050231;C0014758;C0717758;C0031962
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for complete itch resolution i e itch nrs $nmbr$ at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2240043;C4050142;C0332174;C0439230;C0030705;C0332281;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C0449820;C4050231;C0014758;C0717758;C0031962
normal uln n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
high uln and $nmbr$ xuln n $nmbr$,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for c $nmbr$ improvement in psoriasis area and severity index from baseline at the end of the induction period week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population pooled data from uncover $nmbr$ and $nmbr$ nri treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pasi $nmbr$ c $nmbr$ improvement in pasi from baseline pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033860;C0017446;C0205146;C0444930;C2746065;C0336604;C1511726;C3245479;C3714741;C0039798;C0033774;C1422257;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0449820;C4050231;C4050142;C4528685;C0031962;C0439230;C0014758;C0717758
very high $nmbr$ xuln n $nmbr$,C0442804;C4321397
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for absolute psoriasis area and severity index score b $nmbr$ at week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C0457451;C0332174;C0439230;C0336604;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C2240043;C4050142;C0449820;C4050231;C0014758;C0717758;C0031962
age at disease onset years,C0206132;C3870509
normal uln n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
age at disease onset n,C0206132;C3870509
high uln and $nmbr$ xuln n $nmbr$,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
duration of as years,C0449238;C2926735;C0439234
very high $nmbr$ xuln n $nmbr$,C0442804;C4321397
duration of as n,C0449238;C2926735;C0369718;C0441922
age at disease onset years,C0206132;C3870509
prior nsaid n a,C0332152;C0003211;C3536840;C2826257
age at disease onset n,C0206132;C3870509
hla b $nmbr$ n,C1426226
duration of as years,C0449238;C2926735;C0439234
ptga,
duration of as n,C0449238;C2926735;C0369718;C0441922
asdas crp,C3890735;C4048285
prior nsaid n a,C0332152;C0003211;C3536840;C2826257
basdai,C1998004
hla b $nmbr$ n,C1426226
basfi,
ptga,
nbp,
tbp,
asdas crp,C3890735;C4048285
basdai,C1998004
comparison cat $nmbr$ vs cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
basfi,
week $nmbr$ outcomes,C0332174;C1274040;C0439230
nbp,
asdas crp $nmbr$ $nmbr$,C3890735;C4048285
tbp,
cat $nmbr$ n n,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
comparison cat $nmbr$ vs cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
or $nmbr$ ci a,C0008107;C3259781
week $nmbr$ outcomes,C0332174;C1274040;C0439230
pb,C1415801;C3819255
asdas crp $nmbr$ $nmbr$,C3890735;C4048285
high vs normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
cat $nmbr$ n n,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
very high vs normal,C0442804;C4321397;C0205307;C0231683;C0439166;C2347086;C4553972
or $nmbr$ ci a,C0008107;C3259781
week $nmbr$ crp,C3890735;C4048285
pb,C1415801;C3819255
elevated vs normalc,C0205250;C3163633
high vs normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
baseline asdas crp,C3890735;C4048285
very high vs normal,C0442804;C4321397;C0205307;C0231683;C0439166;C2347086;C4553972
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ and $nmbr$ $nmbr$,
week $nmbr$ crp,C3890735;C4048285
male vs female,C0086582;C1706180;C1706428;C1706429;C0043210;C0086287;C1705497;C1705498
elevated vs normalc,C0205250;C3163633
$nmbr$ years vs $nmbr$ years,C0439234
baseline asdas crp,C3890735;C4048285
disease duration,C0872146
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ and $nmbr$ $nmbr$,
$nmbr$ to $nmbr$ years vs $nmbr$ years,C0439234
male vs female,C0086582;C1706180;C1706428;C1706429;C0043210;C0086287;C1705497;C1705498
prior nsaid use,C0042153;C0457083;C1947944
$nmbr$ years vs $nmbr$ years,C0439234
yes vs no,C1549445;C1705108;C1710701
disease duration,C0872146
hla b $nmbr$,C0019737;C0550853;C1415561
$nmbr$ to $nmbr$ years vs $nmbr$ years,C0439234
positive vs negative,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
prior nsaid use,C0042153;C0457083;C1947944
baseline ptga,C0168634;C1442488
yes vs no,C1549445;C1705108;C1710701
$nmbr$ and $nmbr$ vs $nmbr$,
hla b $nmbr$,C0019737;C0550853;C1415561
$nmbr$ vs $nmbr$,
positive vs negative,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
baseline basdai,C0168634;C1998004;C1442488
baseline ptga,C0168634;C1442488
baseline basfi,C0168634;C1442488
$nmbr$ and $nmbr$ vs $nmbr$,
$nmbr$ to $nmbr$ vs $nmbr$,
$nmbr$ vs $nmbr$,
baseline nbp,C0168634;C1442488
baseline basdai,C0168634;C1998004;C1442488
baseline tbp,C0168634;C1442488
baseline basfi,C0168634;C1442488
week $nmbr$ outcome,C0332174;C1274040;C0439230
$nmbr$ to $nmbr$ vs $nmbr$,
potential predictor,C3245505;C2698872
baseline nbp,C0168634;C1442488
high vs normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
baseline tbp,C0168634;C1442488
very high vs normalb,C0442804;C4321397
week $nmbr$ outcome,C0332174;C1274040;C0439230
elevated vs normalb,C0205250;C3163633
potential predictor,C3245505;C2698872
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
high vs normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
boost intensify premix i global patient population,C1511253;C1874596;C0032659;C1257890
very high vs normalb,C0442804;C4321397
boost intensify all pan asian patient population,C1511253;C1874596;C0032659;C1257890
elevated vs normalb,C0205250;C3163633
total included in combined analysis,C0439175;C0439810;C0332257;C0002778;C0936012;C1524024
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
idegasp bid,
boost intensify premix i global patient population,C1511253;C1874596;C0032659;C1257890
biasp $nmbr$ bid,
boost intensify all pan asian patient population,C1511253;C1874596;C0032659;C1257890
full analysis set n,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
total included in combined analysis,C0439175;C0439810;C0332257;C0002778;C0936012;C1524024
idegasp biasp $nmbr$,
idegasp bid,
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C1180255;C0008107;C3259781
biasp $nmbr$ bid,
end of trial,C0444930;C2746065
full analysis set n,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p,C1180255;C0008107;C3259781
idegasp biasp $nmbr$,
etr $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C0008107;C3259781
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C1180255;C0008107;C3259781
subpopulation,C1257890
end of trial,C0444930;C2746065
week $nmbr$ before ee,C0332174;C0439230
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p,C1180255;C0008107;C3259781
week $nmbr$ non ee responders,C0332174;C0439230
etr $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C0008107;C3259781
crp uln,C3890735;C1519815;C4048285
subpopulation,C1257890
abatacept,C1619966
week $nmbr$ before ee,C0332174;C0439230
adjusted mean difference $nmbr$ ci,C0008107;C3259781
week $nmbr$ non ee responders,C0332174;C0439230
facit f,C3272505
crp uln,C3890735;C1519815;C4048285
tnfi na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
abatacept,C1619966
tnfi exposed,C0332157
adjusted mean difference $nmbr$ ci,C0008107;C3259781
china,C0008115
facit f,C3272505
lev n $nmbr$,C0023556
tnfi na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
chinese,C0008120;C0152035
tnfi exposed,C0332157
japanese,C0376247;C1556094
china,C0008115
duration of epilepsy mean sd years,C0449238;C2926735
lev n $nmbr$,C0023556
seizure history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
chinese,C0008120;C0152035
focal,C0205234
japanese,C0376247;C1556094
generalized,C0205246
duration of epilepsy mean sd years,C0449238;C2926735
absence,C0332197;C1689985
seizure history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
atypical absence,C0595948
focal,C0205234
myoclonic,
generalized,C0205246
clonic,
absence,C0332197;C1689985
tonic,C3543842
atypical absence,C0595948
tonic clonic,C3543842
myoclonic,
atonic,
clonic,
cluster seizures,C1555715;C0036572;C1704332
tonic,C3543842
classification of epilepsy type n,C0008902;C0008903;C0678229
tonic clonic,C3543842
idiopathica,
atonic,
juvenile myoclonic epilepsy,C0270853
cluster seizures,C1555715;C0036572;C1704332
epilepsy with grand mal seizures on awakening,C0014549;C1720052
classification of epilepsy type n,C0008902;C0008903;C0678229
symptomaticb,
idiopathica,
specific syndromes,C0039082;C1558916
juvenile myoclonic epilepsy,C0270853
undeterminedc,
epilepsy with grand mal seizures on awakening,C0014549;C1720052
seizure frequency during $nmbr$ week baseline median range,C0149775;C0168634;C1442488
symptomaticb,
prior aeds $nmbr$ n,C0332152;C0180309;C2826257
specific syndromes,C0039082;C1558916
concomitant aeds n,C0521115;C0180309
undeterminedc,
valproate,C0080356
seizure frequency during $nmbr$ week baseline median range,C0149775;C0168634;C1442488
topiramate,C0076829
prior aeds $nmbr$ n,C0332152;C0180309;C2826257
phenobarbital,C0031412
concomitant aeds n,C0521115;C0180309
freedom from gtc seizures n,C0016694;C0036572
valproate,C0080356
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week treatment period full analysis set p values versus placebo calculated using ancova b median percent reduction from combined baseline in generalized tonic clonic seizures week for patients with idiopathic and symptomatic generalized epilepsy during the $nmbr$ week treatment period ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0332174;C0439230;C0332240;C0270854;C0377265;C3693636
topiramate,C0076829
phenobarbital,C0031412
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week evaluation period p values versus placebo calculated using ancova b generalized tonic clonic seizure $nmbr$ responder rates during the $nmbr$ week treatment and $nmbr$ week evaluation periods full analysis set p values versus placebo calculated using logistic regression ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0042295;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0871208;C1521828;C0814908
freedom from gtc seizures n,C0016694;C0036572
onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
faster aspart mealtime,C0123677;C0587119
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week treatment period full analysis set p values versus placebo calculated using ancova b median percent reduction from combined baseline in generalized tonic clonic seizures week for patients with idiopathic and symptomatic generalized epilepsy during the $nmbr$ week treatment period ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0332174;C0439230;C0332240;C0270854;C0377265;C3693636
insulin aspart mealtime,C0123677;C0587119;C1708521
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week evaluation period p values versus placebo calculated using ancova b generalized tonic clonic seizure $nmbr$ responder rates during the $nmbr$ week treatment and $nmbr$ week evaluation periods full analysis set p values versus placebo calculated using logistic regression ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0042295;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0871208;C1521828;C0814908
faster aspart,C0015663;C0123677;C0456962;C2985769
onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
insulin aspart,C0123677;C1708521
faster aspart mealtime,C0123677;C0587119
faster aspart basal,C0123677;C0205112
insulin aspart mealtime,C0123677;C0587119;C1708521
basal insulin,C0650607
faster aspart,C0015663;C0123677;C0456962;C2985769
gender n men,C0079399;C0025266;C1522384
insulin aspart,C0123677;C1708521
lb,
faster aspart basal,C0123677;C0205112
$nmbr$ mmol mol $nmbr$ $nmbr$ n,C3829066
basal insulin,C0650607
change in hbalc after $nmbr$ weeks etd $nmbr$ cl,C0392747;C0443172;C1705241;C4319952;C0439230;C0596019
gender n men,C0079399;C0025266;C1522384
all participants n $nmbr$ $nmbr$,C0679646
lb,
bmi $nmbr$ kg m^ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
$nmbr$ mmol mol $nmbr$ $nmbr$ n,C3829066
hbalc $nmbr$ $nmbr$ $nmbr$,
change in hbalc after $nmbr$ weeks etd $nmbr$ cl,C0392747;C0443172;C1705241;C4319952;C0439230;C0596019
hbalc $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
all participants n $nmbr$ $nmbr$,C0679646
all participantst n $nmbr$ $nmbr$,
bmi $nmbr$ kg m^ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
hbalc $nmbr$ $nmbr$ $nmbr$,
bmi $nmbr$ kg m n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
hbalc $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
hbalc a $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
all participantst n $nmbr$ $nmbr$,
all participants^^ n $nmbr$ $nmbr$,C0679646
bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
dose ratio at week $nmbr$ $nmbr$ cl,C0178602;C0456603;C1547037;C0869039;C1114758
bmi $nmbr$ kg m n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
hbalc $nmbr$ mmol mol,C3829066
hbalc a $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
normal baseline crp,C3890735;C4048285
all participants^^ n $nmbr$ $nmbr$,C0679646
elevated baseline crp,C0742906;C0168634;C1442488
dose ratio at week $nmbr$ $nmbr$ cl,C0178602;C0456603;C1547037;C0869039;C1114758
pooled secukinumab,C1709595;C3179547;C2349200;C4522255
hbalc $nmbr$ mmol mol,C3829066
pooled placebo,C0032042;C1696465;C1706408
normal baseline crp,C3890735;C4048285
positive for hla b $nmbr$ n,C0439178;C1446409;C1514241;C2825490;C3812269
elevated baseline crp,C0742906;C0168634;C1442488
concomitant methotrexate use n,C0025677;C0042153;C0457083;C1947944
pooled secukinumab,C1709595;C3179547;C2349200;C4522255
hscrp mg l median minimum maximum,C0806909;C1552615;C2826546
pooled placebo,C0032042;C1696465;C1706408
ptga of disease activity $nmbr$ $nmbr$ mm mean sd,C1292728;C0444504;C2347634;C2348143
positive for hla b $nmbr$ n,C0439178;C1446409;C1514241;C2825490;C3812269
baseline crp levels,C3890735;C0441889;C4048285
concomitant methotrexate use n,C0025677;C0042153;C0457083;C1947944
baseline crp levels $nmbr$ mg l,C0168634;C0439268;C1442488
hscrp mg l median minimum maximum,C0806909;C1552615;C2826546
basdai mean change from baseline,C0392747;C0443172;C1705241;C4319952
ptga of disease activity $nmbr$ $nmbr$ mm mean sd,C1292728;C0444504;C2347634;C2348143
basdai $nmbr$,C1998004
baseline crp levels,C3890735;C0441889;C4048285
asdas inactive disease,C0544452
baseline crp levels $nmbr$ mg l,C0168634;C0439268;C1442488
asas partial remission,C1521726;C4552913;C4552914
basdai mean change from baseline,C0392747;C0443172;C1705241;C4319952
with prior mi stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
basdai $nmbr$,C1998004
cvd without mi or stroke n $nmbr$,C0007222;C3810814;C0038454;C4554100
asdas inactive disease,C0544452
cardiovascular risk factors alone n $nmbr$,C0850624;C0205171;C0439044;C0679994
asas partial remission,C1521726;C4552913;C4552914
liraglutide n $nmbr$,C1456408
with prior mi stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
age sd y,C0001779;C2699239
cvd without mi or stroke n $nmbr$,C0007222;C3810814;C0038454;C4554100
bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
cardiovascular risk factors alone n $nmbr$,C0850624;C0205171;C0439044;C0679994
diabetes mellitus duration sd y,C0011849;C0449238;C2926735
liraglutide n $nmbr$,C1456408
hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
age sd y,C0001779;C2699239
hba $nmbr$ c sd mmol mol,C0019016;C3829066;C1825777;C3538758
bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
sbp sd mm hg,C0085805;C0439475
diabetes mellitus duration sd y,C0011849;C0449238;C2926735
dbp sd mm hg,C0536221;C0439475;C3813197;C4281799
hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
heart rate sd bpm,C0018810;C2699239
hba $nmbr$ c sd mmol mol,C0019016;C3829066;C1825777;C3538758
egfr from the mdrd equation sd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
sbp sd mm hg,C0085805;C0439475
moderate $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335;C0369718;C0441922
dbp sd mm hg,C0536221;C0439475;C3813197;C4281799
mild $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C2945599;C0439445;C0369718;C0441922
heart rate sd bpm,C0018810;C2699239
normal $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972;C0369718;C0441922
egfr from the mdrd equation sd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
total cholesterol sd mg dl,C0201950;C0439269;C0543421
moderate $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335;C0369718;C0441922
ldl cholesterol sd mg dl,C0023824;C0439269;C0202117
mild $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C2945599;C0439445;C0369718;C0441922
hdl cholesterol sd mg dl,C0023822;C0439269;C0392885
normal $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972;C0369718;C0441922
triglycerides sd mg dl,C0041004;C0439269
total cholesterol sd mg dl,C0201950;C0439269;C0543421
antihypertensive therapy n,C0585941
ldl cholesterol sd mg dl,C0023824;C0439269;C0202117
diuretics n,C0012798
hdl cholesterol sd mg dl,C0023822;C0439269;C0392885
lipid lowering drugs n,C0086440
triglycerides sd mg dl,C0041004;C0439269
platelet aggregation inhibitors n,C0032177
antihypertensive therapy n,C0585941
antithrombotic medications n,C0013227;C0802604;C2598133;C4284232
diuretics n,C0012798
blood glucose lowering drugs excluding insulin n,C0005802;C0441994;C2003888;C0013227;C3687832
lipid lowering drugs n,C0086440
insulin treatment n,C0745343
platelet aggregation inhibitors n,C0032177
insulin naive n,C0021641;C1533581;C1579433;C3714501
antithrombotic medications n,C0013227;C0802604;C2598133;C4284232
micro macroalbuminuria,C0085672;C1553035;C3811161;C4049106
blood glucose lowering drugs excluding insulin n,C0005802;C0441994;C2003888;C0013227;C3687832
smoking n,C0037369;C0453996;C1881674
insulin treatment n,C0745343
prior stroke mi n,C0332152;C0038454;C4554100;C2826257
insulin naive n,C0021641;C1533581;C1579433;C3714501
history of mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
micro macroalbuminuria,C0085672;C1553035;C3811161;C4049106
diabetes mellitus duration y sd,C0011849;C2699239
smoking n,C0037369;C0453996;C1881674
body weight kg sd,C0005910;C2699239;C1305866
prior stroke mi n,C0332152;C0038454;C4554100;C2826257
creatinine mg dl sd,C0439269;C2699239
history of mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
egfr ml min $nmbr$ $nmbr$ m $nmbr$ sd,C1739039;C0439445;C3811844;C3812682;C2699239
diabetes mellitus duration y sd,C0011849;C2699239
normal egfr $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972
body weight kg sd,C0005910;C2699239;C1305866
mild impairment egfr $nmbr$ $nmbr$ n,C0221099;C0684336
creatinine mg dl sd,C0439269;C2699239
moderate impairment egfr $nmbr$ $nmbr$ n,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
egfr ml min $nmbr$ $nmbr$ m $nmbr$ sd,C1739039;C0439445;C3811844;C3812682;C2699239
uacr mg g q $nmbr$ q $nmbr$,C1300563
normal egfr $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972
total cholesterol mmol l sd,C0201950;C2699239;C0543421
mild impairment egfr $nmbr$ $nmbr$ n,C0221099;C0684336
ldl c mmol l sd,C1532563;C2699239
moderate impairment egfr $nmbr$ $nmbr$ n,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
sbp mm hg sd,C0439475;C2699239
uacr mg g q $nmbr$ q $nmbr$,C1300563
dbp mm hg sd,C0439475;C2699239
total cholesterol mmol l sd,C0201950;C2699239;C0543421
hr bpm sd,C2699239
ldl c mmol l sd,C1532563;C2699239
liraglutide n,C1456408
sbp mm hg sd,C0439475;C2699239
hazard ratio [ $nmbr$ ci],C2985465;C0008107;C3259781
dbp mm hg sd,C0439475;C2699239
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
hr bpm sd,C2699239
egfr $nmbr$ ml min $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682
liraglutide n,C1456408
acute increase in serum creatinine,C0442805;C0201976;C0600061
hazard ratio [ $nmbr$ ci],C2985465;C0008107;C3259781
demographic factors,C0011292;C0011298
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
residence in asia n,C0237096;C0003980
egfr $nmbr$ ml min $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682
medical and lifestyle history,C0199168;C0205476;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
acute increase in serum creatinine,C0442805;C0201976;C0600061
history of macrovascular disease at baseline n,C0683519;C0730226;C0850708;C0944983;C0168634;C1442488
demographic factors,C0011292;C0011298
current alcohol drinking n,C0001962;C0001975;C0001948;C0684271;C0369718;C0441922
residence in asia n,C0237096;C0003980
risk factors,C0035648;C1553898
medical and lifestyle history,C0199168;C0205476;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hemoglobin a,C0019016
history of macrovascular disease at baseline n,C0683519;C0730226;C0850708;C0944983;C0168634;C1442488
ecfr ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
current alcohol drinking n,C0001962;C0001975;C0001948;C0684271;C0369718;C0441922
uacr pg mg,C1627892
risk factors,C0035648;C1553898
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
hemoglobin a,C0019016
randomized treatments n,C0034656;C0087111;C3815594
ecfr ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
perindopril indapamide,C1273169
uacr pg mg,C1627892
intensive blood glucose control,C3267174
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
blood glucose lowering treatments n,C0005802;C0441994;C2003888;C0087111
randomized treatments n,C0034656;C0087111;C3815594
oral hypoglycemic agentsj,C0359086
perindopril indapamide,C1273169
bp lowering treatments n,C0037623;C0087111;C1415692;C1708288;C4318478
intensive blood glucose control,C3267174
diuretics^,C0012798
blood glucose lowering treatments n,C0005802;C0441994;C2003888;C0087111
angiotensin converting enzyme inhibitors^,C0003015;C2757044
oral hypoglycemic agentsj,C0359086
angiotensin ii receptor blockers,C0521942;C2757003
bp lowering treatments n,C0037623;C0087111;C1415692;C1708288;C4318478
any bp lowering agents^,C0450442;C1254351;C1521826
diuretics^,C0012798
changes in serum creatinine pmol l,C0392747;C0443172
angiotensin converting enzyme inhibitors^,C0003015;C2757044
first serum creatinine,C0201976;C0600061
angiotensin ii receptor blockers,C0521942;C2757003
second serum creatinine,C0201976;C0600061
any bp lowering agents^,C0450442;C1254351;C1521826
increase in serum creatinine,C0442805;C0201976;C0600061
changes in serum creatinine pmol l,C0392747;C0443172
n events n subjects,C0681850;C1550501;C1706203;C2349001;C2697811
first serum creatinine,C0201976;C0600061
combined major macrovascular events neohrodathv and all cause mortalitv,C0205082;C0205164;C4318856;C4521762;C0015127;C1524003
second serum creatinine,C0201976;C0600061
major macrovascular events,C0441471;C3541888
increase in serum creatinine,C0442805;C0201976;C0600061
new or worsenina neohrodathv,C0205314
n events n subjects,C0681850;C1550501;C1706203;C2349001;C2697811
all cause mortalitv,C0015127;C1524003
combined major macrovascular events neohrodathv and all cause mortalitv,C0205082;C0205164;C4318856;C4521762;C0015127;C1524003
n events,C0441471;C3541888
major macrovascular events,C0441471;C3541888
active,C0205177;C3853793;C3888249
new or worsenina neohrodathv,C0205314
combined major macrovascular events,C0441471;C3541888
all cause mortalitv,C0015127;C1524003
neohrodathv and all cause mortalitv,C0015127;C1524003
n events,C0441471;C3541888
new or worsentna neohrodathv,C0205314
active,C0205177;C3853793;C3888249
golden $nmbr$ and $nmbr$,
combined major macrovascular events,C0441471;C3541888
golden $nmbr$,
neohrodathv and all cause mortalitv,C0015127;C1524003
glycopyrrolate glycopyrrolate eflow cs $nmbr$ meg eflow cs $nmbr$ meg n $nmbr$ n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
new or worsentna neohrodathv,C0205314
tiotropium $nmbr$ meg n $nmbr$,C0024489;C0025175;C0072225
golden $nmbr$ and $nmbr$,
glycopyrrolate eflow cs $nmbr$ meg n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
golden $nmbr$,
black or african heritage,C0005680;C0027567;C0085756;C0439541;C2986513
glycopyrrolate glycopyrrolate eflow cs $nmbr$ meg eflow cs $nmbr$ meg n $nmbr$ n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
body mass index kg rn \ mean sd,C0005893;C2699239;C0578022;C1305855
tiotropium $nmbr$ meg n $nmbr$,C0024489;C0025175;C0072225
number of copd exacerbations within $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
glycopyrrolate eflow cs $nmbr$ meg n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
history of oxygen use yes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
black or african heritage,C0005680;C0027567;C0085756;C0439541;C2986513
high cardiovascular risk n ^,C0332167;C3272283;C4050568;C4319571
body mass index kg rn \ mean sd,C0005893;C2699239;C0578022;C1305855
background laba use yes n,C0042153;C0457083;C1947944
number of copd exacerbations within $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
inhaled corticosteroid yes n,C0004048;C0001617;C3536709
history of oxygen use yes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pulmonary function tests post bronchodilator mean sd,C0024119;C2699239;C2598152
high cardiovascular risk n ^,C0332167;C3272283;C4050568;C4319571
fevi l,C0429706;C0849974;C1561566;C4528367
background laba use yes n,C0042153;C0457083;C1947944
fevi fvc,C0802741;C3815113
inhaled corticosteroid yes n,C0004048;C0001617;C3536709
fevi percent predicted,C0429706;C0439165;C0849974;C1561566;C4528367;C0681842;C1882327
pulmonary function tests post bronchodilator mean sd,C0024119;C2699239;C2598152
post bronchodilator fevi n,C2599594;C0429706;C0849974;C1561566;C4528367
fevi l,C0429706;C0849974;C1561566;C4528367
$nmbr$ predicted to,C0681842;C1882327
fevi fvc,C0802741;C3815113
$nmbr$ predicted,C0681842;C1882327
fevi percent predicted,C0429706;C0439165;C0849974;C1561566;C4528367;C0681842;C1882327
baseline in check pifr l min,C0702093;C1524029;C3813700
post bronchodilator fevi n,C2599594;C0429706;C0849974;C1561566;C4528367
sgrq scores mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ predicted to,C0681842;C1882327
symptoms,C0683368;C1457887
$nmbr$ predicted,C0681842;C1882327
activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
baseline in check pifr l min,C0702093;C1524029;C3813700
impacts,C1825598;C4049986
sgrq scores mean sd,C0444504;C2699239;C2347634;C2348143
sgrq responder,
symptoms,C0683368;C1457887
odds ratio and $nmbr$ cl,C0028873;C0596019
activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
sun $nmbr$ $nmbr$,C0038817;C0376223
impacts,C1825598;C4049986
lcl,C3658298
sgrq responder,
ucl,
odds ratio and $nmbr$ cl,C0028873;C0596019
background laba use,C0042153;C0457083;C1947944
sun $nmbr$ $nmbr$,C0038817;C0376223
fev predicted,C3714541;C0681842;C1882327
lcl,C3658298
pifr l min,C0702093;C1524029;C3813700
ucl,
$nmbr$ l min,C0439393
background laba use,C0042153;C0457083;C1947944
$nmbr$ l_ min,C0439393
fev predicted,C3714541;C0681842;C1882327
participants with hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
pifr l min,C0702093;C1524029;C3813700
participants without hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
$nmbr$ l min,C0439393
total carmelina population,C3258257
$nmbr$ l_ min,C0439393
europe including south africa,C0015176;C0037712
participants with hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
ischemic heart disease n,C0010054;C0151744
participants without hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
egfr mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
total carmelina population,C3258257
egfr mdrd n,C1739039;C3811844;C3812682
europe including south africa,C0015176;C0037712
uacr mg g median $nmbr$ th $nmbr$ th percentile,C1300563;C1264641
ischemic heart disease n,C0010054;C0151744
uacr n,
egfr mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
diabetes mellitus duration y,C0011849;C0449238;C2926735
egfr mdrd n,C1739039;C3811844;C3812682
heart rate bpm mean sd,C0018810;C2699239
uacr mg g median $nmbr$ th $nmbr$ th percentile,C1300563;C1264641
glucose lowering therapy n,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
uacr n,
antihypertensives n,C0003364
diabetes mellitus duration y,C0011849;C0449238;C2926735
asa n,C0004057;C3853627
heart rate bpm mean sd,C0018810;C2699239
patients with event patients analysed,C0030705;C0441471;C4019010
glucose lowering therapy n,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
p for interaetion,C0369773;C2603361
antihypertensives n,C0003364
plaeebo,
asa n,C0004057;C3853627
raee,
blaek afriean ameriean,
patients with event patients analysed,C0030705;C0441471;C4019010
ethnieity,
p for interaetion,C0369773;C2603361
hispanie latino,C0086528
plaeebo,
not hispanie latino,C1518422;C0086528
raee,
regiont,
blaek afriean ameriean,
enrope sonth afriea,
ethnieity,
north ameriea,C1709269
hispanie latino,C0086528
latin ameriea,
not hispanie latino,C1518422;C0086528
glyeated haemoglobin,C0019046
regiont,
enrope sonth afriea,
$nmbr$ ky nr,C0027496;C3844738
north ameriea,C1709269
blood pressure eontrolt,C0005823;C1271104;C1272641
latin ameriea,
$nmbr$ ml niin l $nmbr$ ni,C0028075;C2348274;C3869926;C3869927
glyeated haemoglobin,C0019046
urine albumin to ereatinine ratio,C0042038;C0587185;C2362049
$nmbr$ ky nr,C0027496;C3844738
$nmbr$ to $nmbr$ mg g,C1300563
blood pressure eontrolt,C0005823;C1271104;C1272641
not on metformin,C1518422;C0025598
$nmbr$ ml niin l $nmbr$ ni,C0028075;C2348274;C3869926;C3869927
lipid lowering drugs,C0086440
urine albumin to ereatinine ratio,C0042038;C0587185;C2362049
angiotensin eonverting enzyme inhibitors angiotensin reeeptor bloekers,C0014432;C1152555;C2756995
$nmbr$ to $nmbr$ mg g,C1300563
angiotensin eonverting enzyme inhibitors,C0014432;C1152555;C2756995
not on metformin,C1518422;C0025598
caleium ehannel bloekers ccb,C0006684
lipid lowering drugs,C0086440
beta bloekers,C0330390;C0439096;C2004068
angiotensin eonverting enzyme inhibitors angiotensin reeeptor bloekers,C0014432;C1152555;C2756995
diureties,
angiotensin eonverting enzyme inhibitors,C0014432;C1152555;C2756995
loop diureties,C0445022
caleium ehannel bloekers ccb,C0006684
antiplatelet drugs,C0085826;C2963157
beta bloekers,C0330390;C0439096;C2004068
isehemie heart disease,C0018799
diureties,
duration of type $nmbr$ diabetes,C0449238;C2926735
loop diureties,C0445022
ckd prognosis by kdigo,C0033325;C3854082
antiplatelet drugs,C0085826;C2963157
cardio renal risk,C0035647;C4552904
isehemie heart disease,C0018799
albuminuria and previous maerovaseular disease without established renal disease,C0001925;C0012634;C0022658
duration of type $nmbr$ diabetes,C0449238;C2926735
established renal disease egfr $nmbr$ $nmbr$ $nmbr$ ml inin l $nmbr$ m $nmbr$ with an uacr $nmbr$ mg g without previous maerovaseular and albuminuria disease,C0439268;C0439294;C0456615;C0205156;C1552607;C0001925;C0012634
ckd prognosis by kdigo,C0033325;C3854082
albuminuria and previous maerovaseular disease plus established renal disease egfr $nmbr$ $nmbr$ ml min l $nmbr$ in with an uacr $nmbr$ mg g or egfr $nmbr$,C0001925;C0022658;C0439445;C1300563;C1739039;C3811844;C3812682
cardio renal risk,C0035647;C4552904
established renal disease,C0443211;C0022658;C1272684
albuminuria and previous maerovaseular disease without established renal disease,C0001925;C0012634;C0022658
established maerovaseular disease and albuminuria,C0443211;C0012634;C1272684;C0001925
established renal disease egfr $nmbr$ $nmbr$ $nmbr$ ml inin l $nmbr$ m $nmbr$ with an uacr $nmbr$ mg g without previous maerovaseular and albuminuria disease,C0439268;C0439294;C0456615;C0205156;C1552607;C0001925;C0012634
prevalent kidney disease egfr $nmbr$ ml min usm^ or maeroalbuminuria uacr $nmbr$ mg g,C0022658;C0439445;C1300563
albuminuria and previous maerovaseular disease plus established renal disease egfr $nmbr$ $nmbr$ ml min l $nmbr$ in with an uacr $nmbr$ mg g or egfr $nmbr$,C0001925;C0022658;C0439445;C1300563;C1739039;C3811844;C3812682
patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
established renal disease,C0443211;C0022658;C1272684
patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
established maerovaseular disease and albuminuria,C0443211;C0012634;C1272684;C0001925
empagliflozin pooled n $nmbr$,C1709595;C2349200;C4522255
prevalent kidney disease egfr $nmbr$ ml min usm^ or maeroalbuminuria uacr $nmbr$ mg g,C0022658;C0439445;C1300563
north america plus america and new zealand,C0028405;C0027978;C0324547
patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
estimated glomerular filtration rate mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
time since diagnosis of type $nmbr$ diabetes mellitus,C0040223;C3541383
empagliflozin pooled n $nmbr$,C1709595;C2349200;C4522255
$nmbr$ to $nmbr$ y,
north america plus america and new zealand,C0028405;C0027978;C0324547
multivessel coronary artery disease,C0010054;C0010068;C1956346
estimated glomerular filtration rate mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
single vessel coronary artery disease,C0581374
time since diagnosis of type $nmbr$ diabetes mellitus,C0040223;C3541383
antihypertensive therapy,C0585941
$nmbr$ to $nmbr$ y,
ldl cholesterol lowering therapy,C0023824;C0202117;C0441994;C2003888;C0039798;C0087111;C1363945
multivessel coronary artery disease,C0010054;C0010068;C1956346
antithrombotic therapy,C0039798;C0087111;C1363945
single vessel coronary artery disease,C0581374
glucose lowering medication,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
antihypertensive therapy,C0585941
highest,C1522410
empagllflozin,
ldl cholesterol lowering therapy,C0023824;C0202117;C0441994;C2003888;C0039798;C0087111;C1363945
antithrombotic therapy,C0039798;C0087111;C1363945
randomized group by subgroup interaction,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
rvw,
glucose lowering medication,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
rate $nmbr$ patient years,C0030705;C0439234
highest,C1522410
empagllflozin,
prior ml or stroke at baseline,C0439526;C1705224;C3887665;C0038454;C4554100
randomized group by subgroup interaction,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
all causa mortality,C0026565;C0026566
rvw,
$nmbr$ point mace,C0349381;C0949745;C1445339
rate $nmbr$ patient years,C0030705;C0439234
hospitalization for heart failure or cv death,C3898876;C0011065;C1306577;C4082313;C4552775
prior ml or stroke at baseline,C0439526;C1705224;C3887665;C0038454;C4554100
empagllflozln,
all causa mortality,C0026565;C0026566
history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
$nmbr$ point mace,C0349381;C0949745;C1445339
history of stroke at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
hospitalization for heart failure or cv death,C3898876;C0011065;C1306577;C4082313;C4552775
$nmbr$ n n,C0369718;C0441922
empagllflozln,
estimated cv risk at baseline,C1519101;C0168634;C1442488
history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
lowest,C1708760
history of stroke at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
$nmbr$ polnt mace,C0349381;C0949745;C1445339
$nmbr$ n n,C0369718;C0441922
hospitalization for heart failure or cv,C3898876;C3538987;C4048877;C4318503
estimated cv risk at baseline,C1519101;C0168634;C1442488
gly $nmbr$ g bid,C0017890;C0439267;C0523677
lowest,C1708760
baseline fev $nmbr$ median range l,C0168634;C0549183;C0876920;C2347635;C2348144;C2939193;C1442488
$nmbr$ polnt mace,C0349381;C0949745;C1445339
high cv risk,C0332167;C3272283;C4050568;C4319571
hospitalization for heart failure or cv,C3898876;C3538987;C4048877;C4318503
$nmbr$ yearsa,
gly $nmbr$ g bid,C0017890;C0439267;C0523677
$nmbr$ a n $nmbr$,C0369718;C0441922
baseline fev $nmbr$ median range l,C0168634;C0549183;C0876920;C2347635;C2348144;C2939193;C1442488
post bronchodilator fev $nmbr$ predictedb,C2599594;C3714541
preferred term,C1709637;C2347664
high cv risk,C0332167;C3272283;C4050568;C4319571
$nmbr$ yearsa,
fev $nmbr$ predicted $nmbr$,C0681842;C1882327
$nmbr$ a n $nmbr$,C0369718;C0441922
gly,C0017890;C0523677
post bronchodilator fev $nmbr$ predictedb,C2599594;C3714541
$nmbr$ g bid n $nmbr$,C0439267
any teae,
preferred term,C1709637;C2347664
copd worsening,C0024117;C1412502;C3714496;C0332271;C1457868;C1546960
fev $nmbr$ predicted $nmbr$,C0681842;C1882327
dyspnea,C0013404;C1963100
gly,C0017890;C0523677
$nmbr$ g bid n $nmbr$,C0439267
chest discomfort,C0235710
any teae,
edema peripheral,C0013604;C0205100;C1717255
copd worsening,C0024117;C1412502;C3714496;C0332271;C1457868;C1546960
arthralgia,C0003862;C4551938
dyspnea,C0013404;C1963100
any serious teaes,C0205404
chest discomfort,C0235710
age $nmbr$ yearsa,C0001779
edema peripheral,C0013604;C0205100;C1717255
any teaes,
arthralgia,C0003862;C4551938
notes,C1317574
any serious teaes,C0205404
^ $nmbr$ incidence in any treatment group in the overall safety population,C0021149;C0220856;C0032659;C1257890
age $nmbr$ yearsa,C0001779
asubset of the $nmbr$ years subgroup,C0439234;C1079230;C1515021
any teaes,
abbreviations teae treatment emergent adverse event gly glycopyrrolate inhalation solution bid twice daily,C4684800;C0585361
notes,C1317574
mace category n [ir],C0349381;C0683312;C3889287;C0949745;C1445339;C0022065;C0022071;C1448132
^ $nmbr$ incidence in any treatment group in the overall safety population,C0021149;C0220856;C0032659;C1257890
$nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
asubset of the $nmbr$ years subgroup,C0439234;C1079230;C1515021
chlorthalidone n $nmbr$,C0008294
abbreviations teae treatment emergent adverse event gly glycopyrrolate inhalation solution bid twice daily,C4684800;C0585361
lisinopril n $nmbr$,C0065374
mace category n [ir],C0349381;C0683312;C3889287;C0949745;C1445339;C0022065;C0022071;C1448132
incident dm or change in,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
no incident dm or change in fg $nmbr$,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
chlorthalidone n $nmbr$,C0008294
fg $nmbr$,C0016703;C0439214;C2348814
lisinopril n $nmbr$,C0065374
lvh by ecg echo,C0232306;C0058928;C1655045
incident dm or change in,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
visit $nmbr$ sbp mm hg,C0085805;C0439475
no incident dm or change in fg $nmbr$,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
visit $nmbr$ dbp mm hg,C0536221;C0439475;C3813197;C4281799
fg $nmbr$,C0016703;C0439214;C2348814
serum fg mg dl,C0439269
lvh by ecg echo,C0232306;C0058928;C1655045
quintile range mg dl,C1508496;C0439269
visit $nmbr$ sbp mm hg,C0085805;C0439475
serum cholesterol mg dl,C0587184;C0439269
visit $nmbr$ dbp mm hg,C0536221;C0439475;C3813197;C4281799
mean score min max range,C1514721;C2348147;C3542016
serum fg mg dl,C0439269
grs,C1412761;C3539564
quintile range mg dl,C1508496;C0439269
q $nmbr$ n $nmbr$,
serum cholesterol mg dl,C0587184;C0439269
test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
mean score min max range,C1514721;C2348147;C3542016
with cerebrovascular disease,C0007820
grs,C1412761;C3539564
without cerebrovascular disease,C0007820
q $nmbr$ n $nmbr$,
p value w,C1709380
test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
ith vs without,
with cerebrovascular disease,C0007820
age y meantsd,C0001779
without cerebrovascular disease,C0007820
other region no,C0017446;C0205147
p value w,C1709380
heart failure no,C0018801;C0018802;C4554158
ith vs without,
duration of diabetes microvascular disease no,C0011847;C0872146;C0011849
age y meantsd,C0001779
atherosclerotic vascular disease no,C0004153
other region no,C0017446;C0205147
amputation no,C0002688;C0332840;C1546539
heart failure no,C0018801;C0018802;C4554158
body mass index blood pressure mmhg,C0005893;C0439475;C0578022;C1305855
duration of diabetes microvascular disease no,C0011847;C0872146;C0011849
hba $nmbr$ c cholesterol mmol l,C0008377;C1532563
atherosclerotic vascular disease no,C0004153
ratio of ldl to hdl,C0456603;C1547037;C3715113
amputation no,C0002688;C0332840;C1546539
microalbuminuria no,C0730345
body mass index blood pressure mmhg,C0005893;C0439475;C0578022;C1305855
macroalbuminuria no drug therapy no,C0013216;C0013217
hba $nmbr$ c cholesterol mmol l,C0008377;C1532563
antithrombotic i,C0021966;C0221138
ratio of ldl to hdl,C0456603;C1547037;C3715113
participants with an event per $nmbr$ patient years,C0679646;C0441471;C4019010;C0030705;C0439234
microalbuminuria no,C0730345
rvalue,
macroalbuminuria no drug therapy no,C0013216;C0013217
$nmbr$ kg m^,C0022718;C0439209;C4054209
antithrombotic i,C0021966;C0221138
bp control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
participants with an event per $nmbr$ patient years,C0679646;C0441471;C4019010;C0030705;C0439234
sbp $nmbr$ mmhg or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
rvalue,
duration of diabetes mellitus,C0449238;C2926735
$nmbr$ kg m^,C0022718;C0439209;C4054209
$nmbr$ ml min per $nmbr$ $nmbr$ m^,C0439445
bp control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
history of cerebrovascular disease,C0585890
sbp $nmbr$ mmhg or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
history of pvd,C4534349
duration of diabetes mellitus,C0449238;C2926735
insulin use,C0240016
$nmbr$ ml min per $nmbr$ $nmbr$ m^,C0439445
antithrombotic use,C0042153;C0457083;C1947944
history of cerebrovascular disease,C0585890
raas inhibitor use,C0042153;C0457083;C1947944
history of pvd,C4534349
diuretic use,C0042153;C0457083;C1947944
insulin use,C0240016
hospitalized heart failure,C0018801;C0018802;C4554158
antithrombotic use,C0042153;C0457083;C1947944
progression of albuminuria,C0242656;C0449258
raas inhibitor use,C0042153;C0457083;C1947944
serious decline in kidney function,C0205404;C0232804
diuretic use,C0042153;C0457083;C1947944
not reported unknown,C0439673;C3541433;C4050014
hospitalized heart failure,C0018801;C0018802;C4554158
duration of t $nmbr$ d y,C0449238;C2926735
progression of albuminuria,C0242656;C0449258
baseline hba $nmbr$ c $nmbr$ mmol mol $nmbr$ $nmbr$ n,C0019016;C3829066;C1825777;C3538758
serious decline in kidney function,C0205404;C0232804
fpg mmol la,C0023031;C0023749;C0230347;C2346906;C4553351
not reported unknown,C0439673;C3541433;C4050014
aha status at screeningb n,C0050451;C0449438;C0772110
duration of t $nmbr$ d y,C0449238;C2926735
not on an aha,C0050451;C0772110
baseline hba $nmbr$ c $nmbr$ mmol mol $nmbr$ $nmbr$ n,C0019016;C3829066;C1825777;C3538758
on non metformin aha,C0050451;C0772110
fpg mmol la,C0023031;C0023749;C0230347;C2346906;C4553351
on metformin ir or metformin xr $nmbr$ mg d,C0022065;C0022071;C1448132;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aha status at screeningb n,C0050451;C0449438;C0772110
supplemental figure $nmbr$ point estimates and $nmbr$ confidence intervals for differences in hba $nmbr$ c mean response variable in selected subgroups at week $nmbr$ for each subgroup n is given for sitagliptin placebo treatment groups,C1552961;C0750572;C2347617;C3714763;C0009667;C0439828;C4553760;C0332174;C0439230;C1079230;C1515021;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
not on an aha,C0050451;C0772110
$nmbr$ parameter,C0549193;C1704769;C2350001
on non metformin aha,C0050451;C0772110
baseline hbalc $nmbr$ mmol mol $nmbr$ $nmbr$,C0168634;C3829066;C1442488
on metformin ir or metformin xr $nmbr$ mg d,C0022065;C0022071;C1448132;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glimepiride,C0061323
supplemental figure $nmbr$ point estimates and $nmbr$ confidence intervals for differences in hba $nmbr$ c mean response variable in selected subgroups at week $nmbr$ for each subgroup n is given for sitagliptin placebo treatment groups,C1552961;C0750572;C2347617;C3714763;C0009667;C0439828;C4553760;C0332174;C0439230;C1079230;C1515021;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
stratification factor menopausal status n,C1514984;C1513126
$nmbr$ parameter,C0549193;C1704769;C2350001
female premenopausal,C0043210;C0086287;C1705497;C1705498;C0279752
baseline hbalc $nmbr$ mmol mol $nmbr$ $nmbr$,C0168634;C3829066;C1442488
female perimenopausal or,C0043210;C0086287;C1705497;C1705498;C0849668;C3839366
glimepiride,C0061323
female $nmbr$ years postmenopausal,C0043210;C0232970;C0086287;C1705497;C1705498
stratification factor menopausal status n,C1514984;C1513126
dipeptidyl peptidase $nmbr$ inhibitors,C0003015
female premenopausal,C0043210;C0086287;C1705497;C1705498;C0279752
other blood glucose lowering agents,C0005802;C0441994;C2003888;C0450442;C1254351;C1521826
female perimenopausal or,C0043210;C0086287;C1705497;C1705498;C0849668;C3839366
sulphonamides urea derivatives,C0038760;C0243072
female $nmbr$ years postmenopausal,C0043210;C0232970;C0086287;C1705497;C1705498
site,C0205145;C1515974;C2825164
dipeptidyl peptidase $nmbr$ inhibitors,C0003015
difference in ls means $nmbr$ ci,C1705241;C1705242
other blood glucose lowering agents,C0005802;C0441994;C2003888;C0450442;C1254351;C1521826
ertugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
sulphonamides urea derivatives,C0038760;C0243072
female participants who are $nmbr$ years postmenopausal,C0043210;C3272598;C0086287;C1705497;C1705498;C0439234;C0232970
site,C0205145;C1515974;C2825164
ertugliflozin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
difference in ls means $nmbr$ ci,C1705241;C1705242
ertugliflozin $nmbr$ mg vs placebo glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ertugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
eduglinozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
female participants who are $nmbr$ years postmenopausal,C0043210;C3272598;C0086287;C1705497;C1705498;C0439234;C0232970
ertuglifldzin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ertugliflozin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
erlugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
ertugliflozin $nmbr$ mg vs placebo glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
distal forearm,C0588203
eduglinozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
ertugliflozin $nmbr$ mg vs placebo giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ertuglifldzin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ertuglrflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
erlugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
rivaroxaban $nmbr$ $nmbr$ mg bid aspirin $nmbr$ mg od,C0229089;C0439164;C1512019;C3273373;C3665488
distal forearm,C0588203
no of events total n,C0439175;C0439810
ertugliflozin $nmbr$ mg vs placebo giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
all randomized,C0034656;C3815594
ertuglrflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
peri operative cabg participants,C0010055;C0679646
rivaroxaban $nmbr$ $nmbr$ mg bid aspirin $nmbr$ mg od,C0229089;C0439164;C1512019;C3273373;C3665488
teriparatide n $nmbr$,C0070093
no of events total n,C0439175;C0439810
number of patients with available data,C2360800;C1511726;C3245479;C3714741
all randomized,C0034656;C3815594
daily dose of vitamin d iu day,C2348070;C0014695;C0042866;C2936842;C3537249;C3714503
peri operative cabg participants,C0010055;C0679646
number of patients with dose available,C2360800;C0178602;C0869039;C1114758;C0470187
teriparatide n $nmbr$,C0070093
patients with supplemental vitamin d dose of $nmbr$ iu day starting at screeningc n,C0030705;C0014695;C0042866;C2936842;C3537249;C3714503;C0439659
number of patients with available data,C2360800;C1511726;C3245479;C3714741
serum $nmbr$ oh d concentrations ng ml mean sd,C0229671;C0220853;C1546774;C1550100;C0439275;C2699239
daily dose of vitamin d iu day,C2348070;C0014695;C0042866;C2936842;C3537249;C3714503
patients with serum $nmbr$ oh d $nmbr$ $nmbr$ and,C0030705;C0220853
number of patients with dose available,C2360800;C0178602;C0869039;C1114758;C0470187
teriparatide n n,C0070093
patients with supplemental vitamin d dose of $nmbr$ iu day starting at screeningc n,C0030705;C0014695;C0042866;C2936842;C3537249;C3714503;C0439659
risedronate n n,C0246719
serum $nmbr$ oh d concentrations ng ml mean sd,C0229671;C0220853;C1546774;C1550100;C0439275;C2699239
risk ratio [ $nmbr$ cl],C0028873;C0242492;C0596019
patients with serum $nmbr$ oh d $nmbr$ $nmbr$ and,C0030705;C0220853
a new vertebral fractures mfas,C1549796;C1549980
teriparatide n n,C0070093
baseline vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
risedronate n n,C0246719
sufficient,C0205410
risk ratio [ $nmbr$ cl],C0028873;C0242492;C0596019
insufficient,C0205412;C0231180;C0439856
a new vertebral fractures mfas,C1549796;C1549980
overall vero population,C0032659;C1257890
baseline vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
b pooled new and worsened vertebral fractures mfas,C1709595;C0205314;C2349200;C4522255;C1549796;C1549980
sufficient,C0205410
hazard ratio [ $nmbr$ cl],C2985465;C0596019
insufficient,C0205412;C0231180;C0439856
c clinical fractures fas,C0205210;C0016658
overall vero population,C0032659;C1257890
d non vertebral fragility fractures fas,C0080179;C0302113
b pooled new and worsened vertebral fractures mfas,C1709595;C0205314;C2349200;C4522255;C1549796;C1549980
hazard ratio $nmbr$ cl],C2985465;C0596019
hazard ratio [ $nmbr$ cl],C2985465;C0596019
e major non vertebral fragility fractures fas,C0205082;C0080179;C0205164;C4318856;C4521762
c clinical fractures fas,C0205210;C0016658
rivaroxaban plus,C1739768
d non vertebral fragility fractures fas,C0080179;C0302113
alone,C0205171;C0439044;C0679994
hazard ratio $nmbr$ cl],C2985465;C0596019
rivaroxaban plus aspirin $nmbr$ cl,C1739768;C0004057
e major non vertebral fragility fractures fas,C0205082;C0080179;C0205164;C4318856;C4521762
no of events patients yr,C0030705;C0439234
rivaroxaban plus,C1739768
$nmbr$ to $nmbr$ yr,C0439234
alone,C0205171;C0439044;C0679994
$nmbr$ to $nmbr$ mm hg,C0439475
rivaroxaban plus aspirin $nmbr$ cl,C1739768;C0004057
lei $nmbr$ n $nmbr$,C0023401;C0428209
no of events patients yr,C0030705;C0439234
ldi b $nmbr$ n $nmbr$,
$nmbr$ to $nmbr$ yr,C0439234
integrated analysis set n $nmbr$,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
$nmbr$ to $nmbr$ mm hg,C0439475
age mean years sd gender n,C1510829;C0079399;C1522384
lei $nmbr$ n $nmbr$,C0023401;C0428209
other multiple,C0439064
ldi b $nmbr$ n $nmbr$,
cdmard experience n,C0237607;C0596545
integrated analysis set n $nmbr$,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
mtx at baseline n,C0025677;C1417487
age mean years sd gender n,C1510829;C0079399;C1522384
time since psa onset mean years sd,C0449244
other multiple,C0439064
active pso wi $nmbr$ bsa $nmbr$ n y,C0205177;C0043193;C1520135;C3853793;C3888249
cdmard experience n,C0237607;C0596545
tender joint count $nmbr$ joints mean sd,C0451530;C2699239
mtx at baseline n,C0025677;C1417487
swollen joint count $nmbr$ joints mean sd,C0451521;C2699239
time since psa onset mean years sd,C0449244
current enthesitis n,C0521116;C1282952;C1705970
active pso wi $nmbr$ bsa $nmbr$ n y,C0205177;C0043193;C1520135;C3853793;C3888249
current dactylitis n,C0521116;C0239161;C1705970
tender joint count $nmbr$ joints mean sd,C0451530;C2699239
leeds enthesitis index mean sd,C0451148;C2699239
swollen joint count $nmbr$ joints mean sd,C0451521;C2699239
leeds dactylitis index basic mean sd ^,C0239161;C2699239
current enthesitis n,C0521116;C1282952;C1705970
current dactylitis n,C0521116;C0239161;C1705970
fig $nmbr$ patients reporting no enthesitis a and no dactylitis b at week $nmbr$ integrated analysis set with baseline enthesitis and dactylitis are shown as the percentages of responders $nmbr$ cl nri p vs pbo $nmbr$ $nmbr$ p vs pbo $nmbr$ $nmbr$ abbreviations achill tend insert achilles tendon insertion cl confidence interval ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks lat epicond lateral epicondyle lei leeds enthesitis index ldi b leeds dactylitis index basic med fern cond medial femoral condyle nri nonresponder imputation pbo placebo,C0030705;C0700287;C1282952;C0002778;C0036849;C1442518;C1705195;C0936012;C1524024;C0168634;C1442488;C0239161;C1547282;C0596019;C0031962;C0000723;C0001074;C0009667;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230;C0064678;C0331729;C1856054;C2826243;C0032042;C1696465;C1706408
leeds enthesitis index mean sd,C0451148;C2699239
body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
leeds dactylitis index basic mean sd ^,C0239161;C2699239
currently smoker,C0521116;C0337664
time since ipf diagnosisa mean years sd,C0556970;C0034069;C1800706
fig $nmbr$ patients reporting no enthesitis a and no dactylitis b at week $nmbr$ integrated analysis set with baseline enthesitis and dactylitis are shown as the percentages of responders $nmbr$ cl nri p vs pbo $nmbr$ $nmbr$ p vs pbo $nmbr$ $nmbr$ abbreviations achill tend insert achilles tendon insertion cl confidence interval ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks lat epicond lateral epicondyle lei leeds enthesitis index ldi b leeds dactylitis index basic med fern cond medial femoral condyle nri nonresponder imputation pbo placebo,C0030705;C0700287;C1282952;C0002778;C0036849;C1442518;C1705195;C0936012;C1524024;C0168634;C1442488;C0239161;C1547282;C0596019;C0031962;C0000723;C0001074;C0009667;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230;C0064678;C0331729;C1856054;C2826243;C0032042;C1696465;C1706408
mean ml sd,C0439526;C2699239;C1705224;C3887665
body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
median ml,C0439526;C1705224;C3887665
currently smoker,C0521116;C0337664
predicted value sd,C0681842;C2699239;C1882327
time since ipf diagnosisa mean years sd,C0556970;C0034069;C1800706
total sgrq mean total score sd,C2964552;C2699239
mean ml sd,C0439526;C2699239;C1705224;C3887665
any aes,C1412268;C2699274
median ml,C0439526;C1705224;C3887665
most frequent aesa,C0332183
predicted value sd,C0681842;C2699239;C1882327
diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
total sgrq mean total score sd,C2964552;C2699239
lung infection,C0876973;C4552950
any aes,C1412268;C2699274
ipf,C0034069;C1800706
most frequent aesa,C0332183
upper abdominal pain,C0232492
diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
alt increased,C1266129;C4553172;C0205217;C0442805
lung infection,C0876973;C4552950
ast increased,C1415181;C3891303;C0205217;C0442805
ipf,C0034069;C1800706
ggt increased,C1415053;C0205217;C0442805
upper abdominal pain,C0232492
aes leading to dose reduction of study drugb,C1412268;C2699274;C0861063;C0178602;C0869039;C1114758
alt increased,C1266129;C4553172;C0205217;C0442805
transaminases increased,C0002594;C0919834;C0205217;C0442805
ast increased,C1415181;C3891303;C0205217;C0442805
aes leading to discontinuation of study drugb,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
ggt increased,C1415053;C0205217;C0442805
blood bilirubin increased,C0005767;C0005437;C0005768;C0229664;C0205217;C0442805
aes leading to dose reduction of study drugb,C1412268;C2699274;C0861063;C0178602;C0869039;C1114758
liver disorder,C0023895
transaminases increased,C0002594;C0919834;C0205217;C0442805
decreased appetite,C0232462
aes leading to discontinuation of study drugb,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
lung neoplasm malignant,C0024121;C0205282
blood bilirubin increased,C0005767;C0005437;C0005768;C0229664;C0205217;C0442805
investigator defined drug related aes,C1412268;C2699274
liver disorder,C0023895
severe aes,C1412268;C2699274
decreased appetite,C0232462
fatal aes,C1412268;C2699274
lung neoplasm malignant,C0024121;C0205282
risk factor,C0035648
investigator defined drug related aes,C1412268;C2699274
pioglitazone group n $nmbr$,C0071097;C0441848
severe aes,C1412268;C2699274
continuous variables mean sd ^,C0439828;C2699239
fatal aes,C1412268;C2699274
fasting glucose level mg dl,C0202045;C0439269
risk factor,C0035648
hemoglobin level,C0019029;C1314664
pioglitazone group n $nmbr$,C0071097;C0441848
homa ir score,C0449820;C4050231
continuous variables mean sd ^,C0439828;C2699239
diastolic pressure mm hg,C0428883;C0439475
fasting glucose level mg dl,C0202045;C0439269
total cholesterol level mg dl,C0878805;C0439269;C1445957
hemoglobin level,C0019029;C1314664
triglycerides level mg dl,C0428475;C0439269
homa ir score,C0449820;C4050231
hdl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
diastolic pressure mm hg,C0428883;C0439475
ldl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
total cholesterol level mg dl,C0878805;C0439269;C1445957
categorical variables no,C0439828
triglycerides level mg dl,C0428475;C0439269
adherence $nmbr$,C1510802
hdl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
stroke m $nmbr$,C0038454;C4554100
ldl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
stroke m l hf hospitalization,C0456616;C0019993
categorical variables no,C0439828
intention to treat,C0162425;C1283828
adherence $nmbr$,C1510802
no previous copd medication,C0013227;C3244316;C4284232
stroke m $nmbr$,C0038454;C4554100
previous ics only,C0815320;C4551720
stroke m l hf hospitalization,C0456616;C0019993
previous labd only,C0205156;C0396059;C1552607
intention to treat,C0162425;C1283828
previous ics labd,C0205156;C0396059;C1552607
no previous copd medication,C0013227;C3244316;C4284232
subjects,C0681850;C1550501;C1706203;C2349001;C2697811
previous ics only,C0815320;C4551720
former smokers,C0337671
previous labd only,C0205156;C0396059;C1552607
smoking pack years,C0037369;C1277691;C0453996;C1881674
previous ics labd,C0205156;C0396059;C1552607
screening fev $nmbr$ predicted,C0681842;C1882327
subjects,C0681850;C1550501;C1706203;C2349001;C2697811
one or more exacerbations,C0205447;C4086268
former smokers,C0337671
row,C1552840;C1552846
smoking pack years,C0037369;C1277691;C0453996;C1881674
ff $nmbr$ g,C4554348;C0439267
screening fev $nmbr$ predicted,C0681842;C1882327
vi $nmbr$ g,C0205999;C0439267
one or more exacerbations,C0205447;C4086268
ff vi $nmbr$ $nmbr$ g,C0205999;C0439267
row,C1552840;C1552846
total subjects,C0681850;C1550501;C1706203;C2349001;C2697811
ff $nmbr$ g,C4554348;C0439267
subjects who did not receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1518422;C1514756;C0396059;C0332152
vi $nmbr$ g,C0205999;C0439267
active versus placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
ff vi $nmbr$ $nmbr$ g,C0205999;C0439267
reduction in risk $nmbr$ ci,C0520870;C1137094
total subjects,C0681850;C1550501;C1706203;C2349001;C2697811
ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
subjects who did not receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1518422;C1514756;C0396059;C0332152
subjects who did receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1514756;C0396059;C0332152
active versus placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
labd alone,C0396059;C0205171;C0439044;C0679994
reduction in risk $nmbr$ ci,C0520870;C1137094
ics labd,C0815320;C0396059;C4551720
ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
a those receiving no inhaled pre treatment maintenance medication,C1514756;C2347660
subjects who did receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1514756;C0396059;C0332152
b those on inhaled corticosteroids and long acting bronchodilators as previous treatment use,C0004048;C0001617;C3539185;C3540725;C3540726;C3540727;C0006280;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
labd alone,C0396059;C0205171;C0439044;C0679994
previous ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
ics labd,C0815320;C0396059;C4551720
previous labd alone,C0205156;C0396059;C1552607;C0205171;C0439044;C0679994
a those receiving no inhaled pre treatment maintenance medication,C1514756;C2347660
overall mortality,C0026565;C0026566
b those on inhaled corticosteroids and long acting bronchodilators as previous treatment use,C0004048;C0001617;C3539185;C3540725;C3540726;C3540727;C0006280;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ff vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
previous ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
ff vi $nmbr$ $nmbr$ $nmbr$,C4554348;C0205999
previous labd alone,C0205156;C0396059;C1552607;C0205171;C0439044;C0679994
ff $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
overall mortality,C0026565;C0026566
ff $nmbr$ $nmbr$ $nmbr$,C4554348
ff vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
ff vi $nmbr$ $nmbr$ $nmbr$,C4554348;C0205999
vi $nmbr$ $nmbr$ $nmbr$,C0205999
ff $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
risk of moderate severe exacerbations,C0332166
ff $nmbr$ $nmbr$ $nmbr$,C4554348
ertugliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
age $nmbr$ y n,C0001779
vi $nmbr$ $nmbr$ $nmbr$,C0205999
distribution of metformin dose at randomization n,C0520511;C1704711;C0034656
risk of moderate severe exacerbations,C0332166
background aha therapy at screening a n,C0039798;C0087111;C1363945;C0369718;C0441922
ertugliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alpha glucosidase inhibitors,C1299007;C2756986;C3539108
age $nmbr$ y n,C0001779
meglitinide,C0065880
distribution of metformin dose at randomization n,C0520511;C1704711;C0034656
sulphonylurea,C0038766;C3536898
background aha therapy at screening a n,C0039798;C0087111;C1363945;C0369718;C0441922
number of agents,C0237753;C0449788
alpha glucosidase inhibitors,C1299007;C2756986;C3539108
hong kong,C0019907;C2987742
meglitinide,C0065880
korea republic of,C0022773
sulphonylurea,C0038766;C3536898
taiwan,C0039260
number of agents,C0237753;C0449788
baseline fpg mg dl,C0168634;C0439269;C1442488
hong kong,C0019907;C2987742
baseline egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
korea republic of,C0022773
ertugliflozin,C4079805
taiwan,C0039260
age $nmbr$ years n,C1510829
baseline fpg mg dl,C0168634;C0439269;C1442488
background aha therapy at screening a,C0039798;C0087111;C1363945
baseline egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
change from baseline at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
ertugliflozin,C4079805
ls mean $nmbr$ ci a,C0008107;C3259781
age $nmbr$ years n,C1510829
pairwise comparison,C1707455
background aha therapy at screening a,C0039798;C0087111;C1363945
difference in ls means $nmbr$ ci a,C1705241;C1705242
change from baseline at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ls mean $nmbr$ ci a,C0008107;C3259781
ls mean,C0444504;C2347634;C2348143
pairwise comparison,C1707455
$nmbr$ ci a,C0008107;C3259781
difference in ls means $nmbr$ ci a,C1705241;C1705242
event n,C0441471;C4019010
week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
$nmbr$ ae,C3887670
ls mean,C0444504;C2347634;C2348143
drug relateda,C0013227;C1254351
$nmbr$ ci a,C0008107;C3259781
$nmbr$ sae,C1519255;C1622657;C4553214
event n,C0441471;C4019010
discontinuations,C0457454
$nmbr$ ae,C3887670
because of ae,C3887670
drug relateda,C0013227;C1254351
because of drug relateda ae,C0013227;C3887670;C1254351
$nmbr$ sae,C1519255;C1622657;C4553214
because of sae,C1519255;C1622657;C4553214
discontinuations,C0457454
because of drug relateda sae,C1519255;C1622657;C4553214
because of ae,C3887670
deathsb,
because of drug relateda ae,C0013227;C3887670;C1254351
tier $nmbr$ aes,C1412268;C2699274
because of sae,C1519255;C1622657;C4553214
gmi women,C0043210
because of drug relateda sae,C1519255;C1622657;C4553214
gmi men,C0025266
deathsb,
uti,C0042029;C0077906;C1412376
tier $nmbr$ aes,C1412268;C2699274
symptomatic hypoglycaemia,C0020615;C4553659
gmi women,C0043210
hypovolaemia,C0546884
gmi men,C0025266
other selected aes,C1412268;C2699274
uti,C0042029;C0077906;C1412376
documented hypoglycaemiac,C1301725;C1609436
symptomatic hypoglycaemia,C0020615;C4553659
due to ae,C3887670
hypovolaemia,C0546884
due to drug relateda ae,C0013227;C3887670;C1254351
other selected aes,C1412268;C2699274
due to sae,C1519255;C1622657;C4553214
documented hypoglycaemiac,C1301725;C1609436
due to drug relateda sae,C1519255;C1622657;C4553214
due to ae,C3887670
characteristic a,C1521970
due to drug relateda ae,C0013227;C3887670;C1254351
leader,
due to sae,C1519255;C1622657;C4553214
cv historya,C3538987;C4048877;C4318503
due to drug relateda sae,C1519255;C1622657;C4553214
heart failure nyha ii iii n,C0018801;C0018802;C4554158
characteristic a,C1521970
coronary artery bypass graft n,C0010055;C1260596
leader,
ischaemic stroke n,C0948008
cv historya,C3538987;C4048877;C4318503
carotid artery stenosis n,C0007282
heart failure nyha ii iii n,C0018801;C0018802;C4554158
$nmbr$ stenosis of major artery n,C0038449
coronary artery bypass graft n,C0010055;C1260596
lv systolic dysfunction n,C0023128;C0749225;C0731033;C1881413
ischaemic stroke n,C0948008
lv diastolic dysfunction n,C0023128;C0520863;C0731033;C1881413
carotid artery stenosis n,C0007282
diabetes medication,C0013227;C3244316;C4284232
$nmbr$ stenosis of major artery n,C0038449
oral antihyperglycaemic n,C0359086
lv systolic dysfunction n,C0023128;C0749225;C0731033;C1881413
metformin n,C0025598
lv diastolic dysfunction n,C0023128;C0520863;C0731033;C1881413
su n,C0038642;C1705534
diabetes medication,C0013227;C3244316;C4284232
moderate or severe renal disease n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
oral antihyperglycaemic n,C0359086
cv medication,C0013227;C3244316;C4284232
metformin n,C0025598
acei n,
su n,C0038642;C1705534
lipid lowering therapies n,C0585943
moderate or severe renal disease n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
anti platelet agents n,C0432633
cv medication,C0013227;C3244316;C4284232
other risk factors,C0035648;C1553898
acei n,
sustain,C0443318;C2732140
lipid lowering therapies n,C0585943
moderate or severe renal disease b n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
anti platelet agents n,C0432633
diabetes duration at baseline,C0449238;C2926735
other risk factors,C0035648;C1553898
hazard ratio glp $nmbr$ analogue vs placebo [ $nmbr$ cl],C2985465;C0243071;C0032042;C1696465;C1706408;C0596019
sustain,C0443318;C2732140
glp $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
moderate or severe renal disease b n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
total population,C3258257
diabetes duration at baseline,C0449238;C2926735
bempedoic acid n $nmbr$,C3659310
hazard ratio glp $nmbr$ analogue vs placebo [ $nmbr$ cl],C2985465;C0243071;C0032042;C1696465;C1706408;C0596019
cardiovascular risk factor no,C0850624
glp $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
lipid measures at baseline mg dl,C0079809;C1879489
total population,C3258257
total cholesterol^,C0201950;C0543421
bempedoic acid n $nmbr$,C3659310
ldl cholesterol^,C0023824;C0202117
cardiovascular risk factor no,C0850624
non hdl cholesterol j,C0729627;C1535899
lipid measures at baseline mg dl,C0079809;C1879489
hdl cholesterol^,C0023822;C0392885
total cholesterol^,C0201950;C0543421
apolipoprotein,C0003591
ldl cholesterol^,C0023824;C0202117
triglycerides mg dl^,C0041004;C0439269
non hdl cholesterol j,C0729627;C1535899
high sensitivity c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
hdl cholesterol^,C0023822;C0392885
concomitant lipid modifying therapy no,C1707479;C0023779
apolipoprotein,C0003591
intensity of statin therapy at baseline no,C0522510;C1278454;C0168634;C1442488
triglycerides mg dl^,C0041004;C0439269
bempedoic,
high sensitivity c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
acid,C0001128;C0202406
concomitant lipid modifying therapy no,C1707479;C0023779
least squares mean difference $nmbr$ cl,C0023189;C0596019
intensity of statin therapy at baseline no,C0522510;C1278454;C0168634;C1442488
cardiovascular disease risk category,C3699655
bempedoic,
background lipid lowering therapy,C1706907;C0585943
acid,C0001128;C0202406
intensity of statin therapy,C0522510;C1278454
least squares mean difference $nmbr$ cl,C0023189;C0596019
low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
cardiovascular disease risk category,C3699655
baseline ldl cholesterol,C0023824;C0202117
background lipid lowering therapy,C1706907;C0585943
el n,C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
intensity of statin therapy,C0522510;C1278454
ll n,C0369718;C0441922
low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
age y median q $nmbr$ q $nmbr$,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
baseline ldl cholesterol,C0023824;C0202117
acs presentation,C0742343;C0449450;C4318612
el n,C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
$nmbr$ mg ld,C0024671;C0694649;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ll n,C0369718;C0441922
us site,C0205145;C1515974;C2825164
age y median q $nmbr$ q $nmbr$,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
time from ld to pci min median q $nmbr$ q $nmbr$,C0040223;C3541383;C0702093;C0549183;C0876920;C2347635;C2348144;C2939193;C1524029;C3813700
acs presentation,C0742343;C0449450;C4318612
catheter site femoral,C0449652;C0015811
$nmbr$ mg ld,C0024671;C0694649;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bivalirudin used,C0168273;C1273517
us site,C0205145;C1515974;C2825164
gp iib iiia inhibitor used,C0016011;C1999216;C1273517
time from ld to pci min median q $nmbr$ q $nmbr$,C0040223;C3541383;C0702093;C0549183;C0876920;C2347635;C2348144;C2939193;C1524029;C3813700
no of vessels with $nmbr$ stenosis,C0005847;C0678234;C1261287;C2632116
catheter site femoral,C0449652;C0015811
no of vessels treated,C0005847;C1522326
bivalirudin used,C0168273;C1273517
received drug eluting stent,C1514756;C1322815
gp iib iiia inhibitor used,C0016011;C1999216;C1273517
left main coronary artery bifurcation,C3898614
no of vessels with $nmbr$ stenosis,C0005847;C0678234;C1261287;C2632116
pci duration,C0449238;C2926735
no of vessels treated,C0005847;C1522326
dosing,
received drug eluting stent,C1514756;C1322815
cangrelor n n,C1121991
left main coronary artery bifurcation,C3898614
clopidogrel n n,C0070166
pci duration,C0449238;C2926735
adjusted $nmbr$ or $nmbr$ cl,C0456081;C0596019
dosing,
d mi idfvst,C3810814
cangrelor n n,C1121991
early load,C1550025;C1704782;C1708715
clopidogrel n n,C0070166
late load,C1550025;C1704782;C1708715
adjusted $nmbr$ or $nmbr$ cl,C0456081;C0596019
qmi,
d mi idfvst,C3810814
adjusted or $nmbr$ cl,C0456081;C0596019
early load,C1550025;C1704782;C1708715
severe lite threatening,C0205082;C4050465;C4050466
late load,C1550025;C1704782;C1708715
transfusions,C0005841;C0199960;C1879316
qmi,
hfref n $nmbr$,
adjusted or $nmbr$ cl,C0456081;C0596019
hf without known reduced ef n $nmbr$,C0018488;C1313497;C1538440;C3273279
severe lite threatening,C0205082;C4050465;C4050466
no hx of hf n $nmbr$,C0262926;C3814444
transfusions,C0005841;C0199960;C1879316
age yrs median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
hfref n $nmbr$,
hemoglobin ale median iqr,C0019046;C0549183;C0876920;C2347635;C2348144;C2939193
hf without known reduced ef n $nmbr$,C0018488;C1313497;C1538440;C3273279
duration of diabetes years median iqr,C0449238;C2926735
no hx of hf n $nmbr$,C0262926;C3814444
history of dyslipidemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
age yrs median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
lvef median iqr,C0428772;C0488728
hemoglobin ale median iqr,C0019046;C0549183;C0876920;C2347635;C2348144;C2939193
main etiology of heart failure,C0015127;C1314792;C1524003
duration of diabetes years median iqr,C0449238;C2926735
non ischemic,C1518422;C0475224
history of dyslipidemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
established ascvd,C0443211;C3665365;C1272684
lvef median iqr,C0428772;C0488728
history of coronary arteiy disease,C0683519;C0730226;C0850708;C0944983
main etiology of heart failure,C0015127;C1314792;C1524003
history of peripheral arterial disease,C0683519;C0730226;C0850708;C0944983
non ischemic,C1518422;C0475224
cgfrby ckd epi ml min $nmbr$ $nmbr$ m $nmbr$ median iqr,C0162734;C0439445;C4281721;C0549183;C0876920;C2347635;C2348144;C2939193
established ascvd,C0443211;C3665365;C1272684
antiplatelet,
history of coronary arteiy disease,C0683519;C0730226;C0850708;C0944983
acei or arb,C3888198
history of peripheral arterial disease,C0683519;C0730226;C0850708;C0944983
loop,C0445022
cgfrby ckd epi ml min $nmbr$ $nmbr$ m $nmbr$ median iqr,C0162734;C0439445;C4281721;C0549183;C0876920;C2347635;C2348144;C2939193
thiazide,C0541746
antiplatelet,
mineralcorticoid receptor antagonist,C4543207
acei or arb,C3888198
km rate,C0871208;C1521828
loop,C0445022
cardiovascular death hospitalization for heart failure,C3898876
thiazide,C0541746
hfref,
mineralcorticoid receptor antagonist,C4543207
nothfref,
km rate,C0871208;C1521828
hf without known reduced ef,C0018488;C1313497;C1538440;C3273279
cardiovascular death hospitalization for heart failure,C3898876
without hx of hf,C0262926;C3814444
hfref,
no prior mi n $nmbr$ $nmbr$,C0332152;C2826257
nothfref,
age in years median iqr,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
hf without known reduced ef,C0018488;C1313497;C1538440;C3273279
blaek,
without hx of hf,C0262926;C3814444
duration of diabetes in years median iqr,C0449238;C2926735;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
no prior mi n $nmbr$ $nmbr$,C0332152;C2826257
hbalc in median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
age in years median iqr,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
egfr in ml min $nmbr$ $nmbr$ m^ median iqr,C1739039;C3811844;C3812682;C0549183;C0876920;C2347635;C2348144;C2939193
blaek,
prior cad,C1504769;C2239547;C3813548;C4284121
duration of diabetes in years median iqr,C0449238;C2926735;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
prior ischemic stroke,C0332152;C0948008;C2826257
hbalc in median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
prior pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
egfr in ml min $nmbr$ $nmbr$ m^ median iqr,C1739039;C3811844;C3812682;C0549183;C0876920;C2347635;C2348144;C2939193
antihyperglycemic medications,C0013227;C0802604;C2598133;C4284232
prior cad,C1504769;C2239547;C3813548;C4284121
insulin at baseline,C0021641;C1533581;C1579433;C3714501
prior ischemic stroke,C0332152;C0948008;C2826257
betablocker,C0001645
prior pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
cv death or hhf,C0011065;C1306577;C4082313;C4552775
antihyperglycemic medications,C0013227;C0802604;C2598133;C4284232
patients with prior ml hr $nmbr$ cl,C0030705;C0332152;C2826257
insulin at baseline,C0021641;C1533581;C1579433;C3714501
patients with ascvd but no prior ml hr $nmbr$ cl,C0030705;C3665365;C0332152;C0596019;C2826257
betablocker,C0001645
patients with only mrf hr $nmbr$ cl,C0030705;C0312443;C0596019;C1412879
cv death or hhf,C0011065;C1306577;C4082313;C4552775
absolute risk reductions,C3179139
patients with prior ml hr $nmbr$ cl,C0030705;C0332152;C2826257
no prior mi,C0332152;C3810814;C2826257
patients with ascvd but no prior ml hr $nmbr$ cl,C0030705;C3665365;C0332152;C0596019;C2826257
ascvd no prior ml,C3665365;C0439526;C1705224;C3887665
patients with only mrf hr $nmbr$ cl,C0030705;C0312443;C0596019;C1412879
cv death ml or ischemic stroke,C0439526;C1705224;C3887665;C0948008
absolute risk reductions,C3179139
population,C0032659;C1257890
no prior mi,C0332152;C3810814;C2826257
tanezumab all doses combined,C2346819;C0178602;C0205195
ascvd no prior ml,C3665365;C0439526;C1705224;C3887665
tanezumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cv death ml or ischemic stroke,C0439526;C1705224;C3887665;C0948008
tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
population,C0032659;C1257890
tanezumab all doses combined nsaida,C2346819;C0178602;C0205195
tanezumab all doses combined,C2346819;C0178602;C0205195
tanezumab $nmbr$ $nmbr$ mg nsaid,C0003211;C3536840
tanezumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tanezumab $nmbr$ mg nsaid,C0003211;C3536840
tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
active comparatorb,C0205177;C3853793;C3888249
tanezumab all doses combined nsaida,C2346819;C0178602;C0205195
diabetesc,
tanezumab $nmbr$ $nmbr$ mg nsaid,C0003211;C3536840
severe oa symptoms at baselined,C0436345;C0029408;C3887876
tanezumab $nmbr$ mg nsaid,C0003211;C3536840
less severe oa symptoms at baseline,C0436345;C0029408;C3887876
active comparatorb,C0205177;C3853793;C3888249
aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
diabetesc,
figure $nmbr$ least squares mean change in womac pain from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
severe oa symptoms at baselined,C0436345;C0029408;C3887876
less severe oa symptoms at baseline,C0436345;C0029408;C3887876
figure $nmbr$ least squares mean change in womac physical function from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
figure $nmbr$ least squares mean change in pga from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis pga patient s global assessment sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C0030705;C1710181;C3472647
figure $nmbr$ least squares mean change in womac pain from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
figure $nmbr$ percentage of patients with $nmbr$ $nmbr$ $nmbr$ and $nmbr$ improvement on the womac pain subscale at week $nmbr$ in the subgroups notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily oa osteoarthritis womac western ontario and mcmaster universities osteoarthritis index,C0439165;C1549488;C1561533;C2986411;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132;C0332174;C0439230;C1079230;C1317574;C0032042;C1696465;C1706408;C3472647
sex female n,C0086287
figure $nmbr$ least squares mean change in womac physical function from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
ethnicity not hispanic latino n,C0015031;C0243103;C1518424;C0086528
figure $nmbr$ least squares mean change in pga from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis pga patient s global assessment sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C0030705;C1710181;C3472647
clinical,C0205210
figure $nmbr$ percentage of patients with $nmbr$ $nmbr$ $nmbr$ and $nmbr$ improvement on the womac pain subscale at week $nmbr$ in the subgroups notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily oa osteoarthritis womac western ontario and mcmaster universities osteoarthritis index,C0439165;C1549488;C1561533;C2986411;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132;C0332174;C0439230;C1079230;C1317574;C0032042;C1696465;C1706408;C3472647
systolic bp mmhg mean sd,C0488053;C2699239
sex female n,C0086287
background lipid therapy per acc aha definition n a,C0039798;C0087111;C1363945
ethnicity not hispanic latino n,C0015031;C0243103;C1518424;C0086528
high intensity statin,C4081854;C0360714
clinical,C0205210
moderate intensity statin,C4081855;C0360714
systolic bp mmhg mean sd,C0488053;C2699239
cerebrovascular or peripheral arterial disease n,C1880018;C0085096;C1704436
background lipid therapy per acc aha definition n a,C0039798;C0087111;C1363945
coronary artery stenosis $nmbr$,C0242231
high intensity statin,C4081854;C0360714
coronary artery bypass,C0010055
moderate intensity statin,C4081855;C0360714
copd n,C0024117;C1412502;C3714496
cerebrovascular or peripheral arterial disease n,C1880018;C0085096;C1704436
diabetes related medication use n,C0011847;C0240320;C0011849
coronary artery stenosis $nmbr$,C0242231
insulin use n,C0240016
coronary artery bypass,C0010055
lipid values mean sd,C0023779;C2699239
copd n,C0024117;C1412502;C3714496
non hdl c mmol l mean sd,C1532563;C2699239
diabetes related medication use n,C0011847;C0240320;C0011849
apob g l mean sd,C0439294;C2699239;C0456615
insulin use n,C0240016
lp a nmol l mean sd,C0065058;C2699239;C1439335;C4553379
lipid values mean sd,C0023779;C2699239
triacylglycerol mmol l mean sd,C1532563;C2699239
non hdl c mmol l mean sd,C1532563;C2699239
hba $nmbr$ c mmol mol median q $nmbr$ q $nmbr$,C0019016;C3829066;C1825777;C3538758
apob g l mean sd,C0439294;C2699239;C0456615
fasting serum glucose mmol l median q $nmbr$ q $nmbr$,C0202041;C1532563;C3534430
lp a nmol l mean sd,C0065058;C2699239;C1439335;C4553379
percent change from baseline to week $nmbr$ in auc mean sem,C3272907;C0332174;C0439230;C0376690;C0444504;C2347634;C2348143
triacylglycerol mmol l mean sd,C1532563;C2699239
baseline tg,C0168634;C0337445;C1442488
hba $nmbr$ c mmol mol median q $nmbr$ q $nmbr$,C0019016;C3829066;C1825777;C3538758
baseline tg $nmbr$ $nmbr$ mmol l,C0168634;C1532563;C1442488
fasting serum glucose mmol l median q $nmbr$ q $nmbr$,C0202041;C1532563;C3534430
chylomicron triglycerides,C0008731;C0041004;C1325761
percent change from baseline to week $nmbr$ in auc mean sem,C3272907;C0332174;C0439230;C0376690;C0444504;C2347634;C2348143
chylomicron cholesterol,C0008731;C0008377;C1325761
baseline tg,C0168634;C0337445;C1442488
apob $nmbr$,C0003593;C3252643
baseline tg $nmbr$ $nmbr$ mmol l,C0168634;C1532563;C1442488
simvastatin,C0074554
chylomicron triglycerides,C0008731;C0041004;C1325761
age s $nmbr$ yr,C0001779;C0439234
chylomicron cholesterol,C0008731;C0008377;C1325761
major coronary event,C0205082;C0741923;C0205164;C4318856;C4521762
apob $nmbr$,C0003593;C3252643
age $nmbr$ $nmbr$ yr,C0001779;C0439234
simvastatin,C0074554
c $nmbr$ e $nmbr$ fab bolus n $nmbr$,C1186706;C1511237;C1705509;C3812160
age s $nmbr$ yr,C0001779;C0439234
c $nmbr$ e $nmbr$ fab bolus and infusion n $nmbr$,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
major coronary event,C0205082;C0741923;C0205164;C4318856;C4521762
risk factors of group,C0035648;C1553898
age $nmbr$ $nmbr$ yr,C0001779;C0439234
elevated cholesterol,C0020443
c $nmbr$ e $nmbr$ fab bolus n $nmbr$,C1186706;C1511237;C1705509;C3812160
history of smoking,C1519384
c $nmbr$ e $nmbr$ fab bolus and infusion n $nmbr$,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
vascular disease of group,C0042373
risk factors of group,C0035648;C1553898
cerebral,
elevated cholesterol,C0020443
previous infarction of group,C0205156;C0021308;C1552607
history of smoking,C1519384
previous coronary procedure of group,C0018821;C1279986
vascular disease of group,C0042373
angioplasty,C0162577;C1548817
cerebral,
bypass surgery,C1536078
previous infarction of group,C0205156;C0021308;C1552607
no of diseased vessels of group,C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
previous coronary procedure of group,C0018821;C1279986
coronary procedure of group,C0018821;C1279986
angioplasty,C0162577;C1548817
balloon angioplasty,C0002996;C0002997
bypass surgery,C1536078
atherectomy,C0162513
no of diseased vessels of group,C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
duration of procedure,C2346509
coronary procedure of group,C0018821;C1279986
min,C0702093;C1524029;C3813700
balloon angioplasty,C0002996;C0002997
contrast used ml,C0439526;C1705224;C3887665
atherectomy,C0162513
thrombolytic agents,C0016018
duration of procedure,C2346509
of group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
min,C0702093;C1524029;C3813700
lowest activated clotting,C1708760;C1879547;C0005778;C1328723
contrast used ml,C0439526;C1705224;C3887665
time sec,C0040223;C0565930;C3541383
thrombolytic agents,C0016018
dalteparin n $nmbr$,C0206461
of group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
ulcer,C0041582;C3887532
lowest activated clotting,C1708760;C1879547;C0005778;C1328723
inclusion findings,C2607943;C2926606;C3539655
time sec,C0040223;C0565930;C3541383
unstable but no rest angina,C0002965
dalteparin n $nmbr$,C0206461
rest angina but not past $nmbr$ h,C0002965;C0152172;C1414318;C4284302
ulcer,C0041582;C3887532
rest angina past $nmbr$ h,C0002965;C0152172
inclusion findings,C2607943;C2926606;C3539655
non q wave myocardial infarction,C0542269;C3537181
unstable but no rest angina,C0002965
ecg changes t,C0855329
rest angina but not past $nmbr$ h,C0002965;C0152172;C1414318;C4284302
t wave inversion only,C0520888
rest angina past $nmbr$ h,C0002965;C0152172
st depression only,C0520887
non q wave myocardial infarction,C0542269;C3537181
st depression and t wave inversion,C0520887;C0520888
ecg changes t,C0855329
medication at entry,C0013227;C3244316;C4284232
t wave inversion only,C0520888
oral fi blockers,C0442027;C4050619;C4521986
st depression only,C0520887
long acting nitrates,C0205166;C0028125;C1706317
st depression and t wave inversion,C0520887;C0520888
annanginal drugs $nmbr$ l s $nmbr$ ^,C0013227;C3687832
medication at entry,C0013227;C3244316;C4284232
glyceryl trinitrate infusion,C0574032;C1827465
oral fi blockers,C0442027;C4050619;C4521986
median delay h,C0033727;C0369286;C0441932;C0564385;C4528284
long acting nitrates,C0205166;C0028125;C1706317
age distribution,C0001782
annanginal drugs $nmbr$ l s $nmbr$ ^,C0013227;C3687832
mean sd age in years,C0444504;C1510829;C2347634;C2348143
glyceryl trinitrate infusion,C0574032;C1827465
mean sd bmd in g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
median delay h,C0033727;C0369286;C0441932;C0564385;C4528284
post erior anterior spine,C0037949;C2752558
age distribution,C0001782
vertebral fractures at baseline,C0080179;C0168634;C1442488
mean sd age in years,C0444504;C1510829;C2347634;C2348143
history of postmenopausal fracture,C1272071;C0232970
mean sd bmd in g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
self rated health status,C0036588;C0018759;C1551994
post erior anterior spine,C0037949;C2752558
very g ood ex cellent,C0439267;C4267693
vertebral fractures at baseline,C0080179;C0168634;C1442488
fair poor,C0032854;C0542537;C2700379
history of postmenopausal fracture,C1272071;C0232970
mean sd anthropometry,C0444504;C0003188;C2347634;C2348143
self rated health status,C0036588;C0018759;C1551994
baseline height cm,C0168634;C0489786;C1442488
very g ood ex cellent,C0439267;C4267693
body mass index kg cm $nmbr$,C0005893;C4054689;C0578022;C1305855
fair poor,C0032854;C0542537;C2700379
mean sd calcium intake in mg daily,C0489458;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd anthropometry,C0444504;C0003188;C2347634;C2348143
ever,
baseline height cm,C0168634;C0489786;C1442488
digoxin n $nmbr$,C0012265
body mass index kg cm $nmbr$,C0005893;C4054689;C0578022;C1305855
$nmbr$ $nmbr$ $nmbr$ s,
mean sd calcium intake in mg daily,C0489458;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ s $nmbr$ s $nmbr$,C0565930;C2603362
ever,
median duration of chf mo,C0449238;C2926735
digoxin n $nmbr$,C0012265
of patients $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0030705
$nmbr$ $nmbr$ $nmbr$ s,
method of assessing ejection fraction,C0025663;C0449851;C0871511;C1516048;C0489482;C2700378
$nmbr$ s $nmbr$ s $nmbr$,C0565930;C2603362
radionuclide ventriculography,C0017200;C0034610
median duration of chf mo,C0449238;C2926735
two dimensional echocardiography,C0013524
of patients $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0030705
contrast angiography,C0009924;C0002978;C1979874
method of assessing ejection fraction,C0025663;C0449851;C0871511;C1516048;C0489482;C2700378
cardiothoracic ratio $nmbr$ $nmbr$,C0456603;C1547037
radionuclide ventriculography,C0017200;C0034610
no of signs or symptoms of chff,C0220912;C0220913;C0311392;C0683368;C1457887
two dimensional echocardiography,C0013524
primary cause of chf,C0205225;C0015127;C1524003;C0439612;C0439631
contrast angiography,C0009924;C0002978;C1979874
other vasodilators,C0042402
cardiothoracic ratio $nmbr$ $nmbr$,C0456603;C1547037
daily dose of study medication prescribed,C2348070;C0278329
no of signs or symptoms of chff,C0220912;C0220913;C0311392;C0683368;C1457887
tertile of total cholesterol at baseline mean sd mmol l,C0201950;C0543421;C0168634;C1532563;C1442488
primary cause of chf,C0205225;C0015127;C1524003;C0439612;C0439631
cwt mean se mm,C4330985;C4554674
other vasodilators,C0042402
difference $nmbr$ years baseline,C0168634;C1442488
daily dose of study medication prescribed,C2348070;C0278329
tertile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
tertile of total cholesterol at baseline mean sd mmol l,C0201950;C0543421;C0168634;C1532563;C1442488
p for heterogeneity of treatment effect between tertiles $nmbr$ $nmbr$,C0369773;C2603361
cwt mean se mm,C4330985;C4554674
week $nmbr$ mean sem,C0332174;C0439230
difference $nmbr$ years baseline,C0168634;C1442488
weeko mean sem,C0444504;C2347634;C2348143
tertile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
pretreatment hdl c,C1550147;C3715113;C2709094;C3539075;C3539076
p for heterogeneity of treatment effect between tertiles $nmbr$ $nmbr$,C0369773;C2603361
$nmbr$ $nmbr$ mmol l,C1532563
week $nmbr$ mean sem,C0332174;C0439230
pretreatment triglycerides,C1550147;C0041004;C2709094;C3539075;C3539076
weeko mean sem,C0444504;C2347634;C2348143
no of patients with stroke,C0030705;C0038454;C4554100
pretreatment hdl c,C1550147;C3715113;C2709094;C3539075;C3539076
risk reduction $nmbr$ cl,C1137094;C0596019
$nmbr$ $nmbr$ mmol l,C1532563
pretreatment triglycerides,C1550147;C0041004;C2709094;C3539075;C3539076
no of patients with stroke,C0030705;C0038454;C4554100
risk reduction $nmbr$ cl,C1137094;C0596019
